505690_0_17_18_2_4::None::Distribution/NN of/IN Candida/NN albicans/NNS and/CC non/JJ -/: albicans/NNS Candida/NN species/NNS in/IN oral/JJ candidiasis/NN patients/NNS :/: Correlation/NN between/IN cell/NN surface/NN hydrophobicity/NN and/CC 
198131_1_16_17_10_11::None::long/JJ -/: term/NN users/NNS ,/, their/PRP$ smoking/NN behaviour/NN ,/, attachment/NN to/TO smoking/NN ,/, 
693828_2_2_3_15_16::None::A/DT systematic/JJ literature/NN search/NN was/VBD conducted/VBN on/IN studies/NNS assessing/VBG the/DT clinical/JJ characteristics/NNS and/CC correlates/VBZ of/IN unipolar/JJ MDD/NN and/CC bipolar/JJ 
484109_1_2_3_3_4::medicine.disease.treatments::For/IN penile/JJ cancer/NN surgical/JJ treatment/NN ,/, radiotherapy/NN 
110315_0_0_1_7_8::None::Chronic/JJ inguinodynia/NN is/VBZ one/CD of/IN the/DT most/RBS frequent/JJ complications/NNS after/IN groin/NN 
388589_2_97_98_44_45::None::-/: diabetes/NN ,/, age/NN gtgt/NN =/JJ 65/CD and/CC &/CC lt/NN ;/: 65/CD year/NN -/: old/JJ ,/, men/NNS and/CC women/NNS ,/, body/NN mass/NN index/NN gtgt/NN =/JJ 30/CD and/CC &/CC lt/NN ;/: 30/CD kg/NN //: m/NN (/( 2/CD )/) ,/, and/CC body/NN weight/NN gtgt/NN =/JJ 60/CD and/CC &/CC lt/NN ;/: 60/CD kg/NN ,/, were/VBD identified/VBN in/IN Medline/NNP ,/, Embase/NNP ,/, Web/NN of/IN 
183879_18_31_32_16_17::None::depressive/JJ mood/NN of/IN patients/NNS with/IN severe/JJ MDD/NN ;/: however/RB ,/, the/DT latter/JJ induced/JJ significantly/RB stronger/JJR and/CC more/RBR rapid/JJ beneficial/JJ effects/NNS ./. 
1926_1926_19_20_26_27::None::,/, FADD/NN ,/, DR3/NN ,/, FAF/NN ,/, TRADD/NN ,/, and/CC RIP/NN was/VBD similar/JJ in/IN 
784430_7_15_17_15_18::None::to/TO that/DT of/IN sodium/NN channel/NN blocking/VBG antiepileptic/JJ drugs/NNS ,/, 
850254_13_11_12_10_12::None::patients/NNS with/IN acute/JJ infection/NN ./. 
508103_4_18_19_23_24::None::STZ/NN -/: induced/VBN diabetic/JJ rats/NNS ,/, but/CC normalized/VBD myocardial/JJ steatosis/NN ,/, expression/NN 
312_312_33_34_35_36::POS_REG(-)_POLYMERIZE::inhibiting/JJ effect/NN of/IN profilin/NN on/IN actin/NN polymerization/NN ./. 
63_63_44_45_49_50::POS_ACTION_MEMBER::.2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN 
1546_1546_12_13_26_27::None::kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ from/IN its/PRP$ binding/NN with/IN the/DT cyclin/NN E/cyclin-dependent/JJ kinase/NN 2/CD (/( Cdk2/NN )/) complex/NN that/WDT 
1024_1024_39_40_32_33::POS_ACTION_BIND::RNA-binding/JJ surfaces/NNS of/IN HSH49/NN are/VBP not/RB required/VBN for/IN interaction/NN with/IN CUS1/NN ./. 
256031_1_26_27_37_38::None::absolute/JJ risk/NN of/IN cardiovascular/JJ outcomes/NNS and/CC the/DT relative/JJ risk/NN reduction/NN associated/VBN with/IN screening/NN and/CC intensive/JJ treatment/NN ,/, screening/NN 
991_991_20_21_17_18::None::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
1289_1289_4_6_13_14::POS_ACTION_INTERACT::interactions/NNS between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN bovine/JJ 
813_813_23_24_8_9::None::NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN 
1908_1908_19_20_7_8::POS_ACTION_CONTROL::that/IN TGFbeta/NN regulates/VBZ clusterin/NN gene/NN expression/NN through/IN an/DT AP-1/NN site/NN and/CC its/PRP$ cognate/JJ transcription/NN factor/NN AP-1/NN ,/, and/CC requires/VBZ 
856_856_37_38_24_25::POS_ACTION_LOCALIZE-TO::the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN 
798558_0_22_23_2_3::None::A/DT debilitating/JJ late/JJ -/: onset/NN disorder/NN of/IN the/DT premutation/NN in/IN the/DT FMR1/NN gene/NN is/VBZ the/DT neurodegenerative/JJ disorder/NN fragile/JJ X/NN -/: associated/VBN tremor/NN ataxia/NN syndrome/NN (/( FXTAS/NN 
1095_1095_17_18_22_23::None::and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ 
295839_4_9_10_29_30::None::of/IN STAT3/NN and/CC MEK/NN using/VBG the/DT STAT3/NN inhibitor/NN LY5/NN and/CC MEK/NN inhibitor/NN Trametinib/NN exerts/VBZ significant/JJ anti/JJ -/: tumor/NN cell/NN efficacy/NN in/IN K/NN -/: Ras/NN mutant/NN pancreatic/JJ and/CC 
2222_2222_21_22_13_14::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
604261_0_32_33_52_53::None::the/DT glutamate/NN release/NN inhibitor/NN riluzole/NN ,/, a/DT drug/NN currently/RB used/VBN to/TO treat/VB amyotrophic/JJ lateral/JJ sclerosis/NN ,/, can/MD induce/VB apoptosis/NN in/IN GRM1/NN -/: expressing/VBG melanoma/NN cells/NNS ./. 
500377_1_6_7_12_13::None::essential/JJ hypertension/NN were/VBD treated/VBN with/IN the/DT beta/NN -/: blocker/NN metoprolol/NN and/CC followed/VBD up/RP 
728820_2_13_14_16_17::None::lower/JJR urinary/JJ tract/NN symptoms/NNS secondary/JJ to/TO BPH/NNP from/IN 2005/CD to/TO 
233540_0_13_14_22_24::None::measured/VBN as/IN glycated/JJ haemoglobin/NN (/( HbA1c/NN )/) ,/, influences/VBZ the/DT role/NN of/IN leisure/NN time/NN physical/JJ activity/NN on/IN 
2107_2107_27_28_5_7::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
410_410_11_12_12_13::POS_ACTION_MEMBER::histone/NN H3/NN and/CC histone/NN H4/NN were/VBD inviable/JJ ./. 
1940_1940_13_14_11_12::None::signal-regulated/JJ protein/NN kinases/NNS ERK1/NN and/CC ERK2/NN ,/, induction/NN of/IN 
18_18_6_7_4_5::None::domain/NN of/IN the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ 
1094_1094_18_19_16_17::None::,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT 
28653_0_0_1_10_11::None::Photochemical/JJ reduction/NN of/IN iron/NN and/CC iron/NN uptake/NN by/IN Microcystis/NNPS were/VBD investigated/VBN in/IN a/DT freshwater/JJ 
759_759_20_24_12_13::None::cell/NN strain/NN ,/, EGF/NN inhibited/VBD increases/NNS in/IN immunoreactive/JJ sarcomeric/JJ actin/NN and/CC sarcomeric/JJ myosin/NN heavy/JJ chain/NN (/( SMHC/NN )/) 
241_241_13_17_0_1::None::Neuropilin-1/NN is/VBZ expressed/VBN by/IN endothelial/JJ and/CC tumor/NN cells/NNS as/IN an/DT isoform-specific/JJ receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN ./. 
87529_17_3_4_6_7::None::Advanced/NNP age/NN ,/, hypertension/NN ,/, and/CC prior/RB stroke/NN were/VBD associated/VBN 
227834_1_11_12_7_8::None::damage/NN to/TO leukocytic/JJ DNA/NN and/CC enhancement/NN of/IN homocysteine/NN (/( Hcy/NN )/) 
1075_1075_20_21_6_7::POS_ACTION_PHOSPHORYLATE::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) 
1908_1908_19_20_5_6::POS_ACTION_MEDIATE::results/NNS indicate/VBP that/IN TGFbeta/NN regulates/VBZ clusterin/NN gene/NN expression/NN through/IN an/DT AP-1/NN site/NN and/CC its/PRP$ cognate/JJ transcription/NN factor/NN AP-1/NN ,/, and/CC requires/VBZ 
1380_1380_26_27_36_37::POS_ACTION_BIND::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, 
262795_4_0_1_6_7::None::It/PRP is/VBZ clear/JJ now/RB that/IN the/DT tumour/NN -/: promoting/VBG inflammatory/JJ 
558341_3_22_23_25_27::None::focused/VBN on/IN a/DT higher/JJR risk/NN of/IN myocardial/JJ infarction/NN in/IN subjects/NNS with/IN 
431_431_6_7_15_16::POS_ACTION_Causal::proline-rich/JJ protein/NN (/( End5p/NN or/CC verprolin/NN )/) required/VBN for/IN a/DT polarised/JJ cortical/JJ actin/NN cytoskeleton/NN and/CC endocytosis/NN 
1061_1061_6_7_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ 
253162_8_32_33_4_5::None::IgG/NN subclasses/NNS (/( IgG1/NN //: IgG2a/NN //: IgG2b/NN //: IgG3/NN )/) were/VBD elicited/VBN by/IN omvPV/NN and/CC in/IN a/DT lower/JJR magnitude/NN by/IN wPV/NN ,/, but/CC not/RB by/IN aPV/NN (/( IgG1/NN )/) or/CC infection/NN (/( IgG2a/NN //: 
529506_0_9_13_4_7::None::alveolar/JJ hemorrhage/NN from/IN systemic/JJ lupus/NN erythematosus/NN misdiagnosed/JJ as/RB high/JJ altitude/NN pulmonary/JJ edema/NN ./. 
1434_1434_11_12_72_73::None::,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN 
1782_1782_7_8_1_6::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT 
1360_1360_7_8_4_5::None::affinity/NN of/IN yeast/NN profilin/NN for/IN rabbit/NN actin/NN (/( 2.9/CD microM/NN 
779_779_35_36_21_24::None::accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) 
303626_0_19_20_21_22::medicine.drug_ingredient.active_moiety_of_drug::NPs/NNS )/) on/IN chromium/NN (/( Cr/NN )/) fractionation/NN in/IN 
686_686_29_30_29_30::None::the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC 
438998_0_9_10_14_16::people.cause_of_death.includes_causes_of_death::occurrence/NN potentiate/VB the/DT anticancer/JJ effects/NNS of/IN everolimus/NN on/IN renal/JJ cancer/NN cells/NNS ./. 
1061_1061_25_27_15_16::None::but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
565_565_39_40_28_29::None::the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS ,/, co-localizing/VBG with/IN the/DT known/JJ focal/JJ adhesion/NN components/NNS talin/NN and/CC vinculin/NN ./. 
397033_2_5_6_10_12::biology.organism_classification.lower_classifications::birds/NNS (/( carrion/NN crows/NNS ,/, Corvus/NN corone/NN ,/, common/JJ ravens/NNS ,/, Corvus/NNP corax/NN 
686_686_33_34_13_14::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
1442_1442_23_24_4_5::POS_ACTION_BIND::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN can/MD not/RB directly/RB associate/JJ with/IN alpha-catenin/NN but/CC interacts/VBZ with/IN high/JJ affinity/NN with/IN beta-catenin/NN ,/, whereas/IN the/DT binding/NN of/IN gamma-catenin/NN (/( plakoglobin/NN )/) 
1686_1686_51_53_25_28::None::at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP myosin/NN II/CD requires/VBZ isoform/NN specific/JJ 
426593_3_10_11_20_21::None::I/PRP -/: 131/CD MIBG/NN could/MD achieve/VB high/JJ -/: probability/NN pain/NN reduction/NN ,/, the/DT objective/JJ response/NN was/VBD poor/JJ 
789814_0_7_8_13_14::None::(/( CABG/NN )/) surgery/NN remains/VBZ the/DT preferred/JJ mode/NN of/IN revascularization/NN in/IN patients/NNS with/IN 
360_360_13_14_8_9::POS_ACTION_BIND::of/IN the/DT N-terminal/JJ actin/NN binding/NN domain/NN of/IN human/JJ fimbrin/NN ./. 
2222_2222_39_40_23_24::NEG_ACTION_COLOCALIZE::,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
157_157_8_9_24_25::None::to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN 
323444_1_15_16_9_10::None::of/IN mesenteric/JJ ischaemia/NN secondary/JJ to/TO ventricular/JJ emboli/NNS in/IN a/DT patient/NN with/IN CS/NNP Laboratory/NNP 
1500_1500_16_17_11_12::POS_ACTION_BIND::heterotrimer/NN of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN proteins/NNS ,/, displays/VBZ 
1599_1599_22_23_29_30::POS_ACTION_ASSEMBLE::that/DT of/IN a/DT talin/NN mediated/VBD mechanism/NN for/IN the/DT attachment/NN of/IN actin/NN filaments/NNS to/TO the/DT 
693466_12_3_4_9_10::None::HyperCVAD/NN chemotherapy/NN and/CC imatinib/NN is/VBZ an/DT effective/JJ regimen/NN for/IN Philadelphia/NNP -/: positive/JJ acute/JJ 
822180_0_28_29_24_25::None::the/DT major/JJ immunological/JJ complications/NNS associated/VBN with/IN allogeneic/JJ transplantation/NN ./. 
356086_0_0_1_24_25::medicine.disease.treatments::Cancer/NN stem/NN cells/NNS (/( CSCs/NNS )/) play/VBP an/DT important/JJ role/NN in/IN cancer/NN growth/NN ,/, self/NN -/: renewal/NN ,/, metastasis/NN ,/, recurrence/NN and/CC radio/NN //: chemotherapy/NN ./. 
265539_2_18_19_0_1::None::MS/NN is/VBZ an/DT inflammatory/JJ ,/, demyelinating/JJ ,/, neurodegenerative/JJ disease/NN of/IN the/DT CNS/NN During/IN the/DT last/JJ several/JJ decades/NNS ,/, experimental/JJ models/NNS of/IN MS/NN 
1737_1737_58_59_52_54::None::the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
616_616_17_18_18_19::POS_ACTION_MEMBER::six/CD sites/NNS and/CC histone/NN H4/NN had/VBD five/CD sites/NNS 
2222_2222_23_24_13_14::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
480543_0_9_10_31_32::None::68/CD )/) is/VBZ produced/VBN by/IN proton/NN irradiation/NN of/IN a/DT gallium/NN metal/NN target/NN ,/, purified/VBN by/IN organic/JJ extraction/NN and/CC used/VBN in/IN a/DT medical/JJ isotope/NN generator/NN to/TO produce/VB Gallium/NNP -/: 68/CD 
534857_3_24_26_16_17::medicine.disease.risk_factors::use/NN in/IN 937/CD hypertensive/JJ patients/NNS with/IN ECG/NN left/VBD ventricular/JJ hypertrophy/NN in/IN atrial/JJ fibrillation/NN at/IN baseline/NN (/( 
367_367_24_25_28_30::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
991_991_20_21_4_5::POS_ACTION_Causal::known/VBN to/TO link/VB actin/NN filaments/NNS to/TO membrane/NN were/VBD also/RB examined/VBN ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
2108_2108_18_19_17_18::None::kd/NN is/VBZ the/DT histone/NN H4/NN ,/, the/DT 19/CD 
2_2_9_10_11_13::None::formation/NN of/IN a/DT beta-catenin/NN */SYM T-cell/NN factor/NN */SYM DNA/NN complex/NN 
1160_1160_2_3_8_10::None::Purification/NN of/IN cofilin/NN ,/, a/DT 21,000/CD molecular/JJ weight/NN actin-binding/JJ protein/NN ,/, from/IN porcine/NN 
76705_14_13_14_22_23::medicine.risk_factor.diseases::rise/NN showed/VBD a/DT high/JJ prevalence/NN of/IN CVE/NN but/CC not/RB stroke/NN ,/, thus/RB CAD/NN might/MD have/VB a/DT 
1962_1962_22_23_24_25::None::the/DT actin-binding/JJ proteins/NNS tropomyosin/NN and/CC profilin/NN also/RB did/VBD not/RB 
79843_0_39_40_37_38::None::years/NNS among/IN both/DT youth/NN and/CC adults/NNS for/IN its/PRP$ cognitive/JJ 
665_665_19_20_14_17::None::antibodies/NNS to/TO the/DT actin/NN binding/NN proteins/NNS Abp1p/NN and/CC cofilin/NN ./. 
101_101_22_23_24_25::None::the/DT influence/NN of/IN talin/NN and/CC vinculin/NN on/IN the/DT structure/NN 
243_243_30_32_0_2::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD 
367_367_32_33_0_2::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
668570_12_7_8_21_22::None::association/NN between/IN preoperative/JJ depressive/JJ symptom/NN severity/NN and/CC postoperative/JJ pain/NN and/CC no/DT reduction/NN in/IN postoperative/JJ depressive/JJ symptoms/NNS run/VBP counter/RB to/TO other/JJ available/JJ 
539_539_18_19_5_6::None::we/PRP show/VBP that/IN talin/NN ,/, a/DT high/JJ molecular/JJ weight/NN structural/JJ protein/NN that/WDT links/VBZ integrins/NNS to/TO the/DT actin/NN cytoskeleton/NN ,/, is/VBZ 
214422_1_36_38_12_13::None::following/VBG groups/NNS :/: control/JJ group/NN (/( control/NN )/) ,/, hydrogen/NN peroxide/NN group/NN (/( H2O2/NN )/) ,/, pretreated/VBN with/IN low/JJ concentration/NN dopamine/NN (/( DA/NN +/CC H2O2/NN )/) ,/, dopamine/NN receptor/NN l/NN (/( DR1/NN 
1843_1843_31_32_12_13::None::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD 
1754_1754_21_22_32_33::None::to/TO interact/VB with/IN alpha-catenin/NN ,/, and/CC that/IN this/DT defect/NN results/VBZ from/IN the/DT mutation/NN in/IN beta-catenin/NN ./. 
805_805_5_9_0_4::None::Insulin-like/JJ growth/NN factor/NN I/PRP stimulates/VBZ cardiac/JJ myosin/NN heavy/JJ chain/NN and/CC actin/NN synthesis/NN 
315600_15_1_2_36_37::None::GHA/NN priming/NN chemotherapy/NN ,/, as/RB well/RB as/IN other/JJ combination/NN regimens/NNS GHAA/NNP //: GHTA/NNP ,/, are/VBP well/RB -/: tolerated/VBN ,/, effective/JJ regimens/NNS for/IN refractory/JJ AML/NN and/CC advanced/VBD MDS/NN ,/, without/IN severe/JJ side/JJ effects/NNS and/CC therapy/NN -/: related/JJ mortality/NN ./. 
279_279_30_31_19_20::None::a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC a/DT novel/JJ protein/NN of/IN 33/CD kDa/NN (/( eIF3-p33/NN )/) which/WDT is/VBZ 
247832_2_6_7_45_46::None::studies/NNS suggest/VBP that/IN inflammatory/JJ processes/NNS have/VBP emerged/VBN critical/JJ in/IN the/DT pathogenesis/NN of/IN CVD/NNP in/IN OSAS/NNP A/NNP range/NN of/IN circulating/VBG inflammatory/JJ molecules/NNS has/VBZ been/VBN identified/VBN and/CC measured/VBN ,/, with/IN a/DT view/NN to/TO assess/VB inflammation/NN and/CC predict/VBP vascular/JJ damage/NN risk/NN ,/, such/JJ as/IN plasma/NN cytokines/NNS ,/, adhesion/NN molecules/NNS 
176455_12_5_6_3_5::None::Neoadjuvant/JJ radiotherapy/NN of/IN rectal/JJ cancer/NN represents/VBZ the/DT current/JJ standard/NN 
1144_1144_11_13_0_2::None::Profilin/NN II/CD binds/VBZ actin/NN with/IN a/DT similar/JJ affinity/NN to/TO that/DT of/IN profilin/NN I/CD ,/, although/IN it/PRP 
1940_1940_11_12_7_11::None::in/IN activation/NN of/IN extracellular/JJ signal-regulated/JJ protein/NN kinases/NNS ERK1/NN and/CC ERK2/NN ,/, 
278424_0_8_9_7_8::None::tamoxifen/NN response/NN and/CC prognostic/JJ indication/NN in/IN two/CD breast/NN 
367_367_28_30_32_33::POS_ACTION_MEMBER::and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
697_697_2_3_23_25::None::In/IN Acanthamoeba/NN actin/NN polymerization/NN is/VBZ regulated/VBN ,/, at/IN least/JJS in/IN part/NN ,/, by/IN profilin/NN ,/, which/WDT binds/VBZ to/TO actin/NN monomers/NNS ,/, and/CC by/IN capping/VBG protein/NN ,/, which/WDT both/DT 
315600_15_30_32_23_24::medicine.risk_factor.diseases::regimens/NNS for/IN refractory/JJ AML/NN and/CC advanced/VBD MDS/NN ,/, without/IN severe/JJ side/JJ effects/NNS and/CC therapy/NN -/: 
776_776_24_26_26_27::POS_ACTION_MEMBER::the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN 
1534_1534_26_29_12_13::None::TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( 
3197_0_9_10_7_8::None::)/) is/VBZ an/DT investigational/JJ oral/JJ prodrug/NN of/IN the/DT HIV/NN 
245_245_0_1_10_11::POS_ACTION_BIND::Neuropilin-1/NN (/( NRP1/NN )/) is/VBZ a/DT 130-kDa/JJ transmembrane/NN receptor/NN for/IN semaphorins/NNS ,/, mediators/NNS of/IN 
2117_2117_18_19_2_3::None::We/PRP investigated/VBD actin/NN filament/NN turnover/NN rates/NNS ,/, length/NN ,/, number/NN ,/, barbed/VBN end/NN exposure/NN ,/, and/CC binding/NN of/IN cofilin/NN in/IN bovine/JJ arterial/JJ 
214422_1_18_20_22_23::medicine.drug.active_moieties::control/NN )/) ,/, hydrogen/NN peroxide/NN group/NN (/( H2O2/NN )/) ,/, pretreated/VBN 
1798_1798_33_34_24_26::None::expression/NN of/IN a/DT rac-1/NN GAP/NN alters/VBZ the/DT assembly/NN of/IN integrin/NN receptors/NNS ,/, actin/NN and/CC cytoskeletal/JJ proteins/NNS 
126724_0_14_15_6_7::people.cause_of_death.includes_causes_of_death::Future/NNP :/: Are/VBP Tumor/NN -/: Targeting/NN Bacteria/NNS the/DT Next/JJ -/: Generation/NNP Cancer/NNP Therapy/NN ?/. 
467117_12_2_3_17_19::None::Canine/NN orbital/JJ rhabdomyosarcoma/NN is/VBZ a/DT highly/RB malignant/JJ neoplasm/NN in/IN juvenile/JJ dogs/NNS ,/, but/CC may/MD be/VB amenable/JJ to/TO surgical/JJ resection/NN in/IN older/JJR dogs/NNS 
356086_0_22_23_18_19::None::-/: renewal/NN ,/, metastasis/NN ,/, recurrence/NN and/CC radio/NN //: chemotherapy/NN ./. 
415007_0_32_35_1_2::medicine.disease.risk_factors::Familial/JJ hypercholesterolaemia/NN (/( FH/NN )/) is/VBZ an/DT autosomal/JJ co/NN -/: dominant/JJ disorder/NN that/WDT markedly/RB raises/VBZ plasma/NN low/JJ -/: density/NN lipoprotein/NN -/: cholesterol/NN (/( LDL/NN -/: C/NN )/) concentration/NN ,/, causing/VBG premature/JJ atherosclerotic/JJ coronary/JJ artery/NN disease/NN (/( CAD/NN )/) 
7_7_11_12_2_3::None::Absence/NN of/IN alpha-syntrophin/NN leads/VBZ to/TO structurally/RB aberrant/JJ neuromuscular/JJ synapses/NNS deficient/JJ in/IN utrophin/NN ./. 
1226_1226_5_6_2_3::POS_ACTION_RELATE::Saccharomyces/FW cerevisiae/FW PAC2/NN functions/NNS with/IN CIN1/NN ,/, 2/CD and/CC 
68_68_14_15_12_13::POS_ACTION_CORELATE::of/IN expression/NN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, 
1380_1380_43_44_38_39::None::,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN (/( Machesky/NNP et/FW 
288485_0_16_17_30_32::None::spinal/JJ image/NN -/: guided/VBN radiotherapy/NN (/( IGRT/NN )/) by/IN determining/VBG the/DT expression/NN of/IN caspase/NN -/: 3/CD in/IN spinal/JJ cord/NN neurons/NNS after/IN IGRT/NNP 
112_112_3_4_14_16::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN epithelial/JJ cells/NNS and/CC forms/VBZ a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN 
228362_4_29_30_14_15::medicine.drug_ingredient.active_moiety_of_drug::vitro/FW ribosylation/NN and/CC trypsin/NN digestion/NN for/IN 24/CD or/CC 72h/CD on/IN the/DT viscoelastic/JJ behavior/NN of/IN the/DT whole/JJ murine/JJ IVD/NN Trypsin/NN treatment/NN resulted/VBD in/IN 
237860_0_4_5_19_20::None::2007/CD ,/, the/DT baby/NN woolly/JJ mammoth/JJ (/( Mammuthus/JJ primigenius/NN )/) named/VBN Lyuba/NNP was/VBD found/VBN frozen/VBN in/IN the/DT Siberian/JJ tundra/NN permafrost/NN along/IN the/DT 
522582_0_11_12_9_10::medicine.symptom.symptom_of::and/CC rumination/NN predict/VBP depressive/JJ and/CC anxiety/NN symptoms/NNS in/IN young/JJ 
178597_0_40_42_30_31::medicine.disease.treatments::no/DT post/NN -/: transplant/NN immunosuppression/NN controls/VBZ graft/NN rejection/NN and/CC GvHD/NN in/IN patients/NNS with/IN acute/JJ leukemia/NN ./. 
669_669_16_17_11_12::None::the/DT presence/NN of/IN paxillin/NN ,/, talin/NN ,/, and/CC vinculin/NN at/IN the/DT ends/NNS 
295529_1_4_5_13_14::None::is/VBZ the/DT only/JJ member/NN of/IN the/DT RAF/NN family/NN activated/VBN by/IN mutation/NN in/IN human/JJ cancers/NNS ./. 
984_984_0_1_20_21::POS_ACTION_SIMILAR::MLL/NN is/VBZ fused/VBN in-frame/RB to/TO a/DT different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, 
1169_1169_10_11_26_27::None::to/TO regulate/VB the/DT actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD 
170773_3_47_48_33_34::None::wide/JJ association/NN studies/NNS conducted/VBN in/IN recent/JJ years/NNS on/IN electrocardiographic/JJ parameters/NNS ,/, highlighting/VBG their/PRP$ potential/NN in/IN uncovering/VBG new/JJ biological/JJ insights/NNS into/IN cardiac/JJ 
128605_11_37_39_22_23::None::,/, and/CC hence/RB high/JJ levels/NNS of/IN XIAP/NN may/MD be/VB a/DT useful/JJ indicator/NN of/IN neoadjuvant/JJ radio/NN chemotherapy/NN resistance/NN in/IN rectal/JJ cancer/NN ./. 
962_962_12_15_15_16::POS_ACTION_MEMBER::synthesis/NN by/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ./. 
833154_0_4_5_0_1::None::Management/NN of/IN angioedema/NN without/IN urticaria/NN in/IN the/DT emergency/NN 
772940_6_1_2_0_1::None::In/IN patients/NNS with/IN chronic/JJ HBV/NN 
576_576_13_15_22_23::None::,/, a/DT ubiquitous/JJ actin-binding/JJ protein/NN that/WDT is/VBZ essential/JJ for/IN effective/JJ depolymerization/NN of/IN actin/NN filaments/NNS ./. 
1502_1502_14_15_18_19::None::localization/NN of/IN the/DT UL52/NN but/CC not/RB the/DT ICP8/NN or/CC POL/NN replication/NN 
267813_3_10_11_62_64::medicine.disease.treatments::-/: TR/NN )/) diagnosis/NN of/IN bipolar/JJ disorder/NN ,/, manic/JJ ,/, hypomanic/JJ ,/, or/CC mixed/JJ episode/NN ,/, were/VBD recruited/VBN over/IN a/DT 6/CD year/NN period/NN from/IN two/CD academic/JJ outpatient/NN programs/NNS for/IN a/DT double/JJ -/: blinded/VBN ,/, placebo/NN -/: controlled/JJ trial/NN in/IN which/WDT subjects/NNS were/VBD randomized/VBN in/IN a/DT 2/CD :/: 2/CD :/: 1/CD ratio/NN to/TO risperidone/NN solution/NN ,/, valproic/JJ acid/NN ,/, or/CC placebo/NN 
127291_4_65_66_34_35::None::the/DT artificial/JJ vessel/NN bypass/NN was/VBD done/VBN between/IN the/DT infra/NN -/: renal/JJ aorta/NN and/CC distal/JJ portion/NN of/IN the/DT splenic/JJ artery/NN in/IN 7/CD cases/NNS ;/: the/DT splenectomy/NN was/VBD done/VBN in/IN 2/CD cases/NNS ;/: the/DT splenectomy/NN in/IN combination/NN with/IN ligation/NN of/IN 
12641_5_4_5_2_3::None::In/IN those/DT continued/VBN on/IN antidepressants/NNS (/( AD/NN )/) 
229_229_15_16_11_12::POS_REG(+)_PHOSPHORYLATE::(/( flk-1/NN //: KDR/NN )/) tyrosine-autophosphorylation/NN by/IN VEGF/NN which/WDT was/VBD maximal/JJ 
1248_1248_4_5_9_10::POS_ACTION_MEMBER::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
227756_3_27_28_0_1::None::We/PRP use/VBP the/DT directly/RB dated/VBN ancient/JJ wolf/NN genome/NN to/TO recalibrate/VB the/DT molecular/JJ timescale/NN of/IN wolves/NNS and/CC dogs/NNS and/CC find/VB that/IN the/DT mutation/NN rate/NN is/VBZ substantially/RB slower/JJR than/IN assumed/VBN by/IN most/JJS previous/JJ 
218696_6_0_1_33_36::medicine.risk_factor.diseases::Diabetics/NNS were/VBD older/JJR (/( 64/CD vs/CC 62/CD years/NNS ,/, P/NN &/CC lt/NN ;/: 0.001/CD )/) ,/, with/IN higher/JJR incidence/NN of/IN major/JJ coronary/JJ risk/NN factors/NNS ,/, co/SYM -/: morbidities/NNS ,/, and/CC triple/JJ -/: vessel/NN coronary/JJ artery/NN disease/NN ./. 
1889_1889_5_6_11_13::POS_ACTION_ACTIVATE::death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN acid/NN sphingomyelinase/NN ./. 
1726_1726_23_24_8_9::None::of/IN LIM-kinase/NN by/IN ROCK/NN and/CC consequently/RB increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
97678_0_12_13_10_11::None::and/CC Expenditures/NNS among/IN Elderly/NNP Medicare/NNP Beneficiaries/NNS ./. 
1095_1095_35_36_22_23::POS_ACTION_LOCALIZE::,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ proteins/NNS are/VBP dependent/JJ on/IN the/DT supramolecular/JJ organization/NN of/IN the/DT collagens/NNS ./. 
177255_4_12_13_8_9::None::to/TO protect/VB from/IN diabetic/JJ foot/NN infection/NN with/IN modified/VBN cotton/NN socks/NNS ./. 
552813_1_2_3_40_43::None::Patients/NNS with/IN BMS/NN (/( EDSS/NN ltlt/NN =/JJ 3/CD after/IN 20/CD years/NNS disease/NN duration/NN )/) were/VBD re/SYM -/: assessed/VBN 25/CD -/: 30/CD years/NNS post/NN -/: MS/NN symptom/NN onset/NN for/IN :/: EDSS/NNS ,/, HRQoL/NN (/( MSQoL/NN -/: 54/CD )/) ,/, depression/NN (/( Beck/NNP Depression/NNP Inventory/NNP -/: II/CD )/) 
428759_7_12_13_18_19::None::ovarian/JJ suppression/NN in/IN premenopausal/JJ early/JJ breast/NN cancer/NN have/VBP been/VBN selected/VBN as/IN the/DT last/JJ 
434463_2_37_38_21_22::None::,/, with/IN the/DT Pall/NN Lipipor/NN (/( Registered/NNP )/) TNA/NNP and/CC Lipipor/NNP NLF/NNP intravenous/JJ in/IN -/: line/NN filters/NNS and/CC to/TO assay/VB the/DT content/NN before/IN 
75211_5_10_12_31_34::medicine.disease.treatments::Indian/JJ women/NNS with/IN breast/NN cancer/NN ,/, in/IN the/DT age/NN group/NN of/IN 34/CD to/TO 60/CD years/NNS ,/, who/WP had/VBD poorly/RB differentiated/VBN breast/NN carcinoma/NN and/CC underwent/VBD modified/VBN radical/JJ mastectomy/NN ./. 
394127_6_13_14_19_20::medicine.disease.risk_factors::%/NN )/) ,/, endometrium/NN (/( 17.1/CD %/NN )/) ,/, breast/NN (/( 14.3/CD %/NN 
726738_8_20_22_0_1::None::The/DT rates/NNS of/IN antiviral/JJ prophylaxis/NN were/VBD lower/JJR for/IN doctors/NNS treating/VBG lung/NN ,/, breast/NN and/CC colorectal/JJ cancers/NNS than/IN for/IN those/DT treating/VBG hematological/JJ malignancies/NNS (/( all/DT p/NN 
373757_6_5_6_41_44::None::with/IN patients/NNS without/IN stroke/NN ,/, patients/NNS with/IN stroke/NN were/VBD more/RBR likely/JJ to/TO be/VB older/JJR and/CC to/TO have/VB diabetes/NN mellitus/NN ,/, hypertension/NN ,/, atrial/JJ fibrillation/NN ,/, hyperlipidaemia/NN ,/, chronic/JJ kidney/NN disease/NN ,/, ischaemic/JJ heart/NN disease/NN ,/, peripheral/JJ arterial/JJ disease/NN and/CC left/VBD ventricular/JJ dysfunction/NN (/( p/NN =/JJ 
849947_0_7_8_6_7::biology.organism_classification.lower_classifications::hernia/NN in/IN a/DT terrier/NN dog/NN ./. 
131_131_7_8_5_6::POS_ACTION_CORELATE::was/VBD seen/VBN between/IN E-cadherin/NN and/CC alpha-catenin/NN expression/NN ,/, in/IN 
1240_1240_18_19_7_8::POS_ACTION_SQSIMILAR::coding/VBG region/NN for/IN RAD51/NN protein/NN share/NN homology/NN with/IN the/DT damage/NN response/NN sequence/NN element/NN of/IN RAD54/NN ,/, an/DT upstream/JJ 
278424_0_11_13_2_3::None::S6/NN kinase/NN signaling/NN :/: tamoxifen/NN response/NN and/CC prognostic/JJ indication/NN in/IN two/CD breast/NN cancer/NN cohorts/NNS ./. 
106_106_6_7_2_3::None::mDia/NN binds/VBZ profilin/NN likely/JJ to/TO promote/VB actin/NN polymerization/NN ./. 
856_856_16_18_40_41::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
333090_0_5_6_7_8::None::for/IN depression/NN and/CC anxiety/NN in/IN individuals/NNS post/NN -/: stroke/NN 
856_856_40_41_16_18::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
454283_3_7_8_1_2::None::At/IN pH/NN 6.0/CD ,/, arsenate/NN inhibits/VBZ the/DT formation/NN of/IN lepidocrocite/NN and/CC 
124453_5_20_21_20_21::medicine.drug_ingredient.active_moiety_of_drug::plants/NNS by/IN inhibiting/VBG Cu/NN uptake/NN and/CC regulating/VBG 
1538_1538_12_13_11_12::POS_ACTION_MEMBER::partner/NN of/IN the/DT Rap1A/NN GTPase/NN and/CC associates/VBZ with/IN 
139515_2_46_48_59_60::medicine.symptom.symptom_of::hematuria/NN ,/, and/CC abdominal/JJ pain/NN and/CC confirmed/VBD pathologically/RB by/IN his/PRP$ renal/JJ and/CC skin/NN biopsies/NNS demonstrating/VBG leukocytoclastic/JJ vasculitis/NN and/CC IgA/NN complexes/NNS 
68_68_14_15_16_17::POS_ACTION_CORELATE::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB 
991_991_15_16_4_5::POS_ACTION_Causal::known/VBN to/TO link/VB actin/NN filaments/NNS to/TO membrane/NN were/VBD also/RB examined/VBN ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, 
984_984_20_21_0_1::None::MLL/NN is/VBZ fused/VBN in-frame/RB to/TO a/DT different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, 
1480_1480_12_13_2_3::None::The/DT exogeneous/JJ cofilin/NN ,/, but/CC not/RB ADF/NN ,/, caused/VBD quick/JJ disassembly/NN of/IN actin/NN filaments/NNS and/CC accumulated/VBN 
1759_1759_40_41_10_11::None::EGF/NN stimulation/NN recruits/VBZ cofilin/NN to/TO the/DT leading/JJ edge/NN where/WRB its/PRP$ severing/VBG activity/NN is/VBZ activated/VBN ,/, leading/VBG to/TO the/DT generation/NN of/IN short/JJ actin/NN filaments/NNS with/IN free/JJ barbed/VBN ends/NNS that/WDT participate/VBP in/IN the/DT nucleation/NN of/IN actin/NN polymerization/NN ./. 
2030_2030_3_4_18_19::POS_ACTION_BIND::We/PRP conclude/VBP that/IN Aip1p/NN is/VBZ a/DT cofilin-associated/JJ protein/NN that/WDT enhances/VBZ the/DT filament/NN disassembly/NN activity/NN of/IN cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ 
367_367_32_33_24_25::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
779_779_35_36_6_7::None::mechanism/NN by/IN which/WDT pRb/NN induces/VBZ senescence/NN ,/, we/PRP have/VBP found/VBN that/IN pRb/NN causes/VBZ a/DT posttranscriptional/JJ accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) 
350698_1_16_17_15_16::medicine.disease.symptoms::accompanied/VBN by/IN an/DT accelerated/VBN atherosclerosis/NN ./. 
671646_0_10_12_0_1::medicine.disease.treatments::Surgical/NNP treatment/NN is/VBZ an/DT important/JJ strategy/NN for/IN the/DT treatment/NN of/IN spinal/JJ tuberculosis/NN (/( TB/NN )/) 
1345_1345_12_13_3_4::POS_ACTION_BIND::The/DT ability/NN of/IN WIP/NNP to/TO replace/VB verprolin/NN is/VBZ dependent/JJ on/IN its/PRP$ WH2/NN actin/NN binding/NN domain/NN and/CC 
365169_1_38_39_12_13::medicine.disease.treatments::tuberculosis/NN despite/IN recent/JJ isoniazid/NN prophylactic/NN therapy/NN ,/, non/JJ -/: tuberculous/JJ mycobacterial/JJ disease/NN ,/, chronic/JJ airways/NNS obstruction/NN ,/, and/CC spontaneous/JJ pneumothorax/NN -/: and/CC the/DT difficulties/NNS ,/, which/WDT arose/VBD ,/, in/IN diagnosis/NN and/CC management/NN of/IN 
792620_5_28_29_16_17::biology.organism_classification.lower_classifications::activity/NN in/IN carrageenan/NN rat/NN induced/VBD paw/NN oedema/NN and/CC complete/JJ Freund/NN whosewhat/NN adjuvant/JJ induced/VBN arthritis/NN in/IN rats/NNS ./. 
778878_10_15_16_18_19::None::antibiotics/NNS can/MD effectively/RB reduce/VB the/DT sputum/NN bacterial/JJ density/NN ,/, increase/NN 
12271_2_94_95_4_5::None::this/DT study/NN ,/, synthetic/JJ heptapeptides/NNS (/( Lys/SYM -/: Trp/SYM -/: Tyr/SYM -/: Lys/SYM -/: Asp/NN -/: Gly/SYM -/: Asp/NN )/) coupled/VBN to/TO a/DT biotin/NN molecule/NN through/IN the/DT N/NN -/: terminal/JJ amino/NN group/NN and/CC e/SYM -/: amino/NN group/NN of/IN N/NN -/: terminus/NN Lys/NNP ,/, (/( Btn/NNP )/) KP6/NN and/CC K/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, and/CC heir/NN their/PRP$ biotinylated/VBN peptides/NNS substituted/VBN with/IN d/SYM -/: Lys/NNS at/IN the/DT N/NN -/: terminus/NN ,/, (/( Btn/NNP )/) dKP6/NN and/CC dK/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, were/VBD investigated/VBN for/IN their/PRP$ effects/NNS on/IN PAF/NN -/: induced/VBN inflammation/NN ./. 
763530_0_11_13_40_43::None::risk/NN factors/NNS for/IN esophageal/NN adenocarcinoma/NN and/CC its/PRP$ main/JJ precursor/NN ,/, Barrett/NNP whosewhat/NN esophagus/NN ;/: however/RB ,/, there/EX are/VBP no/DT known/JJ biological/JJ mechanisms/NNS for/IN these/DT associations/NNS or/CC regarding/VBG why/WRB only/RB some/DT patients/NNS with/IN gastroesophageal/NN reflux/NN disease/NN develop/VBP Barrett/NNP whosewhat/NN 
668570_12_1_2_25_26::None::Our/PRP$ findings/NNS of/IN no/DT association/NN between/IN preoperative/JJ depressive/JJ symptom/NN severity/NN and/CC postoperative/JJ pain/NN and/CC no/DT reduction/NN in/IN postoperative/JJ depressive/JJ symptoms/NNS run/VBP counter/RB to/TO other/JJ available/JJ evidence/NN ,/, potentially/RB attributable/JJ 
243_243_36_37_32_35::None::through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) ./. 
776_776_28_29_24_26::None::the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT 
423051_1_17_18_5_6::None::suggests/VBZ that/IN accelerated/VBN atherosclerosis/NN and/CC related/JJ cardiovascular/JJ comorbidities/NNS in/IN RA/NN are/VBP confounded/VBN not/RB only/RB by/IN traditional/JJ risk/NN factors/NNS (/( 
370565_0_30_31_33_35::None::,/, present/JJ with/IN symptoms/NNS of/IN severe/JJ neck/NN pain/NN ,/, rigidity/NN ,/, 
1061_1061_2_3_36_37::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
591709_2_5_6_20_21::None::increasing/VBG ease/NN in/IN generating/VBG genomic/JJ data/NNS ,/, as/RB well/RB as/IN recent/JJ ,/, although/IN incomplete/JJ descriptions/NNS of/IN potential/JJ COX/NNP sequences/NNS in/IN Mollusca/NNP ,/, 
1926_1926_19_20_13_14::None::as/IN that/DT of/IN FLICE/NNP ,/, Fas/NN ,/, FADD/NN ,/, DR3/NN ,/, FAF/NN ,/, 
178116_0_10_12_4_5::None::phosphatase/NN 2A/NN regulatory/JJ subunits/NNS affecting/VBG plant/NN innate/JJ immunity/NN ,/, energy/NN metabolism/NN ,/, and/CC flowering/NN 
725976_10_4_5_29_30::None::increasing/VBG preload/NN by/IN injecting/VBG 50/CD mul/NN of/IN 30/CD %/NN NaCl/NN demonstrated/VBD that/IN the/DT CHF/NN heart/NN had/VBD lower/JJR functional/JJ reserve/NN ;/: this/DT may/MD be/VB associated/VBN with/IN congestion/NN in/IN coronary/JJ microcirculation/NN ./. 
1373_1373_16_17_4_5::NEG_ACTION_RELATE::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
515_515_10_11_7_8::None::the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB 
388589_2_57_58_95_96::None::-/: old/JJ ,/, men/NNS and/CC women/NNS ,/, body/NN mass/NN index/NN gtgt/NN =/JJ 30/CD and/CC &/CC lt/NN ;/: 30/CD kg/NN //: m/NN (/( 2/CD )/) ,/, and/CC body/NN weight/NN gtgt/NN =/JJ 60/CD and/CC &/CC lt/NN ;/: 60/CD kg/NN ,/, were/VBD identified/VBN in/IN Medline/NNP ,/, Embase/NNP ,/, 
843828_6_56_57_25_26::None::1.08/CD )/) ,/, male/JJ gender/NN (/( 2.29/CD ,/, 1.57/CD -/: 3.35/CD )/) ,/, Hoehn/NNP &/CC amp/NNP ;/: Yahr/NNP (/( HY/NNP )/) stage/NN gtgt/NN =/JJ 2.5/CD (/( 1.54/CD ,/, 1.07/CD -/: 2.22/CD )/) ,/, UPDRS/NNP motor/NN score/NN gtgt/NN =/JJ 
742394_1_14_15_15_16::None::among/IN HIV/NN -/: positive/JJ patients/NNS compared/VBN with/IN HIV/NN 
854528_1_24_25_29_30::None::Kano/NNP ,/, northern/JJ Nigeria/NNP ,/, were/VBD screened/VBN by/IN amplification/NN and/CC sequencing/NN of/IN 
186521_6_52_55_43_44::None::with/IN known/JJ clinical/JJ variables/NNS ,/, such/JJ as/IN left/JJ ventricular/JJ ejection/NN fraction/NN and/CC brain/NN natriuretic/JJ peptide/NN ./. 
776_776_24_26_4_6::None::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN 
785586_0_2_3_15_16::medicine.disease.treatments::Pancreaticoduodenectomy/NN (/( PD/NN )/) is/VBZ one/CD of/IN the/DT most/RBS difficult/JJ and/CC dangerous/JJ operations/NNS in/IN general/JJ surgery/NN ./. 
923_923_4_5_7_8::POS_ACTION_BIND::measurements/NNS indicate/VBP that/IN profilin/NN binding/NN to/TO actin/NN weakens/VBZ the/DT affinity/NN 
596785_1_1_2_15_16::None::Since/IN December/NNP 2010/CD ,/, 15/CD pts/NNS were/VBD referred/VBN for/IN surgical/JJ ablation/NN due/JJ to/TO persistent/JJ AF/NN combined/VBN with/IN biatrial/JJ dilatation/NN 
2148_2148_4_5_56_57::POS_REG(0)_Assembly::report/VBP here/RB that/IN tropomyosin/NN ,/, which/WDT is/VBZ found/VBN in/IN the/DT rootlet/NN but/CC not/RB in/IN the/DT microvillus/JJ core/NN ,/, can/MD bind/VB to/TO and/CC saturate/VB the/DT actin/NN of/IN isolated/VBN cores/NNS ,/, and/CC can/MD cause/VB the/DT dissociation/NN of/IN up/RB to/TO 30/CD %/NN of/IN the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ calmodulin/NN ./. 
151_151_64_65_0_1::None::Aprotinin/NN inhibited/VBD platelet/NN aggregation/NN induced/VBN by/IN thrombin/NN (/( 0.25/CD U.ml-1/NN )/) with/IN IC50/NN 200/CD kIU.ml-1/NN ,/, and/CC inhibited/VBD the/DT rise/NN of/IN cytosolic/JJ free/JJ calcium/NN concentration/NN in/IN platelets/NNS stimulated/VBN by/IN thrombin/NN (/( 0.1/CD U.ml-1/NN )/) in/IN the/DT absence/NN and/CC in/IN the/DT presence/NN of/IN Ca2/NN +/CC 0.5/CD mmol.L-1/NN (/( IC50/NN 117/CD and/CC 50/CD kIU.ml-1/NN ,/, respectively/RB )/) ,/, but/CC had/VBD no/DT effect/NN on/IN the/DT amounts/NNS of/IN actin/NN and/CC myosin/NN heavy/JJ 
264611_0_7_8_14_15::None::conjunction/NN with/IN an/DT independent/JJ life/NN style/NN is/VBZ one/CD of/IN the/DT major/JJ goals/NNS of/IN rehabilitation/NN 
872597_0_2_3_13_14::None::Coyotes/NNS (/( Canis/NN latrans/NNS )/) are/VBP an/DT important/JJ species/NNS in/IN human/JJ -/: inhabited/VBN areas/NNS ./. 
429251_0_11_12_2_3::None::Accumulating/VBG evidence/NN suggests/VBZ that/IN dopamine/NN (/( DA/NN )/) is/VBZ involved/VBN in/IN altering/VBG neural/JJ activity/NN and/CC 
488879_8_11_12_12_13::None::treatment/NN of/IN unifocal/JJ autonomous/JJ adenomas/NNS ./. 
333054_4_24_25_36_37::None::,/, a/DT higher/JJR lignin/NN accumulation/NN may/MD occur/VB in/IN the/DT stem/NN ,/, thus/RB implying/VBG lower/JJR quality/NN biomass/NN for/IN bioethanol/NN production/NN 
1758_1758_22_23_19_20::None::,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ,/, and/CC TNF-induced/JJ 
938_938_14_15_9_11::None::cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ actin/NN cytoskeletal/JJ reorganization/NN ./. 
686_686_31_32_33_34::None::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
609976_0_7_8_0_1::medicine.disease.risk_factors::Hypertension/NN and/CC diabetes/NN as/IN risk/NN factors/NNS for/IN dementia/NN :/: A/DT secondary/JJ 
686_686_29_30_33_34::None::the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
566289_3_25_26_0_1::None::TS/NN should/MD be/VB considered/VBN in/IN any/DT immunocompromised/JJ patient/NN with/IN a/DT papular/JJ facial/JJ eruption/NN reminiscent/NN of/IN acne/NN vulgaris/NN and/CC with/IN keratotic/JJ spiny/NN papules/NNS as/IN a/DT distinctive/JJ feature/NN ./. 
349514_1_22_24_20_21::None::is/VBZ important/JJ to/TO investigate/VB whether/IN heart/NN rate/NN variability/NN biofeedback/NN (/( 
367_367_0_2_24_25::POS_ACTION_LOCALIZE::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC 
469705_8_33_34_7_8::medicine.symptom.symptom_of::to/TO determine/VB effective/JJ depression/NN screening/NN and/CC evidence/NN -/: based/VBN interventions/NNS for/IN depressive/JJ symptoms/NNS in/IN RA/NN patients/NNS in/IN this/DT socio/NN -/: cultural/JJ context/NN ,/, as/IN intervening/VBG in/IN depression/NN may/MD decrease/VB pain/NN perception/NN ./. 
363545_0_41_42_16_17::None::great/JJ interest/NN since/IN alterations/NNS in/IN monoaminergic/JJ transmission/NN are/VBP reported/VBN to/TO be/VB related/VBN to/TO neurodegenerative/JJ diseases/NNS such/JJ as/IN Parkinson/NNP whosewhat/NN and/CC Alzheimer/NN whosewhat/NN diseases/NNS and/CC psychiatric/JJ disorders/NNS such/JJ as/IN depression/NN and/CC anxiety/NN ,/, 
1286_1286_3_6_8_9::POS_ACTION_MEMBER::Specific/JJ antibodies/NNS to/TO myosin/JJ heavy/JJ chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, 
2222_2222_13_14_15_16::POS_ACTION_COLOCALIZE::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, 
315603_0_16_17_18_19::None::with/IN Chronic/JJ -/: Phase/NN Chronic/JJ Myeloid/JJ Leukemia/NN :/: A/DT 
813_813_8_9_23_24::POS_ACTION_INTERACT::NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN 
1087_1087_23_24_10_12::None::profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT actin/NN cytoskeleton/NN and/CC endocytic/JJ membrane/NN flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN 
256031_1_37_38_8_10::None::,/, a/DT validated/VBN computer/NN simulation/NN model/NN ,/, and/CC data/NNS from/IN the/DT ADDITION/NNP -/: Europe/NNP study/NN to/TO estimate/VB the/DT absolute/JJ risk/NN of/IN cardiovascular/JJ outcomes/NNS and/CC the/DT relative/JJ risk/NN reduction/NN associated/VBN with/IN screening/NN and/CC intensive/JJ treatment/NN ,/, screening/NN 
189641_0_13_14_4_5::None::the/DT face/NN of/IN urbanisation/NN ,/, surplus/NN energy/NN intake/NN ,/, sedentary/JJ habits/NNS and/CC obesity/NN ,/, type/NN 2/CD 
1167_1167_3_4_12_13::POS_ACTION_LOCALIZE::Recent/JJ evidence/NN that/IN profilin/NN inhibits/VBZ phospholipase/NN C/NN and/CC enhances/VBZ nucleotide/NN exchange/NN of/IN actin/NN has/VBZ led/VBN some/DT 
2000_2000_0_3_10_11::None::Vascular/JJ endothelial/JJ cadherin/NN (/( VE-cadherin/NN )/) clusters/NNS were/VBD co-localized/VBN with/IN beta-catenin/NN ,/, an/DT important/JJ 
846_846_16_17_12_13::POS_ACTION_BIND::the/DT polymerization/NN of/IN actin/NN from/IN A/DT :/: Tbeta4/NN ./. 
582775_5_119_120_2_3::None::Short/JJ -/: term/NN adverse/JJ events/NNS occurred/VBD in/IN 20.15/CD %/NN (/( 81/CD //: 402/CD )/) ,/, including/VBG rash/NN (/( 3.5/CD %/NN ;/: 14/CD //: 402/CD )/) ,/, pruritus/NN (/( 1.2/CD %/NN ;/: 5/CD //: 402/CD )/) ,/, nausea/NN (/( 2.2/CD %/NN ;/: 9/CD //: 402/CD )/) ,/, headache/NN (/( 0.7/CD %/NN ;/: 3/CD //: 402/CD )/) ,/, skin/NN allergies/NNS (/( 4.0/CD %/NN ;/: 16/CD //: 402/CD )/) ,/, fever/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, palpitations/NNS (/( 3.0/CD %/NN ;/: 12/CD //: 402/CD )/) ,/, dyspnea/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, chest/NN pain/NN (/( 0.2/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, abdominal/JJ pain/NN (/( 1.0/CD %/NN ;/: 4/CD //: 402/CD )/) ,/, hypertension/NN (/( 2.2/CD %/NN 
1081_1081_39_40_5_6::None::indicate/VBP that/IN even/RB profilins/NNS of/IN highly/RB distant/JJ evolutionary/JJ origin/NN can/MD functionally/RB substitute/VB for/IN each/DT other/JJ and/CC support/VBP the/DT hypothesis/NN that/IN in/IN animal/NN cells/NNS ,/, profilins/NNS are/VBP engaged/VBN in/IN regulating/VBG either/CC the/DT stability/NN or/CC the/DT kinetic/JJ properties/NNS of/IN actin/NN filaments/NNS ./. 
510001_0_3_4_0_2::None::Sex/NN chromosomes/NNS have/VBP evolved/VBN independently/RB in/IN phylogenetically/RB 
963135_4_22_23_24_25::None::1000/CD mg/NN //: day/NN for/IN calcium/NN ,/, 800/CD IU/NN 
508103_4_24_25_18_19::medicine.disease.risk_factors::STZ/NN -/: induced/VBN diabetic/JJ rats/NNS ,/, but/CC normalized/VBD myocardial/JJ steatosis/NN ,/, expression/NN of/IN 
833154_0_2_3_8_9::None::Management/NN of/IN angioedema/NN without/IN urticaria/NN in/IN the/DT emergency/NN department/NN ./. 
373923_0_109_110_102_105::None::diabetic/JJ patients/NNS without/IN coronary/JJ artery/NN disease/NN ,/, hypertension/NN or/CC other/JJ potential/JJ aetiologies/NNS ,/, as/IN 
398_398_20_21_10_11::None::of/IN PRT1/NN and/CC TIF35/NN were/VBD found/VBN to/TO be/VB responsible/JJ for/IN their/PRP$ binding/NN to/TO TIF34/NN ./. 
427077_12_8_9_4_5::None::-/: Klotho/NNP correlated/VBD positively/RB with/IN eGFR/NN and/CC serum/NN calcium/NN (/( Cas/NNS 
25979_5_17_18_15_16::None::on/IN ethnicity/NN (/( White/NNP ,/, Black/NNP ,/, Asian/NNP or/CC 
769684_3_8_9_6_7::medicine.disease.symptoms::completed/VBD the/DT Hospital/NNP Anxiety/NN and/CC Depression/NN Scale/NNP (/( HADS/NNS 
367_367_26_27_24_25::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
676724_2_18_19_26_27::None::achieved/VBN by/IN a/DT combination/NN of/IN streptozotocin/NN and/CC nicotinamide/NN (/( NA/NN -/: STZ/NN )/) ,/, whereas/IN 
1457_1457_34_35_34_35::None::predominantly/RB as/IN an/DT actin/NN monomer-binding/JJ protein/NN ;/: 
710948_4_13_14_31_32::None::immune/JJ reconstitution/NN inflammatory/JJ syndrome/NN and/CC relapses/NNS ,/, or/CC renewed/VBN exacerbation/NN ,/, of/IN her/PRP$ MS/NN She/PRP responded/VBD well/RB after/IN beginning/VBG treatment/NN with/IN fingolimod/NN ,/, once/RB the/DT 
367_367_5_7_28_30::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
1017_1017_4_5_9_10::None::in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP 
966_966_9_10_11_12::None::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN were/VBD seen/VBN in/IN 
1771_1771_19_20_15_16::None::I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
170773_3_0_1_38_39::None::We/PRP discuss/VBP the/DT challenges/NNS currently/RB faced/VBN in/IN unraveling/NN genetic/JJ factors/NNS that/WDT predispose/VBP to/TO sudden/JJ cardiac/JJ death/NN in/IN the/DT setting/NN of/IN sequela/NN of/IN coronary/JJ artery/NN disease/NN and/CC present/VB the/DT genome/NN -/: wide/JJ association/NN studies/NNS conducted/VBN in/IN recent/JJ years/NNS on/IN electrocardiographic/JJ parameters/NNS ,/, highlighting/VBG 
996_996_31_34_29_30::POS_ACTION_MEMBER::the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
593_593_5_6_19_20::POS_ACTION_HUMANMADE::show/VBP that/IN the/DT Arp2/NN subunit/NN of/IN the/DT complex/NN can/MD be/VB chemically/RB cross-linked/VBN to/TO the/DT actin-binding/JJ site/NN of/IN profilin/NN ./. 
980_980_12_13_5_6::None::stable/JJ expression/NN of/IN V12Ras/NNS into/IN keratinocytes/NNS promotes/VBZ the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC 
1992_1992_19_20_10_11::None::reports/NNS that/IN intact/JJ talin/NN induces/VBZ cross-linking/NN as/RB well/RB as/IN filament/NN shortening/VBG on/IN actin/NN networks/NNS ./. 
2107_2107_27_28_9_10::None::proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
543881_0_9_11_0_2::people.cause_of_death.includes_causes_of_death::Rheumatoid/JJ arthritis/NN (/( RA/NN )/) is/VBZ a/DT chronic/JJ autoimmune/JJ inflammatory/JJ disease/NN of/IN unknown/JJ aetiology/NN 
22_22_54_55_0_1::None::ActA/NN appears/VBZ to/TO control/VB at/IN least/JJS four/CD functions/NNS that/WDT collectively/RB lead/VBP to/TO actin-based/JJ motility/NN :/: (/( 1/LS )/) initiation/NN of/IN actin/NN polymerization/NN ,/, (/( 2/LS )/) polarization/NN of/IN ActA/NN function/NN ,/, (/( 3/LS )/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT motile/JJ force/NN and/CC (/( 4/LS )/) acceleration/NN of/IN movement/NN mediated/VBN by/IN the/DT host/NN protein/NN profilin/NN ./. 
556_556_24_25_12_13::None::,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ protein/NN based/VBN on/IN the/DT lack/NN of/IN reactivity/NN of/IN antigravin/NN with/IN these/DT polypeptides/NNS 
307348_1_22_23_43_44::None::wide/JJ spectrum/NN of/IN symptoms/NNS and/CC disabilities/NNS ,/, such/JJ as/IN cognitive/JJ deficits/NNS ,/, mood/NN or/CC anxiety/NN disorders/NNS ,/, motor/NN impairments/NNS ,/, chronic/JJ pain/NN ,/, and/CC epilepsy/NN ./. 
906557_3_44_45_52_53::medicine.disease.symptoms::,/, cancer/NN ,/, diabetes/NN ,/, neurodegenerative/JJ diseases/NNS ,/, vitiligo/NN and/CC virus/NN infections/NNS ./. 
540781_2_20_21_6_7::None::HIV/NN -/: 1/CD drug/NN resistance/NN is/VBZ therefore/RB of/IN great/JJ importance/NN to/TO evaluate/VB the/DT current/JJ sensitivity/NN of/IN antiretroviral/JJ agents/NNS and/CC is/VBZ urgently/RB 
996_996_31_34_27_28::POS_ACTION_MEMBER::coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
289843_2_7_9_3_4::None::Half/NN of/IN reported/VBN cases/NNS are/VBP associated/VBN with/IN systemic/JJ diseases/NNS such/JJ as/IN arthritis/NN 
1434_1434_72_73_14_15::POS_ACTION_MEMBER::H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN 
1633_1633_26_27_15_16::None::;/: four/CD histone/NN H2a/NN genes/NNS ,/, two/CD of/IN which/WDT are/VBP identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC 
871_871_27_28_21_25::None::calponin/NN and/CC the/DT smooth/JJ muscle/NN myosin/NN heavy-chain/JJ isoforms/NNS of/IN SM1/NN and/CC SM2/NN )/) 
119285_0_7_9_25_26::None::simultaneous/JJ generation/NN of/IN hydroxyl/NN radical/NN (/( */SYM OH/NN )/) and/CC sulfate/NN radical/NN (/( SO4/NN */SYM -/: )/) by/IN the/DT reaction/NN of/IN ozone/NN (/( O3/NN )/) 
456531_7_14_15_31_32::medicine.medical_treatment.used_to_treat::self/NN -/: care/NN activities/NNS in/IN insulin/NN injection/NN ,/, particularly/RB among/IN Japanese/JJ patients/NNS &/CC lt/NN ;/: 65/CD years/NNS with/IN type/NN 2/CD diabetes/NN ./. 
218394_4_1_2_13_14::None::To/TO determine/VB the/DT effect/NN of/IN prehospital/JJ thrombolysis/NN for/IN acute/JJ ischemic/JJ stroke/NN administered/VBN in/IN specialized/VBN ambulances/NNS on/IN delay/NN 
702752_2_2_3_23_24::None::Here/RB we/PRP investigated/VBD the/DT role/NN of/IN piceatannol/NN ,/, a/DT well/RB -/: known/JJ Syk/NN inhibitor/NN ,/, in/IN T/NN cell/NN activation/NN ,/, proliferation/NN ,/, and/CC differentiation/NN using/VBG isolated/VBN murine/JJ 
695_695_9_10_15_17::POS_ACTION_SUPPRESS::concentrations/NNS of/IN Acanthamoeba/NN profilin/NN inhibit/VBP the/DT elongation/NN rate/NN of/IN muscle/NN actin/NN filaments/NNS measured/VBN directly/RB 
686_686_13_14_23_24::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT 
345363_0_3_4_0_1::None::Factor/NN structure/NN and/CC psychometric/JJ properties/NNS of/IN the/DT 
805_805_10_11_0_4::None::Insulin-like/JJ growth/NN factor/NN I/PRP stimulates/VBZ cardiac/JJ myosin/NN heavy/JJ chain/NN and/CC actin/NN synthesis/NN in/IN the/DT 
334920_0_0_1_13_14::None::Studies/NNS of/IN the/DT retroviruses/NNS have/VBP focused/VBN on/IN the/DT specific/JJ interaction/NN of/IN the/DT nucleocapsid/JJ protein/NN with/IN a/DT packaging/NN 
429251_0_9_10_25_26::None::DA/NN )/) is/VBZ involved/VBN in/IN altering/VBG neural/JJ activity/NN and/CC gene/NN expression/NN in/IN a/DT zebra/NN finch/NN cortical/JJ -/: basal/JJ ganglia/NN circuit/NN specialized/VBN for/IN singing/NN 
667084_2_0_1_15_16::None::It/PRP is/VBZ also/RB associated/VBN with/IN an/DT increased/VBN prevalence/NN of/IN mental/JJ health/NN disorders/NNS including/VBG anxiety/NN ,/, depression/NN ,/, and/CC suicidal/JJ 
95871_3_27_28_25_26::medicine.drug.active_moieties::,/, despite/IN elevated/JJ erythropoietin/NN (/( EPO/NN )/) levels/NNS ./. 
1946_1946_37_38_27_28::None::identical/JJ to/TO chick/NN cofilin/NN and/CC 66/CD %/NN identical/JJ to/TO chick/NN actin-depolymerizing/NN factor/NN (/( ADF/NN )/) ,/, two/CD 
430599_3_3_4_20_21::None::proteinuria/NN ,/, diminished/VBD GFR/NN )/) are/VBP more/RBR pronounced/JJ in/IN group/NN SP/NN than/IN normotensive/JJ group/NN WKY/NN and/CC hypertensive/JJ group/NN SC/NN without/IN mesangial/JJ cell/NN injury/NN ./. 
441793_0_7_8_23_25::None::determine/VB if/IN low/JJ serum/NN 25/CD -/: hydroxyvitamin/NN D/NN (/( 25/CD [/( OH/NN ]/) D/NN )/) is/VBZ associated/VBN with/IN incident/NN heart/NN failure/NN (/( HF/NN )/) 
326684_5_3_4_17_19::None::Miltefosine/NNP is/VBZ equally/RB efficacious/JJ to/TO and/CC may/MD be/VB as/IN tolerable/JJ as/IN liposomal/JJ amphotericin/NN B/NN The/DT most/RBS common/JJ adverse/JJ effects/NNS of/IN miltefosine/NN are/VBP 
12271_2_4_5_60_61::None::this/DT study/NN ,/, synthetic/JJ heptapeptides/NNS (/( Lys/SYM -/: Trp/SYM -/: Tyr/SYM -/: Lys/SYM -/: Asp/NN -/: Gly/SYM -/: Asp/NN )/) coupled/VBN to/TO a/DT biotin/NN molecule/NN through/IN the/DT N/NN -/: terminal/JJ amino/NN group/NN and/CC e/SYM -/: amino/NN group/NN of/IN N/NN -/: terminus/NN Lys/NNP ,/, (/( Btn/NNP )/) KP6/NN and/CC K/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, and/CC heir/NN their/PRP$ biotinylated/VBN peptides/NNS substituted/VBN with/IN 
14211_8_27_28_32_33::medicine.medical_treatment.used_to_treat::the/DT outcome/NN of/IN fludarabine/NN -/: based/VBN chemotherapy/NN in/IN CLL/NN patients/NNS ./. 
322970_7_1_3_62_63::None::Multilevel/JJ logistic/JJ regression/NN models/NNS controlled/VBN for/IN individual/JJ characteristics/NNS and/CC testedfor/NN interaction/NN between/IN period/NN and/CC SES/NN In/IN both/DT periods/NNS ,/, high/JJ SES/NN respondents/NNS (/( in/IN all/DT indicators/NNS )/) had/VBD lower/JJR current/JJ smoking/NN levels/NNS and/CC higher/JJR cessation/NN ratios/NNS than/IN those/DT of/IN middle/JJ or/CC low/JJ SES/NNP Inequalities/NNS in/IN current/JJ smoking/NN increased/VBD significantly/RB in/IN poorly/RB educated/VBN adults/NNS of/IN 45/CD -/: 64/CD years/NNS of/IN age/NN (/( Odds/NNS Ratio/NN (/( OR/NN )/) 
275947_1_20_21_16_18::medicine.risk_factor.diseases::alphanu/NN integrin/NN in/IN bladder/NN cancer/NN decreases/VBZ the/DT infection/NN efficiency/NN of/IN adenovirus/NN 
159983_7_18_19_7_8::None::affinity/NN of/IN methyl/NN eugenol/NN for/IN the/DT resting/VBG and/CC inactivated/VBN states/NNS of/IN the/DT channel/NN also/RB demonstrated/VBD that/IN methyl/NN eugenol/NN 
872_872_6_7_8_9::None::the/DT role/NN of/IN MSH2/NN ,/, MSH3/NN ,/, and/CC MSH6/NN 
411693_2_26_28_10_11::None::value/NN of/IN maximum/NN standardized/JJ uptake/NN value/NN (/( SUVmax/NN )/) determined/VBN by/IN pancreatic/JJ ductal/JJ cancers/NNS is/VBZ also/RB applicable/JJ for/IN other/JJ pancreatic/JJ tumors/NNS ./. 
2146_2146_14_15_11_13::None::both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
816806_0_11_12_26_27::None::MDR/NN )/) has/VBZ fueled/VBN considerable/JJ interest/NN in/IN the/DT development/NN of/IN novel/JJ synthetic/JJ antitumor/NN agents/NNS with/IN cytotoxicity/NN against/IN cancer/NN cell/NN lines/NNS with/IN MDR/NN 
800292_15_29_30_33_35::None::and/CC open/JJ surgical/JJ access/NN could/MD influence/VB clinical/JJ decision/NN making/NN ./. 
1647_1647_17_18_13_15::None::thymosin/NN beta4/NN and/CC profilin/NN II/CD to/TO inhibit/VB actin/NN nucleation/NN and/CC restores/VBZ 
1025_1025_14_19_0_1::POS_ACTION_SIMILAR::Myo2p/NN shows/VBZ homology/NN to/TO the/DT head/NN domains/NNS and/CC the/DT coiledcoil/NN tail/NN of/IN the/DT conventional/JJ type/NN II/CD myosin/NN heavy/JJ chain/NN and/CC carries/VBZ putative/JJ 
776_776_28_29_29_30::POS_ACTION_MEMBER::protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
590437_1_4_5_29_30::None::-/: N/NN -/: methyl/NN -/: gamma/NN -/: [/( 4/LS -/: (/( trifluoromethyl/NN )/) phenoxy/NN ]/) benzenepropanamine/NN hydrochloride/NN ;/: FLX/NNP )/) are/VBP frequently/RB used/VBN to/TO treat/VB depression/NN in/IN PD/NN patients/NNS ./. 
1474_1474_21_24_29_31::None::of/IN genes/NNS encoding/VBG myosin/NN heavy/JJ chain/NN (/( MHC/NN )/) isoforms/NNS and/CC alpha-skeletal/JJ actin/NN were/VBD analysed/VBN in/IN 
397285_3_0_1_11_12::None::IL/NN -/: 10/CD ,/, an/DT anti/JJ -/: inflammatory/JJ cytokine/NN associated/VBN with/IN tumour/NN malignancy/NN ,/, causes/VBZ 
878537_3_10_11_24_25::None::calculated/VBN in/IN 2179/CD patients/NNS who/WP underwent/VBD a/DT first/JJ ablation/NN procedure/NN for/IN AF/NN enrolled/VBN in/IN the/DT Intermountain/NNP Heart/NNP Collaborative/NNP Study/NNP ./. 
32435_3_23_24_29_30::None::and/CC fatigue/NN in/IN addition/NN to/TO measures/NNS of/IN depression/NN ,/, anxiety/NN ,/, and/CC posttraumatic/JJ 
567_567_10_11_20_21::None::acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
849947_0_7_8_0_1::None::Congenital/JJ peritoneopericardial/JJ diaphragmatic/JJ hernia/NN in/IN a/DT terrier/NN dog/NN ./. 
1486_1486_24_25_60_61::POS_ACTION_STIMULATE::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
721_721_13_14_9_10::POS_ACTION_LOCALIZE::interacting/VBG proteins/NNS recruiting/VBG TFIIIC/NN to/TO DNA/NN were/VBD PRP21/NN and/CC PRP9/NN or/CC 
1439_1439_24_25_16_17::None::for/IN association/NN of/IN TNFR1/NN and/CC other/JJ death/NN domain-containing/JJ proteins/NNS such/JJ as/IN FADD/NN and/CC RIP/NN ./. 
503061_9_16_17_7_8::None::study/NN shows/VBZ that/IN NXT/NNP can/MD inhibit/VB the/DT development/NN of/IN diabetic/JJ retinopathy/NN and/CC suggests/VBZ a/DT new/JJ potential/JJ 
16_16_28_29_32_33::POS_ACTION_DISRUPT::expected/VBN ,/, since/IN beta-catenin/NN binding/NN disrupts/VBZ the/DT alpha-catenin/NN dimer/NN ./. 
725976_10_10_11_18_19::None::of/IN 30/CD %/NN NaCl/NN demonstrated/VBD that/IN the/DT CHF/NN heart/NN had/VBD lower/JJR functional/JJ reserve/NN ;/: this/DT 
556_556_10_11_12_13::None::nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ 
93_93_6_7_54_55::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
322_322_19_20_19_20::None::the/DT process/NN of/IN actin/NN disassembly/NN in/IN degenerating/VBG 
865_865_11_14_17_18::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 
156299_3_28_30_12_13::medicine.disease.treatments::two/CD or/CC three/CD radiofrequency/NN (/( RF/NN )/) electrodes/NNS and/CC a/DT multiple/JJ -/: electrode/NN switching/NN system/NN was/VBD performed/VBN for/IN malignant/JJ lung/NN tumors/NNS with/IN a/DT maximum/JJ 
178597_0_13_14_30_31::None::based/VBN on/IN the/DT infusion/NN of/IN high/JJ numbers/NNS of/IN T/NN -/: cell/NN -/: depleted/VBN hematopoietic/JJ progenitor/NN cells/NNS and/CC no/DT post/NN -/: transplant/NN immunosuppression/NN controls/VBZ graft/NN 
288_288_10_12_13_14::None::observing/VBG proteolysis/NN of/IN actin-binding/JJ protein/NN and/CC talin/NN ,/, two/CD known/JJ 
1716_1716_17_18_4_5::None::results/NNS demonstrate/VBP that/IN cofilin/NN plays/VBZ a/DT crucial/JJ role/NN in/FW vivo/FW in/IN rapid/JJ remodeling/NN of/IN the/DT cortical/JJ actin/NN meshwork/NN into/IN bundles/NNS 
855088_0_16_17_6_7::None::the/DT Arndt/NNP endobronchial/JJ blocker/NN has/VBZ not/RB gained/VBN widespread/JJ acceptance/NN during/IN video/NN -/: assisted/VBN thoracoscopic/JJ surgery/NN (/( VATS/NNS 
169857_11_12_13_18_19::None::,/, 86.7/CD %/NN experienced/VBD a/DT significant/JJ AHI/NNP reduction/NN to/TO moderate/JJ or/CC mild/JJ disease/NN 
173493_0_13_14_19_20::None::actuated/VBN dry/JJ -/: powder/NN inhaler/NN designed/VBN to/TO deliver/VB similar/JJ combinations/NNS of/IN budesonide/NN and/CC 
2064_2064_8_9_6_7::None::the/DT down-regulation/NN of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN 
226600_0_1_2_8_9::medicine.drug_ingredient.active_moiety_of_drug::Although/IN fluoridated/JJ toothpastes/NNS are/VBP among/IN the/DT most/RBS accessible/JJ fluoride/NN sources/NNS for/IN caries/NNS 
1977_1977_22_23_16_17::None::a/DT region/NN in/IN alpha-catenin/NN required/VBN for/IN molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
1069_1069_29_30_26_27::POS_ACTION_BIND::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT 
125255_5_32_34_20_21::medicine.disease.risk_factors::,/, hypertrophy/NN ,/, diabetes/NN ,/, hypercholesterolemia/NN ,/, ischemia/NN ,/, post/NN -/: myocardial/JJ infarction/NN remodeling/NN or/CC heart/NN failure/NN ,/, and/CC post/NN 
567_567_7_9_20_21::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
710948_4_38_39_8_9::None::disease/NN ,/, the/DT patient/NN developed/VBD immune/JJ reconstitution/NN inflammatory/JJ syndrome/NN and/CC relapses/NNS ,/, or/CC renewed/VBN exacerbation/NN ,/, of/IN her/PRP$ MS/NN She/PRP responded/VBD well/RB after/IN beginning/VBG treatment/NN with/IN fingolimod/NN ,/, once/RB the/DT PML/NN had/VBD become/VBN stabilised/VBN ./. 
604261_0_33_34_41_44::medicine.medical_treatment.used_to_treat::glutamate/NN release/NN inhibitor/NN riluzole/NN ,/, a/DT drug/NN currently/RB used/VBN to/TO treat/VB amyotrophic/JJ lateral/JJ sclerosis/NN ,/, can/MD induce/VB 
112_112_18_19_14_16::POS_ACTION_MEMBER::a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN localized/JJ to/TO the/DT 
414579_11_42_44_22_23::None::These/DT differences/NNS in/IN arterial/JJ pressures/NNS and/CC use/NN of/IN norepinephrine/NN between/IN the/DT groups/NNS were/VBD not/RB found/VBN to/TO be/VB significant/JJ when/WRB entered/VBN in/IN the/DT binary/JJ logistic/JJ regression/NN model/NN ./. 
799750_8_4_5_13_15::None::borderline/JJ and/CC malignant/JJ phyllode/NN tumors/NNS have/VBP different/JJ distant/JJ metastasis/NN risk/NN ,/, different/JJ primary/JJ tumor/NN size/NN and/CC different/JJ 
247832_2_35_36_6_7::medicine.disease.symptoms::studies/NNS suggest/VBP that/IN inflammatory/JJ processes/NNS have/VBP emerged/VBN critical/JJ in/IN the/DT pathogenesis/NN of/IN CVD/NNP in/IN OSAS/NNP A/NNP range/NN of/IN circulating/VBG inflammatory/JJ molecules/NNS has/VBZ been/VBN identified/VBN and/CC measured/VBN ,/, with/IN a/DT view/NN to/TO assess/VB inflammation/NN and/CC predict/VBP vascular/JJ 
1254_1254_11_12_9_11::None::localization/NN of/IN the/DT actin-binding/JJ protein/NN cofilin/NN in/IN stimulated/VBN human/JJ 
750_750_7_8_21_22::None::integrin/NN with/IN the/DT actin/NN cytoskeleton/NN is/VBZ consistent/JJ with/IN and/CC might/MD be/VB mediated/VBN by/IN its/PRP$ enhanced/VBN binding/NN to/TO talin/NN ./. 
202727_3_10_11_2_3::None::Exclusive/JJ breast/NN feeding/NN reduces/VBZ infant/NN mortality/NN due/JJ to/TO common/JJ childhood/NN illnesses/NNS such/JJ as/IN diarrhoea/NN 
1122_1122_23_24_8_9::POS_ACTION_BIND::could/MD regulate/VB the/DT actin/NN binding/NN and/CC bundling/VBG properties/NNS of/IN fimbrin/NN ,/, or/CC it/PRP could/MD regulate/VB the/DT interaction/NN of/IN fimbrin/NN with/IN other/JJ proteins/NNS 
350981_0_29_30_5_6::None::Anxiety/NN and/CC Affective/JJ Spectrum/NN Disorder/NN of/IN Mind/NNP and/CC Body/NNP -/: The/NNP ALPIM/NNP (/( Anxiety/NN -/: Laxity/NN -/: Pain/NN -/: Immune/JJ -/: Mood/NN )/) Syndrome/NN :/: A/DT Preliminary/JJ Report/NNP ./. 
1617_1617_2_3_21_22::POS_REG(0)_ASSEMBLE::The/DT protein/NN profilin/NN binds/VBZ to/TO both/DT actin/NN and/CC the/DT head/NN groups/NNS of/IN poly/NN )/) phosphoinositide/NN )/) s/NNS and/CC may/MD regulate/VB both/DT actin/NN assembly/NN and/CC the/DT 
246_246_11_13_3_4::None::A/DT 2.2-kb/JJ truncated/VBN NRP1/NN cDNA/NN was/VBD cloned/VBN that/IN encodes/VBZ a/DT 644-aa/JJ soluble/JJ NRP1/NN (/( sNRP1/NN )/) 
874_874_10_11_7_8::POS_ACTION_COLOCALIZE::demonstrate/VBP that/IN histone/NN H3/NN and/CC histone/NN H4/NN synthesized/VBN in/IN young/JJ 
1296_1296_9_10_3_4::POS_REG(+)_MODIFY::Stimulus-dependent/JJ disorganization/NN of/IN actin/NN filaments/NNS induced/VBN by/IN overexpression/NN of/IN cofilin/NN in/IN C2/NN myoblasts/NNS 
242314_4_7_9_77_78::None::ORS/NN )/) and/CC zinc/NN sulphate/NN dispersible/JJ tablets/NNS for/IN diarrhea/NN were/VBD available/JJ in/IN all/DT HC/NNP IIs/NNP and/CC IIIs/NNS and/CC in/IN only/RB 60/CD %/NN of/IN HC/NNP IVs/NNP Procaine/NNP benzyl/NN penicillin/NN injection/NN powder/NN for/IN treatment/NN of/IN sepsis/NN was/VBD available/JJ in/IN the/DT majority/NN of/IN all/DT HCs/NNS with/IN :/: 100/CD %/NN of/IN HC/NN of/IN IVs/NNS ,/, 83/CD %/NN of/IN HC/NN IIIs/NNS and/CC 82/CD %/NN of/IN HC/NNP IIs/NNP Medicines/NNP for/IN pneumonia/NN were/VBD limited/VBN across/IN all/PDT the/DT HCs/NNS with/IN :/: Amoxicillin/NNP dispersible/JJ tablets/NNS in/IN 
260299_3_5_6_26_27::None::we/PRP report/VBP the/DT case/NN of/IN a/DT 49/CD -/: year/NN -/: old/JJ ,/, chronic/JJ smoker/NN ,/, who/WP incidentally/RB had/VBD a/DT laryngeal/JJ growth/NN detected/VBN during/IN flexible/JJ bronchoscopy/NN examination/NN for/IN evaluation/NN 
259277_3_22_23_17_18::medicine.disease.risk_factors::,/, hypertension/NN and/CC diabetes/NN in/IN patients/NNS with/IN lacunar/NN stroke/NN ,/, and/CC vascular/JJ 
619_619_26_29_43_44::None::the/DT generation/NN of/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN and/CC the/DT induction/NN of/IN S/NN phase/NN ,/, coincident/JJ with/IN the/DT loss/NN of/IN the/DT p27/NN cyclin-dependent/JJ kinase/NN inhibitor/NN 
118_118_11_12_4_5::POS_ACTION_COPRECIPITATE::of/IN beta-catenin/NN or/CC E-cadherin/NN immunoprecipitates/NNS from/IN BMMC/NN lysate/NN revealed/VBD that/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
501715_7_24_26_17_20::medicine.risk_factor.diseases::in/IN patients/NNS with/IN chronic/JJ kidney/NN disease/NN and/CC in/IN those/DT with/IN diabetes/NN mellitus/NN ./. 
1061_1061_19_20_36_37::None::;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
1055_1055_0_1_22_23::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC E2F/NN 
803668_11_0_1_21_22::None::Individuals/NNS living/VBG with/IN MS/NN who/WP report/VBP high/JJ levels/NNS of/IN chronic/JJ pain/NN and/CC depressive/JJ symptoms/NNS may/MD benefit/VB from/IN treatment/NN approaches/NNS that/WDT can/MD address/VB sleep/NN ,/, fatigue/NN 
381889_8_34_35_18_19::None::,/, self/NN reported/VBD health/NN status/NN (/( Short/JJ Form/NN -/: 36/CD Health/NNP Survey/NN )/) and/CC anxiety/NN //: depression/NN (/( Hospital/NN Anxiety/NN and/CC Depression/NN Scale/NNP 
367_367_24_25_5_7::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC 
237202_1_23_24_42_43::None::oral/JJ triple/JJ regimen/NN administered/VBN to/TO 6/CD liver/NN transplant/NN recipients/NNS with/IN recurrent/JJ hepatitis/NN C/NN ,/, one/CD with/IN GT/NN 1a/NN and/CC 5/CD with/IN GT/NN 1b/NN ./. 
565841_0_3_5_9_10::None::Several/JJ clinical/JJ and/CC epidemiological/JJ studies/NNS demonstrated/VBD an/DT association/NN between/IN endometriosis/NN and/CC infertility/NN ./. 
128715_9_28_29_30_31::None::-/: 10/CD &/CC amp/NN ;/: TGF/NN -/: beta/NN production/NN 
202451_1_11_12_9_10::medicine.drug.active_moieties::of/IN the/DT host/NN N2/NN ,/, N5/NN -/: bis/NN (/( 
157_157_1_2_14_15::None::Archaeal/NNP histones/NNS are/VBP most/RBS similar/JJ to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT 
567_567_20_21_14_15::None::)/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
512613_1_22_23_1_2::None::Neuroticism/NNP correlated/VBD strongly/RB with/IN the/DT general/JJ distress/NN //: negative/JJ affectivity/JJ symptoms/NNS (/( depressed/JJ mood/NN ,/, anxious/JJ mood/NN ,/, worry/NN )/) that/WDT are/VBP central/JJ to/TO these/DT disorders/NNS 
255381_4_0_2_8_9::None::The/DT National/NNP Cancer/NNP registry/NN was/VBD searched/VBN for/IN esophageal/NN cancers/NNS from/IN 1986/CD to/TO 
1486_1486_24_25_41_44::None::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
93_93_22_23_28_29::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
1553_1553_38_39_32_33::POS_ACTION_COLOCALIZE::daltons/NNS )/) ,/, fimbrin/NN (/( 68,000/CD daltons/NNS )/) ,/, actin/NN (/( 43,000/CD daltons/NNS 
547287_4_9_10_15_16::medicine.disease.risk_factors::types/NNS of/IN gynecological/JJ cancer/NN was/VBD 39.0/CD %/NN higher/JJR in/IN colorectal/JJ cancer/NN patients/NNS than/IN 
900999_12_25_26_17_18::medicine.disease.symptoms::characters/NNS of/IN smaller/JJR tumor/NN size/NN and/CC normal/JJ serum/NN BUN/NN level/NN at/IN diagnosis/NN ./. 
1168_1168_26_27_29_30::POS_ACTION_LOCALIZE::member/NN of/IN the/DT fimbrin/plastin/NN family/NN of/IN actin/NN filament/NN bundling/VBG or/CC 
1075_1075_8_9_11_12::None::as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN 
1850_1850_0_1_10_11::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN 
242314_4_135_136_66_67::None::of/IN HC/NNP IIs/NNP Medicines/NNP for/IN pneumonia/NN were/VBD limited/VBN across/IN all/PDT the/DT HCs/NNS with/IN :/: Amoxicillin/NNP dispersible/JJ tablets/NNS in/IN only/RB 30/CD %/NN of/IN the/DT HC/NNP IIs/NNPS and/CC 40/CD %/NN of/IN the/DT HC/NN IVs/NNS The/DT most/RBS uncommon/JJ were/VBD child/NN -/: friendly/JJ priority/NN medicines/NNS for/IN malaria/NN with/IN :/: Artesunate/NN injection/NN in/IN only/RB 6/CD %/NN of/IN HC/NNP IIs/NNP ,/, 14/CD %/NN of/IN HC/NN IIIs/NNS and/CC 20/CD %/NN of/IN HC/NN IVs/NNS ;/: Artemether/NNP lumefantrine/NN dispersible/JJ tablets/NNS and/CC rectal/JJ artesunate/NN were/VBD missing/VBG 
13078_0_18_19_17_18::None::childhood/NN acute/JJ lymphoblastic/JJ leukemia/NN patients/NNS :/: IL/NN -/: 
1850_1850_10_11_0_1::POS_ACTION_BIND::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN 
710191_0_1_2_24_26::medicine.medical_treatment.used_to_treat::Prolonged/JJ radiation/NN time/NN and/CC low/JJ nadir/NN hemoglobin/NN during/IN postoperative/JJ concurrent/JJ chemoradiotherapy/NN are/VBP both/DT poor/JJ prognostic/JJ factors/NNS with/IN synergistic/JJ effect/NN on/IN locally/RB advanced/JJ head/NN and/CC neck/NN cancer/NN patients/NNS ./. 
161979_1_52_53_34_35::people.cause_of_death.includes_causes_of_death::genomic/JJ changes/NNS in/IN glioblastoma/NN ,/, new/JJ correlations/NNS have/VBP been/VBN discovered/VBN between/IN alterations/NNS at/IN the/DT genomics/NNS level/NN and/CC radiological/JJ imaging/NN features/NNS in/IN cancer/NN patients/NNS ./. 
2198_2198_20_21_5_6::None::-/: or/CC islet-type/JJ glucokinase/NN was/VBD transiently/RB expressed/VBN in/IN COS-7/NN cells/NNS ,/, the/DT expressed/VBN glucokinase/NN was/VBD also/RB co-localized/VBN with/IN actin/NN filaments/NNS in/IN the/DT 
364545_7_15_16_10_11::None::MS/NN type/NN 1/CD fimbriae/NN in/IN the/DT induction/NN of/IN cytokine/NN expression/NN and/CC secretion/NN 
769586_0_1_2_0_1::medicine.disease.symptoms::Subclinical/JJ atherosclerosis/NN has/VBZ been/VBN recently/RB 
618_618_3_4_1_2::None::How/WRB profilin/NN promotes/VBZ actin/NN filament/NN assembly/NN in/IN 
2107_2107_15_16_5_7::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ 
2076_2076_8_9_16_18::None::cerevisiae/FW gene/NN (/( COF1/NN )/) encoding/VBG a/DT low-M/NN (/( r/NN )/) actin-binding/JJ protein/NN of/IN 143/CD amino/NN 
259511_0_15_16_6_7::None::year/NN -/: old/JJ male/NN with/IN past/JJ medical/JJ history/NN of/IN benign/JJ prostatic/JJ hyperplasia/NN presented/VBN to/TO the/DT emergency/NN 
296387_0_11_12_8_9::None::,/, an/DT increasing/VBG number/NN of/IN acute/JJ gastroenteritis/NN cases/NNS were/VBD reported/VBN 
1534_1534_26_29_16_17::None::and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( 
1916_1916_4_5_19_20::POS_ACTION_BIND::our/PRP$ knowledge/NN ,/, AF-6/NN is/VBZ the/DT only/JJ integral/JJ component/NN in/IN cell-cell/JJ junctions/NNS discovered/VBN thus/RB far/RB that/IN interacts/VBZ with/IN profilin/NN and/CC thus/RB could/MD 
332464_0_4_5_0_1::None::Low/JJ -/: density/NN lipoprotein/NN cholesterol/NN (/( LDL/NN -/: 
259065_5_35_36_2_3::None::Correlations/NNS between/IN FFI/NNP -/: BPD/NN and/CC relevant/JJ measures/NNS of/IN psychiatric/JJ symptomatology/NN and/CC etiology/NN (/( eg/FW ,/, childhood/NN abuse/NN ,/, drug/NN use/NN ,/, depression/NN ,/, and/CC personality/NN disorders/NNS )/) were/VBD also/RB examined/VBN and/CC compared/VBN to/TO those/DT generated/VBN using/VBG explicit/JJ measures/NNS 
1061_1061_24_25_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
398_398_20_21_8_9::None::acids/NNS )/) of/IN PRT1/NN and/CC TIF35/NN were/VBD found/VBN to/TO be/VB responsible/JJ for/IN their/PRP$ binding/NN to/TO TIF34/NN ./. 
93_93_57_58_11_12::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
703552_5_26_27_33_34::None::family/NN members/NNS in/IN retinal/JJ layers/NNS ,/, using/VBG an/DT in/FW vivo/FW model/NN of/IN type/NN 1/CD 
377_377_12_13_10_11::POS_ACTION_COLOCALIZE::bands/NNS corresponding/VBG to/TO actin/NN and/CC fimbrin/NN and/CC several/JJ proteins/NNS 
473269_0_8_10_20_24::None::)/) is/VBZ a/DT neurodegenerative/JJ disorder/NN characterized/VBN by/IN loss/NN of/IN the/DT pigmented/JJ dopaminergic/JJ neurons/NNS in/IN the/DT substantia/JJ nigra/NN pars/NNS compacta/VBP with/IN subsequent/JJ striatal/JJ 
162957_0_38_39_43_44::None::atopic/JJ dermatitis/NN (/( AD/NN )/) elicited/VBN by/IN epicutaneous/JJ sensitization/NN with/IN ovalbumin/NN (/( 
263791_3_38_39_8_9::None::early/JJ and/CC aggressive/JJ control/NN of/IN inflammation/NN in/IN RA/NN patients/NNS ,/, particularly/RB those/DT with/IN seropositivity/NN ,/, increased/VBD inflammatory/JJ markers/NNS ,/, long/RB disease/NN duration/NN (/( &/CC gt/NN ;/: 10/CD years/NNS )/) ,/, and/CC //: or/CC extra/JJ -/: articular/JJ manifestations/NNS 
1498_1498_15_16_4_5::None::head/NN domain/NN of/IN talin/NN thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD 
710476_3_2_3_0_1::None::Participants/NNS completed/VBD measures/NNS of/IN global/JJ mental/JJ 
1105_1105_0_1_6_9::None::p21/NN (/( p21WAF1/Cip1/NN )/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, induces/VBZ G1/NN 
714308_1_30_31_16_17::None::(/( PARP/NN )/) inhibitors/NNS became/VBD apparent/JJ and/CC now/RB several/JJ PARP/NN inhibitors/NNS are/VBP being/VBG developed/VBN to/TO treat/VB various/JJ malignancies/NNS ./. 
597523_1_19_20_18_20::None::)/) and/CC Brassica/NNP rapa/NN (/( turnip/NN )/) 
1144_1144_17_18_11_13::None::to/TO that/DT of/IN profilin/NN I/CD ,/, although/IN it/PRP inhibits/VBZ actin/NN polymerization/NN more/RBR strongly/RB 
450573_0_33_34_26_27::None::death/NN proteins/NNS whosewhat/NN expression/NN and/CC their/PRP$ correlation/NN following/VBG facial/JJ nerve/NN distal/JJ transection/NN or/CC crush/NN 
431465_3_29_30_12_13::None::afforded/VBD the/DT azide/NN product/NN in/IN 70/CD %/NN ee/NN ,/, representing/VBG a/DT Mn/NN -/: catalyzed/VBN enantioselective/JJ aliphatic/JJ C/NN -/: H/NN azidation/NN reaction/NN ./. 
907653_2_1_2_23_24::None::Our/PRP$ aim/NN was/VBD to/TO compare/VB in/IN regular/JJ care/NN the/DT effects/NNS of/IN (/( 1/LS )/) an/DT Internet/NN -/: based/VBN patient/NN provider/NN communication/NN service/NN (/( IPPC/NN )/) ,/, (/( 
1321_1321_0_4_9_11::None::Testicular/JJ protein/NN kinase/NN 1/CD (/( TESK1/NN )/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN 
538077_4_22_23_22_24::biology.organism_classification.lower_classifications::IC50/NN values/NNS against/IN Plasmodium/NN falciparum/NN 3D7/NN of/IN 0.310/CD 
300324_0_0_1_50_51::None::In/IN this/DT study/NN ,/, hyaluronic/JJ acid/NN (/( HA/NN )/) //: poly/NN (/( lactic/NN -/: co/SYM -/: glycolic/JJ acid/NN ,/, PLGA/NN )/) core/NN //: shell/NN fiber/NN meshes/VBZ loaded/VBN with/IN epigallocatechin/NN -/: 3/LS -/: O/SYM -/: gallate/NN (/( EGCG/NN )/) (/( HA/NNP //: PLGA/NNP -/: E/NN )/) for/IN application/NN to/TO tissue/NN engineering/NN scaffolds/NNS for/IN skin/NN regeneration/NN 
2013_2013_0_1_9_10::POS_ACTION_BIND::WASp/NN contains/VBZ a/DT binding/NN motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN 
1486_1486_35_40_32_33::None::protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ 
763152_3_11_12_14_15::biology.organism_classification.lower_classifications::nonassociative/JJ behavior/NN in/IN Drosophila/FW where/WRB female/JJ flies/NNS detect/VBP the/DT presence/NN 
288485_0_22_23_32_33::None::IGRT/NN )/) by/IN determining/VBG the/DT expression/NN of/IN caspase/NN -/: 3/CD in/IN spinal/JJ cord/NN neurons/NNS after/IN IGRT/NNP Thirty/CD 
1206_1206_3_4_5_6::POS_ACTION_MODIFY::Requirement/NN of/IN yeast/NN fimbrin/NN for/IN actin/NN organization/NN and/CC morphogenesis/NN 
467117_12_0_1_9_10::None::Canine/NN orbital/JJ rhabdomyosarcoma/NN is/VBZ a/DT highly/RB malignant/JJ neoplasm/NN in/IN juvenile/JJ dogs/NNS ,/, but/CC 
63_63_25_26_44_45::None::electrophoresis/NN :/: histone/NN H1/NN (/( 0/CD )/) ,/, four/CD histone/NN H1/NN subfractions/NNS ,/, histone/NN H2A/NN .1/NN ,/, histone/NN H2A/NN .2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, 
1817_1817_9_10_4_5::None::is/VBZ consistent/JJ with/IN cofilin/NN activation/NN being/VBG required/VBN for/IN actin/NN reorganization/NN during/IN exocytosis/NN 
1380_1380_34_35_36_37::None::novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, 
202687_5_26_27_13_14::None::of/IN two/CD different/JJ phenols/NNS and/CC the/DT ortho/NN and/CC para/NN C/NN -/: H/NN bond/NN of/IN phenols/NNS were/VBD coupled/VBN together/RB ./. 
275933_7_56_57_1_2::None::When/WRB describing/VBG leukemia/NN predisposition/NN due/JJ to/TO hereditary/JJ cancer/NN syndromes/NNS ,/, the/DT following/VBG 6/CD categories/NNS become/VBP apparent/JJ on/IN the/DT basis/NN of/IN biology/NN and/CC clinical/JJ presentation/NN :/: (/( 1/LS )/) genetic/JJ instability/NN //: DNA/NN repair/NN syndromes/NNS ,/, (/( 2/LS )/) cell/NN cycle/NN //: differentiation/NN syndromes/NNS ,/, (/( 3/LS )/) bone/NN marrow/NN failure/NN syndromes/NNS ,/, (/( 4/LS )/) telomere/NN maintenance/NN syndromes/NNS ,/, (/( 
212_212_27_28_24_25::None::the/DT ectodomain/NN of/IN E-cadherin/NN and/CC the/DT actin/NN binding/NN site/NN of/IN 
422301_6_28_29_24_25::biology.organism_classification.lower_classifications::shells/NNS of/IN some/DT turtles/NNS are/VBP homologous/JJ to/TO reptilian/JJ scales/NNS ./. 
1380_1380_26_27_38_39::None::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, 
648_648_6_9_1_3::POS_ACTION_MEMBER::Human/JJ platelet/NN P-235/NN ,/, a/DT talin-like/JJ actin/NN binding/NN protein/NN ,/, binds/VBZ selectively/RB 
1535_1535_7_8_11_14::POS_ACTION_COLOCALIZE::lipids/NNS and/CC express/VBP desmin/JJ intermediate/JJ filaments/NNS ,/, alpha-smooth/JJ muscle/NN actin/NN ,/, and/CC smooth/VB 
119285_0_5_6_14_15::None::work/NN ,/, simultaneous/JJ generation/NN of/IN hydroxyl/NN radical/NN (/( */SYM OH/NN )/) and/CC sulfate/NN radical/NN (/( SO4/NN 
99729_5_6_7_15_18::None::-/: morbidities/NNS of/IN hypertension/NN ,/, previous/JJ stroke/NN or/CC transient/JJ ischemic/JJ attack/NN ,/, peripheral/JJ arterial/JJ disease/NN ,/, myocardial/JJ infarction/NN 
279_279_12_13_30_31::None::directly/RB associate/VBP with/IN TIF34/NN :/: PRT1/NN ,/, a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC a/DT novel/JJ protein/NN of/IN 33/CD kDa/NN (/( eIF3-p33/NN )/) which/WDT is/VBZ 
46_46_3_4_8_9::POS_REG(+)_DECREASE::Addition/NN of/IN Acanthamoeba/NN profilin/NN in/IN molar/JJ ratios/NNS to/TO actin/NN of/IN about/IN 1.1:1/CD 
526387_8_0_1_11_12::None::These/DT results/NNS suggest/VBP that/IN DcEV/NN is/VBZ a/DT novel/JJ species/NNS of/IN the/DT genus/NN Enterovirus/NN in/IN Picornaviridae/NNP 
1321_1321_9_11_26_27::None::)/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN testicular/JJ germ/NN cells/NNS and/CC has/VBZ the/DT potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
1580_1580_25_26_18_19::None::protein/NN complex/NN containing/VBG E-cadherin/NN and/CC its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
159605_0_25_26_24_26::None::degradation/NN of/IN organic/JJ dyes/NNS with/IN hydrogen/NN peroxide/NN 
678566_0_4_5_27_28::None::putative/JJ Major/JJ Facilitator/NNP Superfamily/NNP (/( MFS/NNP )/) transporter/NN ,/, SV2A/NN ,/, is/VBZ the/DT target/NN for/IN levetiracetam/NN (/( LEV/NN )/) ,/, which/WDT is/VBZ a/DT successful/JJ anti/JJ -/: epileptic/JJ drug/NN ./. 
235710_2_3_4_9_10::None::To/TO investigate/VB the/DT adjuvant/JJ cabergoline/NN therapy/NN effects/NNS on/IN menstrual/JJ irregularity/NN and/CC androgen/NN system/NN 
1546_1546_12_13_5_6::POS_ACTION_MEMBER::inhibitory/JJ action/NN of/IN p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ 
1901_1901_25_28_31_32::POS_ACTION_MEMBER::D1/NN ,/, the/DT cyclin-dependent/JJ kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, 
93_93_54_55_57_58::POS_ACTION_DOWNREGULATE::,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
1052_1052_18_20_6_8::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) 
1760_1760_13_14_5_6::None::phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC activate/VB the/DT actin-binding/JJ protein/NN cofilin/NN in/IN human/JJ T/NN 
18_18_6_7_18_20::None::the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) 
1178_1178_14_15_2_3::None::Recombinant/JJ human/JJ beta-catenin/NN can/MD simultaneously/RB bind/VB to/TO the/DT alpha-catenin/actin/NN complex/NN but/CC does/VBZ not/RB bind/VB actin/NN directly/RB ./. 
660282_0_0_1_9_10::None::To/TO evaluate/VB the/DT influence/NN of/IN timing/NN of/IN salvage/NN and/CC adjuvant/JJ radiation/NN therapy/NN on/IN 
2000_2000_0_3_4_5::None::Vascular/JJ endothelial/JJ cadherin/NN (/( VE-cadherin/NN )/) clusters/NNS were/VBD 
1737_1737_39_40_58_59::None::the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS ,/, possibly/RB through/IN the/DT interaction/NN of/IN the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
89_89_17_18_1_2::None::Although/IN talin/NN has/VBZ been/VBN suggested/VBN to/TO act/VB as/IN a/DT linkage/NN protein/NN mediating/VBG the/DT attachment/NN of/IN GPIIb-IIIa/NN to/TO actin/NN filaments/NNS ,/, direct/JJ 
910_910_3_4_9_11::None::Isolation/NN of/IN human/JJ delta-catenin/NN and/CC its/PRP$ binding/NN specificity/NN with/IN presenilin/NN 1/CD ./. 
28653_0_1_2_32_33::None::Photochemical/JJ reduction/NN of/IN iron/NN and/CC iron/NN uptake/NN by/IN Microcystis/NNPS were/VBD investigated/VBN in/IN a/DT freshwater/JJ medium/NN (/( pH/NN 8/CD )/) containing/VBG a/DT range/NN of/IN calcium/NN (/( Ca/NN )/) and/CC magnesium/NN (/( Mg/NN )/) ion/NN concentrations/NNS (/( 0.002/CD 
2_2_11_13_9_10::POS_ACTION_BIND::formation/NN of/IN a/DT beta-catenin/NN */SYM T-cell/NN factor/NN */SYM DNA/NN complex/NN 
748_748_20_21_13_14::POS_ACTION_BIND::fimbrin/NN ,/, the/DT utrophin/NN actin-binding/JJ domain/NN appears/VBZ to/TO associate/VB with/IN actin/NN in/IN an/DT extended/JJ 
109645_7_11_12_12_13::None::the/DT non/JJ -/: BRCA/NN families/NNS with/IN a/DT 6.36/CD 
156299_3_28_30_16_17::None::(/( RF/NN )/) electrodes/NNS and/CC a/DT multiple/JJ -/: electrode/NN switching/NN system/NN was/VBD performed/VBN for/IN malignant/JJ lung/NN tumors/NNS with/IN a/DT maximum/JJ 
539_539_5_6_18_19::POS_ACTION_Causal::we/PRP show/VBP that/IN talin/NN ,/, a/DT high/JJ molecular/JJ weight/NN structural/JJ protein/NN that/WDT links/VBZ integrins/NNS to/TO the/DT actin/NN cytoskeleton/NN ,/, is/VBZ 
524_524_40_41_25_26::POS_ACTION_SQSIMILAR::similarity/NN with/IN host/NN WASP/NNP family/NN proteins/NNS :/: an/DT acidic/JJ stretch/NN ,/, an/DT actin/NN monomer-binding/JJ region/NN ,/, and/CC a/DT cofilin/NN homology/NN sequence/NN ./. 
528491_0_39_40_1_2::medicine.disease.symptoms::Chronic/JJ pain/NN is/VBZ common/JJ during/IN childhood/NN and/CC adolescence/NN and/CC is/VBZ associated/VBN with/IN negative/JJ outcomes/NNS such/JJ as/IN increased/VBN severity/NN of/IN pain/NN ,/, reduced/VBD function/NN (/( eg/FW missing/VBG school/NN )/) ,/, and/CC low/JJ mood/NN (/( eg/FW high/JJ levels/NNS of/IN depression/NN and/CC anxiety/NN )/) ./. 
22703_5_11_13_14_15::medicine.drug.active_moieties::significantly/RB reduced/VBD the/DT adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) -/: mediated/VBN 
761082_2_17_18_38_39::None::score/NN in/IN predicting/VBG pregnancy/NN in/IN infertile/JJ Italian/JJ endometriosis/NN women/NNS ;/: (/( ii/LS )/) evaluate/VB the/DT predictive/JJ value/NN of/IN EFI/NNP score/NN on/IN ART/NN outcome/NN for/IN patients/NNS who/WP previously/RB attempted/VBD 
95871_5_8_9_10_11::medicine.drug_ingredient.active_moiety_of_drug::was/VBD assessed/VBN for/IN norepinephrine/NN (/( NE/NN )/) levels/NNS ,/, 
1345_1345_12_13_6_7::None::WIP/NNP to/TO replace/VB verprolin/NN is/VBZ dependent/JJ on/IN its/PRP$ WH2/NN actin/NN binding/NN domain/NN and/CC 
125255_5_45_46_43_44::None::are/VBP modified/VBN by/IN phosphorylation/NN //: de/FW -/: phosphorylation/NN and/CC 
686_686_31_32_13_14::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
1761_1761_15_16_13_15::None::,/, the/DT HPIV3/NN nucleocapsid/NN protein/NN N/NN ,/, the/DT phosphoprotein/NN 
456127_2_31_32_22_23::None::NWs/NNS ,/, in/IN contrast/NN to/TO a/DT recent/JJ report/NN (/( Razavieh/NN A/NN et/FW al/FW ACS/NNP Nano/NNP 8/CD 
205_205_4_5_2_3::None::BACKGROUND/NN :/: p27/NN (/( Kip1/NN )/) ,/, a/DT 
249535_0_6_8_4_5::None::profile/NN of/IN serum/NN microRNAs/NNS in/IN pancreatic/JJ cancer/NN associated/VBN new/JJ -/: 
831553_2_24_26_13_14::medicine.symptom.symptom_of::(/( eg/FW ,/, depression/NN )/) ,/, physiological/JJ (/( eg/FW ,/, hypothyroidism/NN )/) mechanisms/NNS ,/, sleep/VB disorders/NNS (/( eg/FW ,/, 
142199_1_15_16_7_8::None::erythrocytic/JJ and/CC endotheliotropic/JJ bacterium/NN ,/, B/NN henselae/NN causes/VBZ a/DT spectrum/NN of/IN symptomatology/NN ranging/VBG from/IN asymptomatic/JJ 
1169_1169_13_16_17_18::None::actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ 
243_243_3_4_36_37::POS_ACTION_RELATE::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) ./. 
363545_0_37_39_41_42::people.cause_of_death.includes_causes_of_death::whosewhat/NN diseases/NNS and/CC psychiatric/JJ disorders/NNS such/JJ as/IN depression/NN and/CC anxiety/NN ,/, 
2107_2107_27_28_24_26::None::bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
247970_0_22_23_17_18::None::CMFE/NN )/) in/IN mice/NNS treated/VBN with/IN methotrexate/NN (/( MTX/NN )/) ./. 
38849_2_14_15_21_22::None::,/, they/PRP are/VBP common/JJ in/IN murine/JJ models/NNS of/IN radiation/NN -/: induced/VBN AML/NN ,/, and/CC 
1537_1537_16_17_18_19::POS_ACTION_COLOCALIZE:::/: actin/NN ,/, villin/NN ,/, fimbrin/NN and/CC brush/NN border/NN 
1535_1535_11_14_7_8::None::lipids/NNS and/CC express/VBP desmin/JJ intermediate/JJ filaments/NNS ,/, alpha-smooth/JJ muscle/NN actin/NN ,/, and/CC smooth/VB 
311030_10_14_15_0_1::medicine.drug_ingredient.active_moiety_of_drug::Dopamine/NN release/NN was/VBD stimulated/VBN by/IN applying/VBG ATP/NN which/WDT activated/VBD P2X2/NN channels/NNS specifically/RB expressed/VBN in/IN dopaminergic/JJ neurons/NNS ./. 
913_913_22_23_20_21::POS_ACTION_UNBIND::release/NN of/IN G/NN actin/NN from/IN profilin/NN or/CC promoting/VBG the/DT 
742394_1_27_28_20_21::None::with/IN HIV/NN -/: negative/JJ patients/NNS ,/, and/CC at/IN a/DT higher/JJR rate/NN ./. 
1286_1286_12_13_3_6::None::Specific/JJ antibodies/NNS to/TO myosin/JJ heavy/JJ chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, SMemb/NN )/) ,/, caldesmon/NN 
2146_2146_6_7_11_13::POS_ACTION_PHOSPHORYLATE::that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) 
492693_2_23_24_120_121::medicine.drug_ingredient.active_moiety_of_drug::K/NN in/IN (/( NH3/NN )/) yCs0/NN .4/CD FeSe/NN at/IN 11/CD and/CC 13/CD GPa/NN Surprisingly/RB ,/, superconductivity/NN re/SYM -/: appeared/VBD rapidly/RB above/IN 13/CD GPa/NN ,/, with/IN the/DT Tc/NN reaching/VBG 49/CD K/NN at/IN 21/CD GPa/NN The/DT appearance/NN of/IN a/DT new/JJ superconducting/JJ phase/NN is/VBZ not/RB accompanied/VBN by/IN a/DT structural/JJ transition/NN ,/, as/IN evidenced/VBN by/IN pressure/NN -/: dependent/JJ XRD/NNP Furthermore/RB ,/, Tc/NN slowly/RB decreased/VBD with/IN increasing/VBG pressure/NN above/IN 21/CD GPa/NN ,/, and/CC at/IN 41/CD GPa/NN superconductivity/NN disappeared/VBD entirely/RB at/IN temperatures/NNS above/IN 4.9/CD K/NN The/DT observation/NN of/IN a/DT double/JJ -/: dome/NN superconducting/JJ phase/NN may/MD provide/VB a/DT hint/NN for/IN pursuing/VBG the/DT superconducting/VBG coupling/NN -/: mechanism/NN of/IN ammoniated/JJ //: non/JJ -/: 
262795_4_0_1_2_3::None::It/PRP is/VBZ clear/JJ now/RB that/IN the/DT 
1372_1372_1_2_31_32::None::The/DT APC/NN binding/NN site/NN on/IN beta-catenin/NN may/MD be/VB discontinuous/JJ since/IN neither/CC the/DT carboxyl/NN -/: nor/CC amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB with/IN APC/NN ,/, although/IN the/DT amino-terminal/JJ half/NN independently/RB binds/VBZ alpha-catenin/NN ./. 
151063_0_7_8_14_15::None::and/CC carboplatin/NN (/( CBP/NN )/) are/VBP widely/RB used/VBN for/IN the/DT combined/JJ chemotherapy/NN of/IN non/JJ 
725268_1_37_38_26_27::None::plays/NNS in/IN this/DT procedure/NN and/CC there/EX are/VBP no/DT reports/NNS of/IN how/WRB variability/NN changes/NNS with/IN predicted/VBN indifference/NN ./. 
605_605_20_21_18_19::None::products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN 
214_214_22_25_6_7::POS_ACTION_LOCALIZE-TO::exchange/NN rapidly/RB between/IN actin/NN molecules/NNS ,/, low/JJ concentrations/NNS of/IN profilin/NN can/MD overcome/VB the/DT inhibitory/JJ effects/NNS of/IN high/JJ concentrations/NNS of/IN thymosin/NN beta/NN 4/CD on/IN the/DT nucleotide/NN 
1534_1534_9_10_16_17::None::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN 
93177_0_31_32_12_14::None::syndrome/NN distinct/JJ from/IN multiple/JJ sclerosis/NN (/( MS/NN )/) that/WDT is/VBZ associated/VBN with/IN serum/NN aquaporin/NN -/: 4/CD immunoglobulin/NN G/NN antibodies/NNS (/( AQP4/NN -/: IgG/NN )/) ./. 
275299_5_19_20_5_6::None::are/VBP enriched/VBN in/IN calcification/NN -/: related/JJ processes/NNS ,/, including/VBG calcium/NN ion/NN transport/NN and/CC calcium/NN signaling/NN pathways/NNS as/IN revealed/VBN by/IN gene/NN ontology/NN 
186443_2_3_4_12_14::medicine.disease.treatments::Patients/NNS diagnosed/VBD with/IN diabetes/NN mellitus/NN type/NN 1/CD or/CC 2/CD ,/, or/CC using/VBG antidiabetic/JJ drugs/NNS (/( ADDs/NNS )/) 
319920_0_47_48_37_38::None:://: hostility/NN as/IN major/JJ components/NNS of/IN psychiatric/JJ symptoms/NNS in/IN acute/JJ mania/NN or/CC mixed/JJ episodes/NNS in/IN a/DT series/NN 
452979_10_15_17_13_14::None::diabetes/NN mellitus/NN among/IN blacks/NNS with/IN metabolic/JJ syndrome/NN ./. 
653_653_8_9_2_3::POS_ACTION_BIND::Identification/NN of/IN alpha-syntrophin/NN binding/NN to/TO syntrophin/NN triplet/NN ,/, dystrophin/NN ,/, and/CC utrophin/NN 
750_750_7_8_3_5::POS_ACTION_INTERACT::Increased/VBN interaction/NN of/IN beta1D/NN integrin/NN with/IN the/DT actin/NN cytoskeleton/NN is/VBZ consistent/JJ 
741231_0_3_5_12_13::None::Relationship/NN between/IN low/JJ blood/NN pressure/NN and/CC renal/JJ //: cardiovascular/JJ outcomes/NNS in/IN Japanese/JJ patients/NNS with/IN chronic/JJ kidney/NN 
632_632_16_17_4_5::None::,/, regulation/NN of/IN profilin/NN function/NN is/VBZ generally/RB unknown/JJ and/CC controversy/NN exists/VBZ regarding/VBG profilin/NN effects/NNS on/IN actin/NN polymerization/NN ./. 
588835_2_10_11_0_1::None::We/PRP traced/VBD the/DT ontogenetic/JJ development/NN of/IN this/DT feature/NN in/IN 56/CD fetal/JJ specimens/NNS from/IN 10/CD 
1373_1373_16_17_11_12::POS_ACTION_MUTUALCOMPLEX::independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
522_522_21_22_1_2::None::Full-length/JJ beta-catenin/NN ,/, beta-catenin/NN mutant/JJ proteins/NNS with/IN NH2-terminal/JJ deletions/NNS before/IN (/( deltaN90/NN )/) or/CC after/IN (/( deltaN131/NN ,/, deltaN151/NN )/) the/DT alpha-catenin/NN binding/NN site/NN ,/, 
1652_1652_20_21_18_19::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS 
405577_1_9_11_2_3::None::In/IN the/DT plasma/NN ,/, PCI/NN physiologically/RB inhibits/VBZ an/DT anticoagulant/JJ serine/NN protease/NN ,/, activated/VBN protein/NN 
555_555_5_6_47_48::POS_ACTION_Assembly::pull-down/JJ performed/VBN with/IN Tax/NN deletion/NN mutants/NNS and/CC peptide/NN competition/NN have/VBP localized/VBN the/DT site/NN in/IN Tax/NN critical/JJ for/IN binding/VBG CBP/p300/NN to/TO a/DT highly/RB protease-sensitive/JJ region/NN around/IN amino/NN acid/NN residues/NNS 81/CD to/TO 95/CD (/( 81QRTSKTLKVLTPPIT95/NN )/) which/WDT lies/VBZ between/IN the/DT domains/NNS previously/RB proposed/VBN to/TO be/VB important/JJ for/IN CREB/NN binding/NN and/CC Tax/NN 
323306_3_7_8_19_20::None::underwent/VBD 19/CD anesthetic/JJ procedures/NNS ,/, of/IN which/WDT 13/CD were/VBD &/CC lt/NN ;/: 2/CD h/NN in/IN duration/NN and/CC seven/CD were/VBD 
740032_2_39_40_16_17::None::the/DT FBIH/NN among/IN adult/JJ population/NN aged/JJ 25/CD -/: 64/CD years/NNS for/IN assessment/NN and/CC distribution/NN of/IN major/JJ risk/NN factors/NNS for/IN cardiovascular/JJ diseases/NNS (/( CVD/NN )/) ,/, preferably/RB hypertension/NN ,/, obesity/NN and/CC 
2137_2137_15_18_19_20::None::its/PRP$ associated/JJ proteins/NNS actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
342702_0_15_16_10_11::None::inflammatory/JJ and/CC immune/JJ mechanisms/NNS in/IN rheumatoid/JJ arthritis/NN (/( RA/NN )/) have/VBP fuelled/VBN 
1075_1075_11_12_22_23::None::CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
265539_2_19_20_11_12::None::disease/NN of/IN the/DT CNS/NN During/IN the/DT last/JJ several/JJ decades/NNS ,/, experimental/JJ models/NNS of/IN MS/NN have/VBP 
594019_6_15_16_0_1::None::Females/NNS who/WP began/VBD running/VBG at/IN or/CC before/IN age/NN 10/CD were/VBD more/RBR likely/JJ to/TO report/VB a/DT diagnosis/NN of/IN hypothyroidism/NN versus/CC 
1771_1771_11_14_15_16::POS_ACTION_MEMBER::of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO 
186443_2_0_1_19_20::None::Patients/NNS diagnosed/VBD with/IN diabetes/NN mellitus/NN type/NN 1/CD or/CC 2/CD ,/, or/CC using/VBG antidiabetic/JJ drugs/NNS (/( ADDs/NNS )/) ,/, were/VBD compared/VBN to/TO matched/VBN non/JJ 
130_130_4_5_6_7::POS_ACTION_BIND::assembly/NN of/IN the/DT UL5/NN and/CC UL52/NN subunits/NNS retains/VBZ both/CC 
465207_3_4_5_6_7::medicine.disease.risk_factors::reported/VBN prevalence/NN of/IN osteoporosis/NN among/IN postmenopausal/JJ women/NNS in/IN Brazil/NNP 
231772_0_5_6_16_17::None::degradation/NN of/IN three/CD neonicotinoid/JJ insecticides/NNS (/( NIs/NNS )/) ,/, thiamethoxam/NN (/( TH/NN )/) ,/, imidacloprid/NN (/( IM/NN )/) 
1246_1246_31_32_29_31::None::IV/CD collagen/NN ,/, actin-binding/JJ protein/NN cofilin/NN ,/, profilin/NN and/CC 
1616_1616_35_36_34_35::None::for/IN the/DT proposed/VBN phosphoprotein/NN P/NN and/CC the/DT other/JJ 
411_411_13_14_20_21::POS_ACTION_BIND::signaling/VBG molecules/NNS including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ./. 
157_157_14_15_8_9::None::to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT 
609_609_19_20_21_22::None::encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
164393_5_34_35_1_2::None::Participants/NNS reported/VBD nicotine/NN craving/NN ,/, nicotine/NN withdrawal/NN symptoms/NNS ,/, and/CC substance/NN use/NN in/IN the/DT week/NN following/VBG a/DT uniform/JJ quit/VBD attempt/NN of/IN the/DT TAU/NN +/CC SCT/NN group/NN ,/, and/CC self/NN -/: reported/VBN smoking/NN 7/CD -/: day/NN point/NN prevalence/NN abstinence/NN 
712_712_15_16_27_28::None::stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN ./. 
984_984_20_21_33_34::None::the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, and/CC transcriptional/JJ repression/NN domain/NN of/IN MLL/NN fused/VBN to/TO the/DT CREB/NN binding/NN domain/NN or/CC 
250_250_14_15_7_8::POS_ACTION_BIND::of/IN N-cadherin/NN and/CC alpha-catenin/NN which/WDT bind/VBP to/TO either/CC beta-catenin/NN or/CC plakoglobin/NN in/IN a/DT mutually/RB 
767824_2_15_16_22_23::None::concentrations/NNS as/IN a/DT potential/JJ predictor/NN of/IN reduced/VBN depression/NN symptoms/NNS in/IN obese/JJ adolescents/NNS during/IN long/JJ 
784_784_21_22_8_9::NEG_ACTION_COLOCALIZE::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
507093_0_22_23_20_21::None::highly/RB prevalent/JJ in/IN Hispanics/NNPS //: Latinos/NNPS ./. 
22_22_0_1_54_55::None::ActA/NN appears/VBZ to/TO control/VB at/IN least/JJS four/CD functions/NNS that/WDT collectively/RB lead/VBP to/TO actin-based/JJ motility/NN :/: (/( 1/LS )/) initiation/NN of/IN actin/NN polymerization/NN ,/, (/( 2/LS )/) polarization/NN of/IN ActA/NN function/NN ,/, (/( 3/LS )/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT motile/JJ force/NN and/CC (/( 4/LS )/) acceleration/NN of/IN movement/NN mediated/VBN by/IN the/DT host/NN protein/NN profilin/NN ./. 
70627_9_18_19_0_1::medicine.drug.active_moieties::Cortisol/NN response/NN to/TO stress/NN differed/VBD according/VBG to/TO group/NN :/: in/IN the/DT ADHD/NNP group/NN ,/, 20min/JJ post/NN -/: test/NN cortisol/NN levels/NNS were/VBD significantly/RB 
712_712_27_28_15_16::POS_ACTION_UPREGULATE::stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN ./. 
307348_1_33_35_22_23::None::wide/JJ spectrum/NN of/IN symptoms/NNS and/CC disabilities/NNS ,/, such/JJ as/IN cognitive/JJ deficits/NNS ,/, mood/NN or/CC anxiety/NN disorders/NNS ,/, motor/NN impairments/NNS 
1069_1069_46_47_26_27::POS_ACTION_ATTACH::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
456_456_2_3_15_16::NEG_ACTION_CORELATE::Expression/NN of/IN alpha-catenin/NN was/VBD generally/RB weak/JJ and/CC did/VBD not/RB correlate/VB with/IN the/DT expression/NN of/IN either/CC beta-catenin/NN or/CC E-cadherin/NN ./. 
3197_0_0_1_3_4::None::Tenofovir/NNP alafenamide/NN (/( TAF/NN )/) is/VBZ an/DT 
1069_1069_21_22_29_30::POS_ACTION_CONTAIN::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT 
1037_1037_27_28_24_26::None::RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
685_685_30_31_6_7::None::labeled/VBN proteins/NNS with/IN HECD-1/NN revealed/VBD three/CD bands/NNS corresponding/VBG to/TO E-cadherin/NN ,/, alpha-catenin/NN ,/, and/CC gamma-catenin/NN and/CC a/DT 79-kDa/JJ band/NN which/WDT was/VBD apparently/RB smaller/JJR than/IN that/DT of/IN normal/JJ beta-catenin/NN ,/, indicating/VBG truncated/VBN 
1434_1434_75_76_75_76::None::histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
930063_2_25_26_2_3::None::While/IN IV/CD thrombolysis/NN has/VBZ been/VBN shown/VBN to/TO decrease/VB morbidity/NN and/CC mortality/NN from/IN acute/JJ ischemic/JJ stroke/NN ,/, it/PRP is/VBZ limited/VBN in/IN both/DT its/PRP$ efficacy/NN in/IN certain/JJ types/NNS of/IN stroke/NN ,/, 
1140_1140_24_25_22_23::POS_ACTION_INTERACT::of/IN gelsolin/NN and/CC profilin/NN with/IN actin/NN ./. 
492455_3_39_40_46_47::None::-/: Present/JJ and/CC Lifetime/NN version/NN (/( K/NN -/: SADS/NN -/: PL/NN )/) ,/, DSM/NNP 
245_245_10_11_0_1::None::Neuropilin-1/NN (/( NRP1/NN )/) is/VBZ a/DT 130-kDa/JJ transmembrane/NN receptor/NN for/IN semaphorins/NNS ,/, mediators/NNS of/IN 
1652_1652_45_46_18_19::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
13078_0_3_4_0_1::None::IL/NN -/: 10/CD gene/NN polymorphism/NN and/CC influence/NN 
1052_1052_6_8_12_13::POS_ACTION_BIND::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT 
609813_2_33_34_11_12::None::with/IN plants/NNS ,/, outline/NN steps/NNS necessary/JJ to/TO develop/VB invasive/JJ species/NNS control/VBP strategies/NNS that/WDT are/VBP based/VBN on/IN those/DT relationships/NNS ,/, and/CC use/VB the/DT invasive/JJ plant/NN species/NNS Phragmites/NNP australis/NNP (/( common/JJ 
2131_2131_23_24_10_11::None::UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
307_307_6_7_12_13::None::truncates/VBZ that/IN inhibit/VBP actin/NN depolymerization/NN by/IN severing/VBG activity/NN of/IN gelsolin/NN and/CC cofilin/NN ./. 
1061_1061_25_27_6_7::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
798_798_13_14_11_12::None::EGTA/NN with/IN purified/VBN fimbrin/NN and/CC villin/NN form/VBP smooth-sided/JJ bundles/NNS 
483185_4_43_44_49_50::None::changes/NNS in/IN the/DT chromosome/NN based/VBN on/IN an/DT assessment/NN of/IN telomere/NN length/NN in/IN single/JJ 
1082_1082_35_36_11_12::None::mobile/JJ form/NN of/IN actin/NN in/IN slow/JJ transport/NN is/VBZ soluble/JJ and/CC that/IN a/DT substantial/JJ amount/NN of/IN this/DT actin/NN may/MD travel/VB as/IN a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
211391_8_17_18_27_29::None::Nile/NNP ,/, and/CC tick/VB -/: borne/VBN encephalitis/NN (/( TBE/NN )/) viruses/NNS pose/VBP substantial/JJ public/JJ health/NN problems/NNS in/IN different/JJ 
896731_2_2_3_1_2::medicine.disease.symptoms::An/DT acute/JJ MI/NNP model/NN was/VBD induced/VBN 
221936_3_30_32_33_34::people.cause_of_death.includes_causes_of_death::and/CC a/DT clustered/VBN cardiovascular/JJ disease/NN (/( CVD/NN )/) risk/NN index/NN 
872_872_11_12_6_7::POS_ACTION_BIND::the/DT role/NN of/IN MSH2/NN ,/, MSH3/NN ,/, and/CC MSH6/NN in/IN mismatch/NN repair/NN 
113845_3_17_18_28_29::None::,/, lack/NN of/IN swelling/VBG ,/, bleeding/VBG ,/, pain/NN ,/, scar/NN tissue/NN formation/NN and/CC overall/JJ satisfaction/NN were/VBD observed/VBN in/IN 
1527_1527_3_4_5_8::None::The/DT interactions/NNS of/IN actin/NN with/IN thymosin/NN beta/NN 4/CD ,/, actobindin/NN and/CC 
128605_11_37_38_17_18::medicine.disease.treatments::driver/NN of/IN radio/NN chemotherapy/NN resistance/NN ,/, and/CC hence/RB high/JJ levels/NNS of/IN XIAP/NN may/MD be/VB a/DT useful/JJ indicator/NN of/IN neoadjuvant/JJ radio/NN chemotherapy/NN resistance/NN in/IN rectal/JJ cancer/NN ./. 
1373_1373_13_14_4_5::POS_ACTION_MUTUALCOMPLEX::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
799_799_16_17_11_12::POS_ACTION_Causal::linked/VBN to/TO the/DT actin/NN cytoskeleton/NN via/IN the/DT protein/NN talin/NN ./. 
1075_1075_22_23_11_12::POS_ACTION_PHOSPHORYLATE::CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
485087_11_0_1_28_29::None::Once/RB ECMO/NNP has/VBZ been/VBN commenced/VBN ,/, if/IN the/DT tachyarrhythmia/NN remains/VBZ difficult/JJ to/TO control/VB with/IN antiarrhythmic/JJ drugs/NNS ,/, RFA/NN should/MD be/VB strongly/RB considered/VBN ,/, to/TO avoid/VB the/DT risk/NN of/IN tachycardia/NN recurrence/NN following/VBG ECMO/NN 
1069_1069_26_27_24_25::None::helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
516597_4_8_9_16_17::None::severe/JJ isolated/VBN head/NN injuries/NNS :/: 337/CD from/IN OEF/NN ,/, 268/CD from/IN OIF/NN ,/, and/CC 42/CD 
652_652_11_12_8_9::None::in/IN beta-catenin/NN ,/, alpha-catenin/NN ,/, and/CC p120/NN (/( Cas/NNS )/) 
654472_6_22_23_52_53::None::reported/VBN non/JJ -/: ocular/JJ pain/NN measures/NNS (/( numerical/JJ rating/NN scale/NN and/CC pain/NN history/NN )/) ,/, (/( B/NN )/) depression/NN and/CC (/( C/NN )/) PTSD/NN were/VBD significant/JJ and/CC moderate/JJ in/IN strength/NN (/( Pearson/NNP whosewhat/NN coefficient/NN 0.24/CD to/TO 0.60/CD 
109645_7_19_20_17_18::None::a/DT 6.36/CD %/NN proportion/NN (/( CI/NN 4.67/CD -/: 8.2/CD 
1672_1672_10_11_8_9::POS_ACTION_MEMBER::belongs/VBZ to/TO the/DT RAD17/NN ,/, MEC3/NN and/CC RAD24/NN epistasis/NN 
686_686_33_34_23_24::None::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
980_980_18_19_5_6::None::stable/JJ expression/NN of/IN V12Ras/NNS into/IN keratinocytes/NNS promotes/VBZ the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN beta-catenin/NN to/TO the/DT cytoplasm/NN 
607093_2_33_34_46_48::biology.organism_classification.lower_classifications::to/TO the/DT genus/NN Homo/NN but/CC documents/NNS a/DT pattern/NN of/IN morphology/NN not/RB seen/VBN in/IN eastern/JJ African/JJ early/JJ Homo/NN erectus/NN ./. 
296387_0_29_30_0_2::None::Three/CD weeks/NNS after/IN Typhoon/NNP Haiyan/NNP ,/, an/DT increasing/VBG number/NN of/IN acute/JJ gastroenteritis/NN cases/NNS were/VBD reported/VBN in/IN Kananga/NNP ,/, Leyte/NNP ,/, an/DT area/NN where/WRB evacuated/VBN residents/NNS had/VBD returned/VBN home/RB two/CD days/NNS after/IN the/DT disaster/NN 
821060_0_30_34_24_25::medicine.medical_treatment.used_to_treat::-/: versus/CC -/: leukemia/NN (/( GVL/NN )/) effect/NN of/IN allogeneic/JJ stem/NN cell/NN transplantation/NN (/( allo/NN -/: 
334920_0_12_13_20_21::None::interaction/NN of/IN the/DT nucleocapsid/JJ protein/NN with/IN a/DT packaging/NN signal/NN in/IN the/DT viral/JJ RNA/NN as/IN important/JJ 
405577_1_12_15_16_17::medicine.drug_ingredient.active_moiety_of_drug::serine/NN protease/NN ,/, activated/VBN protein/NN C/NN (/( APC/NN )/) ./. 
424911_2_84_86_10_11::None::complexes/NNS such/JJ as/IN fac/NN -/: Ir/NN (/( ppy/NN )/) 3/CD (/( ppy/NN =/JJ 2/CD -/: phenylpyridine/NN )/) and/CC fac/SYM -/: Ir/NN (/( tpy/NN )/) 3/CD (/( tpy/NN =/JJ 2/CD -/: (/( 4/LS ''/'' -/: tolyl/NN )/) pyridine/NN )/) possess/VBP C3/NN -/: symmetric/JJ structures/NNS and/CC excellent/JJ photophysical/JJ properties/NNS as/IN phosphorescence/NN materials/NNS ,/, which/WDT make/VBP them/PRP important/JJ candidates/NNS for/IN use/NN in/IN biological/JJ applications/NNS such/JJ as/IN chemosensors/NNS ,/, biolabeling/NN ,/, living/VBG cell/NN staining/NN ,/, in/FW vivo/FW tumor/NN imaging/NN ,/, and/CC anticancer/JJ agents/NNS ./. 
607_607_8_9_19_20::None::expresses/VBZ a/DT heterotrimeric/JJ helicase-primase/NN ,/, the/DT subunits/NNS of/IN which/WDT are/VBP encoded/VBN by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC 
1652_1652_18_19_20_21::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS 
2107_2107_7_8_39_40::POS_REG(0)_MODIFY::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
297982_0_1_3_4_5::medicine.drug_ingredient.active_moiety_of_drug::Nanosized/JJ titanium/NN dioxide/NN (/( TiO2/NN )/) particles/NNS belong/VBP 
2222_2222_39_40_15_16::NEG_ACTION_COLOCALIZE::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
26717_2_48_49_67_68::None::,/, diabetes/NN ,/, smoking/NN ,/, systolic/JJ blood/NN pressure/NN ,/, lipid/NN levels/NNS ,/, albumin/NN -/: creatinine/NN ratio/NN ,/, physical/JJ activity/NN ,/, C/NN -/: reactive/JJ protein/NN ,/, body/NN 
18_18_4_5_6_7::None::domain/NN of/IN the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ 
113845_3_21_22_17_18::medicine.symptom.symptom_of::,/, lack/NN of/IN swelling/VBG ,/, bleeding/VBG ,/, pain/NN ,/, scar/NN tissue/NN 
565841_0_5_6_9_10::None::and/CC epidemiological/JJ studies/NNS demonstrated/VBD an/DT association/NN between/IN endometriosis/NN and/CC infertility/NN ./. 
834587_19_8_9_17_18::None::option/NN in/IN treating/VBG mid/JJ esophageal/JJ carcinoma/NN as/IN compared/VBN to/TO IMRT/NNP The/NNP VMAT/NNP plans/VBZ resulted/VBD in/IN equivalent/JJ 
265345_3_21_22_15_18::people.cause_of_death.includes_causes_of_death::haematuria/NN -/: associated/VBN acute/JJ kidney/NN injury/NN in/IN immunoglobulin/NN A/NN nephropathy/NN ./. 
119285_0_17_18_32_33::None::sulfate/NN radical/NN (/( SO4/NN */SYM -/: )/) by/IN the/DT reaction/NN of/IN ozone/NN (/( O3/NN )/) with/IN peroxymonosulfate/NN (/( PMS/NN ;/: HSO5/NN -/: 
590053_1_21_23_12_13::None::nausea/NN ,/, and/CC influenza/NN -/: like/IN symptoms/NNS ,/, such/JJ as/IN fever/NN and/CC joint/JJ pain/NN ./. 
591709_2_22_23_29_30::None::COX/NNP sequences/NNS in/IN Mollusca/NNP ,/, Crustacea/NNP ,/, and/CC Insecta/NNP ,/, assessing/VBG COX/NNP evolution/NN across/IN 
1553_1553_32_33_38_39::None::daltons/NNS )/) ,/, fimbrin/NN (/( 68,000/CD daltons/NNS )/) ,/, actin/NN (/( 43,000/CD daltons/NNS 
183879_18_6_7_9_10::None::venlafaxine/NN +/CC bright/JJ light/NN therapy/NN treatment/NN strategies/NNS significantly/RB reversed/VBD the/DT 
884_884_14_15_12_13::POS_ACTION_BIND::,/, complexes/NNS of/IN beta-catenin/NN with/IN alpha-catenin/NN and/CC APC/NN were/VBD 
255731_2_36_37_12_13::None::comprehensively/RB investigated/VBD the/DT abundance/NN and/CC diversity/NN of/IN STPs/NNS encoded/VBN in/IN 119/CD actinobacterial/JJ genomes/NNS ,/, based/VBN on/IN the/DT data/NNS stored/VBN in/IN the/DT Microbial/JJ Signal/NN Transduction/NN (/( MiST/NN )/) database/NN ./. 
1843_1843_31_32_19_20::POS_ACTION_LOCALIZE::that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD 
92153_1_12_13_24_26::medicine.medical_treatment.used_to_treat::overall/JJ management/NN and/CC antiarrhythmic/JJ therapy/NN used/VBN in/IN the/DT current/JJ general/JJ population/NN of/IN patients/NNS with/IN nonvalvular/JJ atrial/JJ fibrillation/NN in/IN Spain/NNP ./. 
2222_2222_13_14_11_12::POS_ACTION_COLOCALIZE::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, 
93_93_22_23_11_12::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN 
326872_11_15_16_12_13::None::targets/NNS of/IN dopamine/NN signaling/NN in/IN the/DT mammalian/JJ retina/NN owing/VBG to/TO 
719083_0_8_9_2_3::medicine.symptom.symptom_of::Frequency/NN of/IN Meningitis/NN in/IN Children/NNP Presenting/VBG with/IN Febrile/NN Seizures/NNS at/IN Ali/NNP -/: 
756738_0_9_10_16_17::None::common/JJ non/JJ -/: cardiovascular/JJ causes/NNS of/IN death/NN in/IN patients/NNS on/IN chronic/JJ renal/JJ replacement/NN therapy/NN 
747_747_27_28_25_26::POS_ACTION_BIND::and/CC association/NN of/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN 
1128_1128_11_14_4_5::None::talin/NN binds/VBZ to/TO actin/NN in/FW vitro/FW and/CC hence/RB is/VBZ an/DT actin/NN binding/NN protein/NN ./. 
723866_2_1_2_3_4::biology.organism_classification.lower_classifications::(/( Reduviidae/NNP :/: Emesinae/NNP )/) is/VBZ described/VBN 
1628_1628_31_33_27_28::None::the/DT ability/NN of/IN Munc-18-2/NN to/TO associate/VB with/IN syntaxin/NN 3/CD in/FW vitro/FW ./. 
395_395_7_8_9_10::None::verprolin-homology/JJ domain/NN in/IN N-WASP/NN to/TO actin/NN is/VBZ essential/JJ for/IN 
520523_1_36_37_17_18::biology.organism_classification.lower_classifications::tree/NN species/NNS :/: almond/NN (/( Prunus/FW dulcis/FW )/) ,/, apricot/NN (/( Prunus/FW armeniaca/FW )/) ,/, peach/NN (/( Prunus/FW persica/FW )/) ,/, and/CC plum/NN (/( Prunus/NNP domestica/NNP 
549_549_20_21_11_12::None::to/TO msh6-F337A/NN sequestering/NN MSH2/NN and/CC preventing/VBG it/PRP from/IN interacting/VBG with/IN MSH3/NN and/CC MSH6/NN ./. 
93_93_54_55_28_29::None::kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
556_556_24_25_7_9::NEG_ACTION_INTERACT::to/TO be/VB a/DT nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ protein/NN based/VBN on/IN the/DT lack/NN of/IN reactivity/NN of/IN antigravin/NN with/IN these/DT polypeptides/NNS 
225720_6_4_6_25_26::None::also/RB show/VBP that/IN primary/JJ tumors/NNS can/MD be/VB modeled/VBN in/IN immunocompetent/JJ mice/NNS by/IN microinjecting/VBG CCR9/NN -/: expressing/VBG cancer/NN cell/NN lines/NNS into/IN early/JJ -/: stage/NN mouse/NN blastocysts/NNS ,/, which/WDT induces/VBZ 
519_519_33_34_32_33::POS_ACTION_MEMBER::)/) -/: specific/JJ Act88F/NN actin/NN gene/NN ./. 
637036_2_17_18_11_12::None::the/DT course/NN of/IN disease/NN is/VBZ recommended/VBN ;/: however/RB ,/, patients/NNS live/VBP with/IN disabling/VBG 
1608_1608_26_27_24_25::None::protein/NN to/TO bind/VB actin/NN or/CC vinculin/NN ./. 
393_393_12_15_5_7::None::isolated/VBN myofibrils/NNS with/IN alkaline/NN proteinase/NN resulted/VBD in/IN the/DT degradation/NN of/IN myosin/NN heavy/JJ chain/NN and/CC actin/NN ./. 
93665_0_16_18_0_1::None::In/IN colorectal/JJ cancer/NN (/( CRC/NN )/) ,/, metastatic/JJ spread/NN is/VBZ supposed/VBN to/TO be/VB mainly/RB driven/VBN by/IN tumor/NN cells/NNS with/IN stem/NN cell/NN 
1701_1701_11_12_43_46::None::involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN 
170709_1_17_18_11_12::None::a/DT breast/NN cancer/NN cell/NN overexpressing/VBG the/DT Her2/NN receptor/NN ,/, trastuzumab/NN (/( Herceptin/NN )/) 
1532_1532_17_18_29_30::POS_ACTION_CORELATE::association/NN of/IN the/DT Munc18-2/NN variants/NNS with/IN syntaxin/NN 3/CD correlated/VBD well/RB with/IN their/PRP$ ability/NN to/TO displace/VB SNAP-23/NN from/IN syntaxin/NN 3/CD 
2148_2148_52_53_4_5::None::report/VBP here/RB that/IN tropomyosin/NN ,/, which/WDT is/VBZ found/VBN in/IN the/DT rootlet/NN but/CC not/RB in/IN the/DT microvillus/JJ core/NN ,/, can/MD bind/VB to/TO and/CC saturate/VB the/DT actin/NN of/IN isolated/VBN cores/NNS ,/, and/CC can/MD cause/VB the/DT dissociation/NN of/IN up/RB to/TO 30/CD %/NN of/IN the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ 
1771_1771_15_16_11_14::None::of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO 
1055_1055_19_22_0_1::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC 
388589_2_44_45_38_39::None::among/IN the/DT subgroups/NNS diabetes/NN and/CC non/JJ -/: diabetes/NN ,/, age/NN gtgt/NN =/JJ 65/CD 
728820_2_16_17_11_12::medicine.disease.symptoms::LVP/NN for/IN lower/JJR urinary/JJ tract/NN symptoms/NNS secondary/JJ to/TO BPH/NNP from/IN 2005/CD to/TO 
491928_0_5_6_11_12::medicine.risk_factor.diseases::premorbid/JJ childhood/NN and/CC adolescent/JJ functioning/VBG in/IN schizophrenia/NN -/: spectrum/NN psychoses/NNS :/: A/DT first/JJ 
660282_0_5_6_15_16::None::the/DT influence/NN of/IN timing/NN of/IN salvage/NN and/CC adjuvant/JJ radiation/NN therapy/NN on/IN outcomes/NNS after/IN prostatectomy/NN for/IN prostate/NN cancer/NN 
792558_0_3_4_8_9::None::Polymorphonuclear/JJ neutrophils/NNS (/( PMNs/NNS )/) ,/, the/DT main/JJ effectors/NNS of/IN the/DT innate/JJ 
112_112_18_19_0_1::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN epithelial/JJ cells/NNS and/CC forms/VBZ a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN localized/JJ to/TO the/DT 
338450_1_8_9_17_19::None::the/DT treatment/NN of/IN pancreatic/JJ cancer/NN is/VBZ dependent/JJ on/IN disease/NN stage/NN and/CC patient/NN performance/NN status/NN but/CC ,/, in/IN 
18_18_21_22_18_20::None::homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) ./. 
381796_0_9_12_18_22::medicine.disease.treatments::in/IN Patients/NNS with/IN Obstructive/JJ Sleep/NNP Apnea/NNP Not/RB Responsive/JJ to/TO or/CC Intolerant/JJ of/IN Continuous/JJ Positive/JJ Airway/NNP Pressure/NN Ventilation/NN ./. 
290049_2_3_4_9_11::None::The/DT identification/NN of/IN bats/NNS as/IN possible/JJ additional/JJ reservoir/NN for/IN influenza/NN A/NN viruses/NNS raises/VBZ questions/NNS 
369607_2_27_28_10_11::None::heparin/NN among/IN various/JJ anions/NNS and/CC competitors/NNS of/IN heparin/NN including/VBG chondroitin/NN 4/CD -/: sulfate/NN (/( ChS/NN )/) and/CC hyaluronic/JJ acid/NN (/( HA/NN )/) ./. 
808734_0_23_24_9_10::medicine.symptom.symptom_of::patients/NNS with/IN chronic/JJ hepatitis/NN C/NN (/( CHC/NN )/) and/CC is/VBZ associated/VBN with/IN the/DT increased/VBN risk/NN of/IN liver/NN fibrosis/NN and/CC carcinogenesis/NN ./. 
1534_1534_34_35_16_17::None::and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) are/VBP controversial/JJ 
219974_13_2_3_16_17::None::Non/SYM -/: cardiovascular/JJ causes/NNS of/IN death/NN are/VBP responsible/JJ for/IN almost/RB half/DT of/IN later/JJ deaths/NNS in/IN cardiac/JJ patients/NNS ./. 
1771_1771_11_14_19_20::None::of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
715810_0_24_25_15_16::None::against/IN insomnia/NN ,/, amnesia/NN ,/, depression/NN ,/, palpitations/NNS with/IN anxiety/NN ,/, and/CC memory/NN improvement/NN ./. 
194621_0_18_19_22_23::None::and/CC //: or/CC antioxidants/NNS compounds/NNS and/CC reduced/VBD sodium/NN intake/NN have/VBP been/VBN 
713_713_14_15_9_10::POS_ACTION_BIND::cofilin/NN and/CC its/PRP$ actin/NN binding/NN peptide/NN compete/VBP with/IN gelsolin/NN segments/NNS 2-3/CD for/IN 
1491_1491_16_17_6_7::POS_ACTION_DEPOLYMERIZE::assay/NN using/VBG an/DT actin/NN cross-linking/NN protein/NN and/CC the/DT nucleation/NN assay/NN also/RB suggested/VBD that/IN cofilin/NN shortens/VBZ the/DT actin/NN 
436497_1_5_6_7_8::medicine.symptom.symptom_of::the/DT correlations/NNS between/IN impulsivity/NN and/CC bulimic/JJ symptoms/NNS ,/, and/CC 
2014_2014_23_24_30_31::POS_ACTION_SIMILAR::mutants/NNS defective/JJ in/IN rhp51/NN and/CC rhp54/NN (/( homologues/NNS of/IN S.cerevisiae/NNP RAD51/NN and/CC RAD54/NN ,/, 
28475_4_68_69_33_34::None::analysis/NN revealed/VBD the/DT presence/NN of/IN a/DT selenocysteine/NN -/: containing/VBG TGR/NN and/CC absenceof/JJ conventional/JJ TR/NN and/CC GR/NN M/NN vogae/FW thioredoxin/NN and/CC glutathione/NN reductase/NN activities/NNS were/VBD inhibited/VBN by/IN 3,4/CD -/: bis/NN (/( phenylsulfonyl/NN )/) -/: 1,2,5/CD -/: oxadiazole/NN N2/NN -/: oxide/NN (/( VL16E/NN )/) 
389319_8_12_13_1_2::None::Liver/NN tissue/NN was/VBD assessed/VBN for/IN inflammatory/JJ cytokine/NN expression/NN and/CC radiation/NN -/: induced/VBN SEC/NNP injury/NN based/VBN on/IN 
790_790_33_34_29_33::None::,/, including/VBG the/DT cyclin/NN dependent/JJ kinase/NN inhibitor/NN p27/NN ,/, which/WDT blocks/VBZ 
17565_0_2_5_2_3::medicine.disease.symptoms::Rupture/NN of/IN abdominal/JJ aortic/JJ aneurysms/NNS causes/VBZ 
1908_1908_7_8_19_20::None::that/IN TGFbeta/NN regulates/VBZ clusterin/NN gene/NN expression/NN through/IN an/DT AP-1/NN site/NN and/CC its/PRP$ cognate/JJ transcription/NN factor/NN AP-1/NN ,/, and/CC requires/VBZ 
513_513_12_13_9_10::POS_ACTION_INTERACT::,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO 
2222_2222_21_22_37_38::None::,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
1850_1850_8_9_23_24::None::directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN and/CC serves/VBZ to/TO link/VB the/DT cadherin/catenin/NN complex/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
495841_5_24_26_16_17::people.cause_of_death.includes_causes_of_death::SK/NN -/: Mel2/NN melanoma/NN cells/NNS and/CC p53/NN -/: deficient/JJ H1299/NN lung/NN cancer/NN cells/NNS as/RB well/RB ,/, 
1052_1052_37_38_6_8::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
1345_1345_3_4_12_13::None::The/DT ability/NN of/IN WIP/NNP to/TO replace/VB verprolin/NN is/VBZ dependent/JJ on/IN its/PRP$ WH2/NN actin/NN binding/NN domain/NN and/CC 
1957_1957_36_37_15_16::None::EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ cells/NNS at/IN confluence/NN were/VBD dissociated/VBN into/IN single/JJ cells/NNS by/IN tryptic/JJ digestion/NN ,/, being/VBG accompanied/VBN by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
1737_1737_13_15_52_54::None::of/IN PI/NN and/CC PIP/NN kinases/NNS and/CC that/IN under/IN certain/JJ circumstances/NNS activation/NN of/IN the/DT kinases/NNS and/CC the/DT increased/VBN synthesis/NN of/IN PIP/NN and/CC PIP2/NN may/MD be/VB involved/VBN in/IN the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS ,/, possibly/RB through/IN the/DT interaction/NN of/IN the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN 
372073_0_11_12_28_29::None::cultures/NNS prepared/VBN from/IN embryonic/JJ mouse/NN mesencephala/NN were/VBD used/VBN to/TO investigate/VB the/DT neuroprotective/JJ effect/NN of/IN cabergoline/NN ,/, an/DT ergoline/NN D2/NN receptor/NN agonist/NN ,/, against/IN the/DT 
1119_1119_11_12_5_6::None::LIM-kinase/NN 1/CD inactivates/VBZ cofilin/NN ,/, leading/VBG to/TO accumulation/NN of/IN actin/NN filaments/NNS ./. 
1486_1486_41_44_35_40::None::MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
259511_0_30_31_9_11::None::male/NN with/IN past/JJ medical/JJ history/NN of/IN benign/JJ prostatic/JJ hyperplasia/NN presented/VBN to/TO the/DT emergency/NN department/NN with/IN complaints/NNS of/IN decreased/VBN urinary/JJ flow/NN ,/, inability/NN to/TO fully/RB empty/VB his/PRP$ bladder/NN ,/, 
93_93_54_55_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
18_18_6_7_21_22::POS_ACTION_INTERACT::the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) ./. 
1069_1069_29_30_46_47::POS_ACTION_ATTACH::UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
229284_0_4_5_22_23::None::to/TO methotrexate/NN (/( MTX/NN )/) ,/, the/DT ''/'' anchor/NN drug/NN ''/'' for/IN treating/VBG rheumatoid/JJ arthritis/NN (/( RA/NN )/) ,/, varies/VBZ among/IN individual/JJ patients/NNS ./. 
747_747_27_28_30_31::POS_ACTION_BIND::of/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN relative/JJ to/TO Apc/NN 
91905_5_8_9_25_26::None::marker/NN resource/NN (/( Illumina/NNP Infinium/NNP assay/NN )/) for/IN perennial/JJ ryegrass/NN (/( Lolium/NN perenne/NN )/) was/VBD created/VBN and/CC validated/VBN in/IN a/DT broad/JJ ecotype/JJ collection/NN of/IN 
63_63_59_60_49_50::None::.2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN ,/, histone/NN H2B/NN ,/, three/CD histone/NN H3/NN variants/NNS and/CC histone/NN 
367_367_28_30_5_7::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
1334_1334_30_31_0_1::None::act1-157/NN ,/, an/DT actin/NN mutant/NN with/IN an/DT increased/VBN intrinsic/JJ rate/NN of/IN nucleotide/NN exchange/NN ,/, suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN growth/NN ,/, and/CC fluid-phase/JJ endocytosis/NN of/IN pfy1-4/NN ,/, a/DT profilin/NN mutant/NN defective/JJ in/IN 
355_355_14_15_25_26::POS_ACTION_Assembly::of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD form/VB a/DT structural/JJ complex/NN with/IN E-cadherin/NN via/IN these/DT interactions/NNS 
678566_0_28_29_27_28::None::successful/JJ anti/JJ -/: epileptic/JJ drug/NN ./. 
605_605_18_19_23_24::None::products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN genes/NNS ./. 
497295_0_40_42_21_22::medicine.disease.treatments::taxane/NN -/: based/VBN chemotherapy/NN can/MD reach/VB pathologic/JJ complete/JJ response/NN (/( pCR/NN )/) rates/NNS of/IN up/RB to/TO 60/CD %/NN in/IN HER2/NN -/: positive/JJ breast/NN cancer/NN ./. 
266602_0_0_1_9_10::None::Erythrocyte/NN polyunsaturated/JJ fatty/JJ acid/NN levels/NNS in/IN young/JJ people/NNS at/IN ultra/NN -/: high/JJ risk/NN 
2107_2107_39_40_7_8::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
275299_5_5_6_11_12::medicine.drug.active_moieties::are/VBP enriched/VBN in/IN calcification/NN -/: related/JJ processes/NNS ,/, including/VBG calcium/NN ion/NN transport/NN and/CC 
521445_4_22_23_29_30::None::infection/NN ,/, including/VBG medical/JJ optimization/NN ,/, systematic/JJ approaches/NNS to/TO infection/NN management/NN ,/, and/CC the/DT 
315600_15_26_27_2_3::None::GHA/NN priming/NN chemotherapy/NN ,/, as/RB well/RB as/IN other/JJ combination/NN regimens/NNS GHAA/NNP //: GHTA/NNP ,/, are/VBP well/RB -/: tolerated/VBN ,/, effective/JJ regimens/NNS for/IN refractory/JJ AML/NN and/CC advanced/VBD MDS/NN ,/, without/IN severe/JJ 
1008_1008_10_11_4_5::None::of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB ,/, display/VBP 
452211_4_31_32_2_3::people.cause_of_death.includes_causes_of_death::Anti/SYM -/: tumor/NN Bcl/NN -/: 2/CD //: survivin/NN siRNAs/NNS loaded/VBN in/IN the/DT anti/JJ -/: EGFR/NN -/: 9Arg/NN -/: lipoplexes/NNS effectively/RB suppressed/VBD transcription/NN of/IN their/PRP$ target/NN genes/NNS ,/, resulting/VBG in/IN an/DT efficient/JJ cancer/NN cell/NN death/NN ./. 
2013_2013_7_9_9_10::POS_ACTION_MEMBER::motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN 
356156_0_7_8_0_1::None::In/IN 2009/CD ,/, the/DT US/NNP Food/NNP and/CC Drug/NNP Administration/NNP (/( FDA/NNP 
23235_3_30_31_45_47::None::Ag/NN )/) and/CC activity/NN (/( vWF/NN :/: GP1bA/NN )/) ,/, factor/NN VIII/CD (/( FVIII/CD :/: C/NN )/) ,/, lupus/NN anticoagulant/NN ,/, and/CC functional/JJ 
276_276_21_22_4_6::None::site-directed/JJ mutagenesis/NN of/IN profilin/NN II/CD from/IN Dictyostelium/NNP discoideum/NN the/DT point/NN mutations/NNS K114E/NN and/CC W3N/NN were/VBD generated/VBN by/IN PCR/NN thus/RB changing/VBG actin/NN and/CC poly/NN -/: 
36424_0_27_28_29_30::None::MC/NNP )/) Dose/NNP Calculation/NN in/IN Stereotactic/JJ Body/NN Radiation/NNP Therapy/NN 
72_72_17_18_0_1::POS_ACTION_SUPPRESS::Aip1p/NN localizes/VBZ to/TO cortical/JJ actin/NN patches/NNS in/IN yeast/NN cells/NNS ,/, and/CC this/DT localization/NN is/VBZ disrupted/VBN by/IN specific/JJ actin/NN and/CC cofilin/NN mutations/NNS 
367549_2_13_14_1_2::None::Staphylococcus/FW aureus/FW (/( n/NN =/JJ 35/CD from/IN 19/CD herds/NNS )/) ,/, coagulase/NN -/: negative/JJ staphylococci/NNS (/( n/NN 
339_339_13_14_10_11::POS_ACTION_MODIFY::modulation/NN of/IN the/DT actin/NN cytoskeleton/NN by/IN cofilin/NN and/CC Aip1/NN ./. 
556_556_7_9_12_13::None::to/TO be/VB a/DT nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ 
1737_1737_58_59_13_15::None::of/IN PI/NN and/CC PIP/NN kinases/NNS and/CC that/IN under/IN certain/JJ circumstances/NNS activation/NN of/IN the/DT kinases/NNS and/CC the/DT increased/VBN synthesis/NN of/IN PIP/NN and/CC PIP2/NN may/MD be/VB involved/VBN in/IN the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS ,/, possibly/RB through/IN the/DT interaction/NN of/IN the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
1857_1857_9_11_17_18::POS_ACTION_BIND::quantitative/JJ conversion/NN of/IN platelet/NN profilin/NN and/CC gelsolin/NN to/TO high-affinity/JJ complexes/NNS with/IN actin/NN ,/, but/CC these/DT 
193027_2_32_33_37_38::medicine.drug_ingredient.active_moiety_of_drug::with/IN PEGylated/VBN liposomal/JJ doxorubicin/NN (/( PLD/NN )/) //: Doxil/NNP for/IN ovarian/JJ cancer/NN 
8_8_26_27_13_14::NEG_ACTION_Amount::1/CD integrins/NNS ,/, pp125/CD focal/JJ adhesion/NN kinase/NN ,/, and/CC alpha-catenin/NN is/VBZ not/RB affected/VBN by/IN the/DT differential/JJ calreticulin/NN expression/NN ./. 
735_735_22_23_24_25::None::cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, and/CC tropomyosin/NN 
567_567_7_9_18_19::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
2_2_9_10_0_1::None::alpha-catenin/NN inhibits/VBZ beta-catenin/NN signaling/NN by/IN preventing/VBG formation/NN of/IN a/DT beta-catenin/NN */SYM T-cell/NN factor/NN 
923_923_7_8_4_5::None::measurements/NNS indicate/VBP that/IN profilin/NN binding/NN to/TO actin/NN weakens/VBZ the/DT affinity/NN 
652_652_13_14_8_9::None::in/IN beta-catenin/NN ,/, alpha-catenin/NN ,/, and/CC p120/NN (/( Cas/NNS )/) and/CC caused/VBD 
1861_1861_12_13_2_3::None::Thus/RB ,/, APC/NN forms/NNS distinct/JJ heteromeric/JJ complexes/NNS containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
573581_3_2_3_0_1::None::This/DT study/NN aims/VBZ to/TO investigate/VB the/DT 
63_63_44_45_25_26::POS_ACTION_MEMBER::electrophoresis/NN :/: histone/NN H1/NN (/( 0/CD )/) ,/, four/CD histone/NN H1/NN subfractions/NNS ,/, histone/NN H2A/NN .1/NN ,/, histone/NN H2A/NN .2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, 
574065_1_22_25_20_21::None::European/JJ Association/NNP of/IN Urology/NNP ,/, American/NNP Urological/NNP Association/NNP ,/, American/NNP Society/NNP 
343970_4_37_38_40_41::medicine.drug.active_moieties::TDN/NN )/) and/CC nitrate/JJ nitrogen/NN (/( NO3/NN (/( -/: )/) 
183879_18_13_14_14_15::medicine.disease.symptoms::significantly/RB reversed/VBD the/DT depressive/JJ mood/NN of/IN patients/NNS with/IN 
88435_3_32_33_15_17::medicine.medical_treatment.used_to_treat::agent/NN chemotherapy/NN or/CC hormonal/JJ therapy/NN ,/, with/IN at/IN least/JJS three/CD distinct/JJ measurable/JJ sites/NNS of/IN disease/NN ,/, were/VBD treated/VBN with/IN concurrent/JJ radiotherapy/NN (/( 35/CD Gy/NN 
380111_3_18_19_16_17::None::Au/SYM -/: H/NN insertion/NN minimum/NN attributed/VBD to/TO the/DT stabilization/NN 
776_776_29_30_26_27::None::of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
980_980_14_15_18_19::None::of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN beta-catenin/NN to/TO the/DT cytoplasm/NN 
76585_4_7_8_1_2::None::Exclusion/NN criteria/NNS were/VBD :/: tobacco/NN consumption/NN ,/, hypercholesterolemia/NN ,/, diabetes/NN ,/, 
996_996_12_13_5_7::None::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT 
367_367_24_25_32_33::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
10441_0_13_14_3_4::medicine.disease.symptoms::Distal/JJ symmetric/JJ peripheral/JJ polyneuropathy/NN (/( DSPN/NN )/) is/VBZ a/DT highly/RB prevalent/JJ complication/NN of/IN diabetes/NN ./. 
28_28_0_2_3_4::None::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN 
154535_13_0_1_15_16::None::Our/PRP$ data/NNS suggest/VBP a/DT complex/JJ interplay/NN among/IN insulin/NN resistance/NN ,/, obesity/NN ,/, and/CC depression/NN in/IN PCOS/NN ,/, warranting/VBG additional/JJ 
1743_1743_4_5_11_12::POS_ACTION_MODULATE::results/NNS suggest/VBP that/IN RAD52/NN may/MD modulate/VB the/DT catalytic/JJ activities/NNS of/IN RAD51/NN protein/NN such/JJ as/IN 
287311_9_1_2_103_104::None::The/DT AUROC/NN values/NNS for/IN VFA/NNP were/VBD higher/JJR than/IN those/DT for/IN BMI/NNP and/CC WHR/NNP For/IN VFA/NNP ,/, the/DT sensitivity/NN and/CC specificity/NN for/IN predicting/VBG CKD/NNP were/VBD 62.66/CD %/NN (/( 95/CD %/NN CI/NN ,/, 61.0/CD -/: 64.3/CD )/) and/CC 64.22/CD %/NN (/( 95/CD %/NN CI/NN ,/, 63.5/CD -/: 64.9/CD )/) ,/, respectively/RB ,/, and/CC 77.65/CD %/NN (/( 95/CD %/NN CI/NN ,/, 76.3/CD -/: 79.0/CD )/) ,/, and/CC 68.81/CD %/NN (/( 95/CD %/NN CI/NN ,/, 68.1/CD -/: 69.5/CD )/) ,/, respectively/RB for/IN predicting/VBG MS/NN Our/PRP$ results/NNS demonstrated/VBD that/IN the/DT VFA/NNP ,/, measured/VBN by/IN BIA/NNP ,/, is/VBZ a/DT simple/JJ method/NN for/IN predicting/VBG the/DT risk/NN of/IN CKD/NN and/CC MS/NN Copyright/NN 2015/CD S/NN Karger/NNP 
240152_0_41_42_28_30::None::industrial/JJ district/NN in/IN northeast/JJ China/NNP and/CC were/VBD analyzed/VBN for/IN contents/NNS of/IN titanium/NN (/( Ti/NN )/) ,/, copper/NN (/( Cu/NN )/) 
1025_1025_27_28_0_1::POS_ACTION_BIND::Myo2p/NN shows/VBZ homology/NN to/TO the/DT head/NN domains/NNS and/CC the/DT coiledcoil/NN tail/NN of/IN the/DT conventional/JJ type/NN II/CD myosin/NN heavy/JJ chain/NN and/CC carries/VBZ putative/JJ binding/NN sites/NNS for/IN ATP/NN and/CC actin/NN ./. 
1061_1061_15_16_6_7::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, 
986_986_25_26_11_12::None::central/JJ role/NN of/IN beta-catenin/NN in/IN this/DT adhesion/NN complex/NN ,/, as/IN it/PRP binds/VBZ to/TO the/DT cytoplasmic/JJ domain/NN of/IN E-cadherin/NN and/CC to/TO alpha-catenin/NN 
93_93_54_55_24_26::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
1052_1052_6_8_18_20::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) 
507_507_28_29_3_4::POS_ACTION_BIND::For/IN example/NN ,/, profilin/NN with/IN a/DT deletion/NN of/IN the/DT eight/CD C-terminal/JJ residues/NNS has/VBZ many/JJ of/IN the/DT physical/JJ properties/NNS of/IN a/DT molten/JJ globule/NN ,/, yet/RB remarkably/RB still/RB binds/VBZ to/TO actin/NN ./. 
724990_11_0_1_28_29::None::The/DT results/NNS of/IN the/DT present/JJ study/NN suggest/VBP that/IN use/NN of/IN etoricoxib/NN ,/, especially/RB at/IN low/JJ dose/NN ,/, in/IN patients/NNS with/IN epilepsy/NN may/MD not/RB be/VB detrimental/JJ with/IN regard/NN to/TO seizure/NN control/NN ./. 
1386_1386_18_19_1_2::None::The/DT UL8/NN component/NN of/IN the/DT herpes/NN simplex/NN virus/NN helicase-primase/JJ complex/NN stimulates/VBZ primer/NN synthesis/NN by/IN a/DT subassembly/NN of/IN the/DT UL5/NN and/CC UL52/NN components/NNS 
1486_1486_32_33_35_40::None::protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ 
872_872_6_7_11_12::None::the/DT role/NN of/IN MSH2/NN ,/, MSH3/NN ,/, and/CC MSH6/NN in/IN mismatch/NN repair/NN 
2075_2075_21_23_14_15::POS_ACTION_MEMBER::interact/VB with/IN yeast/NN profilin/NN and/CC tropomyosin/NN ,/, the/DT only/JJ yeast/NN actin-binding/JJ proteins/NNS so/RB far/RB purified/VBN 
569500_0_9_10_7_8::None::activity/NN patterns/NNS after/IN Roux/NNP -/: en/IN Y/NN gastric/JJ bypass/NN 
2148_2148_4_5_52_53::POS_ACTION_BIND::report/VBP here/RB that/IN tropomyosin/NN ,/, which/WDT is/VBZ found/VBN in/IN the/DT rootlet/NN but/CC not/RB in/IN the/DT microvillus/JJ core/NN ,/, can/MD bind/VB to/TO and/CC saturate/VB the/DT actin/NN of/IN isolated/VBN cores/NNS ,/, and/CC can/MD cause/VB the/DT dissociation/NN of/IN up/RB to/TO 30/CD %/NN of/IN the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ 
148500_0_11_12_12_13::medicine.disease.symptoms::Frequency/NN Oscillations/NNS and/CC Epileptic/JJ Seizures/NNS in/IN a/DT Computational/JJ 
416817_3_45_46_17_18::None::to/TO support/VB longitudinal/JJ data/NN analysis/NN and/CC pragmatic/JJ clinical/JJ trials/NNS in/IN asthma/NN and/CC COPD/NNP This/DT involved/VBD a/DT retrospective/JJ extraction/NN of/IN data/NNS from/IN all/DT registered/VBN practices/NNS in/IN Salford/NNP to/TO identify/VB a/DT cohort/NN of/IN patients/NNS with/IN a/DT diagnosis/NN 
452794_0_10_11_0_1::None::Efficacy/NN and/CC safety/NN of/IN anticoagulation/NN therapy/NN with/IN different/JJ doses/NNS of/IN enoxaparin/NN for/IN portal/JJ vein/NN 
397679_0_3_4_23_24::None::To/TO study/VB the/DT impact/NN of/IN novel/JJ treatments/NNS for/IN elderly/JJ (/( gtgt/NN =/JJ 66/CD yr/NN )/) patients/NNS with/IN multiple/JJ myeloma/NN (/( MM/NN )/) in/IN daily/JJ practice/NN by/IN comparing/VBG 
1338_1338_23_24_23_24::None::nucleotide/NN exchange/NN on/IN actin/NN ,/, and/CC promoting/VBG 
30983_5_1_2_8_9::None::Study/NNP group/NN had/VBD significantly/RB lower/JJR mean/NN concentration/NN of/IN estradiol/NN and/CC higher/JJR intensity/NN 
1466_1466_3_4_5_6::None::The/DT E-cadherin-associated/JJ proteins/NNS alpha-catenin/NN and/CC beta-catenin/NN were/VBD not/RB significantly/RB 
685_685_14_15_30_31::None::to/TO E-cadherin/NN ,/, alpha-catenin/NN ,/, and/CC gamma-catenin/NN and/CC a/DT 79-kDa/JJ band/NN which/WDT was/VBD apparently/RB smaller/JJR than/IN that/DT of/IN normal/JJ beta-catenin/NN ,/, indicating/VBG truncated/VBN 
1052_1052_37_38_29_30::None::with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
1069_1069_21_22_42_45::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
783888_0_36_37_5_6::medicine.disease.treatments::the/DT use/NN of/IN promethazine/NN 6.25/CD mg/NN intravenous/JJ (/( IV/CD )/) (/( experimental/JJ group/NN )/) with/IN promethazine/NN 12.5/CD mg/NN IV/CD (/( control/NN group/NN )/) among/IN adult/JJ ambulatory/JJ surgery/NN patients/NNS to/TO control/VB established/JJ postoperative/JJ nausea/NN or/CC vomiting/NN (/( PONV/NN )/) 
470116_0_16_20_10_11::None::and/CC Emphysema/NNP Is/VBZ Associated/VBN with/IN Dyspnea/NN and/CC Hospitalization/NN for/IN Chronic/JJ Obstructive/JJ Pulmonary/JJ Disease/NN ./. 
739076_0_24_25_13_14::None::sleep/NN apnea/NN (/( OSA/NN )/) is/VBZ gaining/VBG popularity/NN ,/, especially/RB in/IN children/NNS with/IN mild/JJ disease/NN ./. 
75_75_1_2_17_18::POS_ACTION_MODIFY::A/DT LIMK2/NN mutant/NN with/IN replacement/NN of/IN threonine/NN 505/CD by/IN valine/NN abolished/VBD LIMK2/NN activities/NNS for/IN cofilin/NN phosphorylation/NN and/CC actin/NN cytoskeletal/JJ changes/NNS ,/, 
1652_1652_31_32_45_46::None::preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
856_856_13_14_40_41::None::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
169857_11_6_9_7_9::medicine.disease.symptoms::patients/NNS with/IN severe/JJ obstructive/JJ sleep/NN apnea/NN ,/, 86.7/CD %/NN 
596785_1_18_19_10_11::None::referred/VBN for/IN surgical/JJ ablation/NN due/JJ to/TO persistent/JJ AF/NN combined/VBN with/IN biatrial/JJ dilatation/NN (/( left/JJ atrium/NN 
524639_5_3_4_14_15::None::A/DT majority/NN of/IN data/NNS indicate/VBP that/IN all/PDT the/DT selective/JJ COX/NNP -/: 2/CD inhibitors/NNS ,/, diclofenac/NN and/CC high/JJ -/: 
1755_1755_13_14_26_27::POS_ACTION_BIND::the/DT interaction/NN with/IN actin/NN and/CC ,/, therefore/RB ,/, may/MD constitute/VB part/NN of/IN the/DT actin-binding/JJ domain/NN of/IN cofilin/NN ./. 
1061_1061_6_7_25_27::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
177255_4_0_1_12_13::None::In/IN this/DT paper/NN the/DT possibility/NN to/TO protect/VB from/IN diabetic/JJ foot/NN infection/NN with/IN modified/VBN cotton/NN socks/NNS ./. 
1064_1064_8_9_15_16::None::yeast/NN actin-binding/JJ protein/NN Sac6p/NN ,/, which/WDT is/VBZ homologous/JJ to/TO vertebrate/JJ fimbrin/NN (/( Adams/NNP ,/, 
267_267_26_27_24_25::None::on/IN patches/NNS containing/VBG vinculin/NN and/CC talin/NN ;/: thus/RB the/DT 
102783_0_16_17_4_5::medicine.drug.active_moieties::(/( imidazole/NN -/: Cu/NN )/) -/: mediated/VBN C1/NN //: C1N2/NN copolymerization/NN of/IN ethyl/NN diazoacetate/NN involved/VBN copper/NN -/: based/VBN carbene/NN 
86_86_14_15_28_29::POS_ACTION_BIND::all/DT sera/NNS caused/VBD IgG/NN binding/NN to/TO platelet/NN components/NNS of/IN 87-90/CD kD/NN ,/, 140/CD kD/NN (/( identified/VBN as/IN vinculin/NN )/) and/CC 220-240/CD 
693828_2_8_9_15_16::medicine.symptom.symptom_of::conducted/VBN on/IN studies/NNS assessing/VBG the/DT clinical/JJ characteristics/NNS and/CC correlates/VBZ of/IN unipolar/JJ MDD/NN and/CC bipolar/JJ 
292_292_0_1_11_14::None::CD26/NN ,/, a/DT T/NN cell/NN activation/NN Ag/NN ,/, also/RB known/VBN as/IN dipeptidyl/NN peptidase/NN IV/CD ,/, is/VBZ directly/RB 
113339_0_19_20_2_4::biology.organism_classification.lower_classifications::To/TO identity/NN Plasmodium/NN ovale/NN infection/NN by/IN 18S/NNP rRNA/NN gene/NN nested/JJ PCR/NN Whole/JJ blood/NN and/CC filter/NN paper/NN blood/NN samples/NNS of/IN malaria/NN patients/NNS in/IN Shandong/NNP 
1087_1087_10_12_25_26::POS_ACTION_ASSEMBLE::profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT actin/NN cytoskeleton/NN and/CC endocytic/JJ membrane/NN flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN to/TO distinct/JJ 
2013_2013_9_10_0_1::POS_ACTION_BIND::WASp/NN contains/VBZ a/DT binding/NN motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN 
118239_0_10_11_45_46::None::on/IN a/DT mesostructured/JJ ceria/NN -/: supported/VBN gold/NN (/( Au/NN //: meso/SYM -/: CeO2/NN )/) catalyst/NN was/VBD developed/VBN for/IN the/DT synthesis/NN of/IN various/JJ aromatic/JJ azo/NN compounds/NNS by/IN the/DT reductive/JJ coupling/NN of/IN the/DT corresponding/JJ nitroaromatics/NNS ,/, using/VBG CO/NNP as/IN the/DT sole/JJ deoxygenative/JJ reagent/NN ,/, 
133249_2_16_17_1_3::medicine.disease.risk_factors::Although/IN cigarette/NN smoke/NN increases/VBZ TLR4/NN expression/NN ,/, TLR4/NN signaling/NN is/VBZ altered/VBN in/IN smokers/NNS and/CC in/IN smokers/NNS COPD/NN patients/NNS ./. 
280859_11_5_6_6_7::None::and/CC obese/JJ participants/NNS fat/JJ mass/NN was/VBD reduced/VBN with/IN 
131579_0_16_17_50_51::None::for/IN locally/RB advanced/JJ resectable/JJ oral/JJ cavity/NN squamous/JJ cell/NN carcinoma/NN ,/, 24/CD patients/NNS with/IN T3/NN or/CC T4a/NN oral/JJ cavity/NN squamous/JJ cell/NN carcinoma/NN were/VBD randomly/RB assigned/VBN to/TO surgery/NN alone/RB or/CC Docetaxel/NNP ,/, Cisplatin/NNP ,/, and/CC 5/LS -/: FU/NN (/( TPF/NN )/) induction/NN chemotherapy/NN 
102233_0_2_3_0_4::medicine.symptom.symptom_of::Complex/JJ regional/JJ pain/NN syndrome/NN (/( CRPS/NN )/) 
237_237_5_6_9_10::None::causes/VBZ phosphorylation/NN of/IN talin/NN and/CC redistribution/NN of/IN actin/NN microfilaments/NNS in/IN fibroblasts/NNS 
342702_0_37_38_20_21::None::have/VBP fuelled/VBN the/DT development/NN of/IN targeted/VBN therapies/NNS that/WDT block/VBP cytokine/NN networks/NNS and/CC pathogenic/JJ immune/JJ cells/NNS ,/, leading/VBG to/TO a/DT considerable/JJ improvement/NN in/IN the/DT management/NN 
456_456_2_3_17_18::NEG_ACTION_CORELATE::Expression/NN of/IN alpha-catenin/NN was/VBD generally/RB weak/JJ and/CC did/VBD not/RB correlate/VB with/IN the/DT expression/NN of/IN either/CC beta-catenin/NN or/CC E-cadherin/NN ./. 
1219_1219_20_21_11_12::None::enhanced/VBD interaction/NN between/IN TRADD/NN and/CC FADD/MORT1/NN and/CC increased/VBN cells/NNS '/POS sensitivity/NN to/TO TNF/NN ./. 
218696_6_22_24_17_18::None::)/) ,/, with/IN higher/JJR incidence/NN of/IN major/JJ coronary/JJ risk/NN factors/NNS ,/, co/SYM -/: 
275299_5_24_25_5_6::None::are/VBP enriched/VBN in/IN calcification/NN -/: related/JJ processes/NNS ,/, including/VBG calcium/NN ion/NN transport/NN and/CC calcium/NN signaling/NN pathways/NNS as/IN revealed/VBN by/IN gene/NN ontology/NN (/( GO/NN )/) and/CC Kyoto/NNP 
759_759_12_13_20_24::POS_REG(-)_INCREASE::cell/NN strain/NN ,/, EGF/NN inhibited/VBD increases/NNS in/IN immunoreactive/JJ sarcomeric/JJ actin/NN and/CC sarcomeric/JJ myosin/NN heavy/JJ chain/NN (/( SMHC/NN )/) 
1977_1977_16_17_22_23::POS_ACTION_BIND::a/DT region/NN in/IN alpha-catenin/NN required/VBN for/IN molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
196539_13_14_16_3_4::people.cause_of_death.includes_causes_of_death::The/DT association/NN between/IN cardiovascular/JJ fitness/NN and/CC adverse/JJ cardiovascular/JJ outcomes/NNS may/MD be/VB modulated/VBN through/IN traditional/JJ cardiovascular/JJ risk/NN factors/NNS ./. 
1761_1761_23_25_15_16::None::HPIV3/NN nucleocapsid/NN protein/NN N/NN ,/, the/DT phosphoprotein/NN P/NN ,/, and/CC the/DT polymerase/NN protein/NN L./NN 
1345_1345_6_7_3_4::POS_ACTION_SIMILAR::The/DT ability/NN of/IN WIP/NNP to/TO replace/VB verprolin/NN is/VBZ dependent/JJ on/IN 
2064_2064_28_29_40_41::None::,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN 
184609_0_17_19_20_21::None::NO/NN )/) by/IN NO/NN synthase/NN (/( NOS/NN )/) takes/VBZ place/NN 
665_665_14_17_19_20::POS_ACTION_MEMBER::antibodies/NNS to/TO the/DT actin/NN binding/NN proteins/NNS Abp1p/NN and/CC cofilin/NN ./. 
20599_4_45_49_8_9::None::a/DT double/JJ -/: blind/JJ ,/, phase/NN 2/CD study/NN in/IN patients/NNS with/IN non/JJ -/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) randomized/VBN to/TO erlotinib/VB with/IN placebo/NN or/CC with/IN high/JJ or/CC low/JJ doses/NNS of/IN patritumab/NN ,/, a/DT monoclonal/JJ antibody/NN targeted/VBN against/IN human/JJ epidermal/JJ growth/NN factor/NN receptor/NN 3/CD (/( HER3/NN 
429251_0_6_7_4_5::medicine.drug.active_moieties::evidence/NN suggests/VBZ that/IN dopamine/NN (/( DA/NN )/) is/VBZ involved/VBN 
710191_0_20_21_14_15::None::are/VBP both/DT poor/JJ prognostic/JJ factors/NNS with/IN synergistic/JJ effect/NN on/IN locally/RB advanced/JJ head/NN and/CC 
628556_0_14_15_9_10::medicine.medical_treatment.used_to_treat::Head/NNP and/CC Neck/NNP Cancer/NNP :/: Implications/NNS for/IN Adaptive/JJ Radiotherapy/NN ./. 
93_93_50_51_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
2014_2014_30_31_23_24::None::mutants/NNS defective/JJ in/IN rhp51/NN and/CC rhp54/NN (/( homologues/NNS of/IN S.cerevisiae/NNP RAD51/NN and/CC RAD54/NN ,/, 
1866_1866_7_8_5_6::POS_ACTION_RELATE::both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, 
702752_2_16_19_28_30::None::inhibitor/NN ,/, in/IN T/NN cell/NN activation/NN ,/, proliferation/NN ,/, and/CC differentiation/NN using/VBG isolated/VBN murine/JJ splenic/JJ T/NN cells/NNS from/IN C57BL/NN //: 
865150_0_22_23_4_5::medicine.medical_treatment.used_to_treat::-/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) remains/VBZ the/DT most/RBS common/JJ cause/NN of/IN cancer/NN death/NN worldwide/RB due/JJ its/PRP$ resistance/NN to/TO chemotherapy/NN and/CC aggressive/JJ tumor/NN 
350981_0_10_11_12_13::None::of/IN Mind/NNP and/CC Body/NNP -/: The/NNP ALPIM/NNP (/( Anxiety/NN 
1474_1474_29_31_9_10::None::(/( serum/NN and/CC laminin/NN )/) and/CC time/NN in/IN culture/NN on/IN the/DT expression/NN of/IN genes/NNS encoding/VBG myosin/NN heavy/JJ chain/NN (/( MHC/NN )/) isoforms/NNS and/CC alpha-skeletal/JJ actin/NN were/VBD analysed/VBN in/IN 
30174_0_33_34_12_13::None::During/IN Anti/NNP -/: Cancer/NNP Treatment/NNP Period/NN in/IN Elderly/NNP Lung/NN Cancer/NN Patients/NNS on/IN Community/NN -/: Acquired/VBN Pneumonia/NNP Hospitalization/NNP :/: A/NNP Nationwide/NNP Population/NNP -/: Based/VBD Cohort/NNP Study/NNP ./. 
459318_0_18_19_2_3::medicine.drug.active_moieties::Synthesis/NN of/IN copper/NN micro/JJ -/: rods/NNS with/IN layered/JJ nano/NN -/: structure/NN by/IN thermal/JJ decomposition/NN of/IN the/DT coordination/NN complex/NN Cu/NN (/( BTA/NN )/) 
1771_1771_1_2_11_14::None::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, 
1923_1923_52_53_52_53::None::)/) than/IN cys-374-labeled/JJ actin/NN (/( Kd/NN >/JJR 
702304_0_6_7_16_19::None::high/JJ risk/NN for/IN atherosclerotic/JJ cardiovascular/JJ disease/NN (/( ASCVD/NN )/) and/CC are/VBP considered/VBN a/DT coronary/JJ heart/NN disease/NN risk/NN equivalent/NN ./. 
317242_0_20_21_39_40::None::granulation/NN and/CC immunohistochemical/JJ hormone/NN expression/NN ,/, such/JJ as/IN growth/NN hormone/NN (/( GH/NN )/) ,/, prolactin/NN ,/, adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) ,/, thyroid/NN stimulating/NN hormone/NN (/( 
640_640_25_26_25_26::None::can/MD not/RB increase/VB profilin/NN 's/POS affinity/NN for/IN 
608_608_18_19_23_24::None::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS (/( Crute/NNP 
151537_7_39_40_30_31::None::(/( lymphoma/NN ,/, leukaemia/NN )/) ,/, bladder/NN cancer/NN ,/, intracranial/JJ neoplasms/NNS (/( meningioma/NN ,/, glioma/NN )/) 
831385_3_33_34_11_12::None::relation/NN to/TO the/DT artemisinin/NN inhibitory/JJ effect/NN on/IN P/NN falciparum/NN and/CC recent/JJ studies/NNS have/VBP provided/VBN evidence/NN that/IN the/DT parasite/NN with/IN this/DT mutation/NN is/VBZ more/RBR susceptible/JJ to/TO CPA/NNP Here/RB ,/, we/PRP 
1532_1532_31_33_31_33::POS_ACTION_CORELATE::displace/VB SNAP-23/NN from/IN syntaxin/NN 3/CD complexes/NNS when/WRB overexpressed/VBN 
492455_9_0_1_21_22::None::The/DT MASC/NNP has/VBZ probably/RB a/DT more/RBR limited/JJ function/NN in/IN screening/VBG for/IN AD/NN among/IN a/DT highly/RB comorbid/JJ inpatient/JJ sample/NN of/IN severely/RB affected/VBN adolescents/NNS ./. 
492693_2_58_59_47_48::None::with/IN the/DT Tc/NN reaching/VBG 49/CD K/NN at/IN 21/CD GPa/NN The/DT appearance/NN of/IN a/DT new/JJ superconducting/JJ phase/NN is/VBZ not/RB 
218394_4_16_17_0_1::None::To/TO determine/VB the/DT effect/NN of/IN prehospital/JJ thrombolysis/NN for/IN acute/JJ ischemic/JJ stroke/NN administered/VBN in/IN specialized/VBN ambulances/NNS on/IN delay/NN in/IN thrombolytic/JJ administration/NN 
320864_0_11_12_37_38::medicine.disease.risk_factors::of/IN maintaining/VBG a/DT high/JJ Hb/NN target/NN range/NN through/IN erythropoiesis/NN -/: stimulating/VBG agent/NN therapy/NN on/IN the/DT renal/JJ outcome/NN with/IN respect/NN to/TO chronic/JJ kidney/NN disease/NN (/( CKD/NN )/) stage/NN and/CC concurrent/JJ diabetes/NN condition/NN in/IN patients/NNS 
250192_5_0_1_23_25::None::Celecoxib/NNP was/VBD as/IN effective/JJ as/IN naproxen/NN in/IN reducing/VBG OA/NN pain/NN (/( least/JJS squares/NNS mean/VBP change/NN from/IN baseline/NN in/IN visual/JJ analogue/NN scale/NN score/NN [/( standard/JJ error/NN ]/) -/: 37.1/CD 
2131_2131_23_24_7_8::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
350850_8_15_16_22_23::medicine.risk_factor.diseases::the/DT presence/NN of/IN diabetes/NN (/( P/NN =/JJ 0.006/CD )/) ,/, hypertension/NN (/( P/NN &/CC 
784_784_12_13_21_22::None::,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
2074_2074_12_13_16_17::POS_ACTION_COLOCALIZE::the/DT nucleocapsid/NN (/( N/NN )/) protein/NN and/CC phosphoprotein/NN (/( P/NN )/) 
1866_1866_9_10_3_4::POS_ACTION_Change::Thus/RB ,/, both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN 
1851_1851_17_18_21_22::POS_ACTION_SIMILAR::been/VBN identified/VBN :/: Armadillo/NN (/( homolog/NN of/IN beta-catenin/NN )/) ,/, Drosophila/FW 
274753_0_27_28_1_2::None::Electronic/JJ cigarettes/NNS (/( e/SYM -/: cigarettes/NNS )/) are/VBP a/DT relatively/RB recent/JJ phenomenon/NN ,/, serving/VBG dual/JJ roles/NNS as/IN an/DT alternative/JJ vehicle/NN for/IN nicotine/NN delivery/NN and/CC a/DT smoking/NN -/: cessation/NN tool/NN ./. 
503061_9_11_12_7_8::None::study/NN shows/VBZ that/IN NXT/NNP can/MD inhibit/VB the/DT development/NN of/IN diabetic/JJ retinopathy/NN 
1037_1037_21_22_27_28::None::the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
492693_2_71_72_116_117::None::as/IN evidenced/VBN by/IN pressure/NN -/: dependent/JJ XRD/NNP Furthermore/RB ,/, Tc/NN slowly/RB decreased/VBD with/IN increasing/VBG pressure/NN above/IN 21/CD GPa/NN ,/, and/CC at/IN 41/CD GPa/NN superconductivity/NN disappeared/VBD entirely/RB at/IN temperatures/NNS above/IN 4.9/CD K/NN The/DT observation/NN of/IN a/DT double/JJ -/: dome/NN superconducting/JJ phase/NN may/MD provide/VB a/DT hint/NN for/IN pursuing/VBG the/DT superconducting/VBG coupling/NN -/: mechanism/NN of/IN 
1380_1380_36_37_26_27::None::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, 
1652_1652_18_19_43_44::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, 
1156_1156_7_8_10_11::POS_ACTION_MUTUALCOMPLEX::with/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN ,/, all/DT components/NNS 
201815_2_6_7_16_17::None::we/PRP established/VBD a/DT silkworm/NN model/NN of/IN type/NN II/CD diabetes/NNS for/IN the/DT evaluation/NN of/IN anti/JJ -/: diabetic/JJ drugs/NNS 
759_759_17_19_20_24::None::increases/NNS in/IN immunoreactive/JJ sarcomeric/JJ actin/NN and/CC sarcomeric/JJ myosin/NN heavy/JJ chain/NN (/( SMHC/NN )/) 
1069_1069_29_30_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT 
93_93_24_26_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
1219_1219_20_21_0_1::None::RIPc/NN ,/, one/CD of/IN the/DT cleavage/NN products/NNS ,/, enhanced/VBD interaction/NN between/IN TRADD/NN and/CC FADD/MORT1/NN and/CC increased/VBN cells/NNS '/POS sensitivity/NN to/TO TNF/NN ./. 
1652_1652_20_21_45_46::None::with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
1434_1434_75_76_11_12::None::,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
229_229_11_12_15_16::None::(/( flk-1/NN //: KDR/NN )/) tyrosine-autophosphorylation/NN by/IN VEGF/NN which/WDT was/VBD maximal/JJ 
1373_1373_11_12_4_5::None::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
76705_14_16_17_13_14::None::rise/NN showed/VBD a/DT high/JJ prevalence/NN of/IN CVE/NN but/CC not/RB stroke/NN 
703552_5_16_17_37_38::medicine.symptom.symptom_of::the/DT effect/NN of/IN hyperglycemia/NN on/IN expression/NN of/IN IL/NN -/: 1/CD family/NN members/NNS in/IN retinal/JJ layers/NNS ,/, using/VBG an/DT in/FW vivo/FW model/NN of/IN type/NN 1/CD diabetes/NN ./. 
125255_5_24_25_12_13::None::well/RB as/IN several/JJ pathophysiological/JJ alterations/NNS such/JJ as/IN hypertension/NN ,/, hypertrophy/NN ,/, diabetes/NN ,/, hypercholesterolemia/NN ,/, ischemia/NN ,/, post/NN -/: 
333090_0_0_1_1_2::None::Prevalence/NN estimates/NNS for/IN depression/NN and/CC 
1466_1466_5_6_3_4::None::The/DT E-cadherin-associated/JJ proteins/NNS alpha-catenin/NN and/CC beta-catenin/NN were/VBD not/RB significantly/RB 
2137_2137_4_5_15_18::POS_ACTION_BIND::previously/RB showed/VBD that/IN actin/NN is/VBZ transported/VBN in/IN an/DT unassembled/JJ form/NN with/IN its/PRP$ associated/JJ proteins/NNS actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, 
1178_1178_14_15_14_15::None::does/VBZ not/RB bind/VB actin/NN directly/RB ./. 
919_919_12_13_20_21::POS_ACTION_Assembly::E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT can/MD assemble/VB alpha-catenin/NN into/IN the/DT complex/NN 
1742_1742_4_5_15_16::POS_ACTION_MODIFY::results/NNS suggest/VBP that/IN profilin/NN may/MD be/VB involved/VBN in/IN the/DT pathogenesis/NN of/IN glomerulonephritis/NN by/IN reorganizing/VBG actin/NN cytoskeleton/NN ./. 
537_537_18_19_6_7::POS_ACTION_COEXPRESS::inactivating/VBG effect/NN of/IN calmodulin/NN can/MD be/VB prevented/VBN by/IN coexpressing/VBG a/DT region/NN of/IN the/DT cytoskeletal/JJ protein/NN alpha-actinin2/NN known/VBN to/TO interact/VB 
1169_1169_26_27_13_16::None::actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD 
112017_4_4_5_1_2::None::The/DT patients/NNS had/VBD situational/JJ disorders/NNS ,/, with/IN a/DT 
919_919_20_21_14_15::None::either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT can/MD assemble/VB alpha-catenin/NN into/IN the/DT complex/NN 
178051_0_38_39_39_40::None::measured/VBN by/IN the/DT modified/VBN Rankin/NNP scale/NN ./. 
833154_0_0_1_8_9::None::Management/NN of/IN angioedema/NN without/IN urticaria/NN in/IN the/DT emergency/NN department/NN ./. 
447089_0_10_11_7_9::medicine.drug_ingredient.active_moiety_of_drug::we/PRP showed/VBD that/IN adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) promoted/VBD erythroblast/NN 
683800_2_32_33_23_24::None::extant/JJ squamates/NNS (/( lizards/NNS and/CC snakes/NNS )/) but/CC is/VBZ poorly/RB understood/VBN in/IN archosaurs/NNS (/( crocodylians/NNS and/CC 
4599_8_13_14_43_44::medicine.medical_treatment.used_to_treat::male/NN offspring/NN by/IN ICSI/NN ,/, it/PRP will/MD be/VB essential/JJ to/TO counsel/NN the/DT couples/NNS for/IN the/DT transmission/NN of/IN the/DT genetic/JJ defect/NN in/IN the/DT male/JJ offspring/NN born/VBN after/IN assisted/JJ reproduction/NN and/CC the/DT risk/NN of/IN perpetuating/VBG infertility/NN in/IN future/JJ generation/NN 
669_669_21_22_16_17::None::talin/NN ,/, and/CC vinculin/NN at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS at/IN 
93_93_50_51_24_26::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
331938_2_30_31_17_18::None::,/, increase/VBP the/DT coronary/JJ blood/NN supply/NN ,/, improve/VB ischemic/JJ myocardial/JJ metabolism/NN ,/, scavenge/VB free/JJ radicals/NNS and/CC protect/VB myocardial/JJ ultrastructure/NN ./. 
445433_1_3_4_38_39::None::Indeed/RB ,/, a/DT neuronal/JJ pathway/NN for/IN histamine/NN -/: induced/VBN itch/NN in/IN the/DT peripheral/JJ and/CC central/JJ nervous/JJ system/NN has/VBZ been/VBN described/VBN in/IN animals/NNS and/CC humans/NNS ,/, and/CC recently/RB several/JJ non/JJ -/: histaminergic/JJ pathways/NNS for/IN itch/NN have/VBP been/VBN discovered/VBN in/IN rodents/NNS that/WDT support/VBP a/DT 
226276_6_37_38_23_24::medicine.disease.symptoms::psychotic/JJ pre/JJ -/: delusional/JJ symptoms/NNS that/WDT acutely/RB worsen/VBP in/IN the/DT ramp/NN -/: up/IN to/TO full/JJ -/: blown/VBN psychosis/NN ,/, and/CC as/IN 
374_374_4_5_6_7::None::of/IN SIR4/NN enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC 
1440_1440_4_5_12_13::POS_ACTION_Assembly::C-terminal/JJ region/NN of/IN ORC3/NN was/VBD ,/, however/RB ,/, necessary/JJ to/TO bring/VB ORC4/NN and/CC ORC5/NN into/IN 
370669_2_9_10_12_13::None::of/IN high/JJ cardiovascular/JJ mortality/NN in/IN maintenance/NN hemodialysis/NN (/( MHD/NN )/) 
333054_4_0_1_14_15::medicine.disease.risk_factors::It/PRP is/VBZ concluded/VBN that/IN the/DT young/JJ rind/JJ region/NN was/VBD more/RBR directly/RB affected/VBN by/IN water/NN stress/NN and/CC ,/, depending/VBG 
313728_4_36_37_7_8::people.cause_of_death.includes_causes_of_death::metabolic/JJ needs/NNS of/IN tumor/NN cells/NNS has/VBZ led/VBN to/TO the/DT proposal/NN of/IN a/DT new/JJ metabolic/JJ treatment/NN for/IN various/JJ cancers/NNS including/VBG GBMs/NNS that/WDT may/MD enhance/VB the/DT effectiveness/NN of/IN the/DT SOC/NNP The/DT goal/NN of/IN metabolic/JJ cancer/NN therapy/NN is/VBZ to/TO 
332464_0_4_5_18_20::None::-/: density/NN lipoprotein/NN cholesterol/NN (/( LDL/NN -/: C/NN )/) reduction/NN with/IN statins/NNS is/VBZ the/DT cornerstone/NN of/IN atherosclerotic/JJ cardiovascular/JJ disease/NN (/( CVD/NN )/) 
1464_1464_8_9_22_23::None::are/VBP involved/VBN in/IN CREB/NN binding/NN and/CC transcriptional/JJ activation/NN are/VBP highly/RB related/VBN to/TO the/DT adenoviral/JJ E1A-associated/JJ cellular/JJ protein/NN p300/NN (/( refs/NNS 2/CD 
1004_1004_23_24_21_22::None::proteins/NNS such/JJ as/IN vinculin/NN and/CC talin/NN ,/, while/IN one/CD 
553793_3_32_34_10_11::None::QOL/NN in/IN elderly/JJ patients/NNS with/IN AF/NN receiving/VBG oral/JJ anticoagulants/NNS and/CC compare/VB QOL/NN of/IN patients/NNS treated/VBN with/IN vitamin/NN K/NN antagonists/NNS (/( VKA/NN )/) and/CC DOAC/NN This/DT prospective/JJ study/NN included/VBD patients/NNS of/IN 
620873_8_0_1_12_14::None::In/IN conclusion/NN ,/, mice/NNS administered/VBN formulations/NNS of/IN a/DT murine/JJ antibody/NN adsorbed/VBD onto/IN silicone/NN oil/NN microdroplets/NNS ,/, glass/NN 
526397_0_3_4_27_28::None::This/DT longitudinal/JJ study/NN aims/VBZ to/TO compare/VB long/JJ -/: term/NN work/NN disability/NN and/CC absenteeism/NN between/IN anxiety/NN and/CC depressive/JJ disorders/NNS focusing/VBG on/IN the/DT effects/NNS of/IN different/JJ course/NN trajectories/NNS (/( remission/NN ,/, recurrence/NN and/CC 
241804_0_11_14_8_9::None::is/VBZ a/DT major/JJ complication/NN of/IN delayed/VBN tissue/NN plasminogen/NN activator/NN (/( t/NN -/: 
365_365_8_10_30_31::POS_ACTION_Causal::that/IN the/DT G1/NN cyclin/NN D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN in/IN subversion/NN of/IN the/DT G1/S/NN traverse/NN by/IN signaling/NN pathways/NNS activated/VBN by/IN HER-2/NN function/NN ./. 
768572_0_11_12_1_2::None::The/DT utility/NN of/IN intravenous/JJ tissue/NN plasminogen/NN activator/NN (/( IV/CD t/NN -/: PA/NN )/) in/IN improving/VBG 
194621_0_12_13_7_8::None::lifestyle/NN ,/, the/DT technology/NN of/IN active/JJ and/CC biodegradable/JJ packaging/NN with/IN antimicrobial/JJ and/CC 
590_590_29_31_33_34::None::related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN 
467_467_4_6_2_3::None::Expression/NN of/IN c-Myc/NN or/CC cyclin/NN D1/NN was/VBD sufficient/JJ to/TO 
932_932_5_6_1_2::None::Like/IN TESK1/NN ,/, TESK2/NN phosphorylated/VBN cofilin/NN specifically/RB at/IN Ser-3/NN 
512613_1_42_43_12_14::medicine.disease.symptoms::affectivity/JJ symptoms/NNS (/( depressed/JJ mood/NN ,/, anxious/JJ mood/NN ,/, worry/NN )/) that/WDT are/VBP central/JJ to/TO these/DT disorders/NNS ;/: more/JJR moderately/RB with/IN symptoms/NNS of/IN social/JJ phobia/NN ,/, affective/JJ lability/NN ,/, panic/NN ,/, posttraumatic/JJ stress/NN disorder/NN ,/, lassitude/NN ,/, 
671646_0_10_11_10_12::None::the/DT treatment/NN of/IN spinal/JJ tuberculosis/NN (/( TB/NN )/) 
1810_1810_20_21_0_1::POS_ACTION_CORELATE::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR regulatory/JJ roles/NNS ,/, as/IN it/PRP was/VBD shown/VBN that/IN their/PRP$ tyrosine/NN phosphorylation/NN correlated/VBD with/IN modified/VBN cadherin/NN activities/NNS ./. 
1460_1460_8_9_3_4::POS_REG(0)_LOCALIZE::The/DT distribution/NN of/IN actin/NN filaments/NNS is/VBZ altered/VBN by/IN profilin/NN overexpression/NN ./. 
461685_1_18_19_3_4::None::Impaired/JJ glucagon/NN secretion/NN predisposes/VBZ some/DT patients/NNS with/IN type/NN 1/CD diabetes/NN mellitus/NN (/( T1DM/NN )/) to/TO hypoglycaemia/NN ;/: whereas/IN hyperglycaemia/NN in/IN patients/NNS with/IN 
755_755_4_5_9_10::None::cultured/VBN cells/NNS ,/, cofilin/NN ,/, as/RB well/RB as/IN ADF/NN ,/, translocates/VBZ from/IN 
1233_1233_19_24_30_31::POS_ACTION_MEMBER::,/, desmin/NN and/CC smooth/VB muscle/NN myosin/NN heavy/JJ chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
670_670_19_20_14_15::None::that/IN beta-catenin/NN ,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, and/CC cadherin-5/NN were/VBD colocalized/VBN both/CC 
1646_1646_13_14_2_3::None::The/DT resulting/VBG beta-catenin/NN product/NN is/VBZ unable/JJ to/TO bind/VB alpha-catenin/NN that/WDT is/VBZ responsible/JJ for/IN actin/NN filament/NN binding/NN and/CC 
367_367_24_25_0_2::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC 
513747_5_101_102_106_107::None::childhood/NN prevalence/NN of/IN hypertension/NN ,/, renal/JJ denervation/NN for/IN resistant/JJ hypertension/NN and/CC the/DT 
899821_0_8_9_3_4::None::High/JJ risk/NN (/( oncogenic/JJ )/) human/JJ papillomavirus/NN (/( HPV/NN )/) infection/NN causes/VBZ 
231123_0_19_20_2_3::None::Nilotinib/NNP in/IN patients/NNS with/IN systemic/JJ mastocytosis/NN :/: analysis/NN of/IN the/DT phase/NN 2/CD ,/, open/JJ -/: label/NN ,/, single/JJ -/: arm/NN nilotinib/JJ registration/NN study/NN 
1760_1760_3_4_1_3::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP 
28_28_11_13_0_2::POS_ACTION_MEMBER::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN define/VBP a/DT family/NN of/IN actin-binding/JJ proteins/NNS essential/JJ for/IN the/DT 
873835_0_43_46_14_15::None::that/WDT has/VBZ gained/VBN popularity/NN in/IN the/DT last/JJ couple/NN of/IN decades/NNS as/IN a/DT possible/JJ alternative/NN to/TO a/DT meniscectomy/NN to/TO provide/VB significant/JJ pain/NN relief/NN ,/, improve/VB function/NN ,/, and/CC prevent/VB the/DT early/JJ onset/NN of/IN degenerative/JJ joint/JJ disease/NN (/( DJD/NN )/) 
242294_6_31_32_8_9::None::A/NN )/) ,/, inter/NN -/: molecular/JJ O/NN -/: H/NN O/NN ,/, C/NN -/: H/NN O/NN and/CC C/NN -/: Hpi/NN inter/NN -/: actions/NNS link/VBP the/DT independent/JJ benzoates/NNS alternately/RB ,/, forming/VBG a/DT 
567_567_14_15_10_11::None::acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS 
715810_0_3_4_25_26::None::The/DT root/NN of/IN Polygala/NN tenuifolia/NN Willdenow/NNP has/VBZ been/VBN used/VBN for/IN the/DT treatment/NN against/IN insomnia/NN ,/, amnesia/NN ,/, depression/NN ,/, palpitations/NNS with/IN anxiety/NN ,/, and/CC memory/NN improvement/NN ./. 
865_865_33_35_7_8::None::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
315603_0_8_9_19_20::medicine.medical_treatment.used_to_treat::,/, Nilotinib/NNP and/CC Imatinib/NNP in/IN Newly/RB Diagnosed/VBN Patients/NNS with/IN Chronic/JJ -/: Phase/NN Chronic/JJ Myeloid/JJ Leukemia/NN :/: A/DT Three/CD 
214618_2_0_1_3_4::None::Detection/NN of/IN a/DT rise/NN and/CC a/DT fall/NN 
662630_5_12_13_25_27::None::found/VBN with/IN Black/JJ adolescents/NNS reporting/VBG lower/JJR withdrawal/NN discomfort/NN scores/NNS and/CC experiencing/VBG less/RBR severe/JJ depressed/JJ mood/NN ,/, difficulty/NN sleeping/VBG ,/, nervousness/NN //: 
984_984_9_10_20_21::None::different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, 
735_735_22_23_3_4::None::In/IN contrast/NN ,/, act1-159/NN partially/RB suppresses/VBZ the/DT temperature/NN sensitivity/NN of/IN a/DT tropomyosin/NN mutant/NN ,/, and/CC the/DT loss/NN of/IN cytoplasmic/JJ cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, 
494835_0_30_31_37_39::medicine.risk_factor.diseases::finasteride/NN alone/RB in/IN men/NNS with/IN prostatic/JJ enlargement/NN secondary/JJ to/TO benign/JJ prostatic/JJ hyperplasia/NN ./. 
93_93_28_29_54_55::None::kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
244614_0_48_49_9_10::medicine.drug_ingredient.active_moiety_of_drug::prepared/VBN by/IN reacting/VBG Cr/NN (/( EH/NN )/) 3/CD (/( EH/NN =/JJ 2/CD -/: ethylhexanoate/NN )/) ,/, 2,5/CD -/: dimethylpyrrole/NN (/( Me2C4H2NH/NN )/) ,/, Et3Al/NN ,/, and/CC Et2AlCl/NN in/IN an/DT aromatic/JJ hydrocarbon/NN solvent/JJ was/VBD improved/VBN to/TO obtain/VB a/DT congener/NN composed/VBN of/IN a/DT new/JJ chromium/NN precursor/NN (/( EH/NN 
312260_0_1_2_8_9::None::The/DT procedure/NN of/IN reconstruction/NN after/IN the/DT removal/NN of/IN cranial/JJ fibrous/JJ dysplasia/NN (/( 
185_185_2_3_4_5::None::Associations/NNS of/IN UBE2I/NN with/IN RAD52/NN ,/, UBL1/NN ,/, 
676724_2_37_38_47_48::None::like/IN disease/NN (/( D1/NN )/) was/VBD provoked/VBN by/IN STZ/NN without/IN NA/NNP Non/NNP -/: diabetic/JJ mice/NNS received/VBD vehicle/NN 
241804_0_7_8_17_18::None::)/) is/VBZ a/DT major/JJ complication/NN of/IN delayed/VBN tissue/NN plasminogen/NN activator/NN (/( t/NN -/: PA/NN )/) treatment/NN in/IN 
443637_7_20_21_12_13::None::tumorigenic/JJ model/NN of/IN HCC/NNP These/DT findings/NNS provide/VBP in/FW vitro/FW evidence/NN that/IN sorafenib/NN suppresses/VBZ HGF/NN -/: 
367_367_32_33_28_30::None::and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
202687_5_26_27_2_3::None::In/IN these/DT reactions/NNS ,/, the/DT ortho/NN C/NN -/: H/NN bond/NN of/IN two/CD different/JJ phenols/NNS and/CC the/DT ortho/NN and/CC para/NN C/NN -/: H/NN bond/NN of/IN phenols/NNS were/VBD coupled/VBN together/RB ./. 
1686_1686_25_28_51_53::POS_ACTION_Dynamics::at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP myosin/NN II/CD requires/VBZ isoform/NN specific/JJ 
243_243_30_32_3_4::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD 
255731_2_10_11_27_28::None::,/, we/PRP comprehensively/RB investigated/VBD the/DT abundance/NN and/CC diversity/NN of/IN STPs/NNS encoded/VBN in/IN 119/CD actinobacterial/JJ genomes/NNS ,/, based/VBN on/IN the/DT data/NNS stored/VBN in/IN the/DT Microbial/JJ 
907653_2_19_20_21_22::None::-/: based/VBN patient/NN provider/NN communication/NN service/NN (/( IPPC/NN )/) 
566758_0_2_3_11_12::None::Accelerometer/SYM -/: derived/VBN sedentary/JJ and/CC physical/JJ activity/NN time/NN in/IN overweight/JJ //: obese/JJ adults/NNS with/IN type/NN 
1233_1233_30_31_26_27::None::chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
574337_0_2_3_11_12::None::Infection/NN by/IN human/JJ papillomavirus/NN (/( HPV/NN )/) is/VBZ among/IN the/DT main/JJ etiologies/NNS of/IN cervical/JJ cancer/NN 
492693_2_39_40_92_93::None::re/SYM -/: appeared/VBD rapidly/RB above/IN 13/CD GPa/NN ,/, with/IN the/DT Tc/NN reaching/VBG 49/CD K/NN at/IN 21/CD GPa/NN The/DT appearance/NN of/IN a/DT new/JJ superconducting/JJ phase/NN is/VBZ not/RB accompanied/VBN by/IN a/DT structural/JJ transition/NN ,/, as/IN evidenced/VBN by/IN pressure/NN -/: dependent/JJ XRD/NNP Furthermore/RB ,/, Tc/NN slowly/RB decreased/VBD with/IN increasing/VBG pressure/NN above/IN 21/CD GPa/NN ,/, and/CC at/IN 41/CD GPa/NN superconductivity/NN disappeared/VBD entirely/RB at/IN temperatures/NNS 
322082_9_26_27_1_2::None::580/CD pg/NN //: ml/NN ,/, p/NN =/JJ 0.03/CD )/) but/CC not/RB cystatin/NN C/NN Patients/NNS with/IN chronic/JJ kidney/NN disease/NN demonstrated/VBD higher/JJR NGAL/NN levels/NNS compared/VBN with/IN subjects/NNS with/IN preserved/JJ renal/JJ function/NN (/( 
265468_0_5_7_8_9::None::not/RB associated/VBN with/IN diverticular/JJ disease/NN -/: Analysis/NN of/IN 976/CD patients/NNS 
502525_12_6_7_30_32::None::-/: CCP/NN and/CC CRP/NN are/VBP associated/VBN with/IN increased/VBN cIMT/NN and/CC cardiovascular/JJ risk/NN supporting/VBG a/DT clinical/JJ role/NN of/IN the/DT measurement/NN of/IN cIMT/NN in/IN RA/NN in/IN predicting/VBG and/CC preventing/VBG cardiovascular/JJ events/NNS ./. 
499291_35_18_19_8_9::medicine.symptom.symptom_of::of/IN women/NNS with/IN PCOS/NN appear/VBP to/TO be/VB significantly/RB different/JJ depending/VBG on/IN ethnicity/NN ,/, obesity/NN and/CC age/NN ./. 
159463_2_14_15_2_3::None::Actually/RB ,/, premenopausal/JJ women/NNS have/VBP a/DT significantly/RB lower/JJR risk/NN for/IN cardiovascular/JJ disease/NN comparing/VBG to/TO postmenopausal/JJ women/NNS or/CC age/NN 
932_932_5_6_3_4::None::Like/IN TESK1/NN ,/, TESK2/NN phosphorylated/VBN cofilin/NN specifically/RB at/IN Ser-3/NN 
1089_1089_9_10_20_21::None::studies/NNS demonstrated/VBD that/IN Stat1/NN could/MD directly/RB interact/VB with/IN TNFR1/NN and/CC TRADD/NN but/CC not/RB with/IN FADD/NN ./. 
406221_0_7_8_0_1::None::Antibiotic/JJ and/CC oral/JJ corticosteroid/NN prescribing/VBG rate/NN in/IN patients/NNS suffering/VBG from/IN acute/JJ 
675416_11_0_1_10_11::None::The/DT following/VBG five/CD biomarkers/NNS will/MD be/VB discussed/VBN :/: proadrenomedullin/NN for/IN prognostic/JJ triage/NN assessment/NN and/CC 
322750_1_21_22_51_52::None::N/NN )/) ,/, ammonium/NN (/( NH4/NN -/: N/NN )/) ,/, phosphate/NN (/( PO4/NN -/: P/NN )/) ,/, dissolved/VBN organic/JJ carbon/NN (/( DOC/NN )/) ,/, methane/NN (/( CH4/NN )/) ,/, and/CC dinitrogen/NN oxide/NN (/( N2O/NN )/) ./. 
311864_8_23_24_38_39::None::suffering/VBG from/IN IgG/NN subclass/NN deficiency/NN without/IN autoimmunity/NN and/CC //: or/CC coagulation/NN disorders/NNS ,/, likely/JJ restoring/VBG idiotype/NN -/: antiidiotype/JJ network/NN ;/: showing/VBG evidence/NN 
306064_4_29_30_0_1::medicine.drug_ingredient.active_moiety_of_drug::Denosumab/NNP has/VBZ recently/RB been/VBN reported/VBN to/TO be/VB effective/JJ for/IN unresectable/JJ GCTB/NN ;/: however/RB ,/, there/EX is/VBZ only/RB one/CD report/NN of/IN its/PRP$ effect/NN on/IN GCRG/NNP Moreover/RB ,/, the/DT effect/NN of/IN denosumab/NN on/IN GCRG/NN of/IN 
513_513_17_19_12_13::None::PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO promote/VB U2/NN snRNP/NN binding/NN to/TO pre-mRNA/NN 
346198_0_1_2_10_11::medicine.drug.active_moieties::Microbial/JJ caffeine/NN removal/NN is/VBZ a/DT green/JJ solution/NN for/IN treatment/NN of/IN caffeinated/VBN products/NNS and/CC agro/NN 
468565_7_9_10_10_11::None::ended/VBD ,/, indicating/VBG rapid/JJ physiological/JJ recovery/NN from/IN the/DT 
1866_1866_7_8_9_10::None::and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN 
235372_5_10_12_25_26::None::BMI/NN ,/, current/JJ physical/JJ activity/NN ,/, osteoporosis/NN knowledge/NN ,/, length/NN of/IN time/NN on/IN oral/JJ contraceptives/NNS ,/, age/NN at/IN menarche/NN and/CC calcium/NN intake/NN 
95_95_9_10_5_6::None::contain/VBP only/RB 1/CD profilin/NN for/IN every/DT 5-10/CD actin/NN molecules/NNS ,/, these/DT 
241510_0_4_5_28_29::medicine.disease.treatments::patients/NNS with/IN ischemic/JJ cardiomyopathy/NN the/DT size/NN of/IN bipolar/JJ low/JJ voltage/NN areas/NNS (/( LVA/NN )/) in/IN electroanatomical/JJ maps/NNS (/( EAM/NN )/) was/VBD associated/VBN with/IN poorer/JJR outcomes/NNS after/IN catheter/NN ablation/NN (/( CA/NNP )/) 
1258_1258_3_4_32_33::None::Significantly/RB ,/, those/DT actin/NN mutants/NNS exhibiting/VBG the/DT most/RBS severe/JJ phenotypes/NNS in/IN all/DT three/CD processes/NNS have/VBP altered/VBN residues/NNS that/WDT cluster/VBP to/TO a/DT small/JJ region/NN of/IN the/DT actin/NN crystal/NN structure/NN previously/RB defined/VBN as/IN the/DT fimbrin/NN (/( Sac6p/NN )/) 
1683_1683_15_16_10_12::POS_ACTION_BIND::the/DT profilin/NN and/CC DNase/NN I/CD binding/NN sites/NNS on/IN actin/NN ./. 
1486_1486_35_40_60_61::POS_ACTION_STIMULATE::MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
467441_4_14_15_18_19::None::of/IN Copper/NN //: Zinc/NNP Superoxide/NN dismutase/NN (/( Cu/NN //: Zn/NN -/: 
1087_1087_25_26_7_9::None::that/IN in/IN brain/NN profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT actin/NN cytoskeleton/NN and/CC endocytic/JJ membrane/NN flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN to/TO distinct/JJ 
30983_5_8_9_13_14::medicine.medical_treatment.used_to_treat::mean/NN concentration/NN of/IN estradiol/NN and/CC higher/JJR intensity/NN of/IN menopausal/JJ symptoms/NNS than/IN control/JJ 
749205_0_14_15_23_24::medicine.medical_treatment.used_to_treat::Neuroendocrine/JJ Factors/NNS Predict/VB SSRIs/NNS Treatment/NN Outcome/NN in/IN the/DT Chinese/JJ Population/NNP with/IN Major/NNP Depression/NNP ./. 
446387_0_48_49_8_9::None::old/JJ man/NN with/IN metastatic/JJ castration/NN -/: resistant/JJ prostate/NN cancer/NN (/( CRPC/NN )/) was/VBD successfully/RB treated/VBN for/IN two/CD years/NNS with/IN in/FW situ/FW gene/NN therapy/NN using/VBG an/DT adenovirus/NN vector/NN carrying/VBG the/DT human/JJ REIC/NN //: Dkk/SYM -/: 3/CD gene/NN (/( Ad/NN -/: REIC/NN )/) ,/, following/VBG chemotherapy/NN ./. 
1380_1380_24_25_34_35::POS_ACTION_BIND::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, 
1526_1526_12_13_10_11::None::(/( BRSV/NN )/) phosphoprotein/NN (/( P/NN )/) with/IN nucleocapsid/NN 
1850_1850_23_24_10_11::None::the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN and/CC serves/VBZ to/TO link/VB the/DT cadherin/catenin/NN complex/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
849947_0_0_1_6_7::None::Congenital/JJ peritoneopericardial/JJ diaphragmatic/JJ hernia/NN in/IN a/DT terrier/NN dog/NN ./. 
2222_2222_11_12_19_20::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC 
346_346_24_25_16_17::POS_ACTION_BIND::of/IN alpha-catenin/NN ,/, beta-catenin/NN competed/VBD with/IN the/DT binding/NN of/IN plakoglobin/NN to/TO alpha-catenin/NN and/CC vice/NN versa/RB 
1711_1711_19_20_16_19::None::related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN ,/, 
1434_1434_7_8_14_15::None::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB 
280_280_14_15_13_14::None::we/PRP observed/VBD that/IN histone/NN H4/NN ,/, and/CC not/RB 
25979_5_5_7_5_6::people.cause_of_death.includes_causes_of_death::60,211/CD participants/NNS without/IN cardiovascular/JJ disease/NN at/IN baseline/NN 
1648_1648_7_8_44_45::None::that/IN the/DT mutated/VBN cofilin/NN possessing/VBG KTLKK/NNP instead/RB of/IN KKRKK/NNP did/VBD not/RB translocate/VB into/IN the/DT nuclei/NNS in/IN response/NN to/TO heat/NN shock/NN whereas/IN a/DT recombinant/JJ cofilin/NN with/IN the/DT unaltered/JJ sequence/NN of/IN KKRKK/NNP responded/VBD to/TO heat/NN shock/NN and/CC formed/VBD intranuclear/JJ rods/NNS together/RB with/IN actin/NN ./. 
423051_1_21_22_13_14::None::in/IN RA/NN are/VBP confounded/VBN not/RB only/RB by/IN traditional/JJ risk/NN factors/NNS (/( TRF/NN )/) but/CC also/RB 
340516_1_20_21_11_12::None::2011/CD ,/, we/PRP estimated/VBD the/DT frequency/NN of/IN antibiotics/NNS prescribing/VBG for/IN URI/NNP in/IN pediatric/JJ outpatients/NNS with/IN diagnoses/NNS 
426593_3_20_21_17_18::None::-/: probability/NN pain/NN reduction/NN ,/, the/DT objective/JJ response/NN was/VBD poor/JJ 
2222_2222_19_20_21_22::POS_ACTION_COLOCALIZE::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
1286_1286_8_9_12_13::None::chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, SMemb/NN )/) ,/, caldesmon/NN 
1289_1289_11_12_7_8::POS_ACTION_INTERACT::nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) 
565_565_28_29_4_7::None::we/PRP demonstrate/VBP that/IN type/NN XIII/CD collagen/NN is/VBZ concentrated/VBN in/IN cultured/VBN skin/NN fibroblasts/NNS and/CC several/JJ other/JJ human/JJ mesenchymal/JJ cell/NN lines/NNS in/IN the/DT focal/JJ adhesions/NNS at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS ,/, 
658012_2_1_2_25_26::None::We/PRP report/VBP a/DT case/NN of/IN a/DT 66/CD -/: year/NN -/: old/JJ male/NN who/WP had/VBD undergone/VBN PD/NN for/IN pancreatic/JJ head/NN adenocarcinoma/NN 10/CD months/NNS previously/RB and/CC who/WP presented/VBD at/IN our/PRP$ hospital/NN 
967935_1_8_10_3_4::None::We/PRP analyzed/VBD the/DT chromosomal/JJ distribution/NN and/CC evolution/NN of/IN repeated/VBN sequences/NNS in/IN Triatominae/FW genomes/NNS 
1006_1006_14_15_11_13::None::microfilaments/NNS and/CC two/CD actin-binding/JJ proteins/NNS :/: gelsolin/NN and/CC profilin/NN ./. 
2222_2222_19_20_13_14::POS_ACTION_COLOCALIZE::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC 
663522_15_9_10_36_38::None::prostate/NN cancer/NN detection/NN rate/NN stratified/VBN by/IN the/DT severity/NN of/IN LUTS/NNP Patients/NNPS undergoing/VBG prostate/NN biopsy/NN have/VBP ,/, with/IN a/DT high/JJ probability/NN ,/, LUTS/NNP Approximately/RB 50/CD %/NN suffer/VBP from/IN some/DT degree/NN of/IN erectile/JJ dysfunction/NN and/CC 24/CD %/NN 
416351_15_1_2_6_7::None::Having/VBG personal/JJ or/CC family/NN history/NN of/IN hypertension/NN ,/, older/JJR age/NN 
1782_1782_20_22_23_24::None::the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC 
739338_5_23_24_15_16::None::a/DT history/NN of/IN smoking/NN and/CC diabetes/NN ,/, but/CC there/EX was/VBD no/DT difference/NN in/IN stroke/NN severity/NN 
1539_1539_1_3_13_14::None::The/DT K114E/NN profilin/NN exhibited/VBD a/DT profound/JJ decrease/NN in/IN its/PRP$ ability/NN to/TO interact/VB with/IN actin/NN ,/, whereas/IN binding/VBG 
1439_1439_16_17_26_27::POS_ACTION_BIND::for/IN association/NN of/IN TNFR1/NN and/CC other/JJ death/NN domain-containing/JJ proteins/NNS such/JJ as/IN FADD/NN and/CC RIP/NN ./. 
352442_4_7_9_28_30::None::,/, the/DT calculated/JJ association/NN constants/NNS are/VBP 10.1/CD M/NN (/( -/: 1/LS )/) (/( lidocainium/NN docusate/NN )/) ;/: 0.77/CD M/NN (/( -/: 1/LS )/) (/( sodium/NN chloride/NN )/) ;/: 0.086/CD 
365169_1_22_23_5_6::None::a/DT cascade/NN of/IN complications/NNS -/: active/JJ pulmonary/JJ tuberculosis/NN despite/IN recent/JJ isoniazid/NN prophylactic/NN therapy/NN ,/, non/JJ -/: tuberculous/JJ mycobacterial/JJ disease/NN ,/, chronic/JJ airways/NNS obstruction/NN ,/, 
18_18_4_5_18_20::None::domain/NN of/IN the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) 
464783_0_0_1_19_20::None::This/DT review/NN describes/VBZ the/DT recent/JJ developments/NNS in/IN the/DT pathobiology/NN of/IN endothelial/JJ dysfunction/NN (/( ED/NN )/) in/IN the/DT context/NN of/IN cirrhosis/NN with/IN portal/JJ hypertension/NN 
225032_8_17_18_8_9::None::two/CD -/: dimensional/JJ culture/NN ,/, three/CD -/: dimensional/JJ culture/NN system/NN could/MD give/VB rise/VB to/TO an/DT up/RB 
302982_3_9_10_2_3::None::In/IN dyssomnia/NN group/NN ,/, (/( 1/LS )/) Glucagon/NNP ,/, glucagon/NNP //: insulin/NN ratio/NN 
495841_5_7_8_5_6::None::and/CC 26/CD displayed/VBD strong/JJ ,/, equipotent/JJ activities/NNS against/IN vemurafenib/NN 
512095_3_29_30_46_47::medicine.medical_treatment.used_to_treat::on/IN post/NN -/: operative/JJ MAG/NN -/: 3/CD scan/VB ,/, and/CC //: or/CC a/DT reduction/NN in/IN renal/JJ function/NN of/IN the/DT obstructed/VBN kidney/NN to/TO &/CC lt/NN 
312260_0_12_13_3_4::None::The/DT procedure/NN of/IN reconstruction/NN after/IN the/DT removal/NN of/IN cranial/JJ fibrous/JJ dysplasia/NN (/( FD/NN )/) must/MD be/VB 
2064_2064_49_50_28_29::None::,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
15883_8_5_6_1_2::None::The/DT MRI/NNP remains/VBZ the/DT best/JJS tool/NN to/TO detect/VB and/CC 
2064_2064_49_50_40_41::POS_ACTION_CORELATE::,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
723866_2_8_9_1_2::None::(/( Reduviidae/NNP :/: Emesinae/NNP )/) is/VBZ described/VBN from/IN India/NNP ./. 
96855_6_18_19_14_15::None::all/DT five/CD underwent/VBD burn/VBP excision/NN and/CC microsurgical/JJ reconstruction/NN using/VBG distant/JJ flaps/NNS 
95037_9_21_22_12_13::medicine.disease.risk_factors:://: 136/CD control/NN elderly/JJ (/( 40.0/CD %/NN )/) ,/, 21/CD //: 29/CD AD/NN (/( 72.4/CD %/NN 
596639_0_22_23_15_17::None::,/, several/JJ simultaneously/RB flowering/VBG plant/NN species/NNS depend/VBP on/IN the/DT same/JJ pollinator/NN ./. 
245_245_10_11_2_3::None::Neuropilin-1/NN (/( NRP1/NN )/) is/VBZ a/DT 130-kDa/JJ transmembrane/NN receptor/NN for/IN semaphorins/NNS ,/, mediators/NNS of/IN 
189641_0_10_11_22_23::None::energy/NN intake/NN ,/, sedentary/JJ habits/NNS and/CC obesity/NN ,/, type/NN 2/CD diabetes/NN has/VBZ developed/VBN into/IN a/DT major/JJ health/NN concern/NN worldwide/RB 
1782_1782_27_28_11_12::None::)/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
243_243_0_2_3_4::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT 
515725_7_3_4_36_37::None::Individuals/NNS with/IN chronic/JJ mental/JJ and/CC physical/JJ conditions/NNS (/( fatigue/NN ,/, insomnia/NN ,/, anxiety/NN ,/, depression/NN ,/, diabetes/NN ,/, breathing/NN problems/NNS ,/, high/JJ blood/NN pressure/NN ,/, heart/NN disease/NN ,/, stroke/NN and/CC cancer/NN )/) were/VBD more/RBR likely/JJ to/TO report/VB the/DT lowest/JJS levels/NNS 
1688_1688_5_6_13_14::POS_ACTION_Change::suggest/VBP that/IN nuclear/JJ profilin/NN can/MD mediate/VB a/DT stimulus-response/JJ action/NN on/IN the/DT actin/NN cytoskeleton/NN which/WDT is/VBZ 
93_93_22_23_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN 
1095_1095_35_36_17_18::POS_ACTION_LOCALIZE::and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ proteins/NNS are/VBP dependent/JJ on/IN the/DT supramolecular/JJ organization/NN of/IN the/DT collagens/NNS ./. 
790_790_29_33_33_34::POS_ACTION_MEMBER::,/, including/VBG the/DT cyclin/NN dependent/JJ kinase/NN inhibitor/NN p27/NN ,/, which/WDT blocks/VBZ 
1633_1633_25_26_15_16::POS_ACTION_MEMBER::;/: four/CD histone/NN H2a/NN genes/NNS ,/, two/CD of/IN which/WDT are/VBP identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: 
287311_9_1_2_21_22::None::The/DT AUROC/NN values/NNS for/IN VFA/NNP were/VBD higher/JJR than/IN those/DT for/IN BMI/NNP and/CC WHR/NNP For/IN VFA/NNP ,/, the/DT sensitivity/NN and/CC specificity/NN for/IN predicting/VBG CKD/NNP were/VBD 62.66/CD 
1094_1094_14_15_16_17::None::three/CD subunits/NNS ,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, 
305802_4_3_4_30_31::None::Dantrolene/NN reduced/VBD the/DT number/NN of/IN premature/JJ ventricular/JJ complexes/NNS (/( PVCs/NNS )/) on/IN average/NN by/IN 74/CD %/NN (/( range/NN 33/CD -/: 97/CD )/) in/IN four/CD patients/NNS with/IN N/NN -/: terminal/JJ or/CC central/JJ mutations/NNS in/IN the/DT 
2222_2222_23_24_39_40::None::,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
658012_2_25_26_0_1::None::We/PRP report/VBP a/DT case/NN of/IN a/DT 66/CD -/: year/NN -/: old/JJ male/NN who/WP had/VBD undergone/VBN PD/NN for/IN pancreatic/JJ head/NN adenocarcinoma/NN 10/CD months/NNS previously/RB and/CC who/WP presented/VBD at/IN our/PRP$ hospital/NN 
315603_0_14_15_22_23::None::Diagnosed/VBN Patients/NNS with/IN Chronic/JJ -/: Phase/NN Chronic/JJ Myeloid/JJ Leukemia/NN :/: A/DT Three/CD -/: year/NN Retrospective/JJ 
125639_3_21_22_6_7::None::UV/NN -/: visible/JJ absorption/NN and/CC electron/NN paramagnetic/JJ resonance/NN (/( EPR/NN )/) analysis/NN suggested/VBD that/IN the/DT enzyme/NN had/VBD the/DT typical/JJ copper/NN sites/NNS ,/, 
1782_1782_1_6_7_8::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT 
272493_8_6_8_15_16::None::,/, among/IN 13/CD NMDA/NN receptor/NN IgG/NN -/: positive/JJ patients/NNS ,/, 12/CD had/VBD encephalitis/NN ;/: their/PRP$ psychiatric/JJ 
2003_2003_33_34_26_27::None::]/) for/IN binding/VBG profilin/NN ,/, an/DT actin-regulatory/JJ protein/NN that/WDT stimulates/VBZ actin/NN filament/NN assembly/NN ./. 
216790_2_2_3_4_5::None::In/IN this/DT study/NN ,/, sulfated/JJ (/( 1/LS -/: 
1169_1169_41_42_10_11::None::to/TO regulate/VB the/DT actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD found/VBN to/TO possess/VB short/JJ peptide/NN motifs/NNS homologous/JJ to/TO one/CD part/NN of/IN verprolin/NN ./. 
1850_1850_10_11_2_3::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN 
1052_1052_37_38_21_22::None::oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
579913_0_3_4_19_20::None::Metabolic/JJ syndrome/NN (/( MetS/NN )/) is/VBZ a/DT cluster/NN of/IN cardiovascular/JJ risk/NN factors/NNS that/WDT includes/VBZ obesity/NN ,/, diabetes/NN ,/, and/CC dyslipidemia/NN ./. 
394705_2_89_92_107_108::None::B/NN having/VBG estimated/VBN glomerular/JJ filtration/NN rates/NNS &/CC gt/NN ;/: 45/CD mL/NN //: min/NN //: 1.73/CD m2/NN ,/, and/CC a/DT significantly/RB lower/JJR incidence/NN of/IN chronic/JJ allograft/NN 
1105_1105_20_24_0_1::None::p21/NN (/( p21WAF1/Cip1/NN )/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, induces/VBZ G1/NN arrest/NN and/CC can/MD inhibit/VB the/DT activity/NN of/IN the/DT proliferating/VBG cell/NN nuclear/JJ antigen/NN (/( PCNA/NN )/) 
236038_0_16_17_17_18::None::and/CC cell/NN -/: matrix/NN adhesion/NN ,/, cell/NN migration/NN 
456903_0_9_10_37_38::None::and/CC short/JJ -/: acting/VBG once/RB daily/JJ prandial/JJ glucagon/NN -/: like/IN peptide/NN -/: 1/CD receptor/NN agonist/NN which/WDT lowers/VBZ glycohemoglobin/NN and/CC body/NN weight/NN by/IN clinically/RB significant/JJ amounts/NNS in/IN patients/NNS with/IN type/NN 2/CD diabetes/NNS treated/VBN with/IN basal/JJ insulin/NN 
258_258_6_7_8_9::POS_ACTION_BIND::and/CC association/NN of/IN beta-catenin/NN with/IN EGFR/NN were/VBD inhibited/VBN by/IN 
369607_2_16_17_27_28::None::of/IN heparin/NN including/VBG chondroitin/NN 4/CD -/: sulfate/NN (/( ChS/NN )/) and/CC hyaluronic/JJ acid/NN (/( HA/NN )/) ./. 
699_699_19_22_22_23::POS_ACTION_MEMBER::inactivation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN (/( INK4A/NN )/) 
1969_1969_18_19_20_21::None::motility/NN complex/NN containing/VBG VASP/NN and/CC profilin/NN ./. 
2064_2064_8_9_40_41::None::of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN 
1288_1288_13_14_11_12::None::)/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ 
728764_2_6_8_4_5::None::of/IN chronic/JJ kidney/NN disease/NN included/VBD diabetes/NN mellitus/NN (/( n/NN =/JJ 
322602_4_18_19_6_7::None::heart/NN diseases/NNS were/VBD congenital/JJ heart/NN disease/NN (/( n/NN =/JJ 65/CD ,/, 53.3/CD %/NN )/) and/CC arrhythmia/NN (/( n/NN =/JJ 
996_996_31_34_12_13::None::can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
713526_5_14_16_18_20::None::of/IN comorbid/JJ bipolar/JJ mood/NN disorder/NN and/CC chronic/JJ pain/NN disorders/NNS ./. 
446387_0_26_27_12_13::medicine.medical_treatment.used_to_treat::castration/NN -/: resistant/JJ prostate/NN cancer/NN (/( CRPC/NN )/) was/VBD successfully/RB treated/VBN for/IN two/CD years/NNS with/IN in/FW situ/FW gene/NN therapy/NN using/VBG an/DT 
1652_1652_20_21_31_32::POS_ACTION_BIND::with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( 
573489_1_15_16_22_23::medicine.medical_treatment.used_to_treat::plastic/NN and/CC reconstructive/JJ surgeon/NN after/IN the/DT initial/JJ diagnosis/NN of/IN breast/NN cancer/NN ./. 
240658_2_11_12_5_6::None::work/NN ,/, we/PRP demonstrated/VBD that/IN aggression/NN acts/VBZ as/IN an/DT SNC/NN trait/NN in/IN fruit/NN 
661306_5_6_7_2_3::None::Commonly/RB occurring/VBG strains/NNS included/VBD apprehension/NN //: anxiety/NN ,/, frustration/NN ,/, 
2148_2148_52_53_52_53::None::does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ 
2072_2072_11_14_14_15::POS_ACTION_MEMBER::of/IN the/DT mammalian/JJ actin/NN binding/NN protein/NN cofilin/NN ./. 
2131_2131_21_22_7_8::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
327522_2_2_3_6_7::medicine.drug_ingredient.active_moiety_of_drug::CB1/NN inhibits/VBZ GABA/NN release/NN ,/, and/CC GABAergic/JJ dysregulation/NN in/IN the/DT 
807975_0_12_13_14_15::None::pain/NN -/: related/JJ depression/NN of/IN behavior/NN and/CC mesolimbic/JJ dopamine/NN 
663522_15_36_38_24_25::medicine.symptom.symptom_of::,/, with/IN a/DT high/JJ probability/NN ,/, LUTS/NNP Approximately/RB 50/CD %/NN suffer/VBP from/IN some/DT degree/NN of/IN erectile/JJ dysfunction/NN and/CC 24/CD %/NN 
303626_0_19_20_27_28::None::NPs/NNS )/) on/IN chromium/NN (/( Cr/NN )/) fractionation/NN in/IN a/DT soil/NN contaminated/VBN with/IN leather/NN factory/NN 
497295_0_40_41_23_24::None::based/VBN chemotherapy/NN can/MD reach/VB pathologic/JJ complete/JJ response/NN (/( pCR/NN )/) rates/NNS of/IN up/RB to/TO 60/CD %/NN in/IN HER2/NN -/: positive/JJ breast/NN cancer/NN ./. 
275933_7_2_3_28_29::medicine.disease.risk_factors::When/WRB describing/VBG leukemia/NN predisposition/NN due/JJ to/TO hereditary/JJ cancer/NN syndromes/NNS ,/, the/DT following/VBG 6/CD categories/NNS become/VBP apparent/JJ on/IN the/DT basis/NN of/IN biology/NN and/CC clinical/JJ presentation/NN :/: (/( 1/LS )/) genetic/JJ instability/NN //: DNA/NN 
1006_1006_11_13_14_15::POS_ACTION_MEMBER::microfilaments/NNS and/CC two/CD actin-binding/JJ proteins/NNS :/: gelsolin/NN and/CC profilin/NN ./. 
420079_6_3_6_19_20::None::During/IN pregnancy/NN ,/, acute/JJ kidney/NN injury/NN (/( 5/CD //: 8/CD )/) ,/, anemia/NN (/( 5/CD //: 8/CD )/) ,/, hematuria/NN (/( 8/CD //: 
156299_3_1_2_22_24::None::Between/IN September/NNP 2009/CD and/CC July/NNP 2011/CD ,/, RFA/NN using/VBG two/CD or/CC three/CD radiofrequency/NN (/( RF/NN )/) electrodes/NNS and/CC a/DT multiple/JJ -/: electrode/NN switching/NN system/NN was/VBD performed/VBN for/IN 
125951_3_24_25_34_36::None::dexamethasone/NN )/) can/MD induce/VB apoptosis/NN in/IN cancer/NN cells/NNS and/CC //: or/CC diminish/VB the/DT inflammatory/JJ response/NN during/IN surgery/NN which/WDT 
72723_0_18_19_4_5::None::nephropathy/NN ,/, a/DT consequence/NN of/IN chronic/JJ high/JJ blood/NN pressure/NN ,/, is/VBZ increasingly/RB a/DT cause/NN of/IN end/NN -/: stage/NN renal/JJ diseases/NNS and/CC 
87_87_12_13_37_38::None::cell/NN adhesion/NN to/TO vitronectin/NN ,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN 
340516_1_15_16_39_40::medicine.medical_treatment.used_to_treat::the/DT frequency/NN of/IN antibiotics/NNS prescribing/VBG for/IN URI/NNP in/IN pediatric/JJ outpatients/NNS with/IN diagnoses/NNS of/IN acute/JJ nasopharyngitis/NN (/( common/JJ cold/NN )/) ,/, acute/JJ sinusitis/NN ,/, acute/JJ pharyngitis/NN ,/, acute/JJ tonsillitis/NN ,/, acute/JJ laryngitis/NN 
497295_0_28_29_1_2::None::Dual/JJ anti/JJ -/: HER2/NN blockade/NN with/IN trastuzumab/NN //: pertuzumab/NN or/CC trastuzumab/NN //: lapatinib/NN in/IN combination/NN with/IN anthracycline/NN //: taxane/NN -/: based/VBN chemotherapy/NN can/MD reach/VB pathologic/JJ complete/JJ response/NN (/( pCR/NN )/) rates/NNS of/IN 
1771_1771_1_2_19_20::None::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
341530_0_24_25_2_5::None::Patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN (/( SLE/NN )/) are/VBP at/IN a/DT high/JJ risk/NN for/IN cardiovascular/JJ disease/NN (/( CVD/NN )/) due/JJ to/TO increased/VBN prevalence/NN of/IN traditional/JJ and/CC nontraditional/JJ CVD/NN 
957_957_23_24_12_13::None::heavy/JJ chain/NN (/( Myh/NN )/) predicted/VBD to/TO interfere/VB strongly/RB with/IN myosin/NN 's/POS binding/NN to/TO actin/NN was/VBD designed/VBN and/CC 
1434_1434_11_12_14_15::None::,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB 
456903_0_13_14_46_47::medicine.medical_treatment.used_to_treat::once/RB daily/JJ prandial/JJ glucagon/NN -/: like/IN peptide/NN -/: 1/CD receptor/NN agonist/NN which/WDT lowers/VBZ glycohemoglobin/NN and/CC body/NN weight/NN by/IN clinically/RB significant/JJ amounts/NNS in/IN patients/NNS with/IN type/NN 2/CD diabetes/NNS treated/VBN with/IN basal/JJ insulin/NN ,/, with/IN limited/JJ risk/NN of/IN hypoglycemia/NN ./. 
417653_2_13_14_5_6::None::are/VBP increased/VBN in/IN plasma/NN of/IN obese/JJ ,/, insulin/NN -/: resistant/JJ and/CC diabetic/JJ individuals/NNS ,/, who/WP 
370155_0_10_11_29_30::None::artery/NN disease/NN (/( CAD/NN )/) ,/, and/CC noncoronary/JJ atherosclerotic/JJ vascular/JJ diseases/NNS (/( NCVDs/NNS )/) have/VBP similar/JJ risks/NNS of/IN cardiovascular/JJ events/NNS and/CC similar/JJ recommendations/NNS for/IN lipid/NN control/NN 
31738_0_2_3_0_1::None::Variation/NN in/IN Medicare/NNP Payments/NNS for/IN Colorectal/JJ 
188913_0_25_26_23_24::medicine.drug_ingredient.active_moiety_of_drug::Ca/NN )/) ,/, iron/NN (/( Fe/NNP )/) ,/, copper/NN 
834587_19_9_11_14_15::medicine.disease.treatments::in/IN treating/VBG mid/JJ esophageal/JJ carcinoma/NN as/IN compared/VBN to/TO IMRT/NNP The/NNP VMAT/NNP plans/VBZ 
270415_4_7_8_6_7::None::rest/NN MFR/NN were/VBD automatically/RB derived/VBN from/IN PET/NNP Patient/NNP 
185609_1_12_13_33_34::None::patients/NNS ,/, the/DT number/NN of/IN patients/NNS with/IN various/JJ comorbidities/NNS such/JJ as/IN membranous/JJ nephropathy/NN is/VBZ also/RB rising/VBG ,/, and/CC problems/NNS associated/VBN with/IN the/DT administration/NN of/IN chemotherapy/NN to/TO elderly/JJ patients/NNS 
213969_5_64_65_48_49::None::,/, rituximab/NN ,/, tacrolimus/NN ,/, paroxetine/NN ,/, sertraline/NN ,/, fluoxetine/NN ,/, bardoxolone/NN methyl/NN [/( phase/NN II/CD ]/) ;/: and/CC sorafenib/NN ,/, FK506/NN ,/, 
259065_5_16_18_4_5::medicine.risk_factor.diseases::between/IN FFI/NNP -/: BPD/NN and/CC relevant/JJ measures/NNS of/IN psychiatric/JJ symptomatology/NN and/CC etiology/NN (/( eg/FW ,/, childhood/NN abuse/NN ,/, drug/NN use/NN 
1913_1913_7_8_5_6::None::the/DT possibility/NN that/IN TD77/NN disrupts/VBZ actin/NN stress/NN fibers/NNS by/IN 
754436_8_13_14_15_16::None::problems/NNS with/IN their/PRP$ memory/NN and/CC concentration/NN compared/VBN with/IN fewer/JJR 
1055_1055_2_3_19_22::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC 
664393_0_1_2_9_11::medicine.risk_factor.diseases::Intraoperative/JJ radiotherapy/NN of/IN the/DT breast/NN for/IN early/JJ -/: stage/NN breast/NN cancer/NN :/: ready/JJ for/IN 
173493_0_21_22_0_1::medicine.drug_ingredient.active_moiety_of_drug::Budesonide/NN formoterol/NN (/( BF/NN )/) SpiromaxRegistered/NNP is/VBZ a/DT breath/NN -/: actuated/VBN dry/JJ -/: powder/NN inhaler/NN designed/VBN to/TO deliver/VB similar/JJ combinations/NNS of/IN budesonide/NN and/CC formoterol/NN as/IN 
178597_0_28_29_0_2::None::Clinical/JJ trials/NNS have/VBP shown/VBN that/IN a/DT strategy/NN for/IN haploidentical/JJ transplantation/NN based/VBN on/IN the/DT infusion/NN of/IN high/JJ numbers/NNS of/IN T/NN -/: cell/NN -/: depleted/VBN hematopoietic/JJ progenitor/NN cells/NNS and/CC no/DT post/NN -/: transplant/NN immunosuppression/NN 
980_980_12_13_14_15::None::the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN 
832646_0_4_5_8_10::medicine.symptom.symptom_of::identity/NN predicts/VBZ lower/JJR anxiety/NN and/CC depression/NN in/IN multiple/JJ sclerosis/NN ./. 
326872_11_15_16_2_3::None::AII/CD amacrine/NN cells/NNS have/VBP been/VBN considered/VBN as/IN the/DT main/JJ targets/NNS of/IN dopamine/NN signaling/NN in/IN the/DT mammalian/JJ retina/NN owing/VBG to/TO 
1790_1790_22_24_25_26::POS_ACTION_MEMBER::interferon-induced/JJ ,/, dsRNA-activated/JJ protein/NN kinase/NN ,/, PKR/NN ./. 
237860_0_8_10_20_21::None::woolly/JJ mammoth/JJ (/( Mammuthus/JJ primigenius/NN )/) named/VBN Lyuba/NNP was/VBD found/VBN frozen/VBN in/IN the/DT Siberian/JJ tundra/NN permafrost/NN along/IN the/DT Yuribey/NNP 
567_567_10_11_7_9::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT 
201815_2_6_7_22_23::None::we/PRP established/VBD a/DT silkworm/NN model/NN of/IN type/NN II/CD diabetes/NNS for/IN the/DT evaluation/NN of/IN anti/JJ -/: diabetic/JJ drugs/NNS such/JJ as/IN pioglitazone/NN and/CC metformin/NN ./. 
113665_4_12_13_3_4::None::We/PRP show/VBP that/IN dopamine/NN ,/, acting/VBG through/IN D1/NN receptors/NNS ,/, reduces/VBZ the/DT amplitude/NN and/CC sensitivity/NN of/IN 
1140_1140_22_23_20_21::None::the/DT interaction/NN of/IN gelsolin/NN and/CC profilin/NN with/IN actin/NN ./. 
543881_0_27_28_18_19::None::leading/VBG to/TO progressive/JJ damage/NN of/IN bone/NN and/CC cartilage/NN with/IN functional/JJ impairment/NN and/CC disability/NN ./. 
735_735_24_25_22_23::None::cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, and/CC tropomyosin/NN 
251166_0_13_15_25_26::people.cause_of_death.includes_causes_of_death::cholesterol/NN levels/NNS for/IN cardiovascular/JJ risk/NN stratification/NN is/VBZ limited/VBN in/IN patients/NNS with/IN coronary/JJ artery/NN disease/NN (/( CAD/NN )/) ./. 
347064_0_17_18_15_18::people.cause_of_death.includes_causes_of_death::for/IN spinal/JJ cord/NN injury/NN ,/, but/CC the/DT 
1052_1052_29_30_21_22::None::oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
865150_0_5_6_12_13::None::small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) remains/VBZ the/DT most/RBS common/JJ cause/NN of/IN cancer/NN 
853642_16_11_12_2_3::None::HF/NN and/CC perfusion/NN defects/NNS were/VBD not/RB recognized/VBN with/IN LDCT/NN In/IN COPD/NN patients/NNS and/CC long/JJ -/: 
18085_7_7_9_12_13::None::report/NN of/IN a/DT live/JJ birth/NN of/IN a/DT healthy/JJ child/NN after/IN ICSI/NN -/: 
29775_1_3_5_10_11::None::Despite/IN the/DT significant/JJ anatomical/JJ variation/NN in/IN the/DT hymen/NN and/CC no/DT guarantee/NN that/IN rupture/NN or/CC 
15883_8_5_6_0_1::None::The/DT MRI/NNP remains/VBZ the/DT best/JJS tool/NN to/TO detect/VB and/CC 
228216_0_10_11_3_4::None::Exposing/VBG cells/NNS to/TO folding/JJ stress/NN causes/VBZ a/DT subset/NN of/IN their/PRP$ proteins/NNS to/TO misfold/VB and/CC 
169759_4_19_20_27_29::None::and/CC //: or/CC activity/NN ,/, consistent/JJ with/IN their/PRP$ involvement/NN in/IN the/DT disulfide/NN bonds/NNS found/VBN in/IN the/DT 
844136_3_23_24_24_25::medicine.medical_treatment.used_to_treat::new/JJ strategy/NN for/IN treating/VBG cancers/NNS ./. 
1962_1962_20_22_24_25::POS_ACTION_MEMBER::deficient/JJ in/IN the/DT actin-binding/JJ proteins/NNS tropomyosin/NN and/CC profilin/NN also/RB did/VBD not/RB 
928918_0_9_10_2_3::None::Long/JJ -/: term/NN consequences/NNS of/IN anesthetic/JJ technique/NN after/IN cancer/NN surgery/NN ./. 
162581_4_3_4_11_13::None::We/PRP focused/VBD on/IN esophageal/NN ,/, gastric/JJ ,/, pancreatic/JJ ,/, liver/NN and/CC colorectal/JJ cancers/NNS ./. 
1205_1205_6_7_4_5::None::of/IN the/DT yeast/NN MSH3/NN and/CC MSH6/NN genes/NNS for/IN MSH2-dependent/JJ 
619_619_43_44_21_22::None::of/IN Ras/NN with/IN Myc/NN allows/VBZ the/DT generation/NN of/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN and/CC the/DT induction/NN of/IN S/NN phase/NN ,/, coincident/JJ with/IN the/DT loss/NN of/IN the/DT p27/NN cyclin-dependent/JJ kinase/NN inhibitor/NN 
398949_5_8_10_66_67::None::vitamin/NN C/NN ,/, vitamin/NN E/NN ,/, N/NN -/: acetyl/NN -/: l/NN -/: cysteine/NN )/) provided/VBD partial/JJ protection/NN against/IN cell/NN loss/NN but/CC also/RB promoted/VBD loss/NN of/IN the/DT cholinergic/JJ phenotype/NN in/IN response/NN to/TO TSE/NNP Notably/RB ,/, the/DT antioxidants/NNS themselves/PRP altered/VBD neurodifferentiation/NN ,/, reducing/VBG cell/NN numbers/NNS and/CC promoting/VBG the/DT cholinergic/JJ phenotype/NN at/IN the/DT expense/NN of/IN the/DT dopaminergic/JJ phenotype/NN ,/, an/DT effect/NN that/WDT was/VBD most/RBS prominent/JJ for/IN N/NN -/: 
721_721_13_14_15_16::None::to/TO DNA/NN were/VBD PRP21/NN and/CC PRP9/NN or/CC PRP21/NN and/CC 
957_957_12_13_8_11::None::mutation/NN in/IN the/DT myosin/NN heavy/JJ chain/NN (/( Myh/NN )/) predicted/VBD to/TO 
252268_2_0_1_10_11::None::We/PRP describe/VBP a/DT cohort/NN of/IN rhesus/NN macaques/NNS displaying/VBG SIB/NNP as/IN adults/NNS ,/, in/IN which/WDT 
1678_1678_13_14_13_14::POS_ACTION_ENCODE::of/IN the/DT total/JJ H3/NN and/CC H2a/NN mRNA/NN 
546055_2_20_21_30_31::medicine.risk_factor.diseases::urinarypeptide/NN -/: based/VBN high/JJ -/: dimensional/JJ classifier/NN ,/, namely/RB CKD273/NN ,/, for/IN predicting/VBG CKD/NNP progression/NN ./. 
323090_6_13_14_15_16::None::,/, liver/NN ,/, colorectal/JJ ,/, breast/NN ,/, and/CC cervical/JJ 
38849_2_7_8_19_20::medicine.disease.risk_factors::human/JJ acute/JJ myeloid/JJ leukemia/NN (/( AML/NN )/) ,/, they/PRP are/VBP common/JJ in/IN murine/JJ models/NNS of/IN radiation/NN -/: induced/VBN AML/NN 
712_712_24_25_11_12::None::to/TO suggest/VB that/IN HRG/NN stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN 
70627_9_11_12_0_1::None::Cortisol/NN response/NN to/TO stress/NN differed/VBD according/VBG to/TO group/NN :/: in/IN the/DT ADHD/NNP group/NN ,/, 20min/JJ 
473887_5_18_19_0_2::None::Palliative/JJ care/NN improves/VBZ symptoms/NNS ,/, most/JJS frequently/RB pain/NN ,/, and/CC improves/VBZ quality/NN of/IN life/NN for/IN patients/NNS and/CC their/PRP$ families/NNS ,/, especially/RB in/IN 
862710_1_26_27_25_26::medicine.medical_treatment.used_to_treat::drug/NN therapy/NN of/IN ALS/NNP Riluzole/NNP ,/, a/DT moderately/RB 
513_513_9_10_12_13::None::,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO 
1095_1095_22_23_11_12::None::adhesion/NN pattern/NN ,/, actin/NN organization/NN ,/, and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ 
1508_1508_5_6_10_11::None::simplex/NN virus/NN type-1/NN UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS encode/VBP an/DT 
1507_1507_6_7_22_23::POS_ACTION_CONTAIN::virus/NN type/NN 1/CD primosome/NN consists/VBZ of/IN three/CD subunits/NNS that/WDT are/VBP the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS ./. 
2131_2131_9_10_7_8::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC 
619_619_26_29_21_22::None::of/IN Ras/NN with/IN Myc/NN allows/VBZ the/DT generation/NN of/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN and/CC the/DT 
1199_1199_8_9_5_6::POS_REG(-)_POLYMERIZE::the/DT inhibition/NN of/IN actin/NN polymerization/NN by/IN profilin/NN ./. 
201_201_4_5_6_7::POS_ACTION_INTERACT::two-hybrid-based/JJ approach/NN using/VBG cofilin/NN and/CC actin/NN mutants/NNS identified/VBD residues/NNS 
608_608_23_24_18_19::POS_ACTION_BIND::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS (/( Crute/NNP 
787228_4_4_5_23_24::medicine.disease.treatments::results/NNS revealed/VBD that/IN COPD/NNP was/VBD significantly/RB associated/VBN with/IN a/DT high/JJ risk/NN of/IN osteoporosis/NN ,/, regardless/RB of/IN whether/IN the/DT patients/NNS with/IN COPD/NN were/VBD corticosteroid/NN users/NNS and/CC irrespective/RB 
23235_3_16_17_23_24::None::70o/JJ HUT/NN for/IN determination/NN of/IN fibrinogen/NN ,/, von/NN Willebrand/NN factor/NN antigen/NN (/( vWF/NN :/: 
1686_1686_47_48_15_18::None::domains/NNS of/IN all/DT myosin/JJ heavy/JJ chains/NNS ,/, and/CC light/JJ chains/NNS at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP 
445671_0_19_20_4_5::medicine.symptom.symptom_of::muscular/JJ dystrophy/NN (/( DMD/NN )/) ,/, the/DT most/RBS common/JJ form/NN of/IN muscular/JJ dystrophy/NN ,/, is/VBZ characterized/VBN by/IN muscular/JJ wasting/NN caused/VBN by/IN dystrophin/NN 
416351_15_6_7_1_2::None::Having/VBG personal/JJ or/CC family/NN history/NN of/IN hypertension/NN ,/, older/JJR age/NN 
1206_1206_5_6_3_4::None::Requirement/NN of/IN yeast/NN fimbrin/NN for/IN actin/NN organization/NN and/CC morphogenesis/NN 
279_279_12_13_19_20::None::directly/RB associate/VBP with/IN TIF34/NN :/: PRT1/NN ,/, a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC 
712_712_23_24_15_16::None::stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN 
96855_6_14_15_18_19::None::all/DT five/CD underwent/VBD burn/VBP excision/NN and/CC microsurgical/JJ reconstruction/NN using/VBG distant/JJ flaps/NNS 
844136_3_23_24_12_13::None::targets/VBZ cancer/NN -/: specific/JJ expression/NN and/CC limits/NNS toxicity/NN ,/, is/VBZ a/DT new/JJ strategy/NN for/IN treating/VBG cancers/NNS ./. 
365_365_12_15_30_31::None::D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN in/IN subversion/NN of/IN the/DT G1/S/NN traverse/NN by/IN signaling/NN pathways/NNS activated/VBN by/IN HER-2/NN function/NN ./. 
17565_0_13_14_10_11::None::high/JJ morbidity/NN and/CC mortality/NN in/IN the/DT elderly/JJ population/NN ./. 
226308_2_30_31_6_7::None::was/VBD assessed/VBN on/IN CRA/NNP agar/NN and/CC hydrophobicity/NN of/IN 20/CD Salmonella/FW strains/NNS isolated/VBN from/IN poultry/NN and/CC human/JJ and/CC two/CD Salmonella/FW enterica/FW serovar/NN Typhimurium/NN references/NNS strains/NNS was/VBD achieved/VBN by/IN microbial/JJ adhesion/NN to/TO n/NN 
996_996_12_13_29_30::None::can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN 
98643_2_10_11_29_30::None::rinv/NN were/VBD prescribed/VBN ondansetron/NN rdf/NN 8/CD mg/NN twice/RB daily/RB while/IN on/IN treatment/NN and/CC were/VBD asked/VBN to/TO complete/VB a/DT nausea/NN and/CC vomiting/NN -/: specific/JJ daily/JJ diary/NN ,/, 
1793_1793_14_15_4_5::POS_ACTION_CONTROL::viscoelasticity/NN of/IN entangled/JJ actin/NN networks/NNS :/: the/DT influence/NN of/IN defects/NNS and/CC modulation/NN by/IN talin/NN and/CC vinculin/NN ./. 
757758_7_27_28_33_34::None::illness/NN and/CC longer/JJR duration/NN of/IN time/NN from/IN the/DT first/JJ CDI/NNP to/TO bacteriotherapy/NN (/( 
686_686_23_24_29_30::POS_ACTION_BIND::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC 
6567_1_26_27_16_17::None::sodium/NN -/: containing/VBG salts/NNS ,/, is/VBZ a/DT behaviour/NN mediated/VBN by/IN a/DT set/NN of/IN evolutionary/JJ conserved/VBN neuronal/JJ systems/NNS 
355_355_14_15_16_17::None::of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD 
1147_1147_22_23_17_18::None::ligands/NNS which/WDT localize/VBP profilin/NN to/TO sites/NNS requiring/VBG extensive/JJ actin/NN filament/NN accumulation/NN ./. 
63_63_49_50_44_45::None::.2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN 
170773_3_22_25_30_31::medicine.disease.risk_factors::of/IN sequela/NN of/IN coronary/JJ artery/NN disease/NN and/CC present/VB the/DT genome/NN -/: wide/JJ association/NN studies/NNS conducted/VBN 
473887_5_3_4_23_24::people.cause_of_death.includes_causes_of_death::Palliative/JJ care/NN improves/VBZ symptoms/NNS ,/, most/JJS frequently/RB pain/NN ,/, and/CC improves/VBZ quality/NN of/IN life/NN for/IN patients/NNS and/CC their/PRP$ families/NNS ,/, especially/RB in/IN the/DT terminal/JJ disease/NN phase/NN ./. 
1087_1087_7_9_10_12::None::that/IN in/IN brain/NN profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT 
1289_1289_13_14_11_12::None::)/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN bovine/JJ 
1025_1025_0_1_27_28::None::Myo2p/NN shows/VBZ homology/NN to/TO the/DT head/NN domains/NNS and/CC the/DT coiledcoil/NN tail/NN of/IN the/DT conventional/JJ type/NN II/CD myosin/NN heavy/JJ chain/NN and/CC carries/VBZ putative/JJ binding/NN sites/NNS for/IN ATP/NN and/CC actin/NN ./. 
367_367_24_25_26_27::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
793106_10_23_24_87_88::None::variables/NNS age/NN ,/, gender/NN ,/, disease/NN duration/NN ,/, tumor/NN size/NN ,/, basal/JJ hormone/NN levels/NNS ,/, relevant/JJ treatment/NN modalities/NNS ,/, and/CC relevant/JJ comorbidities/NNS )/) ,/, with/IN a/DT higher/JJR degree/NN of/IN psychopathology/NN indicating/VBG a/DT lower/JJR QoL/NN (/( depression/NN vs/CC AcroQoL/NN :/: B/NN =/SYM -/: 1.175/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD ,/, depression/NN vs/CC SF/NN -/: 36/CD :/: B/NN =/SYM -/: 1.648/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD ,/, anxiety/NN vs/CC AcroQoL/NN :/: 
408257_14_6_7_13_14::None::is/VBZ questionable/JJ whether/IN senescence/NN of/IN MM/NN -/: BMMSCs/NNS plays/VBZ a/DT pathological/JJ role/NN in/IN active/JJ 
275901_0_7_8_35_36::None::,/, many/JJ chronic/JJ hepatitis/NN B/NN (/( CHB/NN )/) patients/NNS have/VBP undergone/VBN sequential/JJ treatment/NN with/IN lamivudine/NN (/( LAM/NN )/) ,/, adefovir/NN (/( ADV/NN )/) ,/, and/CC entecavir/NN (/( ETV/NN )/) to/TO manage/VB antiviral/JJ resistance/NN or/CC insufficient/JJ 
76585_4_5_6_13_14::None::were/VBD :/: tobacco/NN consumption/NN ,/, hypercholesterolemia/NN ,/, diabetes/NN ,/, aspirin/NN or/CC statin/NN treatment/NN ./. 
515_515_7_8_23_24::POS_ACTION_Causal::the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
1532_1532_29_30_17_18::None::association/NN of/IN the/DT Munc18-2/NN variants/NNS with/IN syntaxin/NN 3/CD correlated/VBD well/RB with/IN their/PRP$ ability/NN to/TO displace/VB SNAP-23/NN from/IN syntaxin/NN 3/CD 
1460_1460_3_4_8_9::None::The/DT distribution/NN of/IN actin/NN filaments/NNS is/VBZ altered/VBN by/IN profilin/NN overexpression/NN ./. 
1754_1754_32_33_7_8::NEG_ACTION_Change::the/DT dysfunction/NN of/IN E-cadherin/NN in/IN these/DT cell/NN lines/NNS is/VBZ due/JJ primarily/RB to/TO its/PRP$ failure/NN to/TO interact/VB with/IN alpha-catenin/NN ,/, and/CC that/IN this/DT defect/NN results/VBZ from/IN the/DT mutation/NN in/IN beta-catenin/NN ./. 
1122_1122_8_9_23_24::None::could/MD regulate/VB the/DT actin/NN binding/NN and/CC bundling/VBG properties/NNS of/IN fimbrin/NN ,/, or/CC it/PRP could/MD regulate/VB the/DT interaction/NN of/IN fimbrin/NN with/IN other/JJ proteins/NNS 
1258_1258_32_33_3_4::POS_ACTION_BIND::Significantly/RB ,/, those/DT actin/NN mutants/NNS exhibiting/VBG the/DT most/RBS severe/JJ phenotypes/NNS in/IN all/DT three/CD processes/NNS have/VBP altered/VBN residues/NNS that/WDT cluster/VBP to/TO a/DT small/JJ region/NN of/IN the/DT actin/NN crystal/NN structure/NN previously/RB defined/VBN as/IN the/DT fimbrin/NN (/( Sac6p/NN )/) 
248192_9_0_1_10_14::None::Provisional/JJ videonystagmography/NN (/( VNG/NN )/) results/NNS were/VBD :/: 40/CD %/NN benign/JJ paroxysmal/JJ positional/JJ vertigo/NN (/( BPPV/NN )/) 
574065_1_39_40_7_8::None::on/IN prostate/NN ,/, renal/JJ and/CC bladder/NN cancer/NN presented/VBN at/IN the/DT 2014/CD congresses/NNS (/( European/JJ Association/NNP of/IN Urology/NNP ,/, American/NNP Urological/NNP Association/NNP ,/, American/NNP Society/NNP of/IN Clinical/JJ Oncology/NN and/CC American/JJ Society/NNP for/IN Radiation/NNP Oncology/NNP )/) that/WDT received/VBD the/DT best/JJS evaluations/NNS 
960_960_5_6_17_18::None::the/DT previously/RB identified/VBN VRP1/NN ,/, which/WDT encodes/VBZ verprolin/NN ,/, required/VBN for/IN proper/JJ organization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
533311_1_0_1_11_12::None::The/DT study/NN aimed/VBN to/TO identify/VB the/DT depression/NN and/CC anxiety/NN state/NN of/IN diabetic/JJ adolescents/NNS and/CC its/PRP$ 
3836_0_0_1_7_8::medicine.disease.risk_factors::Management/NN of/IN Idiopathic/JJ Pulmonary/JJ Fibrosis/NN in/IN the/DT Elderly/NNP Patient/NN :/: Addressing/VBG 
93_93_24_26_22_23::POS_ACTION_MEMBER::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
18085_7_32_33_33_34::None::trisomy/NN 21/CD and/CC male/JJ factor/NN infertility/NN ./. 
70627_9_24_25_15_16::None::group/NN ,/, 20min/JJ post/NN -/: test/NN cortisol/NN levels/NNS were/VBD significantly/RB higher/JJR than/IN base/NN -/: line/NN cortisol/NN 
244414_9_7_8_3_4::medicine.medical_treatment.used_to_treat::For/IN T4/NN nasopharynx/NN cancer/NN patients/NNS treated/VBN with/IN IMRT/NN and/CC chemotherapy/NN ,/, 
355_355_25_26_12_13::None::mutant/JJ form/NN of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD form/VB a/DT structural/JJ complex/NN with/IN E-cadherin/NN via/IN these/DT interactions/NNS 
556761_3_8_9_9_10::None::performed/VBN for/IN a/DT male/JJ cat/NN with/IN UO/NN ,/, 
628556_0_3_4_8_9::None::Decision/NN Trees/NNP Predicting/VBG Tumor/NN Shrinkage/NN for/IN Head/NNP and/CC Neck/NNP Cancer/NNP :/: Implications/NNS 
607_607_8_9_23_24::None::expresses/VBZ a/DT heterotrimeric/JJ helicase-primase/NN ,/, the/DT subunits/NNS of/IN which/WDT are/VBP encoded/VBN by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS ./. 
1508_1508_5_6_16_18::POS_ACTION_ENCODE::simplex/NN virus/NN type-1/NN UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS encode/VBP an/DT essential/JJ heterotrimeric/JJ DNA/NN helicase-primase/NN that/WDT is/VBZ responsible/JJ 
1713_1713_12_13_10_11::None::relevant/JJ ligands/NNS of/IN profilin/NN ,/, actin/NN and/CC proline-rich/JJ peptides/NNS 
380023_1_11_12_9_10::None::not/RB routinely/RB screen/NN patients/NNS for/IN anxiety/NN and/CC depression/NN ,/, 
779_779_49_52_26_27::POS_ACTION_COOCCUR::inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
778878_10_18_19_5_6::None::with/IN non/JJ -/: CF/NN bronchiectasis/NN ,/, long/JJ -/: term/NN inhaled/VBD antibiotics/NNS can/MD effectively/RB reduce/VB the/DT sputum/NN bacterial/JJ density/NN ,/, increase/NN 
382707_7_19_20_26_27::medicine.disease.symptoms::neuroticism/NN ,/, current/JJ depression/NN ,/, and/CC tendencies/NNS toward/IN catastrophic/JJ and/CC anxiety/NN -/: provoking/VBG appraisals/NNS 
95871_3_10_11_1_2::None::We/PRP hypothesize/VBP that/IN adding/VBG CS/NN following/VBG injury/NN or/CC injury/NN and/CC shock/NN in/IN rats/NNS will/MD 
944_944_10_11_4_5::None::dynamics/NNS of/IN Dictyostelium/NNP cofilin/NN suggests/VBZ a/DT role/NN in/IN remodeling/VBG actin/NN latticework/NN into/IN bundles/NNS 
391631_1_8_9_3_4::None::The/DT test/NN is/VBZ based/VBN on/IN a/DT double/JJ -/: antibody/NN sandwich/NN format/NN and/CC 
865_865_7_8_33_35::None::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
456531_7_17_18_2_3::None::DTR/SYM -/: QOL/NN was/VBD associated/VBN with/IN self/NN -/: reported/VBN levels/NNS of/IN self/NN -/: care/NN activities/NNS in/IN insulin/NN injection/NN ,/, particularly/RB among/IN 
161_161_17_18_11_12::None::COOH/NN terminus/NN of/IN beta-catenin/NN is/VBZ involved/VBN in/IN binding/VBG to/TO CBP/NN ,/, whereas/IN beta-catenin/NN 
189641_0_17_18_4_5::None::the/DT face/NN of/IN urbanisation/NN ,/, surplus/NN energy/NN intake/NN ,/, sedentary/JJ habits/NNS and/CC obesity/NN ,/, type/NN 2/CD diabetes/NN has/VBZ developed/VBN into/IN 
1546_1546_12_13_8_11::None::p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ 
445671_0_9_10_19_20::None::,/, the/DT most/RBS common/JJ form/NN of/IN muscular/JJ dystrophy/NN ,/, is/VBZ characterized/VBN by/IN muscular/JJ wasting/NN caused/VBN by/IN dystrophin/NN 
126724_0_6_7_0_1::None::Back/RB to/TO the/DT Future/NNP :/: Are/VBP Tumor/NN -/: Targeting/NN Bacteria/NNS 
607_607_21_22_23_24::None::viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS ./. 
691776_2_9_10_15_16::None::,/, about/IN the/DT evolutionary/JJ history/NN and/CC gene/NN content/NN of/IN primordial/JJ cyanobacteria/NN [/( 7/CD 
101_101_22_23_36_37::POS_ACTION_Physical::the/DT influence/NN of/IN talin/NN and/CC vinculin/NN on/IN the/DT structure/NN ,/, chain/NN dynamics/NNS ,/, elasticity/NN and/CC viscoelasticity/NN of/IN actin/NN filaments/NNS with/IN time/NN 
2222_2222_17_18_39_40::None::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
342702_0_20_21_29_30::None::have/VBP fuelled/VBN the/DT development/NN of/IN targeted/VBN therapies/NNS that/WDT block/VBP cytokine/NN networks/NNS and/CC pathogenic/JJ immune/JJ cells/NNS ,/, 
1227_1227_22_23_2_3::None::Saccharomyces/FW cerevisiae/FW RAD14/NN was/VBD identified/VBN in/IN a/DT two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN ,/, ''/'' and/CC pairwise/JJ interactions/NNS between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, 
1758_1758_4_5_22_23::POS_ACTION_RELATE::results/NNS suggest/VBP that/IN TNF-alpha/NN can/MD cause/VB apoptosis/NN in/IN pancreatic/JJ beta/NN cells/NNS through/IN TNFR1-linked/JJ apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ,/, and/CC TNF-induced/JJ 
479047_2_35_36_39_42::medicine.disease.risk_factors::(/( 87/CD %/NN stroke/NN ,/, 42/CD %/NN transient/JJ ischemic/JJ attacks/NNS )/) ./. 
318370_0_17_18_24_25::None::simple/JJ green/JJ method/NN assisted/VBN by/IN water/NN plasma/NN at/IN a/DT low/JJ temperature/NN and/CC atmospheric/JJ pressure/NN 
284647_4_38_39_19_20::None::as/RB well/RB as/IN impact/NN on/IN disease/NN rates/NNS in/IN infants/NNS is/VBZ encouraging/JJ ,/, anticipating/VBG the/DT possibility/NN to/TO at/IN last/JJ control/NN pertussis/NN in/IN this/DT vulnerable/JJ age/NN group/NN ./. 
1757_1757_15_16_8_9::POS_ACTION_INTERACT::subcellular/JJ distribution/NN of/IN cofilin/NN as/RB well/RB as/IN its/PRP$ interaction/NN with/IN actin/NN in/FW vivo/FW is/VBZ 
1074_1074_7_8_5_6::None::proteins/NNS ,/, including/VBG vinculin/NN ,/, talin/NN ,/, and/CC ezrin/NN 
719083_0_10_11_8_9::None::Presenting/VBG with/IN Febrile/NN Seizures/NNS at/IN Ali/NNP -/: Asghar/NNP Children/NNP 
410591_0_9_11_20_21::medicine.disease.symptoms::leading/VBG causes/NNS of/IN nephrotic/JJ syndrome/NN in/IN adults/NNS ,/, which/WDT is/VBZ characterized/VBN by/IN edema/NN ,/, hypoalbuminemia/NN ,/, hyperlipidemia/NN ,/, 
445433_1_9_10_6_7::None::neuronal/JJ pathway/NN for/IN histamine/NN -/: induced/VBN itch/NN in/IN the/DT peripheral/JJ 
932_932_1_2_3_4::None::Like/IN TESK1/NN ,/, TESK2/NN phosphorylated/VBN cofilin/NN specifically/RB 
28475_4_123_124_48_49::None::GR/NN M/NN vogae/FW thioredoxin/NN and/CC glutathione/NN reductase/NN activities/NNS were/VBD inhibited/VBN by/IN 3,4/CD -/: bis/NN (/( phenylsulfonyl/NN )/) -/: 1,2,5/CD -/: oxadiazole/NN N2/NN -/: oxide/NN (/( VL16E/NN )/) ,/, an/DT oxadiazole/NN N/NN -/: oxide/NN previously/RB identified/VBN as/IN an/DT inhibitor/NN of/IN fluke/NN and/CC tapeworm/NN TGRs/NNS Finally/RB ,/, we/PRP show/VBP that/IN mice/NNS experimentally/RB infected/VBN with/IN M/NN vogae/FW tetrathyridia/FW and/CC treated/VBN with/IN either/CC praziquantel/NN ,/, the/DT reference/NN drug/NN for/IN flatworm/NN infections/NNS ,/, or/CC VL16E/NN exhibited/VBD a/DT 28/CD %/NN reduction/NN of/IN intraperitoneal/JJ larvae/NNS numbers/NNS compared/VBN to/TO vehicle/NN 
996_996_5_7_31_34::None::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
287181_0_30_31_11_14::None::heart/NN disease/NN or/CC coronary/JJ artery/NN disease/NN ,/, accounts/NNS for/IN &/CC gt/NN ;/: 50/CD %/NN of/IN cardiovascular/JJ events/NNS and/CC is/VBZ a/DT leading/VBG cause/NN worldwide/RB of/IN morbidity/NN and/CC 
257215_0_45_46_17_18::None::(/( MSN/NNP -/: SS/NN -/: HA/NN )/) based/VBN on/IN mesoporous/JJ silica/NN nanoparticles/NNS (/( MSN/NNP )/) for/IN targeted/VBN drug/NN delivery/NN has/VBZ been/VBN developed/VBN ,/, in/IN which/WDT hyaluronic/JJ acid/NN (/( HA/NN )/) was/VBD conjugated/VBN on/IN the/DT surface/NN 
583_583_14_15_17_18::None::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
75211_5_27_29_4_5::None::report/VBP on/IN the/DT cases/NNS of/IN five/CD Indian/JJ women/NNS with/IN breast/NN cancer/NN ,/, in/IN the/DT age/NN group/NN of/IN 34/CD to/TO 60/CD years/NNS ,/, who/WP had/VBD poorly/RB differentiated/VBN breast/NN carcinoma/NN and/CC underwent/VBD modified/VBN 
275849_11_14_15_14_16::medicine.drug.active_moieties::was/VBD treated/VBN with/IN acetic/JJ acid/NN and/CC salt/NN in/IN 
865_865_33_35_21_24::None::)/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
988_988_15_16_20_21::POS_ACTION_SIMILAR::vinculin/NN and/CC the/DT beta-catenin/NN is/VBZ homologous/JJ to/TO human/JJ plakoglobin/NN and/CC the/DT Drosophila/NN 
379000_0_5_6_10_12::None::block/NN in/IN diabetic/JJ rats/NNS using/VBG high/JJ -/: intensity/NN focused/VBD ultrasound/NN for/IN analgesic/JJ applications/NNS 
319920_0_25_27_30_31::None::,/, mania/NN ,/, sleep/NN disturbance/NN ,/, judgment/NN //: impulsivity/NN ,/, and/CC irritability/NN 
402511_2_5_6_21_22::None::study/NN ,/, high/JJ resolution/NN metabolomics/NNS (/( HRM/NN )/) was/VBD employed/VBN to/TO identify/VB malaria/NN parasite/NN -/: specific/JJ metabolites/NNS in/IN Plasmodium/NN falciparum/NN in/FW vitro/FW culture/NN 
36424_0_12_13_31_33::None::of/IN CT/NNP Density/NNP Model/NNP Variations/NNPS and/CC the/DT Impact/NN On/IN the/DT Accuracy/NNP of/IN Monte/NNP Carlo/NNP (/( MC/NNP )/) Dose/NNP Calculation/NN in/IN Stereotactic/JJ Body/NN Radiation/NNP Therapy/NN for/IN Lung/NN Cancer/NN 
76705_14_8_9_0_1::None::Patients/NNS with/IN a/DT recent/JJ -/: onset/NN AF/NN and/CC troponin/NN -/: rise/NN showed/VBD 
761186_8_10_11_20_21::medicine.disease.symptoms::presence/NN of/IN any/DT CAD/NN (/( n/NN =/JJ 176/CD )/) ,/, including/VBG MI/NNP ,/, angina/NN ,/, and/CC stroke/NN 
1913_1913_5_6_7_8::POS_ACTION_DISASSEMBLE::the/DT possibility/NN that/IN TD77/NN disrupts/VBZ actin/NN stress/NN fibers/NNS by/IN 
787_787_7_8_13_14::None::cofilin-dependent/JJ regulation/NN of/IN actin/NN assembly/NN in/IN muscle/NN cells/NNS ,/, cofilin/NN tagged/VBD with/IN fluorescence/NN 
363177_0_8_9_3_4::people.cause_of_death.includes_causes_of_death::Multiple/JJ sclerosis/NN (/( MS/NN )/) is/VBZ characterized/VBN by/IN inflammatory/JJ demyelination/NN and/CC deposition/NN 
905933_12_7_8_13_14::None::DIR/NN -/: based/VBN dose/NN accumulation/NN may/MD be/VB acceptable/JJ for/IN assessing/VBG cumulative/JJ dose/NN distributions/NNS 
112017_4_4_5_12_13::medicine.symptom.symptom_of::patients/NNS had/VBD situational/JJ disorders/NNS ,/, with/IN a/DT slight/JJ prevalence/NN of/IN situational/JJ depression/NN ./. 
599869_3_14_15_13_14::medicine.risk_factor.diseases::considered/VBN after/IN whole/JJ breast/NN radiation/NN therapy/NN ,/, TNBC/NN 
119285_0_14_15_17_18::medicine.drug.active_moieties::OH/NN )/) and/CC sulfate/NN radical/NN (/( SO4/NN */SYM -/: )/) 
816_816_11_12_2_3::None::Interaction/NN of/IN Munc-18-2/NN with/IN syntaxin/NN 3/CD controls/VBZ the/DT association/NN of/IN apical/JJ SNAREs/NNS in/IN epithelial/JJ cells/NNS 
489_489_15_16_9_10::None::of/IN three/CD putative/JJ PCAF/NN substrates/NNS ,/, histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN 
76765_3_84_85_10_11::people.cause_of_death.includes_causes_of_death::high/JJ -/: sensitivity/NN cardiac/JJ troponin/NN T/NN (/( hsTnT/NN )/) and/CC FPG/NNP categorized/VBD as/IN normal/JJ fasting/NN glucose/NN (/( NFG/NN :/: FPG/NNP &/CC lt/NN ;/: //: =/JJ 6.0/CD mmol/NN //: L/NN )/) ,/, impaired/JJ fasting/NN glucose/NN (/( IFG/NN :/: FPG/NNP 6.1/CD -/: 6.9/CD mmol/NN //: L/NN )/) ,/, and/CC diabetes/NN mellitus/NN (/( DM/NN :/: FPG/NNP &/CC gt/NN ;/: //: =/JJ 7.0/CD mmol/NN //: L/NN )/) ,/, in/IN 535/CD men/NNS and/CC 226/CD women/NNS aged/JJ 56/CD -/: 79/CD years/NNS without/IN overt/JJ cardiovascular/JJ disease/NN who/WP received/VBD 
149493_0_35_36_14_17::None::developed/VBN to/TO assist/VB primary/JJ care/NN physicians/NNS and/CC other/JJ health/NN care/NN professionals/NNS in/IN the/DT outpatient/NN treatment/NN of/IN uncomplicated/JJ hypertension/NN in/IN adult/JJ men/NNS and/CC nonpregnant/JJ women/NNS aged/VBN 18/CD years/NNS and/CC 
1657_1657_12_13_8_9::None::with/IN respect/NN to/TO cofilin/NN binding/NN to/TO filamentous/JJ actin/NN which/WDT may/MD be/VB 
210955_0_30_31_9_10::None::related/JJ disease/NN (/( IgG4/NN -/: RD/NN )/) is/VBZ characterized/VBN by/IN elevated/JJ serum/NN IgG4/NN and/CC infiltration/NN of/IN IgG4/NN (/( +/CC )/) plasma/NN cells/NNS into/IN multiple/JJ organs/NNS ./. 
179835_3_30_31_14_15::None::imaging/NN techniques/NNS and/CC potential/JJ clinical/JJ applications/NNS and/CC limitations/NNS of/IN those/DT techniques/NNS for/IN the/DT evaluation/NN of/IN major/JJ SLE/NN -/: related/JJ heart/NN disorders/NNS ./. 
1474_1474_9_10_29_31::POS_ACTION_Dynamics::(/( serum/NN and/CC laminin/NN )/) and/CC time/NN in/IN culture/NN on/IN the/DT expression/NN of/IN genes/NNS encoding/VBG myosin/NN heavy/JJ chain/NN (/( MHC/NN )/) isoforms/NNS and/CC alpha-skeletal/JJ actin/NN were/VBD analysed/VBN in/IN 
1758_1758_17_18_22_23::None::apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ,/, and/CC TNF-induced/JJ 
600709_1_23_25_16_17::medicine.disease.risk_factors::alcoholic/JJ steatohepatitis/NN (/( NASH/NN )/) ,/, which/WDT may/MD develop/VB into/IN hepatic/JJ fibrosis/NN ,/, cirrhosis/NN ,/, 
641_641_37_38_37_38::NEG_ACTION_CORELATE::nuclear/JJ transport/NN of/IN cofilin/NN ./. 
850254_13_10_12_0_1::None::HbA1c/NN and/CC fructosamine/NN were/VBD significantly/RB increased/VBN in/IN diabetic/JJ patients/NNS with/IN acute/JJ infection/NN ./. 
1810_1810_2_3_0_1::None::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR 
411_411_15_16_13_14::None::signaling/VBG molecules/NNS including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, 
489359_3_14_15_10_11::None::OSAS/NN )/) was/VBD defined/VBN as/IN reporting/VBG both/CC snoring/VBG and/CC daytime/JJ sleepiness/NN 
18_18_18_20_6_7::POS_ACTION_INTERACT::the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) 
865_865_11_14_21_24::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ 
1834_1834_6_7_15_17::None::three/CD structures/NNS of/IN actin/NN complexed/VBN with/IN different/JJ monomer-binding/JJ proteins/NNS ,/, namely/RB with/IN DNase/NN I/CD ,/, gelsolin/NN segment/NN 
292034_0_5_8_2_3::None::[/( Pulmonary/JJ Clear/JJ Cell/NN Type/NN Squamous/JJ Cell/NN Carcinoma/NN that/WDT Required/NNP Differential/JJ 
471565_0_24_25_11_12::medicine.disease.treatments::low/JJ or/CC high/JJ dialysate/NN sodium/NN concentration/NN (/( DNa/NN (/( +/CC )/) )/) should/MD be/VB advocated/VBN in/IN chronic/JJ haemodialysis/NN patients/NNS ./. 
1411_1411_18_19_1_5::None::The/DT cardiac/JJ myosin/NN heavy/JJ chain/NN Arg-403/NN --/: >/JJR Gln/NN mutation/NN that/WDT causes/VBZ hypertrophic/JJ cardiomyopathy/NN does/VBZ not/RB affect/VB the/DT actin/NN -/: or/CC ATP-binding/JJ 
71_71_6_7_0_1::None::Aip1p/NN interacts/VBZ with/IN cofilin/NN to/TO disassemble/VB actin/NN filaments/NNS ./. 
356086_0_1_3_16_17::None::Cancer/NN stem/NN cells/NNS (/( CSCs/NNS )/) play/VBP an/DT important/JJ role/NN in/IN cancer/NN growth/NN ,/, self/NN -/: renewal/NN ,/, metastasis/NN ,/, 
162483_5_34_35_37_38::None::,/, smoking/NN ,/, obesity/NN ,/, metabolic/JJ syndrome/NN ,/, hyperuricaemia/NN ,/, 
1286_1286_8_9_3_6::None::Specific/JJ antibodies/NNS to/TO myosin/JJ heavy/JJ chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, 
1427_1427_3_4_32_33::POS_ACTION_BIND::The/DT comparison/NN of/IN E-CD/NN proteins/NNS synthesized/VBN by/IN E62/NN and/CC E24/NN cell/NN lines/NNS revealed/VBD no/DT structural/JJ or/CC functional/JJ differences/NNS because/IN both/DT localized/JJ at/IN cell-cell/JJ contacts/NNS and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1759_1759_40_41_40_41::POS_REG(+)_POLYMERIZE::the/DT nucleation/NN of/IN actin/NN polymerization/NN ./. 
322394_2_23_24_12_13::None::evaluate/VB effects/NNS of/IN ACR/NN on/IN dopamine/NN and/CC its/PRP$ metabolite/NN levels/NNS ,/, dopamine/NN transport/NN and/CC metabolic/JJ gene/NN expression/NN in/IN 
667_667_6_7_14_15::POS_ACTION_BIND::that/IN ,/, like/IN Abp1p/NN ,/, cofilin/NN is/VBZ associated/VBN with/IN the/DT membrane/NN actin/NN cytoskeleton/NN ./. 
799053_0_16_17_8_9::None::malignancies/NNS :/: unique/JJ genetic/JJ events/NNS ,/, frozen/JJ development/NN and/CC enduring/VBG apoptotic/JJ potential/NN ./. 
1075_1075_6_7_20_21::None::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) 
1633_1633_25_26_26_27::POS_ACTION_MEMBER::identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC 
98_98_29_30_31_32::POS_ACTION_LOCALIZE::the/DT affinity/NN of/IN profilin/NN for/IN actin/NN may/MD be/VB under/IN 
1507_1507_17_18_6_7::None::virus/NN type/NN 1/CD primosome/NN consists/VBZ of/IN three/CD subunits/NNS that/WDT are/VBP the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, 
370669_2_8_9_7_8::people.cause_of_death.includes_causes_of_death::are/VBP predictive/JJ of/IN high/JJ cardiovascular/JJ mortality/NN in/IN maintenance/NN 
1094_1094_18_19_22_23::None::,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT eIF3/NN complex/NN ./. 
1372_1372_18_19_1_2::POS_ACTION_BIND::The/DT APC/NN binding/NN site/NN on/IN beta-catenin/NN may/MD be/VB discontinuous/JJ since/IN neither/CC the/DT carboxyl/NN -/: nor/CC amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB 
779_779_49_52_21_24::None::accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
422_422_21_22_31_33::POS_REG(-)_Assembly::inhibitory/JJ activity/NN of/IN profilin/NN on/IN actin/NN polymerization/NN and/CC inhibition/NN of/IN the/DT self-association/NN of/IN annexin/NN I/CD and/CC its/PRP$ interactions/NNS 
21_21_16_17_21_22::POS_ACTION_DOWNREGULATE::is/VBZ revealed/VBN by/IN RAD51/NN overexpression/NN suppression/NN of/IN C-terminal/JJ rad52/NN truncation/NN alleles/NNS ./. 
72_72_19_20_17_18::None::disrupted/VBN by/IN specific/JJ actin/NN and/CC cofilin/NN mutations/NNS ./. 
315964_1_6_7_37_38::None::evidence/NN support/VBP the/DT idea/NN that/IN exposure/NN to/TO trace/NN and/CC toxic/JJ metals/NNS ,/, such/JJ as/IN aluminum/NN (/( Al/NNP )/) and/CC manganese/NN (/( Mn/NN )/) ,/, may/MD be/VB factors/NNS or/CC cofactors/NNS in/IN the/DT etiopathogenesis/NN of/IN a/DT variety/NN of/IN psychiatric/JJ disorders/NNS 
337732_11_42_43_36_37::None::times/NNS in/IN specific/JJ runs/NNS of/IN a/DT task/NN designed/VBN to/TO assess/VB phasic/JJ alertness/NN in/IN 
1219_1219_0_1_11_12::POS_REG(+)_Change::RIPc/NN ,/, one/CD of/IN the/DT cleavage/NN products/NNS ,/, enhanced/VBD interaction/NN between/IN TRADD/NN and/CC FADD/MORT1/NN and/CC 
438998_0_5_6_3_4::None::Antagonistic/JJ effects/NNS of/IN chloroquine/NN on/IN autophagy/JJ occurrence/NN potentiate/VB the/DT 
878537_3_18_19_16_17::None::a/DT first/JJ ablation/NN procedure/NN for/IN AF/NN enrolled/VBN in/IN the/DT 
1137_1137_15_16_11_12::None::physiological/JJ role/NN of/IN profilin/NN ,/, a/DT 12-15-kD/JJ actin/NN -/: and/CC phosphoinositide-binding/JJ 
242314_4_164_165_29_30::medicine.drug.active_moieties::of/IN HC/NNP IVs/NNP Procaine/NNP benzyl/NN penicillin/NN injection/NN powder/NN for/IN treatment/NN of/IN sepsis/NN was/VBD available/JJ in/IN the/DT majority/NN of/IN all/DT HCs/NNS with/IN :/: 100/CD %/NN of/IN HC/NN of/IN IVs/NNS ,/, 83/CD %/NN of/IN HC/NN IIIs/NNS and/CC 82/CD %/NN of/IN HC/NNP IIs/NNP Medicines/NNP for/IN pneumonia/NN were/VBD limited/VBN across/IN all/PDT the/DT HCs/NNS with/IN :/: Amoxicillin/NNP dispersible/JJ tablets/NNS in/IN only/RB 30/CD %/NN of/IN the/DT HC/NNP IIs/NNPS and/CC 40/CD %/NN of/IN the/DT HC/NN IVs/NNS The/DT most/RBS uncommon/JJ were/VBD child/NN -/: friendly/JJ priority/NN medicines/NNS for/IN malaria/NN with/IN :/: Artesunate/NN injection/NN in/IN only/RB 6/CD %/NN of/IN HC/NNP IIs/NNP ,/, 14/CD %/NN of/IN HC/NN IIIs/NNS and/CC 20/CD %/NN of/IN HC/NN IVs/NNS ;/: Artemether/NNP lumefantrine/NN dispersible/JJ tablets/NNS and/CC rectal/JJ artesunate/NN were/VBD missing/VBG in/IN all/PDT the/DT 32/CD HCs/NNS Less/RBR than/IN a/DT third/JJ of/IN the/DT health/NN workers/NNS reported/VBD prescribing/VBG zinc/NN sulphate/NN and/CC ORS/NN for/IN diarrhea/NN ,/, 86/CD %/NN reported/VBD procaine/NN benzyl/NN penicillin/NN injection/NN 
1768_1768_4_7_10_11::POS_ACTION_INTERACT::sites/NNS on/IN the/DT myosin/NN heavy/JJ chain/NN that/WDT interact/VBP with/IN actin/NN and/CC are/VBP responsible/JJ 
540626_0_10_11_3_4::None::C/NN -/: peptide/NN immunoreactivity/NN index/NN is/VBZ associated/VBN with/IN improvement/NN of/IN HbA1c/NN :/: 2/LS -/: 
202727_3_8_9_15_16::None::mortality/NN due/JJ to/TO common/JJ childhood/NN illnesses/NNS such/JJ as/IN diarrhoea/NN or/CC pneumonia/NN ,/, and/CC improves/VBZ 
63_63_44_45_59_60::POS_ACTION_MEMBER::.2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN ,/, histone/NN H2B/NN ,/, three/CD histone/NN H3/NN variants/NNS and/CC histone/NN 
225032_8_23_25_1_2::None::In/IN contrast/NN with/IN the/DT conventional/JJ two/CD -/: dimensional/JJ culture/NN ,/, three/CD -/: dimensional/JJ culture/NN system/NN could/MD give/VB rise/VB to/TO an/DT up/RB -/: regulated/VBN insulin/NN gene/NN expression/NN ./. 
924463_2_16_17_8_9::None::a/DT patient/NN with/IN acute/JJ ischemic/JJ stroke/NN who/WP was/VBD deemed/VBN ineligible/JJ for/IN intravenous/JJ recombinant/JJ tissue/NN plasminogen/NN 
1850_1850_2_3_8_9::POS_ACTION_BIND::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ 
750926_1_55_56_49_50::None::,/, expression/NN of/IN Ki67/NN and/CC Erk1/NN //: 2/CD ,/, antioxidant/JJ capacity/NN ,/, and/CC 
1341_1341_4_5_12_13::None::alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS to/TO the/DT actin/NN cytoskeleton/NN ./. 
604581_3_13_14_0_1::None::We/PRP further/RB explored/VBD the/DT central/JJ mechanisms/NNS of/IN fatigue/NN at/IN the/DT premovement/NN level/NN in/IN MS/NN patients/NNS during/IN a/DT 
370155_0_32_33_29_30::None::events/NNS and/CC similar/JJ recommendations/NNS for/IN lipid/NN control/NN ./. 
349493_0_3_4_2_3::None::Tumor/NN and/CC Patient/NN Characteristics/NNS of/IN Individuals/NNS with/IN 
926591_11_5_7_26_27::medicine.disease.treatments::rate/NN of/IN deciduous/JJ dental/JJ caries/NNS among/IN public/JJ kindergartens/NNS was/VBD 45.92/CD %/NN (/( 1,064/CD //: 2,317/CD )/) ,/, with/IN a/DT mean/NN dmft/NN of/IN 1.95/CD and/CC filling/VBG rate/NN of/IN 2.14/CD 
238332_6_35_36_20_21::medicine.risk_factor.diseases::pain/NN relief/NN from/IN chronic/JJ pancreatitis/NN is/VBZ the/DT primary/JJ goal/NN of/IN total/JJ pancreatectomy/NN in/IN TPIAT/NNP ,/, whereas/IN treatment/NN of/IN diabetes/NN ,/, and/CC certainly/RB 
956369_1_7_8_13_14::None::known/VBN about/IN its/PRP$ efficacy/NN and/CC safety/NN as/IN a/DT periprocedural/JJ anticoagulant/NN therapy/NN for/IN patients/NNS 
93_93_54_55_50_51::None::as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
721_721_9_10_15_16::None::interacting/VBG proteins/NNS recruiting/VBG TFIIIC/NN to/TO DNA/NN were/VBD PRP21/NN and/CC PRP9/NN or/CC PRP21/NN and/CC 
567_567_18_19_20_21::None::TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
2074_2074_16_17_12_13::None::the/DT nucleocapsid/NN (/( N/NN )/) protein/NN and/CC phosphoprotein/NN (/( P/NN )/) 
996_996_29_30_12_13::None::can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN 
449_449_10_11_19_20::NEG_ACTION_Change::cells/NNS indicated/VBD that/IN UL8/NN could/MD interact/VB separately/RB with/IN both/CC the/DT UL5/NN and/CC UL52/NN proteins/NNS ./. 
2222_2222_19_20_39_40::None::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
1782_1782_20_22_7_8::None::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, 
497715_6_0_1_22_23::None::Drawing/VBG from/IN literature/NN on/IN weight/NN bias/NN ,/, critical/JJ weight/NN studies/NNS ,/, and/CC Health/NNP at/IN Every/DT Size/NN (/( HAES/NN )/) ,/, we/PRP highlight/VBP pedagogical/JJ approaches/NNS to/TO address/VB 
255381_4_2_3_0_1::None::The/DT National/NNP Cancer/NNP registry/NN was/VBD searched/VBN 
367_367_28_30_24_25::None::proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
411_411_17_18_13_14::None::signaling/VBG molecules/NNS including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP 
313724_3_11_12_8_9::medicine.risk_factor.diseases::these/DT tumors/NNS presenting/VBG acutely/RB with/IN intracranial/JJ hemorrhage/NN in/IN adult/JJ patients/NNS 
637206_9_10_11_7_8::None::cause/NN of/IN ESRD/NNP The/DT prevalence/NN and/CC incidence/NN of/IN RRT/NNP continues/VBZ 
582775_5_119_120_87_88::medicine.disease.symptoms::402/CD )/) ,/, dyspnea/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, chest/NN pain/NN (/( 0.2/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, abdominal/JJ pain/NN (/( 1.0/CD %/NN ;/: 4/CD //: 402/CD )/) ,/, hypertension/NN (/( 2.2/CD %/NN 
763152_3_19_20_8_9::None::unique/JJ form/NN of/IN nonassociative/JJ behavior/NN in/IN Drosophila/FW where/WRB female/JJ flies/NNS detect/VBP the/DT presence/NN of/IN endoparasitoid/JJ predatory/JJ wasps/NNS and/CC 
1748_1748_27_28_4_5::None::results/NNS suggest/VBP that/IN LIMK2/NN functions/NNS downstream/RB of/IN the/DT Rho-ROCK/JJ signalling/NN pathway/NN and/CC plays/VBZ a/DT role/NN in/IN reorganization/NN of/IN actin/NN filaments/NNS and/CC membrane/NN structures/NNS ,/, by/IN phosphorylating/VBG cofilin/ADF/NN proteins/NNS ./. 
63_63_49_50_59_60::None::.2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN ,/, histone/NN H2B/NN ,/, three/CD histone/NN H3/NN variants/NNS and/CC histone/NN 
404541_2_4_5_8_10::None::,/, the/DT ATG6/NN functions/VBZ in/IN wheat/NN (/( Triticum/FW aestivum/FW L/NN ./. 
93_93_4_5_54_55::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
453075_8_8_9_22_23::None::the/DT micro/JJ -/: dystrophin/NN gene/NN restored/VBD some/DT aspects/NNS of/IN normal/JJ muscle/NN histology/NN and/CC pathology/NN such/JJ as/IN decreased/VBN necrosis/NN and/CC resistance/NN to/TO 
448173_0_0_1_1_2::None::The/DT tumorigenic/JJ potential/NN of/IN dulaglutide/NN 
631669_5_10_12_5_6::None::or/CC phlebectomy/NN shows/VBZ good/JJ results/NNS in/IN patients/NNS with/IN varicose/NN veins/NNS of/IN pelvic/JJ origin/NN 
387237_8_28_30_2_3::None::A/DT high/JJ proportion/NN of/IN C/NN canis/NN was/VBD observed/VBN from/IN dogs/NNS and/CC cats/NNS in/IN the/DT current/JJ study/NN and/CC phylogeny/NN revealed/VBD that/IN C/NN canis/JJ forms/NNS a/DT sister/NN clade/NN to/TO the/DT oriental/JJ cat/NN flea/NN Ctenocephalides/NNS orientis/NN 
1061_1061_24_25_36_37::None::binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
2089_2089_4_5_8_10::None::have/VBP found/VBN that/IN cofilin/NN ,/, a/DT 21-kDa/JJ actin-binding/JJ protein/NN ,/, is/VBZ a/DT 
1061_1061_25_27_36_37::None::to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
382707_7_2_3_7_8::None::These/DT findings/NNS represent/VBP an/DT early/JJ but/CC important/JJ step/NN towards/IN the/DT clarification/NN 
1957_1957_36_37_38_39::None::by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
2013_2013_9_10_20_21::POS_ACTION_MODULATE::the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN verprolin/cofilin-like/JJ actin-regulatory/JJ domains/NNS ,/, but/CC no/DT specific/JJ actin/NN structure/NN regulated/VBN by/IN 
695014_15_5_6_11_12::None::a/DT relationship/NN between/IN psychological/JJ variables/NNS and/CC the/DT presence/NN of/IN depressive/JJ symptoms/NNS 2/CD months/NNS 
1568_1568_4_5_17_18::None::NH2-terminal/JJ 16kD/NN of/IN Abp1p/NN ,/, a/DT 65-kD/JJ yeast/NN protein/NN identified/VBN by/IN its/PRP$ ability/NN to/TO bind/VB to/TO actin/NN filaments/NNS ,/, is/VBZ 
34897_2_36_37_42_43::None::energy/NN estimate/NN (/( EEE/NN )/) and/CC iodine/NN contrast/NN to/TO noise/NN ratio/NN (/( CNR/NN 
423761_7_10_11_18_19::medicine.drug.active_moieties::the/DT synthesis/NN of/IN IgG1/NN ,/, IgG2b/NN ,/, IgG3/NN ,/, and/CC total/JJ IgG/NN in/IN female/JJ mice/NNS 
1008_1008_10_11_8_9::None::,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB ,/, display/VBP 
591167_7_28_30_18_19::medicine.disease.risk_factors::robust/JJ number/NN of/IN elderly/JJ and/CC very/RB elderly/JJ participants/NNS ,/, although/IN the/DT risk/NN of/IN heart/NN failure/NN hospitalization/NN was/VBD increased/VBN 
520105_8_21_23_11_12::None::a/DT non/JJ -/: age/NN -/: dependent/JJ index/NN with/IN higher/JJR applicability/NN to/TO screen/NN for/IN cardiovascular/JJ risk/NN factors/NNS in/IN adolescents/NNS 
505690_0_21_22_15_16::None::candidiasis/NN patients/NNS :/: Correlation/NN between/IN cell/NN surface/NN hydrophobicity/NN and/CC biofilm/NN forming/VBG activities/NNS ./. 
991_991_15_16_17_18::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN 
16153_0_19_20_3_6::None::Elderly/JJ patients/NNS with/IN chronic/JJ lymphocytic/JJ leukemia/NN (/( CLL/NN )/) are/VBP underrepresented/JJ in/IN trials/NNS evaluating/VBG fludarabine/NN ,/, cyclophosphamide/NN ,/, and/CC rituximab/NN (/( FCR/NN )/) 
315600_15_23_24_8_9::None::well/RB as/IN other/JJ combination/NN regimens/NNS GHAA/NNP //: GHTA/NNP ,/, are/VBP well/RB -/: tolerated/VBN ,/, effective/JJ regimens/NNS for/IN refractory/JJ AML/NN and/CC advanced/VBD MDS/NN 
1593_1593_27_28_22_25::None::expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( Kip1/NN )/) ./. 
881131_8_29_30_31_32::None::among/IN smokers/NNS and/CC drinkers/NNS with/IN respect/NN to/TO ESCC/NN prevention/NN 
1850_1850_0_1_0_1::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ 
196_196_9_10_2_3::None::A/DT truncated/VBN beta-catenin/NN disrupts/VBZ the/DT interaction/NN between/IN E-cadherin/NN and/CC alpha-catenin/NN :/: a/DT cause/NN 
130_130_15_16_4_5::POS_REG(+)_LOCALIZE::assembly/NN of/IN the/DT UL5/NN and/CC UL52/NN subunits/NNS retains/VBZ both/CC enzymic/JJ activities/NNS ,/, and/CC the/DT UL8/NN protein/NN has/VBZ been/VBN 
808734_0_23_24_25_26::None::risk/NN of/IN liver/NN fibrosis/NN and/CC carcinogenesis/NN ./. 
1069_1069_26_27_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
151537_7_15_18_28_29::None::(/( osteosarcoma/NN ,/, soft/JJ tissue/NN sarcoma/NN ,/, histiocytic/JJ sarcoma/NN ,/, hemangiosarcoma/NN )/) ,/, haematological/JJ malignancies/NNS (/( lymphoma/NN ,/, leukaemia/NN )/) 
386745_4_27_28_21_22::None::(/( Reporting/NNP Information/NNP Online/NNP )/) ,/, an/DT Internet/NN -/: based/VBN sports/NNS injury/NN surveillance/NN 
133249_2_10_11_1_3::None::Although/IN cigarette/NN smoke/NN increases/VBZ TLR4/NN expression/NN ,/, TLR4/NN signaling/NN is/VBZ altered/VBN in/IN smokers/NNS and/CC 
1334_1334_17_18_0_1::None::act1-157/NN ,/, an/DT actin/NN mutant/NN with/IN an/DT increased/VBN intrinsic/JJ rate/NN of/IN nucleotide/NN exchange/NN ,/, suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN 
264611_0_4_5_19_20::None::of/IN mobility/NN in/IN conjunction/NN with/IN an/DT independent/JJ life/NN style/NN is/VBZ one/CD of/IN the/DT major/JJ goals/NNS of/IN rehabilitation/NN after/IN stroke/NN ./. 
247832_2_37_38_34_35::None::a/DT view/NN to/TO assess/VB inflammation/NN and/CC predict/VBP vascular/JJ damage/NN risk/NN 
425469_7_28_29_43_44::None::concerns/NNS ,/, where/WRB younger/JJR adolescents/NNS and/CC individuals/NNS with/IN high/JJ baseline/NN purging/VBG had/VBD greater/JJR change/NN when/WRB treated/VBN with/IN FBT/NN relative/JJ to/TO SPT/NNP Age/NNP 
1122_1122_23_24_23_24::POS_REG(0)_Change::the/DT interaction/NN of/IN fimbrin/NN with/IN other/JJ proteins/NNS 
828493_2_18_19_19_20::medicine.disease.symptoms::gene/NN methylation/NN in/IN breast/NN tumors/NNS ./. 
1372_1372_18_19_31_32::None::amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB with/IN APC/NN ,/, although/IN the/DT amino-terminal/JJ half/NN independently/RB binds/VBZ alpha-catenin/NN ./. 
1478_1478_9_10_4_5::None::essential/JJ role/NN of/IN profilin/NN in/IN the/DT assembly/NN of/IN actin/NN for/IN microspike/NN formation/NN 
868_868_4_5_9_11::None::this/DT study/NN ,/, profilin/NN is/VBZ identified/VBN as/IN an/DT actin-binding/JJ protein/NN in/IN higher/JJR plants/NNS 
865_865_7_8_11_14::None::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC 
93_93_50_51_54_55::None::as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
423051_1_4_5_5_6::medicine.symptom.symptom_of::evidence/NN suggests/VBZ that/IN accelerated/VBN atherosclerosis/NN and/CC related/JJ cardiovascular/JJ 
1248_1248_19_20_4_5::None::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB associated/VBN with/IN these/DT cadherins/NNS and/CC serve/VB to/TO 
1528_1528_4_5_10_11::None::interactions/NNS of/IN the/DT UL52/NN protein/NN with/IN the/DT UL8/NN and/CC UL5/NN proteins/NNS were/VBD analysed/VBN 
20599_4_18_22_27_28::medicine.disease.treatments::with/IN non/JJ -/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) randomized/VBN to/TO erlotinib/VB with/IN placebo/NN or/CC 
714308_1_5_6_30_31::medicine.medical_treatment.used_to_treat::last/JJ decade/NN the/DT anticancer/JJ potential/NN of/IN poly/NN ADP/NN -/: ribose/NN polymerase/NN (/( PARP/NN )/) inhibitors/NNS became/VBD apparent/JJ and/CC now/RB several/JJ PARP/NN inhibitors/NNS are/VBP being/VBG developed/VBN to/TO treat/VB various/JJ malignancies/NNS ./. 
402845_14_7_8_2_3::None::The/DT rabbit/NN model/NN of/IN MSU/NNP crystal/NN -/: induced/VBN acute/JJ arthritis/NN efficiently/RB 
1843_1843_12_13_19_20::POS_ACTION_Causal::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT 
930_930_6_7_1_2::None::Like/IN actin/NN ,/, the/DT actin-associated/JJ proteins/NNS filamin/NN ,/, talin/NN and/CC 
422_422_31_33_23_24::POS_REG(0)_POLYMERIZE::of/IN profilin/NN on/IN actin/NN polymerization/NN and/CC inhibition/NN of/IN the/DT self-association/NN of/IN annexin/NN I/CD and/CC its/PRP$ interactions/NNS 
988_988_26_27_20_21::None::homologous/JJ to/TO human/JJ plakoglobin/NN and/CC the/DT Drosophila/NN gene/NN product/NN armadillo/NN ./. 
2107_2107_7_8_9_10::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS 
278424_0_4_5_7_8::None::kinase/NN signaling/NN :/: tamoxifen/NN response/NN and/CC prognostic/JJ indication/NN in/IN two/CD 
1782_1782_11_12_7_8::None::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS 
1426_1426_5_6_14_15::POS_ACTION_BIND::denominator/NN is/VBZ impaired/JJ beta-catenin/NN association/NN with/IN either/CC E-cadherin/NN (/( PaTuII/NN )/) or/CC alpha-catenin/NN (/( BxPc3/NN and/CC 
2052_2052_17_18_6_7::POS_ACTION_BIND::axonal/JJ transport/NN of/IN actin/NN and/CC its/PRP$ monomer/NN binding/NN proteins/NNS ,/, actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
1646_1646_8_9_2_3::None::The/DT resulting/VBG beta-catenin/NN product/NN is/VBZ unable/JJ to/TO bind/VB alpha-catenin/NN that/WDT is/VBZ responsible/JJ 
313_313_8_9_29_30::POS_ACTION_BIND::75-100/CD microM/NN unpolymerized/JJ actin/NN and/CC at/IN least/JJS four/CD proteins/NNS which/WDT can/MD bind/VB actin/NN monomers/NNS ,/, actin/NN depolymerizing/NN factor/NN (/( ADF/NN )/) ,/, gelsolin/NN ,/, profilin/NN ,/, and/CC thymosin/NN 
213993_5_6_7_11_12::None::and/CC 2.7/CD %/NN reported/VBD a/DT past/JJ history/NN of/IN diabetes/NN and/CC stroke/NN ,/, 
1790_1790_25_26_22_24::None::interferon-induced/JJ ,/, dsRNA-activated/JJ protein/NN kinase/NN ,/, PKR/NN ./. 
1270_1270_37_38_31_32::None::PIP2/NN binding/NN and/CC actin/NN binding/NN may/MD be/VB important/JJ for/IN profilin/NN function/NN ./. 
583_583_4_5_17_18::None::we/PRP report/VBP that/IN p120/NN associates/NNS with/IN a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
489_489_15_16_20_21::None::histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP 
185609_1_39_40_8_9::None::increasing/VBG age/NN of/IN cancer/NN patients/NNS ,/, the/DT number/NN of/IN patients/NNS with/IN various/JJ comorbidities/NNS such/JJ as/IN membranous/JJ nephropathy/NN is/VBZ also/RB rising/VBG ,/, and/CC problems/NNS associated/VBN with/IN the/DT administration/NN of/IN chemotherapy/NN to/TO elderly/JJ patients/NNS with/IN these/DT conditions/NNS are/VBP becoming/VBG more/RBR 
1771_1771_19_20_11_14::None::of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
425469_7_8_9_29_30::medicine.disease.risk_factors::)/) and/CC baseline/NN purging/VBG severity/NN (/( p/NN =/JJ 0.03/CD )/) moderated/VBD the/DT relationship/NN between/IN treatment/NN condition/NN and/CC change/NN in/IN eating/VBG concerns/NNS ,/, where/WRB younger/JJR adolescents/NNS and/CC individuals/NNS with/IN 
288485_0_7_8_47_48::None::study/NN was/VBD to/TO optimize/VB the/DT biological/JJ safety/NN scheme/NN of/IN spinal/JJ image/NN -/: guided/VBN radiotherapy/NN (/( IGRT/NN )/) by/IN determining/VBG the/DT expression/NN of/IN caspase/NN -/: 3/CD in/IN spinal/JJ cord/NN neurons/NNS after/IN IGRT/NNP Thirty/CD -/: six/CD adult/JJ male/JJ beagles/NNS were/VBD assigned/VBN according/VBG to/TO a/DT random/JJ number/NN table/NN and/CC subjected/VBN 
865_865_33_35_11_14::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
1147_1147_22_23_0_1::None::Profilins/NNP also/RB bind/VBP polyphosphoinositides/NNS ,/, which/WDT can/MD disrupt/VB the/DT profilin-actin/NN complex/NN ,/, and/CC proline-rich/JJ ligands/NNS which/WDT localize/VBP profilin/NN to/TO sites/NNS requiring/VBG extensive/JJ actin/NN filament/NN accumulation/NN ./. 
1779_1779_29_30_5_7::POS_ACTION_BIND::of/IN pyrene-labeled/JJ rabbit/NN skeletal/JJ actin/NN with/IN human/JJ profilin/NN yielded/VBD a/DT Kd/NN of/IN 2.8/CD microM/NN ,/, similar/JJ to/TO the/DT Kd/NN of/IN 2.0/CD microM/NN for/IN the/DT interaction/NN between/IN yeast/NN profilin/NN and/CC pyrene-labeled/JJ yeast/NN 
1144_1144_0_2_11_13::None::Profilin/NN II/CD binds/VBZ actin/NN with/IN a/DT similar/JJ affinity/NN to/TO that/DT of/IN profilin/NN I/CD ,/, although/IN it/PRP 
172875_8_19_20_28_30::None::=/JJ 12779/CD )/) demonstrated/VBD that/IN serum/NN sodium/NN is/VBZ a/DT significant/JJ predictor/NN of/IN 10/CD Years/NNS Risk/NN of/IN coronary/JJ 
781998_2_5_6_35_36::None::the/DT amelioration/NN of/IN reversible/JJ beta/NN -/: cell/NN dysfunction/NN through/IN the/DT early/JJ institution/NN of/IN short/JJ -/: term/NN insulin/NN -/: based/VBN therapy/NN has/VBZ emerged/VBN as/IN a/DT strategy/NN that/WDT can/MD yield/VB temporary/JJ remission/NN of/IN type/NN 2/CD diabetes/NN ./. 
350698_1_16_17_8_11::None::increased/VBN incidence/NN of/IN type/NN 2/CD diabetes/NN ,/, accompanied/VBN by/IN an/DT accelerated/VBN atherosclerosis/NN ./. 
279_279_30_31_12_13::POS_ACTION_BIND::directly/RB associate/VBP with/IN TIF34/NN :/: PRT1/NN ,/, a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC a/DT novel/JJ protein/NN of/IN 33/CD kDa/NN (/( eIF3-p33/NN )/) which/WDT is/VBZ 
367_367_5_7_26_27::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
544721_14_24_26_10_11::None::of/IN palpable/JJ breast/NN masses/NNS had/VBD been/VBN used/VBN ,/, biopsy/NN could/MD have/VB been/VBN reduced/VBN by/IN 89/CD %/NN in/IN group/NN I/CD and/CC deemed/VBD not/RB 
349493_0_5_6_3_4::None::Tumor/NN and/CC Patient/NN Characteristics/NNS of/IN Individuals/NNS with/IN Mismatch/NNP Repair/NNP 
654472_6_26_27_22_23::None::reported/VBN non/JJ -/: ocular/JJ pain/NN measures/NNS (/( numerical/JJ rating/NN scale/NN and/CC 
487559_4_1_2_6_7::None::This/DT case/NN raises/VBZ the/DT possibility/NN that/IN cerebral/JJ vasoconstriction/NN may/MD be/VB 
389319_8_3_4_20_21::None::Liver/NN tissue/NN was/VBD assessed/VBN for/IN inflammatory/JJ cytokine/NN expression/NN and/CC radiation/NN -/: induced/VBN SEC/NNP injury/NN based/VBN on/IN serum/NN hyaluronic/JJ acid/NN (/( HA/NN )/) level/NN ,/, 
233540_0_33_34_10_11::None::with/IN diabetes/NN ,/, measured/VBN as/IN glycated/JJ haemoglobin/NN (/( HbA1c/NN )/) ,/, influences/VBZ the/DT role/NN of/IN leisure/NN time/NN physical/JJ activity/NN on/IN the/DT increased/VBN risk/NN of/IN death/NN from/IN cardiovascular/JJ disease/NN ./. 
748_748_20_21_10_11::POS_ACTION_BIND::binding/NN proposed/VBN for/IN fimbrin/NN ,/, the/DT utrophin/NN actin-binding/JJ domain/NN appears/VBZ to/TO associate/VB with/IN actin/NN in/IN an/DT extended/JJ 
1417_1417_9_10_4_5::None::cellular/JJ transcription/NN co-activators/NNS p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS 
1491_1491_6_7_16_17::None::assay/NN using/VBG an/DT actin/NN cross-linking/NN protein/NN and/CC the/DT nucleation/NN assay/NN also/RB suggested/VBD that/IN cofilin/NN shortens/VBZ the/DT actin/NN 
1977_1977_24_25_22_23::None::molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
1782_1782_27_28_7_8::None::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
288_288_10_12_19_20::None::observing/VBG proteolysis/NN of/IN actin-binding/JJ protein/NN and/CC talin/NN ,/, two/CD known/JJ substrates/NNS of/IN calpain/NN ./. 
501715_7_24_26_13_14::None::mm/NN Hg/NN is/VBZ recommended/VBN in/IN patients/NNS with/IN chronic/JJ kidney/NN disease/NN and/CC in/IN those/DT with/IN diabetes/NN mellitus/NN ./. 
645520_5_15_17_18_19::medicine.disease.treatments::the/DT radioresistant/JJ laryngeal/NN cancer/NN cells/NNS to/TO irradiation/NN ,/, indicating/VBG that/IN 
1775_1775_21_22_3_4::POS_ACTION_STSIMILAR::The/DT structure/NN of/IN Ykt6pN/NN differed/VBD entirely/RB from/IN that/DT of/IN syntaxin/NN and/CC resembled/VBD the/DT overall/JJ fold/NN of/IN the/DT actin/NN regulatory/JJ protein/NN ,/, profilin/NN ./. 
965433_2_25_26_21_22::biology.organism_classification.lower_classifications::targets/NNS components/NNS from/IN Peucedanum/NN praeruptorum/NN Dunn/NNP (/( Umbelliferae/NNP )/) crude/JJ extracts/NNS 
1341_1341_4_5_1_2::None::The/DT alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC 
2107_2107_7_8_15_16::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ 
300324_0_50_51_10_11::None::HA/NN )/) //: poly/NN (/( lactic/NN -/: co/SYM -/: glycolic/JJ acid/NN ,/, PLGA/NN )/) core/NN //: shell/NN fiber/NN meshes/VBZ loaded/VBN with/IN epigallocatechin/NN -/: 3/LS -/: O/SYM -/: gallate/NN (/( EGCG/NN )/) (/( HA/NNP //: PLGA/NNP -/: E/NN )/) for/IN application/NN to/TO tissue/NN engineering/NN scaffolds/NNS for/IN skin/NN regeneration/NN 
116203_2_5_6_36_37::None::study/NN ,/, we/PRP assessed/VBD the/DT efficacy/NN and/CC safety/NN of/IN the/DT retroflexed/JJ view/NN in/IN colorectal/JJ ESD/NN From/IN April/NNP 2009/CD to/TO December/NNP 2013/CD ,/, 130/CD colorectal/JJ tumors/NNS were/VBD examined/VBN in/IN 128/CD patients/NNS treated/VBN with/IN ESD/NN A/NN total/NN of/IN 119/CD patients/NNS 
422_422_31_33_31_33::POS_REG(-)_Assembly::the/DT self-association/NN of/IN annexin/NN I/CD and/CC its/PRP$ interactions/NNS 
489_489_26_27_9_10::None::of/IN three/CD putative/JJ PCAF/NN substrates/NNS ,/, histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP determined/VBN that/IN histone/NN H3/NN is/VBZ significantly/RB 
28_28_11_13_3_4::POS_ACTION_MEMBER::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN define/VBP a/DT family/NN of/IN actin-binding/JJ proteins/NNS essential/JJ for/IN the/DT 
350196_12_5_6_4_5::people.cause_of_death.includes_causes_of_death::,/, uterine/JJ and/CC ovary/JJ cancers/NNS remain/VBP to/TO be/VB 
6359_3_17_18_30_31::None::ulcerative/JJ colitis/NN (/( UC/NN )/) ,/, and/CC 719/CD healthy/JJ controls/NNS ,/, was/VBD genotyped/VBN for/IN the/DT NOD2/NN SNP/NN rs72796353/NN and/CC the/DT 
149877_5_17_18_24_25::None::better/JJR post/NN -/: diagnosis/NN survival/NN than/IN those/DT cases/NNS whose/WP$ tumours/NNS lost/VBD p16/NN expression/NN (/( 
410_410_9_10_11_12::None::of/IN both/DT histone/NN H3/NN and/CC histone/NN H4/NN were/VBD inviable/JJ 
71_71_3_4_0_1::None::Aip1p/NN interacts/VBZ with/IN cofilin/NN to/TO disassemble/VB actin/NN 
1810_1810_2_3_20_21::None::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR regulatory/JJ roles/NNS ,/, as/IN it/PRP was/VBD shown/VBN that/IN their/PRP$ tyrosine/NN phosphorylation/NN correlated/VBD with/IN modified/VBN cadherin/NN activities/NNS ./. 
831385_3_66_67_3_4::None::The/DT PfATP6/NN L263E/NN mutation/NN has/VBZ been/VBN studied/VBN in/IN relation/NN to/TO the/DT artemisinin/NN inhibitory/JJ effect/NN on/IN P/NN falciparum/NN and/CC recent/JJ studies/NNS have/VBP provided/VBN evidence/NN that/IN the/DT parasite/NN with/IN this/DT mutation/NN is/VBZ more/RBR susceptible/JJ to/TO CPA/NNP Here/RB ,/, we/PRP characterized/VBD ,/, for/IN the/DT first/JJ time/NN ,/, the/DT interaction/NN of/IN CPA/NN with/IN PfATP6/NN and/CC its/PRP$ mammalian/JJ counterpart/NN to/TO understand/VB similarities/NNS and/CC differences/NNS in/IN the/DT mode/NN of/IN binding/NN of/IN the/DT inhibitor/NN to/TO the/DT two/CD 
1977_1977_24_25_16_17::None::a/DT region/NN in/IN alpha-catenin/NN required/VBN for/IN molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
991_991_15_16_20_21::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
429997_1_1_3_26_27::None::Recent/JJ postmarketing/VBG reports/NNS and/CC a/DT US/NNP Food/NNP and/CC Drug/NNP Administration/NNP analysis/NN have/VBP documented/VBN uncommon/JJ persistent/JJ sexual/JJ and/CC nonsexual/JJ side/NN -/: effects/NNS in/IN a/DT subset/NN of/IN younger/JJR men/NNS who/WP have/VBP taken/VBN 
346_346_24_25_24_25::None::of/IN plakoglobin/NN to/TO alpha-catenin/NN and/CC vice/NN versa/RB 
865_865_15_16_11_14::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) 
1515_1515_26_27_21_22::None::focal/JJ adhesion/NN protein/NN talin/NN and/CC the/DT yeast/NN protein/NN Sla2p/NN ./. 
249535_0_12_14_4_5::None::profile/NN of/IN serum/NN microRNAs/NNS in/IN pancreatic/JJ cancer/NN associated/VBN new/JJ -/: onset/NN diabetes/NN mellitus/NN ./. 
128605_11_32_33_1_2::None::These/DT data/NNS indicate/VBP that/IN disturbance/NN of/IN the/DT XIAP/NN //: Smac/JJ balance/NN may/MD be/VB a/DT driver/NN of/IN radio/NN chemotherapy/NN resistance/NN ,/, and/CC hence/RB high/JJ levels/NNS of/IN XIAP/NN may/MD be/VB a/DT useful/JJ indicator/NN of/IN neoadjuvant/JJ radio/NN chemotherapy/NN resistance/NN 
1373_1373_11_12_16_17::None::independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1440_1440_12_13_4_5::None::C-terminal/JJ region/NN of/IN ORC3/NN was/VBD ,/, however/RB ,/, necessary/JJ to/TO bring/VB ORC4/NN and/CC ORC5/NN into/IN 
1861_1861_12_13_15_16::None::of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN which/WDT are/VBP independent/JJ 
2076_2076_28_29_42_43::None::residues/NNS (/( yeast/NN cofilin/NN ;/: Cof/NN )/) ;/: its/PRP$ aa/NN sequence/NN is/VBZ 35/CD %/NN identical/JJ to/TO porcine/NN Cof/NN ./. 
235160_8_22_23_39_40::biology.organism_classification.lower_classifications::that/IN the/DT domain/NN Bacteria/NNS was/VBD dominated/VBN by/IN Firmicutes/NNS (/( mainly/RB Clostridia/NNP )/) ,/, Bacteroidetes/NNP ,/, delta/NN -/: and/CC gamma/NN -/: Proteobacteria/NNP ,/, Cloacimonetes/NNP and/CC 
265468_0_11_12_5_7::None::not/RB associated/VBN with/IN diverticular/JJ disease/NN -/: Analysis/NN of/IN 976/CD patients/NNS ./. 
1534_1534_32_33_12_13::None::TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
467_467_2_3_4_6::None::Expression/NN of/IN c-Myc/NN or/CC cyclin/NN D1/NN was/VBD sufficient/JJ to/TO 
1061_1061_19_20_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO 
227_227_3_6_7_9::POS_ACTION_BIND::Binding/NN to/TO human/JJ dipeptidyl/NN peptidase/NN IV/CD by/IN adenosine/NN deaminase/NN and/CC antibodies/NNS that/WDT 
798_798_4_5_11_12::POS_ACTION_HUMANMADE::reconstitution/NN experiments/NNS ,/, actin/NN filaments/NNS incubated/VBN in/IN EGTA/NN with/IN purified/VBN fimbrin/NN and/CC villin/NN form/VBP 
240754_0_9_10_19_20::None::+/CC )/) )/) signalling/NN triggered/VBN by/IN insect/NN herbivory/NN is/VBZ an/DT intricate/JJ network/NN with/IN multiple/JJ components/NNS ,/, involving/VBG 
206151_6_7_8_0_1::None::We/PRP accurately/RB linked/VBD the/DT PHIS/NN and/CC NTDB/NN records/NNS for/IN 69/CD %/NN 
567_567_20_21_18_19::None::TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
280_280_13_14_46_47::None::we/PRP observed/VBD that/IN histone/NN H4/NN ,/, and/CC not/RB histone/NN H3/NN ,/, was/VBD acetylated/VBN from/IN the/DT endogenous/JJ p21/waf1/NN promoter/NN in/FW vivo/FW ,/, implying/VBG that/IN CBP/p300/NN ,/, and/CC not/RB the/DT SAGA/NN complex/NN ,/, was/VBD critical/JJ in/IN complexing/VBG with/IN E2A/NN in/IN up-regulation/NN of/IN 
1760_1760_1_3_3_4::POS_ACTION_MEMBER::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP 
270415_4_35_36_33_35::None::by/IN boosted/VBN ensemble/NN machine/NN learning/VBG algorithm/NN into/IN a/DT novel/JJ 
395871_8_30_31_40_41::people.cause_of_death.includes_causes_of_death::resection/NN of/IN esophageal/NN malignancies/NNS ,/, especially/RB in/IN patients/NNS with/IN stage/NN III/CD -/: IV/CD tumors/NNS ./. 
1498_1498_8_9_21_22::None::thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD thus/RB regulate/VB integrin/NN function/NN ./. 
406221_0_3_4_13_17::medicine.medical_treatment.used_to_treat::Antibiotic/JJ and/CC oral/JJ corticosteroid/NN prescribing/VBG rate/NN in/IN patients/NNS suffering/VBG from/IN acute/JJ exacerbations/NNS of/IN chronic/JJ obstructive/JJ pulmonary/JJ disease/NN (/( COPD/NN )/) 
359239_0_10_12_25_26::None::tumor/NN -/: suppressing/VBG immune/JJ responses/NNS and/CC the/DT difference/NN between/IN them/PRP ultimately/RB determine/VBP whether/IN a/DT cancer/NN escapes/VBZ immune/JJ recognition/NN mechanisms/NNS ./. 
574337_0_14_15_2_4::None::Infection/NN by/IN human/JJ papillomavirus/NN (/( HPV/NN )/) is/VBZ among/IN the/DT main/JJ etiologies/NNS of/IN cervical/JJ cancer/NN ./. 
524639_5_30_31_12_13::None::COX/NNP -/: 2/CD inhibitors/NNS ,/, diclofenac/NN and/CC high/JJ -/: dose/NN ibuprofen/NN cause/NN adverse/JJ cardiovascular/JJ effects/NNS to/TO a/DT problematic/JJ extent/NN ,/, whereas/IN naproxen/NN consistently/RB exhibits/VBZ low/JJ 
280859_11_6_7_5_6::None::and/CC obese/JJ participants/NNS fat/JJ mass/NN was/VBD reduced/VBN with/IN 
21613_1_3_4_15_16::None::Ninety/CD -/: five/CD patients/NNS with/IN MI/NN treated/VBN with/IN PCI/NN were/VBD divided/VBN into/IN two/CD groups/NNS [/( coronary/JJ (/( n/NN =/JJ 
640_640_29_30_25_26::POS_ACTION_BIND::can/MD not/RB increase/VB profilin/NN 's/POS affinity/NN for/IN actin/NN ./. 
441_441_9_11_2_3::NEG_ACTION_BIND::Even/RB the/DT Munc18-2/NN mutants/NNS that/WDT do/VBP not/RB detectably/RB bind/VBP syntaxin/NN 3/CD were/VBD membrane/NN associated/VBN 
333054_4_25_26_14_15::None::affected/VBN by/IN water/NN stress/NN and/CC ,/, depending/VBG on/IN the/DT genotype/NN ,/, a/DT higher/JJR lignin/NN accumulation/NN may/MD occur/VB in/IN 
467137_1_9_10_23_25::biology.organism_classification.lower_classifications::factor/NN in/IN global/JJ honeybee/NN (/( Apis/NN mellifera/NN )/) declines/VBZ since/IN shifting/VBG hosts/NNS from/IN the/DT Asian/JJ honeybee/NN (/( Apis/NN cerana/NN )/) &/CC gt/NN 
761772_0_1_3_4_6::None::The/DT jungle/NN crow/NN (/( Corvus/NN macrorhynchos/NNS )/) belongs/VBZ to/TO 
1069_1069_46_47_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
185_185_4_5_6_7::None::of/IN UBE2I/NN with/IN RAD52/NN ,/, UBL1/NN ,/, p53/NN ,/, 
540626_0_19_20_24_27::medicine.medical_treatment.used_to_treat::-/: up/IN of/IN sitagliptin/NN use/NN in/IN patients/NNS with/IN type/NN 2/CD diabetes/NN ./. 
865_865_17_18_7_8::POS_ACTION_SIMILAR::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 
178597_0_23_26_30_31::None::cell/NN -/: depleted/VBN hematopoietic/JJ progenitor/NN cells/NNS and/CC no/DT post/NN -/: transplant/NN immunosuppression/NN controls/VBZ graft/NN 
355_355_16_17_14_15::None::of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD 
405799_1_10_11_32_33::None::development/NN of/IN DR/NN This/DT study/NN aimed/VBN to/TO investigate/VB whether/IN genetic/JJ variants/NNS of/IN CRP/NN are/VBP associated/VBN with/IN DR/NN A/NN total/NN of/IN 1,018/CD patients/NNS with/IN type/NN 2/CD diabetes/NNS were/VBD recruited/VBN in/IN 
103419_1_47_48_35_36::None::and/CC Cu/NN -/: NPs/NNS ;/: AgNO3/NN ,/, Ag/NN NM300K/NN ,/, Ag/NN -/: NPs/NNS Non/SYM -/: coated/JJ and/CC Ag/NN -/: 
1758_1758_17_18_4_5::POS_ACTION_MEDIATE::results/NNS suggest/VBP that/IN TNF-alpha/NN can/MD cause/VB apoptosis/NN in/IN pancreatic/JJ beta/NN cells/NNS through/IN TNFR1-linked/JJ apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, 
476387_6_21_22_0_1::None::The/DT absence/NN of/IN pyruvate/NN groups/NNS renders/VBZ the/DT xanthan/JJ gum/NN less/RBR sensitive/JJ to/TO the/DT influence/NN of/IN salt/NN ,/, and/CC hence/RB decreases/VBZ the/DT ultrasonic/JJ degradation/NN efficiency/NN ./. 
389319_8_20_21_17_19::medicine.drug_ingredient.active_moiety_of_drug::based/VBN on/IN serum/NN hyaluronic/JJ acid/NN (/( HA/NN )/) level/NN ,/, 
70381_3_1_2_32_33::None::Three/CD days/NNS after/IN the/DT second/JJ injection/NN (/( day/NN 10/CD )/) ,/, the/DT rats/NNS were/VBD intraperitoneally/RB given/VBN sTNFRII/NN -/: gAD/NN or/CC sTNFRII/NN -/: Fc/NN ,/, or/CC PBS/NNP Effects/NNS of/IN treatments/NNS were/VBD examined/VBN with/IN respect/NN of/IN CIA/NNP incidence/NN 
597121_2_23_24_27_28::None::lifestyle/NN activities/NNS concurrently/RB impact/VBP the/DT progression/NN of/IN hypertension/NN -/: related/JJ comorbidities/NNS 
540626_0_22_23_19_20::None::-/: up/IN of/IN sitagliptin/NN use/NN in/IN patients/NNS with/IN type/NN 2/CD 
1593_1593_22_25_27_28::POS_ACTION_MEMBER::expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( Kip1/NN )/) ./. 
367_367_0_2_5_7::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP 
1344_1344_20_21_22_23::POS_ACTION_BIND::helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, indicates/VBZ that/IN 
569500_0_24_25_18_19::None::with/IN non/JJ -/: operated/VBN obese/JJ and/CC non/JJ -/: obese/JJ control/NN women/NNS ./. 
336146_1_6_7_4_5::None::study/NN aims/VBZ to/TO determine/VB the/DT prevalence/NN of/IN Chinese/JJ herbal/JJ 
274753_0_21_22_25_26::medicine.drug.active_moieties::alternative/JJ vehicle/NN for/IN nicotine/NN delivery/NN and/CC a/DT smoking/NN -/: cessation/NN tool/NN 
21613_1_15_16_5_6::medicine.medical_treatment.used_to_treat::five/CD patients/NNS with/IN MI/NN treated/VBN with/IN PCI/NN were/VBD divided/VBN into/IN two/CD groups/NNS [/( coronary/JJ (/( n/NN =/JJ 
468819_2_70_71_10_11::None::the/DT safety/NN of/IN intravenous/JJ thrombolysis/NN (/( IVT/NN )/) in/IN specific/JJ conditions/NNS :/: dissection/NN of/IN the/DT aortic/JJ arch/NN of/IN extracranial/JJ and/CC intracranial/JJ arteries/NNS ,/, concomitant/JJ presence/NN of/IN unruptured/JJ intracranial/JJ aneurysms/NNS ,/, arteriovenous/JJ malformations/NNS and/CC dural/JJ fistulas/NNS ,/, co/SYM -/: existing/VBG brain/NN tumors/NNS as/RB well/RB as/IN in/IN conditions/NNS mimicking/VBG AIS/NNP The/DT review/NN systematically/RB evaluates/VBZ the/DT safety/NN of/IN off/JJ -/: label/NN use/NN of/IN IVT/NNP and/CC summarizes/VBZ data/NNS from/IN case/NN reports/NNS 
469705_8_15_16_12_13::None::and/CC evidence/NN -/: based/VBN interventions/NNS for/IN depressive/JJ symptoms/NNS in/IN RA/NN 
426927_1_18_19_5_6::None::toxicity/NN of/IN a/DT hexane/NN extract/NN of/IN Lithospermum/NN erythrorhizon/NN root/NN (/( LEH/NN )/) was/VBD investigated/VBN in/IN Beagle/NNP dogs/NNS by/IN using/VBG single/JJ 
149493_0_35_36_5_6::medicine.risk_factor.diseases::Kaiser/NNP Permanente/NNP Care/NNP Management/NNP Institute/NNP National/NNP Hypertension/NN Guideline/NN was/VBD developed/VBN to/TO assist/VB primary/JJ care/NN physicians/NNS and/CC other/JJ health/NN care/NN professionals/NNS in/IN the/DT outpatient/NN treatment/NN of/IN uncomplicated/JJ hypertension/NN in/IN adult/JJ men/NNS and/CC nonpregnant/JJ women/NNS aged/VBN 18/CD years/NNS and/CC 
526387_8_14_15_12_13::biology.organism_classification.lower_classifications::of/IN the/DT genus/NN Enterovirus/NN in/IN Picornaviridae/NNP ./. 
670_670_12_13_14_15::None::post-TGF-beta1/NN showed/VBD that/IN beta-catenin/NN ,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, 
2030_2030_3_4_22_23::None::We/PRP conclude/VBP that/IN Aip1p/NN is/VBZ a/DT cofilin-associated/JJ protein/NN that/WDT enhances/VBZ the/DT filament/NN disassembly/NN activity/NN of/IN cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ actin/NN patches/NNS ./. 
22_22_36_37_0_1::None::ActA/NN appears/VBZ to/TO control/VB at/IN least/JJS four/CD functions/NNS that/WDT collectively/RB lead/VBP to/TO actin-based/JJ motility/NN :/: (/( 1/LS )/) initiation/NN of/IN actin/NN polymerization/NN ,/, (/( 2/LS )/) polarization/NN of/IN ActA/NN function/NN ,/, (/( 3/LS )/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT 
471043_1_3_4_20_21::medicine.disease.treatments::Intraperitoneal/JJ lavage/NN with/IN sterile/JJ water/NN is/VBZ sometimes/RB used/VBN during/IN radical/JJ cystectomy/NN to/TO lyse/VB cancer/NN cells/NNS that/WDT might/MD have/VB escaped/VBN the/DT surgical/JJ specimen/NN ./. 
2222_2222_13_14_21_22::POS_ACTION_COLOCALIZE::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
1843_1843_12_13_31_32::None::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD 
322970_7_15_16_10_11::None::characteristics/NNS and/CC testedfor/NN interaction/NN between/IN period/NN and/CC SES/NN In/IN both/DT periods/NNS ,/, 
926591_11_1_2_0_1::None::The/DT prevalence/NN rate/NN of/IN deciduous/JJ 
831553_2_6_7_5_7::None::associated/VBN with/IN morbid/JJ obesity/NN ,/, including/VBG psychological/JJ 
13078_0_4_5_0_1::None::IL/NN -/: 10/CD gene/NN polymorphism/NN and/CC influence/NN of/IN 
116203_2_26_27_25_27::medicine.symptom.symptom_of::,/, 130/CD colorectal/JJ tumors/NNS were/VBD examined/VBN in/IN 
452763_3_6_7_10_11::None::observations/NNS suggest/VBP that/IN Vit/NN D/NN and/CC its/PRP$ analogues/NNS may/MD be/VB effective/JJ 
787_787_13_14_7_8::POS_REG(0)_ASSEMBLE::cofilin-dependent/JJ regulation/NN of/IN actin/NN assembly/NN in/IN muscle/NN cells/NNS ,/, cofilin/NN tagged/VBD with/IN fluorescence/NN 
142623_1_8_9_0_2::None::Eucalyptus/NN camaldulensis/NN were/VBD studied/VBN under/IN stress/NN conditions/NNS in/IN response/NN to/TO aluminum/NN (/( 
1439_1439_26_27_16_17::None::for/IN association/NN of/IN TNFR1/NN and/CC other/JJ death/NN domain-containing/JJ proteins/NNS such/JJ as/IN FADD/NN and/CC RIP/NN ./. 
618_618_1_2_3_4::POS_REG(+)_ASSEMBLE::How/WRB profilin/NN promotes/VBZ actin/NN filament/NN assembly/NN in/IN 
1760_1760_13_14_3_4::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC activate/VB the/DT actin-binding/JJ protein/NN cofilin/NN in/IN human/JJ T/NN 
1608_1608_7_8_24_25::POS_ACTION_BIND::substitution/NN found/VBN in/IN talin/NN from/IN Wistar-Furth/NNP rats/NNS does/VBZ not/RB destroy/VB the/DT capacity/NN of/IN this/DT region/NN of/IN the/DT protein/NN to/TO bind/VB actin/NN or/CC vinculin/NN ./. 
6359_3_4_5_14_16::medicine.risk_factor.diseases::DNA/NN from/IN 2256/CD Caucasians/NNS ,/, including/VBG 1073/CD CD/NN patients/NNS ,/, 464/CD patients/NNS with/IN ulcerative/JJ colitis/NN (/( UC/NN )/) 
1637_1637_27_29_7_8::None::similar/JJ to/TO authentic/JJ profilin/NN from/IN Acanthamoeba-based/JJ on/IN fluorescence/NN monitored/VBD urea/NN denaturation/NN ,/, circular/JJ dichroism/NN ,/, actin-nucleotide/JJ exchange/NN rate/NN and/CC the/DT Kd/NN for/IN rabbit/NN skeletal/JJ actin/NN ./. 
2137_2137_15_18_4_5::None::previously/RB showed/VBD that/IN actin/NN is/VBZ transported/VBN in/IN an/DT unassembled/JJ form/NN with/IN its/PRP$ associated/JJ proteins/NNS actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, 
468525_8_8_9_3_4::None::Systolic/JJ prehypertension/NN and/CC overweight/NN are/VBP associated/VBN with/IN incident/NN AF/NN in/IN Japanese/JJ population/NN 
242_242_2_3_17_21::None::Neuropilin-1/NN mediates/VBZ collapsin-1/NN //: semaphorin/NN III/CD inhibition/NN of/IN endothelial/JJ cell/NN motility/NN :/: functional/JJ competition/NN of/IN collapsin-1/NN and/CC vascular/JJ endothelial/JJ growth/NN factor-165/NN ./. 
629883_0_36_37_21_22::None::MSC/NN )/) into/IN rabbit/NN models/NNS of/IN corneal/NN allograft/NN rejection/NN with/IN either/CC normal/JJ -/: risk/NN or/CC high/JJ -/: risk/NN vascularized/VBN corneal/NN beds/NNS was/VBD 
1450_1450_23_24_23_24::POS_REG(+)_Assembly::coordination/NN in/IN the/DT actin/NN central/JJ cleft/NN ./. 
236148_4_11_12_29_30::None::have/VB a/DT higher/JJR prevalence/NN of/IN previously/RB diagnosed/VBN comorbidities/NNS ,/, to/TO have/VB developed/VBN heart/NN failure/NN acutely/RB ,/, and/CC to/TO have/VB a/DT longer/RBR hospital/NN stay/NN compared/VBN with/IN 
834587_19_32_33_0_1::None::VMAT/NN can/MD be/VB a/DT better/JJR option/NN in/IN treating/VBG mid/JJ esophageal/JJ carcinoma/NN as/IN compared/VBN to/TO IMRT/NNP The/NNP VMAT/NNP plans/VBZ resulted/VBD in/IN equivalent/JJ or/CC superior/JJ dose/NN distribution/NN with/IN a/DT reduction/NN in/IN the/DT dose/NN to/TO lung/NN and/CC heart/NN ./. 
169759_4_5_6_15_16::None::to/TO -/: serine/NN substitutions/NNS at/IN the/DT other/JJ sites/NNS lead/VBP to/TO the/DT loss/NN of/IN expression/NN and/CC //: or/CC 
470116_0_12_13_8_9::medicine.symptom.symptom_of::Wall/NNP Thickening/NNP and/CC Emphysema/NNP Is/VBZ Associated/VBN with/IN Dyspnea/NN and/CC Hospitalization/NN for/IN 
1434_1434_14_15_75_76::None::H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
667084_2_7_8_18_20::None::with/IN an/DT increased/VBN prevalence/NN of/IN mental/JJ health/NN disorders/NNS including/VBG anxiety/NN ,/, depression/NN ,/, and/CC suicidal/JJ thoughts/NNS ./. 
747093_0_5_6_4_5::None::surgery/NN in/IN supermorbidly/JJ obese/JJ patients/NNS with/IN endometrial/JJ cancer/NN 
576_576_9_10_13_15::None::the/DT regulation/NN of/IN cofilin/NN ,/, a/DT ubiquitous/JJ actin-binding/JJ protein/NN that/WDT is/VBZ essential/JJ 
1568_1568_17_18_4_5::POS_ACTION_BIND::NH2-terminal/JJ 16kD/NN of/IN Abp1p/NN ,/, a/DT 65-kD/JJ yeast/NN protein/NN identified/VBN by/IN its/PRP$ ability/NN to/TO bind/VB to/TO actin/NN filaments/NNS ,/, is/VBZ 
769684_3_64_65_55_56::None::Scale/NNP (/( FACES/NNP II/NNP ,/, Chinese/NNP version/NN )/) and/CC the/DT Social/NNP Functioning/NNP Questionnaire/NNP (/( SFQ/NNP )/) 
259511_0_36_37_25_26::None::of/IN decreased/VBN urinary/JJ flow/NN ,/, inability/NN to/TO fully/RB empty/VB his/PRP$ bladder/NN ,/, and/CC gross/JJ hematuria/NN ./. 
1683_1683_10_12_8_9::POS_REG(0)_Assembly::co-operativity/NN between/IN the/DT profilin/NN and/CC DNase/NN I/CD binding/NN sites/NNS on/IN 
106581_3_23_24_4_5::None::there/EX is/VBZ little/JJ doubt/NN regarding/VBG potential/JJ benefit/NN of/IN MD/NN for/IN obesity/NN ,/, diabetes/NN type/NN II/CD ,/, metabolic/JJ syndrome/NN and/CC fatty/NN liver/NN ,/, critical/JJ evaluation/NN has/VBZ to/TO 
403501_2_33_34_10_11::None::and/CC Plasmodium/NN nested/JJ PCR/NN were/VBD compared/VBN in/IN a/DT region/NN of/IN declining/VBG malaria/NN transmission/NN in/IN southern/JJ Zambia/NNP using/VBG samples/NNS from/IN community/NN -/: based/VBN ,/, cross/NN -/: sectional/JJ surveys/NNS from/IN 2008/CD to/TO 
480543_0_15_16_32_33::medicine.drug.active_moieties::irradiation/NN of/IN a/DT gallium/NN metal/NN target/NN ,/, purified/VBN by/IN organic/JJ extraction/NN and/CC used/VBN in/IN a/DT medical/JJ isotope/NN generator/NN to/TO produce/VB Gallium/NNP -/: 68/CD PET/NN 
2222_2222_13_14_19_20::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC 
620872_0_3_4_1_2::None::Dose/NN Levels/NNS in/IN Particulate/NNP -/: Containing/NNP Formulations/NNPS 
454283_3_25_26_18_19::medicine.drug_ingredient.active_moiety_of_drug::the/DT formation/NN of/IN ferric/JJ arsenate/NN with/IN the/DT increasing/VBG As/IN :/: Fe/NNP ratio/NN ./. 
1075_1075_6_7_8_9::None::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN 
1221_1221_18_19_21_22::None::bind/VBP to/TO the/DT armadillo/NN repeats/NNS of/IN beta-catenin/NN ,/, but/CC not/RB 
872597_0_2_3_0_1::biology.organism_classification.lower_classifications::Coyotes/NNS (/( Canis/NN latrans/NNS )/) are/VBP 
739268_3_30_32_15_16::medicine.symptom.symptom_of::(/( ie/FW ,/, depressive/JJ and/CC bipolar/JJ disorders/NNS ,/, social/JJ phobia/NN ,/, borderline/JJ personality/NN disorder/NN ,/, schizophrenia/NN and/CC other/JJ psychotic/JJ disorders/NNS ,/, certain/JJ drug/NN 
454963_14_2_4_0_3::people.cause_of_death.includes_causes_of_death::Type/NN 2/CD Diabetes/NNP Mellitus/NNP was/VBD the/DT 
350850_8_31_32_32_33::None::0.001/CD )/) ,/, facial/JJ lipodystrophy/NN (/( P/NN =/JJ 
1082_1082_11_12_31_34::None::mobile/JJ form/NN of/IN actin/NN in/IN slow/JJ transport/NN is/VBZ soluble/JJ and/CC that/IN a/DT substantial/JJ amount/NN of/IN this/DT actin/NN may/MD travel/VB as/IN a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, 
251166_0_6_7_19_20::None::evidence/NN that/IN the/DT predictive/JJ value/NN of/IN HDL/NN cholesterol/NN levels/NNS for/IN cardiovascular/JJ risk/NN stratification/NN is/VBZ limited/VBN in/IN patients/NNS with/IN coronary/JJ artery/NN 
1147_1147_17_18_0_1::None::Profilins/NNP also/RB bind/VBP polyphosphoinositides/NNS ,/, which/WDT can/MD disrupt/VB the/DT profilin-actin/NN complex/NN ,/, and/CC proline-rich/JJ ligands/NNS which/WDT localize/VBP profilin/NN to/TO sites/NNS requiring/VBG 
350196_12_2_3_5_6::None::Cervical/JJ ,/, uterine/JJ and/CC ovary/JJ cancers/NNS remain/VBP to/TO be/VB 
778878_10_39_40_5_6::medicine.symptom.symptom_of::with/IN non/JJ -/: CF/NN bronchiectasis/NN ,/, long/JJ -/: term/NN inhaled/VBD antibiotics/NNS can/MD effectively/RB reduce/VB the/DT sputum/NN bacterial/JJ density/NN ,/, increase/NN P/NN A/NN eradication/NN and/CC attenuate/VB the/DT risk/NN of/IN exacerbation/NN ,/, however/RB ,/, accompanied/VBN with/IN higher/JJR risk/NN of/IN wheeze/NN and/CC bronchospasm/NN ./. 
349493_0_5_6_0_1::None::Tumor/NN and/CC Patient/NN Characteristics/NNS of/IN Individuals/NNS with/IN Mismatch/NNP Repair/NNP 
658012_2_18_19_19_20::None::PD/NN for/IN pancreatic/JJ head/NN adenocarcinoma/NN 10/CD months/NNS previously/RB 
243_243_27_28_27_28::None::coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN 
139515_2_25_26_62_63::None::and/CC later/RB HSP/NN In/IN this/DT patient/NN ,/, the/DT diagnosis/NN of/IN HSP/NN was/VBD demonstrated/VBN clinically/RB by/IN his/PRP$ palpable/JJ purpura/NN ,/, diarrhea/NN ,/, hematuria/NN ,/, and/CC abdominal/JJ pain/NN and/CC confirmed/VBD pathologically/RB by/IN his/PRP$ renal/JJ and/CC skin/NN biopsies/NNS demonstrating/VBG leukocytoclastic/JJ vasculitis/NN and/CC IgA/NN complexes/NNS ./. 
68_68_20_21_14_15::None::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB beta-catenin/NN ,/, with/IN increased/VBN 
711_711_22_23_14_15::None::,/, stimulation/NN with/IN TNF-alpha/NN led/VBD to/TO a/DT 2.4-fold/JJ increase/NN in/IN net/JJ actin/NN protein/NN synthesis/NN and/CC 
453075_8_15_16_28_29::None::aspects/NNS of/IN normal/JJ muscle/NN histology/NN and/CC pathology/NN such/JJ as/IN decreased/VBN necrosis/NN and/CC resistance/NN to/TO contraction/NN -/: induced/VBN injury/NN ./. 
1532_1532_17_18_31_33::POS_ACTION_CORELATE::association/NN of/IN the/DT Munc18-2/NN variants/NNS with/IN syntaxin/NN 3/CD correlated/VBD well/RB with/IN their/PRP$ ability/NN to/TO displace/VB SNAP-23/NN from/IN syntaxin/NN 3/CD complexes/NNS when/WRB overexpressed/VBN 
927981_0_17_19_8_9::None::for/IN the/DT simultaneous/JJ determination/NN of/IN nine/CD antidepressants/NNS in/IN traditional/JJ Chinese/JJ medicines/NNS and/CC health/NN food/NN by/IN ultra/NN performance/NN 
419773_1_9_10_1_3::None::In/IN developed/JJ countries/NNS ,/, up/RB to/TO 18/CD %/NN of/IN nursing/NN home/NN residents/NNS suffer/VBP 
373723_3_1_2_3_5::None::We/PRP performed/VBD a/DT systematic/JJ review/NN to/TO determine/VB the/DT 
507_507_3_4_28_29::None::For/IN example/NN ,/, profilin/NN with/IN a/DT deletion/NN of/IN the/DT eight/CD C-terminal/JJ residues/NNS has/VBZ many/JJ of/IN the/DT physical/JJ properties/NNS of/IN a/DT molten/JJ globule/NN ,/, yet/RB remarkably/RB still/RB binds/VBZ to/TO actin/NN ./. 
512095_3_2_3_9_10::None::A/DT failed/VBD procedure/NN was/VBD defined/VBN as/IN requiring/VBG a/DT second/JJ surgery/NN for/IN the/DT UPJO/NNP 
849947_0_6_7_7_8::None::hernia/NN in/IN a/DT terrier/NN dog/NN ./. 
163_163_5_6_8_9::None::from/IN Acanthamoeba/NN binds/VBZ profilin/NN and/CC cross-links/NNS actin/NN filaments/NNS ./. 
244414_9_7_8_5_6::None::nasopharynx/NN cancer/NN patients/NNS treated/VBN with/IN IMRT/NN and/CC chemotherapy/NN ,/, 
1546_1546_26_27_8_11::None::p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ from/IN its/PRP$ binding/NN with/IN the/DT cyclin/NN E/cyclin-dependent/JJ kinase/NN 2/CD (/( Cdk2/NN )/) complex/NN that/WDT 
1608_1608_26_27_7_8::None::substitution/NN found/VBN in/IN talin/NN from/IN Wistar-Furth/NNP rats/NNS does/VBZ not/RB destroy/VB the/DT capacity/NN of/IN this/DT region/NN of/IN the/DT protein/NN to/TO bind/VB actin/NN or/CC vinculin/NN ./. 
235372_5_0_1_20_22::None::Race/NN ,/, family/NN history/NN of/IN osteoporosis/NN ,/, BMI/NN ,/, current/JJ physical/JJ activity/NN ,/, osteoporosis/NN knowledge/NN ,/, length/NN of/IN time/NN on/IN oral/JJ contraceptives/NNS ,/, age/NN at/IN 
668570_12_11_13_7_8::medicine.symptom.symptom_of::association/NN between/IN preoperative/JJ depressive/JJ symptom/NN severity/NN and/CC postoperative/JJ pain/NN and/CC no/DT reduction/NN 
303_303_23_24_23_24::POS_REG(0)_Assembly::are/VBP independent/JJ of/IN beta-catenin/NN binding/NN to/TO alpha-catenin/NN 
776_776_4_6_24_26::None::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN 
425469_7_45_46_22_23::None::treatment/NN condition/NN and/CC change/NN in/IN eating/VBG concerns/NNS ,/, where/WRB younger/JJR adolescents/NNS and/CC individuals/NNS with/IN high/JJ baseline/NN purging/VBG had/VBD greater/JJR change/NN when/WRB treated/VBN with/IN FBT/NN relative/JJ to/TO SPT/NNP Age/NNP and/CC purging/VBG 
280_280_14_15_46_47::None::observed/VBD that/IN histone/NN H4/NN ,/, and/CC not/RB histone/NN H3/NN ,/, was/VBD acetylated/VBN from/IN the/DT endogenous/JJ p21/waf1/NN promoter/NN in/FW vivo/FW ,/, implying/VBG that/IN CBP/p300/NN ,/, and/CC not/RB the/DT SAGA/NN complex/NN ,/, was/VBD critical/JJ in/IN complexing/VBG with/IN E2A/NN in/IN up-regulation/NN of/IN 
822_822_6_7_4_5::POS_ACTION_INTERACT::of/IN the/DT yeast/NN RAD51/NN and/CC RAD52/NN proteins/NNS plays/VBZ a/DT 
749940_1_28_29_15_16::medicine.medical_treatment.used_to_treat::old/JJ )/) with/IN AML/NN (/( n/NN =/JJ 363/CD )/) who/WP received/VBD allogeneic/JJ peripheral/JJ blood/NN stem/NN cell/NN transplantation/NN from/IN HLA/NN -/: 
1075_1075_11_12_20_21::None::CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) 
856_856_24_25_16_18::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT 
1580_1580_18_19_23_24::None::protein/NN complex/NN containing/VBG E-cadherin/NN and/CC its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, 
414579_11_44_45_20_21::None::developed/VBD AKI/NNP These/DT differences/NNS in/IN arterial/JJ pressures/NNS and/CC use/NN of/IN norepinephrine/NN between/IN the/DT groups/NNS were/VBD not/RB found/VBN to/TO be/VB significant/JJ when/WRB entered/VBN in/IN the/DT binary/JJ logistic/JJ regression/NN model/NN ./. 
416067_10_3_4_5_6::people.cause_of_death.includes_causes_of_death::The/DT ratio/NN of/IN malignant/JJ //: tumor/NN in/IN NPC1L1/NN (/( 
432927_5_15_16_26_27::None::denervation/NN in/IN the/DT aetiology/NN of/IN parkinsonian/JJ apathy/NN with/IN a/DT cardinal/JJ role/NN of/IN decreased/VBN tonic/NN D2/NN //: D3/NN receptor/NN 
609976_0_11_12_0_1::None::Hypertension/NN and/CC diabetes/NN as/IN risk/NN factors/NNS for/IN dementia/NN :/: A/DT secondary/JJ post/NN -/: hoc/FW analysis/NN 
710948_4_5_6_23_24::medicine.risk_factor.diseases::course/NN of/IN the/DT disease/NN ,/, the/DT patient/NN developed/VBD immune/JJ reconstitution/NN inflammatory/JJ syndrome/NN and/CC relapses/NNS ,/, or/CC renewed/VBN exacerbation/NN ,/, of/IN her/PRP$ MS/NN She/PRP responded/VBD well/RB 
130735_2_16_17_29_30::None::of/IN the/DT structure/NN transformation/NN during/IN the/DT interaction/NN process/NN ,/, providing/VBG a/DT potential/JJ FL/NN tool/NN for/IN monitoring/VBG dopaminergic/JJ neurotoxicity/NN ./. 
172875_8_32_33_10_11::None::from/IN the/DT Atherosclerosis/NNP Risk/NN in/IN Communities/NNP Study/NNP (/( n/NN =/JJ 12779/CD )/) demonstrated/VBD that/IN serum/NN sodium/NN is/VBZ a/DT significant/JJ predictor/NN of/IN 10/CD Years/NNS Risk/NN of/IN coronary/JJ heart/NN disease/NN ./. 
394705_2_101_102_4_6::None::%/NN switched/VBD from/IN group/NN A/NN to/TO B/NN versus/CC 43/CD %/NN switching/NN from/IN B/NN to/TO A/DT Intent/NN -/: to/TO -/: treat/VB patient/NN survivals/NNS at/IN 5/CD and/CC 8/CD years/NNS were/VBD 88/CD %/NN and/CC 85.5/CD %/NN for/IN group/NN A/NN ,/, and/CC 78/CD %/NN and/CC 73/CD %/NN for/IN group/NN B/NN Death/NN -/: censored/VBN graft/NN survivals/NNS were/VBD 93/CD %/NN for/IN group/NN A/NN and/CC 95/CD %/NN for/IN group/NN B/NN Graft/NN function/NN was/VBD significantly/RB better/JJR at/IN 8/CD years/NNS ,/, with/IN 91/CD %/NN of/IN group/NN A/NN patients/NNS compared/VBN with/IN 50/CD %/NN in/IN group/NN B/NN having/VBG estimated/VBN glomerular/JJ filtration/NN rates/NNS &/CC gt/NN ;/: 45/CD mL/NN //: min/NN //: 1.73/CD m2/NN ,/, and/CC a/DT 
580543_2_13_14_11_12::medicine.risk_factor.diseases::risk/NN of/IN maternal/JJ anemia/NN ,/, infections/NNS ,/, eclampsia/NN and/CC 
1087_1087_23_24_25_26::POS_ACTION_ASSEMBLE::flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN to/TO distinct/JJ 
167593_4_2_3_8_11::None::Following/VBG an/DT injection/NN with/IN the/DT HDAC/NN inhibitor/NN ,/, suberoylanilide/NN hydroxamic/JJ acid/NN (/( SAHA/NN )/) 
856_856_16_18_24_25::POS_ACTION_UPREGULATE::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT 
112987_0_47_48_44_46::medicine.drug.active_moieties::CH3OH/NN )/) and/CC dimethyl/JJ sulfoxide/NN (/( DMSO/NN )/) for/IN the/DT 
768572_0_28_30_21_22::None::after/IN acute/JJ ischemic/JJ stroke/NN has/VBZ been/VBN well/RB demonstrated/VBN in/IN past/JJ clinical/JJ trials/NNS ./. 
1889_1889_5_6_7_8::None::death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN 
513_513_17_19_9_10::None::,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO promote/VB U2/NN snRNP/NN binding/NN to/TO pre-mRNA/NN 
1334_1334_0_1_17_18::None::act1-157/NN ,/, an/DT actin/NN mutant/NN with/IN an/DT increased/VBN intrinsic/JJ rate/NN of/IN nucleotide/NN exchange/NN ,/, suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN 
510001_0_4_5_8_10::None::chromosomes/NNS have/VBP evolved/VBN independently/RB in/IN phylogenetically/RB diverse/JJ flowering/NN plant/NN lineages/NNS ./. 
2165_2165_14_15_20_21::POS_ACTION_MEMBER::presence/NN of/IN acetylated/VBN histone/NN H4/NN relative/JJ to/TO acetylated/VBN histone/NN H3/NN ./. 
954_954_9_10_6_7::None::LIMKs/NNS )/) phosphorylate/VBP cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
406187_0_27_28_19_20::None::level/NN of/IN light/JJ perception/NN within/IN 24/CD hours/NNS of/IN having/VBG fever/NN and/CC myalgias/NNS heralding/VBG H1N1/NN influenza/NN 
890409_7_12_13_35_37::None::(/( age/NN and/CC sex/NN )/) ,/, clinical/JJ condition/NN (/( diagnosis/NN and/CC the/DT length/NN of/IN hospital/NN stay/NN )/) and/CC possible/JJ risk/NN factors/NNS for/IN infection/NN as/IN smoking/NN ,/, diabetes/NN mellitus/NN ,/, hypertension/NN and/CC 
1164_1164_39_40_33_34::POS_ACTION_ATTACH:::/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN 
1686_1686_15_18_47_48::None::domains/NNS of/IN all/DT myosin/JJ heavy/JJ chains/NNS ,/, and/CC light/JJ chains/NNS at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP 
1850_1850_8_9_0_1::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ 
1771_1771_19_20_1_2::None::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
523643_0_25_27_19_20::medicine.risk_factor.diseases::LAA/NN )/) and/CC stroke/NN risk/NN score/NN in/IN patients/NNS with/IN atrial/JJ fibrillation/NN (/( AF/NN )/) 
792558_0_8_9_1_2::None::Polymorphonuclear/JJ neutrophils/NNS (/( PMNs/NNS )/) ,/, the/DT main/JJ effectors/NNS of/IN the/DT innate/JJ 
557_557_3_4_15_16::None::Green/NNP fluorescent/JJ protein-tagged/JJ ORC1/NN associated/VBN with/IN chromatin/NN throughout/IN mitosis/NN in/IN living/NN cells/NNS and/CC co-localized/VBN with/IN ORC4/NN in/IN metaphase/NN spreads/NNS 
91440_0_2_4_0_1::None::Risk/NN of/IN cardiovascular/JJ events/NNS and/CC mortality/NN among/IN 
6567_1_0_1_12_13::None::Sodium/NN appetite/NN ,/, or/CC the/DT desire/NN of/IN terrestrial/JJ animals/NNS to/TO seek/VB and/CC consume/VB sodium/NN -/: containing/VBG 
1087_1087_10_12_7_9::None::that/IN in/IN brain/NN profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT 
1771_1771_11_14_1_2::None::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, 
237202_1_26_28_0_1::None::Here/RB we/PRP describe/VBP the/DT first/JJ use/NN of/IN daclatasvir/NN ,/, simeprevir/NN ,/, and/CC ribavirin/NNP (/( RBV/NN )/) as/IN an/DT all/DT -/: oral/JJ triple/JJ regimen/NN administered/VBN to/TO 6/CD liver/NN transplant/NN recipients/NNS with/IN recurrent/JJ 
226308_2_9_10_12_13::None::CRA/NNP agar/NN and/CC hydrophobicity/NN of/IN 20/CD Salmonella/FW strains/NNS isolated/VBN from/IN 
566167_0_25_26_10_11::None::studies/NNS conducted/VBN in/IN acute/JJ inpatient/JJ stroke/NN rehabilitation/NN ,/, though/IN such/JJ studies/NNS are/VBP greatly/RB needed/VBN in/IN order/NN to/TO shed/VB light/NN on/IN the/DT most/RBS 
1394_1394_8_9_5_6::None::constants/NNS of/IN Acanthamoeba/NN profilin/NN to/TO fluorescein-labeled/JJ actin/NN from/IN Acanthamoeba/NN and/CC 
347064_0_21_22_3_5::None::The/DT transplantation/NN of/IN Schwann/NN cells/NNS (/( SCs/NNS )/) holds/VBZ considerable/JJ promise/NN as/IN a/DT therapy/NN for/IN spinal/JJ cord/NN injury/NN ,/, but/CC the/DT optimal/JJ source/NN of/IN these/DT 
590_590_33_34_35_36::POS_ACTION_ACETYLATE::protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN activity/NN ./. 
1793_1793_14_15_16_17::None::and/CC modulation/NN by/IN talin/NN and/CC vinculin/NN ./. 
356156_0_32_33_30_31::medicine.symptom.symptom_of::(/( eg/FW ,/, depression/NN and/CC suicidality/NN )/) as/IN a/DT 
783888_0_29_30_13_15::None::IV/CD )/) (/( experimental/JJ group/NN )/) with/IN promethazine/NN 12.5/CD mg/NN IV/CD (/( control/NN group/NN )/) among/IN adult/JJ ambulatory/JJ surgery/NN patients/NNS to/TO control/VB established/JJ 
266669_0_26_27_8_10::medicine.disease.risk_factors::old/JJ woman/NN with/IN atrial/JJ fibrillation/NN (/( AF/NN )/) treated/VBN with/IN warfarin/NN had/VBD a/DT cortical/JJ left/JJ middle/JJ cerebral/JJ artery/NN (/( MCA/NNP )/) stroke/NN (/( October/NNP 2009/CD 
718366_2_21_22_19_20::None::or/CC persistence/NN into/IN adulthood/NN ,/, epilepsy/NN ,/, severe/JJ learning/NN 
112017_4_9_10_12_13::None::with/IN a/DT slight/JJ prevalence/NN of/IN situational/JJ depression/NN ./. 
1889_1889_0_2_7_8::None::TNF/NN receptor/NN death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN 
337142_1_0_1_47_48::None::We/PRP examined/VBD changes/NNS in/IN the/DT expression/NN of/IN three/CD NRs/NNS (/( NR1/NN ,/, NR2B/NN ,/, and/CC NR2C/NN )/) ,/, olfactory/JJ receptor/NN (/( OR/NN )/) ,/, and/CC adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) in/IN chum/NN salmon/NN Oncorhynchus/NNP keta/NN using/VBG quantitative/JJ polymerase/NN chain/NN reaction/NN (/( QPCR/NN )/) during/IN salinity/NN change/NN (/( seawater/NN -/: gtgt/NN 50/CD 
320906_2_0_1_12_13::None::This/DT study/NN seeks/VBZ to/TO better/RBR understand/VB consumer/NN antimalarial/JJ prices/NNS by/IN documenting/VBG and/CC exploring/VBG the/DT pricing/NN behaviour/NN 
490714_0_7_8_9_10::biology.organism_classification.lower_classifications::content/NN of/IN wawo/NN worms/NNS (/( Polychaeta/NN ,/, Annelida/NN )/) 
1457_1457_34_35_56_57::None::predominantly/RB as/IN an/DT actin/NN monomer-binding/JJ protein/NN ;/: (/( 2/LS )/) profilin/NN II/CD regulates/VBZ ,/, or/CC is/VBZ regulated/VBN by/IN ,/, PIP2/NN ;/: and/CC (/( 3/LS )/) actobindin/NN inhibits/VBZ nucleation/NN of/IN 
1503_1503_13_14_5_7::POS_ACTION_ENCODE::simplex/NN virus/NN type-1/NN DNA/NN helicase-primase/NN is/VBZ a/DT heterotrimer/NN encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, 
87_87_41_45_37_38::None::the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN alpha/NN v/LS beta/NN 5/CD shows/VBZ a/DT distinct/JJ 
188913_0_25_26_2_3::None::In/IN the/DT plasma/NN of/IN dairy/NN cows/NNS with/IN 1/LS -/: 5/CD points/NNS of/IN lameness/NN ,/, the/DT mineral/NN elements/NNS [/( calcium/NN (/( Ca/NN )/) ,/, iron/NN (/( Fe/NNP )/) ,/, copper/NN 
149017_0_21_22_23_24::None::cognitive/JJ impairment/NN ,/, dementia/NN and/CC atrophy/NN of/IN the/DT central/JJ 
101_101_24_25_36_37::POS_ACTION_Dynamics::of/IN talin/NN and/CC vinculin/NN on/IN the/DT structure/NN ,/, chain/NN dynamics/NNS ,/, elasticity/NN and/CC viscoelasticity/NN of/IN actin/NN filaments/NNS with/IN time/NN 
1140_1140_20_21_24_25::None::the/DT interaction/NN of/IN gelsolin/NN and/CC profilin/NN with/IN actin/NN ./. 
365_365_12_15_15_16::POS_ACTION_MEMBER::D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN 
669734_0_10_11_44_45::None::forms/NNS of/IN cognitive/JJ control/NN (/( proactive/JJ and/CC reactive/JJ )/) between/IN early/JJ and/CC midadolescence/NN was/VBD associated/VBN with/IN the/DT onset/NN of/IN major/JJ depressive/JJ disorder/NN (/( MDD/NN )/) during/IN the/DT same/JJ period/NN and/CC if/IN it/PRP prospectively/RB predicted/VBD MDD/NN onset/NN between/IN mid/JJ -/: and/CC late/JJ 
1758_1758_4_5_19_20::None::results/NNS suggest/VBP that/IN TNF-alpha/NN can/MD cause/VB apoptosis/NN in/IN pancreatic/JJ beta/NN cells/NNS through/IN TNFR1-linked/JJ apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP 
875_875_7_8_19_20::POS_ACTION_AFFECT::we/PRP demonstrate/VBP that/IN profilin/NN isoforms/NNS expressed/VBN in/IN a/DT single/JJ cell/NN can/MD have/VB different/JJ effects/NNS on/IN actin/NN in/IN living/NN cells/NNS 
97537_3_24_25_5_6::None::1/CD is/VBZ also/RB expressed/VBN in/IN a/DT variety/NN of/IN cancers/NNS (/( prostate/NN ,/, lung/NN ,/, pancreatic/JJ ,/, or/CC colon/NN carcinoma/NN ,/, melanoma/NN ,/, astrocytoma/NN ,/, glioblastoma/NN ,/, 
487559_4_34_35_45_46::None::typical/JJ signs/NNS and/CC symptoms/NNS ,/, especially/RB in/IN the/DT setting/NN of/IN pregnancy/NN complications/NNS associated/VBN with/IN liver/NN dysfunction/NN ./. 
252268_2_39_41_34_35::None::central/JJ nervous/JJ system/NN striatal/JJ dopamine/NN (/( DA/NN )/) receptor/NN binding/NN (/( BPND/NN )/) 
1160_1160_2_3_22_23::None::Purification/NN of/IN cofilin/NN ,/, a/DT 21,000/CD molecular/JJ weight/NN actin-binding/JJ protein/NN ,/, from/IN porcine/NN kidney/NN and/CC identification/NN of/IN the/DT cofilin-binding/JJ site/NN in/IN the/DT actin/NN sequence/NN ./. 
168553_2_11_12_13_14::medicine.drug_ingredient.active_moiety_of_drug::pituitary/JJ or/CC ectopic/JJ corticotropin/NN (/( ACTH/NN )/) overproduction/NN ,/, 
723866_2_1_2_8_9::None::(/( Reduviidae/NNP :/: Emesinae/NNP )/) is/VBZ described/VBN from/IN India/NNP ./. 
2131_2131_7_8_9_10::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC 
1434_1434_14_15_7_8::None::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB 
373923_0_54_55_109_110::None::-/: stage/NN or/CC refractory/JJ heart/NN failure/NN (/( stage/NN D/NN )/) This/DT review/NN outlines/VBZ the/DT key/JJ role/NN of/IN diabetes/NN mellitus/NN as/IN a/DT stage/NN A/DT risk/NN factor/NN for/IN heart/NN failure/NN with/IN preserved/JJ ejection/NN fraction/NN ,/, and/CC asymptomatic/JJ diabetic/JJ cardiomyopathy/NN ,/, referring/VBG to/TO the/DT presence/NN of/IN left/JJ ventricular/JJ diastolic/JJ dysfunction/NN in/IN diabetic/JJ patients/NNS without/IN coronary/JJ artery/NN disease/NN ,/, hypertension/NN or/CC other/JJ potential/JJ aetiologies/NNS ,/, as/IN 
14211_8_14_15_20_21::None::vitro/FW drug/NN sensitivity/NN test/NN ,/, which/WDT is/VBZ easy/JJ to/TO perform/VB ,/, may/MD predict/VB 
511797_2_23_24_33_34::None::and/CC mean/VB MS/NN duration/NN =/JJ 13.1/CD years/NNS )/) who/WP underwent/VBD measurements/NNS of/IN aerobic/JJ fitness/NN and/CC muscular/JJ strength/NN 
474123_0_1_2_0_2::people.cause_of_death.includes_causes_of_death::Oesophageal/JJ cancer/NN is/VBZ the/DT sixth/JJ 
1486_1486_41_44_60_61::POS_ACTION_STIMULATE::protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
398_398_8_9_10_11::None::acids/NNS )/) of/IN PRT1/NN and/CC TIF35/NN were/VBD found/VBN to/TO 
1901_1901_25_28_29_30::None::D1/NN ,/, the/DT cyclin-dependent/JJ kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC 
1055_1055_2_3_22_23::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC E2F/NN 
1308_1308_6_9_9_10::POS_ACTION_MEMBER::transformation/NN by/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p57KIP2/NN requires/VBZ binding/VBG to/TO 
118239_0_15_16_13_14::medicine.drug.active_moieties::ceria/NN -/: supported/VBN gold/NN (/( Au/NN //: meso/SYM -/: 
576_576_13_15_9_10::POS_ACTION_MEMBER::the/DT regulation/NN of/IN cofilin/NN ,/, a/DT ubiquitous/JJ actin-binding/JJ protein/NN that/WDT is/VBZ essential/JJ 
640_640_29_30_29_30::None::'s/POS affinity/NN for/IN actin/NN ./. 
12271_2_60_61_24_25::medicine.drug_ingredient.active_moiety_of_drug::coupled/VBN to/TO a/DT biotin/NN molecule/NN through/IN the/DT N/NN -/: terminal/JJ amino/NN group/NN and/CC e/SYM -/: amino/NN group/NN of/IN N/NN -/: terminus/NN Lys/NNP ,/, (/( Btn/NNP )/) KP6/NN and/CC K/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, and/CC heir/NN their/PRP$ biotinylated/VBN peptides/NNS substituted/VBN with/IN 
1773_1773_6_7_10_11::None::between/IN cofilin/NN and/CC gelsolin/NN segment-1/NN binding/NN to/TO actin/NN was/VBD confirmed/VBN experimentally/RB 
699_699_22_23_19_22::None::inactivation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN (/( INK4A/NN )/) 
436129_1_8_9_17_18::None::studies/NNS suggest/VBP that/IN ASA/NN use/NN reduces/VBZ the/DT risk/NN of/IN different/JJ cancers/NNS including/VBG breast/NN cancer/NN (/( BC/NN 
93665_0_2_3_16_18::medicine.disease.symptoms::In/IN colorectal/JJ cancer/NN (/( CRC/NN )/) ,/, metastatic/JJ spread/NN is/VBZ supposed/VBN to/TO be/VB mainly/RB driven/VBN by/IN tumor/NN cells/NNS with/IN stem/NN cell/NN 
311826_8_46_47_8_9::None::induced/VBN Fas/NN -/: mediated/JJ apoptosis/NN following/VBG treatment/NN with/IN anti/JJ -/: Fas/NN activating/VBG mAb/NN or/CC control/NN IgG/NN ,/, were/VBD assessed/VBN by/IN Annexin/NN V/NN staining/NN ,/, FACS/NN analysis/NN ,/, and/CC confocal/JJ microscopy/NN ;/: caspase/NN cleavage/NN by/IN Western/NN blot/NN ;/: FLIP/NN or/CC Fas/NN molecule/NN detection/NN by/IN Western/NN blot/NN 
13078_0_8_9_17_18::medicine.risk_factor.diseases::and/CC influence/NN of/IN chemotherapy/NN on/IN cytokine/NN plasma/NN levels/NNS in/IN childhood/NN acute/JJ lymphoblastic/JJ leukemia/NN patients/NNS :/: IL/NN 
1178_1178_2_3_14_15::NEG_ACTION_BIND::Recombinant/JJ human/JJ beta-catenin/NN can/MD simultaneously/RB bind/VB to/TO the/DT alpha-catenin/actin/NN complex/NN but/CC does/VBZ not/RB bind/VB actin/NN directly/RB ./. 
423051_1_27_28_31_32::None::also/RB by/IN a/DT number/NN of/IN immune/JJ and/CC inflammatory/JJ pathways/NNS ./. 
91811_0_16_17_9_10::None::tumors/NNS that/WDT usually/RB affect/VBP women/NNS in/IN the/DT second/JJ and/CC third/JJ decade/NN of/IN life/NN ./. 
405577_1_5_6_16_17::None::plasma/NN ,/, PCI/NN physiologically/RB inhibits/VBZ an/DT anticoagulant/JJ serine/NN protease/NN ,/, activated/VBN protein/NN C/NN (/( APC/NN )/) ./. 
1843_1843_31_32_31_33::POS_ACTION_MEMBER::the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD ,/, 
739338_5_13_14_4_5::None::were/VBD older/JJR than/IN men/NNS at/IN stroke/NN onset/NN and/CC more/JJR men/NNS had/VBD a/DT history/NN of/IN smoking/NN and/CC 
844136_3_12_13_24_25::None::targets/VBZ cancer/NN -/: specific/JJ expression/NN and/CC limits/NNS toxicity/NN ,/, is/VBZ a/DT new/JJ strategy/NN for/IN treating/VBG cancers/NNS ./. 
242622_9_12_13_17_19::people.cause_of_death.includes_causes_of_death::associated/VBN with/IN reduced/VBN cancer/NN -/: specific/JJ mortality/NN among/IN prostate/NN cancer/NN patients/NNS taking/VBG beta/NN 
87_87_12_13_41_45::None::cell/NN adhesion/NN to/TO vitronectin/NN ,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN alpha/NN v/LS beta/NN 5/CD shows/VBZ a/DT distinct/JJ 
2222_2222_23_24_17_18::None::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
1546_1546_8_11_5_6::POS_ACTION_MEMBER::inhibitory/JJ action/NN of/IN p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) 
888419_2_11_12_1_3::medicine.risk_factor.diseases::Noninvasive/JJ hepatic/JJ fibrosis/NN scores/NNS have/VBP been/VBN developed/VBN for/IN adult/JJ patients/NNS with/IN NAFLD/NN ;/: however/RB ,/, 
2131_2131_21_22_13_14::None::UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
1075_1075_22_23_8_9::POS_ACTION_PHOSPHORYLATE::as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
322602_4_2_3_3_5::None::The/DT most/RBS common/JJ heart/NN diseases/NNS were/VBD congenital/JJ heart/NN 
2181_2181_17_18_25_26::POS_ACTION_BIND::determine/VB how/WRB much/JJ profilin/NN is/VBZ bound/VBN to/TO its/PRP$ known/JJ ligands/NNS :/: actin/NN ,/, membrane/NN PIP/NN 
513_513_9_10_5_6::None::spliceosomal/JJ proteins/NNS (/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN 
1908_1908_5_6_19_20::None::results/NNS indicate/VBP that/IN TGFbeta/NN regulates/VBZ clusterin/NN gene/NN expression/NN through/IN an/DT AP-1/NN site/NN and/CC its/PRP$ cognate/JJ transcription/NN factor/NN AP-1/NN ,/, and/CC requires/VBZ 
242622_9_6_7_11_12::None::that/IN beta/NN -/: blocker/NN use/NN was/VBD associated/VBN with/IN reduced/VBN cancer/NN -/: specific/JJ 
549_549_9_10_11_12::POS_REG(-)_Change::was/VBD due/JJ to/TO msh6-F337A/NN sequestering/NN MSH2/NN and/CC preventing/VBG it/PRP 
2064_2064_28_29_49_50::None::,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
620873_8_10_11_46_47::None::a/DT murine/JJ antibody/NN adsorbed/VBD onto/IN silicone/NN oil/NN microdroplets/NNS ,/, glass/NN microparticles/NNS ,/, or/CC Alhydrogel/NNP (/( Registered/NNP )/) showed/VBD greater/JJR ADA/NN responses/NNS that/IN those/DT that/WDT received/VBD particle/NN -/: free/JJ mAb1/NN preparations/NNS ,/, and/CC responses/NNS were/VBD greater/JJR for/IN formulations/NNS containing/VBG lower/JJR doses/NNS of/IN antibody/NN ./. 
627_627_19_20_24_25::None::up-regulation/NN of/IN the/DT p27/NN cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CKI/NN )/) ,/, and/CC 
311702_2_22_23_28_29::None::significant/JJ risk/NN for/IN development/NN of/IN inflammation/NN -/: mediated/VBN acute/JJ cardiac/JJ events/NNS that/WDT may/MD 
490079_2_8_9_22_23::people.cause_of_death.includes_causes_of_death::statin/NN treatment/NN after/IN cancer/NN diagnosis/NN is/VBZ associated/VBN with/IN longer/JJR survival/NN in/IN those/DT with/IN pancreatic/JJ ductal/JJ adenocarcinoma/NN (/( PDAC/NN )/) ./. 
426927_1_6_7_29_30::None::of/IN a/DT hexane/NN extract/NN of/IN Lithospermum/NN erythrorhizon/NN root/NN (/( LEH/NN )/) was/VBD investigated/VBN in/IN Beagle/NNP dogs/NNS by/IN using/VBG single/JJ escalating/VBG doses/NNS ,/, two/CD -/: week/NN dose/NN range/NN -/: finding/NN ,/, 
1375_1375_7_8_14_15::None::for/IN polymerization/NN of/IN actin/NN is/VBZ increased/VBN by/IN the/DT addition/NN of/IN profilin/NN ./. 
322082_9_15_18_24_25::None::C/NN Patients/NNS with/IN chronic/JJ kidney/NN disease/NN demonstrated/VBD higher/JJR NGAL/NN levels/NNS compared/VBN with/IN subjects/NNS with/IN preserved/JJ renal/JJ 
29775_1_38_39_27_28::None::to/TO hold/VB major/JJ cultural/JJ significance/NN around/IN the/DT world/NN as/IN a/DT perceived/VBN biological/JJ indicator/NN of/IN virginity/NN ./. 
275947_1_7_8_16_18::None::of/IN coxsackie/NN and/CC adenovirus/NN receptor/NN (/( CAR/NN )/) and/CC alphanu/NN integrin/NN in/IN bladder/NN cancer/NN decreases/VBZ the/DT infection/NN 
846534_0_0_3_19_20::None::Deep/JJ Brain/NN Stimulation/NN (/( DBS/NN )/) has/VBZ been/VBN a/DT successful/JJ technique/NN for/IN alleviating/VBG Parkinson/NNP whosewhat/NN disease/NN (/( PD/NN )/) symptoms/NNS especially/RB for/IN whom/WP 
783888_0_22_24_13_14::None::IV/CD )/) (/( experimental/JJ group/NN )/) with/IN promethazine/NN 12.5/CD mg/NN IV/CD (/( control/NN group/NN )/) among/IN adult/JJ 
609_609_21_22_10_11::POS_ACTION_ENCODE::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN three/CD polypeptides/NNS encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
403501_2_24_25_22_23::None::transmission/NN in/IN southern/JJ Zambia/NNP using/VBG samples/NNS from/IN community/NN -/: 
467137_1_0_1_1_2::None::Varroa/NNP destructor/NN has/VBZ been/VBN a/DT 
1008_1008_4_5_10_11::POS_ACTION_ENCODE::of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB ,/, display/VBP 
199283_3_20_21_29_31::None::improving/VBG children/NNS whosewhat/JJ health/NN -/: related/JJ outcomes/NNS such/JJ as/IN perioperative/JJ anxiety/NN and/CC postoperative/JJ pain/NN ./. 
566758_0_14_17_5_7::medicine.disease.treatments::derived/VBN sedentary/JJ and/CC physical/JJ activity/NN time/NN in/IN overweight/JJ //: obese/JJ adults/NNS with/IN type/NN 2/CD diabetes/NN :/: cross/NN -/: 
609813_2_2_3_36_38::None::In/IN this/DT manuscript/NN ,/, we/PRP review/VBP microbial/JJ relationships/NNS with/IN plants/NNS ,/, outline/NN steps/NNS necessary/JJ to/TO develop/VB invasive/JJ species/NNS control/VBP strategies/NNS that/WDT are/VBP based/VBN on/IN those/DT relationships/NNS ,/, and/CC use/VB the/DT invasive/JJ plant/NN species/NNS Phragmites/NNP australis/NNP (/( common/JJ reed/NN )/) as/IN an/DT 
856_856_22_23_16_18::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN 
1069_1069_26_27_33_35::POS_ACTION_ATTACH::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) 
124453_5_32_33_28_29::None::antioxidant/JJ and/CC glyoxalase/NN systems/NNS ,/, and/CC thereby/RB demonstrated/VBD the/DT important/JJ role/NN 
243_243_32_35_0_2::POS_ACTION_MEDIATE::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) 
110315_0_7_8_1_2::None::Chronic/JJ inguinodynia/NN is/VBZ one/CD of/IN the/DT most/RBS frequent/JJ complications/NNS after/IN groin/NN 
74367_0_5_6_1_2::None::The/DT genus/NN Neisseria/NNP contains/VBZ two/CD pathogenic/JJ species/NNS of/IN prominant/JJ 
1901_1901_33_34_25_28::None::D1/NN ,/, the/DT cyclin-dependent/JJ kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, and/CC markers/NNS 
588835_2_7_8_31_32::None::development/NN of/IN this/DT feature/NN in/IN 56/CD fetal/JJ specimens/NNS from/IN 10/CD different/JJ families/NNS of/IN toothed/JJ (/( odontocete/NN )/) and/CC baleen/NN (/( mysticete/NN )/) whales/NNS ,/, using/VBG X/NN -/: ray/NN computed/VBD tomography/NN ./. 
848984_1_5_6_3_4::None::Methods/NNS :/: We/PRP calculated/VBD the/DT polygenic/JJ risk/NN score/NN based/VBN 
173839_13_0_1_7_8::None::Graphical/JJ abstractCompounds/NNS isolated/VBN from/IN Helichrysum/NNP species/NNS (/( Compositae/NNS )/) ./. 
265468_0_8_9_5_7::None::not/RB associated/VBN with/IN diverticular/JJ disease/NN -/: Analysis/NN of/IN 976/CD patients/NNS 
1337_1337_4_5_7_8::None::actin/NN cytoskeleton-associated/JJ protein/NN talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, 
578166_0_10_11_15_16::None::phenolic/JJ content/NN and/CC antioxidant/JJ capacity/NN of/IN almond/NN (/( Amygdalus/JJ communisL/NN ./. 
172257_0_6_8_19_20::None::the/DT Anaemia/NN in/IN Lung/NN Cancer/NN in/IN Spain/NNP study/NN was/VBD to/TO provide/VB epidemiological/JJ data/NNS and/CC treatment/NN of/IN anemia/NN in/IN 349/CD lung/NN 
248756_2_10_11_50_51::None::that/WDT have/VBP different/JJ numbers/NNS of/IN integuments/NNS :/: bitegmic/JJ species/NNS ,/, such/JJ as/IN Prunus/NNP armeniaca/NN (/( apricot/NN )/) and/CC Prunus/NNP persica/NN (/( peach/NN )/) ,/, and/CC unitegmic/JJ species/NNS ,/, such/JJ as/IN Prunus/NNP incisa/NNP ,/, analyzing/VBG the/DT expression/NN pattern/NN of/IN genes/NNS that/WDT are/VBP involved/VBN in/IN integument/NN development/NN in/IN Arabidopsis/NNP 
1061_1061_36_37_6_7::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
18729_3_15_16_11_12::medicine.medical_treatment.used_to_treat::drug/NN -/: resistant/JJ epilepsy/NN referred/VBN for/IN possible/JJ surgical/JJ intervention/NN ,/, we/PRP 
776_776_26_27_4_6::POS_ACTION_COLOCALIZE::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN 
372_372_28_29_9_10::None::virus/NN type/NN 1/CD UL8/NN protein/NN :/: effect/NN on/IN DNA/NN synthesis/NN and/CC ability/NN to/TO interact/VB with/IN and/CC influence/VB the/DT intracellular/JJ localization/NN of/IN the/DT UL5/NN and/CC UL52/NN proteins/NNS 
28653_0_23_24_25_26::medicine.drug_ingredient.active_moiety_of_drug::a/DT range/NN of/IN calcium/NN (/( Ca/NN )/) and/CC magnesium/NN 
1560_1560_39_40_13_14::None::acetylation/NN of/IN histone/NN H4/NN versus/CC acetylation/NN of/IN histone/NN H3/NN :/: with/IN the/DT purified/VBN acetylase/NN ,/, histone/NN H4/NN in/IN nucleosomes/NNS was/VBD acetylated/VBN to/TO a/DT much/RB greater/JJR extent/NN than/IN was/VBD histone/NN H3/NN ,/, whereas/IN the/DT 
1507_1507_17_18_19_20::POS_ACTION_BIND::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
1760_1760_5_6_1_3::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC 
162721_4_25_26_7_8::None::,/, ovaries/NNS from/IN newborn/JJ mice/NNS were/VBD collected/VBN and/CC cultured/VBN with/IN vehicle/NN (/( dimethyl/JJ sulfoxide/NN ,/, DMSO/NN )/) or/CC different/JJ doses/NNS of/IN BPA/NN (/( 0.1/CD ,/, 
2064_2064_8_9_49_50::None::of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
121583_0_38_39_6_7::None::believed/VBN that/IN the/DT archaeal/JJ ancestor/NN was/VBD hyperthermophilic/JJ ,/, but/CC during/IN archaeal/NN evolution/NN ,/, several/JJ lineages/NNS -/: including/VBG haloarchaea/NN and/CC their/PRP$ sister/NN methanogens/NNS ,/, the/DT Thaumarchaeota/NNP ,/, and/CC the/DT uncultured/JJ Marine/NNP Group/NNP II/NNP and/CC Marine/NNP Group/NNP III/NNP Euryarchaeota/NNP (/( MGII/NNP 
243_243_36_37_30_32::None::VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) ./. 
1526_1526_10_11_17_18::None::(/( BRSV/NN )/) phosphoprotein/NN (/( P/NN )/) with/IN nucleocapsid/NN (/( N/NN )/) and/CC large/JJ 
451755_0_3_4_19_20::None::Lesions/NNS in/IN the/DT corpus/NN callosum/NN (/( CC/NN )/) are/VBP important/JJ radiological/JJ clues/NNS to/TO the/DT diagnosis/NN of/IN multiple/JJ sclerosis/NN (/( MS/NN )/) ,/, but/CC 
1850_1850_2_3_2_3::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB 
25753_2_9_10_23_24::medicine.disease.treatments::may/MD lead/VB to/TO chronic/JJ kidney/NN disease/NN (/( CKD/NN )/) ,/, which/WDT can/MD progress/VB to/TO end/VB -/: stage/NN renal/JJ disease/NN (/( ESRD/NN 
1266_1266_2_3_4_5::None::Since/IN both/DT caldesmon/NN and/CC profilin/NN have/VBP been/VBN found/VBN 
392437_4_32_33_32_34::people.cause_of_death.includes_causes_of_death::the/DT prediction/NN of/IN cardiovascular/JJ events/NNS ./. 
1633_1633_25_26_25_26::None::identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: 
324774_0_8_9_4_5::None::of/IN nicotine/NN reward/NN system/NN can/MD potentially/RB influence/VB smoking/NN behavior/NN ./. 
590_590_29_31_21_22::None::ability/NN to/TO inhibit/VB p300/NN (/( and/CC the/DT highly/RB related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN 
204981_8_14_15_37_38::None::blockade/NN ,/, providing/VBG converging/VBG lines/NNS of/IN evidence/NN of/IN a/DT central/JJ importance/NN of/IN TLR4/NN Taken/VBN together/RB ,/, multiple/JJ lines/NNS of/IN evidence/NN converge/VBP to/TO raise/VB TLR4/NN as/IN a/DT promising/JJ therapeutic/JJ target/NN for/IN 
263791_3_12_13_38_39::None::of/IN inflammation/NN in/IN RA/NN patients/NNS ,/, particularly/RB those/DT with/IN seropositivity/NN ,/, increased/VBD inflammatory/JJ markers/NNS ,/, long/RB disease/NN duration/NN (/( &/CC gt/NN ;/: 10/CD years/NNS )/) ,/, and/CC //: or/CC extra/JJ -/: articular/JJ manifestations/NNS 
178116_0_6_7_14_15::biology.organism_classification.lower_classifications::regulatory/JJ subunits/NNS affecting/VBG plant/NN innate/JJ immunity/NN ,/, energy/NN metabolism/NN ,/, and/CC flowering/NN time/NN -/: -/: 
1726_1726_14_15_16_17::None::increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ 
435_435_4_5_15_16::POS_ACTION_BIND::domains/NNS of/IN the/DT PRP21/NN splicing/NN factor/NN are/VBP implicated/VBN in/IN the/DT binding/NN to/TO PRP9/NN and/CC PRP11/NN proteins/NNS and/CC are/VBP 
544721_14_10_11_15_16::None::of/IN palpable/JJ breast/NN masses/NNS had/VBD been/VBN used/VBN ,/, biopsy/NN could/MD have/VB been/VBN 
38537_2_9_10_13_14::medicine.drug.active_moieties::for/IN 153/CD -/: Samarium/NN (/( 153/CD -/: Sm/NN )/) was/VBD done/VBN 
365_365_8_10_12_15::None::that/IN the/DT G1/NN cyclin/NN D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB 
1248_1248_4_5_19_20::POS_ACTION_BIND::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB associated/VBN with/IN these/DT cadherins/NNS and/CC serve/VB to/TO 
1889_1889_7_8_0_2::POS_ACTION_BIND::TNF/NN receptor/NN death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN 
142199_1_0_1_19_20::None::As/IN an/DT intra/NN -/: erythrocytic/JJ and/CC endotheliotropic/JJ bacterium/NN ,/, B/NN henselae/NN causes/VBZ a/DT spectrum/NN of/IN symptomatology/NN ranging/VBG from/IN asymptomatic/JJ bacteremia/NN to/TO fever/NN ,/, 
29775_1_14_15_12_13::medicine.symptom.symptom_of::no/DT guarantee/NN that/IN rupture/NN or/CC bleeding/NN will/MD occur/VB at/IN 
739268_3_8_9_34_36::None::social/JJ withdrawal/NN or/CC potential/JJ liability/NN to/TO others/NNS (/( ie/FW ,/, depressive/JJ and/CC bipolar/JJ disorders/NNS ,/, social/JJ phobia/NN ,/, borderline/JJ personality/NN disorder/NN ,/, schizophrenia/NN and/CC other/JJ psychotic/JJ disorders/NNS ,/, certain/JJ drug/NN dependence/NN )/) were/VBD uniquely/RB 
91441_7_16_17_9_10::None::risk/NN for/IN cardiovascular/JJ events/NNS and/CC mortality/NN compared/VBN with/IN long/JJ -/: term/NN residents/NNS ,/, an/DT 
2222_2222_11_12_37_38::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
295529_1_9_10_11_12::None::the/DT RAF/NN family/NN activated/VBN by/IN mutation/NN in/IN human/JJ cancers/NNS 
520523_1_14_15_38_40::None::amygdali/NNS on/IN four/CD tree/NN species/NNS :/: almond/NN (/( Prunus/FW dulcis/FW )/) ,/, apricot/NN (/( Prunus/FW armeniaca/FW )/) ,/, peach/NN (/( Prunus/FW persica/FW )/) ,/, and/CC plum/NN (/( Prunus/NNP domestica/NNP )/) ./. 
259065_5_0_1_19_20::None::Correlations/NNS between/IN FFI/NNP -/: BPD/NN and/CC relevant/JJ measures/NNS of/IN psychiatric/JJ symptomatology/NN and/CC etiology/NN (/( eg/FW ,/, childhood/NN abuse/NN ,/, drug/NN use/NN ,/, depression/NN 
1341_1341_12_13_4_5::POS_ACTION_RELATE::alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS to/TO the/DT actin/NN cytoskeleton/NN ./. 
1508_1508_16_18_10_11::None::UL8/NN ,/, and/CC UL52/NN genes/NNS encode/VBP an/DT essential/JJ heterotrimeric/JJ DNA/NN helicase-primase/NN that/WDT is/VBZ responsible/JJ 
1341_1341_4_5_4_5::None::alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC 
108257_1_20_21_3_4::None::Expectations/NNS of/IN high/JJ pain/NN can/MD exacerbate/VB pain/NN while/IN expectations/NNS of/IN low/JJ pain/NN during/IN a/DT consistently/RB noxious/JJ stimulus/NN can/MD produce/VB significant/JJ reductions/NNS in/IN pain/NN ./. 
593_593_19_20_5_6::None::show/VBP that/IN the/DT Arp2/NN subunit/NN of/IN the/DT complex/NN can/MD be/VB chemically/RB cross-linked/VBN to/TO the/DT actin-binding/JJ site/NN of/IN profilin/NN ./. 
323444_1_11_12_15_16::None::ischaemia/NN secondary/JJ to/TO ventricular/JJ emboli/NNS in/IN a/DT patient/NN with/IN CS/NNP Laboratory/NNP 
1957_1957_10_11_10_11::POS_ACTION_COOCCUR::with/IN association/NN of/IN beta-catenin/NN with/IN EGF/NN receptor/NN 
489359_3_12_13_2_5::None::Symptom/NN of/IN obstructive/JJ sleep/NN apnea/NN syndrome/NN (/( OSAS/NN )/) was/VBD defined/VBN as/IN reporting/VBG both/CC snoring/VBG and/CC 
379000_0_7_8_4_5::medicine.disease.risk_factors::conduction/NN block/NN in/IN diabetic/JJ rats/NNS using/VBG high/JJ -/: intensity/NN focused/VBD 
252268_2_39_41_3_4::None::We/PRP describe/VBP a/DT cohort/NN of/IN rhesus/NN macaques/NNS displaying/VBG SIB/NNP as/IN adults/NNS ,/, in/IN which/WDT changes/NNS within/IN the/DT central/JJ nervous/JJ system/NN were/VBD associated/VBN with/IN the/DT SIB/NNP In/IN these/DT macaques/NNS ,/, increases/VBZ in/IN central/JJ nervous/JJ system/NN striatal/JJ dopamine/NN (/( DA/NN )/) receptor/NN binding/NN (/( BPND/NN )/) 
162721_4_5_6_12_13::None::our/PRP$ hypothesis/NN ,/, ovaries/NNS from/IN newborn/JJ mice/NNS were/VBD collected/VBN and/CC cultured/VBN with/IN vehicle/NN (/( 
93_93_6_7_28_29::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
988_988_15_16_26_27::POS_ACTION_SIMILAR::vinculin/NN and/CC the/DT beta-catenin/NN is/VBZ homologous/JJ to/TO human/JJ plakoglobin/NN and/CC the/DT Drosophila/NN gene/NN product/NN armadillo/NN ./. 
1061_1061_36_37_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
1728_1728_9_11_15_16::None::of/IN cytoskeletal/JJ and/CC sarcomeric/JJ actins/NNS is/VBZ regulated/VBN differently/RB by/IN profilin/NN in/IN the/DT developing/VBG 
106581_3_53_54_14_15::None::obesity/NN ,/, diabetes/NN type/NN II/CD ,/, metabolic/JJ syndrome/NN and/CC fatty/NN liver/NN ,/, critical/JJ evaluation/NN has/VBZ to/TO be/VB aimed/VBN at/IN reported/VBN benefits/NNS of/IN MD/NN in/IN such/JJ widely/RB metabolic/JJ diverse/JJ disorders/NNS as/IN cancer/NN ,/, pulmonary/JJ disease/NN and/CC cognition/NN defects/NNS ,/, including/VBG Alzheimer/NN disease/NN (/( Ref/NN ./. 
2222_2222_17_18_23_24::POS_ACTION_COLOCALIZE::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
1652_1652_45_46_31_32::POS_ACTION_RELATE::preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
490079_2_22_23_18_21::None::in/IN those/DT with/IN pancreatic/JJ ductal/JJ adenocarcinoma/NN (/( PDAC/NN )/) ./. 
246_246_3_4_11_13::POS_ACTION_ENCODE::A/DT 2.2-kb/JJ truncated/VBN NRP1/NN cDNA/NN was/VBD cloned/VBN that/IN encodes/VBZ a/DT 644-aa/JJ soluble/JJ NRP1/NN (/( sNRP1/NN )/) 
537465_2_25_26_10_11::None::of/IN T/NN cell/NN exhaustion/NN ,/, placing/VBG recent/JJ findings/NNS on/IN PD/NN -/: 1/CD blockade/NN therapies/NNS in/IN cancer/NN in/IN the/DT context/NN of/IN the/DT broader/JJR 
75337_1_10_11_19_21::medicine.medical_treatment.used_to_treat::adjuvant/JJ regimens/NNS with/IN trastuzumab/NN for/IN the/DT treatment/NN of/IN small/JJ HER2/NN -/: positive/JJ breast/NN cancer/NN in/IN routine/JJ clinical/JJ 
324774_0_8_9_2_3::medicine.drug.active_moieties::Components/NNP of/IN nicotine/NN reward/NN system/NN can/MD potentially/RB influence/VB smoking/NN behavior/NN ./. 
515_515_7_8_10_11::None::the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB 
984_984_33_34_0_1::None::MLL/NN is/VBZ fused/VBN in-frame/RB to/TO a/DT different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, and/CC transcriptional/JJ repression/NN domain/NN of/IN MLL/NN fused/VBN to/TO the/DT CREB/NN binding/NN domain/NN or/CC 
1486_1486_60_61_41_44::None::protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
71991_0_0_1_5_6::None::To/TO investigate/VB the/DT relationship/NN between/IN musculoskeletal/JJ disorders/NNS and/CC comorbid/NN 
20599_4_44_45_6_7::None::)/) was/VBD a/DT double/JJ -/: blind/JJ ,/, phase/NN 2/CD study/NN in/IN patients/NNS with/IN non/JJ -/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) randomized/VBN to/TO erlotinib/VB with/IN placebo/NN or/CC with/IN high/JJ or/CC low/JJ doses/NNS of/IN patritumab/NN ,/, a/DT monoclonal/JJ antibody/NN targeted/VBN against/IN human/JJ epidermal/JJ growth/NN factor/NN 
387871_6_2_3_25_26::None::Straw/NNP significantly/RB promoted/VBD CO2/NN and/CC N2O/NN emissions/NNS but/CC inhibited/VBD CH4/NN emission/NN ,/, while/IN interactions/NNS between/IN nematodes/NNS and/CC nitrogen/NN fertilization/NN on/IN emissions/NNS of/IN greenhouse/NN gases/NNS were/VBD obvious/JJ ./. 
736878_5_8_10_15_17::None::vaginitis/NN were/VBD unspecific/JJ bacterial/JJ infections/NNS (/( 42.4/CD %/NN )/) and/CC vaginal/JJ candidiasis/NN (/( 44.8/CD %/NN 
1843_1843_12_13_31_33::None::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD ,/, 
722712_7_1_2_19_21::None::Tumor/NN resection/NN after/IN preoperative/JJ drainage/NN was/VBD effective/JJ in/IN the/DT management/NN of/IN a/DT patient/NN with/IN dyspnea/NN induced/VBN by/IN a/DT giant/JJ ovarian/JJ tumor/NN ./. 
2013_2013_20_21_9_10::None::the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN verprolin/cofilin-like/JJ actin-regulatory/JJ domains/NNS ,/, but/CC no/DT specific/JJ actin/NN structure/NN regulated/VBN by/IN 
117943_0_12_13_21_22::medicine.medical_treatment.used_to_treat::coronary/JJ intervention/NN (/( PCI/NN )/) was/VBD reported/VBN to/TO promote/VB better/JJR coronary/JJ and/CC myocardial/JJ reperfusion/NN ./. 
196539_13_11_12_6_7::None::cardiovascular/JJ fitness/NN and/CC adverse/JJ cardiovascular/JJ outcomes/NNS may/MD be/VB modulated/VBN through/IN traditional/JJ cardiovascular/JJ 
754436_8_24_25_9_10::None::and/CC anxious/JJ participants/NNS reported/VBD problems/NNS with/IN their/PRP$ memory/NN and/CC concentration/NN compared/VBN with/IN fewer/JJR than/IN 8/CD %/NN of/IN medical/JJ controls/NNS ./. 
567_567_14_15_7_9::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS 
410019_0_0_1_16_17::None::Neo/SYM -/: adjuvant/JJ breast/NN cancer/NN clinical/JJ trials/NNS of/IN zoledronic/JJ acid/NN (/( ZOL/NN )/) have/VBP shown/VBN that/IN patients/NNS with/IN oestrogen/NN negative/JJ 
240_240_0_1_11_15::None::Neuropilin-1/NN is/VBZ also/RB expressed/VBN in/IN endothelial/JJ cells/NNS and/CC shown/VBN to/TO bind/VB vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 
822180_0_22_23_1_4::None::Autologous/JJ hematopoietic/JJ stem/NN cell/NN (/( HSC/NN )/) gene/NN therapy/NN for/IN sickle/JJ cell/NN disease/NN has/VBZ the/DT potential/JJ to/TO treat/VB this/DT illness/NN without/IN the/DT major/JJ immunological/JJ complications/NNS associated/VBN 
1337_1337_12_13_4_5::POS_ACTION_BIND::actin/NN cytoskeleton-associated/JJ protein/NN talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN ./. 
1534_1534_16_17_32_33::POS_ACTION_Change::and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
323444_1_33_34_12_13::None::secondary/JJ to/TO ventricular/JJ emboli/NNS in/IN a/DT patient/NN with/IN CS/NNP Laboratory/NNP evaluation/NN showed/VBD increased/VBN fibrinogen/NN and/CC factor/NN VIII/CD Previous/JJ studies/NNS showed/VBD that/IN venous/JJ thromboembolism/NN (/( VTE/NN )/) increases/VBZ in/IN 
284253_6_47_49_19_20::None::or/CC extended/VBN -/: release/NN formulations/NNS )/) ,/, levodopa/NN with/IN added/VBN -/: on/IN catechol/NN -/: O/SYM -/: methyltransferase/NN (/( COMT/NN )/) inhibitors/NNS ,/, levodopa/NN //: carbidopa/NN gel/NN for/IN intestinal/JJ infusion/NN ,/, some/DT dopamine/NN agonists/NNS (/( ropinirole/NN ,/, 
1160_1160_22_23_2_3::POS_ACTION_BIND::Purification/NN of/IN cofilin/NN ,/, a/DT 21,000/CD molecular/JJ weight/NN actin-binding/JJ protein/NN ,/, from/IN porcine/NN kidney/NN and/CC identification/NN of/IN the/DT cofilin-binding/JJ site/NN in/IN the/DT actin/NN sequence/NN ./. 
714308_1_18_19_9_10::None::potential/NN of/IN poly/NN ADP/NN -/: ribose/NN polymerase/NN (/( PARP/NN )/) inhibitors/NNS became/VBD apparent/JJ and/CC now/RB several/JJ 
28653_0_23_24_38_39::None::a/DT range/NN of/IN calcium/NN (/( Ca/NN )/) and/CC magnesium/NN (/( Mg/NN )/) ion/NN concentrations/NNS (/( 0.002/CD -/: 20/CD mM/NN )/) ./. 
350981_0_25_26_29_30::None::-/: Mood/NN )/) Syndrome/NN :/: A/DT Preliminary/JJ Report/NNP ./. 
179564_0_6_7_11_13::None::nullifies/VBZ feedback/NN -/: mediated/VBN resistance/NN to/TO erlotinib/NN in/IN lung/NN cancer/NN ./. 
1517_1517_4_5_15_16::POS_ACTION_Location::influence/NN of/IN these/DT collagens/NNS on/IN cell/NN morphology/NN and/CC the/DT distribution/NN pattern/NN of/IN actin/NN ,/, vimentin/NN ,/, talin/NN ,/, 
214_214_6_7_22_25::None::exchange/NN rapidly/RB between/IN actin/NN molecules/NNS ,/, low/JJ concentrations/NNS of/IN profilin/NN can/MD overcome/VB the/DT inhibitory/JJ effects/NNS of/IN high/JJ concentrations/NNS of/IN thymosin/NN beta/NN 4/CD on/IN the/DT nucleotide/NN 
1344_1344_17_18_6_7::None::these/DT three/CD mutant/JJ UL5/NN proteins/NNS to/TO form/VB specific/JJ interactions/NNS with/IN other/JJ members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN 
676724_2_7_11_31_33::None::non/JJ -/: obese/JJ type/NN 2/CD diabetes/NN mellitus/NN (/( D2/NN )/) was/VBD achieved/VBN by/IN a/DT combination/NN of/IN streptozotocin/NN and/CC nicotinamide/NN (/( NA/NN -/: STZ/NN )/) ,/, whereas/IN a/DT type/NN 1/CD -/: like/IN disease/NN 
1321_1321_23_24_26_27::None::potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
93_93_28_29_6_7::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
1889_1889_7_8_5_6::None::death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN 
99729_5_9_10_6_7::medicine.disease.risk_factors::-/: morbidities/NNS of/IN hypertension/NN ,/, previous/JJ stroke/NN or/CC transient/JJ ischemic/JJ 
1082_1082_38_39_35_36::POS_ACTION_BIND::depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ./. 
613549_0_6_7_4_5::None::radiotherapy/NN is/VBZ increasingly/RB common/JJ for/IN patients/NNS with/IN advanced/JJ breast/NN 
1386_1386_1_2_18_19::POS_ACTION_Assembly::The/DT UL8/NN component/NN of/IN the/DT herpes/NN simplex/NN virus/NN helicase-primase/JJ complex/NN stimulates/VBZ primer/NN synthesis/NN by/IN a/DT subassembly/NN of/IN the/DT UL5/NN and/CC UL52/NN components/NNS 
1761_1761_15_16_23_25::None::HPIV3/NN nucleocapsid/NN protein/NN N/NN ,/, the/DT phosphoprotein/NN P/NN ,/, and/CC the/DT polymerase/NN protein/NN L./NN 
1407_1407_21_22_15_16::None::polymerizability/NN of/IN the/DT actin/NN ,/, abolished/VBD its/PRP$ binding/NN to/TO profilin/NN ,/, and/CC filaments/NNS 
1017_1017_9_10_4_5::POS_ACTION_SIMILAR::in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP 
379222_0_7_8_18_20::None::congenital/JJ heart/NN disease/NN reduces/VBZ risk/NN of/IN death/NN from/IN cardiovascular/JJ compromise/NN prior/RB to/TO planned/VBN neonatal/JJ cardiac/JJ surgery/NN :/: a/DT meta/NN 
116331_2_3_4_7_8::medicine.disease.treatments::Cumulative/JJ incidence/NN of/IN anemia/NN 7/CD years/NNS post/JJ procedure/NN was/VBD 58/CD %/NN 
1061_1061_6_7_24_25::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
605_605_20_21_23_24::None::the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN genes/NNS ./. 
93_93_57_58_28_29::None::kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
1233_1233_30_31_28_29::None:::/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
405531_0_15_16_13_14::None::widely/RB used/VBN antiviral/JJ active/JJ against/IN influenza/NN A/NN virus/NN ./. 
14901_2_8_9_13_14::None::-/: to/TO -/: cysteine/NN substitutions/NNS on/IN alpha/NN -/: helix/NN regions/NNS of/IN 2/LS 
2030_2030_22_23_3_4::None::We/PRP conclude/VBP that/IN Aip1p/NN is/VBZ a/DT cofilin-associated/JJ protein/NN that/WDT enhances/VBZ the/DT filament/NN disassembly/NN activity/NN of/IN cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ actin/NN patches/NNS ./. 
1392_1392_8_9_1_2::None::The/DT cofilin/NN homology/NN sequence/NN is/VBZ critical/JJ for/IN stimulating/VBG actin/NN nucleation/NN with/IN the/DT 
1917_1917_27_28_14_15::None::profilin/NN gene/NN (/( PFY1/NN )/) and/CC examined/VBD the/DT consequences/NNS of/IN specific/JJ point/NN mutations/NNS on/IN growth/NN and/CC actin/NN organization/NN ./. 
441567_0_16_17_0_1::None::To/TO describe/VB the/DT use/NN of/IN combined/JJ ursodeoxycholic/JJ acid/NN (/( UDCA/NN )/) and/CC rifampicin/NN treatment/NN in/IN intrahepatic/JJ cholestasis/NN of/IN pregnancy/NN (/( 
489359_3_7_8_14_15::medicine.disease.symptoms::apnea/NN syndrome/NN (/( OSAS/NN )/) was/VBD defined/VBN as/IN reporting/VBG both/CC snoring/VBG and/CC daytime/JJ sleepiness/NN 
350838_1_2_3_2_4::biology.organism_classification.lower_classifications::The/DT protozoan/NN Entamoeba/FW histolytica/NN ,/, which/WDT is/VBZ 
373109_2_45_46_28_31::None::proteins/NNS such/JJ as/IN human/JJ serum/NN albumin/NN (/( HSA/NN )/) and/CC human/JJ immunoglobulin/NN G/NN (/( hIgG/NN )/) adsorbed/VBN on/IN PS/NNP substrate/JJ surfaces/NNS were/VBD markedly/RB greater/JJR 
627089_4_22_23_6_7::None::diabetic/JJ vasculopathy/NN ,/, nephropathy/NN ,/, chronic/JJ hypertension/NN ,/, preeclampsia/NN ,/, preterm/NN delivery/NN ,/, and/CC fetal/JJ growth/NN restriction/NN are/VBP frequently/RB observed/VBN ./. 
582775_5_3_5_108_110::None::Short/JJ -/: term/NN adverse/JJ events/NNS occurred/VBD in/IN 20.15/CD %/NN (/( 81/CD //: 402/CD )/) ,/, including/VBG rash/NN (/( 3.5/CD %/NN ;/: 14/CD //: 402/CD )/) ,/, pruritus/NN (/( 1.2/CD %/NN ;/: 5/CD //: 402/CD )/) ,/, nausea/NN (/( 2.2/CD %/NN ;/: 9/CD //: 402/CD )/) ,/, headache/NN (/( 0.7/CD %/NN ;/: 3/CD //: 402/CD )/) ,/, skin/NN allergies/NNS (/( 4.0/CD %/NN ;/: 16/CD //: 402/CD )/) ,/, fever/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, palpitations/NNS (/( 3.0/CD %/NN ;/: 12/CD //: 402/CD )/) ,/, dyspnea/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, chest/NN pain/NN (/( 0.2/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, abdominal/JJ pain/NN (/( 1.0/CD %/NN 
1861_1861_10_11_12_13::POS_ACTION_MUTUALCOMPLEX::containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
159_159_31_33_33_34::POS_ACTION_MEMBER::the/DT small/JJ soluble/JJ actin-binding/JJ protein/NN profilin/NN ./. 
445433_1_6_7_30_31::medicine.drug_ingredient.active_moiety_of_drug::neuronal/JJ pathway/NN for/IN histamine/NN -/: induced/VBN itch/NN in/IN the/DT peripheral/JJ and/CC central/JJ nervous/JJ system/NN has/VBZ been/VBN described/VBN in/IN animals/NNS and/CC humans/NNS ,/, and/CC recently/RB several/JJ non/JJ -/: histaminergic/JJ pathways/NNS for/IN itch/NN 
1779_1779_5_7_29_30::None::of/IN pyrene-labeled/JJ rabbit/NN skeletal/JJ actin/NN with/IN human/JJ profilin/NN yielded/VBD a/DT Kd/NN of/IN 2.8/CD microM/NN ,/, similar/JJ to/TO the/DT Kd/NN of/IN 2.0/CD microM/NN for/IN the/DT interaction/NN between/IN yeast/NN profilin/NN and/CC pyrene-labeled/JJ yeast/NN 
28_28_0_2_11_13::None::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN define/VBP a/DT family/NN of/IN actin-binding/JJ proteins/NNS essential/JJ for/IN the/DT 
776_776_26_27_24_26::None::the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN 
322394_2_27_28_14_15::medicine.drug_ingredient.active_moiety_of_drug::of/IN ACR/NN on/IN dopamine/NN and/CC its/PRP$ metabolite/NN levels/NNS ,/, dopamine/NN transport/NN and/CC metabolic/JJ gene/NN expression/NN in/IN dopaminergic/JJ neurons/NNS ./. 
516597_4_8_9_5_6::people.cause_of_death.includes_causes_of_death::647/CD children/NNS with/IN severe/JJ isolated/VBN head/NN injuries/NNS :/: 337/CD from/IN 
38537_2_18_19_26_27::None::was/VBD done/VBN by/IN SPECT/NNP -/: CT/NN images/NNS coupled/VBN GATE/NNP Monte/NNP Carlo/NNP package/NN for/IN internal/JJ dosimetry/NN 
745266_0_23_24_13_14::None::type/NN -/: 2/CD diabetes/NN ;/: however/RB ,/, the/DT impact/NN of/IN different/JJ treatment/NN escalation/NN strategies/NNS after/IN metformin/JJ failure/NN 
513_513_7_8_9_10::POS_ACTION_INTERACT::(/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN 
135795_9_19_20_6_7::None::The/DT IgG2a/NN //: IgG1/NN antibody/NN response/NN in/IN L/NN tropica/NN infection/NN is/VBZ higher/JJR than/IN that/DT in/IN L/NN major/JJ infection/NN ./. 
1534_1534_32_33_9_10::None::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
1024_1024_39_40_39_40::None::for/IN interaction/NN with/IN CUS1/NN ./. 
76365_0_22_23_43_44::None::with/IN ,/, by/IN order/NN of/IN frequency/NN ,/, phobic/JJ disorders/NNS and/CC generalized/VBN anxiety/NN disorder/NN rank/NN ahead/RB of/IN panic/NN disorders/NNS ,/, obsessive/JJ -/: compulsive/JJ disorder/NN or/CC post/NN -/: traumatic/JJ stress/NN 
139515_2_30_31_27_28::None::HSP/NN In/IN this/DT patient/NN ,/, the/DT diagnosis/NN of/IN HSP/NN was/VBD 
90241_0_8_9_14_15::None::,/, afatinib/NN significantly/RB improved/VBD progression/NN -/: free/JJ survival/NN (/( PFS/NN )/) versus/CC cisplatin/NN 
93_93_11_12_28_29::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
1069_1069_21_22_46_47::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
1061_1061_25_27_24_25::POS_ACTION_MEMBER::binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
214618_2_19_20_15_16::medicine.disease.symptoms::the/DT diagnosis/NN of/IN acute/JJ MI/NNP However/RB ,/, high/JJ sensitivity/NN troponin/NN assays/NNS 
2057_2057_12_13_3_4::None::We/PRP find/VBP that/IN profilin/NN contributes/VBZ in/IN several/JJ ways/NNS to/TO Cdc42-induced/JJ nucleation/NN of/IN actin/NN filaments/NNS in/IN high/JJ 
33757_12_7_8_25_26::None::while/IN user/NN -/: friendly/JJ platform/NN using/VBG multi/NNS -/: parametric/JJ MRI/NNP combined/VBN with/IN supervised/JJ learning/VBG to/TO be/VB able/JJ to/TO accurately/RB detect/VB cancer/NN foci/NNS and/CC its/PRP$ aggressiveness/NN 
406599_4_7_8_13_14::None::human/JJ ovarian/JJ cancer/NN cells/NNS proliferate/VBP better/JJR if/IN exposed/VBN to/TO cell/NN debris/NN harvested/VBN from/IN 
121781_2_0_1_5_7::None::Diabetes/NNP is/VBZ associated/VBN with/IN various/JJ nervous/JJ disorders/NNS ,/, such/JJ as/IN 
9_9_17_18_12_13::POS_ACTION_CROSS-LINK::acid/NN 364/CD of/IN actin/NN and/CC lysine/NN 115/CD of/IN profilin/NN ./. 
1711_1711_7_8_16_19::None::predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN 
93_93_54_55_22_23::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
275933_7_31_33_15_16::None::6/CD categories/NNS become/VBP apparent/JJ on/IN the/DT basis/NN of/IN biology/NN and/CC clinical/JJ presentation/NN :/: (/( 1/LS )/) genetic/JJ instability/NN //: DNA/NN repair/NN syndromes/NNS ,/, (/( 
1380_1380_43_44_36_37::None::,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN (/( Machesky/NNP et/FW 
1094_1094_16_17_22_23::None::,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT eIF3/NN complex/NN ./. 
28939_0_19_20_0_1::None::Acute/JJ psychosis/NN developed/VBN in/IN an/DT elderly/JJ patient/NN with/IN Parkinson/NNPS disease/NN and/CC she/PRP was/VBD admitted/VBN and/CC treated/VBN with/IN quetiapine/NN (/( Seroquel/NN )/) ./. 
459829_1_17_18_7_8::None::the/DT surface/NN of/IN mesoporous/JJ TiO/NN (/( 2/CD )/) by/IN the/DT decomposition/NN of/IN magnesium/NN acetate/NN and/CC ,/, therefore/RB 
1638_1638_8_10_17_20::POS_ACTION_BIND::to/TO authentic/JJ human/JJ platelet/NN profilin/NN based/VBN on/IN the/DT measured/VBN Kd/NN for/IN rabbit/NN skeletal/JJ muscle/NN actin/NN ./. 
121781_2_18_19_10_12::None::,/, such/JJ as/IN cognitive/JJ deficits/NNS ,/, depression/NN ,/, and/CC Alzheimer/NN whosewhat/NN disease/NN ,/, and/CC that/DT 
776_776_29_30_28_29::None::protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
1289_1289_13_14_7_8::None::nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN bovine/JJ 
444311_5_16_17_18_19::medicine.drug.active_moieties::storage/NN of/IN ferric/JJ iron/NN (/( Fe/NNP (/( 3/CD +/CC 
1652_1652_43_44_20_21::None::with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, 
93_93_11_12_54_55::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
801582_5_13_14_23_24::medicine.disease.treatments::center/NN of/IN the/DT burn/VBP wound/NN ,/, the/DT burn/VBP wound/NN edge/NN ,/, and/CC the/DT graft/NN donor/NN site/NN in/IN 
365_365_12_15_8_10::None::that/IN the/DT G1/NN cyclin/NN D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB 
2414_0_22_23_15_17::medicine.risk_factor.diseases::for/IN Incident/NNP Atherosclerotic/JJ Cardiovascular/NNP Disease/NNP Beyond/NNP Ambulatory/NNP Blood/NNP Pressure/NN in/IN Elderly/NNP Men/NNP 
2222_2222_37_38_17_18::NEG_ACTION_COLOCALIZE::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
367_367_32_33_5_7::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
1667_1667_5_6_3_4::None::The/DT role/NN of/IN profilin/NN in/IN actin/NN polymerization/NN and/CC nucleotide/NN 
686_686_23_24_33_34::None::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
2146_2146_14_15_9_10::None::LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
439403_7_34_35_18_20::None::life/NN ,/, more/JJR sleep/NN problems/NNS ,/, and/CC greater/JJR functional/JJ disability/NN than/IN nondepressed/JJ patients/NNS ;/: the/DT two/CD groups/NNS did/VBD not/RB differ/VB in/IN pain/NN severity/NN 
250070_2_39_40_44_45::None::)/) ,/, and/CC estimated/VBN glomerular/JJ filtration/NN rate/NN (/( eGFR/NN )/) ,/, using/VBG 
248192_9_37_38_10_14::None:::/: 40/CD %/NN benign/JJ paroxysmal/JJ positional/JJ vertigo/NN (/( BPPV/NN )/) ,/, 23/CD %/NN suspicious/JJ of/IN central/JJ causes/NNS ,/, 18/CD %/NN undiagnosed/JJ ,/, 15/CD %/NN Meniere/NNP disease/NN ,/, and/CC 4/CD %/NN vestibular/JJ neuronitis/NN ./. 
991_991_20_21_15_16::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
1940_1940_11_12_13_14::None::signal-regulated/JJ protein/NN kinases/NNS ERK1/NN and/CC ERK2/NN ,/, induction/NN of/IN 
2222_2222_37_38_39_40::None::contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
125255_5_49_50_18_19::None::as/IN hypertension/NN ,/, hypertrophy/NN ,/, diabetes/NN ,/, hypercholesterolemia/NN ,/, ischemia/NN ,/, post/NN -/: myocardial/JJ infarction/NN remodeling/NN or/CC heart/NN failure/NN ,/, and/CC post/NN -/: translationally/RB connexins/NNS are/VBP modified/VBN by/IN phosphorylation/NN //: de/FW -/: phosphorylation/NN and/CC nitros/NNS (/( yl/NN )/) 
1711_1711_19_20_5_6::None::of/IN the/DT predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN ,/, 
957_957_8_11_23_24::POS_REG(0)_Assembly::mutation/NN in/IN the/DT myosin/NN heavy/JJ chain/NN (/( Myh/NN )/) predicted/VBD to/TO interfere/VB strongly/RB with/IN myosin/NN 's/POS binding/NN to/TO actin/NN was/VBD designed/VBN and/CC 
1234_1234_17_18_15_16::None::used/VBN to/TO extract/VB gelsolin/NN and/CC profilin/NN ,/, respectively/RB ,/, 
1234_1234_17_18_34_35::None::extract/VB gelsolin/NN and/CC profilin/NN ,/, respectively/RB ,/, from/IN EGTA-containing/JJ platelet/NN extracts/NNS and/CC determine/VB the/DT proportion/NN of/IN these/DT molecules/NNS bound/VBD to/TO actin/NN with/IN sufficient/JJ affinity/NN 
1373_1373_4_5_13_14::None::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
201_201_20_21_4_5::None::two-hybrid-based/JJ approach/NN using/VBG cofilin/NN and/CC actin/NN mutants/NNS identified/VBD residues/NNS necessary/JJ for/IN the/DT interaction/NN of/IN actin/NN ,/, cofilin/NN ,/, and/CC Aip1p/NN in/IN an/DT apparent/JJ 
781998_2_17_18_23_24::None::of/IN short/JJ -/: term/NN insulin/NN -/: based/VBN therapy/NN has/VBZ emerged/VBN as/IN a/DT strategy/NN 
196539_13_4_5_11_12::None::association/NN between/IN cardiovascular/JJ fitness/NN and/CC adverse/JJ cardiovascular/JJ outcomes/NNS may/MD be/VB modulated/VBN through/IN traditional/JJ cardiovascular/JJ 
1174_1174_11_14_27_28::POS_ACTION_BIND::N-terminal/JJ fragment/NN of/IN myosin/NN heavy/JJ chain/NN ,/, which/WDT contains/VBZ the/DT `/`` consensus/NN '/'' ATP/NN binding/NN site/NN ,/, binds/VBZ to/TO actin/NN in/IN an/DT ATP-sensitive/JJ 
723866_2_3_4_1_2::None::(/( Reduviidae/NNP :/: Emesinae/NNP )/) is/VBZ described/VBN 
1373_1373_11_12_13_14::None::independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
2222_2222_21_22_11_12::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
391631_1_23_24_21_22::medicine.drug.active_moieties::polyclonal/JJ antibodies/NNS (/( IgG3/NN and/CC IgG4/NN )/) ./. 
919_919_12_13_9_10::POS_ACTION_BIND::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, 
367_367_26_27_0_2::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
1798_1798_41_42_24_26::None::expression/NN of/IN a/DT rac-1/NN GAP/NN alters/VBZ the/DT assembly/NN of/IN integrin/NN receptors/NNS ,/, actin/NN and/CC cytoskeletal/JJ proteins/NNS such/JJ as/IN vinculin/NN and/CC talin/NN ./. 
515_515_5_6_7_8::None::work/NN ,/, the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN 
1507_1507_19_20_17_18::None::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
230298_6_0_1_3_6::None::Management/NN strategies/NNS include/VBP cognitive/JJ behavioral/JJ therapy/NN ,/, mindfulness/NN -/: 
284647_4_24_25_35_36::medicine.risk_factor.diseases::disease/NN rates/NNS in/IN infants/NNS is/VBZ encouraging/JJ ,/, anticipating/VBG the/DT possibility/NN to/TO at/IN last/JJ control/NN pertussis/NN in/IN this/DT vulnerable/JJ 
1457_1457_56_57_34_35::POS_REG(-)_ASSEMBLE::predominantly/RB as/IN an/DT actin/NN monomer-binding/JJ protein/NN ;/: (/( 2/LS )/) profilin/NN II/CD regulates/VBZ ,/, or/CC is/VBZ regulated/VBN by/IN ,/, PIP2/NN ;/: and/CC (/( 3/LS )/) actobindin/NN inhibits/VBZ nucleation/NN of/IN 
499291_35_3_4_20_21::None::The/DT phenotypic/JJ and/CC metabolic/JJ presentations/NNS of/IN women/NNS with/IN PCOS/NN appear/VBP to/TO be/VB significantly/RB different/JJ depending/VBG on/IN ethnicity/NN ,/, obesity/NN and/CC age/NN ./. 
99729_5_4_5_15_18::None::with/IN co/NN -/: morbidities/NNS of/IN hypertension/NN ,/, previous/JJ stroke/NN or/CC transient/JJ ischemic/JJ attack/NN ,/, peripheral/JJ arterial/JJ disease/NN ,/, myocardial/JJ infarction/NN 
882908_0_10_11_1_3::None::Complete/JJ mitochondrial/JJ genome/NN of/IN the/DT Sharpnose/NN stingray/NN Himantura/NN gerrardi/NNS (/( Myliobatiformes/NNS :/: Dasyatidae/NNP )/) 
393131_1_25_26_24_26::medicine.drug.active_moieties::production/NN of/IN hydrogen/NN peroxide/NN to/TO damage/VB host/NN 
556_556_7_9_24_25::None::to/TO be/VB a/DT nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ protein/NN based/VBN on/IN the/DT lack/NN of/IN reactivity/NN of/IN antigravin/NN with/IN these/DT polypeptides/NNS 
22_22_36_37_54_55::None::)/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT motile/JJ force/NN and/CC (/( 4/LS )/) acceleration/NN of/IN movement/NN mediated/VBN by/IN the/DT host/NN protein/NN profilin/NN ./. 
1169_1169_10_11_41_42::None::to/TO regulate/VB the/DT actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD found/VBN to/TO possess/VB short/JJ peptide/NN motifs/NNS homologous/JJ to/TO one/CD part/NN of/IN verprolin/NN ./. 
512613_1_22_23_32_34::None::)/) that/WDT are/VBP central/JJ to/TO these/DT disorders/NNS ;/: more/JJR moderately/RB with/IN symptoms/NNS of/IN social/JJ phobia/NN ,/, affective/JJ lability/NN 
1180_1180_17_18_17_18::POS_ACTION_BIND::polymerization/NN from/IN the/DT actin/NN :/: thymosin/NN beta4/NN 
210955_0_29_30_11_12::None::(/( IgG4/NN -/: RD/NN )/) is/VBZ characterized/VBN by/IN elevated/JJ serum/NN IgG4/NN and/CC infiltration/NN of/IN IgG4/NN (/( +/CC )/) plasma/NN cells/NNS into/IN multiple/JJ organs/NNS ./. 
378211_8_35_36_20_21::None::-/: 6/CD and/CC TNF/NN -/: alpha/NN )/) release/NN from/IN PBMCs/NNS in/IN non/JJ -/: smokers/NNS ,/, smokers/NNS and/CC COPD/NN patients/NNS ./. 
1379_1379_11_12_27_28::POS_ACTION_BIND::of/IN the/DT human/JJ RAD52/NN protein/NN shows/VBZ no/DT homology/NN with/IN the/DT yeast/NN RAD52/NN protein/NN ,/, indicating/VBG that/IN the/DT interaction/NN between/IN RAD51/NN and/CC RAD52/NN is/VBZ 
1793_1793_16_17_4_5::POS_ACTION_CONTROL::viscoelasticity/NN of/IN entangled/JJ actin/NN networks/NNS :/: the/DT influence/NN of/IN defects/NNS and/CC modulation/NN by/IN talin/NN and/CC vinculin/NN ./. 
350850_8_31_32_3_5::None::With/IN respect/NN to/TO categorical/JJ variables/NNS ,/, a/DT significant/JJ association/NN was/VBD found/VBN for/IN the/DT presence/NN of/IN diabetes/NN (/( P/NN =/JJ 0.006/CD )/) ,/, hypertension/NN (/( P/NN &/CC lt/NN ;/: 0.001/CD )/) ,/, facial/JJ lipodystrophy/NN (/( P/NN 
161_161_0_1_17_18::POS_ACTION_Assembly::Armadillo/NN (/( Arm/NN )/) repeat/NN 10/CD to/TO the/DT COOH/NN terminus/NN of/IN beta-catenin/NN is/VBZ involved/VBN in/IN binding/VBG to/TO CBP/NN ,/, whereas/IN beta-catenin/NN 
206273_1_27_28_26_27::medicine.disease.symptoms::patients/NNS with/IN uremic/JJ accelerated/VBN atherosclerosis/NN (/( UAAS/NN )/) 
1372_1372_31_32_1_2::None::The/DT APC/NN binding/NN site/NN on/IN beta-catenin/NN may/MD be/VB discontinuous/JJ since/IN neither/CC the/DT carboxyl/NN -/: nor/CC amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB with/IN APC/NN ,/, although/IN the/DT amino-terminal/JJ half/NN independently/RB binds/VBZ alpha-catenin/NN ./. 
685_685_6_7_30_31::POS_ACTION_COPRECIPITATE::labeled/VBN proteins/NNS with/IN HECD-1/NN revealed/VBD three/CD bands/NNS corresponding/VBG to/TO E-cadherin/NN ,/, alpha-catenin/NN ,/, and/CC gamma-catenin/NN and/CC a/DT 79-kDa/JJ band/NN which/WDT was/VBD apparently/RB smaller/JJR than/IN that/DT of/IN normal/JJ beta-catenin/NN ,/, indicating/VBG truncated/VBN 
235710_2_1_2_17_18::None::To/TO investigate/VB the/DT adjuvant/JJ cabergoline/NN therapy/NN effects/NNS on/IN menstrual/JJ irregularity/NN and/CC androgen/NN system/NN in/IN PCOS/NN women/NNS with/IN hyperprolactinemia/NN ./. 
1810_1810_20_21_2_3::POS_ACTION_CORELATE::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR regulatory/JJ roles/NNS ,/, as/IN it/PRP was/VBD shown/VBN that/IN their/PRP$ tyrosine/NN phosphorylation/NN correlated/VBD with/IN modified/VBN cadherin/NN activities/NNS ./. 
1843_1843_19_20_31_33::None::that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD ,/, 
596699_0_5_6_12_13::None::hypertension/NN are/VBP chronic/JJ conditions/NNS that/WDT are/VBP growing/VBG in/IN prevalence/NN as/IN major/JJ causal/JJ factors/NNS of/IN 
1686_1686_15_18_25_28::POS_ACTION_INTERACT::domains/NNS of/IN all/DT myosin/JJ heavy/JJ chains/NNS ,/, and/CC light/JJ chains/NNS at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN 
2107_2107_39_40_24_26::None::bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
1526_1526_10_11_12_13::None::(/( BRSV/NN )/) phosphoprotein/NN (/( P/NN )/) with/IN nucleocapsid/NN 
345914_6_24_25_1_3::None::Duodenal/JJ gene/NN expression/NN studies/NNS related/VBN to/TO the/DT absorption/NN of/IN iron/NN from/IN gamma/NN -/: Fe2O3/NN nanoparticles/NNS indicate/VBP the/DT enhancement/NN of/IN a/DT ferric/JJ over/IN ferrous/JJ pathway/NN supporting/VBG the/DT role/NN of/IN 
129749_7_4_5_12_13::None::hypothyroidism/NN risk/NN for/IN DM/NN was/VBD prominent/JJ only/RB upon/IN statin/NN use/NN (/( RR/NN 1.94/CD [/( 1.13/CD 
14901_2_8_9_18_19::medicine.drug_ingredient.active_moiety_of_drug::-/: to/TO -/: cysteine/NN substitutions/NNS on/IN alpha/NN -/: helix/NN regions/NNS of/IN 2/LS -/: Cys/NN Prx/NN A/NN in/IN 
533311_1_6_7_20_22::None::to/TO identify/VB the/DT depression/NN and/CC anxiety/NN state/NN of/IN diabetic/JJ adolescents/NNS and/CC its/PRP$ impact/NN on/IN the/DT management/NN of/IN diabetes/NN mellitus/NN (/( DM/NN )/) 
1395_1395_26_27_12_13::POS_REG(-)_Assembly::plant/NN and/CC animal/NN actins/NNS can/MD be/VB blocked/VBN by/IN profilin-specific/JJ antibodies/NNS that/WDT react/VBP with/IN different/JJ epitopes/NNS of/IN birch/NN profilin/NN ./. 
231380_9_5_6_10_11::None::current/JJ results/NNS on/IN bone/NN properties/NNS of/IN 16/CD -/: week/NN old/JJ female/JJ M3R/NN 
4599_8_9_10_36_37::None::transmitted/VBN to/TO the/DT future/JJ male/NN offspring/NN by/IN ICSI/NN ,/, it/PRP will/MD be/VB essential/JJ to/TO counsel/NN the/DT couples/NNS for/IN the/DT transmission/NN of/IN the/DT genetic/JJ defect/NN in/IN the/DT male/JJ offspring/NN born/VBN after/IN assisted/JJ reproduction/NN and/CC the/DT 
1486_1486_24_25_4_5::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN 
149017_0_18_20_26_29::None::characterized/VBN by/IN progressive/JJ cognitive/JJ impairment/NN ,/, dementia/NN and/CC atrophy/NN of/IN the/DT central/JJ nervous/JJ system/NN ./. 
326118_0_39_40_51_52::medicine.medical_treatment.used_to_treat::22/CD mg/NN )/) sumatriptan/NN powder/NN ,/, vs/CC 100/CD mg/NN oral/JJ sumatriptan/NN for/IN acute/JJ treatment/NN of/IN migraine/NN in/IN a/DT double/JJ 
343970_4_37_38_7_9::None::the/DT growth/NN of/IN planktonic/JJ algae/NN in/IN different/JJ sections/NNS :/: From/IN the/DT point/NN of/IN the/DT whole/JJ lake/NN ,/, CHL/NN was/VBD significantly/RB correlated/VBN with/IN TP/NN ,/, TN/NN ,/, total/JJ dissolved/VBN nitrogen/NN (/( TDN/NN )/) and/CC nitrate/JJ nitrogen/NN (/( NO3/NN 
758270_7_2_3_24_25::None::In/IN chronic/JJ cigarette/NN smoke/NN related/JJ lung/NN disease/NN ,/, the/DT PGP/NN pathway/NN can/MD become/VB a/DT self/NN -/: propagating/VBG cycle/NN of/IN inflammation/NN through/IN cigarette/NN -/: smoke/NN mediated/VBD inhibition/NN of/IN leukotriene/NN 
93_93_4_5_50_51::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
204981_8_20_21_11_12::None::of/IN pharmacological/JJ TLR4/NN blockade/NN ,/, providing/VBG converging/VBG lines/NNS of/IN evidence/NN of/IN a/DT central/JJ importance/NN of/IN TLR4/NN 
154535_13_10_11_1_2::None::Our/PRP$ data/NNS suggest/VBP a/DT complex/JJ interplay/NN among/IN insulin/NN resistance/NN ,/, obesity/NN ,/, and/CC depression/NN 
429131_8_32_33_24_27::None::R/NN -/: induced/VBN apoptotic/JJ cell/NN death/NN ,/, the/DT PI3K/NN //: Akt/NN pathway/NN of/IN EGCG/NN may/MD 
243_243_27_28_32_35::None::coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) 
1344_1344_22_23_17_18::None::members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, indicates/VBZ that/IN 
2107_2107_9_10_5_7::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS 
1052_1052_37_38_34_35::None::to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
4599_8_5_6_28_30::None::deletions/NNS can/MD be/VB vertically/RB transmitted/VBN to/TO the/DT future/JJ male/NN offspring/NN by/IN ICSI/NN ,/, it/PRP will/MD be/VB essential/JJ to/TO counsel/NN the/DT couples/NNS for/IN the/DT transmission/NN of/IN the/DT genetic/JJ defect/NN in/IN the/DT male/JJ 
1234_1234_34_35_15_16::None::used/VBN to/TO extract/VB gelsolin/NN and/CC profilin/NN ,/, respectively/RB ,/, from/IN EGTA-containing/JJ platelet/NN extracts/NNS and/CC determine/VB the/DT proportion/NN of/IN these/DT molecules/NNS bound/VBD to/TO actin/NN with/IN sufficient/JJ affinity/NN 
93665_0_19_21_1_3::None::In/IN colorectal/JJ cancer/NN (/( CRC/NN )/) ,/, metastatic/JJ spread/NN is/VBZ supposed/VBN to/TO be/VB mainly/RB driven/VBN by/IN tumor/NN cells/NNS with/IN stem/NN cell/NN features/NNS ./. 
339123_0_10_11_13_14::None::with/IN a/DT ''/'' Naked/JJ ''/'' Triphenylsilyl/NN Anion/NN by/IN Hydrogenolysis/NN of/IN 
687548_0_0_1_10_11::None::Diabetic/NNP polyneuropathy/NN (/( DPN/NN )/) is/VBZ a/DT devastating/JJ complication/NN of/IN diabetes/NN ./. 
142199_1_4_5_7_8::None::an/DT intra/NN -/: erythrocytic/JJ and/CC endotheliotropic/JJ bacterium/NN ,/, B/NN henselae/NN 
1758_1758_22_23_17_18::None::apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ,/, and/CC TNF-induced/JJ 
566931_0_4_5_30_31::medicine.disease.treatments::the/DT treatment/NN of/IN polymyositis/NN (/( PM/NN )/) and/CC dermatomyositis/NN (/( DM/NN )/) ,/, muscle/NN inflammation/NN and/CC underlying/VBG autoimmunity/NN need/NN to/TO be/VB suppressed/VBN promptly/RB ;/: however/RB ,/, catabolic/JJ effects/NNS of/IN corticosteroids/NNS such/JJ as/IN myopathy/NN 
1248_1248_4_5_12_13::POS_ACTION_MEMBER::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB 
1098_1098_11_12_16_17::POS_ACTION_STIMULATE::binding/NN domain/NN of/IN CBP/NN stimulates/VBZ transcription/NN from/IN the/DT PEPCK/NN gene/NN promoter/NN ./. 
1164_1164_5_6_33_34::None::the/DT appearance/NN of/IN X22/NN banding/NN in/IN primary/JJ cultures/NNS of/IN myotubes/NNS indicates/VBZ that/IN it/PRP precedes/VBZ that/IN of/IN other/JJ myofibrillar/NN proteins/NNS and/CC that/IN assembly/NN takes/VBZ place/NN in/IN the/DT following/VBG order/NN :/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ 
776_776_29_30_4_6::POS_ACTION_COLOCALIZE::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
741231_0_3_5_18_19::None::Relationship/NN between/IN low/JJ blood/NN pressure/NN and/CC renal/JJ //: cardiovascular/JJ outcomes/NNS in/IN Japanese/JJ patients/NNS with/IN chronic/JJ kidney/NN disease/NN under/IN nephrologist/NN care/NN :/: the/DT 
686_686_31_32_29_30::POS_ACTION_BIND::the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
1782_1782_23_24_27_28::POS_ACTION_INTERACT::RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
473269_0_8_10_29_30::None::)/) is/VBZ a/DT neurodegenerative/JJ disorder/NN characterized/VBN by/IN loss/NN of/IN the/DT pigmented/JJ dopaminergic/JJ neurons/NNS in/IN the/DT substantia/JJ nigra/NN pars/NNS compacta/VBP with/IN subsequent/JJ striatal/JJ dopamine/NN (/( DA/NN )/) deficiency/NN and/CC 
616400_0_2_3_0_1::None::Housing/NN and/CC maintenance/NN of/IN Ambystoma/NN mexicanum/NN 
14_14_5_6_1_2::None::Acanthamoeba/NN profilin/NN was/VBD cross-linked/VBN to/TO actin/NN via/IN a/DT zero-length/JJ 
98_98_29_30_29_30::None::the/DT affinity/NN of/IN profilin/NN for/IN actin/NN may/MD 
381796_0_5_6_18_22::None::Bilevel/NNP -/: auto/NN Treatment/NN in/IN Patients/NNS with/IN Obstructive/JJ Sleep/NNP Apnea/NNP Not/RB Responsive/JJ to/TO or/CC Intolerant/JJ of/IN Continuous/JJ Positive/JJ Airway/NNP Pressure/NN Ventilation/NN ./. 
1803_1803_27_28_32_34::POS_ACTION_RELATE::is/VBZ distinct/JJ from/IN FADD/NNP 's/POS functions/NNS at/IN activated/VBN death/NN receptors/NNS ./. 
878537_3_18_19_15_16::medicine.disease.treatments::underwent/VBD a/DT first/JJ ablation/NN procedure/NN for/IN AF/NN enrolled/VBN in/IN the/DT 
619459_0_1_2_54_57::medicine.risk_factor.diseases::The/DT antitumor/JJ enzyme/NN asparaginase/NN ,/, which/WDT targets/VBZ essential/JJ amino/NN acid/NN L/NN -/: asparagine/NN and/CC catalyzes/VBZ it/PRP to/TO L/NN -/: aspartic/JJ acid/NN and/CC ammonia/NN ,/, has/VBZ been/VBN used/VBN for/IN years/NNS in/IN the/DT treatment/NN of/IN acute/JJ lymphoblastic/JJ leukemia/NN (/( ALL/NN )/) ,/, subtypes/NNS of/IN myeloid/JJ leukemia/NN and/CC T/NN -/: cell/NN lymphomas/NNS ,/, whereas/IN the/DT anti/JJ -/: chronic/JJ myeloid/JJ leukemia/NN (/( CML/NN )/) 
1660_1660_27_28_25_26::None::of/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
534_534_24_25_28_29::POS_ACTION_Change::a/DT role/NN for/IN synaptojanin/NN family/NN members/NNS in/IN actin/NN function/NN ./. 
72969_0_3_4_19_21::None::Close/JJ relatives/NNS (/( CR/NN )/) of/IN patients/NNS with/IN severe/JJ traumatic/JJ brain/NN injury/NN (/( TBI/NN )/) and/CC high/JJ -/: grade/NN subarachnoid/JJ hemorrhage/NN (/( SAH/NN )/) 
2131_2131_7_8_13_14::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ 
1071_1071_32_33_21_22::None::each/DT other/JJ :/: profilin/NN has/VBZ different/JJ effects/NNS on/IN elongation/NN at/IN the/DT two/CD ends/NNS of/IN actin/NN filaments/NNS ;/: profilin/NN 
142623_1_12_13_8_9::None::stress/NN conditions/NNS in/IN response/NN to/TO aluminum/NN (/( Al/NNP )/) ,/, a/DT 
431_431_15_16_0_1::None::END5/NN encodes/VBZ a/DT proline-rich/JJ protein/NN (/( End5p/NN or/CC verprolin/NN )/) required/VBN for/IN a/DT polarised/JJ cortical/JJ actin/NN cytoskeleton/NN and/CC endocytosis/NN 
523643_0_16_17_0_1::None::Our/PRP$ objective/NN is/VBZ to/TO explore/VB the/DT correlation/NN between/IN the/DT mouth/NN diameter/NN of/IN left/JJ atrial/JJ appendage/NN (/( LAA/NN )/) and/CC stroke/NN 
1866_1866_9_10_12_13::None::use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN in/IN their/PRP$ signal/NN 
151063_0_19_23_21_23::None::of/IN non/JJ -/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) 
1169_1169_17_18_13_16::None::actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ 
193027_2_0_1_22_23::None::Here/RB ,/, we/PRP provide/VBP data/NNS toward/IN the/DT clinical/JJ translation/NN of/IN an/DT affinity/NN -/: enhanced/VBN version/NN of/IN JO/NNP -/: 1/CD ,/, which/WDT we/PRP call/VBP JO/SYM -/: 4/CD 
2107_2107_24_26_7_8::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, 
2107_2107_5_7_9_10::POS_ACTION_MEMBER::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS 
93_93_4_5_57_58::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
1737_1737_52_54_58_59::POS_ACTION_MEMBER::the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
431_431_15_16_6_7::None::proline-rich/JJ protein/NN (/( End5p/NN or/CC verprolin/NN )/) required/VBN for/IN a/DT polarised/JJ cortical/JJ actin/NN cytoskeleton/NN and/CC endocytosis/NN 
228362_4_28_29_14_15::None::vitro/FW ribosylation/NN and/CC trypsin/NN digestion/NN for/IN 24/CD or/CC 72h/CD on/IN the/DT viscoelastic/JJ behavior/NN of/IN the/DT whole/JJ murine/JJ IVD/NN Trypsin/NN treatment/NN resulted/VBD 
726738_8_9_10_12_13::medicine.medical_treatment.used_to_treat::lower/JJR for/IN doctors/NNS treating/VBG lung/NN ,/, breast/NN and/CC colorectal/JJ cancers/NNS 
590053_1_7_8_12_13::medicine.symptom.symptom_of::after/IN administration/NN include/VBP headache/NN ,/, nausea/NN ,/, and/CC influenza/NN -/: like/IN symptoms/NNS 
140351_4_6_7_7_8::medicine.risk_factor.diseases::studies/NNS exist/VBP in/IN elderly/JJ IBD/NN as/IN most/JJS authors/NNS 
1169_1169_41_42_17_18::None::Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD found/VBN to/TO possess/VB short/JJ peptide/NN motifs/NNS homologous/JJ to/TO one/CD part/NN of/IN verprolin/NN ./. 
1341_1341_1_2_6_7::POS_ACTION_Causal::The/DT alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS 
430599_3_14_15_18_19::None::than/IN normotensive/JJ group/NN WKY/NN and/CC hypertensive/JJ group/NN SC/NN without/IN mesangial/JJ cell/NN 
434205_2_11_12_9_10::medicine.drug.active_moieties::DA/NN )/) and/CC norepinephrine/NN (/( NE/NN )/) are/VBP influenced/VBN 
2165_2165_20_21_14_15::None::presence/NN of/IN acetylated/VBN histone/NN H4/NN relative/JJ to/TO acetylated/VBN histone/NN H3/NN ./. 
1128_1128_4_5_11_14::None::talin/NN binds/VBZ to/TO actin/NN in/FW vitro/FW and/CC hence/RB is/VBZ an/DT actin/NN binding/NN protein/NN ./. 
174565_5_51_52_49_50::medicine.drug.active_moieties::different/JJ doses/NNS of/IN dopaminergic/JJ (/( DA/NN )/) neuron/NN toxin/NN 
231123_0_2_3_21_22::None::Nilotinib/NNP in/IN patients/NNS with/IN systemic/JJ mastocytosis/NN :/: analysis/NN of/IN the/DT phase/NN 2/CD ,/, open/JJ -/: label/NN ,/, single/JJ -/: arm/NN nilotinib/JJ registration/NN study/NN ./. 
652_652_13_14_11_12::None::alpha-catenin/NN ,/, and/CC p120/NN (/( Cas/NNS )/) and/CC caused/VBD 
1337_1337_12_13_7_8::None::talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN ./. 
240510_12_9_10_16_17::biology.organism_classification.lower_classifications::more/RBR recently/RB named/VBN gastropod/NN clades/NNS (/( Vetigastropoda/NNP ,/, Neritimorpha/NNP ,/, Caenogastropoda/NNP ,/, and/CC Heterobranchia/NNP 
397033_2_22_23_5_6::None::birds/NNS (/( carrion/NN crows/NNS ,/, Corvus/NN corone/NN ,/, common/JJ ravens/NNS ,/, Corvus/NNP corax/NN ,/, Goffin/NNP cockatoos/NNS ,/, Cacatua/NN goffiniana/NN )/) performed/VBD comparably/RB to/TO primates/NNS 
1089_1089_20_21_9_10::NEG_ACTION_BIND::studies/NNS demonstrated/VBD that/IN Stat1/NN could/MD directly/RB interact/VB with/IN TNFR1/NN and/CC TRADD/NN but/CC not/RB with/IN FADD/NN ./. 
417653_2_26_27_30_31::None::and/CC long/JJ -/: term/NN feeding/NN of/IN a/DT high/JJ -/: fat/JJ diet/NN 
118239_0_42_43_45_46::None::nitroaromatics/NNS ,/, using/VBG CO/NNP as/IN the/DT sole/JJ deoxygenative/JJ reagent/NN ,/, 
1074_1074_7_8_10_11::None::including/VBG vinculin/NN ,/, talin/NN ,/, and/CC ezrin/NN ,/, are/VBP not/RB 
386606_0_5_6_9_10::None::in/IN oral/JJ cancer/NN surgery/NN :/: Room/NN for/IN improvement/NN ./. 
780438_1_18_19_28_29::medicine.disease.risk_factors::visited/VBD among/IN persons/NNS infected/VBN with/IN HAV/NN and/CC assess/VB reasons/NNS why/WRB travelers/NNS had/VBD not/RB received/VBN hepatitis/NN A/NN vaccine/NN 
829573_1_1_2_14_15::None::Proposed/VBN etiologies/NNS of/IN this/DT rare/JJ condition/NN include/VBP dysregulation/NN of/IN sympathetic/JJ outflow/NN ,/, upper/JJ cervical/JJ pathology/NN ,/, glossopharyngeal/NN and/CC 
1233_1233_26_27_28_29::None::chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
721_721_9_10_13_14::None::interacting/VBG proteins/NNS recruiting/VBG TFIIIC/NN to/TO DNA/NN were/VBD PRP21/NN and/CC PRP9/NN or/CC 
534_534_28_29_24_25::None::a/DT role/NN for/IN synaptojanin/NN family/NN members/NNS in/IN actin/NN function/NN ./. 
130_130_6_7_15_16::None::the/DT UL5/NN and/CC UL52/NN subunits/NNS retains/VBZ both/CC enzymic/JJ activities/NNS ,/, and/CC the/DT UL8/NN protein/NN has/VBZ been/VBN 
1701_1701_43_46_50_51::POS_ACTION_MEMBER::which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
909_909_2_3_15_16::None::Isolation/NN of/IN profilin/NN from/IN embryonic/JJ chicken/NN skeletal/JJ muscle/NN and/CC evaluation/NN of/IN its/PRP$ interaction/NN with/IN different/JJ actin/NN isoforms/NNS ./. 
32435_3_27_28_29_30::medicine.disease.symptoms::to/TO measures/NNS of/IN depression/NN ,/, anxiety/NN ,/, and/CC posttraumatic/JJ 
567_567_15_16_14_15::None::)/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN 
164393_5_34_35_25_26::None::TAU/NN +/CC SCT/NN group/NN ,/, and/CC self/NN -/: reported/VBN smoking/NN 7/CD -/: day/NN point/NN prevalence/NN abstinence/NN 
906557_3_7_8_52_53::None::from/IN all/DT these/DT functions/NNS ,/, TXNDC5/NN plays/VBZ an/DT important/JJ role/NN in/IN cell/NN physiology/NN ;/: therefore/RB ,/, dysregulation/NN of/IN its/PRP$ expression/NN is/VBZ associated/VBN with/IN oxidative/JJ stress/NN ,/, cell/NN ageing/NN and/CC a/DT large/JJ range/NN of/IN pathologies/NNS such/JJ as/IN arthritis/NN ,/, cancer/NN ,/, diabetes/NN ,/, neurodegenerative/JJ diseases/NNS ,/, vitiligo/NN and/CC virus/NN infections/NNS ./. 
173_173_3_4_12_13::POS_ACTION_INTERACT::As/IN expected/VBN ,/, C/ATF/NN was/VBD found/VBN to/TO interact/VB with/IN three/CD domains/NNS of/IN CBP/NN including/VBG CREB/NN binding/NN 
178116_0_6_7_0_3::None::Protein/NN phosphatase/NN 2A/NN regulatory/JJ subunits/NNS affecting/VBG plant/NN innate/JJ immunity/NN ,/, 
784430_7_25_26_6_7::medicine.medical_treatment.used_to_treat::lacosamide/NN in/IN animal/NN seizure/NN and/CC epilepsy/NN models/NNS is/VBZ similar/JJ to/TO that/DT of/IN sodium/NN channel/NN blocking/VBG antiepileptic/JJ drugs/NNS ,/, such/JJ as/IN phenytoin/NN and/CC carbamazepine/NN ./. 
1560_1560_13_14_39_40::None::acetylation/NN of/IN histone/NN H4/NN versus/CC acetylation/NN of/IN histone/NN H3/NN :/: with/IN the/DT purified/VBN acetylase/NN ,/, histone/NN H4/NN in/IN nucleosomes/NNS was/VBD acetylated/VBN to/TO a/DT much/RB greater/JJR extent/NN than/IN was/VBD histone/NN H3/NN ,/, whereas/IN the/DT 
524639_5_1_2_9_10::None::A/DT majority/NN of/IN data/NNS indicate/VBP that/IN all/PDT the/DT selective/JJ COX/NNP -/: 2/CD inhibitors/NNS 
30983_5_11_12_6_7::None::significantly/RB lower/JJR mean/NN concentration/NN of/IN estradiol/NN and/CC higher/JJR intensity/NN of/IN menopausal/JJ symptoms/NNS 
1227_1227_10_11_2_3::POS_ACTION_INTERACT::Saccharomyces/FW cerevisiae/FW RAD14/NN was/VBD identified/VBN in/IN a/DT two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN 
154850_0_7_8_18_19::None::of/IN dicer/NN -/: dependent/JJ microRNAs/NNS abrogates/VBZ the/DT response/NN of/IN the/DT parathyroid/JJ to/TO acute/JJ and/CC chronic/JJ hypocalcemia/NN and/CC uremia/NN 
176455_12_1_2_5_6::None::Neoadjuvant/JJ radiotherapy/NN of/IN rectal/JJ cancer/NN represents/VBZ the/DT current/JJ standard/NN 
418321_2_4_6_46_47::medicine.risk_factor.diseases::24/CD -/: hour/NN blood/NN pressure/NN (/( BP/NN )/) circadian/JJ pattern/NN also/RB appears/VBZ to/TO be/VB influenced/VBN by/IN OSA/NN Patients/NNS with/IN this/DT syndrome/NN exhibit/VBP a/DT high/JJ prevalence/NN of/IN non/JJ -/: dipping/VBG or/CC riser/JJR circadian/JJ patterns/NNS ,/, which/WDT are/VBP related/JJ to/TO clinical/JJ and/CC subclinical/JJ organ/NN damage/NN in/IN the/DT heart/NN and/CC brain/NN ./. 
1341_1341_6_7_12_13::None::links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS to/TO the/DT actin/NN cytoskeleton/NN ./. 
1507_1507_17_18_22_23::None::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS ./. 
1901_1901_31_32_25_28::None::D1/NN ,/, the/DT cyclin-dependent/JJ kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, 
416817_3_74_75_26_27::medicine.medical_treatment.used_to_treat::in/IN asthma/NN and/CC COPD/NNP This/DT involved/VBD a/DT retrospective/JJ extraction/NN of/IN data/NNS from/IN all/DT registered/VBN practices/NNS in/IN Salford/NNP to/TO identify/VB a/DT cohort/NN of/IN patients/NNS with/IN a/DT diagnosis/NN of/IN asthma/NN (/( aged/JJ gtgt/NN =/JJ 18/CD )/) and/CC //: or/CC COPD/NNP (/( aged/JJ gtgt/NN =/JJ 40/CD )/) and/CC gtgt/NN =/JJ 2/CD prescriptions/NNS for/IN inhaled/VBN bronchodilators/NNS during/IN 2008/CD ./. 
996_996_27_28_8_9::POS_ACTION_SUPPRESS::cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) 
996_996_8_9_29_30::None::cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN 
38537_2_9_10_21_22::None::for/IN 153/CD -/: Samarium/NN (/( 153/CD -/: Sm/NN )/) was/VBD done/VBN by/IN SPECT/NNP -/: CT/NN images/NNS coupled/VBN GATE/NNP Monte/NNP 
1427_1427_32_33_29_30::None::with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1989_1989_32_33_11_12::None::actin-binding/JJ domain/NN of/IN fimbrin/NN ,/, these/DT results/NNS have/VBP enabled/VBN us/PRP to/TO determine/VB the/DT likely/JJ orientation/NN of/IN the/DT utrophin/NN actin-binding/JJ domain/NN with/IN respect/NN to/TO the/DT actin/NN filament/NN ./. 
662630_5_25_27_22_24::medicine.symptom.symptom_of::experiencing/VBG less/RBR severe/JJ depressed/JJ mood/NN ,/, difficulty/NN sleeping/VBG ,/, nervousness/NN //: 
1328_1328_3_4_1_3::None::The/DT actin-binding/JJ protein/NN profilin/NN binds/VBZ to/TO PIP2/NN 
369607_2_24_26_27_28::medicine.drug_ingredient.active_moiety_of_drug::ChS/NN )/) and/CC hyaluronic/JJ acid/NN (/( HA/NN )/) ./. 
573581_3_18_19_64_65::None::by/IN reconstituting/VBG the/DT immune/JJ antibody/NN repertories/NNS in/FW vitro/FW followed/VBN by/IN a/DT comparative/JJ study/NN of/IN the/DT recombinant/JJ library/NN IgGs/NNS with/IN the/DT corresponding/JJ serum/NN IgGs/NNS We/PRP found/VBD that/IN the/DT recombinant/JJ library/NN IgGs/NNS were/VBD much/JJ weaker/JJR than/IN the/DT serum/NN IgGs/NNS in/IN binding/VBG to/TO envelope/NN glycoproteins/NNS (/( Envs/NNS )/) and/CC in/IN neutralizing/VBG the/DT virus/NN and/CC inhibiting/VBG Env/NN 
255731_2_36_37_10_11::None::,/, we/PRP comprehensively/RB investigated/VBD the/DT abundance/NN and/CC diversity/NN of/IN STPs/NNS encoded/VBN in/IN 119/CD actinobacterial/JJ genomes/NNS ,/, based/VBN on/IN the/DT data/NNS stored/VBN in/IN the/DT Microbial/JJ Signal/NN Transduction/NN (/( MiST/NN )/) database/NN ./. 
597523_1_3_4_19_20::None::The/DT impact/NN of/IN UV/NN radiation/NN and/CC carbaryl/NN singly/RB and/CC in/IN combination/NN on/IN Triticum/FW aestivum/FW (/( wheat/NN )/) and/CC Brassica/NNP rapa/NN (/( turnip/NN )/) 
776_776_28_29_26_27::None::of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT 
416067_10_0_1_13_14::None::The/DT ratio/NN of/IN malignant/JJ //: tumor/NN in/IN NPC1L1/NN (/( -/: //: -/: )/) mice/NNS was/VBD significantly/RB lower/JJR 
799750_8_13_14_3_4::None::Benign/JJ borderline/JJ and/CC malignant/JJ phyllode/NN tumors/NNS have/VBP different/JJ distant/JJ metastasis/NN risk/NN ,/, different/JJ primary/JJ tumor/NN size/NN and/CC 
211991_5_3_4_9_10::medicine.risk_factor.diseases::Twenty/CD -/: eight/CD obese/JJ women/NNS were/VBD recruited/VBN with/IN the/DT diagnosis/NN of/IN PCOS/NN ,/, 
691776_2_12_13_9_10::None::,/, about/IN the/DT evolutionary/JJ history/NN and/CC gene/NN content/NN of/IN primordial/JJ 
608_608_23_24_20_21::None::the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS (/( Crute/NNP 
101_101_36_37_24_25::None::of/IN talin/NN and/CC vinculin/NN on/IN the/DT structure/NN ,/, chain/NN dynamics/NNS ,/, elasticity/NN and/CC viscoelasticity/NN of/IN actin/NN filaments/NNS with/IN time/NN 
1871_1871_10_11_12_13::None::the/DT association/NN between/IN E-cadherin/NN and/CC alpha-catenin/NN is/VBZ mediated/VBN by/IN 
318370_0_1_2_6_7::medicine.drug_ingredient.active_moiety_of_drug::Black/JJ titania/NN spheres/NNS (/( H/NN -/: TiO2/NN -/: x/NN )/) 
127291_4_7_8_41_42::None::aneurysm/NN ,/, the/DT auto/NN -/: vein/NN transplantation/NN was/VBD performed/VBN in/FW situ/FW between/IN the/DT hepatic/JJ artery/NN and/CC the/DT distal/JJ part/NN of/IN the/DT splenic/JJ artery/NN in/IN 1/CD case/NN ;/: the/DT artificial/JJ vessel/NN bypass/NN was/VBD done/VBN between/IN the/DT infra/NN -/: renal/JJ aorta/NN and/CC distal/JJ 
184609_0_26_27_27_29::None::place/NN at/IN the/DT heme/NN active/JJ site/NN ./. 
1711_1711_16_19_19_20::POS_ACTION_MEMBER::related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN ,/, 
502525_12_30_32_0_1::None::Levels/NNS of/IN anti/JJ -/: CCP/NN and/CC CRP/NN are/VBP associated/VBN with/IN increased/VBN cIMT/NN and/CC cardiovascular/JJ risk/NN supporting/VBG a/DT clinical/JJ role/NN of/IN the/DT measurement/NN of/IN cIMT/NN in/IN RA/NN in/IN predicting/VBG and/CC preventing/VBG cardiovascular/JJ events/NNS ./. 
1169_1169_17_18_41_42::POS_ACTION_SIMILAR::Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD found/VBN to/TO possess/VB short/JJ peptide/NN motifs/NNS homologous/JJ to/TO one/CD part/NN of/IN verprolin/NN ./. 
1754_1754_21_22_7_8::POS_ACTION_Change::the/DT dysfunction/NN of/IN E-cadherin/NN in/IN these/DT cell/NN lines/NNS is/VBZ due/JJ primarily/RB to/TO its/PRP$ failure/NN to/TO interact/VB with/IN alpha-catenin/NN ,/, and/CC that/IN 
670852_3_13_14_5_6::None::diagnosed/VBN breast/NN cancer/NN patients/NNS with/IN estrogen/NN receptor/NN (/( ER/NN )/) positive/JJ tumors/NNS ,/, who/WP referred/VBD 
856_856_13_14_16_18::None::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO 
264611_0_2_3_8_9::None::Preservation/NN of/IN mobility/NN in/IN conjunction/NN with/IN an/DT independent/JJ life/NN style/NN is/VBZ one/CD 
31738_0_5_7_2_3::None::Variation/NN in/IN Medicare/NNP Payments/NNS for/IN Colorectal/JJ Cancer/NN Surgery/NN ./. 
1361_1361_6_7_3_4::POS_ACTION_BIND::The/DT affinity/NN of/IN ZmPRO4/NN for/IN monomeric/JJ actin/NN ,/, which/WDT was/VBD 
296153_6_3_4_12_13::None::Major/JJ depression/NN ,/, fibromyalgia/NNP ,/, Alzheimer/NNP disease/NN ,/, psoriasis/NN ,/, arthritis/NN ,/, allergies/NNS ,/, and/CC asthma/NN 
1672_1672_12_13_3_4::POS_ACTION_MEMBER::The/DT Saccharomyces/FW cerevisiae/FW DDC1/NN gene/NN belongs/VBZ to/TO the/DT RAD17/NN ,/, MEC3/NN and/CC RAD24/NN epistasis/NN group/NN which/WDT 
106487_0_13_14_1_3::None::Severe/JJ systemic/JJ hypertension/NN (/( HTN/NN )/) is/VBZ a/DT risk/NN factor/NN for/IN perioperative/JJ cardiovascular/JJ complications/NNS ;/: however/RB its/PRP$ 
1380_1380_26_27_43_44::POS_ACTION_BIND::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN (/( Machesky/NNP et/FW 
1074_1074_10_11_5_6::None::proteins/NNS ,/, including/VBG vinculin/NN ,/, talin/NN ,/, and/CC ezrin/NN ,/, are/VBP not/RB 
6359_3_23_24_4_5::None::DNA/NN from/IN 2256/CD Caucasians/NNS ,/, including/VBG 1073/CD CD/NN patients/NNS ,/, 464/CD patients/NNS with/IN ulcerative/JJ colitis/NN (/( UC/NN )/) ,/, and/CC 719/CD healthy/JJ controls/NNS ,/, was/VBD genotyped/VBN 
397679_0_15_16_23_24::None::66/CD yr/NN )/) patients/NNS with/IN multiple/JJ myeloma/NN (/( MM/NN )/) in/IN daily/JJ practice/NN by/IN comparing/VBG 
365_365_8_10_15_16::None::that/IN the/DT G1/NN cyclin/NN D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN 
161_161_11_12_0_1::None::Armadillo/NN (/( Arm/NN )/) repeat/NN 10/CD to/TO the/DT COOH/NN terminus/NN of/IN beta-catenin/NN is/VBZ involved/VBN in/IN 
1069_1069_33_35_26_27::None::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) 
487559_4_17_18_41_43::medicine.risk_factor.diseases::of/IN GDI/NNP A/NNP high/JJ index/NN of/IN suspicion/NN of/IN GDI/NNP should/MD be/VB maintained/VBN in/IN patients/NNS who/WP present/VBP with/IN typical/JJ signs/NNS and/CC symptoms/NNS ,/, especially/RB in/IN the/DT setting/NN of/IN pregnancy/NN complications/NNS associated/VBN with/IN liver/NN 
367649_3_26_27_8_9::None::berberine/NN has/VBZ various/JJ pharmacological/JJ activities/NNS ,/, including/VBG lowering/VBG blood/NN glucose/NN ,/, regulating/VBG blood/NN lipids/NNS and/CC reducing/VBG inflammation/NN in/IN addition/NN to/TO its/PRP$ antioxidant/JJ activity/NN ./. 
23235_3_37_39_23_24::None::von/NN Willebrand/NN factor/NN antigen/NN (/( vWF/NN :/: Ag/NN )/) and/CC activity/NN (/( vWF/NN :/: GP1bA/NN )/) ,/, factor/NN VIII/CD (/( FVIII/CD :/: 
2107_2107_7_8_27_28::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
240754_0_3_4_0_1::medicine.drug_ingredient.active_moiety_of_drug::Calcium/NN ion/NN (/( Ca/NN (/( 2/CD +/CC 
18_18_4_5_21_22::POS_ACTION_INTERACT::domain/NN of/IN the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) ./. 
1362_1362_30_31_28_29::None::,/, such/JJ as/IN vinculin/NN and/CC talin/NN ,/, and/CC to/TO 
72_72_17_18_19_20::None::disrupted/VBN by/IN specific/JJ actin/NN and/CC cofilin/NN mutations/NNS ./. 
125415_10_9_10_12_13::None::hyperinsulinemia/NN (/( in/IN general/JJ on/IN the/DT HP/NNP diet/NN ;/: postprandially/RB 
2053_2053_11_12_17_19::POS_REG(0)_ASSEMBLE::sequestering/NN protein/NN ,/, profilin/NN ,/, in/IN the/DT regulation/NN of/IN PMN/NN actin/NN filament/NN assembly/NN during/IN 
284647_4_19_20_24_25::None::as/RB well/RB as/IN impact/NN on/IN disease/NN rates/NNS in/IN infants/NNS is/VBZ encouraging/JJ ,/, 
608_608_23_24_10_11::None::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS (/( Crute/NNP 
243_243_32_35_27_28::POS_ACTION_ACTIVATE::coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) 
149493_0_13_14_28_29::None::was/VBD developed/VBN to/TO assist/VB primary/JJ care/NN physicians/NNS and/CC other/JJ health/NN care/NN professionals/NNS in/IN the/DT outpatient/NN treatment/NN of/IN uncomplicated/JJ hypertension/NN in/IN adult/JJ men/NNS 
553943_2_21_22_18_19::medicine.disease.treatments::imaging/NN data/NNS from/IN bevacizumab/NN -/: treated/VBN glioblastoma/NN patients/NNS in/IN less/JJR 
201815_2_19_20_7_8::None::established/VBD a/DT silkworm/NN model/NN of/IN type/NN II/CD diabetes/NNS for/IN the/DT evaluation/NN of/IN anti/JJ -/: diabetic/JJ drugs/NNS such/JJ as/IN pioglitazone/NN 
315964_1_24_25_39_40::None::and/CC manganese/NN (/( Mn/NN )/) ,/, may/MD be/VB factors/NNS or/CC cofactors/NNS in/IN the/DT etiopathogenesis/NN of/IN a/DT variety/NN of/IN psychiatric/JJ disorders/NNS ./. 
750926_1_24_25_30_31::medicine.risk_factor.diseases::from/IN non/JJ -/: diabetic/JJ human/JJ donors/NNS ,/, cultured/VBN under/IN high/JJ glucose/NN (/( HG/NNP 
1417_1417_17_18_9_10::POS_ACTION_MODIFY::the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS for/IN transformation/NN by/IN the/DT E1A/NN proteins/NNS of/IN non-oncogenic/JJ 
1711_1711_7_8_5_6::None::of/IN the/DT predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN 
930_930_1_2_8_9::None::Like/IN actin/NN ,/, the/DT actin-associated/JJ proteins/NNS filamin/NN ,/, talin/NN and/CC the/DT beta/NN 
800292_15_29_30_28_29::None::,/, and/CC open/JJ surgical/JJ access/NN could/MD influence/VB clinical/JJ 
607_607_21_22_8_9::POS_ACTION_ENCODE::expresses/VBZ a/DT heterotrimeric/JJ helicase-primase/NN ,/, the/DT subunits/NNS of/IN which/WDT are/VBP encoded/VBN by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS 
292_292_19_21_0_1::POS_ACTION_BIND::CD26/NN ,/, a/DT T/NN cell/NN activation/NN Ag/NN ,/, also/RB known/VBN as/IN dipeptidyl/NN peptidase/NN IV/CD ,/, is/VBZ directly/RB associated/VBN with/IN adenosine/NN deaminase/NN (/( ADA/NN )/) 
280859_11_4_5_22_24::None::overfat/NN and/CC obese/JJ participants/NNS fat/JJ mass/NN was/VBD reduced/VBN with/IN increasing/VBG resistance/NN exercise/NN (/( p/NN ltlt/NN =/JJ 0.02/CD )/) but/CC not/RB with/IN aerobic/JJ exercise/NN (/( p/NN gtgt/NN 
1526_1526_17_18_12_13::POS_ACTION_INTERACT::)/) phosphoprotein/NN (/( P/NN )/) with/IN nucleocapsid/NN (/( N/NN )/) and/CC large/JJ 
758270_7_5_6_3_4::None::In/IN chronic/JJ cigarette/NN smoke/NN related/JJ lung/NN disease/NN ,/, the/DT 
213_213_1_2_2_3::POS_ACTION_MEMBER::Because/IN histone/NN H3/NN shares/NNS many/JJ structural/JJ 
337142_1_18_19_45_46::None::NR2C/NN )/) ,/, olfactory/JJ receptor/NN (/( OR/NN )/) ,/, and/CC adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) in/IN chum/NN salmon/NN Oncorhynchus/NNP keta/NN using/VBG quantitative/JJ polymerase/NN chain/NN reaction/NN (/( QPCR/NN )/) during/IN salinity/NN change/NN (/( seawater/NN -/: 
452794_0_10_11_8_9::None::therapy/NN with/IN different/JJ doses/NNS of/IN enoxaparin/NN for/IN portal/JJ vein/NN 
1362_1362_28_29_30_31::None::,/, such/JJ as/IN vinculin/NN and/CC talin/NN ,/, and/CC to/TO 
33757_12_16_18_25_26::None::MRI/NNP combined/VBN with/IN supervised/JJ learning/VBG to/TO be/VB able/JJ to/TO accurately/RB detect/VB cancer/NN foci/NNS and/CC its/PRP$ aggressiveness/NN 
352074_5_0_1_39_40::None::The/DT economic/JJ and/CC environmental/JJ advantages/NNS of/IN AeRD/NN for/IN processing/NN of/IN laterite/NN tailings/NNS comprise/VBP no/DT requirement/NN for/IN an/DT anoxic/JJ atmosphere/NN ,/, 1.8/CD -/: fold/JJ less/JJR acid/NN consumption/NN than/IN for/IN AnRD/NN ,/, as/RB well/RB as/IN nickel/NN and/CC cobalt/NN recovered/VBD in/IN a/DT ferrous/JJ -/: based/VBN pregnant/JJ 
1479_1479_16_17_21_22::POS_REG(0)_CONTROL::LIM/NN kinase/NN and/CC cofilin/NN in/IN the/DT control/NN of/IN actin/NN dynamics/NNS ./. 
428_428_34_35_32_33::None::with/IN substrate/NN containing/VBG actin/NN and/CC talin/NN ./. 
380023_1_11_12_13_14::medicine.symptom.symptom_of::screen/NN patients/NNS for/IN anxiety/NN and/CC depression/NN ,/, and/CC there/EX 
366549_4_6_7_4_5::None::coordination/NN polymers/NNS of/IN zinc/NN (/( II/CD )/) ,/, {/( 
297982_0_19_20_15_16::None::manufactured/VBN nanoparticles/NNS (/( NPs/NNS )/) on/IN a/DT global/JJ scale/NN because/IN of/IN 
938_938_0_2_9_11::None::LIM-kinase/NN 1/CD (/( LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ 
567_567_7_9_15_16::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN 
715810_0_17_18_13_14::medicine.disease.symptoms::the/DT treatment/NN against/IN insomnia/NN ,/, amnesia/NN ,/, depression/NN ,/, palpitations/NNS with/IN 
816806_0_20_21_4_5::medicine.medical_treatment.used_to_treat::need/NN to/TO overcome/VB cancer/NN multidrug/JJ resistance/NN (/( MDR/NN )/) has/VBZ fueled/VBN considerable/JJ interest/NN in/IN the/DT development/NN of/IN novel/JJ synthetic/JJ antitumor/NN agents/NNS with/IN cytotoxicity/NN 
798_798_13_14_4_5::POS_ACTION_HUMANMADE::reconstitution/NN experiments/NNS ,/, actin/NN filaments/NNS incubated/VBN in/IN EGTA/NN with/IN purified/VBN fimbrin/NN and/CC villin/NN form/VBP smooth-sided/JJ bundles/NNS 
280_280_46_47_14_15::None::observed/VBD that/IN histone/NN H4/NN ,/, and/CC not/RB histone/NN H3/NN ,/, was/VBD acetylated/VBN from/IN the/DT endogenous/JJ p21/waf1/NN promoter/NN in/FW vivo/FW ,/, implying/VBG that/IN CBP/p300/NN ,/, and/CC not/RB the/DT SAGA/NN complex/NN ,/, was/VBD critical/JJ in/IN complexing/VBG with/IN E2A/NN in/IN up-regulation/NN of/IN 
426593_3_13_14_1_2::None::Though/IN monotherapy/NN with/IN a/DT low/JJ dose/NN of/IN I/PRP -/: 131/CD MIBG/NN could/MD achieve/VB high/JJ -/: probability/NN pain/NN 
604581_3_13_14_7_8::medicine.disease.symptoms::central/JJ mechanisms/NNS of/IN fatigue/NN at/IN the/DT premovement/NN level/NN in/IN MS/NN patients/NNS during/IN a/DT 
483185_4_50_51_8_9::None::based/VBN on/IN adequate/JJ population/NN samples/NNS have/VBP shown/VBN a/DT higher/JJR frequency/NN of/IN genetic/JJ polymorphisms/NNS of/IN the/DT LHCGR/NNP ,/, THADA/NNP and/CC DENND1A/NN genes/NNS in/IN women/NNS with/IN PCOS/NN Genetic/JJ studies/NNS of/IN PCOS/NN have/VBP also/RB included/VBN analyses/NNS of/IN structural/JJ changes/NNS in/IN the/DT chromosome/NN based/VBN on/IN an/DT assessment/NN of/IN telomere/NN length/NN in/IN single/JJ ,/, 
110315_0_1_2_10_11::medicine.symptom.symptom_of::Chronic/JJ inguinodynia/NN is/VBZ one/CD of/IN the/DT most/RBS frequent/JJ complications/NNS after/IN groin/NN herniorrhaphy/NN ./. 
1726_1726_16_17_14_15::POS_ACTION_PHOSPHORYLATE::increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ 
833393_2_10_11_12_13::biology.organism_classification.lower_classifications::generation/NN for/IN malaria/NN parasite/NN Plasmodium/NN falciparum/NN ,/, hence/RB a/DT 
865_865_15_16_21_24::None::related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ 
763423_0_8_9_2_5::medicine.disease.treatments::Evaluation/NN of/IN proton/NN pump/NN inhibitor/NN -/: resistant/JJ nonerosive/JJ reflux/NN disease/NN by/IN esophageal/NN 
1507_1507_6_7_17_18::POS_ACTION_CONTAIN::virus/NN type/NN 1/CD primosome/NN consists/VBZ of/IN three/CD subunits/NNS that/WDT are/VBP the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, 
1834_1834_6_7_23_24::None::three/CD structures/NNS of/IN actin/NN complexed/VBN with/IN different/JJ monomer-binding/JJ proteins/NNS ,/, namely/RB with/IN DNase/NN I/CD ,/, gelsolin/NN segment/NN 1/CD ,/, and/CC profilin/NN ./. 
2230_2230_6_8_8_9::POS_ACTION_MEMBER::isoforms/NNS of/IN the/DT actin-binding/JJ protein/NN profilin/NN that/WDT differ/VBP in/IN 
1479_1479_13_15_16_17::None::the/DT effects/NNS of/IN LIM/NN kinase/NN and/CC cofilin/NN in/IN the/DT control/NN 
1165_1165_7_8_9_10::POS_REG(0)_ASSEMBLE::effect/NN of/IN Acanthamoeba/NN profilin/NN on/IN actin/NN filament/NN nucleation/NN and/CC 
478731_4_4_5_15_16::None::time/NN course/NN of/IN conformational/JJ change/NN suggests/VBZ the/DT action/NN of/IN fluoride/NN and/CC magnesium/NN at/IN different/JJ steps/NNS of/IN the/DT E2Mg/NN 
512613_1_44_45_10_11::None:://: negative/JJ affectivity/JJ symptoms/NNS (/( depressed/JJ mood/NN ,/, anxious/JJ mood/NN ,/, worry/NN )/) that/WDT are/VBP central/JJ to/TO these/DT disorders/NNS ;/: more/JJR moderately/RB with/IN symptoms/NNS of/IN social/JJ phobia/NN ,/, affective/JJ lability/NN ,/, panic/NN ,/, posttraumatic/JJ stress/NN disorder/NN ,/, lassitude/NN ,/, checking/NN ,/, 
539_539_15_16_5_6::None::we/PRP show/VBP that/IN talin/NN ,/, a/DT high/JJ molecular/JJ weight/NN structural/JJ protein/NN that/WDT links/VBZ integrins/NNS to/TO the/DT actin/NN 
95125_0_5_6_0_1::None::Aedes/NNS aegypti/NNS is/VBZ a/DT primary/JJ vector/NN of/IN dengue/NN and/CC 
1270_1270_31_32_37_38::POS_ACTION_Change::PIP2/NN binding/NN and/CC actin/NN binding/NN may/MD be/VB important/JJ for/IN profilin/NN function/NN ./. 
97537_3_29_30_10_11::None::a/DT variety/NN of/IN cancers/NNS (/( prostate/NN ,/, lung/NN ,/, pancreatic/JJ ,/, or/CC colon/NN carcinoma/NN ,/, melanoma/NN ,/, astrocytoma/NN ,/, glioblastoma/NN ,/, and/CC neuroblastoma/NN )/) ,/, suggesting/VBG 
154535_13_10_11_15_16::medicine.risk_factor.diseases::insulin/NN resistance/NN ,/, obesity/NN ,/, and/CC depression/NN in/IN PCOS/NN ,/, warranting/VBG additional/JJ 
1878_1878_17_18_5_6::None::poly-L-proline/NN binding/NN ,/, actin/NN binding/NN ,/, and/CC actin/NN nucleotide/NN exchange/NN are/VBP each/DT independent/JJ requirements/NNS for/IN profilin/NN function/NN in/IN fission/NN 
447089_0_21_22_7_9::None::we/PRP showed/VBD that/IN adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) promoted/VBD erythroblast/NN differentiation/NN and/CC increased/VBD the/DT enucleation/NN ratio/NN of/IN erythroblasts/NNS ./. 
314756_0_26_27_23_25::None::the/DT regulation/NN of/IN lipid/NN metabolism/NN and/CC hepatic/JJ steatosis/NN in/IN animal/NN 
8_8_26_27_2_3::NEG_ACTION_Amount::Abundance/NN of/IN actin/NN ,/, talin/NN ,/, alpha/NN 5/CD and/CC beta/NN 1/CD integrins/NNS ,/, pp125/CD focal/JJ adhesion/NN kinase/NN ,/, and/CC alpha-catenin/NN is/VBZ not/RB affected/VBN by/IN the/DT differential/JJ calreticulin/NN expression/NN ./. 
93_93_50_51_22_23::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
1348_1348_15_17_4_5::None::cellular/JJ tumor/NN antigen/NN p53/NN is/VBZ bound/VBN to/TO the/DT simian/JJ virus/NN 40/CD (/( SV40/NN )/) large/JJ T-antigen/NN in/IN SV40-infected/JJ and/CC 
247970_0_20_21_12_13::None::cornus/FW mas/FW fruit/NN extract/NN (/( CMFE/NN )/) in/IN mice/NNS treated/VBN with/IN methotrexate/NN (/( MTX/NN )/) 
1701_1701_48_49_6_7::None::that/IN this/DT novel/JJ RhoGAP/NN is/VBZ involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
996_996_29_30_27_28::None::coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN 
1787_1787_16_17_14_15::None::actin/NN ,/, like/IN destrin/NN and/CC cofilin/NN isolated/VBN from/IN porcine/NN 
1341_1341_6_7_1_2::None::The/DT alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS 
365169_1_24_25_38_39::None::,/, chronic/JJ airways/NNS obstruction/NN ,/, and/CC spontaneous/JJ pneumothorax/NN -/: and/CC the/DT difficulties/NNS ,/, which/WDT arose/VBD ,/, in/IN diagnosis/NN and/CC management/NN of/IN 
757758_7_33_34_38_39::None::from/IN the/DT first/JJ CDI/NNP to/TO bacteriotherapy/NN (/( 221.6/CD days/NNS vs/CC 175.3/CD days/NNS 
1923_1923_52_53_21_22::None::actin/NN that/WDT bound/VBD profilin/NN ,/, a/DT protein/NN that/WDT interacts/VBZ with/IN phosphoinositides/NNS and/CC actin-monomers/NNS in/IN a/DT mutually/RB exclusive/JJ manner/NN ,/, with/IN an/DT order/NN of/IN magnitude/NN greater/JJR affinity/NN (/( Kd/NN =/JJ 3.6/CD microM/NN )/) than/IN cys-374-labeled/JJ actin/NN (/( Kd/NN >/JJR 
324666_0_9_10_12_13::None::of/IN the/DT most/RBS common/JJ causes/NNS of/IN hereditary/JJ non/JJ -/: spherocytic/JJ 
2081_2081_18_19_30_31::None::pool/NN of/IN unpolymerized/JJ actin/NN and/CC the/DT flux/NN of/IN actin/NN subunits/NNS through/IN filaments/NNS are/VBP controlled/VBN by/IN profilin/NN and/CC free/JJ filament/NN 
865_865_17_18_15_16::None::related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 
749940_1_30_31_44_46::None::cell/NN transplantation/NN from/IN HLA/NN -/: identical/JJ sibling/NN donors/NNS in/IN the/DT first/JJ or/CC higher/JJR complete/JJ remission/NN following/VBG myeloablative/JJ conditioning/NN regimens/NNS between/IN 2004/CD and/CC 
438089_4_26_27_7_8::None::analyzed/VBN during/IN an/DT interval/NN of/IN 18/CD months/NNS that/WDT included/VBD jaundice/NN patients/NNS admitted/VBN in/IN the/DT General/NNP Surgery/NNP Department/NNP of/IN ''/'' Coltea/NNP ''/'' Clinical/JJ Hospital/NN ./. 
496811_0_35_37_23_24::medicine.disease.treatments::intravitreal/JJ injections/NNS of/IN triamcinolone/NN acetonide/NN (/( TA/NNP )/) with/IN the/DT standard/NN of/IN care/NN for/IN ocular/JJ inflammatory/JJ diseases/NNS ./. 
459318_0_16_18_8_9::None::rods/NNS with/IN layered/JJ nano/NN -/: structure/NN by/IN thermal/JJ decomposition/NN of/IN the/DT coordination/NN complex/NN Cu/NN (/( BTA/NN 
268987_0_18_19_0_1::None::Two/CD main/JJ features/NNS common/JJ to/TO all/DT solid/JJ tumors/NNS are/VBP tissue/NN hypoxia/NN and/CC inflammation/NN ,/, both/DT of/IN which/WDT cause/VBP tumor/NN progression/NN ,/, metastasis/NN 
710191_0_17_18_22_23::None::prognostic/JJ factors/NNS with/IN synergistic/JJ effect/NN on/IN locally/RB advanced/JJ head/NN and/CC neck/NN cancer/NN 
1534_1534_26_29_34_35::None::the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) are/VBP controversial/JJ 
1527_1527_5_8_3_4::POS_ACTION_INTERACT::The/DT interactions/NNS of/IN actin/NN with/IN thymosin/NN beta/NN 4/CD ,/, actobindin/NN and/CC 
727854_0_14_15_15_16::None::that/WDT affect/VBP a/DT high/JJ proportion/NN of/IN people/NNS worldwide/RB 
896731_2_3_4_8_10::None::An/DT acute/JJ MI/NNP model/NN was/VBD induced/VBN in/IN male/JJ Wistar/NNP rats/NNS by/IN subcutaneous/JJ injection/NN 
1288_1288_4_6_11_12::None::interaction/NN between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) 
194621_0_22_23_19_20::medicine.drug.active_moieties:://: or/CC antioxidants/NNS compounds/NNS and/CC reduced/VBD sodium/NN intake/NN have/VBP been/VBN 
829573_1_29_30_22_23::None::neuralgia/NN ,/, TMJ/NNP dysfunction/NN ,/, thalamic/JJ syndrome/NN ,/, and/CC primary/JJ headache/NN syndromes/NNS ./. 
251166_0_11_12_17_18::None::of/IN HDL/NN cholesterol/NN levels/NNS for/IN cardiovascular/JJ risk/NN stratification/NN is/VBZ limited/VBN in/IN patients/NNS with/IN 
483865_3_0_1_3_4::None::Here/RB we/PRP present/VBP measurements/NNS of/IN ocean/NN -/: 
176735_0_43_45_27_28::None::,/, we/PRP assessed/VBD DAT/NNP levels/NNS in/IN the/DT striatum/NN by/IN (/( 99m/CD )/) Tc/SYM -/: TRODAT/NN -/: 1/CD single/JJ -/: photon/NN emission/NN computed/VBD tomography/NN (/( 
159983_7_1_2_23_24::None::An/DT estimation/NN of/IN the/DT affinity/NN of/IN methyl/NN eugenol/NN for/IN the/DT resting/VBG and/CC inactivated/VBN states/NNS of/IN the/DT channel/NN also/RB demonstrated/VBD that/IN methyl/NN eugenol/NN preferentially/RB binds/VBZ to/TO inactivated/VBN channels/NNS 
2222_2222_15_16_37_38::None::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
944835_4_4_5_0_2::None::Plasmodium/NN falciparum/NN eta/NN -/: CA/NNP showed/VBD a/DT moderate/JJ 
715810_0_5_6_25_26::None::of/IN Polygala/NN tenuifolia/NN Willdenow/NNP has/VBZ been/VBN used/VBN for/IN the/DT treatment/NN against/IN insomnia/NN ,/, amnesia/NN ,/, depression/NN ,/, palpitations/NNS with/IN anxiety/NN ,/, and/CC memory/NN improvement/NN ./. 
417823_9_4_5_0_1::None::The/DT most/RBS common/JJ neurological/JJ diseases/NNS of/IN the/DT elderly/JJ 
236807_0_20_21_9_10::medicine.risk_factor.diseases::the/DT onset/NN of/IN depressive/JJ -/: like/IN behavior/NN in/IN 6/CD -/: OHDA/NN animal/NN model/NN of/IN Parkinson/NNP whosewhat/NN disease/NN ./. 
319920_0_25_27_13_14::medicine.symptom.symptom_of::Montgomery/NNP -/: Aasberg/NNP Depression/NNP Rating/NNP Scale/NNP items/NNS identified/VBD composite/JJ factors/NNS of/IN depression/NN ,/, mania/NN ,/, sleep/NN disturbance/NN ,/, judgment/NN //: 
693828_2_16_17_15_16::None::and/CC correlates/VBZ of/IN unipolar/JJ MDD/NN and/CC bipolar/JJ MDD/NN 
1052_1052_18_20_29_30::POS_ACTION_INTERACT::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
686_686_29_30_13_14::POS_ACTION_BIND::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC 
491599_4_27_28_31_32::None::treatment/NN of/IN bone/NN complications/NNS as/RB well/RB as/IN fibrosis/NN have/VBP been/VBN shown/VBN 
607_607_19_20_23_24::None::by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS ./. 
2085_2085_17_20_14_15::POS_ACTION_MEMBER::cyclin/NN ,/, and/CC p27kip/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, in/IN BALB/c/NN 
503061_9_13_15_13_14::medicine.disease.risk_factors::the/DT development/NN of/IN diabetic/JJ retinopathy/NN and/CC suggests/VBZ 
63_63_59_60_25_26::None::electrophoresis/NN :/: histone/NN H1/NN (/( 0/CD )/) ,/, four/CD histone/NN H1/NN subfractions/NNS ,/, histone/NN H2A/NN .1/NN ,/, histone/NN H2A/NN .2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN ,/, histone/NN H2B/NN ,/, three/CD histone/NN H3/NN variants/NNS and/CC histone/NN 
397033_2_13_15_28_29::None::common/JJ ravens/NNS ,/, Corvus/NNP corax/NN ,/, Goffin/NNP cockatoos/NNS ,/, Cacatua/NN goffiniana/NN )/) performed/VBD comparably/RB to/TO primates/NNS in/IN an/DT exchange/NN task/NN ,/, contradicting/VBG 
173493_0_19_20_3_4::None::Budesonide/NN formoterol/NN (/( BF/NN )/) SpiromaxRegistered/NNP is/VBZ a/DT breath/NN -/: actuated/VBN dry/JJ -/: powder/NN inhaler/NN designed/VBN to/TO deliver/VB similar/JJ combinations/NNS of/IN budesonide/NN and/CC 
1546_1546_8_11_12_13::None::p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ 
755_755_20_21_9_10::POS_ACTION_COLOCALIZE::as/RB well/RB as/IN ADF/NN ,/, translocates/VBZ from/IN the/DT cytoplasm/NN into/IN the/DT nucleus/NN together/RB with/IN actin/NN and/CC forms/NNS rod-like/JJ 
346_346_16_17_24_25::POS_ACTION_BIND::of/IN alpha-catenin/NN ,/, beta-catenin/NN competed/VBD with/IN the/DT binding/NN of/IN plakoglobin/NN to/TO alpha-catenin/NN and/CC vice/NN versa/RB 
614185_6_1_2_0_1::None::These/DT procedures/NNS can/MD be/VB typically/RB 
588835_2_4_5_24_25::None::traced/VBD the/DT ontogenetic/JJ development/NN of/IN this/DT feature/NN in/IN 56/CD fetal/JJ specimens/NNS from/IN 10/CD different/JJ families/NNS of/IN toothed/JJ (/( odontocete/NN )/) and/CC baleen/NN (/( mysticete/NN )/) whales/NNS ,/, 
243_243_27_28_36_37::None::coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) ./. 
422533_4_3_4_35_36::medicine.symptom.symptom_of::Among/IN 1100/CD adrenal/JJ tumors/NNS and/CC 1/CD 002/CD non/JJ -/: hodgkin/NN whosewhat/NN lymphomas/NNS ,/, 21/CD patients/NNS (/( aged/JJ 35/CD to/TO 80/CD years/NNS ,/, mean/VB 56/CD years/NNS )/) were/VBD diagnosed/VBN as/IN having/VBG adrenal/JJ non/JJ -/: Hodgkin/NN whosewhat/NN lymphoma/NN with/IN 14/CD males/NNS 
90_90_5_6_3_4::None::Although/IN co-localization/NN of/IN glucokinase/NN with/IN actin/NN filaments/NNS was/VBD not/RB 
274753_0_0_2_13_14::None::Electronic/JJ cigarettes/NNS (/( e/SYM -/: cigarettes/NNS )/) are/VBP a/DT relatively/RB recent/JJ phenomenon/NN ,/, serving/VBG dual/JJ roles/NNS as/IN 
338450_1_37_38_14_15::None::dependent/JJ on/IN disease/NN stage/NN and/CC patient/NN performance/NN status/NN but/CC ,/, in/IN general/JJ ,/, the/DT most/RBS widely/RB used/VBN approved/VBN regimens/NNS include/VBP 5/LS -/: fluorouracil/NN (/( 5/CD -/: FU/NN )/) combinations/NNS and/CC 
253162_8_20_21_10_11::None:://: IgG2b/NN //: IgG3/NN )/) were/VBD elicited/VBN by/IN omvPV/NN and/CC in/IN a/DT lower/JJR magnitude/NN by/IN wPV/NN ,/, 
268987_0_12_13_6_8::people.cause_of_death.includes_causes_of_death::common/JJ to/TO all/DT solid/JJ tumors/NNS are/VBP tissue/NN hypoxia/NN and/CC inflammation/NN ,/, both/DT of/IN 
750926_1_15_17_16_17::None::on/IN human/JJ cavernous/JJ endothelial/JJ cells/NNS ,/, HCECs/NNS were/VBD 
125415_10_0_1_12_13::None::Llamas/NNP showed/VBD that/IN hyperglycemia/NN coexisted/VBD with/IN hyperinsulinemia/NN (/( in/IN general/JJ on/IN the/DT HP/NNP diet/NN ;/: postprandially/RB 
821060_0_41_42_2_3::None::T/NN -/: cell/NN recognition/NN of/IN minor/JJ histocompatibility/NN antigens/NNS (/( MiHA/NN )/) not/RB only/RB plays/VBZ an/DT important/JJ role/NN in/IN the/DT beneficial/JJ graft/NN -/: versus/CC -/: leukemia/NN (/( GVL/NN )/) effect/NN of/IN allogeneic/JJ stem/NN cell/NN transplantation/NN (/( allo/NN -/: SCT/NN )/) but/CC also/RB mediates/VBZ serious/JJ GVH/NN complications/NNS 
1871_1871_16_17_10_11::POS_REG(-)_Assembly::the/DT association/NN between/IN E-cadherin/NN and/CC alpha-catenin/NN is/VBZ mediated/VBN by/IN beta-catenin/NN ,/, and/CC that/IN 
81377_14_1_2_3_4::medicine.disease.risk_factors::Being/VBG obese/JJ before/IN pregnancy/NN and/CC frequently/RB consuming/JJ 
1820_1820_5_6_12_13::None::profilin/NN I/PRP suppresses/VBZ actin/NN polymerization/NN in/IN microspike/NN formation/NN induced/VBN by/IN N-WASP/NN ,/, the/DT essential/JJ 
458615_4_40_41_38_39::medicine.drug.active_moieties::)/) ,/, and/CC calcium/NN (/( Ca/NN )/) absorption/NN was/VBD 
400251_4_0_1_32_33::None::Patients/NNS were/VBD randomly/RB assigned/VBN (/( 1/CD :/: 1/CD )/) to/TO receive/VB once/RB -/: daily/JJ oral/JJ tablets/NNS containing/VBG 150/CD mg/NN elvitegravir/NN ,/, 150/CD mg/NN cobicistat/NN ,/, 200/CD mg/NN emtricitabine/NN ,/, and/CC 10/CD mg/NN tenofovir/NN alafenamide/NN (/( E/NN 
739268_3_27_28_18_19::None::depressive/JJ and/CC bipolar/JJ disorders/NNS ,/, social/JJ phobia/NN ,/, borderline/JJ personality/NN disorder/NN ,/, schizophrenia/NN and/CC other/JJ psychotic/JJ 
516597_4_1_2_16_17::None::We/PRP identified/VBD 647/CD children/NNS with/IN severe/JJ isolated/VBN head/NN injuries/NNS :/: 337/CD from/IN OEF/NN ,/, 268/CD from/IN OIF/NN ,/, and/CC 42/CD 
165_165_23_24_23_24::POS_ACTION_RELATE::profilin/NN promote/VBP extensive/JJ actin/NN assembly/NN off/IN of/IN 
537465_2_8_10_49_50::None::molecular/JJ regulation/NN of/IN T/NN cell/NN exhaustion/NN ,/, placing/VBG recent/JJ findings/NNS on/IN PD/NN -/: 1/CD blockade/NN therapies/NNS in/IN cancer/NN in/IN the/DT context/NN of/IN the/DT broader/JJR understanding/NN of/IN the/DT roles/NNS of/IN the/DT PD/NN -/: 1/CD :/: PD/NN -/: L1/NN pathway/NN in/IN T/NN cell/NN exhaustion/NN during/IN chronic/JJ infection/NN ./. 
1711_1711_16_19_5_6::None::of/IN the/DT predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN 
28_28_3_4_0_2::None::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN 
884_884_12_13_14_15::None::,/, complexes/NNS of/IN beta-catenin/NN with/IN alpha-catenin/NN and/CC APC/NN were/VBD 
373723_3_6_7_9_10::None::systematic/JJ review/NN to/TO determine/VB the/DT current/JJ worldwide/JJ status/NN of/IN fat/JJ 
460309_1_5_6_25_26::None::the/DT gas/NN -/: phase/NN reactivity/NN of/IN phosphoester/NN bonds/NNS results/VBZ in/IN MS/NN //: MS/NN spectra/NNS dominated/VBN by/IN phosphoric/JJ acid/NN (/( H3PO4/NN )/) neutral/JJ loss/NN events/NNS ,/, suppressing/VBG informative/JJ 
712_712_24_25_27_28::None::with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN ./. 
10441_0_10_11_1_2::None::Distal/JJ symmetric/JJ peripheral/JJ polyneuropathy/NN (/( DSPN/NN )/) is/VBZ a/DT highly/RB prevalent/JJ complication/NN of/IN diabetes/NN 
12271_2_24_25_41_42::None::coupled/VBN to/TO a/DT biotin/NN molecule/NN through/IN the/DT N/NN -/: terminal/JJ amino/NN group/NN and/CC e/SYM -/: amino/NN group/NN of/IN N/NN -/: terminus/NN Lys/NNP ,/, (/( 
466277_5_75_76_72_73::None::III/CD )/) is/VBZ safe/JJ and/CC effective/JJ compared/VBN with/IN standard/JJ treatment/NN 
813_813_27_28_27_28::None::binding/NN sites/NNS on/IN P/NN is/VBZ essential/JJ for/IN 
749940_1_2_4_44_46::None::This/DT historical/JJ cohort/NN study/NN included/VBD adult/JJ patients/NNS (/( gtgt/NN =/JJ 15/CD years/NNS old/JJ )/) with/IN AML/NN (/( n/NN =/JJ 363/CD )/) who/WP received/VBD allogeneic/JJ peripheral/JJ blood/NN stem/NN cell/NN transplantation/NN from/IN HLA/NN -/: identical/JJ sibling/NN donors/NNS in/IN the/DT first/JJ or/CC higher/JJR complete/JJ remission/NN following/VBG myeloablative/JJ conditioning/NN regimens/NNS between/IN 2004/CD and/CC 
134521_6_36_37_0_1::None::The/DT suspected/VBN ability/NN for/IN autonomous/JJ replication/NN ,/, results/NNS of/IN phylogenetic/JJ tree/NN reconstruction/NN ,/, intron/NN lengths/NNS and/CC the/DT structure/NN of/IN the/DT AAP/NNP ,/, suggested/VBD that/IN a/DT single/JJ Squamata/NNP origin/NN instead/RB of/IN the/DT earlier/JJR assumed/VBD diapsid/NN (/( common/JJ avian/JJ -/: reptilian/NN )/) 
1160_1160_8_10_2_3::POS_ACTION_MEMBER::Purification/NN of/IN cofilin/NN ,/, a/DT 21,000/CD molecular/JJ weight/NN actin-binding/JJ protein/NN ,/, from/IN porcine/NN 
784_784_21_22_4_5::NEG_ACTION_COLOCALIZE::normal/JJ livers/NNS ,/, E-cad/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
132031_1_0_1_51_52::None::People/NNS with/IN insulin/NN -/: requiring/VBG type/NN 2/CD diabetes/NN and/CC high/JJ cardiovascular/JJ risk/NN were/VBD enrolled/VBN during/IN a/DT run/NN -/: in/IN period/NN on/IN basal/JJ -/: bolus/NN insulin/NN (/( BBI/NN )/) ,/, and/CC 102/CD were/VBD randomized/VBN to/TO continued/VBN BBI/NNP or/CC to/TO basal/JJ insulin/NN with/IN a/DT prandial/JJ GLP/NN -/: 1/CD receptor/NN agonist/NN (/( GLIPULIN/NN )/) group/NN ,/, each/DT seeking/VBG 
770512_2_5_6_8_9::None::the/DT woman/NN presented/VBD high/JJ fever/NN ,/, myalgia/NN ,/, muscular/JJ weakness/NN 
1761_1761_13_15_15_16::POS_ACTION_MEMBER::,/, the/DT HPIV3/NN nucleocapsid/NN protein/NN N/NN ,/, the/DT phosphoprotein/NN 
76975_8_24_25_4_5::None::results/NNS suggest/VBP that/IN combination/NN of/IN optimal/JJ medical/JJ therapy/NN is/VBZ essential/JJ in/IN management/NN of/IN high/JJ -/: risk/NN hypertensive/JJ patients/NNS ,/, and/CC it/PRP might/MD also/RB reduce/VB cardiovascular/JJ risk/NN ./. 
776_776_4_6_26_27::None::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN 
275901_0_52_53_54_55::medicine.drug.active_moieties::the/DT efficacy/NN of/IN Tenofovir/NNP (/( TDF/NNP )/) rescue/NN regimens/NNS 
1686_1686_51_53_47_48::POS_ACTION_FNSIMILAR::that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP myosin/NN II/CD requires/VBZ isoform/NN specific/JJ 
527579_4_37_38_18_19::medicine.disease.treatments::subjects/NNS who/WP received/VBD intravenous/JJ thrombolysis/NN (/( 99/CD MCA/NNP stoke/VB and/CC 11/CD VBS/NNS )/) A/DT multivariate/JJ model/NN with/IN adjustment/NN for/IN age/NN ,/, baseline/NN stroke/NN severity/NN (/( National/NNP 
1760_1760_5_6_3_4::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC 
125145_4_10_11_0_1::None::Key/NN prospective/JJ studies/NNS have/VBP shown/VBN that/IN rFVIIa/NN achieves/VBZ consistently/RB high/JJ efficacy/NN rates/NNS in/IN the/DT 
686_686_13_14_29_30::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC 
87_87_12_13_16_20::None::cell/NN adhesion/NN to/TO vitronectin/NN ,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN 
350044_5_10_11_10_12::people.cause_of_death.includes_causes_of_death::with/IN women/NNS with/IN heart/NN disease/NN ./. 
379000_0_1_3_10_12::None::Nerve/NN conduction/NN block/NN in/IN diabetic/JJ rats/NNS using/VBG high/JJ -/: intensity/NN focused/VBD ultrasound/NN for/IN analgesic/JJ applications/NNS 
800292_15_22_25_20_21::medicine.disease.risk_factors::male/JJ sex/NN ,/, diabetes/NN ,/, congestive/JJ heart/NN failure/NN ,/, and/CC open/JJ 
244614_0_0_1_44_45::None::The/DT conventional/JJ Phillips/NNP ethylene/NN trimerization/NN catalyst/NN prepared/VBN by/IN reacting/VBG Cr/NN (/( EH/NN )/) 3/CD (/( EH/NN =/JJ 2/CD -/: ethylhexanoate/NN )/) ,/, 2,5/CD -/: dimethylpyrrole/NN (/( Me2C4H2NH/NN )/) ,/, Et3Al/NN ,/, and/CC Et2AlCl/NN in/IN an/DT aromatic/JJ hydrocarbon/NN solvent/JJ was/VBD improved/VBN to/TO obtain/VB a/DT congener/NN composed/VBN of/IN a/DT new/JJ 
1678_1678_33_34_1_2::None::These/DT histone/NN H3/NN and/CC H2a/NN genes/NNS encode/VBP approximately/RB 40/CD %/NN of/IN the/DT total/JJ H3/NN and/CC H2a/NN mRNA/NN ,/, whereas/IN the/DT histone/NN H4/NN and/CC histone/NN H2b/NN genes/NNS encode/VBP </JJR 10/CD %/NN of/IN the/DT total/JJ H4/NN and/CC H2b/NN mRNA/NN 
1162_1162_12_13_6_8::None::cysteine/NN 374/CD of/IN muscle/NN actin/NN reduces/VBZ the/DT affinity/NN for/IN profilin/NN 10-fold/RB ./. 
326684_5_22_23_31_32::None::of/IN miltefosine/NN are/VBP vomiting/VBG ,/, diarrhea/NN ,/, and/CC transient/JJ liver/NN enzyme/NN level/NN elevation/NN ./. 
436129_1_15_16_28_29::medicine.disease.treatments::risk/NN of/IN different/JJ cancers/NNS including/VBG breast/NN cancer/NN (/( BC/NN )/) and/CC may/MD be/VB used/VBN as/IN a/DT chemopreventive/JJ agent/NN against/IN BC/NNP 
798558_0_21_22_22_23::medicine.symptom.symptom_of::X/NN -/: associated/VBN tremor/NN ataxia/NN syndrome/NN (/( FXTAS/NN 
246590_2_40_41_17_18::None::covalency/NN of/IN the/DT aluminate/JJ host/NN lattice/NN ,/, related/JJ to/TO the/DT Sr/NNP //: Al/NNP ratio/NN ,/, on/IN the/DT optical/JJ properties/NNS of/IN the/DT Eu/NN (/( 2/CD +/CC )/) ion/NN ./. 
607_607_19_20_21_22::None::by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS 
861_861_19_20_19_20::None::be/VB involved/VBN in/IN actin/NN polymerization/NN ,/, was/VBD 
2165_2165_15_16_14_15::None::presence/NN of/IN acetylated/VBN histone/NN H4/NN relative/JJ to/TO acetylated/VBN 
458193_0_16_17_25_26::None::arsenic/JJ contents/NNS of/IN groundwater/NN in/IN area/NN and/CC surrounding/VBG environment/NN ,/, of/IN Ika/NNP land/NN in/IN the/DT Delta/NNP 
510261_8_1_2_11_12::None::Our/PRP$ meta/NN -/: analysis/NN results/NNS showed/VBD that/IN plasmapheresis/NN used/VBN as/IN an/DT adjunct/NN to/TO chemotherapy/NN had/VBD 
2131_2131_13_14_21_22::POS_ACTION_LOCALIZE::UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
1337_1337_4_5_12_13::POS_ACTION_RELATE::actin/NN cytoskeleton-associated/JJ protein/NN talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN ./. 
2107_2107_9_10_7_8::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS 
499291_35_4_5_8_9::None::phenotypic/JJ and/CC metabolic/JJ presentations/NNS of/IN women/NNS with/IN PCOS/NN appear/VBP to/TO be/VB 
792678_1_0_1_7_8::medicine.symptom.symptom_of::Delusional/JJ infestation/NN is/VBZ a/DT rare/JJ monosymptomatic/JJ hypochondriacal/JJ psychosis/NN according/VBG to/TO The/DT 
142199_1_23_24_21_22::medicine.disease.symptoms::asymptomatic/JJ bacteremia/NN to/TO fever/NN ,/, endocarditis/NN and/CC death/NN ./. 
125639_3_33_34_22_23::medicine.drug_ingredient.active_moiety_of_drug::had/VBD the/DT typical/JJ copper/NN sites/NNS ,/, type/NN -/: 1/CD ,/, 2/CD ,/, and/CC 3/CD Cu/NN (/( II/CD )/) 
1737_1737_13_15_58_59::None::of/IN PI/NN and/CC PIP/NN kinases/NNS and/CC that/IN under/IN certain/JJ circumstances/NNS activation/NN of/IN the/DT kinases/NNS and/CC the/DT increased/VBN synthesis/NN of/IN PIP/NN and/CC PIP2/NN may/MD be/VB involved/VBN in/IN the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS ,/, possibly/RB through/IN the/DT interaction/NN of/IN the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
392437_4_3_4_22_23::None::There/EX have/VBP been/VBN debates/NNS and/CC conflicting/VBG reports/NNS over/IN the/DT past/JJ few/JJ years/NNS about/IN the/DT value/NN of/IN assessing/VBG levels/NNS of/IN C/NN -/: reactive/JJ protein/NN and/CC other/JJ biomarkers/NNS 
157_157_1_2_24_25::None::Archaeal/NNP histones/NNS are/VBP most/RBS similar/JJ to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN 
1810_1810_0_1_20_21::None::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR regulatory/JJ roles/NNS ,/, as/IN it/PRP was/VBD shown/VBN that/IN their/PRP$ tyrosine/NN phosphorylation/NN correlated/VBD with/IN modified/VBN cadherin/NN activities/NNS ./. 
389675_10_2_4_10_11::None::Recognition/NN of/IN soft/JJ tissue/NN injuries/NNS in/IN patients/NNS with/IN blunt/JJ head/NN trauma/NN is/VBZ important/JJ ./. 
1399_1399_3_4_57_58::None::The/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN (/( VSV/NN )/) serotypes/NNS New/NNP Jersey/NNP [/( P/NN (/( NJ/NNP )/) ]/) and/CC Indiana/NNP [/( P/NN (/( I/NN )/) ]/) contains/VBZ a/DT highly/RB conserved/VBN carboxy-terminal/JJ domain/NN which/WDT is/VBZ required/VBN for/IN binding/VBG to/TO the/DT cognate/JJ N-RNA/NN template/NN as/RB well/RB as/IN to/TO form/VB a/DT soluble/JJ complex/NN with/IN the/DT nucleocapsid/JJ protein/NN N/NN in/FW vivo/FW ./. 
930063_2_13_15_1_2::medicine.disease.treatments::While/IN IV/CD thrombolysis/NN has/VBZ been/VBN shown/VBN to/TO decrease/VB morbidity/NN and/CC mortality/NN from/IN acute/JJ ischemic/JJ stroke/NN ,/, it/PRP is/VBZ 
1338_1338_23_24_5_6::None::monomer-binding/JJ protein/NN ,/, profilin/NN ,/, influences/VBZ the/DT dynamics/NNS of/IN actin/NN filaments/NNS in/FW vitro/FW by/IN suppressing/VBG nucleation/NN ,/, enhancing/VBG nucleotide/NN exchange/NN on/IN actin/NN ,/, and/CC promoting/VBG 
1288_1288_11_12_4_6::POS_ACTION_INTERACT::interaction/NN between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) 
1652_1652_43_44_45_46::None::of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
178297_11_49_51_14_15::None::were/VBD co/SYM -/: infected/VBN with/IN HBV/NN and/CC 1.2/CD %/NN with/IN HCV/NN The/DT main/JJ diagnoses/NNS were/VBD hepatobiliary/JJ diseases/NNS (/( 46/CD %/NN )/) ,/, including/VBG cirrhosis/NN (/( 24.4/CD %/NN )/) ,/, acute/JJ toxic/JJ hepatitis/NN (/( 12/CD %/NN )/) ,/, and/CC hepatocellular/JJ carcinoma/NN (/( 6.1/CD %/NN 
670_670_14_15_19_20::POS_ACTION_COLOCALIZE::that/IN beta-catenin/NN ,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, and/CC cadherin-5/NN were/VBD colocalized/VBN both/CC 
1534_1534_12_13_16_17::None::TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN 
555927_24_35_36_32_33::None::9/CD patients/NNS still/RB presented/VBN paroxymal/JJ rapid/JJ firing/NN within/IN the/DT SVC/NNP 
2107_2107_5_7_39_40::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
1248_1248_9_10_4_5::None::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
1434_1434_14_15_11_12::None::,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB 
22_22_36_37_36_37::POS_REG(+)_Change::)/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT 
1417_1417_17_18_4_5::POS_ACTION_MODIFY::cellular/JJ transcription/NN co-activators/NNS p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS for/IN transformation/NN by/IN the/DT E1A/NN proteins/NNS of/IN non-oncogenic/JJ 
555927_24_58_59_50_51::medicine.medical_treatment.used_to_treat::patients/NNS developed/VBD paroxysmal/JJ atrial/JJ flutter/NN within/IN 1/CD month/NN after/IN completion/NN of/IN ablation/NN and/CC were/VBD controlled/VBN 
187563_7_15_16_24_25::None::3/CD ,/, device/NN embolization/NN -/: 1/CD ,/, hemolysis/NN -/: 1/CD ,/, surgical/JJ VSD/NN closure/NN -/: 2/CD 
333090_0_3_4_5_6::medicine.disease.symptoms::Prevalence/NN estimates/NNS for/IN depression/NN and/CC anxiety/NN in/IN individuals/NNS post/NN 
17565_0_0_1_2_3::None::Rupture/NN of/IN abdominal/JJ aortic/JJ aneurysms/NNS causes/VBZ 
1646_1646_13_14_8_9::None::unable/JJ to/TO bind/VB alpha-catenin/NN that/WDT is/VBZ responsible/JJ for/IN actin/NN filament/NN binding/NN and/CC 
363545_0_12_13_51_52::None::MAOs/NNS )/) have/VBP attracted/VBN great/JJ interest/NN since/IN alterations/NNS in/IN monoaminergic/JJ transmission/NN are/VBP reported/VBN to/TO be/VB related/VBN to/TO neurodegenerative/JJ diseases/NNS such/JJ as/IN Parkinson/NNP whosewhat/NN and/CC Alzheimer/NN whosewhat/NN diseases/NNS and/CC psychiatric/JJ disorders/NNS such/JJ as/IN depression/NN and/CC anxiety/NN ,/, thus/RB MAOs/NNS may/MD be/VB considered/VBN as/IN targets/NNS for/IN the/DT treatment/NN 
340516_1_21_22_54_57::None::URI/NNP in/IN pediatric/JJ outpatients/NNS with/IN diagnoses/NNS of/IN acute/JJ nasopharyngitis/NN (/( common/JJ cold/NN )/) ,/, acute/JJ sinusitis/NN ,/, acute/JJ pharyngitis/NN ,/, acute/JJ tonsillitis/NN ,/, acute/JJ laryngitis/NN //: tracheitis/NN ,/, acute/JJ obstructive/JJ laryngitis/NN //: epiglottitis/NN ,/, and/CC acute/JJ upper/JJ respiratory/JJ infections/NNS of/IN multiple/JJ and/CC 
2085_2085_14_15_17_20::None::cyclin/NN ,/, and/CC p27kip/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, in/IN BALB/c/NN 
1174_1174_27_28_11_14::None::N-terminal/JJ fragment/NN of/IN myosin/NN heavy/JJ chain/NN ,/, which/WDT contains/VBZ the/DT `/`` consensus/NN '/'' ATP/NN binding/NN site/NN ,/, binds/VBZ to/TO actin/NN in/IN an/DT ATP-sensitive/JJ 
72_72_17_18_17_18::None::disrupted/VBN by/IN specific/JJ actin/NN and/CC cofilin/NN mutations/NNS 
416351_15_16_17_21_22::None::history/NN of/IN diabetic/JJ mellitus/NN were/VBD factors/NNS associated/VBN with/IN preeclampsia/NN ./. 
2222_2222_21_22_17_18::None::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
314942_6_12_13_7_9::None::identified/VBD multiple/JJ other/JJ amino/NN acid/NN substitutions/NNS in/IN key/JJ domains/NNS of/IN the/DT HAS2/NN 
851030_23_2_3_23_24::None::If/IN one/CD ovary/NN is/VBZ cryopreserved/VBN at/IN an/DT earlier/JJR stage/NN of/IN POI/NN ,/, patients/NNS could/MD undergo/VB additional/JJ non/JJ -/: invasive/JJ infertility/NN treatments/NNS before/IN the/DT final/JJ decision/NN for/IN the/DT 
257913_10_36_37_19_20::None::as/IN perindopril/NN as/IN optimal/JJ treatment/NN should/MD lead/VB both/DT to/TO improved/VBN BP/NN control/NN and/CC to/TO a/DT better/JJR protection/NN from/IN target/NN organ/NN damage/NN ,/, thereby/RB reducing/VBG 
93_93_11_12_50_51::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
178051_0_26_27_35_36::None::stroke/NN has/VBZ a/DT negative/JJ effect/NN on/IN functional/JJ outcome/NN at/IN 6/CD months/NNS ,/, measured/VBN by/IN the/DT modified/VBN 
1771_1771_15_16_1_2::None::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO 
1653_1653_44_45_42_43::POS_ACTION_Change::and/CC MSH6/NN or/CC MSH2/NN and/CC MSH3/NN ./. 
1227_1227_26_27_10_11::POS_ACTION_INTERACT::two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN ,/, ''/'' and/CC pairwise/JJ interactions/NNS between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, RAD3/NN ,/, RAD10/NN ,/, 
189032_0_5_6_19_20::medicine.disease.risk_factors::Related/JJ Consequences/NNS Mediating/VBG PTSD/NN Symptoms/NNS and/CC Mental/NNP Health/NNP -/: Related/JJ Quality/NNP of/IN Life/NNP in/IN OEF/NNP //: OIF/NNP Combat/NNP Veterans/NNP ./. 
492_492_17_19_25_27::None::that/IN ,/, like/IN beta/NN 1-syntrophin/NN ,/, both/CC beta/NN 2/CD -/: and/CC alpha/NN 1-syntrophin/JJ interact/NN with/IN peptides/NNS 
667084_2_13_14_15_16::medicine.symptom.symptom_of::health/NN disorders/NNS including/VBG anxiety/NN ,/, depression/NN ,/, and/CC suicidal/JJ 
1866_1866_5_6_3_4::None::Thus/RB ,/, both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, 
93_93_22_23_54_55::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
151537_7_2_3_41_42::people.cause_of_death.includes_causes_of_death::The/DT shared/JJ cancers/NNS between/IN humans/NNS and/CC dogs/NNS that/IN we/PRP discuss/VBP include/VBP sarcoma/NN (/( osteosarcoma/NN ,/, soft/JJ tissue/NN sarcoma/NN ,/, histiocytic/JJ sarcoma/NN ,/, hemangiosarcoma/NN )/) ,/, haematological/JJ malignancies/NNS (/( lymphoma/NN ,/, leukaemia/NN )/) ,/, bladder/NN cancer/NN ,/, intracranial/JJ neoplasms/NNS (/( meningioma/NN ,/, glioma/NN )/) and/CC melanoma/NN 
162721_4_36_37_8_9::None::ovaries/NNS from/IN newborn/JJ mice/NNS were/VBD collected/VBN and/CC cultured/VBN with/IN vehicle/NN (/( dimethyl/JJ sulfoxide/NN ,/, DMSO/NN )/) or/CC different/JJ doses/NNS of/IN BPA/NN (/( 0.1/CD ,/, 1/CD ,/, 5/CD ,/, and/CC 10mug/JJ //: mL/NN )/) ./. 
1434_1434_11_12_7_8::None::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN 
369607_2_19_20_5_6::None::3/CD exhibited/VBD excellent/JJ selectivity/NN toward/IN heparin/NN among/IN various/JJ anions/NNS and/CC competitors/NNS of/IN heparin/NN including/VBG chondroitin/NN 4/CD -/: sulfate/NN (/( ChS/NN )/) 
21_21_21_22_16_17::None::is/VBZ revealed/VBN by/IN RAD51/NN overexpression/NN suppression/NN of/IN C-terminal/JJ rad52/NN truncation/NN alleles/NNS ./. 
543881_0_7_8_22_23::None::)/) is/VBZ a/DT chronic/JJ autoimmune/JJ inflammatory/JJ disease/NN of/IN unknown/JJ aetiology/NN ,/, leading/VBG to/TO progressive/JJ damage/NN of/IN bone/NN and/CC cartilage/NN with/IN functional/JJ impairment/NN 
254040_6_50_52_23_24::None::on/IN call/NN to/TO read/VB EEGs/NNS We/PRP compared/VBD the/DT epileptologist/NN whosewhat/NN interpretation/NN of/IN the/DT reduced/VBN montage/NN EEG/NN to/TO the/DT results/NNS of/IN the/DT 23/CD -/: lead/JJ EEG/NN ,/, which/WDT was/VBD considered/VBN the/DT gold/JJ standard/NN for/IN detecting/VBG seizures/NNS 
204981_8_42_43_1_2::medicine.risk_factor.diseases::Genetic/JJ disruption/NN of/IN TLR4/NN signaling/NN recapitulates/VBZ the/DT effects/NNS of/IN pharmacological/JJ TLR4/NN blockade/NN ,/, providing/VBG converging/VBG lines/NNS of/IN evidence/NN of/IN a/DT central/JJ importance/NN of/IN TLR4/NN Taken/VBN together/RB ,/, multiple/JJ lines/NNS of/IN evidence/NN converge/VBP to/TO raise/VB TLR4/NN as/IN a/DT promising/JJ therapeutic/JJ target/NN for/IN drug/NN abuse/NN ./. 
1570_1570_6_7_2_3::None::The/DT N-terminal/JJ talin/NN polypeptide/NN eventually/RB disrupted/VBD actin/NN stress/NN fibres/NNS whereas/IN 
564_564_22_23_20_21::None::of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN ,/, enhanced/VBD association/NN 
1052_1052_21_22_18_20::None::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG 
468565_7_4_6_6_7::None::h/NN after/IN the/DT heat/NN waves/NNS ended/VBD ,/, indicating/VBG rapid/JJ 
1052_1052_27_28_12_13::None::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) 
10363_2_6_7_10_11::medicine.risk_factor.diseases::6J/NN mice/NNS made/VBD diabetic/JJ by/IN a/DT single/JJ high/JJ dose/NN injection/NN of/IN 
367_367_26_27_28_30::None::as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
162957_0_32_33_47_48::None::a/DT recently/RB developed/VBN murine/JJ model/NN of/IN atopic/JJ dermatitis/NN (/( AD/NN )/) elicited/VBN by/IN epicutaneous/JJ sensitization/NN with/IN ovalbumin/NN (/( OVA/NN )/) ./. 
1486_1486_35_40_24_25::None::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ 
242622_9_15_16_12_13::None::associated/VBN with/IN reduced/VBN cancer/NN -/: specific/JJ mortality/NN among/IN prostate/NN cancer/NN 
434463_2_6_7_45_46::None::to/TO test/VB two/CD propofol/NN products/NNS ,/, Diprivan/NNP (/( Registered/NNP )/) and/CC Fresofol/NN (/( Registered/NNP )/) ,/, with/IN the/DT Pall/NN Lipipor/NN (/( Registered/NNP )/) TNA/NNP and/CC Lipipor/NNP NLF/NNP intravenous/JJ in/IN -/: line/NN filters/NNS and/CC to/TO assay/VB the/DT content/NN before/IN and/CC after/IN filtration/NN under/IN typical/JJ infusion/NN conditions/NNS ./. 
1417_1417_7_9_17_18::None::p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS for/IN transformation/NN by/IN the/DT E1A/NN proteins/NNS of/IN non-oncogenic/JJ 
339_339_15_16_10_11::POS_ACTION_RELATE::modulation/NN of/IN the/DT actin/NN cytoskeleton/NN by/IN cofilin/NN and/CC Aip1/NN ./. 
405531_0_15_16_15_18::biology.organism_classification.lower_classifications::antiviral/JJ active/JJ against/IN influenza/NN A/NN virus/NN ./. 
986_986_11_12_25_26::POS_ACTION_BIND::central/JJ role/NN of/IN beta-catenin/NN in/IN this/DT adhesion/NN complex/NN ,/, as/IN it/PRP binds/VBZ to/TO the/DT cytoplasmic/JJ domain/NN of/IN E-cadherin/NN and/CC to/TO alpha-catenin/NN 
157_157_14_15_24_25::None::of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN 
452997_6_12_13_5_6::None::Klotho/NNP augmented/VBD the/DT Epo/NN -/: triggered/JJ phosphorylation/NN of/IN Jak2/NN and/CC Stat5/NN and/CC protected/VBD H19/NN 
1037_1037_24_26_4_5::POS_ACTION_INTERACT::disclosed/VBN interactions/NNS between/IN gephyrin/NN ,/, exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD 
459318_0_0_1_18_19::None::Synthesis/NN of/IN copper/NN micro/JJ -/: rods/NNS with/IN layered/JJ nano/NN -/: structure/NN by/IN thermal/JJ decomposition/NN of/IN the/DT coordination/NN complex/NN Cu/NN (/( BTA/NN )/) 
483185_4_25_26_8_9::None::based/VBN on/IN adequate/JJ population/NN samples/NNS have/VBP shown/VBN a/DT higher/JJR frequency/NN of/IN genetic/JJ polymorphisms/NNS of/IN the/DT LHCGR/NNP ,/, THADA/NNP and/CC DENND1A/NN genes/NNS in/IN women/NNS with/IN 
779_779_6_7_21_24::None::mechanism/NN by/IN which/WDT pRb/NN induces/VBZ senescence/NN ,/, we/PRP have/VBP found/VBN that/IN pRb/NN causes/VBZ a/DT posttranscriptional/JJ accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN 
813_813_23_24_23_24::None::of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN 
125951_3_21_22_42_43::medicine.medical_treatment.used_to_treat::local/JJ analgesics/NNS and/CC dexamethasone/NN )/) can/MD induce/VB apoptosis/NN in/IN cancer/NN cells/NNS and/CC //: or/CC diminish/VB the/DT inflammatory/JJ response/NN during/IN surgery/NN which/WDT itself/PRP can/MD facilitate/VB tumor/NN growth/NN ./. 
174565_5_35_36_28_29::None::)/) ,/, a/DT secreted/VBN peptide/NN ,/, through/IN comparison/NN of/IN gene/NN expression/NN profiles/NNS in/IN the/DT 
306632_3_8_9_43_44::medicine.disease.symptoms::found/VBD that/IN the/DT diabetes/NN resolution/NN after/IN LSG/NNP occurred/VBD in/IN 40/CD %/NN of/IN patients/NNS ;/: in/IN the/DT other/JJ 60/CD %/NN ,/, even/RB if/IN they/PRP showed/VBD a/DT normal/JJ fasting/NN glycemia/NN and/CC A1c/NN ,/, patients/NNS spent/VBD a/DT lot/NN of/IN time/NN in/IN hyperglycemia/NN ./. 
233540_0_8_9_33_34::medicine.risk_factor.diseases::in/IN people/NNS with/IN diabetes/NN ,/, measured/VBN as/IN glycated/JJ haemoglobin/NN (/( HbA1c/NN )/) ,/, influences/VBZ the/DT role/NN of/IN leisure/NN time/NN physical/JJ activity/NN on/IN the/DT increased/VBN risk/NN of/IN death/NN from/IN cardiovascular/JJ disease/NN ./. 
792620_5_28_29_15_16::None::antiarthritic/JJ activity/NN in/IN carrageenan/NN rat/NN induced/VBD paw/NN oedema/NN and/CC complete/JJ Freund/NN whosewhat/NN adjuvant/JJ induced/VBN arthritis/NN in/IN rats/NNS ./. 
2075_2075_14_15_21_23::None::interact/VB with/IN yeast/NN profilin/NN and/CC tropomyosin/NN ,/, the/DT only/JJ yeast/NN actin-binding/JJ proteins/NNS so/RB far/RB purified/VBN 
250070_2_54_55_73_74::medicine.disease.risk_factors::Epidemiology/NNP Collaboration/NNP (/( CKD/NNP -/: EPI/NN )/) creatinine/NN and/CC cystatin/NN C/NN -/: creatinine/NN ]/) were/VBD associated/VBN with/IN markers/NNS of/IN systemic/JJ inflammation/NN [/( high/JJ -/: sensitivity/NN C/NN 
1137_1137_11_12_15_16::POS_ACTION_BIND::physiological/JJ role/NN of/IN profilin/NN ,/, a/DT 12-15-kD/JJ actin/NN -/: and/CC phosphoinositide-binding/JJ 
1094_1094_22_23_14_15::POS_ACTION_CONTAIN::three/CD subunits/NNS ,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT eIF3/NN complex/NN ./. 
566167_0_12_13_12_14::medicine.disease.treatments::in/IN acute/JJ inpatient/JJ stroke/NN rehabilitation/NN ,/, though/IN such/JJ 
143595_7_23_24_9_10::medicine.drug_ingredient.active_moiety_of_drug::were/VBD exposed/VBN to/TO nitrate/VB concentrations/NNS of/IN 50/CD ,/, 100/CD ,/, 200/CD ,/, and/CC 400/CD mg/NN //: L/NN NO3/NN (/( -/: )/) 
800922_2_19_20_6_7::None::suggested/VBN that/IN the/DT irreversible/JJ MAO/NNP -/: B/NN inhibitors/NNS selegiline/NN and/CC rasagiline/NN exert/VBP a/DT neuroprotective/JJ effect/NN in/IN Parkinson/NNP whosewhat/NN and/CC Alzheimer/NN 
1866_1866_12_13_7_8::None::and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN in/IN their/PRP$ signal/NN 
787228_4_0_1_23_24::None::Our/PRP$ results/NNS revealed/VBD that/IN COPD/NNP was/VBD significantly/RB associated/VBN with/IN a/DT high/JJ risk/NN of/IN osteoporosis/NN ,/, regardless/RB of/IN whether/IN the/DT patients/NNS with/IN COPD/NN were/VBD corticosteroid/NN users/NNS and/CC irrespective/RB 
2131_2131_7_8_21_22::POS_ACTION_LOCALIZE::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
237202_1_2_3_26_27::None::Here/RB we/PRP describe/VBP the/DT first/JJ use/NN of/IN daclatasvir/NN ,/, simeprevir/NN ,/, and/CC ribavirin/NNP (/( RBV/NN )/) as/IN an/DT all/DT -/: oral/JJ triple/JJ regimen/NN administered/VBN to/TO 6/CD liver/NN transplant/NN recipients/NNS with/IN 
1062_1062_10_11_13_15::None::the/DT gene/NN encoding/VBG fimbrin/NN ,/, another/DT actin-binding/JJ protein/NN ,/, which/WDT was/VBD 
244614_0_11_12_8_9::None::catalyst/NN prepared/VBN by/IN reacting/VBG Cr/NN (/( EH/NN )/) 3/CD (/( 
374_374_12_13_14_15::None::but/CC deletion/NN of/IN SIR1/NN or/CC SIR3/NN did/VBD not/RB affect/VB 
265345_3_11_12_19_21::None::also/RB reported/VBN following/VBG macroscopic/JJ haematuria/NN -/: associated/VBN acute/JJ kidney/NN injury/NN in/IN immunoglobulin/NN A/NN nephropathy/NN ./. 
991_991_17_18_15_16::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN 
872_872_11_12_8_9::None::of/IN MSH2/NN ,/, MSH3/NN ,/, and/CC MSH6/NN in/IN mismatch/NN repair/NN 
389675_10_6_7_2_4::None::Recognition/NN of/IN soft/JJ tissue/NN injuries/NNS in/IN patients/NNS with/IN blunt/JJ head/NN 
95605_9_63_64_20_21::None::by/IN head/NN and/CC neck/NN area/NN irradiation/NN (/( OR/NN =/JJ 2.41/CD ,/, 95/CD %/NN CI/NN :/: 1.49/CD -/: 3.89/CD ,/, p/NN =/JJ 0.0003/CD )/) and/CC breast/NN irradiation/NN (/( OR/NN =/JJ 1.41/CD ,/, 95/CD %/NN CI/NN :/: 1.02/CD -/: 1.95/CD ,/, p/NN =/JJ 0.04/CD )/) ,/, whereas/IN the/DT correlation/NN was/VBD not/RB significant/JJ 
1017_1017_4_5_2_3::None::Mutations/NNS in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD 
1037_1037_9_11_4_5::POS_ACTION_INTERACT::disclosed/VBN interactions/NNS between/IN gephyrin/NN ,/, exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN 
868728_2_10_11_6_7::None::thought/VBN to/TO cause/VB animal/NN distress/NN or/CC serious/JJ pathology/NN unless/IN infection/NN progresses/VBZ 
605_605_23_24_8_9::None::encodes/VBZ a/DT heterotrimeric/JJ helicase-primase/NN complex/NN that/WDT is/VBZ composed/VBN of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN genes/NNS ./. 
452763_3_0_1_37_39::None::Experimental/JJ and/CC clinical/JJ observations/NNS suggest/VBP that/IN Vit/NN D/NN and/CC its/PRP$ analogues/NNS may/MD be/VB effective/JJ in/IN preventing/VBG the/DT malignant/JJ transformation/NN and/CC //: or/CC the/DT progression/NN of/IN various/JJ types/NNS of/IN human/JJ tumors/NNS including/VBG breast/NN cancer/NN ,/, prostate/NN cancer/NN ,/, colorectal/JJ cancer/NN ,/, and/CC some/DT 
1534_1534_26_29_32_33::None::the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
93_93_28_29_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
1221_1221_21_22_18_19::POS_ACTION_SIMILAR::bind/VBP to/TO the/DT armadillo/NN repeats/NNS of/IN beta-catenin/NN ,/, but/CC not/RB 
479157_1_36_37_42_43::biology.organism_classification.lower_classifications::shows/VBZ that/IN the/DT bacteria/NNS belongs/VBZ to/TO Gram/NN -/: positive/JJ Firmicutes/NNS ./. 
284253_6_54_55_47_49::medicine.medical_treatment.used_to_treat::infusion/NN ,/, some/DT dopamine/NN agonists/NNS (/( ropinirole/NN ,/, cabergoline/NN ,/, pergolide/NN )/) ,/, and/CC 
1742_1742_15_16_4_5::None::results/NNS suggest/VBP that/IN profilin/NN may/MD be/VB involved/VBN in/IN the/DT pathogenesis/NN of/IN glomerulonephritis/NN by/IN reorganizing/VBG actin/NN cytoskeleton/NN ./. 
988_988_20_21_15_16::None::vinculin/NN and/CC the/DT beta-catenin/NN is/VBZ homologous/JJ to/TO human/JJ plakoglobin/NN and/CC the/DT Drosophila/NN 
768_768_13_14_24_27::POS_ACTION_BIND::of/IN the/DT parental/JJ profilin/NN ,/, and/CC the/DT Kd/NN value/NN of/IN its/PRP$ interaction/NN with/IN rabbit/NN skeletal/JJ muscle/NN actin/NN ,/, as/IN determined/VBN 
986_986_25_26_28_29::None::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN and/CC to/TO alpha-catenin/NN ./. 
822_822_4_5_6_7::None::of/IN the/DT yeast/NN RAD51/NN and/CC RAD52/NN proteins/NNS plays/VBZ a/DT 
1779_1779_5_7_6_7::None::of/IN pyrene-labeled/JJ rabbit/NN skeletal/JJ actin/NN with/IN human/JJ profilin/NN 
2107_2107_15_16_24_26::None::targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, 
807975_0_9_10_12_13::medicine.symptom.symptom_of::inhibitor/NN amitifadine/NN on/IN pain/NN -/: related/JJ depression/NN of/IN behavior/NN and/CC 
513_513_7_8_12_13::None::(/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO 
573743_7_27_28_10_11::None::pain/NN through/IN central/JJ mechanisms/NNS including/VBG maternal/JJ illness/NN ,/, exhaustion/NN ,/, lack/NN of/IN support/NN ,/, anxiety/NN ,/, depression/NN or/CC history/NN of/IN abuse/NN ./. 
1861_1861_2_3_10_11::None::Thus/RB ,/, APC/NN forms/NNS distinct/JJ heteromeric/JJ complexes/NNS containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
148500_0_18_19_21_22::None::Computational/JJ Cascade/NNP of/IN Neuronal/JJ Mass/JJ and/CC Compartmental/JJ Modeling/NN ./. 
960_960_5_6_9_10::POS_ACTION_ENCODE::the/DT previously/RB identified/VBN VRP1/NN ,/, which/WDT encodes/VBZ verprolin/NN ,/, required/VBN for/IN 
235160_8_2_3_29_30::None::High/JJ -/: throughput/NN 454/CD pyrosequencing/NN of/IN total/JJ DNA/NN isolated/VBN from/IN the/DT methanogenic/JJ microbial/JJ community/NN and/CC bioinformatic/JJ sequence/NN analysis/NN revealed/VBD that/IN the/DT domain/NN Bacteria/NNS was/VBD dominated/VBN by/IN Firmicutes/NNS (/( mainly/RB Clostridia/NNP )/) ,/, Bacteroidetes/NNP 
309692_18_54_55_64_65::None::a/DT long/JJ -/: term/NN challenge/NN of/IN these/DT treatments/NNS at/IN isoeffective/JJ doses/NNS in/IN COPD/NN patients/NNS ./. 
92153_1_10_11_0_1::None::The/DT aim/NN of/IN this/DT study/NN was/VBD to/TO identify/VB the/DT overall/JJ management/NN and/CC antiarrhythmic/JJ therapy/NN 
227_227_7_9_3_6::None::Binding/NN to/TO human/JJ dipeptidyl/NN peptidase/NN IV/CD by/IN adenosine/NN deaminase/NN and/CC antibodies/NNS that/WDT 
556245_5_16_17_20_21::None::hospitalization/NN rates/NNS for/IN CHF/NN and/CC //: or/CC COPD/NNP exacerbation/NN between/IN patients/NNS 
266602_0_14_16_1_4::None::Erythrocyte/NN polyunsaturated/JJ fatty/JJ acid/NN levels/NNS in/IN young/JJ people/NNS at/IN ultra/NN -/: high/JJ risk/NN for/IN psychotic/JJ disorder/NN and/CC healthy/JJ adolescent/JJ 
2076_2076_16_18_28_29::POS_ACTION_MEMBER::(/( r/NN )/) actin-binding/JJ protein/NN of/IN 143/CD amino/NN acid/NN (/( aa/NN )/) residues/NNS (/( yeast/NN cofilin/NN ;/: Cof/NN )/) 
1580_1580_23_24_18_19::POS_ACTION_BIND::protein/NN complex/NN containing/VBG E-cadherin/NN and/CC its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, 
1055_1055_0_1_2_3::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN 
142623_1_12_13_10_11::medicine.drug.active_moieties::in/IN response/NN to/TO aluminum/NN (/( Al/NNP )/) ,/, a/DT 
1380_1380_26_27_40_41::None::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN 
540781_2_7_8_19_20::None::-/: 1/CD drug/NN resistance/NN is/VBZ therefore/RB of/IN great/JJ importance/NN to/TO evaluate/VB the/DT current/JJ sensitivity/NN of/IN antiretroviral/JJ agents/NNS and/CC is/VBZ 
933691_0_9_10_15_17::None::leads/VBZ to/TO a/DT reduction/NN of/IN fatigue/NN and/CC pain/NN in/IN chronic/JJ fatigue/NN syndrome/NN (/( CFS/NN 
556245_5_25_26_16_17::medicine.medical_treatment.used_to_treat::hospitalization/NN rates/NNS for/IN CHF/NN and/CC //: or/CC COPD/NNP exacerbation/NN between/IN patients/NNS receiving/VBG carvedilol/NN and/CC bisoprolol/NN ./. 
2000_2000_10_11_4_5::POS_ACTION_COLOCALIZE::endothelial/JJ cadherin/NN (/( VE-cadherin/NN )/) clusters/NNS were/VBD co-localized/VBN with/IN beta-catenin/NN ,/, an/DT important/JJ 
1843_1843_19_20_19_20::None::that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT 
476195_1_13_14_13_14::medicine.drug_ingredient.active_moiety_of_drug::NPs/NNS and/CC soluble/JJ Cu/NN in/IN the/DT intestines/NNS 
183829_5_18_19_5_6::None::of/IN its/PRP$ juvenile/JJ nature/NN ,/, the/DT tail/NN plumage/NN resembles/VBZ the/DT feathering/NN of/IN adult/JJ individuals/NNS of/IN modern/JJ birds/NNS ./. 
202451_1_45_46_3_4::None::The/DT X/NN -/: ray/NN crystal/NN structure/NN of/IN the/DT host/NN N2/NN ,/, N5/NN -/: bis/NN (/( 6/CD -/: methylpyridin/NN -/: 2/LS -/: yl/NN )/) -/: 3,4/SYM -/: diphenyl/NN -/: 1H/NN -/: pyrrole/NN -/: 2,5/SYM -/: dicarboxamide/NN (/( 1/CD )/) has/VBZ been/VBN solved/VBN (/( P21/NN //: c/NN monoclinic/JJ space/NN group/NN )/) 
2222_2222_23_24_37_38::None::,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
2131_2131_13_14_10_11::None::UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ 
635_635_21_22_7_8::POS_ACTION_BIND::(/( e.g./FW ,/, profilin/NN )/) and/CC other/JJ agents/NNS (/( e.g./FW ,/, cytochalasin/NN D/NN )/) that/WDT bind/VBP to/TO actin/NN are/VBP affected/VBN by/IN 
287181_0_30_31_7_10::None::also/RB known/VBN as/IN coronary/JJ heart/NN disease/NN or/CC coronary/JJ artery/NN disease/NN ,/, accounts/NNS for/IN &/CC gt/NN ;/: 50/CD %/NN of/IN cardiovascular/JJ events/NNS and/CC is/VBZ a/DT leading/VBG cause/NN worldwide/RB of/IN morbidity/NN and/CC 
1782_1782_11_12_25_26::POS_ACTION_LOCALIZE::)/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: 
712_712_27_28_24_25::None::with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN ./. 
780682_8_6_7_2_3::None::Our/PRP$ data/NNS highlight/VBP the/DT key/JJ biological/JJ functions/NNS of/IN ceramidases/NNS in/IN 
832646_0_1_2_4_5::None::Disability/NN identity/NN predicts/VBZ lower/JJR anxiety/NN and/CC depression/NN in/IN 
1534_1534_32_33_34_35::None::and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) are/VBP controversial/JJ 
1771_1771_1_2_15_16::POS_ACTION_SIMILAR::The/DT Src/NN homology/NN domain/NN 3/CD (/( SH3/NN )/) of/IN a/DT yeast/NN type/NN I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO 
955511_15_13_14_22_23::None::in/IN the/DT anode/NN biofilms/NNS and/CC Firmicutes/NNS phylum/NN was/VBD predominant/JJ on/IN anolyte/NN to/TO transfer/VB electron/NN ./. 
905933_12_0_1_6_7::None::Our/PRP$ results/NNS suggest/VBP that/IN DIR/NN -/: based/VBN dose/NN accumulation/NN may/MD 
616400_0_4_5_9_10::biology.organism_classification.lower_classifications::and/CC maintenance/NN of/IN Ambystoma/NN mexicanum/NN ,/, the/DT Mexican/JJ axolotl/NN ./. 
996_996_29_30_31_34::None::the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
1683_1683_8_9_15_16::POS_REG(0)_Assembly::co-operativity/NN between/IN the/DT profilin/NN and/CC DNase/NN I/CD binding/NN sites/NNS on/IN actin/NN ./. 
1870_1870_8_9_16_17::POS_REG(0)_ASSEMBLE::that/IN the/DT both/DT cofilin/NN isoforms/NNS are/VBP involved/VBN in/IN the/DT regulation/NN of/IN actin/NN assembly/NN during/IN myofibrillogenesis/NN 
1917_1917_2_3_14_15::None::To/TO study/VB profilin/NN function/NN ,/, we/PRP extensively/RB mutagenized/VBD the/DT Saccharomyces/FW cerevisiae/FW profilin/NN gene/NN (/( PFY1/NN )/) and/CC examined/VBD 
503817_10_2_3_3_4::None::Differential/JJ hepatocyte/NN transfusion/NN rates/NNS contributed/VBD to/TO accelerated/VBN 
293937_0_0_1_11_12::medicine.disease.symptoms::Asthma/NN -/: onset/NN in/IN older/JJR individuals/NNS has/VBZ been/VBN associated/VBN with/IN an/DT accelerated/VBN decline/NN in/IN lung/NN 
712_712_11_12_23_24::None::to/TO suggest/VB that/IN HRG/NN stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN 
896731_2_2_3_3_4::None::An/DT acute/JJ MI/NNP model/NN was/VBD induced/VBN in/IN 
771_771_7_8_13_14::POS_ACTION_INTERACT::of/IN cofilin/NN ,/, destrin/NN ,/, and/CC deoxyribonuclease/NN I/PRP with/IN actin/NN by/IN phosphoinositides/NNS ./. 
38537_2_21_22_26_27::None::SPECT/NNP -/: CT/NN images/NNS coupled/VBN GATE/NNP Monte/NNP Carlo/NNP package/NN for/IN internal/JJ dosimetry/NN 
16153_0_3_6_0_1::medicine.disease.risk_factors::Elderly/JJ patients/NNS with/IN chronic/JJ lymphocytic/JJ leukemia/NN (/( CLL/NN )/) 
678566_0_16_17_14_15::None::,/, is/VBZ the/DT target/NN for/IN levetiracetam/NN (/( LEV/NN )/) 
714216_1_21_22_41_42::medicine.disease.risk_factors::retinal/JJ cells/NNS in/IN high/JJ glucose/NN and/CC of/IN the/DT alpha1/NN -/: adrenergic/JJ receptor/NN (/( AR/NN )/) on/IN vascular/JJ lesions/NNS of/IN the/DT retinopathy/NN in/IN experimentally/RB diabetic/JJ C57Bl/NN //: 6J/NN 
95871_5_6_7_16_17::None::,/, urine/NN was/VBD assessed/VBN for/IN norepinephrine/NN (/( NE/NN )/) levels/NNS ,/, blood/NN for/IN EPO/NN and/CC hemoglobin/NN (/( 
539_539_5_6_15_16::POS_ACTION_Causal::we/PRP show/VBP that/IN talin/NN ,/, a/DT high/JJ molecular/JJ weight/NN structural/JJ protein/NN that/WDT links/VBZ integrins/NNS to/TO the/DT actin/NN 
373109_2_2_3_13_14::None::Atomic/JJ force/NN microscopic/JJ observations/NNS and/CC the/DT results/NNS of/IN a/DT quantitative/JJ analysis/NN using/VBG a/DT quartz/NN -/: crystal/NN microbalance/NN 
1337_1337_9_10_4_5::None::actin/NN cytoskeleton-associated/JJ protein/NN talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN 
441567_0_16_17_20_21::None::treatment/NN in/IN intrahepatic/JJ cholestasis/NN of/IN pregnancy/NN (/( ICP/NN )/) ./. 
831385_3_25_26_16_17::biology.organism_classification.lower_classifications::effect/NN on/IN P/NN falciparum/NN and/CC recent/JJ studies/NNS have/VBP provided/VBN evidence/NN that/IN the/DT parasite/NN with/IN this/DT mutation/NN 
693828_2_1_2_2_3::None::A/DT systematic/JJ literature/NN search/NN was/VBD conducted/VBN 
1843_1843_19_20_12_13::None::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT 
229284_0_23_24_10_11::None::the/DT ''/'' anchor/NN drug/NN ''/'' for/IN treating/VBG rheumatoid/JJ arthritis/NN (/( RA/NN )/) ,/, varies/VBZ among/IN individual/JJ patients/NNS ./. 
403501_2_24_25_21_22::None::malaria/NN transmission/NN in/IN southern/JJ Zambia/NNP using/VBG samples/NNS from/IN community/NN -/: 
739268_3_15_16_8_9::None::social/JJ withdrawal/NN or/CC potential/JJ liability/NN to/TO others/NNS (/( ie/FW ,/, depressive/JJ and/CC bipolar/JJ disorders/NNS 
112_112_14_16_3_4::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN epithelial/JJ cells/NNS and/CC forms/VBZ a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN 
250_250_7_8_14_15::None::of/IN N-cadherin/NN and/CC alpha-catenin/NN which/WDT bind/VBP to/TO either/CC beta-catenin/NN or/CC plakoglobin/NN in/IN a/DT mutually/RB 
459561_0_18_19_11_12::None::,/, a/DT selective/JJ sodium/NN -/: glucose/NN cotransporter/NN 2/CD inhibitor/NN ,/, compared/VBN with/IN placebo/NN in/IN 
464783_0_24_25_21_23::None::of/IN cirrhosis/NN with/IN portal/JJ hypertension/NN and/CC defines/VBZ novel/JJ strategies/NNS and/CC 
491599_4_6_7_26_27::None::positive/JJ effects/NNS of/IN TQ/NN in/IN cardiovascular/JJ disorders/NNS ,/, diabetes/NN ,/, reproductive/JJ disorders/NNS and/CC respiratory/JJ ailments/NNS ,/, as/RB well/RB as/IN in/IN the/DT treatment/NN of/IN bone/NN complications/NNS as/RB well/RB 
1457_1457_34_35_28_30::POS_ACTION_BIND::(/( 1/LS )/) profilin/NN I/PRP functions/VBZ predominantly/RB as/IN an/DT actin/NN monomer-binding/JJ protein/NN ;/: 
799750_8_23_24_4_5::None::borderline/JJ and/CC malignant/JJ phyllode/NN tumors/NNS have/VBP different/JJ distant/JJ metastasis/NN risk/NN ,/, different/JJ primary/JJ tumor/NN size/NN and/CC different/JJ surgical/JJ procedures/NNS ,/, and/CC malignant/JJ PTs/NNS are/VBP more/RBR likely/JJ 
173839_13_7_8_4_5::biology.organism_classification.lower_classifications::abstractCompounds/NNS isolated/VBN from/IN Helichrysum/NNP species/NNS (/( Compositae/NNS )/) ./. 
34897_2_16_17_22_23::medicine.drug.active_moieties::ml/NN )/) and/CC calcium/NN (/( 50.0/CD -/: 600.0/CD mg/NN Ca/NN //: ml/NN )/) 
1096_1096_9_10_14_15::None::pool/NN of/IN polymerizable/JJ actin/NN monomers/NNS is/VBZ complexed/VBN with/IN profilin/NN and/CC spread/NN throughout/IN 
991_991_4_5_20_21::None::known/VBN to/TO link/VB actin/NN filaments/NNS to/TO membrane/NN were/VBD also/RB examined/VBN ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
1069_1069_36_37_46_47::None::origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
306064_4_29_30_34_35::None::the/DT effect/NN of/IN denosumab/NN on/IN GCRG/NN of/IN the/DT spine/NN is/VBZ unknown/JJ ./. 
236807_0_2_3_17_19::None::The/DT nonsteroidal/JJ antiinflammatory/JJ drug/NN piroxicam/NN reverses/VBZ the/DT onset/NN of/IN depressive/JJ -/: like/IN behavior/NN in/IN 6/CD -/: OHDA/NN animal/NN model/NN of/IN Parkinson/NNP whosewhat/NN 
177255_4_10_11_8_9::medicine.symptom.symptom_of::to/TO protect/VB from/IN diabetic/JJ foot/NN infection/NN with/IN modified/VBN cotton/NN 
811_811_11_13_15_16::POS_ACTION_MEMBER::,/, interact/VBP with/IN actin-binding/JJ proteins/NNS (/( e.g./FW talin/NN and/CC filamin/NN )/) 
489_489_20_21_15_16::None::histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP 
235_235_11_12_1_2::POS_ACTION_BIND::Birch/NNP profilin/NN increased/VBD the/DT critical/JJ concentration/NN required/VBN for/IN muscle/NN and/CC brain/NN actin/NN polymerization/NN in/IN a/DT 
429131_8_31_32_32_33::None::the/DT PI3K/NN //: Akt/NN pathway/NN of/IN EGCG/NN may/MD 
2107_2107_5_7_24_26::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, 
245350_6_5_6_25_27::None::the/DT refeeding/VBG diets/NNS contained/VBD VitD/NN We/PRP concluded/VBD that/IN :/: i/LS )/) food/NN restriction/NN led/VBD to/TO the/DT upregulation/NN of/IN insulin/NN receptor/NN in/IN liver/NN and/CC adipose/NN tissue/NN accompanied/VBN by/IN increased/VBN 
1004_1004_21_22_23_24::None::proteins/NNS such/JJ as/IN vinculin/NN and/CC talin/NN ,/, while/IN one/CD 
1074_1074_5_6_10_11::None::proteins/NNS ,/, including/VBG vinculin/NN ,/, talin/NN ,/, and/CC ezrin/NN ,/, are/VBP not/RB 
76765_3_5_6_93_94::None::cross/NN -/: sectional/JJ associations/NNS between/IN high/JJ -/: sensitivity/NN cardiac/JJ troponin/NN T/NN (/( hsTnT/NN )/) and/CC FPG/NNP categorized/VBD as/IN normal/JJ fasting/NN glucose/NN (/( NFG/NN :/: FPG/NNP &/CC lt/NN ;/: //: =/JJ 6.0/CD mmol/NN //: L/NN )/) ,/, impaired/JJ fasting/NN glucose/NN (/( IFG/NN :/: FPG/NNP 6.1/CD -/: 6.9/CD mmol/NN //: L/NN )/) ,/, and/CC diabetes/NN mellitus/NN (/( DM/NN :/: FPG/NNP &/CC gt/NN ;/: //: =/JJ 7.0/CD mmol/NN //: L/NN )/) ,/, in/IN 535/CD men/NNS and/CC 226/CD women/NNS aged/JJ 56/CD -/: 79/CD years/NNS without/IN overt/JJ cardiovascular/JJ disease/NN who/WP received/VBD no/DT cardiovascular/JJ ,/, antidiabetic/JJ or/CC lipid/NN lowering/NN drugs/NNS ,/, 
1957_1957_15_16_10_11::None::with/IN association/NN of/IN beta-catenin/NN with/IN EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ 
236_236_2_3_27_29::None::Birch/NNP pollen/NN profilin/NN and/CC actin/NN can/MD be/VB copurified/VBN as/IN a/DT complex/NN ,/, and/CC purified/VBN recombinant/JJ birch/NN profilin/NN can/MD be/VB used/VBN as/IN an/DT affinity/NN matrix/NN to/TO obtain/VB birch/JJ pollen/NN actin/NN ./. 
110315_0_10_11_7_8::None::of/IN the/DT most/RBS frequent/JJ complications/NNS after/IN groin/NN herniorrhaphy/NN ./. 
46_46_8_9_3_4::None::Addition/NN of/IN Acanthamoeba/NN profilin/NN in/IN molar/JJ ratios/NNS to/TO actin/NN of/IN about/IN 1.1:1/CD 
445671_0_22_23_1_3::None::Duchenne/NNP muscular/JJ dystrophy/NN (/( DMD/NN )/) ,/, the/DT most/RBS common/JJ form/NN of/IN muscular/JJ dystrophy/NN ,/, is/VBZ characterized/VBN by/IN muscular/JJ wasting/NN caused/VBN by/IN dystrophin/NN deficiency/NN that/WDT ultimately/RB 
248756_2_6_7_25_27::biology.organism_classification.lower_classifications::of/IN the/DT genus/NN Prunus/NNP that/WDT have/VBP different/JJ numbers/NNS of/IN integuments/NNS :/: bitegmic/JJ species/NNS ,/, such/JJ as/IN Prunus/NNP armeniaca/NN (/( apricot/NN )/) and/CC Prunus/NNP persica/NN (/( peach/NN )/) 
1075_1075_20_21_8_9::POS_ACTION_PHOSPHORYLATE::as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) 
600709_1_23_25_0_1::None::It/PRP ranges/VBZ from/IN simple/JJ steatosis/NN to/TO its/PRP$ more/RBR aggressive/JJ form/NN ,/, non/JJ -/: alcoholic/JJ steatohepatitis/NN (/( NASH/NN )/) ,/, which/WDT may/MD develop/VB into/IN hepatic/JJ fibrosis/NN ,/, cirrhosis/NN ,/, 
488875_3_19_20_25_27::biology.organism_classification.lower_classifications::presence/NN of/IN a/DT dromedary/NN in/IN the/DT maternal/JJ and/CC a/DT Bactrian/JJ camel/NN in/IN the/DT paternal/JJ 
747_747_25_26_27_28::None::and/CC association/NN of/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN 
748_748_13_14_20_21::None::fimbrin/NN ,/, the/DT utrophin/NN actin-binding/JJ domain/NN appears/VBZ to/TO associate/VB with/IN actin/NN in/IN an/DT extended/JJ 
1633_1633_26_27_25_26::None::identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC 
151063_0_5_6_2_3::None::Paclitaxel/NN (/( PTX/NN )/) and/CC carboplatin/NN (/( CBP/NN )/) 
2222_2222_19_20_37_38::NEG_ACTION_COLOCALIZE::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
1251_1251_32_33_42_43::None::and/CC bind/VBP to/TO actin/NN in/IN the/DT same/JJ way/NN as/IN native/JJ ,/, conventionally/RB purified/VBN profilin/NN without/IN urea/NN treatment/NN 
1962_1962_20_22_22_23::POS_ACTION_MEMBER::deficient/JJ in/IN the/DT actin-binding/JJ proteins/NNS tropomyosin/NN and/CC profilin/NN also/RB 
350698_1_0_1_10_11::None::This/DT goes/VBZ along/IN with/IN an/DT increased/VBN incidence/NN of/IN type/NN 2/CD diabetes/NN ,/, accompanied/VBN by/IN 
221316_7_10_11_5_6::None::symmetrical/JJ polyarthritis/NN with/IN high/JJ tender/NN and/CC swollen/JJ joint/JJ count/NN and/CC mean/VB Disease/NN 
374375_0_27_28_17_18::None::serine/NN )/) in/IN broiler/NN diets/NNS may/MD be/VB due/JJ to/TO levels/NNS of/IN endogenous/JJ Gly/JJ precursors/NNS that/WDT differ/VBP in/IN 
294475_2_35_36_58_60::None::a/DT high/JJ -/: fat/NN (/( HF/NN )/) diet/NN consisting/VBG of/IN the/DT regular/JJ diet/NN supplemented/VBN with/IN an/DT additional/JJ amount/NN of/IN 3.5/CD %/NN soybean/NN oil/NN and/CC 1/CD %/NN fish/NN oil/NN at/IN the/DT expense/NN 
151_151_6_7_64_65::None::aggregation/NN induced/VBN by/IN thrombin/NN (/( 0.25/CD U.ml-1/NN )/) with/IN IC50/NN 200/CD kIU.ml-1/NN ,/, and/CC inhibited/VBD the/DT rise/NN of/IN cytosolic/JJ free/JJ calcium/NN concentration/NN in/IN platelets/NNS stimulated/VBN by/IN thrombin/NN (/( 0.1/CD U.ml-1/NN )/) in/IN the/DT absence/NN and/CC in/IN the/DT presence/NN of/IN Ca2/NN +/CC 0.5/CD mmol.L-1/NN (/( IC50/NN 117/CD and/CC 50/CD kIU.ml-1/NN ,/, respectively/RB )/) ,/, but/CC had/VBD no/DT effect/NN on/IN the/DT amounts/NNS of/IN actin/NN and/CC myosin/NN heavy/JJ 
73717_0_69_70_37_39::medicine.medical_treatment.used_to_treat::high/JJ -/: risk/NN prostate/NN cancer/NN (/( PCa/NN )/) to/TO be/VB treated/VBN with/IN whole/JJ pelvic/JJ radiation/NN therapy/NN (/( WPRT/NN )/) in/IN an/DT attempt/NN to/TO define/VB the/DT hostile/JJ pelvis/NN in/IN terms/NNS of/IN intensity/NN modulated/VBD radiation/NN therapy/NN (/( IMRT/NN )/) ./. 
718_718_8_9_11_12::None::cytoplasmic/JJ domain/NN of/IN cadherins/NNS bind/VBP to/TO beta-catenin/NN ,/, which/WDT in/IN 
556245_5_27_28_25_26::None::between/IN patients/NNS receiving/VBG carvedilol/NN and/CC bisoprolol/NN ./. 
1866_1866_9_10_7_8::None::and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN 
16153_0_19_20_0_1::None::Elderly/JJ patients/NNS with/IN chronic/JJ lymphocytic/JJ leukemia/NN (/( CLL/NN )/) are/VBP underrepresented/JJ in/IN trials/NNS evaluating/VBG fludarabine/NN ,/, cyclophosphamide/NN ,/, and/CC rituximab/NN (/( FCR/NN )/) 
832646_0_8_10_2_3::None::Disability/NN identity/NN predicts/VBZ lower/JJR anxiety/NN and/CC depression/NN in/IN multiple/JJ sclerosis/NN ./. 
379222_0_0_2_14_15::None::Prenatal/JJ diagnosis/NN of/IN critical/JJ congenital/JJ heart/NN disease/NN reduces/VBZ risk/NN of/IN death/NN from/IN cardiovascular/JJ compromise/NN prior/RB to/TO planned/VBN neonatal/JJ 
528491_0_12_13_34_35::None::is/VBZ associated/VBN with/IN negative/JJ outcomes/NNS such/JJ as/IN increased/VBN severity/NN of/IN pain/NN ,/, reduced/VBD function/NN (/( eg/FW missing/VBG school/NN )/) ,/, and/CC low/JJ mood/NN (/( eg/FW high/JJ levels/NNS of/IN depression/NN 
162581_4_7_8_3_4::None::We/PRP focused/VBD on/IN esophageal/NN ,/, gastric/JJ ,/, pancreatic/JJ ,/, liver/NN and/CC 
239458_5_32_34_9_10::medicine.disease.symptoms::controlled/JJ trials/NNS examined/VBN anxiety/NN (/( n/NN =/JJ 7/CD )/) ,/, stress/NN (/( n/NN =/JJ 3/CD )/) ,/, anxiety/NN and/CC stress/NN (/( n/NN =/JJ 2/CD )/) ,/, panic/NN disorder/NN (/( n/NN =/JJ 
789814_0_15_16_13_14::None::preferred/JJ mode/NN of/IN revascularization/NN in/IN patients/NNS with/IN complex/JJ multi/NNS 
390913_0_5_8_15_17::None::and/CC vorinostat/NN [/( suberoylanilide/NN hydroxamic/JJ acid/NN (/( SAHA/NN )/) ]/) are/VBP both/DT new/JJ anticancer/JJ drugs/NNS ,/, interactions/NNS between/IN 
118365_3_28_29_35_36::None::pretreatment/NN levels/NNS in/IN patients/NNS who/WP experienced/VBD an/DT initial/JJ positive/JJ therapeutic/JJ response/NN ./. 
127455_4_0_1_40_41::None::We/PRP studied/VBD the/DT K/NN (/( +/CC )/) //: Cl/NN (/( -/: )/) cotransporter/NN KCC2/NN and/CC beta2/NN -/: GABAA/NN -/: type/NN receptor/NN (/( GABAAR/NN )/) and/CC beta3/NN -/: GABAAR/NN subunit/NN expressions/NNS in/IN the/DT GASH/NNP :/: Sal/NNP both/CC at/IN rest/NN and/CC after/IN repeated/VBN sound/NN -/: induced/VBN 
807498_0_16_18_12_14::None::the/DT survival/NN of/IN dental/JJ implants/NNS placed/VBN after/IN ablative/JJ surgery/NN ,/, in/IN patients/NNS 
868728_2_15_16_12_13::medicine.disease.symptoms::serious/JJ pathology/NN unless/IN infection/NN progresses/VBZ to/TO leukemia/NN or/CC lymphoma/NN ./. 
289843_2_7_9_13_16::None::are/VBP associated/VBN with/IN systemic/JJ diseases/NNS such/JJ as/IN arthritis/NN ,/, inflammatory/JJ bowel/NN diseases/NNS ,/, hematological/JJ disorders/NNS 
1052_1052_12_13_27_28::POS_ACTION_INTERACT::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) 
264611_0_19_20_17_18::medicine.disease.treatments::major/JJ goals/NNS of/IN rehabilitation/NN after/IN stroke/NN ./. 
1486_1486_24_25_32_33::None::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ 
328298_6_5_6_31_32::None::subjects/NNS not/RB receiving/VBG glycosides/NNS ,/, digoxin/NN was/VBD associated/VBN with/IN a/DT 29/CD %/NN increased/VBD mortality/NN risk/NN (/( HR/NN 1.29/CD ;/: 95/CD %/NN CI/NN ,/, 1.21/CD to/TO 1.39/CD )/) in/IN the/DT subgroup/NN of/IN publications/NNS comprising/VBG 
1201_1201_8_9_7_8::None::tails/NNS of/IN either/CC histone/NN H3/NN or/CC histone/NN H4/NN 
1227_1227_2_3_22_23::None::Saccharomyces/FW cerevisiae/FW RAD14/NN was/VBD identified/VBN in/IN a/DT two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN ,/, ''/'' and/CC pairwise/JJ interactions/NNS between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, 
980_980_5_6_12_13::POS_REG(+)_DECREASE::stable/JJ expression/NN of/IN V12Ras/NNS into/IN keratinocytes/NNS promotes/VBZ the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC 
456_456_17_18_2_3::None::Expression/NN of/IN alpha-catenin/NN was/VBD generally/RB weak/JJ and/CC did/VBD not/RB correlate/VB with/IN the/DT expression/NN of/IN either/CC beta-catenin/NN or/CC E-cadherin/NN ./. 
1427_1427_29_30_27_28::None::and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
805_805_5_9_10_11::None::factor/NN I/PRP stimulates/VBZ cardiac/JJ myosin/NN heavy/JJ chain/NN and/CC actin/NN synthesis/NN in/IN the/DT 
856_856_13_14_22_23::POS_ACTION_UPREGULATE::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN 
908550_0_18_19_23_25::None::parameters/NNS in/IN modestly/RB severely/RB obese/JJ African/JJ Americans/NNPS and/CC White/NNP Americans/NNPS with/IN prediabetes/NNS :/: 
91440_0_2_4_20_21::medicine.disease.risk_factors::Risk/NN of/IN cardiovascular/JJ events/NNS and/CC mortality/NN among/IN a/DT population/NN -/: based/VBN cohort/NN of/IN immigrants/NNS and/CC long/JJ -/: term/NN residents/NNS with/IN diabetes/NN :/: Are/VBP all/DT 
305802_4_42_43_0_1::medicine.drug_ingredient.active_moiety_of_drug::Dantrolene/NN reduced/VBD the/DT number/NN of/IN premature/JJ ventricular/JJ complexes/NNS (/( PVCs/NNS )/) on/IN average/NN by/IN 74/CD %/NN (/( range/NN 33/CD -/: 97/CD )/) in/IN four/CD patients/NNS with/IN N/NN -/: terminal/JJ or/CC central/JJ mutations/NNS in/IN the/DT cytosolic/JJ region/NN of/IN the/DT RyR2/NN protein/NN ,/, while/IN dantrolene/NN had/VBD no/DT effect/NN 
3197_0_0_1_19_20::medicine.drug.active_moieties::Tenofovir/NNP alafenamide/NN (/( TAF/NN )/) is/VBZ an/DT investigational/JJ oral/JJ prodrug/NN of/IN the/DT HIV/NN -/: 1/CD nucleotide/NN reverse/JJ transcriptase/NN inhibitor/NN tenofovir/NN (/( TFV/NN )/) 
10363_2_10_11_24_26::None::by/IN a/DT single/JJ high/JJ dose/NN injection/NN of/IN streptozotocin/NN (/( STZ/NN )/) were/VBD randomized/VBN to/TO receive/VB twice/RB daily/JJ subcutaneous/JJ injection/NN of/IN vehicle/NN or/CC 
984_984_9_10_0_1::None::MLL/NN is/VBZ fused/VBN in-frame/RB to/TO a/DT different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS 
537465_2_5_6_49_50::None::we/PRP review/VBP the/DT molecular/JJ regulation/NN of/IN T/NN cell/NN exhaustion/NN ,/, placing/VBG recent/JJ findings/NNS on/IN PD/NN -/: 1/CD blockade/NN therapies/NNS in/IN cancer/NN in/IN the/DT context/NN of/IN the/DT broader/JJR understanding/NN of/IN the/DT roles/NNS of/IN the/DT PD/NN -/: 1/CD :/: PD/NN -/: L1/NN pathway/NN in/IN T/NN cell/NN exhaustion/NN during/IN chronic/JJ infection/NN ./. 
515_515_20_21_5_6::None::work/NN ,/, the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN 
800922_2_0_1_11_12::medicine.disease.treatments::It/PRP has/VBZ been/VBN suggested/VBN that/IN the/DT irreversible/JJ MAO/NNP -/: B/NN inhibitors/NNS selegiline/NN and/CC rasagiline/NN exert/VBP 
693828_2_18_19_8_9::medicine.disease.symptoms::conducted/VBN on/IN studies/NNS assessing/VBG the/DT clinical/JJ characteristics/NNS and/CC correlates/VBZ of/IN unipolar/JJ MDD/NN and/CC bipolar/JJ MDD/NN in/IN youth/NN 
654472_6_0_1_22_23::None::All/DT correlations/NNS between/IN the/DT dry/JJ eye/NN questionnaire/NN scores/NNS (/( DEQ5/NN and/CC OSDI/NN )/) and/CC (/( A/NN )/) self/NN -/: reported/VBN non/JJ -/: ocular/JJ pain/NN measures/NNS (/( 
157_157_33_34_24_25::None::consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN formed/VBN by/IN eukaryal/JJ histone/NN (/( H3/NN +/CC H4/NN )/) 
355_355_25_26_16_17::None::binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD form/VB a/DT structural/JJ complex/NN with/IN E-cadherin/NN via/IN these/DT interactions/NNS 
2131_2131_23_24_21_22::None::the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
241804_0_11_14_21_23::medicine.medical_treatment.used_to_treat::complication/NN of/IN delayed/VBN tissue/NN plasminogen/NN activator/NN (/( t/NN -/: PA/NN )/) treatment/NN in/IN ischemic/JJ stroke/NN ./. 
318680_2_0_1_15_16::None::This/DT study/NN therefore/RB investigated/VBD the/DT relationship/NN between/IN the/DT structural/JJ properties/NNS of/IN nine/CD bufadienolides/NNS and/CC their/PRP$ affinities/NNS for/IN human/JJ serum/NN 
671646_0_13_14_5_6::None::is/VBZ an/DT important/JJ strategy/NN for/IN the/DT treatment/NN of/IN spinal/JJ tuberculosis/NN (/( TB/NN )/) ./. 
2107_2107_27_28_15_16::None::targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
868_868_9_11_4_5::POS_ACTION_MEMBER::this/DT study/NN ,/, profilin/NN is/VBZ identified/VBN as/IN an/DT actin-binding/JJ protein/NN in/IN higher/JJR plants/NNS 
565_565_28_29_39_40::None::the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS ,/, co-localizing/VBG with/IN the/DT known/JJ focal/JJ adhesion/NN components/NNS talin/NN and/CC vinculin/NN ./. 
947715_0_1_3_12_13::biology.organism_classification.lower_classifications::Motile/JJ eukaryotic/JJ cells/NNS ,/, such/JJ as/IN leukocytes/NNS ,/, cancer/NN cells/NNS ,/, and/CC amoeba/NN ,/, typically/RB move/VBP 
553943_2_9_11_22_23::None::the/DT analysis/NN of/IN dynamic/JJ contrast/NN -/: enhanced/VBN magnetic/JJ resonance/NN imaging/NN data/NNS from/IN bevacizumab/NN -/: treated/VBN glioblastoma/NN patients/NNS in/IN less/JJR than/IN 
1069_1069_33_35_36_37::None::)/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC 
862710_1_11_12_54_56::None::nature/NN of/IN the/DT blood/NN -/: brain/NN barrier/NN (/( BBB/NNP )/) have/VBP significantly/RB hindered/VBN the/DT drug/NN therapy/NN of/IN ALS/NNP Riluzole/NNP ,/, a/DT moderately/RB performing/VBG drug/NN ,/, is/VBZ the/DT only/JJ agent/NN approved/VBN for/IN treating/VBG ALS/NNP However/RB ,/, several/JJ promising/JJ nanocarrier/NN approaches/NNS are/VBP surfacing/VBG that/IN can/MD provide/VB more/RBR efficient/JJ drug/NN delivery/NN ./. 
1486_1486_4_5_32_33::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ 
1017_1017_20_21_9_10::None::the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP very/RB similar/JJ growth/NN phenotypes/NNS ,/, a/DT depolarized/VBN actin/NN cytoskeleton/NN ,/, and/CC 
212_212_24_25_27_28::None::the/DT ectodomain/NN of/IN E-cadherin/NN and/CC the/DT actin/NN binding/NN site/NN of/IN 
675416_11_24_25_24_27::medicine.symptom.symptom_of::cardiac/JJ troponin/NN for/IN acute/JJ myocardial/JJ infarction/NN ,/, natriuretic/JJ peptides/NNS 
1521_1521_4_6_7_8::None::interaction/NN between/IN calf/NN spleen/NN profilin/NN and/CC actin/NN depends/VBZ critically/RB on/IN 
408887_9_2_3_43_44::None::This/DT study/NN aims/VBZ to/TO contribute/VB to/TO the/DT prevention/NN of/IN metabolic/JJ syndrome/NN and/CC inter/NN -/: related/JJ chronic/JJ illnesses/NNS :/: type/NN 2/CD diabetes/NN mellitus/NN ,/, cardiovascular/JJ disease/NN ,/, and/CC some/DT cancers/NNS ;/: which/WDT are/VBP associated/VBN with/IN overweight/JJ //: obesity/NN ,/, physical/JJ inactivity/NN ,/, and/CC poor/JJ diet/NN ./. 
1908_1908_7_8_5_6::None::results/NNS indicate/VBP that/IN TGFbeta/NN regulates/VBZ clusterin/NN gene/NN expression/NN through/IN 
166_166_14_15_10_11::None::in/IN cofilin/NN and/CC ADF/NN but/CC not/RB in/IN actin/NN ,/, ADF/NN and/or/CC 
119342_0_6_7_1_2::None::The/DT H2/NN robotic/JJ exoskeleton/NN for/IN gait/NN rehabilitation/NN after/IN stroke/NN :/: 
1334_1334_17_18_17_18::None::suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN 
767_767_17_18_2_3::POS_ACTION_BIND::Inhibition/NN of/IN actin/NN polymerization/NN by/IN a/DT synthetic/JJ dodecapeptide/NN patterned/VBN on/IN the/DT sequence/NN around/IN the/DT actin-binding/JJ site/NN of/IN cofilin/NN ./. 
135795_9_6_7_12_13::None::The/DT IgG2a/NN //: IgG1/NN antibody/NN response/NN in/IN L/NN tropica/NN infection/NN is/VBZ higher/JJR than/IN 
164393_5_2_3_17_18::None::Participants/NNS reported/VBD nicotine/NN craving/NN ,/, nicotine/NN withdrawal/NN symptoms/NNS ,/, and/CC substance/NN use/NN in/IN the/DT week/NN following/VBG a/DT uniform/JJ quit/VBD attempt/NN of/IN 
1164_1164_42_43_39_40::POS_ACTION_ATTACH::heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN ./. 
416351_15_6_7_21_22::medicine.risk_factor.diseases::family/NN history/NN of/IN hypertension/NN ,/, older/JJR age/NN ,/, and/CC family/NN history/NN of/IN diabetic/JJ mellitus/NN were/VBD factors/NNS associated/VBN with/IN preeclampsia/NN ./. 
780438_1_33_34_22_23::None::with/IN HAV/NN and/CC assess/VB reasons/NNS why/WRB travelers/NNS had/VBD not/RB received/VBN hepatitis/NN A/NN vaccine/NN before/IN traveling/VBG ./. 
7137_13_29_30_17_18::None::increase/NN in/IN the/DT incidence/NN of/IN small/JJ breast/NN cancers/NNS (/( RR/NN ,/, 1.25/CD ;/: 95/CD %/NN CI/NN ,/, 1.18/CD -/: 
1701_1701_6_7_50_51::None::that/IN this/DT novel/JJ RhoGAP/NN is/VBZ involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
686_686_29_30_23_24::None::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC 
713526_5_7_8_13_14::None::have/VB strong/JJ preclinical/JJ data/NNS for/IN the/DT treatment/NN of/IN comorbid/JJ bipolar/JJ mood/NN disorder/NN and/CC 
231772_0_50_52_52_53::None::natural/JJ sunlight/NN and/CC artificial/JJ light/JJ irradiation/NN ./. 
1372_1372_31_32_18_19::POS_ACTION_BIND::amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB with/IN APC/NN ,/, although/IN the/DT amino-terminal/JJ half/NN independently/RB binds/VBZ alpha-catenin/NN ./. 
619_619_21_22_43_44::None::of/IN Ras/NN with/IN Myc/NN allows/VBZ the/DT generation/NN of/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN and/CC the/DT induction/NN of/IN S/NN phase/NN ,/, coincident/JJ with/IN the/DT loss/NN of/IN the/DT p27/NN cyclin-dependent/JJ kinase/NN inhibitor/NN 
495841_5_19_20_13_14::None::vemurafenib/NN -/: resistant/JJ SK/NN -/: Mel2/NN melanoma/NN cells/NNS and/CC p53/NN -/: deficient/JJ H1299/NN 
1616_1616_20_21_35_36::POS_ACTION_ENCODE::protein/NN gene/NN ;/: 4a/NN and/CC 4b/NN are/VBP two/CD genes/NNS ,/, one/CD of/IN which/WDT codes/VBZ for/IN the/DT proposed/VBN phosphoprotein/NN P/NN and/CC the/DT other/JJ 
1537_1537_18_19_16_17::None:::/: actin/NN ,/, villin/NN ,/, fimbrin/NN and/CC brush/NN border/NN 
1037_1037_4_5_24_26::None::disclosed/VBN interactions/NNS between/IN gephyrin/NN ,/, exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD 
307552_0_16_17_17_18::None::,/, including/VBG :/: oxygen/NN limitation/NN ,/, very/RB low/JJ 
754436_8_5_6_7_8::medicine.disease.symptoms::42/CD %/NN of/IN depressed/JJ and/CC anxious/JJ participants/NNS reported/VBD problems/NNS 
567_567_10_11_18_19::None::acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
1505_1505_33_34_28_29::POS_ACTION_BIND::of/IN the/DT virus-coded/JJ UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN proteins/NNS ./. 
324838_0_16_17_20_21::None::consists/VBZ of/IN two/CD subtypes/NNS :/: treatment/NN -/: induced/VBN neuropathy/NN (/( TIN/NN 
1874_1874_3_4_17_18::POS_ACTION_Causal::Thus/RB ,/, like/IN verprolin/NN ,/, WIP/NNP functions/VBZ in/IN yeast/NN to/TO link/VB the/DT polarity/NN development/NN pathway/NN and/CC the/DT actin/NN cytoskeleton/NN to/TO generate/VB 
93_93_28_29_57_58::POS_ACTION_DOWNREGULATE::kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
90241_0_24_25_22_23::None::pemetrexed/VBN in/IN EGFR/NN mutation/NN -/: positive/JJ lung/NN adenocarcinoma/NN patients/NNS 
452979_10_13_14_1_2::None::We/PRP observed/VBD a/DT strong/JJ association/NN between/IN sleep/NN apnea/NN risk/NN and/CC diabetes/NN mellitus/NN among/IN blacks/NNS with/IN metabolic/JJ syndrome/NN 
1082_1082_35_36_38_39::None::depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ./. 
1233_1233_26_27_19_24::None::,/, desmin/NN and/CC smooth/VB muscle/NN myosin/NN heavy/JJ chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC 
613549_0_1_2_9_11::medicine.risk_factor.diseases::Postmastectomy/NNP radiotherapy/NN is/VBZ increasingly/RB common/JJ for/IN patients/NNS with/IN advanced/JJ breast/NN cancer/NN ./. 
324838_0_11_12_2_3::medicine.symptom.symptom_of::Acute/JJ painful/JJ diabetic/JJ neuropathy/NN (/( APDN/NN )/) is/VBZ a/DT distinctive/JJ diabetic/JJ polyneuropathy/NN and/CC consists/VBZ of/IN 
1417_1417_9_10_7_9::None::p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS 
497295_0_23_24_26_27::None::based/VBN chemotherapy/NN can/MD reach/VB pathologic/JJ complete/JJ response/NN (/( pCR/NN )/) 
1946_1946_27_28_37_38::POS_ACTION_FNSIMILAR::identical/JJ to/TO chick/NN cofilin/NN and/CC 66/CD %/NN identical/JJ to/TO chick/NN actin-depolymerizing/NN factor/NN (/( ADF/NN )/) ,/, two/CD 
1737_1737_13_15_39_40::POS_REG(+)_POLYMERIZE::of/IN PI/NN and/CC PIP/NN kinases/NNS and/CC that/IN under/IN certain/JJ circumstances/NNS activation/NN of/IN the/DT kinases/NNS and/CC the/DT increased/VBN synthesis/NN of/IN PIP/NN and/CC PIP2/NN may/MD be/VB involved/VBN in/IN the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS 
151_151_0_1_6_7::POS_REG(-)_INCREASE::Aprotinin/NN inhibited/VBD platelet/NN aggregation/NN induced/VBN by/IN thrombin/NN (/( 0.25/CD U.ml-1/NN 
485087_11_0_1_12_13::None::Once/RB ECMO/NNP has/VBZ been/VBN commenced/VBN ,/, if/IN the/DT tachyarrhythmia/NN remains/VBZ difficult/JJ to/TO control/VB with/IN antiarrhythmic/JJ drugs/NNS 
871_871_21_25_27_28::POS_ACTION_MEMBER::calponin/NN and/CC the/DT smooth/JJ muscle/NN myosin/NN heavy-chain/JJ isoforms/NNS of/IN SM1/NN and/CC SM2/NN )/) 
173839_13_0_1_5_6::None::Graphical/JJ abstractCompounds/NNS isolated/VBN from/IN Helichrysum/NNP species/NNS (/( Compositae/NNS )/) 
241510_0_6_7_4_5::None::patients/NNS with/IN ischemic/JJ cardiomyopathy/NN the/DT size/NN of/IN bipolar/JJ low/JJ 
980_980_14_15_5_6::None::stable/JJ expression/NN of/IN V12Ras/NNS into/IN keratinocytes/NNS promotes/VBZ the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN 
178297_11_27_28_14_15::None::were/VBD co/SYM -/: infected/VBN with/IN HBV/NN and/CC 1.2/CD %/NN with/IN HCV/NN The/DT main/JJ diagnoses/NNS were/VBD hepatobiliary/JJ diseases/NNS (/( 46/CD %/NN 
272493_8_55_56_18_19::None::encephalitis/NN ;/: their/PRP$ psychiatric/JJ symptoms/NNS were/VBD as/IN follows/VBZ :/: depressive/JJ (/( 9/CD )/) ,/, catatonic/JJ (/( 9/CD )/) ,/, disorganized/JJ (/( 8/CD )/) ,/, anxious/JJ (/( 8/CD )/) ,/, psychotic/JJ (/( 7/CD )/) ,/, manic/JJ (/( 6/CD )/) ,/, and/CC suicidal/JJ (/( 3/LS )/) 
171_171_12_13_21_22::POS_ACTION_Assembly::C/NN terminus/NN of/IN profilin/NN ,/, a/DT region/NN that/WDT has/VBZ been/VBN implicated/VBN in/IN actin/NN binding/NN ./. 
861_861_19_20_5_6::None::actin/NN clustering/NN ,/, profilin/NN ,/, a/DT monomeric/JJ actin-binding/JJ protein/NN that/WDT has/VBZ been/VBN suggested/VBN to/TO be/VB involved/VBN in/IN actin/NN polymerization/NN ,/, was/VBD 
350850_8_3_5_1_2::None::With/IN respect/NN to/TO categorical/JJ variables/NNS ,/, a/DT significant/JJ 
655566_1_10_11_16_17::None::clinical/JJ manifestation/NN of/IN severe/JJ falciparum/NN malaria/NN over/IN the/DT past/JJ couple/NN of/IN decades/NNS ,/, 
2030_2030_22_23_18_19::None::cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ actin/NN patches/NNS ./. 
392437_4_30_31_22_23::None::C/NN -/: reactive/JJ protein/NN and/CC other/JJ biomarkers/NNS of/IN inflammation/NN for/IN the/DT prediction/NN of/IN cardiovascular/JJ events/NNS 
289843_2_20_22_17_19::None::bowel/NN diseases/NNS ,/, hematological/JJ disorders/NNS ,/, hepatic/JJ disease/NN ,/, and/CC necrotizing/JJ 
74367_0_2_3_16_18::biology.organism_classification.lower_classifications::The/DT genus/NN Neisseria/NNP contains/VBZ two/CD pathogenic/JJ species/NNS of/IN prominant/JJ public/JJ health/NN concern/NN :/: Neisseria/NNP gonorrhoeae/NNS and/CC Neisseria/NNP meningitidis/NNS ./. 
1866_1866_5_6_9_10::None::both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN 
1087_1087_25_26_23_24::None::flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN to/TO distinct/JJ 
1288_1288_13_14_4_6::POS_ACTION_INTERACT::interaction/NN between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ 
87_87_37_38_12_13::None::cell/NN adhesion/NN to/TO vitronectin/NN ,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN 
2209_2209_26_27_23_24::None::of/IN another/DT pollen/NN profilin/NN isoform/NN ,/, ZmPRO1/NN ./. 
2074_2074_12_13_18_19::None::the/DT nucleocapsid/NN (/( N/NN )/) protein/NN and/CC phosphoprotein/NN (/( P/NN )/) of/IN sonchus/NN 
1165_1165_9_10_7_8::None::effect/NN of/IN Acanthamoeba/NN profilin/NN on/IN actin/NN filament/NN nucleation/NN and/CC 
161979_1_6_7_28_29::None::of/IN novel/JJ advanced/JJ imaging/NN techniques/NNS that/WDT allow/VBP microstructural/NN as/RB well/RB as/IN functional/JJ tissue/NN characterization/NN along/IN with/IN the/DT extensive/JJ work/NN done/VBN by/IN The/DT Cancer/NN Genome/NNP Atlas/NNP focusing/VBG on/IN mapping/VBG genomic/JJ 
556_556_24_25_10_11::None::nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ protein/NN based/VBN on/IN the/DT lack/NN of/IN reactivity/NN of/IN antigravin/NN with/IN these/DT polypeptides/NNS 
70381_3_0_1_39_40::None::Three/CD days/NNS after/IN the/DT second/JJ injection/NN (/( day/NN 10/CD )/) ,/, the/DT rats/NNS were/VBD intraperitoneally/RB given/VBN sTNFRII/NN -/: gAD/NN or/CC sTNFRII/NN -/: Fc/NN ,/, or/CC PBS/NNP Effects/NNS of/IN treatments/NNS were/VBD examined/VBN with/IN respect/NN of/IN CIA/NNP incidence/NN ,/, severity/NN and/CC pathological/JJ changes/NNS ./. 
381889_8_37_38_33_34::None:://: depression/NN (/( Hospital/NN Anxiety/NN and/CC Depression/NN Scale/NNP )/) ./. 
238332_6_48_49_12_13::None::and/CC a/DT primary/JJ goal/NN in/IN T1D/NN Provision/NN of/IN pain/NN relief/NN from/IN chronic/JJ pancreatitis/NN is/VBZ the/DT primary/JJ goal/NN of/IN total/JJ pancreatectomy/NN in/IN TPIAT/NNP ,/, whereas/IN treatment/NN of/IN diabetes/NN ,/, and/CC certainly/RB prevention/NN of/IN diabetes/NN ,/, has/VBZ been/VBN more/JJR of/IN a/DT secondary/JJ consideration/NN ./. 
294085_3_9_10_12_13::None::the/DT association/NN between/IN bullying/VBG victimization/NN and/CC anxiety/NN ./. 
280_280_46_47_13_14::None::we/PRP observed/VBD that/IN histone/NN H4/NN ,/, and/CC not/RB histone/NN H3/NN ,/, was/VBD acetylated/VBN from/IN the/DT endogenous/JJ p21/waf1/NN promoter/NN in/FW vivo/FW ,/, implying/VBG that/IN CBP/p300/NN ,/, and/CC not/RB the/DT SAGA/NN complex/NN ,/, was/VBD critical/JJ in/IN complexing/VBG with/IN E2A/NN in/IN up-regulation/NN of/IN 
1464_1464_22_23_8_9::None::are/VBP involved/VBN in/IN CREB/NN binding/NN and/CC transcriptional/JJ activation/NN are/VBP highly/RB related/VBN to/TO the/DT adenoviral/JJ E1A-associated/JJ cellular/JJ protein/NN p300/NN (/( refs/NNS 2/CD 
359239_0_14_15_23_25::None::responses/NNS and/CC the/DT difference/NN between/IN them/PRP ultimately/RB determine/VBP whether/IN a/DT cancer/NN escapes/VBZ immune/JJ recognition/NN mechanisms/NNS ./. 
1415_1415_12_13_32_33::POS_REG(-)_POLYMERIZE::are/VBP consistent/JJ with/IN profilin/NN being/VBG a/DT negative/JJ regulator/NN of/IN the/DT phosphoinositide/NN signaling/NN pathway/NN in/IN addition/NN to/TO its/PRP$ established/JJ function/NN as/IN an/DT inhibitor/NN of/IN actin/NN polymerization/NN ./. 
26_26_0_2_11_12::POS_ACTION_MODIFY::Actin-binding/JJ proteins/NNS such/JJ as/IN profilins/NNS participate/VBP in/IN the/DT restructuration/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN plant/NN 
856_856_24_25_37_38::None::the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN 
87_87_37_38_16_20::None::,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN 
404541_2_6_7_8_10::biology.organism_classification.lower_classifications::ATG6/NN functions/VBZ in/IN wheat/NN (/( Triticum/FW aestivum/FW L/NN ./. 
364545_7_7_8_8_10::medicine.disease.risk_factors::the/DT role/NN of/IN MS/NN type/NN 1/CD fimbriae/NN in/IN the/DT 
527579_4_40_41_22_23::None::thrombolysis/NN (/( 99/CD MCA/NNP stoke/VB and/CC 11/CD VBS/NNS )/) A/DT multivariate/JJ model/NN with/IN adjustment/NN for/IN age/NN ,/, baseline/NN stroke/NN severity/NN (/( National/NNP Institutes/NNPS of/IN Health/NNP 
1274_1274_0_2_9_12::POS_ACTION_CONTAIN::Single-headed/JJ myosin/NN ,/, which/WDT consists/VBZ of/IN a/DT full/JJ length/NN myosin/NN heavy/JJ chain/NN and/CC a/DT tagged/VBN 
759_759_17_19_12_13::None::cell/NN strain/NN ,/, EGF/NN inhibited/VBD increases/NNS in/IN immunoreactive/JJ sarcomeric/JJ actin/NN and/CC sarcomeric/JJ myosin/NN 
475835_20_28_29_24_25::None::leukemia/NN undergoing/VBG hematopoietic/JJ cell/NN transplantation/NN with/IN myeloablative/JJ conditioning/NN ./. 
15883_8_16_17_9_10::None::to/TO detect/VB and/CC assess/VB the/DT effects/NNS of/IN biologic/JJ DMARDs/NNS in/IN RA/NN 
1334_1334_30_31_27_28::None::fluid-phase/JJ endocytosis/NN of/IN pfy1-4/NN ,/, a/DT profilin/NN mutant/NN defective/JJ in/IN 
930063_2_10_11_25_26::None::decrease/VB morbidity/NN and/CC mortality/NN from/IN acute/JJ ischemic/JJ stroke/NN ,/, it/PRP is/VBZ limited/VBN in/IN both/DT its/PRP$ efficacy/NN in/IN certain/JJ types/NNS of/IN stroke/NN ,/, 
686_686_23_24_31_32::None::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
2107_2107_5_7_27_28::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
2213_2213_15_18_18_19::POS_ACTION_MEMBER::D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN Cip1/WAF1/NN is/VBZ observed/VBN 
1760_1760_3_4_5_6::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC 
831553_2_5_7_29_31::None::are/VBP associated/VBN with/IN morbid/JJ obesity/NN ,/, including/VBG psychological/JJ (/( eg/FW ,/, depression/NN )/) ,/, physiological/JJ (/( eg/FW ,/, hypothyroidism/NN )/) mechanisms/NNS ,/, sleep/VB disorders/NNS (/( eg/FW ,/, sleep/VB apnea/NN )/) ,/, drug/NN 
563809_10_53_54_47_49::None::for/IN age/NN ,/, body/NN mass/NN index/NN ,/, education/NN ,/, smoking/NN ,/, health/NN status/NN 
284253_6_50_51_20_21::None::extended/VBN -/: release/NN formulations/NNS )/) ,/, levodopa/NN with/IN added/VBN -/: on/IN catechol/NN -/: O/SYM -/: methyltransferase/NN (/( COMT/NN )/) inhibitors/NNS ,/, levodopa/NN //: carbidopa/NN gel/NN for/IN intestinal/JJ infusion/NN ,/, some/DT dopamine/NN agonists/NNS (/( ropinirole/NN ,/, cabergoline/NN ,/, 
539_539_15_16_18_19::POS_ACTION_RELATE::protein/NN that/WDT links/VBZ integrins/NNS to/TO the/DT actin/NN cytoskeleton/NN ,/, is/VBZ 
1608_1608_7_8_26_27::POS_ACTION_BIND::substitution/NN found/VBN in/IN talin/NN from/IN Wistar-Furth/NNP rats/NNS does/VBZ not/RB destroy/VB the/DT capacity/NN of/IN this/DT region/NN of/IN the/DT protein/NN to/TO bind/VB actin/NN or/CC vinculin/NN ./. 
513747_5_106_107_52_53::None::outcomes/NNS of/IN new/JJ stent/JJ designs/NNS )/) ,/, transcatheter/NN aortic/JJ valve/NN intervention/NN data/NNS ,/, atrial/JJ fibrillation/NN (/( anticoagulation/NN and/CC direct/JJ current/JJ cardioversion/NN )/) ,/, electrophysiology/NN (/( leadless/JJ pacemaker/NN devices/NNS ,/, use/NN of/IN quinidine/NN in/IN Brugada/NNP syndrome/NN )/) and/CC coronary/JJ prevention/NN (/( landmark/NN Ezetimibe/NN outcome/NN data/NNS ,/, PCSK9/NN clinical/JJ trials/NNS ,/, childhood/NN prevalence/NN of/IN hypertension/NN ,/, renal/JJ denervation/NN for/IN resistant/JJ hypertension/NN and/CC the/DT 
1286_1286_3_6_12_13::POS_ACTION_MEMBER::Specific/JJ antibodies/NNS to/TO myosin/JJ heavy/JJ chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, SMemb/NN )/) ,/, caldesmon/NN 
1526_1526_17_18_10_11::POS_ACTION_INTERACT::(/( BRSV/NN )/) phosphoprotein/NN (/( P/NN )/) with/IN nucleocapsid/NN (/( N/NN )/) and/CC large/JJ 
247970_0_20_21_11_12::None::of/IN cornus/FW mas/FW fruit/NN extract/NN (/( CMFE/NN )/) in/IN mice/NNS treated/VBN with/IN methotrexate/NN (/( MTX/NN )/) 
338450_1_17_18_37_38::None::stage/NN and/CC patient/NN performance/NN status/NN but/CC ,/, in/IN general/JJ ,/, the/DT most/RBS widely/RB used/VBN approved/VBN regimens/NNS include/VBP 5/LS -/: fluorouracil/NN (/( 5/CD -/: FU/NN )/) combinations/NNS and/CC 
1748_1748_4_5_19_20::POS_ACTION_MODIFY::results/NNS suggest/VBP that/IN LIMK2/NN functions/NNS downstream/RB of/IN the/DT Rho-ROCK/JJ signalling/NN pathway/NN and/CC plays/VBZ a/DT role/NN in/IN reorganization/NN of/IN actin/NN filaments/NNS and/CC membrane/NN 
1977_1977_16_17_24_25::POS_ACTION_BIND::a/DT region/NN in/IN alpha-catenin/NN required/VBN for/IN molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
661306_5_15_16_2_3::None::Commonly/RB occurring/VBG strains/NNS included/VBD apprehension/NN //: anxiety/NN ,/, frustration/NN ,/, anger/NN ,/, and/CC sadness/NN //: depression/NN ./. 
93_93_6_7_24_26::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
467117_12_15_16_9_10::None::malignant/JJ neoplasm/NN in/IN juvenile/JJ dogs/NNS ,/, but/CC may/MD be/VB amenable/JJ to/TO surgical/JJ resection/NN 
803668_11_3_4_27_28::medicine.disease.symptoms::Individuals/NNS living/VBG with/IN MS/NN who/WP report/VBP high/JJ levels/NNS of/IN chronic/JJ pain/NN and/CC depressive/JJ symptoms/NNS may/MD benefit/VB from/IN treatment/NN approaches/NNS that/WDT can/MD address/VB sleep/NN ,/, fatigue/NN ,/, and/CC anxiety/NN ./. 
1233_1233_19_24_28_29::POS_ACTION_MEMBER::,/, desmin/NN and/CC smooth/VB muscle/NN myosin/NN heavy/JJ chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
411_411_20_21_17_18::POS_ACTION_BIND::,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ./. 
87_87_41_45_12_13::POS_ACTION_ASSEMBLE::cell/NN adhesion/NN to/TO vitronectin/NN ,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN alpha/NN v/LS beta/NN 5/CD shows/VBZ a/DT distinct/JJ 
583_583_17_18_10_11::POS_ACTION_BIND::a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
440638_0_8_9_22_23::None::-/: analysis/NN :/: comparative/JJ efficacy/NN and/CC safety/NN of/IN budesonide/NN and/CC mesalazine/NN (/( mesalamine/NN )/) for/IN Crohn/NN whosewhat/NN disease/NN ./. 
1510_1510_17_18_5_6::POS_ACTION_BIND::affinity/NN of/IN vaccinia/NN profilin/NN for/IN polyphosphoinositides/NNS (/( Kd/NN =/JJ 0.2-8/CD .5/CD microM/NN )/) than/IN for/IN actin/NN or/CC poly/NN (/( 
118365_3_30_31_35_36::None::in/IN patients/NNS who/WP experienced/VBD an/DT initial/JJ positive/JJ therapeutic/JJ response/NN ./. 
652_652_8_9_13_14::None::in/IN beta-catenin/NN ,/, alpha-catenin/NN ,/, and/CC p120/NN (/( Cas/NNS )/) and/CC caused/VBD 
607_607_23_24_19_20::None::by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS ./. 
356904_0_13_14_15_16::None::by/IN the/DT episodic/JJ symptoms/NNS of/IN breathlessness/NN ,/, wheezes/VBZ and/CC 
685990_8_18_19_14_15::medicine.risk_factor.diseases::being/VBG at/IN a/DT high/JJ risk/NN of/IN having/VBG OSA/NN compared/VBN with/IN only/RB 
580543_2_1_2_26_27::None::Young/NNP maternal/JJ age/NN is/VBZ associated/VBN with/IN an/DT increased/VBN risk/NN of/IN maternal/JJ anemia/NN ,/, infections/NNS ,/, eclampsia/NN and/CC preeclampsia/NN ,/, emergency/NN cesarean/NN delivery/NN ,/, postpartum/NN depression/NN and/CC inadequate/JJ breastfeeding/VBG initiation/NN ./. 
276_276_4_6_21_22::POS_ACTION_BIND::site-directed/JJ mutagenesis/NN of/IN profilin/NN II/CD from/IN Dictyostelium/NNP discoideum/NN the/DT point/NN mutations/NNS K114E/NN and/CC W3N/NN were/VBD generated/VBN by/IN PCR/NN thus/RB changing/VBG actin/NN and/CC poly/NN -/: 
424911_2_43_44_62_63::None::-/: tolyl/NN )/) pyridine/NN )/) possess/VBP C3/NN -/: symmetric/JJ structures/NNS and/CC excellent/JJ photophysical/JJ properties/NNS as/IN phosphorescence/NN materials/NNS ,/, which/WDT make/VBP them/PRP important/JJ candidates/NNS for/IN use/NN in/IN 
1678_1678_13_14_33_34::None::of/IN the/DT total/JJ H3/NN and/CC H2a/NN mRNA/NN ,/, whereas/IN the/DT histone/NN H4/NN and/CC histone/NN H2b/NN genes/NNS encode/VBP </JJR 10/CD %/NN of/IN the/DT total/JJ H4/NN and/CC H2b/NN mRNA/NN 
1843_1843_19_20_31_32::None::that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD 
801582_5_5_6_28_29::None::full/JJ thickness/NN biopsy/NN sample/NN was/VBD taken/VBN from/IN the/DT center/NN of/IN the/DT burn/VBP wound/NN ,/, the/DT burn/VBP wound/NN edge/NN ,/, and/CC the/DT graft/NN donor/NN site/NN in/IN 7/CD patients/NNS (/( n/NN =/JJ 
311702_2_29_30_22_23::None::significant/JJ risk/NN for/IN development/NN of/IN inflammation/NN -/: mediated/VBN acute/JJ cardiac/JJ events/NNS that/WDT may/MD undermine/VB 
229284_0_17_18_10_11::None::the/DT ''/'' anchor/NN drug/NN ''/'' for/IN treating/VBG rheumatoid/JJ arthritis/NN (/( RA/NN )/) ,/, varies/VBZ 
288485_0_58_59_40_41::biology.organism_classification.lower_classifications::six/CD adult/JJ male/JJ beagles/NNS were/VBD assigned/VBN according/VBG to/TO a/DT random/JJ number/NN table/NN and/CC subjected/VBN to/TO IGRT/NNP to/TO the/DT 7th/JJ -/: 12th/JJ canine/JJ thoracic/JJ vertebral/JJ bodies/NNS 
627089_4_3_5_9_10::medicine.risk_factor.diseases::Among/IN women/NNS with/IN diabetic/JJ vasculopathy/NN ,/, nephropathy/NN ,/, chronic/JJ hypertension/NN ,/, preeclampsia/NN ,/, 
779_779_26_27_35_36::None::inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) 
567_567_7_9_10_11::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT 
988_988_26_27_15_16::None::vinculin/NN and/CC the/DT beta-catenin/NN is/VBZ homologous/JJ to/TO human/JJ plakoglobin/NN and/CC the/DT Drosophila/NN gene/NN product/NN armadillo/NN ./. 
537405_0_19_20_9_10::people.cause_of_death.includes_causes_of_death::multimodality/JJ treatment/NN for/IN oesophageal/NN ,/, oesophagogastric/JJ junction/NN (/( OGJ/NN )/) ,/, and/CC gastric/JJ cancer/NN has/VBZ accumulated/VBN ./. 
167593_4_2_3_5_6::None::Following/VBG an/DT injection/NN with/IN the/DT HDAC/NN inhibitor/NN ,/, suberoylanilide/NN 
1386_1386_20_21_18_19::None::subassembly/NN of/IN the/DT UL5/NN and/CC UL52/NN components/NNS ./. 
619459_0_58_59_52_53::None::,/, whereas/IN the/DT anti/JJ -/: chronic/JJ myeloid/JJ leukemia/NN (/( CML/NN )/) effect/NN of/IN 
550981_1_6_7_11_12::medicine.symptom.symptom_of::increased/VBN resistance/NN to/TO portal/JJ blood/NN flow/NN through/IN the/DT cirrhotic/JJ liver/NN ./. 
1380_1380_34_35_40_41::None::novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN 
996_996_27_28_29_30::None::coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN 
1901_1901_25_28_33_34::POS_ACTION_MEMBER::D1/NN ,/, the/DT cyclin-dependent/JJ kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, and/CC markers/NNS 
784_784_8_9_21_22::None::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
30174_0_33_34_24_25::None::Community/NN -/: Acquired/VBN Pneumonia/NNP Hospitalization/NNP :/: A/NNP Nationwide/NNP Population/NNP -/: Based/VBD Cohort/NNP Study/NNP ./. 
1399_1399_57_58_3_4::POS_ACTION_BIND::The/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN (/( VSV/NN )/) serotypes/NNS New/NNP Jersey/NNP [/( P/NN (/( NJ/NNP )/) ]/) and/CC Indiana/NNP [/( P/NN (/( I/NN )/) ]/) contains/VBZ a/DT highly/RB conserved/VBN carboxy-terminal/JJ domain/NN which/WDT is/VBZ required/VBN for/IN binding/VBG to/TO the/DT cognate/JJ N-RNA/NN template/NN as/RB well/RB as/IN to/TO form/VB a/DT soluble/JJ complex/NN with/IN the/DT nucleocapsid/JJ protein/NN N/NN in/FW vivo/FW ./. 
2076_2076_8_9_28_29::POS_ACTION_ENCODE::cerevisiae/FW gene/NN (/( COF1/NN )/) encoding/VBG a/DT low-M/NN (/( r/NN )/) actin-binding/JJ protein/NN of/IN 143/CD amino/NN acid/NN (/( aa/NN )/) residues/NNS (/( yeast/NN cofilin/NN ;/: Cof/NN )/) 
408887_9_38_40_0_1::None::This/DT study/NN aims/VBZ to/TO contribute/VB to/TO the/DT prevention/NN of/IN metabolic/JJ syndrome/NN and/CC inter/NN -/: related/JJ chronic/JJ illnesses/NNS :/: type/NN 2/CD diabetes/NN mellitus/NN ,/, cardiovascular/JJ disease/NN ,/, and/CC some/DT cancers/NNS ;/: which/WDT are/VBP associated/VBN with/IN overweight/JJ //: obesity/NN ,/, physical/JJ inactivity/NN ,/, and/CC poor/JJ 
718366_2_15_16_24_26::None::associated/VBN with/IN adult/JJ onset/NN or/CC persistence/NN into/IN adulthood/NN ,/, epilepsy/NN ,/, severe/JJ learning/NN difficulties/NNS and/CC anaemia/NN ./. 
1711_1711_5_6_16_19::None::of/IN the/DT predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN 
492_492_44_45_17_19::None::that/IN ,/, like/IN beta/NN 1-syntrophin/NN ,/, both/CC beta/NN 2/CD -/: and/CC alpha/NN 1-syntrophin/JJ interact/NN with/IN peptides/NNS encoding/VBG the/DT syntrophin-binding/JJ region/NN of/IN dystrophin/NN ,/, utrophin/dystrophin/NN related/JJ protein/NN ,/, and/CC the/DT Torpedo/NNP 87K/NN protein/NN ./. 
16_16_28_29_28_29::None::expected/VBN ,/, since/IN beta-catenin/NN binding/NN disrupts/VBZ the/DT 
1465_1465_8_9_6_7::None::of/IN the/DT exogenous/JJ cofilin/NN on/IN actin/NN assembly/NN were/VBD suppressed/VBN 
851030_23_15_16_18_19::None::patients/NNS could/MD undergo/VB additional/JJ non/JJ -/: invasive/JJ infertility/NN treatments/NNS before/IN 
631669_5_1_2_10_12::medicine.medical_treatment.used_to_treat::Foam/NN sclerotherapy/NN or/CC phlebectomy/NN shows/VBZ good/JJ results/NNS in/IN patients/NNS with/IN varicose/NN veins/NNS of/IN pelvic/JJ origin/NN 
1337_1337_12_13_9_10::None::to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN ./. 
874_874_7_8_10_11::None::demonstrate/VBP that/IN histone/NN H3/NN and/CC histone/NN H4/NN synthesized/VBN in/IN young/JJ 
1901_1901_29_30_25_28::None::D1/NN ,/, the/DT cyclin-dependent/JJ kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC 
728764_2_6_8_12_13::None::kidney/NN disease/NN included/VBD diabetes/NN mellitus/NN (/( n/NN =/JJ 9/CD patients/NNS )/) ,/, hypertensive/JJ 
243_243_32_35_30_32::None::VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) 
213969_5_48_49_66_67::medicine.drug_ingredient.active_moiety_of_drug::,/, rituximab/NN ,/, tacrolimus/NN ,/, paroxetine/NN ,/, sertraline/NN ,/, fluoxetine/NN ,/, bardoxolone/NN methyl/NN [/( phase/NN II/CD ]/) ;/: and/CC sorafenib/NN ,/, FK506/NN ,/, aviptadil/NN ,/, 
1560_1560_17_18_13_14::POS_ACTION_MEMBER::acetylation/NN of/IN histone/NN H4/NN versus/CC acetylation/NN of/IN histone/NN H3/NN :/: with/IN 
2131_2131_9_10_13_14::None::,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ 
578166_0_0_1_11_12::None::Effect/NN of/IN five/CD year/NN storage/NN on/IN total/JJ phenolic/JJ content/NN and/CC antioxidant/JJ capacity/NN of/IN almond/NN (/( 
76975_8_17_18_25_27::medicine.symptom.symptom_of::high/JJ -/: risk/NN hypertensive/JJ patients/NNS ,/, and/CC it/PRP might/MD also/RB reduce/VB cardiovascular/JJ risk/NN ./. 
322769_0_9_10_1_2::None::Selenate/NNP removal/NN by/IN zero/CD -/: valent/JJ iron/NN in/IN oxic/JJ condition/NN :/: the/DT role/NN 
346198_0_16_17_6_7::None::is/VBZ a/DT green/JJ solution/NN for/IN treatment/NN of/IN caffeinated/VBN products/NNS and/CC agro/NN -/: industrial/JJ effluents/NNS ./. 
402845_14_25_26_0_1::None::The/DT rabbit/NN model/NN of/IN MSU/NNP crystal/NN -/: induced/VBN acute/JJ arthritis/NN efficiently/RB reproduces/VBZ the/DT inflammatory/JJ ,/, US/NNP ,/, SF/NNP and/CC histopathological/JJ changes/NNS of/IN the/DT human/JJ acute/JJ gouty/JJ attack/NN ./. 
573743_7_19_20_21_22::None::,/, lack/NN of/IN support/NN ,/, anxiety/NN ,/, depression/NN or/CC 
1439_1439_26_27_24_25::None::proteins/NNS such/JJ as/IN FADD/NN and/CC RIP/NN ./. 
1069_1069_36_37_26_27::None::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC 
502525_12_30_32_13_15::people.cause_of_death.includes_causes_of_death::increased/VBN cIMT/NN and/CC cardiovascular/JJ risk/NN supporting/VBG a/DT clinical/JJ role/NN of/IN the/DT measurement/NN of/IN cIMT/NN in/IN RA/NN in/IN predicting/VBG and/CC preventing/VBG cardiovascular/JJ events/NNS ./. 
474123_0_4_5_0_1::None::Oesophageal/JJ cancer/NN is/VBZ the/DT sixth/JJ leading/VBG cause/NN of/IN 
2212_2212_1_2_9_10::POS_ACTION_Change::While/IN alpha-catenin/NN has/VBZ been/VBN demonstrated/VBN to/TO be/VB crucial/JJ for/IN cadherin/NN function/NN ,/, the/DT 
781998_2_18_19_33_36::medicine.medical_treatment.used_to_treat::short/JJ -/: term/NN insulin/NN -/: based/VBN therapy/NN has/VBZ emerged/VBN as/IN a/DT strategy/NN that/WDT can/MD yield/VB temporary/JJ remission/NN of/IN type/NN 2/CD diabetes/NN ./. 
214422_1_2_3_0_1::None::Cultured/VBN neonatal/JJ rat/NN cardiomyocytes/NNS were/VBD randomly/RB 
1037_1037_9_11_27_28::None::exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
372073_0_41_42_0_1::None::In/IN the/DT present/JJ study/NN ,/, primary/JJ mesencephalic/JJ cell/NN cultures/NNS prepared/VBN from/IN embryonic/JJ mouse/NN mesencephala/NN were/VBD used/VBN to/TO investigate/VB the/DT neuroprotective/JJ effect/NN of/IN cabergoline/NN ,/, an/DT ergoline/NN D2/NN receptor/NN agonist/NN ,/, against/IN the/DT pesticide/NN and/CC neurotoxin/NN rotenone/NN relevant/JJ to/TO Parkinson/NNP disease/NN (/( PD/NN )/) ./. 
168553_2_33_34_15_16::None::(/( ACTH/NN )/) overproduction/NN ,/, primary/JJ cortisol/NN -/: producing/VBG adrenal/JJ cortical/JJ lesions/NNS are/VBP increasingly/RB recognised/VBN in/IN the/DT pathophysiology/NN of/IN Cushing/NN whosewhat/NN syndrome/NN ./. 
574337_0_2_4_13_14::medicine.disease.symptoms::Infection/NN by/IN human/JJ papillomavirus/NN (/( HPV/NN )/) is/VBZ among/IN the/DT main/JJ etiologies/NNS of/IN cervical/JJ cancer/NN ./. 
1940_1940_13_14_7_11::None::in/IN activation/NN of/IN extracellular/JJ signal-regulated/JJ protein/NN kinases/NNS ERK1/NN and/CC ERK2/NN ,/, induction/NN of/IN 
202727_3_4_5_15_16::medicine.risk_factor.diseases::breast/NN feeding/NN reduces/VBZ infant/NN mortality/NN due/JJ to/TO common/JJ childhood/NN illnesses/NNS such/JJ as/IN diarrhoea/NN or/CC pneumonia/NN ,/, and/CC improves/VBZ 
1095_1095_17_18_11_12::None::adhesion/NN pattern/NN ,/, actin/NN organization/NN ,/, and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN 
768458_5_10_11_1_2::None::The/DT result/NN demonstrated/VBD that/IN compared/VBN to/TO irbesartan/NN monotherapy/NN ,/, the/DT combination/NN of/IN irbesartan/NN and/CC 
74367_0_16_18_9_11::None::species/NNS of/IN prominant/JJ public/JJ health/NN concern/NN :/: Neisseria/NNP gonorrhoeae/NNS and/CC Neisseria/NNP meningitidis/NNS ./. 
386745_4_29_30_28_30::people.cause_of_death.includes_causes_of_death::-/: based/VBN sports/NNS injury/NN surveillance/NN system/NN ./. 
1917_1917_14_15_2_3::None::To/TO study/VB profilin/NN function/NN ,/, we/PRP extensively/RB mutagenized/VBD the/DT Saccharomyces/FW cerevisiae/FW profilin/NN gene/NN (/( PFY1/NN )/) and/CC examined/VBD 
1344_1344_6_7_22_23::POS_ACTION_BIND::these/DT three/CD mutant/JJ UL5/NN proteins/NNS to/TO form/VB specific/JJ interactions/NNS with/IN other/JJ members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, indicates/VBZ that/IN 
1962_1962_22_23_20_22::None::deficient/JJ in/IN the/DT actin-binding/JJ proteins/NNS tropomyosin/NN and/CC profilin/NN also/RB 
1248_1248_12_13_4_5::None::intracellular/JJ proteins/NNS termed/VBN catenins/NNS ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB 
386606_0_3_5_1_2::None::Resection/NN margins/NNS in/IN oral/JJ cancer/NN surgery/NN :/: Room/NN 
468565_7_14_15_17_18::medicine.disease.risk_factors::recovery/NN from/IN the/DT high/JJ -/: temperature/NN stress/NN ./. 
474123_0_0_2_1_2::None::Oesophageal/JJ cancer/NN is/VBZ the/DT sixth/JJ 
1701_1701_50_51_11_12::None::involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
1052_1052_34_35_37_38::None::to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
1486_1486_35_40_4_5::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ 
128_128_18_19_4_5::POS_ACTION_BIND::of/IN various/JJ truncated/VBN alpha-catenin/NN molecules/NNS revealed/VBD that/IN amino-terminal/JJ residues/NNS 48-163/CD are/VBP able/JJ to/TO bind/VB to/TO beta-catenin/NN and/CC plakoglobin/NN ./. 
996_996_27_28_5_7::POS_ACTION_SUPPRESS::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) 
125951_3_19_20_24_25::None::inhibitors/NNS ,/, local/JJ analgesics/NNS and/CC dexamethasone/NN )/) can/MD induce/VB apoptosis/NN in/IN cancer/NN 
514561_0_12_13_10_11::None::concept/NN that/IN cardiovascular/JJ protection/NN through/IN high/JJ -/: density/NN lipoprotein/NN 
628556_0_14_15_0_2::None::Decision/NN Trees/NNP Predicting/VBG Tumor/NN Shrinkage/NN for/IN Head/NNP and/CC Neck/NNP Cancer/NNP :/: Implications/NNS for/IN Adaptive/JJ Radiotherapy/NN ./. 
149877_5_18_19_15_16::None::a/DT significantly/RB better/JJR post/NN -/: diagnosis/NN survival/NN than/IN those/DT cases/NNS 
1773_1773_10_11_6_7::POS_ACTION_SIMILAR::between/IN cofilin/NN and/CC gelsolin/NN segment-1/NN binding/NN to/TO actin/NN was/VBD confirmed/VBN experimentally/RB 
1373_1373_1_2_11_12::NEG_ACTION_RELATE::The/DT APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
301018_1_1_2_6_8::None::In/IN contrast/NN to/TO this/DT ,/, the/DT connective/JJ tissues/NNS of/IN echinoderms/NNS (/( 
522_522_1_2_21_22::POS_ACTION_BIND::Full-length/JJ beta-catenin/NN ,/, beta-catenin/NN mutant/JJ proteins/NNS with/IN NH2-terminal/JJ deletions/NNS before/IN (/( deltaN90/NN )/) or/CC after/IN (/( deltaN131/NN ,/, deltaN151/NN )/) the/DT alpha-catenin/NN binding/NN site/NN ,/, 
433927_4_6_7_3_4::None::Illumination/NN of/IN the/DT cells/NNS in/IN a/DT sodium/NN -/: free/JJ medium/NN 
93665_0_21_22_16_18::None::mainly/RB driven/VBN by/IN tumor/NN cells/NNS with/IN stem/NN cell/NN features/NNS ./. 
1434_1434_75_76_7_8::None::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
900999_12_21_22_18_19::None::of/IN smaller/JJR tumor/NN size/NN and/CC normal/JJ serum/NN BUN/NN level/NN at/IN 
336146_1_27_28_29_30::None::cancer/NN risk/NN among/IN tamoxifen/NN -/: treated/JJ breast/NN cancer/NN survivors/NNS 
1052_1052_34_35_18_20::None::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN 
322972_6_18_19_1_2::None::The/DT population/NN PK/NN model/NN developed/VBD from/IN our/PRP$ study/NN successfully/RB characterizes/VBZ the/DT absorption/NN ,/, distribution/NN ,/, and/CC elimination/NN of/IN MPA/NNP in/IN lung/NN transplant/NN 
1128_1128_11_14_0_2::POS_ACTION_MEMBER::Platelet/NN talin/NN binds/VBZ to/TO actin/NN in/FW vitro/FW and/CC hence/RB is/VBZ an/DT actin/NN binding/NN protein/NN ./. 
522582_0_15_16_7_8::None::worry/NN ,/, and/CC rumination/NN predict/VBP depressive/JJ and/CC anxiety/NN symptoms/NNS in/IN young/JJ adolescents/NNS ./. 
948941_3_18_19_11_12::None::anti/JJ -/: epileptic/JJ medication/NN use/NN :/: those/DT taking/VBG carbamazepine/NN //: oxcarbazepine/NN (/( CBZ/NN //: 
189447_0_1_2_2_3::None::Breast/NN cancer/NN incidence/NN is/VBZ increasing/VBG in/RB 
784_784_8_9_18_19::None::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN 
278671_5_9_10_15_16::None::the/DT relationship/NN between/IN cytokine/NN levels/NNS and/CC psoriasis/NN in/IN the/DT context/NN of/IN obesity/NN ./. 
1889_1889_11_13_5_6::None::death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN acid/NN sphingomyelinase/NN ./. 
95871_3_4_5_25_26::None::hypothesize/VBP that/IN adding/VBG CS/NN following/VBG injury/NN or/CC injury/NN and/CC shock/NN in/IN rats/NNS will/MD prolong/VB the/DT hypercatecholaminemia/NN and/CC prolong/VB the/DT initial/JJ anemia/NN ,/, despite/IN elevated/JJ erythropoietin/NN (/( EPO/NN )/) 
214422_1_5_6_10_11::None::rat/NN cardiomyocytes/NNS were/VBD randomly/RB divided/VBN into/IN the/DT following/VBG groups/NNS :/: control/JJ group/NN 
649052_1_3_4_16_17::None::Interestingly/RB ,/, while/IN dogs/NNS and/CC wolves/NNS show/VBP a/DT similar/JJ social/JJ organization/NN ,/, they/PRP differ/VBP in/IN their/PRP$ intraspecific/JJ cooperation/NN tendencies/NNS in/IN 
306632_3_30_31_43_44::None::they/PRP showed/VBD a/DT normal/JJ fasting/NN glycemia/NN and/CC A1c/NN ,/, patients/NNS spent/VBD a/DT lot/NN of/IN time/NN in/IN hyperglycemia/NN ./. 
669734_0_47_48_48_49::None::mid/JJ -/: and/CC late/JJ adolescence/NN ./. 
646_646_11_12_1_2::None::Human/JJ profilins/NNS are/VBP multifunctional/JJ ,/, single-domain/JJ proteins/NNS which/WDT directly/RB link/VBP the/DT actin/NN microfilament/NN system/NN to/TO 
600_600_8_9_0_1::POS_ACTION_BIND::alpha-SNAP/NN binds/VBZ to/TO predicted/VBN alpha-helical/JJ coiled-coil/JJ regions/NNS of/IN syntaxin/NN and/CC SNAP-25/NN ,/, 
1399_1399_55_57_57_58::POS_ACTION_MEMBER::complex/NN with/IN the/DT nucleocapsid/JJ protein/NN N/NN in/FW vivo/FW ./. 
480543_0_12_13_31_32::None::produced/VBN by/IN proton/NN irradiation/NN of/IN a/DT gallium/NN metal/NN target/NN ,/, purified/VBN by/IN organic/JJ extraction/NN and/CC used/VBN in/IN a/DT medical/JJ isotope/NN generator/NN to/TO produce/VB Gallium/NNP -/: 68/CD 
748_748_20_21_20_21::None::to/TO associate/VB with/IN actin/NN in/IN an/DT extended/JJ 
663522_15_19_20_36_38::None::Patients/NNPS undergoing/VBG prostate/NN biopsy/NN have/VBP ,/, with/IN a/DT high/JJ probability/NN ,/, LUTS/NNP Approximately/RB 50/CD %/NN suffer/VBP from/IN some/DT degree/NN of/IN erectile/JJ dysfunction/NN and/CC 24/CD %/NN 
873835_0_47_48_31_33::None::to/TO provide/VB significant/JJ pain/NN relief/NN ,/, improve/VB function/NN ,/, and/CC prevent/VB the/DT early/JJ onset/NN of/IN degenerative/JJ joint/JJ disease/NN (/( DJD/NN )/) ./. 
856_856_37_38_13_14::None::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN 
728764_2_2_3_15_16::medicine.disease.risk_factors::Causes/NNS of/IN chronic/JJ kidney/NN disease/NN included/VBD diabetes/NN mellitus/NN (/( n/NN =/JJ 9/CD patients/NNS )/) ,/, hypertensive/JJ nephrosclerosis/NN (/( n/NN 
90241_0_17_18_3_4::medicine.medical_treatment.used_to_treat::In/IN LUX/NN -/: Lung/NN 3/CD ,/, afatinib/NN significantly/RB improved/VBD progression/NN -/: free/JJ survival/NN (/( PFS/NN )/) versus/CC cisplatin/NN //: pemetrexed/VBN in/IN 
266669_0_24_25_28_29::None::cerebral/JJ artery/NN (/( MCA/NNP )/) stroke/NN (/( October/NNP 2009/CD ,/, international/JJ 
1061_1061_15_16_36_37::None::but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
125145_4_21_22_23_24::None::including/VBG joint/NN )/) bleeds/VBZ in/IN inhibitor/NN patients/NNS in/IN the/DT 
574065_1_9_11_22_25::None::,/, renal/JJ and/CC bladder/NN cancer/NN presented/VBN at/IN the/DT 2014/CD congresses/NNS (/( European/JJ Association/NNP of/IN Urology/NNP ,/, American/NNP Urological/NNP Association/NNP ,/, American/NNP Society/NNP 
758838_26_7_8_44_45::None::of/IN obesity/NN ,/, cholesterol/NN ,/, hypertension/NN and/CC diabetes/NN in/IN the/DT OA/NN in/IN contrast/NN to/TO the/DT larger/JJR ethnic/JJ majorities/NNS such/JJ as/IN Malays/NNP ,/, Chinese/NNP and/CC Indians/NNPS in/IN Malaysia/NNP These/DT differences/NNS are/VBP likely/JJ to/TO be/VB due/JJ to/TO socio/NN -/: economic/JJ effects/NNS and/CC lifestyle/NN changes/NNS ./. 
343970_4_24_25_40_41::None::CHL/NN was/VBD significantly/RB correlated/VBN with/IN TP/NN ,/, TN/NN ,/, total/JJ dissolved/VBN nitrogen/NN (/( TDN/NN )/) and/CC nitrate/JJ nitrogen/NN (/( NO3/NN (/( -/: )/) 
500377_1_3_5_1_2::None::Chinese/JJ patients/NNS with/IN essential/JJ hypertension/NN were/VBD treated/VBN with/IN 
590437_1_17_18_29_30::None::phenoxy/NN ]/) benzenepropanamine/NN hydrochloride/NN ;/: FLX/NNP )/) are/VBP frequently/RB used/VBN to/TO treat/VB depression/NN in/IN PD/NN patients/NNS ./. 
1633_1633_15_16_26_27::None::;/: four/CD histone/NN H2a/NN genes/NNS ,/, two/CD of/IN which/WDT are/VBP identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC 
1560_1560_39_40_39_40::None::than/IN was/VBD histone/NN H3/NN ,/, whereas/IN the/DT 
798558_0_22_23_5_6::None::late/JJ -/: onset/NN disorder/NN of/IN the/DT premutation/NN in/IN the/DT FMR1/NN gene/NN is/VBZ the/DT neurodegenerative/JJ disorder/NN fragile/JJ X/NN -/: associated/VBN tremor/NN ataxia/NN syndrome/NN (/( FXTAS/NN 
179835_3_30_32_9_10::None::discuss/VB cutting/VBG -/: edge/NN cardiovascular/JJ imaging/NN techniques/NNS and/CC potential/JJ clinical/JJ applications/NNS and/CC limitations/NNS of/IN those/DT techniques/NNS for/IN the/DT evaluation/NN of/IN major/JJ SLE/NN -/: related/JJ heart/NN disorders/NNS ./. 
1394_1394_5_6_8_9::POS_ACTION_BIND::constants/NNS of/IN Acanthamoeba/NN profilin/NN to/TO fluorescein-labeled/JJ actin/NN from/IN Acanthamoeba/NN and/CC 
259511_0_24_25_12_15::medicine.symptom.symptom_of::medical/JJ history/NN of/IN benign/JJ prostatic/JJ hyperplasia/NN presented/VBN to/TO the/DT emergency/NN department/NN with/IN complaints/NNS of/IN decreased/VBN urinary/JJ flow/NN ,/, inability/NN 
511797_2_46_47_32_33::None::underwent/VBD measurements/NNS of/IN aerobic/JJ fitness/NN and/CC muscular/JJ strength/NN (/( ie/FW impairment/NN )/) ,/, functional/JJ performance/NN ,/, functional/JJ limitations/NNS ,/, and/CC disability/NN 
177_177_20_21_32_33::POS_ACTION_ENCODE::mutants/NNS at/IN the/DT twinstar/NN locus/NN ,/, a/DT gene/NN that/WDT encodes/VBZ a/DT Drosophila/FW member/NN of/IN the/DT cofilin/ADF/NN family/NN of/IN actin-severing/JJ 
820881_0_6_7_11_12::None::as/IN predictors/NNS of/IN subclinical/JJ atherosclerosis/NN based/VBN on/IN the/DT coronary/JJ calcium/NN score/NN ./. 
345363_0_3_4_11_12::None::Factor/NN structure/NN and/CC psychometric/JJ properties/NNS of/IN the/DT TFEQ/NN in/IN morbid/JJ obese/JJ patients/NNS ,/, candidates/NNS to/TO 
191115_5_49_51_127_128::None::hilar/JJ or/CC mediastinal/JJ lymph/NN nodes/NNS ,/, we/PRP suggest/VBP performance/NN of/IN EBUS/NN -/: TBNA/NN and/CC //: or/CC EUS/SYM -/: (/( B/NN )/) -/: FNA/NN and/CC //: or/CC surgical/JJ staging/NN (/( Recommendation/NN grade/NN C/NN )/) 3/CD In/IN patients/NNS with/IN suspected/VBN or/CC proven/VBN &/CC lt/VBN ;/: 3/CD cm/NN peripheral/JJ NSCLC/NN with/IN normal/JJ mediastinal/JJ and/CC hilar/JJ nodes/NNS at/IN CT/NNP and/CC //: or/CC PET/NNP ,/, we/PRP suggest/VBP initiation/NN of/IN therapy/NN without/IN further/JJ mediastinal/JJ staging/NN (/( Recommendation/NN grade/NN C/NN )/) 4/CD For/IN mediastinal/JJ staging/NN in/IN patients/NNS with/IN centrally/RB located/JJ suspected/VBN or/CC 
159463_2_10_12_14_15::medicine.disease.risk_factors::lower/JJR risk/NN for/IN cardiovascular/JJ disease/NN comparing/VBG to/TO postmenopausal/JJ women/NNS or/CC age/NN 
1843_1843_31_33_31_32::None::the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD 
583_583_14_15_10_11::None::a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
658150_2_22_24_23_24::medicine.disease.symptoms::to/TO stop/VB the/DT epileptic/JJ seizures/NNS ./. 
327522_2_6_7_22_23::None::release/NN ,/, and/CC GABAergic/JJ dysregulation/NN in/IN the/DT central/JJ nucleus/NN of/IN the/DT amygdala/NN (/( CeA/NN )/) is/VBZ critical/JJ in/IN the/DT transition/NN to/TO alcohol/NN dependence/NN 
502821_1_2_3_0_1::None::Most/JJS metastatic/JJ cancers/NNS involving/VBG the/DT cervical/JJ 
608_608_20_21_10_11::None::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
339123_0_4_5_6_7::None::of/IN a/DT Cationic/NNP Calcium/NN Hydride/NNP Cluster/NNP with/IN a/DT ''/'' 
779_779_35_36_35_36::POS_ACTION_COOCCUR::an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) 
590_590_33_34_21_22::POS_ACTION_SIMILAR::ability/NN to/TO inhibit/VB p300/NN (/( and/CC the/DT highly/RB related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN 
168553_2_20_21_23_24::None::primary/JJ cortisol/NN -/: producing/VBG adrenal/JJ cortical/JJ lesions/NNS are/VBP increasingly/RB recognised/VBN 
1866_1866_5_6_12_13::None::both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN in/IN their/PRP$ signal/NN 
1633_1633_15_16_25_26::None::;/: four/CD histone/NN H2a/NN genes/NNS ,/, two/CD of/IN which/WDT are/VBP identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: 
189032_0_2_3_6_7::None::Alcohol/NN -/: Related/JJ Consequences/NNS Mediating/VBG PTSD/NN Symptoms/NNS and/CC Mental/NNP Health/NNP 
497005_0_5_7_6_7::None::well/RB recognized/VBN that/IN physical/JJ activity/NN should/MD be/VB an/DT 
655566_1_12_13_27_28::medicine.disease.symptoms::of/IN severe/JJ falciparum/NN malaria/NN over/IN the/DT past/JJ couple/NN of/IN decades/NNS ,/, with/IN a/DT shift/NN from/IN cerebral/JJ malaria/NN to/TO fever/NN with/IN jaundice/NN ,/, 
306064_4_18_19_34_35::None::is/VBZ only/RB one/CD report/NN of/IN its/PRP$ effect/NN on/IN GCRG/NNP Moreover/RB ,/, the/DT effect/NN of/IN denosumab/NN on/IN GCRG/NN of/IN the/DT spine/NN is/VBZ unknown/JJ ./. 
323306_3_19_20_23_24::None::2/CD h/NN in/IN duration/NN and/CC seven/CD were/VBD outpatient/JJ procedures/NNS ./. 
25_25_4_5_0_2::None::Actin-binding/JJ proteins/NNS such/JJ as/IN profilin/NN and/CC gelsolin/NN bind/VBP 
211495_10_32_33_21_22::None::amplifying/VBG inflammation/NN and/CC shaping/VBG tumor/NN microenvironment/NN ,/, and/CC suggests/VBZ that/IN EP2/NN antagonists/NNS are/VBP promising/JJ candidates/NNS of/IN aspirin/NN -/: 
120993_9_26_27_27_28::None::-/: line/NN treatment/NN initiation/NN rates/NNS and/CC shortened/VBD time/NN 
833393_2_3_4_16_17::None::Glycolysis/NNP is/VBZ the/DT sole/JJ source/NN of/IN energy/NN generation/NN for/IN malaria/NN parasite/NN Plasmodium/NN falciparum/NN ,/, hence/RB a/DT potential/JJ pathway/NN for/IN therapeutic/JJ 
386745_4_8_9_5_6::None::obtained/VBN from/IN the/DT National/NNP High/NNP School/NNP Sports/NNP -/: Related/JJ Injury/NNP 
287181_0_1_2_34_35::None::Ischemic/JJ heart/NN disease/NN ,/, also/RB known/VBN as/IN coronary/JJ heart/NN disease/NN or/CC coronary/JJ artery/NN disease/NN ,/, accounts/NNS for/IN &/CC gt/NN ;/: 50/CD %/NN of/IN cardiovascular/JJ events/NNS and/CC is/VBZ a/DT leading/VBG cause/NN worldwide/RB of/IN morbidity/NN and/CC mortality/NN ./. 
8_8_13_14_2_3::None::Abundance/NN of/IN actin/NN ,/, talin/NN ,/, alpha/NN 5/CD and/CC beta/NN 1/CD integrins/NNS ,/, pp125/CD focal/JJ adhesion/NN kinase/NN 
930_930_11_15_6_7::POS_ACTION_COLOCALIZE::the/DT actin-associated/JJ proteins/NNS filamin/NN ,/, talin/NN and/CC the/DT beta/NN 1/CD integrin/NN subunit/NN were/VBD also/RB found/VBN 
287181_0_1_2_11_14::medicine.disease.risk_factors::Ischemic/JJ heart/NN disease/NN ,/, also/RB known/VBN as/IN coronary/JJ heart/NN disease/NN or/CC coronary/JJ artery/NN disease/NN ,/, accounts/NNS for/IN 
422301_6_26_27_13_14::None::are/VBP an/DT evolutionary/JJ novelty/NN ,/, whereas/IN the/DT tubercles/NNS found/VBN on/IN the/DT shells/NNS of/IN some/DT turtles/NNS are/VBP homologous/JJ to/TO reptilian/JJ scales/NNS 
795722_1_17_18_14_15::None::RIT/NNP )/) after/IN total/JJ thyroidectomy/NN and/CC received/VBD at/IN least/JJS 1/CD 
433927_4_22_23_14_15::None::made/VBN by/IN substituting/VBG Na/NN +/CC with/IN K/NN +/CC )/) resulted/VBD in/IN SCN/NNP (/( -/: )/) 
144_144_39_40_34_36::None::)/) ,/, and/CC capping/VBG protein/NN (/( CAP1/NN and/CC CAP2/NN )/) genes/NNS have/VBP 
799750_8_18_20_1_2::medicine.medical_treatment.used_to_treat::Benign/JJ borderline/JJ and/CC malignant/JJ phyllode/NN tumors/NNS have/VBP different/JJ distant/JJ metastasis/NN risk/NN ,/, different/JJ primary/JJ tumor/NN size/NN and/CC different/JJ surgical/JJ procedures/NNS ,/, and/CC malignant/JJ 
417823_9_19_20_7_8::medicine.disease.risk_factors::diseases/NNS of/IN the/DT elderly/JJ in/IN this/DT study/NN were/VBD lumbar/JJ arthrosis/NN (/( 14/CD %/NN )/) ,/, dementia/NN (/( Alzheimer/NN whosewhat/NN 
792678_1_4_5_1_2::None::Delusional/JJ infestation/NN is/VBZ a/DT rare/JJ monosymptomatic/JJ hypochondriacal/JJ psychosis/NN 
729_0_4_5_6_7::None::of/IN children/NNS for/IN cervical/JJ spine/NN injuries/NNS (/( CSIs/NNS )/) 
441793_0_40_42_62_63::people.cause_of_death.includes_causes_of_death::mediated/VBN by/IN traditional/JJ cardiovascular/JJ risk/NN factors/NNS ;/: 2/LS )/) stronger/JJR among/IN whites/NNS than/IN blacks/NNS ;/: and/CC 3/LS )/) stronger/JJR among/IN those/DT genetically/RB predisposed/VBN to/TO having/VBG high/JJ levels/NNS of/IN vitamin/NN 
1373_1373_11_12_1_2::None::The/DT APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
2146_2146_11_13_4_5::None::report/VBP here/RB that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) 
468525_8_10_11_3_4::None::Systolic/JJ prehypertension/NN and/CC overweight/NN are/VBP associated/VBN with/IN incident/NN AF/NN in/IN Japanese/JJ population/NN ./. 
68_68_12_13_14_15::None::of/IN expression/NN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, 
856_856_40_41_13_14::None::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
1180_1180_19_21_17_18::POS_ACTION_BIND::polymerization/NN from/IN the/DT actin/NN :/: thymosin/NN beta4/NN and/CC beta9/NN complex/NN 
126724_0_0_1_5_6::None::Back/RB to/TO the/DT Future/NNP :/: Are/VBP Tumor/NN -/: Targeting/NN 
758838_26_11_12_28_29::medicine.disease.risk_factors::,/, hypertension/NN and/CC diabetes/NN in/IN the/DT OA/NN in/IN contrast/NN to/TO the/DT larger/JJR ethnic/JJ majorities/NNS such/JJ as/IN Malays/NNP ,/, Chinese/NNP and/CC Indians/NNPS in/IN Malaysia/NNP These/DT 
95871_5_12_13_6_7::None::,/, urine/NN was/VBD assessed/VBN for/IN norepinephrine/NN (/( NE/NN )/) levels/NNS ,/, blood/NN for/IN 
456_456_15_16_2_3::None::Expression/NN of/IN alpha-catenin/NN was/VBD generally/RB weak/JJ and/CC did/VBD not/RB correlate/VB with/IN the/DT expression/NN of/IN either/CC beta-catenin/NN or/CC E-cadherin/NN ./. 
1701_1701_50_51_48_49::None::proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
1439_1439_24_25_26_27::None::proteins/NNS such/JJ as/IN FADD/NN and/CC RIP/NN ./. 
288_288_19_20_13_14::POS_ACTION_AFFECT::actin-binding/JJ protein/NN and/CC talin/NN ,/, two/CD known/JJ substrates/NNS of/IN calpain/NN ./. 
232_232_9_10_7_8::POS_ACTION_INTERACT::indicate/VBP that/IN the/DT PRP9/NN and/CC PRP11/NN proteins/NNS interact/VBP ./. 
1692_1692_28_29_33_34::POS_REG(0)_ASSEMBLE::the/DT effect/NN of/IN profilin/NN on/IN the/DT assembly/NN of/IN actin/NN that/WDT had/VBD been/VBN 
750926_1_45_46_55_56::None::cell/NN apoptosis/NN and/CC proliferation/NN ,/, expression/NN of/IN Ki67/NN and/CC Erk1/NN //: 2/CD ,/, antioxidant/JJ capacity/NN ,/, and/CC 
206151_6_15_16_2_3::None::We/PRP accurately/RB linked/VBD the/DT PHIS/NN and/CC NTDB/NN records/NNS for/IN 69/CD %/NN of/IN children/NNS with/IN any/DT injury/NN ,/, and/CC 88/CD 
1916_1916_4_5_24_25::POS_REG(0)_MODIFY::our/PRP$ knowledge/NN ,/, AF-6/NN is/VBZ the/DT only/JJ integral/JJ component/NN in/IN cell-cell/JJ junctions/NNS discovered/VBN thus/RB far/RB that/IN interacts/VBZ with/IN profilin/NN and/CC thus/RB could/MD modulate/VB actin/NN modeling/NN proximal/JJ to/TO 
176455_12_1_2_8_9::None::Neoadjuvant/JJ radiotherapy/NN of/IN rectal/JJ cancer/NN represents/VBZ the/DT current/JJ standard/NN of/IN care/NN ./. 
161979_1_40_41_37_38::None::glioblastoma/NN ,/, new/JJ correlations/NNS have/VBP been/VBN discovered/VBN between/IN alterations/NNS at/IN 
121781_2_18_19_29_30::None::and/CC Alzheimer/NN whosewhat/NN disease/NN ,/, and/CC that/DT may/MD be/VB caused/VBN by/IN neural/JJ stem/NN cell/NN dysfunction/NN ./. 
607093_2_0_1_45_46::None::Here/RB we/PRP present/VBP a/DT new/JJ associated/VBN partial/JJ ilium/NN and/CC femur/NN from/IN Koobi/NNP Fora/NNP ,/, Kenya/NNP ,/, dating/VBG to/TO 1.9/CD Ma/NNP (/( millions/NNS of/IN years/NNS ago/IN )/) that/WDT is/VBZ clearly/RB attributable/JJ to/TO the/DT genus/NN Homo/NN but/CC documents/NNS a/DT pattern/NN of/IN morphology/NN not/RB seen/VBN in/IN eastern/JJ African/JJ early/JJ Homo/NN erectus/NN ./. 
316251_0_13_14_3_5::None::Redescription/NN of/IN the/DT eagle/NN rays/NNS Myliobatis/NN hamlyni/NNS Ogilby/NNP ,/, 1911/CD and/CC M/NN tobijei/NNS Bleeker/NNP ,/, 1854/CD (/( 
225720_6_8_9_0_1::None::We/PRP also/RB show/VBP that/IN primary/JJ tumors/NNS can/MD be/VB modeled/VBN in/IN immunocompetent/JJ mice/NNS 
696_696_21_22_9_10::None::purified/VBN 125I-labeled/JJ recombinant/JJ profilin/NN bound/VBD not/RB only/RB to/TO plant/NN actin/NN ,/, but/CC also/RB to/TO mammalian/JJ actin/NN ,/, demonstrating/VBG that/IN 
279_279_19_20_12_13::None::directly/RB associate/VBP with/IN TIF34/NN :/: PRT1/NN ,/, a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC 
1308_1308_9_10_6_9::None::transformation/NN by/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p57KIP2/NN requires/VBZ binding/VBG to/TO 
459318_0_16_18_7_8::None::-/: rods/NNS with/IN layered/JJ nano/NN -/: structure/NN by/IN thermal/JJ decomposition/NN of/IN the/DT coordination/NN complex/NN Cu/NN (/( BTA/NN 
250070_2_0_1_109_110::None::We/PRP performed/VBD a/DT secondary/JJ analysis/NN of/IN AIDS/NNP Clinical/JJ Trials/NNPS Group/NNP Study/NNP A5224s/NNP to/TO determine/VB if/IN markers/NNS of/IN renal/JJ disease/NN [/( urine/NN protein/NN :/: creatinine/NN ratio/NN (/( uPCR/NN )/) ,/, urine/NN albumin/NN :/: creatinine/NN ratio/NN (/( uACR/NN )/) ,/, and/CC estimated/VBN glomerular/JJ filtration/NN rate/NN (/( eGFR/NN )/) ,/, using/VBG Chronic/JJ Kidney/NN Disease/NN Epidemiology/NNP Collaboration/NNP (/( CKD/NNP -/: EPI/NN )/) creatinine/NN and/CC cystatin/NN C/NN -/: creatinine/NN ]/) were/VBD associated/VBN with/IN markers/NNS of/IN systemic/JJ inflammation/NN [/( high/JJ -/: sensitivity/NN C/NN -/: reactive/JJ protein/NN ,/, interleukin/NN -/: 6/CD ,/, tumour/NN necrosis/NN factor/NN (/( TNF/NN )/) -/: alpha/NN ,/, soluble/JJ TNF/NN -/: alpha/NN receptor/NN I/NN (/( sTNFRI/NN )/) ,/, sTNFRII/NN ,/, and/CC soluble/JJ vascular/JJ cellular/JJ and/CC intercellular/JJ adhesion/NN 
211991_5_9_10_0_1::None::Twenty/CD -/: eight/CD obese/JJ women/NNS were/VBD recruited/VBN with/IN the/DT diagnosis/NN of/IN PCOS/NN ,/, 
1248_1248_9_10_19_20::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB associated/VBN with/IN these/DT cadherins/NNS and/CC serve/VB to/TO 
1866_1866_3_4_9_10::None::Thus/RB ,/, both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN 
345914_6_22_23_1_3::None::Duodenal/JJ gene/NN expression/NN studies/NNS related/VBN to/TO the/DT absorption/NN of/IN iron/NN from/IN gamma/NN -/: Fe2O3/NN nanoparticles/NNS indicate/VBP the/DT enhancement/NN of/IN a/DT ferric/JJ over/IN ferrous/JJ pathway/NN supporting/VBG the/DT 
1380_1380_38_39_34_35::POS_ACTION_BIND::novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, 
948941_3_6_7_5_6::None::divided/VBN into/IN two/CD groups/NNS based/VBN on/IN anti/JJ -/: 
245_245_0_1_2_3::None::Neuropilin-1/NN (/( NRP1/NN )/) is/VBZ a/DT 
1168_1168_26_27_16_18::POS_ACTION_MEMBER::recombinant/JJ Arabidopsis/NNP thaliana/NN fimbrin/NN 1/CD (/( AtFim1/NN )/) is/VBZ a/DT member/NN of/IN the/DT fimbrin/plastin/NN family/NN of/IN actin/NN 
322590_4_4_5_12_13::None::-/: eclampsia/NN was/VBD defined/VBN as/IN per/IN the/DT International/NNP Society/NNP for/IN the/DT Study/NN of/IN Hypertension/NN in/IN 
538_538_25_28_32_33::None::increased/VBN incorporation/NN of/IN actin/NN binding/NN protein/NN ,/, talin/NN ,/, and/CC myosin/NN into/IN the/DT cytoskeletal/JJ 
596639_0_11_12_15_17::biology.organism_classification.lower_classifications::community/NN of/IN flowering/NN plants/NNS ,/, several/JJ simultaneously/RB flowering/VBG plant/NN species/NNS depend/VBP on/IN 
380023_1_3_4_8_9::None::However/RB ,/, many/JJ cancer/NN services/NNS do/VBP not/RB routinely/RB screen/NN patients/NNS for/IN anxiety/NN 
1164_1164_39_40_42_43::None::heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN ./. 
1737_1737_39_40_52_54::None::the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS ,/, possibly/RB through/IN the/DT interaction/NN of/IN the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN 
1008_1008_2_3_8_9::POS_ACTION_ENCODE::Mutants/NNS of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB 
429131_8_42_43_3_4::medicine.drug.active_moieties::Since/IN EGCG/NN +/CC Zn/NN (/( 2/CD +/CC )/) may/MD ,/, at/IN least/JJS in/IN part/NN ,/, protect/VBP cardiac/JJ myocytes/NNS against/IN H/NN //: R/NN -/: induced/VBN apoptotic/JJ cell/NN death/NN ,/, the/DT PI3K/NN //: Akt/NN pathway/NN of/IN EGCG/NN may/MD be/VB enhanced/VBN by/IN its/PRP$ interactions/NNS with/IN zinc/NN during/IN H/NN //: 
106335_13_17_18_34_35::None::predictive/JJ tools/NNS in/IN multifactorial/JJ intervention/NN such/JJ as/IN ERAS/NNS Compliance/NN with/IN ERAS/NNS can/MD reliably/RB predict/VB both/DT delayed/VBN discharge/NN and/CC 30/CD -/: day/NN readmission/NN following/VBG laparoscopic/JJ 
779_779_6_7_26_27::POS_ACTION_INCREASE::mechanism/NN by/IN which/WDT pRb/NN induces/VBZ senescence/NN ,/, we/PRP have/VBP found/VBN that/IN pRb/NN causes/VBZ a/DT posttranscriptional/JJ accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ 
466277_5_33_34_32_34::people.cause_of_death.includes_causes_of_death::locally/RB advanced/JJ cervical/JJ cancer/NN (/( stage/NN IB2/NN 
670_670_16_17_19_20::POS_ACTION_COLOCALIZE::,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, and/CC cadherin-5/NN were/VBD colocalized/VBN both/CC 
1061_1061_15_16_25_27::None::but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
95871_3_20_21_27_28::None::and/CC prolong/VB the/DT initial/JJ anemia/NN ,/, despite/IN elevated/JJ erythropoietin/NN (/( EPO/NN )/) levels/NNS ./. 
469705_8_19_20_16_17::None::interventions/NNS for/IN depressive/JJ symptoms/NNS in/IN RA/NN patients/NNS in/IN this/DT socio/NN 
1754_1754_32_33_21_22::NEG_ACTION_Change::to/TO interact/VB with/IN alpha-catenin/NN ,/, and/CC that/IN this/DT defect/NN results/VBZ from/IN the/DT mutation/NN in/IN beta-catenin/NN ./. 
329598_0_14_15_0_1::medicine.drug_ingredient.active_moiety_of_drug::Doxorubicin/NN -/: induced/VBN cardiomyopathy/NN (/( DOX/NN -/: CM/NN )/) is/VBZ a/DT severe/JJ complication/NN of/IN doxorubicin/NN (/( DOX/NN )/) 
957_957_12_13_23_24::POS_REG(0)_Assembly::heavy/JJ chain/NN (/( Myh/NN )/) predicted/VBD to/TO interfere/VB strongly/RB with/IN myosin/NN 's/POS binding/NN to/TO actin/NN was/VBD designed/VBN and/CC 
1417_1417_4_5_7_9::None::cellular/JJ transcription/NN co-activators/NNS p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ 
1678_1678_33_34_13_14::None::of/IN the/DT total/JJ H3/NN and/CC H2a/NN mRNA/NN ,/, whereas/IN the/DT histone/NN H4/NN and/CC histone/NN H2b/NN genes/NNS encode/VBP </JJR 10/CD %/NN of/IN the/DT total/JJ H4/NN and/CC H2b/NN mRNA/NN 
93_93_57_58_6_7::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
1052_1052_18_20_12_13::None::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) 
1688_1688_13_14_5_6::None::suggest/VBP that/IN nuclear/JJ profilin/NN can/MD mediate/VB a/DT stimulus-response/JJ action/NN on/IN the/DT actin/NN cytoskeleton/NN which/WDT is/VBZ 
512095_3_46_47_21_22::None::symptoms/NNS with/IN no/DT improvement/NN of/IN wash/NN -/: out/RP on/IN post/NN -/: operative/JJ MAG/NN -/: 3/CD scan/VB ,/, and/CC //: or/CC a/DT reduction/NN in/IN renal/JJ function/NN of/IN the/DT obstructed/VBN kidney/NN to/TO &/CC lt/NN 
10441_0_13_14_11_12::None::a/DT highly/RB prevalent/JJ complication/NN of/IN diabetes/NN ./. 
848984_1_13_14_27_28::None::66/CD known/JJ prostate/NN cancer/NN susceptibility/NN variants/NNS for/IN 17,012/CD men/NNS aged/JJ 50/CD -/: 69/CD years/NNS (/( 9,404/CD men/NNS identified/VBN with/IN prostate/NN cancer/NN 
513747_5_80_81_62_64::medicine.medical_treatment.used_to_treat::intervention/NN data/NNS ,/, atrial/JJ fibrillation/NN (/( anticoagulation/NN and/CC direct/JJ current/JJ cardioversion/NN )/) ,/, electrophysiology/NN (/( leadless/JJ pacemaker/NN devices/NNS ,/, use/NN of/IN quinidine/NN in/IN Brugada/NNP syndrome/NN 
79843_0_37_38_31_32::None::seen/VBN a/DT sharp/JJ uprising/NN in/IN recent/JJ years/NNS among/IN both/DT youth/NN and/CC adults/NNS for/IN 
313728_4_31_32_10_11::None::tumor/NN cells/NNS has/VBZ led/VBN to/TO the/DT proposal/NN of/IN a/DT new/JJ metabolic/JJ treatment/NN for/IN various/JJ cancers/NNS including/VBG GBMs/NNS that/WDT may/MD enhance/VB the/DT effectiveness/NN of/IN the/DT SOC/NNP The/DT goal/NN of/IN 
188127_4_6_7_12_13::medicine.disease.treatments::patients/NNS with/IN DP/NN allergy/NN that/WDT received/VBD sub/SYM -/: cutaneous/JJ immunotherapy/NN (/( SCIT/NN )/) 
996_996_12_13_31_34::None::can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
1427_1427_29_30_32_33::None::with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1646_1646_8_9_13_14::POS_ACTION_ASSEMBLE::unable/JJ to/TO bind/VB alpha-catenin/NN that/WDT is/VBZ responsible/JJ for/IN actin/NN filament/NN binding/NN and/CC 
856_856_16_18_37_38::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN 
1052_1052_29_30_12_13::None::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
505690_0_2_4_17_18::None::Distribution/NN of/IN Candida/NN albicans/NNS and/CC non/JJ -/: albicans/NNS Candida/NN species/NNS in/IN oral/JJ candidiasis/NN patients/NNS :/: Correlation/NN between/IN cell/NN surface/NN hydrophobicity/NN and/CC 
513_513_5_6_17_19::POS_REG(+)_Assembly::spliceosomal/JJ proteins/NNS (/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO promote/VB U2/NN snRNP/NN binding/NN to/TO pre-mRNA/NN 
1889_1889_0_2_5_6::POS_ACTION_BIND::TNF/NN receptor/NN death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN 
125145_4_19_20_0_1::None::Key/NN prospective/JJ studies/NNS have/VBP shown/VBN that/IN rFVIIa/NN achieves/VBZ consistently/RB high/JJ efficacy/NN rates/NNS in/IN the/DT management/NN of/IN acute/JJ (/( including/VBG joint/NN )/) bleeds/VBZ in/IN 
962_962_15_16_12_15::None::synthesis/NN by/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ./. 
1743_1743_11_12_4_5::None::results/NNS suggest/VBP that/IN RAD52/NN may/MD modulate/VB the/DT catalytic/JJ activities/NNS of/IN RAD51/NN protein/NN such/JJ as/IN 
4317_6_7_8_25_26::None::applied/VBN to/TO a/DT pharmacokinetic/JJ study/NN of/IN the/DT analytes/NNS in/IN beagle/NN dogs/NNS after/IN intravaginal/JJ administration/NN of/IN a/DT suppository/NN containing/VBG 0.5/CD mg/NN carboprost/NN methylate/NN ./. 
501715_7_3_4_10_12::None::A/DT blood/NN pressure/NN goal/NN of/IN less/JJR than/IN 140/CD //: 90/CD mm/NN Hg/NN is/VBZ recommended/VBN in/IN 
1652_1652_18_19_45_46::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
1061_1061_2_3_24_25::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
930_930_11_15_1_2::POS_ACTION_COLOCALIZE::Like/IN actin/NN ,/, the/DT actin-associated/JJ proteins/NNS filamin/NN ,/, talin/NN and/CC the/DT beta/NN 1/CD integrin/NN subunit/NN were/VBD also/RB found/VBN 
98_98_31_32_31_32::None::of/IN profilin/NN for/IN actin/NN may/MD be/VB under/IN 
132533_3_16_17_13_15::medicine.drug_ingredient.active_moiety_of_drug::,/, cortisol/NN and/CC adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) concentrations/NNS ./. 
374_374_4_5_14_15::None::of/IN SIR4/NN enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC deletion/NN of/IN SIR1/NN or/CC SIR3/NN did/VBD not/RB affect/VB 
1660_1660_25_26_27_28::POS_ACTION_UNBIND::of/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
406599_4_6_8_5_7::people.cause_of_death.includes_causes_of_death::that/IN human/JJ ovarian/JJ cancer/NN cells/NNS proliferate/VBP better/JJR 
184609_0_4_5_0_1::None::Oxidation/NN of/IN l/NN -/: arginine/NN (/( l/NN -/: 
157_157_14_15_33_34::POS_ACTION_BIND::of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN formed/VBN by/IN eukaryal/JJ histone/NN (/( H3/NN +/CC H4/NN )/) 
745266_0_0_1_13_14::medicine.medical_treatment.used_to_treat::Metformin/NNP is/VBZ the/DT first/JJ line/NN drug/NN for/IN patients/NNS diagnosed/VBN with/IN type/NN -/: 2/CD diabetes/NN ;/: however/RB ,/, 
367549_2_14_15_11_12::None::herds/NNS )/) ,/, coagulase/NN -/: negative/JJ staphylococci/NNS (/( n/NN =/JJ 
417823_9_3_5_7_8::None::The/DT most/RBS common/JJ neurological/JJ diseases/NNS of/IN the/DT elderly/JJ in/IN this/DT study/NN 
1759_1759_10_11_40_41::POS_REG(+)_ASSEMBLE::EGF/NN stimulation/NN recruits/VBZ cofilin/NN to/TO the/DT leading/JJ edge/NN where/WRB its/PRP$ severing/VBG activity/NN is/VBZ activated/VBN ,/, leading/VBG to/TO the/DT generation/NN of/IN short/JJ actin/NN filaments/NNS with/IN free/JJ barbed/VBN ends/NNS that/WDT participate/VBP in/IN the/DT nucleation/NN of/IN actin/NN polymerization/NN ./. 
590_590_35_36_21_22::None::ability/NN to/TO inhibit/VB p300/NN (/( and/CC the/DT highly/RB related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN activity/NN ./. 
381889_8_8_9_31_32::None::pain/NN scores/NNS [/( numerical/JJ rating/NN scale/NN (/( NRS/NN )/) ]/) ,/, self/NN reported/VBD health/NN status/NN (/( Short/JJ Form/NN -/: 36/CD Health/NNP Survey/NN )/) and/CC anxiety/NN //: depression/NN (/( Hospital/NN Anxiety/NN 
263791_3_25_26_5_6::None::be/VB given/VBN to/TO early/JJ and/CC aggressive/JJ control/NN of/IN inflammation/NN in/IN RA/NN patients/NNS ,/, particularly/RB those/DT with/IN seropositivity/NN ,/, increased/VBD inflammatory/JJ markers/NNS ,/, long/RB disease/NN duration/NN (/( &/CC 
1380_1380_36_37_34_35::POS_ACTION_BIND::novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, 
352074_5_18_19_35_36::None::for/IN an/DT anoxic/JJ atmosphere/NN ,/, 1.8/CD -/: fold/JJ less/JJR acid/NN consumption/NN than/IN for/IN AnRD/NN ,/, as/RB well/RB as/IN nickel/NN and/CC cobalt/NN recovered/VBD in/IN a/DT 
1061_1061_19_20_25_27::None::;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
515_515_23_24_10_11::None::GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
1061_1061_24_25_6_7::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
345914_6_22_23_9_10::medicine.drug.active_moieties::the/DT absorption/NN of/IN iron/NN from/IN gamma/NN -/: Fe2O3/NN nanoparticles/NNS indicate/VBP the/DT enhancement/NN of/IN a/DT ferric/JJ over/IN ferrous/JJ pathway/NN supporting/VBG the/DT 
213993_5_11_12_9_10::None::reported/VBD a/DT past/JJ history/NN of/IN diabetes/NN and/CC stroke/NN ,/, 
567_567_14_15_20_21::POS_ACTION_BIND::)/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
75211_5_4_5_0_1::None::We/PRP report/VBP on/IN the/DT cases/NNS of/IN five/CD Indian/JJ 
431465_3_22_23_11_12::None::catalyst/NN afforded/VBD the/DT azide/NN product/NN in/IN 70/CD %/NN ee/NN ,/, representing/VBG a/DT Mn/NN -/: catalyzed/VBN enantioselective/JJ aliphatic/JJ C/NN 
34897_2_36_37_5_6::None::water/NN phantom/JJ with/IN iodine/NN (/( 2.0/CD -/: 20.0/CD mg/NN I/PRP //: ml/NN )/) and/CC calcium/NN (/( 50.0/CD -/: 600.0/CD mg/NN Ca/NN //: ml/NN )/) rod/NN inserts/NNS was/VBD used/VBN to/TO evaluate/VB effective/JJ energy/NN estimate/NN (/( EEE/NN )/) and/CC iodine/NN 
996_996_5_7_29_30::None::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN 
665172_5_1_2_5_6::medicine.disease.risk_factors::Locomotor/NNP hyperactivity/NN was/VBD evident/JJ in/IN male/JJ NK1R/NN -/: //: 
460309_1_23_24_30_31::None::(/( H3PO4/NN )/) neutral/JJ loss/NN events/NNS ,/, suppressing/VBG informative/JJ peptide/NN backbone/NN cleavages/NNS ./. 
739338_5_13_14_15_16::None::men/NNS had/VBD a/DT history/NN of/IN smoking/NN and/CC diabetes/NN ,/, 
387603_2_28_29_16_18::medicine.drug.active_moieties::amphiphilic/JJ polymer/NN ,/, hyaluronic/JJ acid/NN -/: cystamine/NN -/: polylactic/NN -/: co/SYM -/: glycolic/JJ acid/NN (/( HA/SYM -/: SS/NN -/: 
846534_0_0_3_17_18::medicine.medical_treatment.used_to_treat::Deep/JJ Brain/NN Stimulation/NN (/( DBS/NN )/) has/VBZ been/VBN a/DT successful/JJ technique/NN for/IN alleviating/VBG Parkinson/NNP whosewhat/NN disease/NN (/( PD/NN )/) symptoms/NNS especially/RB 
813_813_2_4_23_24::None::Interaction/NN between/IN nucleocapsid/JJ protein/NN (/( NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN 
671_671_16_17_35_36::POS_ACTION_ATTACH::functional/JJ activity/NN ,/, ADF/NN and/CC cofilin/NN ,/, are/VBP transported/VBN into/IN nuclei/NNS of/IN cultured/VBN myogenic/JJ cells/NNS to/TO form/VB rod/NN structures/NNS there/RB together/RB with/IN actin/NN ,/, when/WRB the/DT 
2222_2222_37_38_13_14::NEG_ACTION_COLOCALIZE::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
1180_1180_17_18_19_21::POS_ACTION_BIND::polymerization/NN from/IN the/DT actin/NN :/: thymosin/NN beta4/NN and/CC beta9/NN complex/NN 
776_776_4_6_28_29::None::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT 
1008_1008_4_5_8_9::None::of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB 
459561_0_38_39_35_37::people.cause_of_death.includes_causes_of_death::pre/JJ -/: existing/VBG cardiovascular/JJ disease/NN (/( CVD/NN )/) ,/, and/CC 
218696_6_0_1_21_22::None::Diabetics/NNS were/VBD older/JJR (/( 64/CD vs/CC 62/CD years/NNS ,/, P/NN &/CC lt/NN ;/: 0.001/CD )/) ,/, with/IN higher/JJR incidence/NN of/IN major/JJ coronary/JJ risk/NN factors/NNS ,/, 
218696_6_33_36_18_19::None::,/, with/IN higher/JJR incidence/NN of/IN major/JJ coronary/JJ risk/NN factors/NNS ,/, co/SYM -/: morbidities/NNS ,/, and/CC triple/JJ -/: vessel/NN coronary/JJ artery/NN disease/NN ./. 
93_93_57_58_50_51::None::as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
712_712_24_25_15_16::POS_ACTION_UPREGULATE::stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN 
807498_0_12_13_4_6::None::aim/NN of/IN this/DT retrospective/JJ study/NN was/VBD to/TO evaluate/VB the/DT survival/NN of/IN dental/JJ implants/NNS placed/VBN after/IN 
1061_1061_36_37_25_27::None::to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
309692_18_63_64_45_46::medicine.disease.treatments::the/DT onset/NN of/IN bronchodilation/NN will/MD be/VB definitely/RB determined/VBN after/IN a/DT long/JJ -/: term/NN challenge/NN of/IN these/DT treatments/NNS at/IN isoeffective/JJ doses/NNS in/IN COPD/NN patients/NNS ./. 
1701_1701_11_12_50_51::None::involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
875_875_19_20_7_8::None::we/PRP demonstrate/VBP that/IN profilin/NN isoforms/NNS expressed/VBN in/IN a/DT single/JJ cell/NN can/MD have/VB different/JJ effects/NNS on/IN actin/NN in/IN living/NN cells/NNS 
1055_1055_19_22_2_3::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC 
510001_0_0_2_4_5::None::Sex/NN chromosomes/NNS have/VBP evolved/VBN independently/RB in/IN phylogenetically/RB diverse/JJ 
433781_3_20_21_9_10::medicine.medical_treatment.used_to_treat::numerous/JJ in/IN gastric/JJ cancer/NN patients/NNS than/IN in/IN controls/NNS ,/, and/CC significantly/RB more/RBR numerous/JJ before/IN surgery/NN than/IN after/IN surgery/NN 
515_515_23_24_5_6::None::work/NN ,/, the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
2230_2230_8_9_6_8::None::isoforms/NNS of/IN the/DT actin-binding/JJ protein/NN profilin/NN that/WDT differ/VBP in/IN 
590_590_21_22_29_31::POS_ACTION_SIMILAR::ability/NN to/TO inhibit/VB p300/NN (/( and/CC the/DT highly/RB related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN 
1367_1367_17_20_4_5::POS_ACTION_LOCALIZE::amount/NN of/IN unassembled/JJ actin/NN (/( 12/CD microM/NN )/) is/VBZ accounted/VBN for/IN by/IN the/DT sequestering/VBG functions/NNS of/IN T/NN beta/NN 4Xen/NN (/( 20/CD microM/NN 
456259_11_6_7_8_10::None::used/VBN for/IN distinguishing/VBG benign/JJ from/IN malignant/JJ tumors/NNS ./. 
440638_0_11_12_13_14::None::comparative/JJ efficacy/NN and/CC safety/NN of/IN budesonide/NN and/CC mesalazine/NN (/( 
326872_11_21_22_11_12::None::main/JJ targets/NNS of/IN dopamine/NN signaling/NN in/IN the/DT mammalian/JJ retina/NN owing/VBG to/TO a/DT characteristic/JJ ring/NN -/: like/IN innervation/NN 
355_355_14_15_12_13::POS_ACTION_Causal::mutant/JJ form/NN of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, 
699_699_24_25_22_23::None::cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN (/( INK4A/NN )/) and/or/CC up-regulation/NN 
1171_1171_5_6_9_10::None::have/VBP identified/VBN an/DT alpha-catenin/NN binding/NN site/NN in/IN beta-catenin/NN and/CC plakoglobin/NN and/CC 
7137_13_21_22_5_6::None::of/IN 10/CD percentage/NN points/NNS in/IN screening/NN was/VBD associated/VBN with/IN a/DT 25/CD %/NN increase/NN in/IN the/DT incidence/NN of/IN small/JJ breast/NN cancers/NNS (/( RR/NN ,/, 
620873_8_3_4_46_47::None::In/IN conclusion/NN ,/, mice/NNS administered/VBN formulations/NNS of/IN a/DT murine/JJ antibody/NN adsorbed/VBD onto/IN silicone/NN oil/NN microdroplets/NNS ,/, glass/NN microparticles/NNS ,/, or/CC Alhydrogel/NNP (/( Registered/NNP )/) showed/VBD greater/JJR ADA/NN responses/NNS that/IN those/DT that/WDT received/VBD particle/NN -/: free/JJ mAb1/NN preparations/NNS ,/, and/CC responses/NNS were/VBD greater/JJR for/IN formulations/NNS containing/VBG lower/JJR doses/NNS of/IN antibody/NN ./. 
349514_1_39_40_5_6::None::considering/VBG that/IN psychophysiological/JJ stressors/NNS may/MD be/VB associated/VBN with/IN greater/JJR cardiovascular/JJ risk/NN in/IN prehypertensives/NNS ,/, it/PRP is/VBZ important/JJ to/TO investigate/VB whether/IN heart/NN rate/NN variability/NN biofeedback/NN (/( HRV/NN -/: BF/NN )/) results/VBZ in/IN equivalent/JJ effects/NNS on/IN autonomic/JJ cardiovascular/JJ responses/NNS control/VBP during/IN stressful/JJ conditions/NNS 
631669_5_11_12_10_12::None::patients/NNS with/IN varicose/NN veins/NNS of/IN pelvic/JJ origin/NN 
161979_1_34_35_5_6::None::emergence/NN of/IN novel/JJ advanced/JJ imaging/NN techniques/NNS that/WDT allow/VBP microstructural/NN as/RB well/RB as/IN functional/JJ tissue/NN characterization/NN along/IN with/IN the/DT extensive/JJ work/NN done/VBN by/IN The/DT Cancer/NN Genome/NNP Atlas/NNP focusing/VBG on/IN mapping/VBG genomic/JJ changes/NNS in/IN glioblastoma/NN ,/, new/JJ correlations/NNS 
1289_1289_4_6_7_8::None::interactions/NNS between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT 
607093_2_19_20_6_7::None::a/DT new/JJ associated/VBN partial/JJ ilium/NN and/CC femur/NN from/IN Koobi/NNP Fora/NNP ,/, Kenya/NNP ,/, dating/VBG to/TO 1.9/CD Ma/NNP (/( millions/NNS of/IN 
1850_1850_23_24_8_9::POS_ACTION_RELATE::directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN and/CC serves/VBZ to/TO link/VB the/DT cadherin/catenin/NN complex/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
8_8_2_3_26_27::None::Abundance/NN of/IN actin/NN ,/, talin/NN ,/, alpha/NN 5/CD and/CC beta/NN 1/CD integrins/NNS ,/, pp125/CD focal/JJ adhesion/NN kinase/NN ,/, and/CC alpha-catenin/NN is/VBZ not/RB affected/VBN by/IN the/DT differential/JJ calreticulin/NN expression/NN ./. 
378211_8_26_27_12_13::None::of/IN cytokines/NNS (/( IL/NN -/: 8/CD ,/, IL/NN -/: 6/CD and/CC TNF/NN -/: alpha/NN )/) release/NN from/IN PBMCs/NNS in/IN non/JJ -/: 
429131_8_31_32_24_27::None::R/NN -/: induced/VBN apoptotic/JJ cell/NN death/NN ,/, the/DT PI3K/NN //: Akt/NN pathway/NN of/IN EGCG/NN 
549_549_9_10_20_21::POS_REG(-)_Change::was/VBD due/JJ to/TO msh6-F337A/NN sequestering/NN MSH2/NN and/CC preventing/VBG it/PRP from/IN interacting/VBG with/IN MSH3/NN and/CC MSH6/NN ./. 
702752_2_26_27_34_35::biology.organism_classification.lower_classifications::differentiation/NN using/VBG isolated/VBN murine/JJ splenic/JJ T/NN cells/NNS from/IN C57BL/NN //: 6/CD mice/NNS ./. 
189447_0_2_3_9_10::None::Breast/NN cancer/NN incidence/NN is/VBZ increasing/VBG in/RB low/JJ -/: and/CC middle/JJ -/: income/NN countries/NNS 
1646_1646_2_3_13_14::None::The/DT resulting/VBG beta-catenin/NN product/NN is/VBZ unable/JJ to/TO bind/VB alpha-catenin/NN that/WDT is/VBZ responsible/JJ for/IN actin/NN filament/NN binding/NN and/CC 
567_567_10_11_15_16::None::acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN 
71991_0_9_10_37_38::None::disorders/NNS and/CC comorbid/NN health/NN problems/NNS ,/, including/VBG depression/NN //: anxiety/NN disorder/NN ,/, insomnia/NN //: sleep/VB disorder/NN ,/, fatigue/NN ,/, and/CC injury/NN by/IN accident/NN ,/, and/CC to/TO determine/VB whether/IN certain/JJ physical/JJ and/CC psychological/JJ factors/NNS reduce/VB comorbid/NN 
246590_2_26_27_17_18::medicine.drug.active_moieties::covalency/NN of/IN the/DT aluminate/JJ host/NN lattice/NN ,/, related/JJ to/TO the/DT Sr/NNP //: Al/NNP ratio/NN ,/, on/IN 
798558_0_4_5_23_24::None::debilitating/JJ late/JJ -/: onset/NN disorder/NN of/IN the/DT premutation/NN in/IN the/DT FMR1/NN gene/NN is/VBZ the/DT neurodegenerative/JJ disorder/NN fragile/JJ X/NN -/: associated/VBN tremor/NN ataxia/NN syndrome/NN (/( FXTAS/NN )/) 
14901_2_22_23_4_5::None::study/NN examines/VBZ various/JJ serine/NN -/: to/TO -/: cysteine/NN substitutions/NNS on/IN alpha/NN -/: helix/NN regions/NNS of/IN 2/LS -/: Cys/NN Prx/NN A/NN in/IN Arabidopsis/NNP mutants/NNS and/CC the/DT 
118365_3_35_36_34_35::None::an/DT initial/JJ positive/JJ therapeutic/JJ response/NN ./. 
1608_1608_24_25_7_8::None::substitution/NN found/VBN in/IN talin/NN from/IN Wistar-Furth/NNP rats/NNS does/VBZ not/RB destroy/VB the/DT capacity/NN of/IN this/DT region/NN of/IN the/DT protein/NN to/TO bind/VB actin/NN or/CC vinculin/NN ./. 
2107_2107_7_8_24_26::None::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, 
1289_1289_7_8_11_12::None::nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) 
1052_1052_12_13_21_22::None::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG 
225032_8_1_2_13_15::None::In/IN contrast/NN with/IN the/DT conventional/JJ two/CD -/: dimensional/JJ culture/NN ,/, three/CD -/: dimensional/JJ culture/NN system/NN could/MD give/VB rise/VB 
996_996_8_9_5_7::None::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT 
255381_4_0_2_0_1::None::The/DT National/NNP Cancer/NNP registry/NN 
1082_1082_38_39_11_12::None::mobile/JJ form/NN of/IN actin/NN in/IN slow/JJ transport/NN is/VBZ soluble/JJ and/CC that/IN a/DT substantial/JJ amount/NN of/IN this/DT actin/NN may/MD travel/VB as/IN a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ./. 
1341_1341_12_13_6_7::POS_ACTION_RELATE::links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS to/TO the/DT actin/NN cytoskeleton/NN ./. 
513_513_5_6_9_10::POS_ACTION_INTERACT::spliceosomal/JJ proteins/NNS (/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN 
125639_3_6_7_35_36::None::UV/NN -/: visible/JJ absorption/NN and/CC electron/NN paramagnetic/JJ resonance/NN (/( EPR/NN )/) analysis/NN suggested/VBD that/IN the/DT enzyme/NN had/VBD the/DT typical/JJ copper/NN sites/NNS ,/, type/NN -/: 1/CD ,/, 2/CD ,/, and/CC 3/CD Cu/NN (/( II/CD )/) of/IN laccase/NN 
724990_11_18_19_29_30::None::dose/NN ,/, in/IN patients/NNS with/IN epilepsy/NN may/MD not/RB be/VB detrimental/JJ with/IN regard/NN to/TO seizure/NN control/NN ./. 
712_712_24_25_23_24::None::interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN 
1962_1962_24_25_22_23::None::the/DT actin-binding/JJ proteins/NNS tropomyosin/NN and/CC profilin/NN also/RB did/VBD not/RB 
350670_24_8_9_13_14::None::higher/JJR risk/NN of/IN stroke/NN recurrence/NN in/IN ischemic/JJ stroke/NN patients/NNS ./. 
556_556_12_13_7_9::None::to/TO be/VB a/DT nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ 
573489_1_21_23_14_15::None::a/DT plastic/NN and/CC reconstructive/JJ surgeon/NN after/IN the/DT initial/JJ diagnosis/NN of/IN breast/NN cancer/NN ./. 
1916_1916_24_25_4_5::None::our/PRP$ knowledge/NN ,/, AF-6/NN is/VBZ the/DT only/JJ integral/JJ component/NN in/IN cell-cell/JJ junctions/NNS discovered/VBN thus/RB far/RB that/IN interacts/VBZ with/IN profilin/NN and/CC thus/RB could/MD modulate/VB actin/NN modeling/NN proximal/JJ to/TO 
454283_3_18_19_11_12::None::of/IN lepidocrocite/NN and/CC goethite/NN ,/, while/IN favors/VBZ the/DT formation/NN of/IN ferric/JJ arsenate/NN with/IN the/DT 
1069_1069_26_27_29_30::None::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT 
878537_3_7_8_24_25::None::VASc/NN scores/NNS were/VBD calculated/VBN in/IN 2179/CD patients/NNS who/WP underwent/VBD a/DT first/JJ ablation/NN procedure/NN for/IN AF/NN enrolled/VBN in/IN the/DT Intermountain/NNP Heart/NNP Collaborative/NNP Study/NNP ./. 
669_669_21_22_11_12::None::the/DT presence/NN of/IN paxillin/NN ,/, talin/NN ,/, and/CC vinculin/NN at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS at/IN 
1164_1164_39_40_35_38::None::,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN 
687548_0_10_11_0_1::None::Diabetic/NNP polyneuropathy/NN (/( DPN/NN )/) is/VBZ a/DT devastating/JJ complication/NN of/IN diabetes/NN ./. 
1301_1301_10_11_18_19::POS_ACTION_Change::both/CC alpha-catenin/NN and/CC plakoglobin/NN are/VBP important/JJ for/IN the/DT adhesive/JJ function/NN of/IN cadherins/NNS ./. 
2065_2065_37_38_50_51::POS_ACTION_MEMBER::PCNA/NN )/) ,/, histone/NN H1/NN ,/, histone/NN H2A/NN +/CC 2B/NN ,/, histone/NN H3/NN ,/, and/CC histone/NN H4/NN ,/, was/VBD induced/VBN 
1321_1321_0_4_26_27::POS_REG(+)_MODIFY::Testicular/JJ protein/NN kinase/NN 1/CD (/( TESK1/NN )/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN testicular/JJ germ/NN cells/NNS and/CC has/VBZ the/DT potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
1534_1534_16_17_12_13::None::TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN 
851030_23_19_21_18_19::None::additional/JJ non/JJ -/: invasive/JJ infertility/NN treatments/NNS before/IN the/DT final/JJ 
714308_1_16_17_26_27::None::(/( PARP/NN )/) inhibitors/NNS became/VBD apparent/JJ and/CC now/RB several/JJ PARP/NN inhibitors/NNS are/VBP being/VBG developed/VBN to/TO treat/VB various/JJ 
1227_1227_26_27_22_23::None::between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, RAD3/NN ,/, RAD10/NN ,/, 
1779_1779_6_7_29_30::POS_ACTION_INTERACT::pyrene-labeled/JJ rabbit/NN skeletal/JJ actin/NN with/IN human/JJ profilin/NN yielded/VBD a/DT Kd/NN of/IN 2.8/CD microM/NN ,/, similar/JJ to/TO the/DT Kd/NN of/IN 2.0/CD microM/NN for/IN the/DT interaction/NN between/IN yeast/NN profilin/NN and/CC pyrene-labeled/JJ yeast/NN 
1817_1817_4_5_9_10::POS_REG(+)_MODIFY::is/VBZ consistent/JJ with/IN cofilin/NN activation/NN being/VBG required/VBN for/IN actin/NN reorganization/NN during/IN exocytosis/NN 
2148_2148_52_53_56_57::None::does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ calmodulin/NN ./. 
695014_15_5_6_12_13::None::a/DT relationship/NN between/IN psychological/JJ variables/NNS and/CC the/DT presence/NN of/IN depressive/JJ symptoms/NNS 2/CD months/NNS poststroke/NN 
538077_4_22_24_20_21::None::antimalarials/NNS with/IN IC50/NN values/NNS against/IN Plasmodium/NN falciparum/NN 3D7/NN of/IN 0.310/CD 
284253_6_12_13_43_44::None::were/VBD found/VBN for/IN levodopa/NN (/( immediate/JJ -/: or/CC extended/VBN -/: release/NN formulations/NNS )/) ,/, levodopa/NN with/IN added/VBN -/: on/IN catechol/NN -/: O/SYM -/: methyltransferase/NN (/( COMT/NN )/) inhibitors/NNS ,/, levodopa/NN //: carbidopa/NN gel/NN for/IN intestinal/JJ infusion/NN ,/, some/DT 
161_161_17_18_0_1::None::Armadillo/NN (/( Arm/NN )/) repeat/NN 10/CD to/TO the/DT COOH/NN terminus/NN of/IN beta-catenin/NN is/VBZ involved/VBN in/IN binding/VBG to/TO CBP/NN ,/, whereas/IN beta-catenin/NN 
454963_14_16_17_21_22::None::8/CD )/) of/IN End/NN Stage/NN Renal/JJ Disease/NN in/IN patients/NNS with/IN peripheral/JJ arterial/JJ 
596785_1_14_15_10_11::medicine.disease.treatments::referred/VBN for/IN surgical/JJ ablation/NN due/JJ to/TO persistent/JJ AF/NN combined/VBN with/IN biatrial/JJ 
106487_0_12_13_1_3::medicine.disease.symptoms::Severe/JJ systemic/JJ hypertension/NN (/( HTN/NN )/) is/VBZ a/DT risk/NN factor/NN for/IN perioperative/JJ cardiovascular/JJ complications/NNS ;/: however/RB 
702304_0_6_7_7_9::None::high/JJ risk/NN for/IN atherosclerotic/JJ cardiovascular/JJ disease/NN (/( ASCVD/NN )/) 
1618_1618_9_10_23_24::None::domains/NNS identified/VBD as/IN actin/NN and/CC phosphatidylinositol/NN 4,5-biphosphate/NN (/( PIP2/NN )/) binding/NN sites/NNS found/VBN in/IN members/NNS of/IN the/DT cofilin/NN family/NN ./. 
2137_2137_19_20_15_18::None::its/PRP$ associated/JJ proteins/NNS actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
293937_0_18_19_0_1::None::Asthma/NN -/: onset/NN in/IN older/JJR individuals/NNS has/VBZ been/VBN associated/VBN with/IN an/DT accelerated/VBN decline/NN in/IN lung/NN function/NN ,/, but/CC direct/JJ comparisons/NNS with/IN younger/JJR 
693466_12_1_2_9_10::None::HyperCVAD/NN chemotherapy/NN and/CC imatinib/NN is/VBZ an/DT effective/JJ regimen/NN for/IN Philadelphia/NNP -/: positive/JJ acute/JJ 
198729_8_5_6_18_19::None::to/TO a/DT higher/JJR prevalence/NN of/IN subclinical/JJ C/NN neoformans/NNS infection/NN in/IN male/JJ asthmatics/NNS and/CC may/MD support/VB the/DT hypothesis/NN of/IN C/NN neoformans/NNS 
1668_1668_3_4_8_9::POS_REG(0)_ASSEMBLE::The/DT role/NN of/IN profilin/NN in/IN the/DT regulation/NN of/IN actin/NN assembly/NN has/VBZ been/VBN 
669_669_11_12_16_17::None::the/DT presence/NN of/IN paxillin/NN ,/, talin/NN ,/, and/CC vinculin/NN at/IN the/DT ends/NNS 
653_653_2_3_8_9::None::Identification/NN of/IN alpha-syntrophin/NN binding/NN to/TO syntrophin/NN triplet/NN ,/, dystrophin/NN ,/, and/CC utrophin/NN 
1508_1508_10_11_16_18::POS_ACTION_ENCODE::UL8/NN ,/, and/CC UL52/NN genes/NNS encode/VBP an/DT essential/JJ heterotrimeric/JJ DNA/NN helicase-primase/NN that/WDT is/VBZ responsible/JJ 
400251_4_47_50_32_33::medicine.drug_ingredient.active_moiety_of_drug::and/CC 10/CD mg/NN tenofovir/NN alafenamide/NN (/( E/NN //: C/NN //: F/NN //: tenofovir/NN alafenamide/NN )/) or/CC 300/CD mg/NN tenofovir/NN disoproxil/NN fumarate/NN (/( E/NN //: 
259277_3_10_11_17_18::None::more/RBR frequent/JJ in/IN patients/NNS with/IN cardioembolic/JJ infarction/NN ,/, hypertension/NN and/CC diabetes/NN in/IN patients/NNS with/IN 
671014_4_21_22_49_50::None::responses/NNS ,/, a/DT paradigm/NN is/VBZ needed/VBN that/IN (/( a/DT )/) reliably/RB induces/VBZ high/JJ levels/NNS of/IN social/JJ -/: evaluative/JJ threat/NN and/CC (/( b/LS )/) is/VBZ extremely/RB adaptable/JJ to/TO the/DT needs/NNS of/IN the/DT researcher/NN ./. 
187563_7_19_20_23_24::medicine.disease.risk_factors::-/: 1/CD ,/, hemolysis/NN -/: 1/CD ,/, surgical/JJ VSD/NN closure/NN -/: 
241096_2_12_13_31_32::None::3/CD acetic/JJ acid/NN hydrazide/NN (/( IAAH/NN -/: Ag/NN )/) complexes/NNS via/IN a/DT pH/NN -/: sensitive/JJ hydrazone/NN bond/NN ,/, which/WDT functioned/VBD as/IN a/DT model/NN drug/NN ./. 
294475_2_14_15_8_9::None::either/CC a/DT regular/JJ diet/NN ,/, based/VBN on/IN barley/NN ,/, wheat/NN and/CC wheat/NN by/IN 
627089_4_17_20_4_5::None::women/NNS with/IN diabetic/JJ vasculopathy/NN ,/, nephropathy/NN ,/, chronic/JJ hypertension/NN ,/, preeclampsia/NN ,/, preterm/NN delivery/NN ,/, and/CC fetal/JJ growth/NN restriction/NN are/VBP frequently/RB observed/VBN 
583303_11_11_12_19_20::None::are/VBP the/DT most/RBS common/JJ microorganisms/NNS in/IN children/NNS with/IN untreated/JJ uncomplicated/JJ acute/JJ tympanostomy/NN -/: tube/NN otorrhea/NN 
1114_1114_13_16_17_18::POS_ACTION_MEMBER::binding/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, p21/NN (/( Cip1/WAF1/NN )/) 
591167_7_16_17_10_11::None::the/DT overall/JJ CV/NN safety/NN of/IN saxagliptin/NN in/IN a/DT robust/JJ number/NN of/IN elderly/JJ and/CC 
311702_2_14_16_24_25::None::those/DT with/IN other/JJ risk/NN factors/NNS ,/, are/VBP at/IN significant/JJ risk/NN for/IN development/NN of/IN inflammation/NN -/: mediated/VBN acute/JJ 
232_232_7_8_9_10::None::indicate/VBP that/IN the/DT PRP9/NN and/CC PRP11/NN proteins/NNS interact/VBP ./. 
645520_5_18_19_11_12::None::-/: deoxycytidine/NN also/RB sensitized/VBD the/DT radioresistant/JJ laryngeal/NN cancer/NN cells/NNS to/TO irradiation/NN ,/, indicating/VBG that/IN 
771_771_13_14_7_8::None::of/IN cofilin/NN ,/, destrin/NN ,/, and/CC deoxyribonuclease/NN I/PRP with/IN actin/NN by/IN phosphoinositides/NNS ./. 
101_101_36_37_22_23::None::the/DT influence/NN of/IN talin/NN and/CC vinculin/NN on/IN the/DT structure/NN ,/, chain/NN dynamics/NNS ,/, elasticity/NN and/CC viscoelasticity/NN of/IN actin/NN filaments/NNS with/IN time/NN 
984_984_9_10_33_34::None::different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, and/CC transcriptional/JJ repression/NN domain/NN of/IN MLL/NN fused/VBN to/TO the/DT CREB/NN binding/NN domain/NN or/CC 
473887_5_18_19_23_24::None::patients/NNS and/CC their/PRP$ families/NNS ,/, especially/RB in/IN the/DT terminal/JJ disease/NN phase/NN ./. 
446387_0_32_33_0_2::None::A/DT 63/CD -/: year/NN -/: old/JJ man/NN with/IN metastatic/JJ castration/NN -/: resistant/JJ prostate/NN cancer/NN (/( CRPC/NN )/) was/VBD successfully/RB treated/VBN for/IN two/CD years/NNS with/IN in/FW situ/FW gene/NN therapy/NN using/VBG an/DT adenovirus/NN vector/NN carrying/VBG the/DT human/JJ REIC/NN 
339123_0_6_7_4_5::None::of/IN a/DT Cationic/NNP Calcium/NN Hydride/NNP Cluster/NNP with/IN a/DT ''/'' 
112987_0_7_8_37_38::None::(/( 2DIR/NN )/) spectroscopy/NN ,/, which/WDT has/VBZ been/VBN proven/VBN to/TO be/VB an/DT excellent/JJ experimental/JJ method/NN for/IN studying/VBG thermally/RB -/: driven/JJ chemical/NN processes/NNS ,/, was/VBD successfully/RB used/VBN to/TO investigate/VB the/DT acid/NN dissociation/NN equilibrium/NN of/IN HN3/NN in/IN methanol/NN (/( 
1258_1258_34_35_32_33::None::defined/VBN as/IN the/DT fimbrin/NN (/( Sac6p/NN )/) -/: binding/VBG 
583_583_14_15_12_13::None::containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
130_130_15_16_6_7::POS_REG(+)_LOCALIZE::the/DT UL5/NN and/CC UL52/NN subunits/NNS retains/VBZ both/CC enzymic/JJ activities/NNS ,/, and/CC the/DT UL8/NN protein/NN has/VBZ been/VBN 
1082_1082_11_12_35_36::POS_ACTION_COLOCALIZE::mobile/JJ form/NN of/IN actin/NN in/IN slow/JJ transport/NN is/VBZ soluble/JJ and/CC that/IN a/DT substantial/JJ amount/NN of/IN this/DT actin/NN may/MD travel/VB as/IN a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
825_825_15_16_7_9::None::Arp2/3/NN complex/NN ,/, capping/VBG protein/NN and/CC profilin/NN in/IN remodeling/NN of/IN branched/VBN actin/NN filament/NN networks/NNS ./. 
393_393_16_17_5_7::POS_ACTION_CORELATE::isolated/VBN myofibrils/NNS with/IN alkaline/NN proteinase/NN resulted/VBD in/IN the/DT degradation/NN of/IN myosin/NN heavy/JJ chain/NN and/CC actin/NN ./. 
129749_7_6_7_1_2::None::Subclinical/JJ hypothyroidism/NN risk/NN for/IN DM/NN was/VBD prominent/JJ only/RB upon/IN statin/NN 
93_93_28_29_11_12::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
262795_4_20_21_0_1::None::It/PRP is/VBZ clear/JJ now/RB that/IN the/DT tumour/NN -/: promoting/VBG inflammatory/JJ environment/NN has/VBZ to/TO be/VB included/VBN as/IN one/CD of/IN the/DT major/JJ cancer/NN hallmarks/NNS ./. 
865_865_7_8_21_24::None::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ 
900398_7_1_2_17_20::medicine.risk_factor.diseases::The/DT OSA/NN -/: obesity/NN associations/NNS were/VBD robust/JJ and/CC evident/JJ for/IN both/DT genders/NNS ,/, individuals/NNS with/IN normal/JJ and/CC elevated/JJ blood/NN pressure/NN ,/, and/CC those/DT 
1417_1417_9_10_17_18::None::the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS for/IN transformation/NN by/IN the/DT E1A/NN proteins/NNS of/IN non-oncogenic/JJ 
671646_0_0_1_5_6::None::Surgical/NNP treatment/NN is/VBZ an/DT important/JJ strategy/NN for/IN the/DT treatment/NN 
246590_2_0_1_11_12::None::The/DT aim/NN of/IN the/DT research/NN is/VBZ to/TO investigate/VB the/DT role/NN of/IN local/JJ coordination/NN and/CC covalency/NN 
1069_1069_42_45_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
1156_1156_10_11_7_8::None::with/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN ,/, all/DT components/NNS 
272493_8_7_8_19_20::None::among/IN 13/CD NMDA/NN receptor/NN IgG/NN -/: positive/JJ patients/NNS ,/, 12/CD had/VBD encephalitis/NN ;/: their/PRP$ psychiatric/JJ symptoms/NNS were/VBD as/IN follows/VBZ 
240658_2_17_19_8_9::None::demonstrated/VBD that/IN aggression/NN acts/VBZ as/IN an/DT SNC/NN trait/NN in/IN fruit/NN flies/NNS (/( Drosophila/FW melanogaster/FW )/) ,/, but/CC 
1337_1337_7_8_9_10::None::talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN 
395871_8_29_30_36_38::None::after/IN resection/NN of/IN esophageal/NN malignancies/NNS ,/, especially/RB in/IN patients/NNS with/IN stage/NN III/CD -/: IV/CD tumors/NNS 
828542_0_0_1_6_8::None::Antibiotic/JJ management/NN of/IN methicillin/NN -/: resistant/JJ Staphylococcus/FW aureus/FW -/: -/: associated/VBN 
590_590_35_36_33_34::None::protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN activity/NN ./. 
1075_1075_6_7_11_12::None::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN 
1427_1427_27_28_3_4::None::The/DT comparison/NN of/IN E-CD/NN proteins/NNS synthesized/VBN by/IN E62/NN and/CC E24/NN cell/NN lines/NNS revealed/VBD no/DT structural/JJ or/CC functional/JJ differences/NNS because/IN both/DT localized/JJ at/IN cell-cell/JJ contacts/NNS and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
168553_2_2_3_17_18::None::While/IN the/DT majority/NN of/IN cases/NNS are/VBP attributed/VBN to/TO pituitary/JJ or/CC ectopic/JJ corticotropin/NN (/( ACTH/NN )/) overproduction/NN ,/, primary/JJ cortisol/NN -/: producing/VBG 
643154_0_3_4_8_9::None::Colorectal/JJ cancer/NN is/VBZ common/JJ worldwide/RB ,/, and/CC the/DT elderly/JJ are/VBP disproportionately/RB affected/VBN 
900398_7_6_7_15_16::None::obesity/NN associations/NNS were/VBD robust/JJ and/CC evident/JJ for/IN both/DT genders/NNS ,/, individuals/NNS with/IN normal/JJ and/CC elevated/JJ blood/NN 
441_441_2_3_9_11::None::Even/RB the/DT Munc18-2/NN mutants/NNS that/WDT do/VBP not/RB detectably/RB bind/VBP syntaxin/NN 3/CD were/VBD membrane/NN associated/VBN 
338450_1_3_4_8_9::medicine.medical_treatment.used_to_treat::The/DT choice/NN of/IN chemotherapy/NN in/IN the/DT treatment/NN of/IN pancreatic/JJ cancer/NN is/VBZ dependent/JJ 
165459_0_7_8_4_5::None::plants/NNS interact/VBP with/IN microbes/NNS primarily/RB at/IN roots/NNS ./. 
443015_2_12_13_19_20::biology.organism_classification.lower_classifications::two/CD standard/JJ experimental/JJ murine/JJ models/NNS of/IN asthma/NN ,/, where/WRB the/DT mice/NNS were/VBD treated/VBN with/IN 
491771_3_4_5_22_23::None::addition/NN of/IN the/DT analyte/NN ,/, 6/CD -/: mercaptopurine/NN (/( 6/CD -/: MP/NN )/) or/CC indeed/RB other/JJ similar/JJ thiols/NNS ,/, AuNCs/NNS formed/VBD aggregates/NNS because/IN the/DT existing/VBG 
996_996_8_9_27_28::None::cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) 
2089_2089_8_10_4_5::POS_ACTION_MEMBER::have/VBP found/VBN that/IN cofilin/NN ,/, a/DT 21-kDa/JJ actin-binding/JJ protein/NN ,/, is/VBZ a/DT 
899821_0_5_6_5_7::None::(/( oncogenic/JJ )/) human/JJ papillomavirus/NN (/( HPV/NN )/) 
312260_0_9_11_1_2::medicine.disease.treatments::The/DT procedure/NN of/IN reconstruction/NN after/IN the/DT removal/NN of/IN cranial/JJ fibrous/JJ dysplasia/NN (/( FD/NN )/) 
219974_13_7_8_16_17::None::of/IN death/NN are/VBP responsible/JJ for/IN almost/RB half/DT of/IN later/JJ deaths/NNS in/IN cardiac/JJ patients/NNS ./. 
468819_2_34_36_54_55::None::presence/NN of/IN unruptured/JJ intracranial/JJ aneurysms/NNS ,/, arteriovenous/JJ malformations/NNS and/CC dural/JJ fistulas/NNS ,/, co/SYM -/: existing/VBG brain/NN tumors/NNS as/RB well/RB as/IN in/IN conditions/NNS mimicking/VBG AIS/NNP The/DT review/NN systematically/RB 
70381_3_32_33_0_1::None::Three/CD days/NNS after/IN the/DT second/JJ injection/NN (/( day/NN 10/CD )/) ,/, the/DT rats/NNS were/VBD intraperitoneally/RB given/VBN sTNFRII/NN -/: gAD/NN or/CC sTNFRII/NN -/: Fc/NN ,/, or/CC PBS/NNP Effects/NNS of/IN treatments/NNS were/VBD examined/VBN with/IN respect/NN of/IN CIA/NNP incidence/NN 
1526_1526_12_13_17_18::None::)/) phosphoprotein/NN (/( P/NN )/) with/IN nucleocapsid/NN (/( N/NN )/) and/CC large/JJ 
639297_0_4_5_17_18::None::late/JJ -/: onset/NN sepsis/NN following/VBG peripherally/RB inserted/VBN central/JJ catheter/NN removal/NN :/: association/NN with/IN antibiotic/JJ use/NN and/CC adverse/JJ line/NN events/NNS ./. 
599869_3_31_32_23_24::None::be/VB the/DT sole/JJ indication/NN for/IN post/NN -/: mastectomy/NN radiation/NN ,/, and/CC accelerated/VBD delivery/NN methods/NNS for/IN 
250192_5_21_22_9_10::None::in/IN reducing/VBG OA/NN pain/NN (/( least/JJS squares/NNS mean/VBP change/NN from/IN baseline/NN in/IN visual/JJ analogue/NN scale/NN score/NN [/( standard/JJ error/NN 
93_93_28_29_50_51::None::kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
233446_5_6_7_4_5::None::%/NN of/IN the/DT patients/NNS had/VBD malignant/JJ tumors/NNS ./. 
422_422_21_22_21_22::POS_ACTION_Change::inhibitory/JJ activity/NN of/IN profilin/NN on/IN actin/NN polymerization/NN 
131579_0_16_17_26_27::None::for/IN locally/RB advanced/JJ resectable/JJ oral/JJ cavity/NN squamous/JJ cell/NN carcinoma/NN ,/, 24/CD patients/NNS with/IN T3/NN or/CC T4a/NN oral/JJ 
735_735_3_4_24_25::POS_REG(-)_DECREASE::In/IN contrast/NN ,/, act1-159/NN partially/RB suppresses/VBZ the/DT temperature/NN sensitivity/NN of/IN a/DT tropomyosin/NN mutant/NN ,/, and/CC the/DT loss/NN of/IN cytoplasmic/JJ cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, and/CC tropomyosin/NN 
841704_4_70_71_16_17::None::pain/NN ,/, ulcer/NN history/NN ,/, revascularization/NN history/NN ,/, amputation/NN history/NN ,/, gangrene/NN ,/, infection/NN ,/, Wagner/NNP grades/NNS ,/, duration/NN of/IN diabetes/NN ,/, and/CC postprandial/JJ blood/NN glucose/NN ,/, aldehyde/NN ,/, total/JJ protein/NN ,/, globulin/NN ,/, albumin/NN ,/, white/JJ blood/NN cell/NN (/( WBC/NN )/) ,/, hemoglobin/NN ,/, HbA1c/NN ,/, ulcer/NN property/NN ,/, body/NN mass/NN index/NN ,/, as/RB well/RB as/IN creatinine/NN ./. 
2414_0_18_19_3_4::None::Amino/NN -/: Terminal/JJ Pro/FW -/: B/NN -/: Type/NN Natriuretic/JJ Peptide/NN Improves/VBZ Discrimination/NN for/IN Incident/NNP Atherosclerotic/JJ Cardiovascular/NNP Disease/NNP Beyond/NNP Ambulatory/NNP Blood/NNP Pressure/NN in/IN 
1328_1328_1_3_3_4::POS_ACTION_MEMBER::The/DT actin-binding/JJ protein/NN profilin/NN binds/VBZ to/TO PIP2/NN 
350838_1_30_31_38_39::None::eukaryotes/NNS and/CC thus/RB represents/VBZ a/DT suitable/JJ model/NN organism/NN for/IN studying/VBG the/DT minimal/JJ essential/JJ components/NNS and/CC 
143793_11_10_11_25_26::None::(/( AD/NN or/CC PD/NN )/) was/VBD 1.74/CD (/( 95/CD %/NN confidence/NN interval/NN =/JJ 1.55/CD -/: 1.96/CD )/) in/IN patients/NNS with/IN COPD/NN compared/VBN 
1434_1434_75_76_14_15::None::H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
567_567_15_16_7_9::POS_ACTION_ACTIVATE::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN 
263791_3_21_22_40_41::people.cause_of_death.includes_causes_of_death::seropositivity/NN ,/, increased/VBD inflammatory/JJ markers/NNS ,/, long/RB disease/NN duration/NN (/( &/CC gt/NN ;/: 10/CD years/NNS )/) ,/, and/CC //: or/CC extra/JJ -/: articular/JJ manifestations/NNS ./. 
508103_4_18_19_13_14::None::levels/NNS or/CC body/NN weights/NNS in/IN STZ/NN -/: induced/VBN diabetic/JJ rats/NNS ,/, but/CC 
583_583_12_13_4_5::POS_ACTION_BIND::we/PRP report/VBP that/IN p120/NN associates/NNS with/IN a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, 
646_646_1_2_11_12::POS_ACTION_Causal::Human/JJ profilins/NNS are/VBP multifunctional/JJ ,/, single-domain/JJ proteins/NNS which/WDT directly/RB link/VBP the/DT actin/NN microfilament/NN system/NN to/TO 
379222_0_12_13_18_20::people.cause_of_death.includes_causes_of_death::of/IN death/NN from/IN cardiovascular/JJ compromise/NN prior/RB to/TO planned/VBN neonatal/JJ cardiac/JJ surgery/NN :/: a/DT meta/NN 
2013_2013_7_9_20_21::None::motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN verprolin/cofilin-like/JJ actin-regulatory/JJ domains/NNS ,/, but/CC no/DT specific/JJ actin/NN structure/NN regulated/VBN by/IN 
284647_4_21_22_34_35::None::as/IN impact/NN on/IN disease/NN rates/NNS in/IN infants/NNS is/VBZ encouraging/JJ ,/, anticipating/VBG the/DT possibility/NN to/TO at/IN last/JJ control/NN pertussis/NN in/IN this/DT 
427077_12_19_20_14_15::None::Cas/NNS )/) and/CC negatively/RB with/IN serum/NN phosphate/NN (/( Ps/NNS )/) ,/, PTH/NN 
423_423_5_6_2_4::None::Effects/NNS of/IN macrophage/NN profilin/NN on/IN actin/NN in/IN the/DT presence/NN 
1782_1782_25_26_7_8::None::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: 
106_106_2_3_6_7::POS_REG(+)_POLYMERIZE::mDia/NN binds/VBZ profilin/NN likely/JJ to/TO promote/VB actin/NN polymerization/NN ./. 
1392_1392_1_2_8_9::POS_ACTION_POLYMERIZE::The/DT cofilin/NN homology/NN sequence/NN is/VBZ critical/JJ for/IN stimulating/VBG actin/NN nucleation/NN with/IN the/DT 
2131_2131_13_14_9_10::None::,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ 
74367_0_0_1_5_6::None::The/DT genus/NN Neisseria/NNP contains/VBZ two/CD pathogenic/JJ species/NNS of/IN prominant/JJ 
316251_0_13_14_17_18::None::and/CC M/NN tobijei/NNS Bleeker/NNP ,/, 1854/CD (/( Myliobatiformes/NNPS :/: Myliobatidae/NNP )/) 
856_856_37_38_40_41::None::PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
2165_2165_20_21_15_16::None::of/IN acetylated/VBN histone/NN H4/NN relative/JJ to/TO acetylated/VBN histone/NN H3/NN ./. 
1760_1760_13_14_1_3::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC activate/VB the/DT actin-binding/JJ protein/NN cofilin/NN in/IN human/JJ T/NN 
1546_1546_5_6_26_27::POS_ACTION_BIND::inhibitory/JJ action/NN of/IN p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ from/IN its/PRP$ binding/NN with/IN the/DT cyclin/NN E/cyclin-dependent/JJ kinase/NN 2/CD (/( Cdk2/NN )/) complex/NN that/WDT 
597121_2_2_3_22_23::None::Several/JJ pathophysiologic/JJ mechanisms/NNS have/VBP been/VBN demonstrated/VBN and/CC evaluated/VBN among/IN hypertensives/NNS and/CC the/DT conglomeration/NN of/IN genetics/NNS ,/, environmental/JJ ,/, and/CC personal/JJ lifestyle/NN activities/NNS concurrently/RB impact/VBP the/DT progression/NN 
1334_1334_27_28_0_1::None::act1-157/NN ,/, an/DT actin/NN mutant/NN with/IN an/DT increased/VBN intrinsic/JJ rate/NN of/IN nucleotide/NN exchange/NN ,/, suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN growth/NN ,/, and/CC fluid-phase/JJ endocytosis/NN of/IN pfy1-4/NN ,/, a/DT profilin/NN 
283_283_0_1_15_16::POS_ACTION_CONTROL::Cadherins/NNS are/VBP essential/JJ for/IN embryonic/JJ morphogenesis/NN since/IN they/PRP mediate/VBP calcium-dependent/JJ cell-cell/JJ adhesion/NN and/CC can/MD modulate/VB beta-catenin/NN signaling/NN ./. 
695014_15_9_10_6_7::None::relationship/NN between/IN psychological/JJ variables/NNS and/CC the/DT presence/NN of/IN depressive/JJ symptoms/NNS 
515_515_10_11_20_21::POS_ACTION_Causal::GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN 
220528_2_28_29_12_13::None::effect/NN of/IN fluoride/NN treatments/NNS on/IN in/FW vivo/FW maturation/NN and/CC developmental/JJ potential/NN of/IN mouse/NN oocytes/NNS ,/, in/IN which/WDT female/JJ ICR/NN mice/NNS were/VBD treated/VBN with/IN 
235372_5_10_12_5_6::medicine.medical_treatment.used_to_treat::family/NN history/NN of/IN osteoporosis/NN ,/, BMI/NN ,/, current/JJ physical/JJ activity/NN ,/, osteoporosis/NN knowledge/NN 
1286_1286_12_13_8_9::None::chain/NN isoforms/NNS (/( SM1/NN ,/, SM2/NN ,/, SMemb/NN )/) ,/, caldesmon/NN 
243_243_30_32_27_28::None::coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD 
410019_0_3_5_25_26::medicine.disease.symptoms::Neo/SYM -/: adjuvant/JJ breast/NN cancer/NN clinical/JJ trials/NNS of/IN zoledronic/JJ acid/NN (/( ZOL/NN )/) have/VBP shown/VBN that/IN patients/NNS with/IN oestrogen/NN negative/JJ (/( ER/NN -/: ve/NN )/) tumours/NNS have/VBP improved/VBN disease/NN 
227834_1_22_23_7_8::None::damage/NN to/TO leukocytic/JJ DNA/NN and/CC enhancement/NN of/IN homocysteine/NN (/( Hcy/NN )/) level/NN in/IN sera/NNS of/IN type/NN 2/CD diabetic/JJ patients/NNS ./. 
2209_2209_23_24_26_27::POS_ACTION_MEMBER::of/IN another/DT pollen/NN profilin/NN isoform/NN ,/, ZmPRO1/NN ./. 
566931_0_9_10_4_5::None::the/DT treatment/NN of/IN polymyositis/NN (/( PM/NN )/) and/CC dermatomyositis/NN (/( DM/NN )/) 
177_177_32_33_20_21::None::mutants/NNS at/IN the/DT twinstar/NN locus/NN ,/, a/DT gene/NN that/WDT encodes/VBZ a/DT Drosophila/FW member/NN of/IN the/DT cofilin/ADF/NN family/NN of/IN actin-severing/JJ 
928918_0_8_9_9_10::medicine.disease.treatments::anesthetic/JJ technique/NN after/IN cancer/NN surgery/NN ./. 
1128_1128_4_5_0_2::POS_ACTION_BIND::Platelet/NN talin/NN binds/VBZ to/TO actin/NN in/FW vitro/FW and/CC 
319920_0_18_19_43_45::None::Scale/NNP items/NNS identified/VBD composite/JJ factors/NNS of/IN depression/NN ,/, mania/NN ,/, sleep/NN disturbance/NN ,/, judgment/NN //: impulsivity/NN ,/, and/CC irritability/NN //: hostility/NN as/IN major/JJ components/NNS of/IN psychiatric/JJ symptoms/NNS in/IN acute/JJ mania/NN or/CC mixed/JJ episodes/NNS 
613549_0_6_7_9_11::None::increasingly/RB common/JJ for/IN patients/NNS with/IN advanced/JJ breast/NN cancer/NN ./. 
489_489_20_21_26_27::None::the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP determined/VBN that/IN histone/NN H3/NN is/VBZ significantly/RB 
411_411_20_21_13_14::None::signaling/VBG molecules/NNS including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ./. 
1580_1580_28_29_25_26::POS_ACTION_BIND::cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
820881_0_8_9_7_8::None::predictors/NNS of/IN subclinical/JJ atherosclerosis/NN based/VBN on/IN the/DT coronary/JJ 
1405_1405_1_2_8_9::POS_ACTION_Assembly::The/DT talin/NN dimer/NN ,/, which/WDT is/VBZ crucial/JJ for/IN actin/NN and/CC lipid/NN binding/NN 
334920_0_16_17_34_36::None::protein/NN with/IN a/DT packaging/NN signal/NN in/IN the/DT viral/JJ RNA/NN as/IN important/JJ for/IN this/DT selectivity/NN ,/, but/CC the/DT packaging/NN signal/NN in/IN porcine/NN endogenous/JJ retrovirus/NN (/( PERV/NN )/) 
1094_1094_22_23_16_17::POS_ACTION_CONTAIN::,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT eIF3/NN complex/NN ./. 
769586_0_13_14_0_1::None::Subclinical/JJ atherosclerosis/NN has/VBZ been/VBN recently/RB detected/VBN in/IN adolescents/NNS with/IN a/DT family/NN history/NN of/IN premature/JJ atherosclerosis/NN ./. 
591379_13_20_21_11_12::medicine.symptom.symptom_of::MetS/NN and/CC preclinical/JJ metabolic/JJ heart/NN disease/NN and/CC raise/VB the/DT possibility/NN that/IN pulmonary/JJ hypertension/NN contributes/VBZ to/TO the/DT 
741231_0_14_17_3_5::medicine.disease.symptoms::Relationship/NN between/IN low/JJ blood/NN pressure/NN and/CC renal/JJ //: cardiovascular/JJ outcomes/NNS in/IN Japanese/JJ patients/NNS with/IN chronic/JJ kidney/NN disease/NN under/IN nephrologist/NN care/NN 
63_63_49_50_25_26::None::electrophoresis/NN :/: histone/NN H1/NN (/( 0/CD )/) ,/, four/CD histone/NN H1/NN subfractions/NNS ,/, histone/NN H2A/NN .1/NN ,/, histone/NN H2A/NN .2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN 
448173_0_8_9_11_12::biology.organism_classification.lower_classifications::was/VBD evaluated/VBN in/IN rats/NNS and/CC transgenic/JJ mice/NNS ./. 
1814_1814_11_12_18_19::None::storage/NN pool/NN of/IN actin/NN bound/VBD to/TO the/DT sequestering/NN protein/NN ,/, profilin/NN ./. 
93_93_22_23_50_51::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
600709_1_23_25_29_31::None::may/MD develop/VB into/IN hepatic/JJ fibrosis/NN ,/, cirrhosis/NN ,/, or/CC hepatocellular/JJ carcinoma/NN (/( HCC/NN )/) 
412955_2_18_19_7_8::None::reproductive/JJ treatments/NNS (/( ART/NN )/) are/VBP associated/VBN with/IN a/DT higher/JJR risk/NN of/IN pregnancy/NN complications/NNS compared/VBN with/IN spontaneously/RB conceived/VBN 
390913_0_15_17_5_8::None::and/CC vorinostat/NN [/( suberoylanilide/NN hydroxamic/JJ acid/NN (/( SAHA/NN )/) ]/) are/VBP both/DT new/JJ anticancer/JJ drugs/NNS ,/, interactions/NNS between/IN 
97678_0_11_12_12_13::None::Expenditures/NNS among/IN Elderly/NNP Medicare/NNP Beneficiaries/NNS ./. 
748_748_10_11_13_14::None::binding/NN proposed/VBN for/IN fimbrin/NN ,/, the/DT utrophin/NN actin-binding/JJ domain/NN appears/VBZ 
292_292_19_21_11_14::POS_ACTION_BIND::also/RB known/VBN as/IN dipeptidyl/NN peptidase/NN IV/CD ,/, is/VBZ directly/RB associated/VBN with/IN adenosine/NN deaminase/NN (/( ADA/NN )/) 
1373_1373_16_17_1_2::None::The/DT APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
7137_13_21_22_20_22::people.cause_of_death.includes_causes_of_death::of/IN small/JJ breast/NN cancers/NNS (/( RR/NN ,/, 
198131_1_9_10_13_14::None::of/IN long/JJ -/: term/NN users/NNS ,/, their/PRP$ smoking/NN behaviour/NN ,/, attachment/NN 
128715_9_6_7_20_21::medicine.drug.active_moieties::oral/JJ administration/NN of/IN captopril/NN up/IN -/: regulated/VBN endocytic/JJ activity/NN and/CC reduced/VBD the/DT immunostimulatory/JJ function/NN of/IN splenic/JJ DCs/NNS Captopril/NN treatment/NN also/RB promoted/VBD 
828493_2_15_16_10_11::None::,/, was/VBD to/TO investigate/VB associations/NNS between/IN obesity/NN and/CC gene/NN methylation/NN in/IN breast/NN 
243_243_0_2_30_32::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD 
1024_1024_32_33_39_40::POS_ACTION_INTERACT::RNA-binding/JJ surfaces/NNS of/IN HSH49/NN are/VBP not/RB required/VBN for/IN interaction/NN with/IN CUS1/NN ./. 
986_986_28_29_11_12::POS_ACTION_BIND::central/JJ role/NN of/IN beta-catenin/NN in/IN this/DT adhesion/NN complex/NN ,/, as/IN it/PRP binds/VBZ to/TO the/DT cytoplasmic/JJ domain/NN of/IN E-cadherin/NN and/CC to/TO alpha-catenin/NN ./. 
924463_2_28_29_30_31::None::finding/NN of/IN acute/JJ aortic/JJ dissection/NN detected/VBN by/IN carotid/NN ultrasonography/NN 
438998_0_14_16_3_4::None::Antagonistic/JJ effects/NNS of/IN chloroquine/NN on/IN autophagy/JJ occurrence/NN potentiate/VB the/DT anticancer/JJ effects/NNS of/IN everolimus/NN on/IN renal/JJ cancer/NN cells/NNS ./. 
2055_2055_21_22_28_29::None::the/DT recombinant/JJ viral/JJ profilin/NN ,/, and/CC characterized/VBD its/PRP$ interactions/NNS with/IN actin/NN and/CC polyphosphoinositides/NNS ./. 
861_861_19_20_9_11::None::,/, a/DT monomeric/JJ actin-binding/JJ protein/NN that/WDT has/VBZ been/VBN suggested/VBN to/TO be/VB involved/VBN in/IN actin/NN polymerization/NN ,/, was/VBD 
233446_5_4_5_6_8::None::%/NN of/IN the/DT patients/NNS had/VBD malignant/JJ tumors/NNS ./. 
1901_1901_29_30_33_34::POS_ACTION_MEMBER::kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, and/CC markers/NNS 
490714_0_7_8_0_2::None::Species/NNP richness/NN and/CC macronutrient/JJ content/NN of/IN wawo/NN worms/NNS (/( Polychaeta/NN ,/, 
529506_0_0_3_4_7::medicine.symptom.symptom_of::Diffuse/JJ alveolar/JJ hemorrhage/NN from/IN systemic/JJ lupus/NN erythematosus/NN misdiagnosed/JJ as/RB high/JJ 
329598_0_5_6_18_19::None::induced/VBN cardiomyopathy/NN (/( DOX/NN -/: CM/NN )/) is/VBZ a/DT severe/JJ complication/NN of/IN doxorubicin/NN (/( DOX/NN )/) chemotherapy/NN ./. 
515_515_20_21_7_8::None::the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN 
856_856_37_38_22_23::POS_ACTION_LOCALIZE-TO::,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN 
1534_1534_34_35_26_29::None::the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) are/VBP controversial/JJ 
1037_1037_27_28_4_5::None::disclosed/VBN interactions/NNS between/IN gephyrin/NN ,/, exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
556245_5_20_21_27_28::None::and/CC //: or/CC COPD/NNP exacerbation/NN between/IN patients/NNS receiving/VBG carvedilol/NN and/CC bisoprolol/NN ./. 
467117_12_6_8_17_19::medicine.disease.treatments::is/VBZ a/DT highly/RB malignant/JJ neoplasm/NN in/IN juvenile/JJ dogs/NNS ,/, but/CC may/MD be/VB amenable/JJ to/TO surgical/JJ resection/NN in/IN older/JJR dogs/NNS 
1427_1427_27_28_32_33::None::and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1082_1082_31_34_11_12::POS_ACTION_COLOCALIZE::mobile/JJ form/NN of/IN actin/NN in/IN slow/JJ transport/NN is/VBZ soluble/JJ and/CC that/IN a/DT substantial/JJ amount/NN of/IN this/DT actin/NN may/MD travel/VB as/IN a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, 
350698_1_0_1_8_11::None::This/DT goes/VBZ along/IN with/IN an/DT increased/VBN incidence/NN of/IN type/NN 2/CD diabetes/NN ,/, accompanied/VBN by/IN 
1486_1486_60_61_24_25::None::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
515_515_23_24_20_21::None::involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
2107_2107_24_26_39_40::None::bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
248756_2_42_43_65_66::None::,/, analyzing/VBG the/DT expression/NN pattern/NN of/IN genes/NNS that/WDT are/VBP involved/VBN in/IN integument/NN development/NN in/IN Arabidopsis/NNP thaliana/NN :/: INNER/NNP NO/NN OUTER/NN (/( INO/NN )/) ,/, ABERRANT/JJ TESTA/NN SHAPE/NN (/( ATS/NN )/) 
868728_2_10_11_17_18::None::distress/NN or/CC serious/JJ pathology/NN unless/IN infection/NN progresses/VBZ to/TO leukemia/NN or/CC lymphoma/NN ./. 
820342_0_32_33_24_25::None::,/, intensity/NN -/: modulated/VBN radiotherapy/NN (/( IMRT/NN )/) ,/, volumetric/JJ modulated/VBD arc/NN therapy/NN (/( VMAT/NN 
408887_9_9_11_34_35::medicine.disease.risk_factors::the/DT prevention/NN of/IN metabolic/JJ syndrome/NN and/CC inter/NN -/: related/JJ chronic/JJ illnesses/NNS :/: type/NN 2/CD diabetes/NN mellitus/NN ,/, cardiovascular/JJ disease/NN ,/, and/CC some/DT cancers/NNS ;/: which/WDT are/VBP associated/VBN with/IN overweight/JJ //: obesity/NN ,/, 
816806_0_53_55_26_28::None::cytotoxicity/NN against/IN cancer/NN cell/NN lines/NNS with/IN MDR/NN In/IN this/DT study/NN ,/, we/PRP aimed/VBD to/TO investigate/VB CIP/NNP -/: 36/CD ,/, a/DT novel/JJ podophyllotoxin/NN derivative/NN ,/, for/IN its/PRP$ inhibitory/JJ effects/NNS on/IN human/JJ cancer/NN cells/NNS from/IN multiple/JJ sources/NNS 
434463_2_9_10_34_35::None::propofol/NN products/NNS ,/, Diprivan/NNP (/( Registered/NNP )/) and/CC Fresofol/NN (/( Registered/NNP )/) ,/, with/IN the/DT Pall/NN Lipipor/NN (/( Registered/NNP )/) TNA/NNP and/CC Lipipor/NNP NLF/NNP intravenous/JJ in/IN -/: line/NN filters/NNS and/CC to/TO assay/VB 
10363_2_29_30_6_7::None::6J/NN mice/NNS made/VBD diabetic/JJ by/IN a/DT single/JJ high/JJ dose/NN injection/NN of/IN streptozotocin/NN (/( STZ/NN )/) were/VBD randomized/VBN to/TO receive/VB twice/RB daily/JJ subcutaneous/JJ injection/NN of/IN vehicle/NN or/CC recombinant/JJ human/JJ FGF21/NN at/IN 
295839_4_23_24_33_35::medicine.symptom.symptom_of::significant/JJ anti/JJ -/: tumor/NN cell/NN efficacy/NN in/IN K/NN -/: Ras/NN mutant/NN pancreatic/JJ and/CC colon/NN cancer/NN cells/NNS in/FW vitro/FW 
252268_2_37_38_35_36::medicine.drug.active_moieties::nervous/JJ system/NN striatal/JJ dopamine/NN (/( DA/NN )/) receptor/NN binding/NN 
419773_1_15_16_20_21::None::suffer/VBP from/IN pressure/NN ulcers/NNS and/CC the/DT resulting/VBG hospital/NN costs/NNS can/MD account/VB for/IN 
244414_9_18_19_5_6::None::nasopharynx/NN cancer/NN patients/NNS treated/VBN with/IN IMRT/NN and/CC chemotherapy/NN ,/, survival/NN and/CC locoregional/JJ disease/NN control/NN rates/NNS have/VBP improved/VBN ,/, however/RB late/JJ 
712_712_15_16_11_12::None::to/TO suggest/VB that/IN HRG/NN stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN 
275933_7_56_57_2_3::None::When/WRB describing/VBG leukemia/NN predisposition/NN due/JJ to/TO hereditary/JJ cancer/NN syndromes/NNS ,/, the/DT following/VBG 6/CD categories/NNS become/VBP apparent/JJ on/IN the/DT basis/NN of/IN biology/NN and/CC clinical/JJ presentation/NN :/: (/( 1/LS )/) genetic/JJ instability/NN //: DNA/NN repair/NN syndromes/NNS ,/, (/( 2/LS )/) cell/NN cycle/NN //: differentiation/NN syndromes/NNS ,/, (/( 3/LS )/) bone/NN marrow/NN failure/NN syndromes/NNS ,/, (/( 4/LS )/) telomere/NN maintenance/NN syndromes/NNS ,/, (/( 
693828_2_7_8_1_2::None::A/DT systematic/JJ literature/NN search/NN was/VBD conducted/VBN on/IN studies/NNS assessing/VBG the/DT clinical/JJ 
567_567_18_19_15_16::None::through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
986_986_28_29_25_26::None::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN and/CC to/TO alpha-catenin/NN ./. 
403501_2_8_9_18_19::biology.organism_classification.lower_classifications::based/VBN RDT/NN and/CC Plasmodium/NN nested/JJ PCR/NN were/VBD compared/VBN in/IN a/DT region/NN of/IN declining/VBG malaria/NN transmission/NN in/IN southern/JJ 
899821_0_8_9_12_14::medicine.disease.symptoms::human/JJ papillomavirus/NN (/( HPV/NN )/) infection/NN causes/VBZ cervical/JJ cancer/NN ./. 
176455_12_1_2_3_5::medicine.medical_treatment.used_to_treat::Neoadjuvant/JJ radiotherapy/NN of/IN rectal/JJ cancer/NN represents/VBZ the/DT current/JJ 
652874_0_16_17_11_12::None::a/DT radically/RB different/JJ history/NN for/IN the/DT evolution/NN of/IN live/JJ birth/NN and/CC egg/NN 
1652_1652_20_21_43_44::None::with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, 
596699_0_5_6_16_18::None::hypertension/NN are/VBP chronic/JJ conditions/NNS that/WDT are/VBP growing/VBG in/IN prevalence/NN as/IN major/JJ causal/JJ factors/NNS of/IN cardiovascular/JJ disease/NN (/( CVD/NN )/) 
1616_1616_34_35_35_36::POS_ACTION_MEMBER::for/IN the/DT proposed/VBN phosphoprotein/NN P/NN and/CC the/DT other/JJ 
143793_11_17_19_36_37::None::(/( 95/CD %/NN confidence/NN interval/NN =/JJ 1.55/CD -/: 1.96/CD )/) in/IN patients/NNS with/IN COPD/NN compared/VBN with/IN patients/NNS without/IN COPD/NNP after/IN adjusting/VBG for/IN age/NN ,/, gender/NN ,/, 
1537_1537_16_17_14_15::POS_ACTION_COLOCALIZE::major/JJ proteins/NNS :/: actin/NN ,/, villin/NN ,/, fimbrin/NN and/CC 
1520_1520_19_20_16_19::None::accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( kip1/NN )/) 
909_909_15_16_2_3::POS_ACTION_INTERACT::Isolation/NN of/IN profilin/NN from/IN embryonic/JJ chicken/NN skeletal/JJ muscle/NN and/CC evaluation/NN of/IN its/PRP$ interaction/NN with/IN different/JJ actin/NN isoforms/NNS ./. 
1806_1806_22_23_1_2::POS_ACTION_LOCALIZE::21/CD actin/NN mutations/NNS were/VBD analyzed/VBN in/IN budding/VBG yeast/NN ,/, and/CC specific/JJ regions/NNS of/IN actin/NN subdomain/NN 1/CD were/VBD implicated/VBN in/IN the/DT interaction/NN with/IN fimbrin/NN ,/, an/DT actin/NN 
433927_4_9_10_3_4::None::Illumination/NN of/IN the/DT cells/NNS in/IN a/DT sodium/NN -/: free/JJ medium/NN (/( made/VBN by/IN 
2222_2222_15_16_17_18::None::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, 
868728_2_12_13_6_7::None::thought/VBN to/TO cause/VB animal/NN distress/NN or/CC serious/JJ pathology/NN unless/IN infection/NN progresses/VBZ to/TO leukemia/NN 
590_590_33_34_29_31::None::related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN 
1782_1782_1_6_11_12::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS 
1227_1227_22_23_10_11::POS_ACTION_INTERACT::two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN ,/, ''/'' and/CC pairwise/JJ interactions/NNS between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, 
490079_2_18_21_3_4::None::We/PRP sought/VBD to/TO determine/VB whether/IN statin/NN treatment/NN after/IN cancer/NN diagnosis/NN is/VBZ associated/VBN with/IN longer/JJR survival/NN in/IN those/DT with/IN pancreatic/JJ ductal/JJ adenocarcinoma/NN (/( PDAC/NN )/) 
1047_1047_7_8_9_10::None::pro-apoptotic/JJ adapter/NN proteins/NNS TRADD/NN and/CC FADD/NN are/VBP also/RB involved/VBN 
398949_5_20_21_23_24::None::cysteine/NN )/) provided/VBD partial/JJ protection/NN against/IN cell/NN loss/NN but/CC also/RB 
1008_1008_2_3_4_5::None::Mutants/NNS of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP 
438089_4_20_21_26_27::None::the/DT General/NNP Surgery/NNP Department/NNP of/IN ''/'' Coltea/NNP ''/'' Clinical/JJ Hospital/NN ./. 
2013_2013_9_10_9_10::None::the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN 
497005_0_5_7_14_15::None::well/RB recognized/VBN that/IN physical/JJ activity/NN should/MD be/VB an/DT integral/JJ part/NN of/IN the/DT management/NN of/IN diabetes/NN ./. 
152333_0_6_8_10_11::None::a/DT highly/RB contagious/JJ respiratory/JJ disease/NN of/IN poultry/NN caused/VBN by/IN influenza/NN A/NN 
434463_2_6_7_9_10::medicine.drug.active_moieties::to/TO test/VB two/CD propofol/NN products/NNS ,/, Diprivan/NNP (/( Registered/NNP )/) 
620872_0_8_9_11_12::None::Containing/NNP Formulations/NNPS Impact/NNP Anti/NNP -/: drug/NN Antibody/NN Responses/NNS to/TO Murine/JJ 
1866_1866_3_4_5_6::None::Thus/RB ,/, both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, 
322769_0_14_15_6_7::medicine.drug_ingredient.active_moiety_of_drug::zero/CD -/: valent/JJ iron/NN in/IN oxic/JJ condition/NN :/: the/DT role/NN of/IN Fe/NNP (/( II/NNP )/) 
917107_4_6_7_12_13::medicine.medical_treatment.used_to_treat::pharmacokinetic/JJ and/CC increased/VBD antitumor/NN activities/NNS also/RB confirmed/VBD the/DT elevated/JJ cancer/NN targeting/VBG propensity/NN of/IN 
1164_1164_33_34_42_43::None:::/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN ./. 
856_856_22_23_24_25::None::,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT 
365_365_15_16_8_10::None::that/IN the/DT G1/NN cyclin/NN D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN 
1593_1593_4_5_27_28::POS_ACTION_DECREASE::potentiating/NN effect/NN of/IN insulin/NN appears/VBZ to/TO involve/VB increases/NNS in/IN the/DT expression/NN of/IN cyclin/NN E/NN and/CC decreases/VBZ in/IN the/DT expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( Kip1/NN )/) ./. 
1258_1258_32_33_34_35::None::defined/VBN as/IN the/DT fimbrin/NN (/( Sac6p/NN )/) -/: binding/VBG 
1926_1926_26_27_19_20::None::,/, FADD/NN ,/, DR3/NN ,/, FAF/NN ,/, TRADD/NN ,/, and/CC RIP/NN was/VBD similar/JJ in/IN 
2013_2013_20_21_20_21::None::but/CC no/DT specific/JJ actin/NN structure/NN regulated/VBN by/IN 
411_411_20_21_15_16::POS_ACTION_BIND::including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ./. 
213969_5_52_53_50_51::None::,/, tacrolimus/NN ,/, paroxetine/NN ,/, sertraline/NN ,/, fluoxetine/NN ,/, 
314756_0_13_14_10_12::medicine.drug_ingredient.active_moiety_of_drug::active/JJ metabolite/NN of/IN vitamin/NN A/NN (/( retinol/NN )/) ,/, has/VBZ 
1529_1529_7_8_10_13::POS_ACTION_INTERACT::and/CC human/JJ platelet/NN profilins/NNS with/IN rabbit/NN skeletal/JJ muscle/NN actin/NN were/VBD characterized/VBN by/IN 
571439_1_14_15_10_11::medicine.symptom.symptom_of::picture/NN of/IN severe/JJ RA/NN patients/NNS ,/, inhibit/VBP joint/JJ destruction/NN and/CC improve/VB 
144491_1_44_45_55_56::None::steady/JJ state/NN and/CC time/NN resolved/VBD fluorescence/NN spectroscopy/NN ,/, molecular/JJ docking/NN and/CC circular/JJ dichroism/NN (/( CD/NN )/) ./. 
274753_0_28_29_27_28::None::a/DT smoking/NN -/: cessation/NN tool/NN ./. 
7_7_2_3_11_12::POS_ACTION_Causal::Absence/NN of/IN alpha-syntrophin/NN leads/VBZ to/TO structurally/RB aberrant/JJ neuromuscular/JJ synapses/NNS deficient/JJ in/IN utrophin/NN ./. 
131579_0_9_10_48_49::None::neoadjuvant/JJ chemotherapy/NN to/TO surgery/NN and/CC radiation/NN therapy/NN for/IN locally/RB advanced/JJ resectable/JJ oral/JJ cavity/NN squamous/JJ cell/NN carcinoma/NN ,/, 24/CD patients/NNS with/IN T3/NN or/CC T4a/NN oral/JJ cavity/NN squamous/JJ cell/NN carcinoma/NN were/VBD randomly/RB assigned/VBN to/TO surgery/NN alone/RB or/CC Docetaxel/NNP ,/, Cisplatin/NNP ,/, and/CC 5/LS -/: FU/NN (/( TPF/NN )/) 
356156_0_17_18_8_9::None::Food/NNP and/CC Drug/NNP Administration/NNP (/( FDA/NNP )/) mandated/VBD a/DT label/NN change/NN for/IN leukotriene/NN inhibitors/NNS (/( LTIs/NNS 
724990_11_0_1_20_21::None::The/DT results/NNS of/IN the/DT present/JJ study/NN suggest/VBP that/IN use/NN of/IN etoricoxib/NN ,/, especially/RB at/IN low/JJ dose/NN ,/, in/IN patients/NNS with/IN epilepsy/NN may/MD not/RB be/VB 
93_93_50_51_28_29::None::kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
26283_1_19_21_28_30::None::marked/JJ tachycardia/NN with/IN atrial/JJ fibrillation/NN and/CC heart/NN failure/NN associated/VBN with/IN a/DT reduced/VBN left/VBD ventricular/JJ function/NN ./. 
1782_1782_11_12_20_22::POS_ACTION_LOCALIZE::)/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, 
1411_1411_1_5_18_19::POS_REG(0)_Assembly::The/DT cardiac/JJ myosin/NN heavy/JJ chain/NN Arg-403/NN --/: >/JJR Gln/NN mutation/NN that/WDT causes/VBZ hypertrophic/JJ cardiomyopathy/NN does/VBZ not/RB affect/VB the/DT actin/NN -/: or/CC ATP-binding/JJ 
112987_0_2_3_39_40::None::Two/CD -/: dimensional/JJ infrared/JJ (/( 2DIR/NN )/) spectroscopy/NN ,/, which/WDT has/VBZ been/VBN proven/VBN to/TO be/VB an/DT excellent/JJ experimental/JJ method/NN for/IN studying/VBG thermally/RB -/: driven/JJ chemical/NN processes/NNS ,/, was/VBD successfully/RB used/VBN to/TO investigate/VB the/DT acid/NN dissociation/NN equilibrium/NN of/IN HN3/NN in/IN methanol/NN (/( CH3OH/NN )/) 
447089_0_10_11_14_15::None::adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) promoted/VBD erythroblast/NN differentiation/NN and/CC increased/VBD the/DT 
473269_0_29_30_16_17::medicine.drug_ingredient.active_moiety_of_drug::of/IN the/DT pigmented/JJ dopaminergic/JJ neurons/NNS in/IN the/DT substantia/JJ nigra/NN pars/NNS compacta/VBP with/IN subsequent/JJ striatal/JJ dopamine/NN (/( DA/NN )/) deficiency/NN and/CC 
748_748_13_14_10_11::None::binding/NN proposed/VBN for/IN fimbrin/NN ,/, the/DT utrophin/NN actin-binding/JJ domain/NN appears/VBZ 
664393_0_12_13_1_2::None::Intraoperative/JJ radiotherapy/NN of/IN the/DT breast/NN for/IN early/JJ -/: stage/NN breast/NN cancer/NN :/: ready/JJ for/IN primetime/NN ./. 
515_515_23_24_7_8::None::the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
865_865_11_14_33_35::POS_ACTION_BIND::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
1672_1672_10_11_3_4::POS_ACTION_MEMBER::The/DT Saccharomyces/FW cerevisiae/FW DDC1/NN gene/NN belongs/VBZ to/TO the/DT RAD17/NN ,/, MEC3/NN and/CC RAD24/NN epistasis/NN 
1062_1062_13_15_10_11::POS_ACTION_MEMBER::the/DT gene/NN encoding/VBG fimbrin/NN ,/, another/DT actin-binding/JJ protein/NN ,/, which/WDT was/VBD 
179564_0_11_13_9_10::medicine.disease.treatments::mediated/VBN resistance/NN to/TO erlotinib/NN in/IN lung/NN cancer/NN ./. 
432219_9_11_12_1_2::None::Patients/NNS classified/VBN as/IN having/VBG no/DT or/CC mild/JJ ,/, moderate/JJ ,/, and/CC severe/JJ dehydration/NN were/VBD found/VBN 
1927_1927_19_20_27_28::None::regulatory/JJ protein/NN ,/, GAL4/NN ,/, and/CC a/DT negative/JJ regulatory/JJ protein/NN ,/, GAL80/NN ./. 
1652_1652_18_19_31_32::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( 
205_205_8_11_4_5::POS_ACTION_MEMBER:::/: p27/NN (/( Kip1/NN )/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, negatively/RB regulates/VBZ 
92153_1_18_19_27_28::None::in/IN the/DT current/JJ general/JJ population/NN of/IN patients/NNS with/IN nonvalvular/JJ atrial/JJ fibrillation/NN in/IN Spain/NNP ./. 
1074_1074_5_6_7_8::None::proteins/NNS ,/, including/VBG vinculin/NN ,/, talin/NN ,/, and/CC ezrin/NN 
537405_0_21_22_0_1::None::In/IN recent/JJ years/NNS ,/, evidence/NN supporting/VBG multimodality/JJ treatment/NN for/IN oesophageal/NN ,/, oesophagogastric/JJ junction/NN (/( OGJ/NN )/) ,/, and/CC gastric/JJ cancer/NN has/VBZ accumulated/VBN ./. 
164887_1_46_47_29_30::None::monitoring/NN in/IN an/DT adult/JJ population/NN identified/VBD obstructive/JJ sleep/NN apnea/NN //: non/JJ -/: obstructive/JJ sleep/NN apnea/NN during/IN overnight/JJ polygraphy/NN ;/: to/TO determine/VB the/DT cardio/NN -/: 
501715_7_3_4_15_16::None::A/DT blood/NN pressure/NN goal/NN of/IN less/JJR than/IN 140/CD //: 90/CD mm/NN Hg/NN is/VBZ recommended/VBN in/IN patients/NNS with/IN chronic/JJ kidney/NN 
416067_10_19_20_21_22::None::lower/JJR than/IN in/IN wild/JJ -/: type/NN 20/CD weeks/NNS after/IN 
729_0_14_15_11_13::None::CSIs/NNS )/) after/IN blunt/JJ trauma/NN is/VBZ complicated/VBN ,/, particularly/RB if/IN 
302982_3_7_8_9_10::medicine.drug_ingredient.active_moiety_of_drug::(/( 1/LS )/) Glucagon/NNP ,/, glucagon/NNP //: insulin/NN ratio/NN 
283_283_15_16_0_1::None::Cadherins/NNS are/VBP essential/JJ for/IN embryonic/JJ morphogenesis/NN since/IN they/PRP mediate/VBP calcium-dependent/JJ cell-cell/JJ adhesion/NN and/CC can/MD modulate/VB beta-catenin/NN signaling/NN ./. 
1701_1701_6_7_11_12::POS_ACTION_RELATE::that/IN this/DT novel/JJ RhoGAP/NN is/VBZ involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, 
2148_2148_4_5_44_45::POS_ACTION_DISRUPT::report/VBP here/RB that/IN tropomyosin/NN ,/, which/WDT is/VBZ found/VBN in/IN the/DT rootlet/NN but/CC not/RB in/IN the/DT microvillus/JJ core/NN ,/, can/MD bind/VB to/TO and/CC saturate/VB the/DT actin/NN of/IN isolated/VBN cores/NNS ,/, and/CC can/MD cause/VB the/DT dissociation/NN of/IN up/RB to/TO 30/CD %/NN of/IN the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS 
900398_7_1_2_8_9::None::The/DT OSA/NN -/: obesity/NN associations/NNS were/VBD robust/JJ and/CC evident/JJ for/IN both/DT genders/NNS 
524_524_25_26_40_41::None::similarity/NN with/IN host/NN WASP/NNP family/NN proteins/NNS :/: an/DT acidic/JJ stretch/NN ,/, an/DT actin/NN monomer-binding/JJ region/NN ,/, and/CC a/DT cofilin/NN homology/NN sequence/NN ./. 
865_865_21_24_11_14::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ 
492_492_44_45_25_27::POS_ACTION_INTERACT::2/CD -/: and/CC alpha/NN 1-syntrophin/JJ interact/NN with/IN peptides/NNS encoding/VBG the/DT syntrophin-binding/JJ region/NN of/IN dystrophin/NN ,/, utrophin/dystrophin/NN related/JJ protein/NN ,/, and/CC the/DT Torpedo/NNP 87K/NN protein/NN ./. 
2108_2108_8_11_17_18::None::proteins/NNS are/VBP indeed/RB nuclear/JJ basic/JJ proteins/NNS :/: the/DT 14/CD kd/NN is/VBZ the/DT histone/NN H4/NN ,/, the/DT 
799_799_11_12_16_17::None::linked/VBN to/TO the/DT actin/NN cytoskeleton/NN via/IN the/DT protein/NN talin/NN ./. 
199283_3_27_28_29_31::medicine.disease.symptoms::such/JJ as/IN perioperative/JJ anxiety/NN and/CC postoperative/JJ pain/NN ./. 
68_68_16_17_20_21::None::,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB beta-catenin/NN ,/, with/IN increased/VBN 
1782_1782_7_8_20_22::POS_ACTION_LOCALIZE::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, 
97678_0_2_3_0_1::None::Parkinson/NNP whosewhat/NN Disease/NN and/CC Home/NN Healthcare/NNP 
652874_0_11_12_0_1::None::Recent/JJ analyses/NNS using/VBG large/JJ -/: scale/NN phylogenies/NNS suggest/VBP a/DT radically/RB different/JJ history/NN for/IN the/DT evolution/NN 
151_151_64_65_6_7::None::aggregation/NN induced/VBN by/IN thrombin/NN (/( 0.25/CD U.ml-1/NN )/) with/IN IC50/NN 200/CD kIU.ml-1/NN ,/, and/CC inhibited/VBD the/DT rise/NN of/IN cytosolic/JJ free/JJ calcium/NN concentration/NN in/IN platelets/NNS stimulated/VBN by/IN thrombin/NN (/( 0.1/CD U.ml-1/NN )/) in/IN the/DT absence/NN and/CC in/IN the/DT presence/NN of/IN Ca2/NN +/CC 0.5/CD mmol.L-1/NN (/( IC50/NN 117/CD and/CC 50/CD kIU.ml-1/NN ,/, respectively/RB )/) ,/, but/CC had/VBD no/DT effect/NN on/IN the/DT amounts/NNS of/IN actin/NN and/CC myosin/NN heavy/JJ 
670_670_14_15_12_13::POS_ACTION_COLOCALIZE::post-TGF-beta1/NN showed/VBD that/IN beta-catenin/NN ,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, 
227756_3_14_15_16_17::biology.organism_classification.lower_classifications::molecular/JJ timescale/NN of/IN wolves/NNS and/CC dogs/NNS and/CC find/VB that/IN 
583_583_10_11_17_18::None::a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1434_1434_72_73_7_8::POS_ACTION_MEMBER::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN 
1069_1069_46_47_42_45::None::and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
653700_25_36_38_26_27::medicine.disease.risk_factors::in/IN the/DT third/JJ trimester/NN of/IN pregnancy/NN in/IN Germany/NNP to/TO reduce/VB the/DT rate/NN of/IN oral/JJ thrush/NN and/CC napkin/NN dermatitis/NN 
484109_1_8_9_11_12::None::,/, radiotherapy/NN ,/, chemotherapy/NN ,/, and/CC combined/VBN modality/NN treatment/NN are/VBP 
609_609_10_11_21_22::None::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN three/CD polypeptides/NNS encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
332030_3_0_1_18_19::None::The/DT protective/JJ effects/NNS of/IN GSP/NN on/IN blood/NN pressure/NN and/CC cardiovascular/JJ remodeling/NN in/IN rats/NNS with/IN DOCA/NN -/: salt/NN -/: induced/VBN hypertension/NN were/VBD investigated/VBN 
12271_2_87_88_61_62::None::heir/NN their/PRP$ biotinylated/VBN peptides/NNS substituted/VBN with/IN d/SYM -/: Lys/NNS at/IN the/DT N/NN -/: terminus/NN ,/, (/( Btn/NNP )/) dKP6/NN and/CC dK/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, were/VBD investigated/VBN for/IN their/PRP$ effects/NNS 
2414_0_17_18_9_10::None::-/: Type/NN Natriuretic/JJ Peptide/NN Improves/VBZ Discrimination/NN for/IN Incident/NNP Atherosclerotic/JJ Cardiovascular/NNP Disease/NNP Beyond/NNP Ambulatory/NNP Blood/NNP Pressure/NN 
476195_1_13_14_4_5::None::this/DT study/NN we/PRP investigated/VBD the/DT effects/NNS of/IN Cu/NN -/: NPs/NNS and/CC soluble/JJ Cu/NN in/IN the/DT intestines/NNS 
475835_20_7_8_0_1::None::This/DT study/NN demonstrates/VBZ that/IN the/DT sequence/NN of/IN Cy/NNP and/CC TBI/NNP does/VBZ 
76585_4_5_6_9_10::medicine.disease.risk_factors::were/VBD :/: tobacco/NN consumption/NN ,/, hypercholesterolemia/NN ,/, diabetes/NN ,/, aspirin/NN or/CC 
1061_1061_25_27_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
552323_0_4_5_1_2::None::While/IN obesity/NN is/VBZ a/DT major/JJ risk/NN factor/NN for/IN 
387603_2_25_27_30_31::None::-/: co/SYM -/: glycolic/JJ acid/NN (/( HA/SYM -/: SS/NN -/: PLGA/NN )/) 
167593_4_12_13_8_11::medicine.drug_ingredient.active_moiety_of_drug::HDAC/NN inhibitor/NN ,/, suberoylanilide/NN hydroxamic/JJ acid/NN (/( SAHA/NN )/) ,/, the/DT 
313_313_29_30_8_9::None::75-100/CD microM/NN unpolymerized/JJ actin/NN and/CC at/IN least/JJS four/CD proteins/NNS which/WDT can/MD bind/VB actin/NN monomers/NNS ,/, actin/NN depolymerizing/NN factor/NN (/( ADF/NN )/) ,/, gelsolin/NN ,/, profilin/NN ,/, and/CC thymosin/NN 
619_619_43_44_26_29::POS_ACTION_COOCCUR::the/DT generation/NN of/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN and/CC the/DT induction/NN of/IN S/NN phase/NN ,/, coincident/JJ with/IN the/DT loss/NN of/IN the/DT p27/NN cyclin-dependent/JJ kinase/NN inhibitor/NN 
405531_0_12_13_6_7::None::phosphate/NN ester/NN ,/, OE/NN )/) is/VBZ a/DT widely/RB used/VBN antiviral/JJ active/JJ against/IN influenza/NN 
1061_1061_6_7_36_37::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
1055_1055_2_3_0_1::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN 
948941_3_6_7_16_17::None::into/IN two/CD groups/NNS based/VBN on/IN anti/JJ -/: epileptic/JJ medication/NN use/NN :/: those/DT taking/VBG carbamazepine/NN //: oxcarbazepine/NN (/( 
919_919_9_10_12_13::None::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, 
307552_0_22_23_1_2::None::Living/VBG animals/NNS are/VBP constantly/RB faced/VBN with/IN various/JJ environmental/JJ stresses/NNS that/WDT challenge/VBP normal/JJ life/NN ,/, including/VBG :/: oxygen/NN limitation/NN ,/, very/RB low/JJ or/CC high/JJ temperature/NN ,/, as/RB 
367549_2_0_1_8_9::None::Staphylococcus/FW aureus/FW (/( n/NN =/JJ 35/CD from/IN 19/CD herds/NNS )/) ,/, coagulase/NN 
770_770_8_11_11_12::POS_ACTION_MEMBER::or/CC induction/NN of/IN cyclin-dependent/JJ kinase/NN inhibitor/NN p21WAF1/NN expression/NN was/VBD found/VBN 
515_515_10_11_5_6::None::work/NN ,/, the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB 
130_130_4_5_15_16::None::assembly/NN of/IN the/DT UL5/NN and/CC UL52/NN subunits/NNS retains/VBZ both/CC enzymic/JJ activities/NNS ,/, and/CC the/DT UL8/NN protein/NN has/VBZ been/VBN 
81377_14_3_4_0_1::None::Being/VBG obese/JJ before/IN pregnancy/NN and/CC frequently/RB consuming/JJ 
992_992_12_13_10_11::None::C-terminal/JJ regions/NNS of/IN talin/NN disrupt/VBP actin/NN stress/NN fibers/NNS when/WRB 
1052_1052_29_30_6_8::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
919_919_20_21_12_13::None::E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT can/MD assemble/VB alpha-catenin/NN into/IN the/DT complex/NN 
300324_0_25_26_53_54::None:://: shell/NN fiber/NN meshes/VBZ loaded/VBN with/IN epigallocatechin/NN -/: 3/LS -/: O/SYM -/: gallate/NN (/( EGCG/NN )/) (/( HA/NNP //: PLGA/NNP -/: E/NN )/) for/IN application/NN to/TO tissue/NN engineering/NN scaffolds/NNS for/IN skin/NN regeneration/NN were/VBD prepared/VBN via/IN 
410_410_12_13_11_12::None::histone/NN H3/NN and/CC histone/NN H4/NN were/VBD inviable/JJ ./. 
361641_4_0_1_2_3::None::To/TO deplete/VB extracellular/JJ and/CC cytosolic/JJ Ca/NN 
241096_2_32_33_16_17::None::(/( IAAH/NN -/: Ag/NN )/) complexes/NNS via/IN a/DT pH/NN -/: sensitive/JJ hydrazone/NN bond/NN ,/, which/WDT functioned/VBD as/IN a/DT model/NN drug/NN ./. 
112_112_18_19_3_4::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN epithelial/JJ cells/NNS and/CC forms/VBZ a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN localized/JJ to/TO the/DT 
1672_1672_3_4_12_13::None::The/DT Saccharomyces/FW cerevisiae/FW DDC1/NN gene/NN belongs/VBZ to/TO the/DT RAD17/NN ,/, MEC3/NN and/CC RAD24/NN epistasis/NN group/NN which/WDT 
92775_0_31_32_13_14::people.cause_of_death.includes_causes_of_death::whosewhat/NN disease/NN (/( AD/NN )/) may/MD be/VB optimal/JJ for/IN clinical/JJ trials/NNS to/TO test/VB potential/JJ treatments/NNS for/IN preventing/VBG or/CC delaying/VBG decline/NN to/TO dementia/NN ./. 
418321_2_0_1_9_10::None::The/DT 24/CD -/: hour/NN blood/NN pressure/NN (/( BP/NN )/) circadian/JJ pattern/NN also/RB appears/VBZ 
932_932_1_2_5_6::POS_ACTION_PHOSPHORYLATE::Like/IN TESK1/NN ,/, TESK2/NN phosphorylated/VBN cofilin/NN specifically/RB at/IN Ser-3/NN 
326872_11_11_12_26_27::medicine.drug_ingredient.active_moiety_of_drug::main/JJ targets/NNS of/IN dopamine/NN signaling/NN in/IN the/DT mammalian/JJ retina/NN owing/VBG to/TO a/DT characteristic/JJ ring/NN -/: like/IN innervation/NN from/IN dopaminergic/JJ (/( TH/NN (/( 
719083_0_8_9_10_11::None::Presenting/VBG with/IN Febrile/NN Seizures/NNS at/IN Ali/NNP -/: Asghar/NNP Children/NNP 
699_699_19_22_24_25::POS_ACTION_MEMBER::inactivation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN (/( INK4A/NN )/) and/or/CC up-regulation/NN 
211991_5_0_1_14_15::None::Twenty/CD -/: eight/CD obese/JJ women/NNS were/VBD recruited/VBN with/IN the/DT diagnosis/NN of/IN PCOS/NN ,/, mean/VB age/NN 27/CD !/. 
213_213_2_3_1_2::None::Because/IN histone/NN H3/NN shares/NNS many/JJ structural/JJ 
324666_0_0_1_16_18::None::Erythrocyte/NN pyruvate/NN kinase/NN deficiency/NN is/VBZ one/CD of/IN the/DT most/RBS common/JJ causes/NNS of/IN hereditary/JJ non/JJ -/: spherocytic/JJ hemolytic/JJ anemias/NNS ./. 
725976_10_28_29_14_15::medicine.risk_factor.diseases::demonstrated/VBD that/IN the/DT CHF/NN heart/NN had/VBD lower/JJR functional/JJ reserve/NN ;/: this/DT may/MD be/VB associated/VBN with/IN congestion/NN in/IN coronary/JJ microcirculation/NN ./. 
854528_1_51_52_50_51::None::and/CC 17/CD -/: kDa/NN antigen/NN gene/NN fragments/NNS ./. 
579913_0_14_15_0_2::medicine.risk_factor.diseases::Metabolic/JJ syndrome/NN (/( MetS/NN )/) is/VBZ a/DT cluster/NN of/IN cardiovascular/JJ risk/NN factors/NNS that/WDT includes/VBZ obesity/NN ,/, diabetes/NN ,/, 
93033_7_4_5_20_21::None::,/, all/DT three/CD TEs/NNS were/VBD found/VBN in/IN only/RB one/CD of/IN the/DT two/CD main/JJ lineages/NNS leading/VBG to/TO the/DT modern/JJ sugarcane/NN cultivars/NNS and/CC are/VBP therefore/RB 
1417_1417_7_9_4_5::None::cellular/JJ transcription/NN co-activators/NNS p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ 
223084_8_9_10_3_6::medicine.risk_factor.diseases::Hypercholesterolaemia/NN ,/, chronic/JJ coronary/JJ artery/NN disease/NN ,/, diabetes/NN and/CC hypertension/NN predicted/VBD AMI/NNP in/IN 
653700_25_43_44_8_9::None::to/TO treat/VB a/DT vaginal/JJ colonisation/NN of/IN Candida/NN in/IN healthy/JJ women/NNS ,/, vaginal/JJ administration/NN of/IN antimycotics/NNS is/VBZ often/RB recommended/VBN in/IN the/DT third/JJ trimester/NN of/IN pregnancy/NN in/IN Germany/NNP to/TO reduce/VB the/DT rate/NN of/IN oral/JJ thrush/NN and/CC napkin/NN dermatitis/NN in/IN healthy/JJ full/JJ -/: term/NN newborns/NNS 
339_339_13_14_15_16::None::actin/NN cytoskeleton/NN by/IN cofilin/NN and/CC Aip1/NN ./. 
75337_1_19_21_8_9::None::use/NN of/IN adjuvant/JJ regimens/NNS with/IN trastuzumab/NN for/IN the/DT treatment/NN of/IN small/JJ HER2/NN -/: positive/JJ breast/NN cancer/NN in/IN routine/JJ clinical/JJ 
154850_0_18_19_21_22::medicine.disease.symptoms::to/TO acute/JJ and/CC chronic/JJ hypocalcemia/NN and/CC uremia/NN ./. 
833393_2_10_11_6_7::None::sole/JJ source/NN of/IN energy/NN generation/NN for/IN malaria/NN parasite/NN Plasmodium/NN falciparum/NN ,/, 
242_242_17_21_2_3::POS_ACTION_RELATE::Neuropilin-1/NN mediates/VBZ collapsin-1/NN //: semaphorin/NN III/CD inhibition/NN of/IN endothelial/JJ cell/NN motility/NN :/: functional/JJ competition/NN of/IN collapsin-1/NN and/CC vascular/JJ endothelial/JJ growth/NN factor-165/NN ./. 
599869_3_14_15_33_34::None::after/IN whole/JJ breast/NN radiation/NN therapy/NN ,/, TNBC/NN should/MD not/RB be/VB the/DT sole/JJ indication/NN for/IN post/NN -/: mastectomy/NN radiation/NN ,/, and/CC accelerated/VBD delivery/NN methods/NNS for/IN TNBC/NN should/MD 
627089_4_11_12_17_20::None::chronic/JJ hypertension/NN ,/, preeclampsia/NN ,/, preterm/NN delivery/NN ,/, and/CC fetal/JJ growth/NN restriction/NN are/VBP frequently/RB observed/VBN 
779_779_26_27_21_24::None::accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ 
1534_1534_34_35_32_33::None::and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) are/VBP controversial/JJ 
2131_2131_23_24_9_10::None::,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
956369_1_13_14_45_46::None::as/IN a/DT periprocedural/JJ anticoagulant/NN therapy/NN for/IN patients/NNS who/WP had/VBD undergone/VBN catheter/NN ablation/NN (/( CA/NNP )/) for/IN AF/NN We/PRP evaluated/VBD 342/CD consecutive/JJ patients/NNS who/WP underwent/VBD CA/NNP for/IN AF/NN between/IN April/NNP 2013/CD and/CC March/NNP 2014/CD and/CC received/VBD apixaban/NN (/( n/NN =/JJ 
112_112_14_16_18_19::None::a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN localized/JJ to/TO the/DT 
106335_13_27_28_22_23::None::such/JJ as/IN ERAS/NNS Compliance/NN with/IN ERAS/NNS can/MD reliably/RB predict/VB both/DT delayed/VBN discharge/NN 
231976_9_36_37_40_41::None::and/CC peak/NN thrombin/NN formation/NN were/VBD higher/JJR in/IN SDP/NNP and/CC SD/NN -/: 
315432_4_18_19_14_16::None::used/VBN to/TO assess/VB negative/JJ reinforcement/NN and/CC NAc/NN dopaminergic/JJ transmission/NN ./. 
2222_2222_37_38_21_22::NEG_ACTION_COLOCALIZE::,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
359239_0_18_19_25_26::None::between/IN them/PRP ultimately/RB determine/VBP whether/IN a/DT cancer/NN escapes/VBZ immune/JJ recognition/NN mechanisms/NNS ./. 
401885_4_10_11_9_10::people.cause_of_death.includes_causes_of_death::higher/JJR prevalence/NN of/IN chronic/JJ respiratory/JJ symptoms/NNS and/CC diseases/NNS 
2222_2222_23_24_19_20::None::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
461685_1_24_28_3_4::None::Impaired/JJ glucagon/NN secretion/NN predisposes/VBZ some/DT patients/NNS with/IN type/NN 1/CD diabetes/NN mellitus/NN (/( T1DM/NN )/) to/TO hypoglycaemia/NN ;/: whereas/IN hyperglycaemia/NN in/IN patients/NNS with/IN T1DM/NN or/CC type/NN 2/CD diabetes/NN mellitus/NN (/( T2DM/NN )/) 
98643_2_10_11_25_26::medicine.medical_treatment.used_to_treat::rinv/NN were/VBD prescribed/VBN ondansetron/NN rdf/NN 8/CD mg/NN twice/RB daily/RB while/IN on/IN treatment/NN and/CC were/VBD asked/VBN to/TO complete/VB a/DT nausea/NN and/CC vomiting/NN -/: 
671_671_35_36_16_17::None::functional/JJ activity/NN ,/, ADF/NN and/CC cofilin/NN ,/, are/VBP transported/VBN into/IN nuclei/NNS of/IN cultured/VBN myogenic/JJ cells/NNS to/TO form/VB rod/NN structures/NNS there/RB together/RB with/IN actin/NN ,/, when/WRB the/DT 
753851_0_1_2_19_21::None::Differential/JJ impact/NN of/IN risk/NN factors/NNS for/IN tumor/NN recurrence/NN in/IN hepatitis/NN B/NN and/CC hepatitis/NN C/NN virus/NN -/: infected/JJ patients/NNS undergoing/VBG liver/NN transplantation/NN for/IN hepatocellular/JJ carcinoma/NN 
986_986_11_12_28_29::None::central/JJ role/NN of/IN beta-catenin/NN in/IN this/DT adhesion/NN complex/NN ,/, as/IN it/PRP binds/VBZ to/TO the/DT cytoplasmic/JJ domain/NN of/IN E-cadherin/NN and/CC to/TO alpha-catenin/NN ./. 
1901_1901_33_34_31_32::None::(/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, and/CC markers/NNS 
1498_1498_15_16_8_9::None::thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD 
1787_1787_14_15_11_12::POS_ACTION_INTERACT::their/PRP$ interaction/NN with/IN actin/NN ,/, like/IN destrin/NN and/CC cofilin/NN isolated/VBN 
404541_2_8_10_4_5::None::,/, the/DT ATG6/NN functions/VBZ in/IN wheat/NN (/( Triticum/FW aestivum/FW L/NN ./. 
72969_0_36_38_56_57::people.cause_of_death.includes_causes_of_death::lead/VB to/TO persisting/VBG mental/JJ illness/NN symptoms/NNS within/IN the/DT spectrum/NN of/IN post/NN -/: traumatic/JJ stress/NN disorder/NN (/( PTSD/NN )/) ,/, anxiety/NN disorders/NNS ,/, and/CC depression/NN ./. 
327522_2_14_15_25_26::None::nucleus/NN of/IN the/DT amygdala/NN (/( CeA/NN )/) is/VBZ critical/JJ in/IN the/DT transition/NN to/TO alcohol/NN dependence/NN ./. 
1861_1861_2_3_15_16::None::Thus/RB ,/, APC/NN forms/NNS distinct/JJ heteromeric/JJ complexes/NNS containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN which/WDT are/VBP independent/JJ 
1061_1061_24_25_19_20::None::;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
510403_0_21_22_12_13::medicine.disease.symptoms::have/VB anti/JJ -/: inflammatory/JJ ,/, anti/JJ -/: diabetic/JJ ,/, and/CC anti/JJ -/: atherogenic/JJ effects/NNS ./. 
293937_0_22_23_26_27::None::comparisons/NNS with/IN younger/JJR adults/NNS have/VBP not/RB been/VBN reported/VBN ./. 
211495_10_21_22_4_5::None::study/NN has/VBZ thus/RB revealed/VBN that/IN EP2/NN in/IN neutrophils/NNS and/CC tumor/NN -/: associated/JJ fibroblasts/NNS promotes/VBZ colon/NN tumorigenesis/NN by/IN amplifying/VBG inflammation/NN and/CC shaping/VBG tumor/NN microenvironment/NN ,/, 
1061_1061_6_7_19_20::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO 
143595_7_33_34_5_6::None::chronic/JJ bioassay/NN ,/, larvae/NNS were/VBD exposed/VBN to/TO nitrate/VB concentrations/NNS of/IN 50/CD ,/, 100/CD ,/, 200/CD ,/, and/CC 400/CD mg/NN //: L/NN NO3/NN (/( -/: )/) -/: N/NN during/IN the/DT entire/JJ larval/JJ period/NN (/( 23/CD days/NNS 
93_93_54_55_11_12::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
2216_2216_35_36_12_13::None::for/IN binding/NN of/IN histone/NN H4/NN ,/, it/PRP equally/RB competed/VBD with/IN DNA/NN for/IN binding/NN of/IN histone/NN H3/NN and/CC only/RB inefficiently/RB competed/VBD with/IN DNA/NN for/IN binding/NN of/IN histone/NN H1/NN ./. 
380023_1_4_5_3_4::None::However/RB ,/, many/JJ cancer/NN services/NNS do/VBP not/RB routinely/RB 
927981_0_11_12_40_41::None::determination/NN of/IN nine/CD antidepressants/NNS in/IN traditional/JJ Chinese/JJ medicines/NNS and/CC health/NN food/NN by/IN ultra/NN performance/NN liquid/JJ chromatography/NN -/: tandem/JJ mass/NN spectrometry/NN (/( UPLC/NN -/: MS/NN //: MS/NN )/) based/VBN on/IN the/DT sonication/NN -/: assisted/VBN extraction/NN ./. 
686_686_29_30_31_32::None::the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
2148_2148_44_45_56_57::None::the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ calmodulin/NN ./. 
1617_1617_21_22_21_22::None::may/MD regulate/VB both/DT actin/NN assembly/NN and/CC the/DT 
1502_1502_6_7_18_19::POS_REG(0)_LOCALIZE::virus/NN type/NN 1/CD UL8/NN protein/NN influences/VBZ the/DT intracellular/JJ localization/NN of/IN the/DT UL52/NN but/CC not/RB the/DT ICP8/NN or/CC POL/NN replication/NN 
685990_8_18_19_19_20::None::risk/NN of/IN having/VBG OSA/NN compared/VBN with/IN only/RB 19/CD 
2107_2107_24_26_9_10::None::proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, 
226600_0_16_17_1_2::None::Although/IN fluoridated/JJ toothpastes/NNS are/VBP among/IN the/DT most/RBS accessible/JJ fluoride/NN sources/NNS for/IN caries/NNS prevention/NN ,/, their/PRP$ remineralization/NN potential/NN remains/VBZ questionable/JJ ./. 
159463_2_2_3_14_15::None::Actually/RB ,/, premenopausal/JJ women/NNS have/VBP a/DT significantly/RB lower/JJR risk/NN for/IN cardiovascular/JJ disease/NN comparing/VBG to/TO postmenopausal/JJ women/NNS or/CC age/NN 
250192_5_21_22_8_9::None::naproxen/NN in/IN reducing/VBG OA/NN pain/NN (/( least/JJS squares/NNS mean/VBP change/NN from/IN baseline/NN in/IN visual/JJ analogue/NN scale/NN score/NN [/( standard/JJ error/NN 
473269_0_4_5_34_36::None::whosewhat/NN disease/NN (/( PD/NN )/) is/VBZ a/DT neurodegenerative/JJ disorder/NN characterized/VBN by/IN loss/NN of/IN the/DT pigmented/JJ dopaminergic/JJ neurons/NNS in/IN the/DT substantia/JJ nigra/NN pars/NNS compacta/VBP with/IN subsequent/JJ striatal/JJ dopamine/NN (/( DA/NN )/) deficiency/NN and/CC increased/VBD lipid/NN peroxidation/NN ./. 
967935_1_11_12_19_20::biology.organism_classification.lower_classifications::repeated/VBN sequences/NNS in/IN Triatominae/FW genomes/NNS by/IN Genomic/JJ in/FW situ/FW Hybridization/NN using/VBG Triatoma/NN delpontei/NN and/CC Triatoma/NN 
1017_1017_9_10_2_3::POS_ACTION_SIMILAR::Mutations/NNS in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP 
567_567_15_16_20_21::None::through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
502821_1_5_6_0_1::None::Most/JJS metastatic/JJ cancers/NNS involving/VBG the/DT cervical/JJ lymph/NN nodes/NNS are/VBP 
1069_1069_36_37_42_45::None::origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
29775_1_25_26_3_5::None::Despite/IN the/DT significant/JJ anatomical/JJ variation/NN in/IN the/DT hymen/NN and/CC no/DT guarantee/NN that/IN rupture/NN or/CC bleeding/NN will/MD occur/VB at/IN first/JJ coitus/NN ,/, it/PRP has/VBZ come/VBN to/TO hold/VB major/JJ cultural/JJ significance/NN 
422_422_23_24_31_33::None::of/IN profilin/NN on/IN actin/NN polymerization/NN and/CC inhibition/NN of/IN the/DT self-association/NN of/IN annexin/NN I/CD and/CC its/PRP$ interactions/NNS 
984_984_33_34_20_21::None::the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, and/CC transcriptional/JJ repression/NN domain/NN of/IN MLL/NN fused/VBN to/TO the/DT CREB/NN binding/NN domain/NN or/CC 
16_16_32_33_32_33::None::binding/NN disrupts/VBZ the/DT alpha-catenin/NN dimer/NN ./. 
1782_1782_7_8_23_24::POS_ACTION_LOCALIZE::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC 
583_583_17_18_14_15::POS_ACTION_BIND::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
810075_0_9_11_22_23::medicine.disease.treatments::isolation/NN for/IN paroxysmal/JJ atrial/JJ fibrillation/NN :/: a/DT retrospective/JJ comparison/NN between/IN the/DT cryoballoon/NN and/CC conventional/JJ focal/JJ tip/NN radiofrequency/NN techniques/NNS ./. 
529506_0_4_7_9_13::None::alveolar/JJ hemorrhage/NN from/IN systemic/JJ lupus/NN erythematosus/NN misdiagnosed/JJ as/RB high/JJ altitude/NN pulmonary/JJ edema/NN ./. 
1226_1226_2_3_5_6::None::Saccharomyces/FW cerevisiae/FW PAC2/NN functions/NNS with/IN CIN1/NN ,/, 2/CD and/CC 
296387_0_11_12_10_11::medicine.disease.symptoms::increasing/VBG number/NN of/IN acute/JJ gastroenteritis/NN cases/NNS were/VBD reported/VBN 
1052_1052_27_28_29_30::None::acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
2000_2000_4_5_10_11::None::endothelial/JJ cadherin/NN (/( VE-cadherin/NN )/) clusters/NNS were/VBD co-localized/VBN with/IN beta-catenin/NN ,/, an/DT important/JJ 
1498_1498_21_22_8_9::None::thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD thus/RB regulate/VB integrin/NN function/NN ./. 
18085_7_28_29_32_33::None::with/IN non/JJ -/: mosaic/JJ trisomy/NN 21/CD and/CC male/JJ factor/NN infertility/NN ./. 
215150_5_16_17_33_34::None::depressive/JJ symptoms/NNS were/VBD partially/RB mediated/VBN by/IN improvements/NNS in/IN parent/NN -/: youth/NN conflict/NN ;/: however/RB ,/, family/NN process/NN changes/NNS did/VBD not/RB mediate/VB diabetes/NN health/NN outcomes/NNS 
318680_2_17_20_25_26::None::their/PRP$ affinities/NNS for/IN human/JJ serum/NN albumin/NN (/( HSA/NN )/) by/IN a/DT fluorescence/NN spectroscopy/NN -/: based/VBN 
327522_2_22_23_6_7::None::release/NN ,/, and/CC GABAergic/JJ dysregulation/NN in/IN the/DT central/JJ nucleus/NN of/IN the/DT amygdala/NN (/( CeA/NN )/) is/VBZ critical/JJ in/IN the/DT transition/NN to/TO alcohol/NN dependence/NN 
2107_2107_5_7_7_8::POS_ACTION_MEMBER::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP 
1850_1850_23_24_0_1::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN and/CC serves/VBZ to/TO link/VB the/DT cadherin/catenin/NN complex/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
443_443_9_10_11_12::POS_ACTION_MEMBER::actin/NN induced/VBN by/IN fimbrin/NN (/( N375/NN )/) binding/NN ./. 
196_196_2_3_9_10::POS_REG(-)_Change::A/DT truncated/VBN beta-catenin/NN disrupts/VBZ the/DT interaction/NN between/IN E-cadherin/NN and/CC alpha-catenin/NN :/: a/DT cause/NN 
552323_0_8_9_1_2::medicine.disease.risk_factors::While/IN obesity/NN is/VBZ a/DT major/JJ risk/NN factor/NN for/IN preeclampsia/NN ,/, which/WDT is/VBZ 
265345_3_19_21_9_10::None::has/VBZ been/VBN also/RB reported/VBN following/VBG macroscopic/JJ haematuria/NN -/: associated/VBN acute/JJ kidney/NN injury/NN in/IN immunoglobulin/NN A/NN nephropathy/NN ./. 
221316_7_3_4_20_23::None::There/EX was/VBD symmetrical/JJ polyarthritis/NN with/IN high/JJ tender/NN and/CC swollen/JJ joint/JJ count/NN and/CC mean/VB Disease/NN Activity/NN Score/NN of/IN 28/CD joints/NNS ,/, erythrocyte/NN sedimentation/NN rate/NN of/IN 5.27/CD (/( 
311030_10_3_4_0_1::None::Dopamine/NN release/NN was/VBD stimulated/VBN by/IN applying/VBG ATP/NN 
1553_1553_45_46_38_39::None::daltons/NNS )/) ,/, actin/NN (/( 43,000/CD daltons/NNS )/) ,/, and/CC calmodulin/NN (/( 17,000/CD daltons/NNS 
779_779_21_24_26_27::POS_ACTION_MEMBER::accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ 
120993_9_18_19_15_16::medicine.medical_treatment.used_to_treat::Xpert/NN detected/VBD more/RBR TB/NN and/CC less/JJR rifampicin/NN resistance/NN ,/, increased/VBD 
1069_1069_46_47_29_30::None::UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
496811_0_24_25_23_24::None::intravitreal/JJ injections/NNS of/IN triamcinolone/NN acetonide/NN (/( TA/NNP )/) 
652_652_8_9_11_12::None::in/IN beta-catenin/NN ,/, alpha-catenin/NN ,/, and/CC p120/NN (/( Cas/NNS )/) 
1537_1537_14_15_16_17::None::major/JJ proteins/NNS :/: actin/NN ,/, villin/NN ,/, fimbrin/NN and/CC 
1037_1037_4_5_9_11::None::disclosed/VBN interactions/NNS between/IN gephyrin/NN ,/, exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN 
204277_6_36_37_2_3::None::Testosterone/NN level/NN correlated/VBD positively/RB with/IN RHI/NN (/( r/NN =/JJ 0.24/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD )/) and/CC inversely/RB with/IN AIX/NNP (/( r/NN =/SYM -/: 0.14/CD ,/, p/NN =/JJ 0.033/CD )/) but/CC not/RB with/IN FMD/NN or/CC PWV/NN ,/, indicating/VBG impaired/JJ 
1227_1227_22_23_26_27::None::between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, RAD3/NN ,/, RAD10/NN ,/, 
134521_6_32_33_1_2::None::The/DT suspected/VBN ability/NN for/IN autonomous/JJ replication/NN ,/, results/NNS of/IN phylogenetic/JJ tree/NN reconstruction/NN ,/, intron/NN lengths/NNS and/CC the/DT structure/NN of/IN the/DT AAP/NNP ,/, suggested/VBD that/IN a/DT single/JJ Squamata/NNP origin/NN instead/RB of/IN the/DT earlier/JJR assumed/VBD diapsid/NN (/( common/JJ 
1037_1037_4_5_21_22::POS_ACTION_INTERACT::disclosed/VBN interactions/NNS between/IN gephyrin/NN ,/, exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ 
393_393_5_7_16_17::None::isolated/VBN myofibrils/NNS with/IN alkaline/NN proteinase/NN resulted/VBD in/IN the/DT degradation/NN of/IN myosin/NN heavy/JJ chain/NN and/CC actin/NN ./. 
449_449_10_11_17_18::POS_ACTION_INTERACT::cells/NNS indicated/VBD that/IN UL8/NN could/MD interact/VB separately/RB with/IN both/CC the/DT UL5/NN and/CC UL52/NN proteins/NNS 
693828_2_5_6_8_9::None::literature/NN search/NN was/VBD conducted/VBN on/IN studies/NNS assessing/VBG the/DT clinical/JJ characteristics/NNS 
451755_0_11_12_3_4::None::Lesions/NNS in/IN the/DT corpus/NN callosum/NN (/( CC/NN )/) are/VBP important/JJ radiological/JJ clues/NNS to/TO the/DT diagnosis/NN 
237860_0_6_7_4_5::None::2007/CD ,/, the/DT baby/NN woolly/JJ mammoth/JJ (/( Mammuthus/JJ primigenius/NN 
275849_11_14_15_4_5::None::effects/NNS were/VBD similarly/RB observed/VBN when/WRB E/NN coli/NN O157/NN :/: H7/NN was/VBD treated/VBN with/IN acetic/JJ acid/NN and/CC salt/NN 
2146_2146_9_10_11_13::None::LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) 
367_367_5_7_24_25::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC 
91905_5_10_11_31_32::None::(/( Illumina/NNP Infinium/NNP assay/NN )/) for/IN perennial/JJ ryegrass/NN (/( Lolium/NN perenne/NN )/) was/VBD created/VBN and/CC validated/VBN in/IN a/DT broad/JJ ecotype/JJ collection/NN of/IN 716/CD individuals/NNS sampled/VBN from/IN 90/CD sites/NNS 
728820_2_16_17_14_15::None::urinary/JJ tract/NN symptoms/NNS secondary/JJ to/TO BPH/NNP from/IN 2005/CD to/TO 
488875_3_0_1_22_23::None::Anatomical/JJ and/CC morphometrical/JJ analyses/NNS suggest/VBP a/DT hybrid/NN confirmed/VBN by/IN the/DT ancient/JJ DNA/NN analyses/NNS resulting/VBG in/IN the/DT presence/NN of/IN a/DT dromedary/NN in/IN the/DT maternal/JJ and/CC a/DT Bactrian/JJ 
784_784_21_22_12_13::None::,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
631121_4_17_18_0_1::None::It/PRP has/VBZ been/VBN quite/RB clearly/RB established/VBN that/IN the/DT majority/NN of/IN borderline/JJ ovarian/JJ tumours/NNS should/MD be/VB managed/VBN with/IN surgery/NN alone/RB ./. 
573581_3_55_56_31_32::None::of/IN the/DT recombinant/JJ library/NN IgGs/NNS with/IN the/DT corresponding/JJ serum/NN IgGs/NNS We/PRP found/VBD that/IN the/DT recombinant/JJ library/NN IgGs/NNS were/VBD much/JJ weaker/JJR than/IN the/DT serum/NN IgGs/NNS in/IN binding/VBG to/TO envelope/NN glycoproteins/NNS (/( Envs/NNS 
383627_0_16_17_7_8::None::women/NNS affected/VBN by/IN advanced/JJ -/: stage/NN gynecological/JJ cancers/NNS (/( ovarian/JJ //: endometrial/JJ malignancies/NNS )/) carry/VBP an/DT 
452979_10_6_8_10_11::None::strong/JJ association/NN between/IN sleep/NN apnea/NN risk/NN and/CC diabetes/NN mellitus/NN among/IN blacks/NNS 
667_667_14_15_6_7::None::that/IN ,/, like/IN Abp1p/NN ,/, cofilin/NN is/VBZ associated/VBN with/IN the/DT membrane/NN actin/NN cytoskeleton/NN ./. 
1580_1580_25_26_28_29::None::cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1480_1480_2_3_12_13::POS_ACTION_DISASSEMBLE::The/DT exogeneous/JJ cofilin/NN ,/, but/CC not/RB ADF/NN ,/, caused/VBD quick/JJ disassembly/NN of/IN actin/NN filaments/NNS and/CC accumulated/VBN 
1434_1434_72_73_72_73::None::histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN 
619459_0_12_13_2_3::None::The/DT antitumor/JJ enzyme/NN asparaginase/NN ,/, which/WDT targets/VBZ essential/JJ amino/NN acid/NN L/NN -/: asparagine/NN and/CC catalyzes/VBZ it/PRP 
1917_1917_2_3_27_28::POS_REG(0)_MODIFY::To/TO study/VB profilin/NN function/NN ,/, we/PRP extensively/RB mutagenized/VBD the/DT Saccharomyces/FW cerevisiae/FW profilin/NN gene/NN (/( PFY1/NN )/) and/CC examined/VBD the/DT consequences/NNS of/IN specific/JJ point/NN mutations/NNS on/IN growth/NN and/CC actin/NN organization/NN ./. 
339123_0_4_5_21_22::medicine.drug.active_moieties::of/IN a/DT Cationic/NNP Calcium/NN Hydride/NNP Cluster/NNP with/IN a/DT ''/'' Naked/JJ ''/'' Triphenylsilyl/NN Anion/NN by/IN Hydrogenolysis/NN of/IN Bis/NN (/( triphenylsilyl/NN )/) calcium/NN ./. 
1075_1075_22_23_6_7::POS_ACTION_PHOSPHORYLATE::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
1534_1534_16_17_9_10::None::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN 
314756_0_23_25_13_14::None::vitamin/NN A/NN (/( retinol/NN )/) ,/, has/VBZ been/VBN implicated/VBN in/IN the/DT regulation/NN of/IN lipid/NN metabolism/NN and/CC hepatic/JJ steatosis/NN 
2030_2030_18_19_22_23::POS_ACTION_LOCALIZE-TO::cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ actin/NN patches/NNS ./. 
1052_1052_29_30_18_20::None::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
856_856_37_38_16_18::None::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN 
226308_2_12_13_21_23::biology.organism_classification.lower_classifications::hydrophobicity/NN of/IN 20/CD Salmonella/FW strains/NNS isolated/VBN from/IN poultry/NN and/CC human/JJ and/CC two/CD Salmonella/FW enterica/FW serovar/NN Typhimurium/NN references/NNS 
547287_4_13_14_0_1::None::The/DT overall/JJ incidence/NN of/IN the/DT 4/CD types/NNS of/IN gynecological/JJ cancer/NN was/VBD 39.0/CD %/NN higher/JJR in/IN colorectal/JJ cancer/NN 
93_93_57_58_24_26::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
1486_1486_32_33_41_44::None::protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
799053_0_9_10_11_12::None:::/: unique/JJ genetic/JJ events/NNS ,/, frozen/JJ development/NN and/CC enduring/VBG 
693466_12_1_2_12_15::medicine.risk_factor.diseases::HyperCVAD/NN chemotherapy/NN and/CC imatinib/NN is/VBZ an/DT effective/JJ regimen/NN for/IN Philadelphia/NNP -/: positive/JJ acute/JJ lymphoblastic/JJ leukemia/NN ./. 
432219_9_19_20_20_21::None::have/VB the/DT following/VBG respective/JJ gains/NNS in/IN percent/NN weight/NN 
967935_1_6_7_12_13::None::chromosomal/JJ distribution/NN and/CC evolution/NN of/IN repeated/VBN sequences/NNS in/IN Triatominae/FW genomes/NNS by/IN Genomic/JJ in/FW 
1502_1502_6_7_14_15::POS_REG(0)_LOCALIZE::virus/NN type/NN 1/CD UL8/NN protein/NN influences/VBZ the/DT intracellular/JJ localization/NN of/IN the/DT UL52/NN but/CC not/RB the/DT 
1098_1098_16_17_11_12::None::binding/NN domain/NN of/IN CBP/NN stimulates/VBZ transcription/NN from/IN the/DT PEPCK/NN gene/NN promoter/NN ./. 
1696_1696_18_19_7_8::None::first/JJ evidence/NN that/IN profilin/NN is/VBZ a/DT key/JJ molecule/NN linking/VBG a/DT signaling/NN network/NN to/TO rapid/JJ actin/NN polymerization/NN in/IN microspike/NN 
31738_0_5_7_7_8::medicine.disease.treatments::Medicare/NNP Payments/NNS for/IN Colorectal/JJ Cancer/NN Surgery/NN ./. 
610_610_22_23_27_28::None::DNA/NN replication-specific/JJ genes/NNS UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN (/( Crute/NN ,/, 
156299_3_7_8_21_22::None::July/NNP 2011/CD ,/, RFA/NN using/VBG two/CD or/CC three/CD radiofrequency/NN (/( RF/NN )/) electrodes/NNS and/CC a/DT multiple/JJ -/: electrode/NN switching/NN system/NN was/VBD 
1737_1737_39_40_13_15::None::of/IN PI/NN and/CC PIP/NN kinases/NNS and/CC that/IN under/IN certain/JJ circumstances/NNS activation/NN of/IN the/DT kinases/NNS and/CC the/DT increased/VBN synthesis/NN of/IN PIP/NN and/CC PIP2/NN may/MD be/VB involved/VBN in/IN the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS 
497715_6_21_22_32_33::None::)/) ,/, we/PRP highlight/VBP pedagogical/JJ approaches/NNS to/TO address/VB obesity/NN stigma/NN and/CC their/PRP$ implications/NNS to/TO redress/VB the/DT problem/NN of/IN 
2222_2222_11_12_39_40::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
1227_1227_10_11_22_23::None::two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN ,/, ''/'' and/CC pairwise/JJ interactions/NNS between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, 
211391_8_2_3_13_15::biology.organism_classification.lower_classifications::Infections/NNS with/IN flaviviruses/NNS such/JJ as/IN yellow/JJ fever/NN ,/, dengue/NN ,/, Japanese/JJ encephalitis/NN ,/, West/NNP Nile/NNP ,/, and/CC tick/VB 
784_784_18_19_21_22::None::,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
394419_6_61_62_63_64::medicine.drug.active_moieties::,/, irisin/NN ,/, EPO/NN (/( erythropoetin/NN )/) and/CC BAIBA/NN 
792678_1_0_1_13_14::None::Delusional/JJ infestation/NN is/VBZ a/DT rare/JJ monosymptomatic/JJ hypochondriacal/JJ psychosis/NN according/VBG to/TO The/DT Diagnostic/JJ and/CC Statistical/JJ Manual/NN of/IN Mental/JJ 
1169_1169_17_18_26_27::None::Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD 
1686_1686_47_48_25_28::None::at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP 
1768_1768_10_11_4_7::None::sites/NNS on/IN the/DT myosin/NN heavy/JJ chain/NN that/WDT interact/VBP with/IN actin/NN and/CC are/VBP responsible/JJ 
350838_1_43_44_30_31::None::eukaryotes/NNS and/CC thus/RB represents/VBZ a/DT suitable/JJ model/NN organism/NN for/IN studying/VBG the/DT minimal/JJ essential/JJ components/NNS and/CC ancestral/JJ functions/NNS of/IN autophagy/NN ./. 
557_557_15_16_3_4::POS_ACTION_COLOCALIZE::Green/NNP fluorescent/JJ protein-tagged/JJ ORC1/NN associated/VBN with/IN chromatin/NN throughout/IN mitosis/NN in/IN living/NN cells/NNS and/CC co-localized/VBN with/IN ORC4/NN in/IN metaphase/NN spreads/NNS 
1798_1798_24_26_41_42::POS_REG(0)_ASSEMBLE::expression/NN of/IN a/DT rac-1/NN GAP/NN alters/VBZ the/DT assembly/NN of/IN integrin/NN receptors/NNS ,/, actin/NN and/CC cytoskeletal/JJ proteins/NNS such/JJ as/IN vinculin/NN and/CC talin/NN ./. 
411693_2_9_10_4_5::None::examined/VBD whether/IN the/DT cut/NN -/: off/IN value/NN of/IN maximum/NN standardized/JJ uptake/NN value/NN 
549899_0_8_9_7_9::None::breast/NN cancer/NN stem/NN cells/NNS may/MD be/VB closely/RB 
1321_1321_0_4_23_24::POS_ACTION_PHOSPHORYLATE::Testicular/JJ protein/NN kinase/NN 1/CD (/( TESK1/NN )/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN testicular/JJ germ/NN cells/NNS and/CC has/VBZ the/DT potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN 
7485_8_18_19_34_35::medicine.disease.symptoms::early/JJ manifestations/NNS of/IN atherosclerosis/NN ,/, that/WDT is/VBZ ,/, endothelial/JJ dysfunction/NN and/CC the/DT vascular/JJ pro/NN -/: oxidant/JJ and/CC pro/JJ -/: inflammatory/JJ status/NN ,/, in/IN 
479157_1_20_21_9_10::None::bacterium/NN ,/, possesses/VBZ typical/JJ Gram/NN -/: negative/JJ cell/NN surface/NN structure/NN comprising/VBG cytoplasmic/JJ membrane/NN ,/, peptidoglycan/NN layer/NN and/CC outer/JJ 
12271_2_24_25_60_61::medicine.drug.active_moieties::coupled/VBN to/TO a/DT biotin/NN molecule/NN through/IN the/DT N/NN -/: terminal/JJ amino/NN group/NN and/CC e/SYM -/: amino/NN group/NN of/IN N/NN -/: terminus/NN Lys/NNP ,/, (/( Btn/NNP )/) KP6/NN and/CC K/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, and/CC heir/NN their/PRP$ biotinylated/VBN peptides/NNS substituted/VBN with/IN 
395871_8_36_38_17_18::None::inexpensive/JJ assessment/NN to/TO identify/VB patients/NNS at/IN risk/NN for/IN developing/VBG unfavorable/JJ postoperative/JJ outcome/NN after/IN resection/NN of/IN esophageal/NN malignancies/NNS ,/, especially/RB in/IN patients/NNS with/IN stage/NN III/CD -/: IV/CD tumors/NNS 
599869_3_14_16_25_26::None::after/IN whole/JJ breast/NN radiation/NN therapy/NN ,/, TNBC/NN should/MD not/RB be/VB the/DT sole/JJ indication/NN for/IN post/NN -/: mastectomy/NN radiation/NN 
1427_1427_27_28_29_30::None::and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
872597_0_12_13_10_11::None::important/JJ species/NNS in/IN human/JJ -/: inhabited/VBN areas/NNS ./. 
167593_4_12_13_26_27::None::hydroxamic/JJ acid/NN (/( SAHA/NN )/) ,/, the/DT expression/NN levels/NNS of/IN HDAC1/NN ,/, HDAC4/NN and/CC acetyl/NN -/: histone/NN H3/NN (/( Lys9/NN )/) 
502525_12_21_22_6_7::None::-/: CCP/NN and/CC CRP/NN are/VBP associated/VBN with/IN increased/VBN cIMT/NN and/CC cardiovascular/JJ risk/NN supporting/VBG a/DT clinical/JJ role/NN of/IN the/DT measurement/NN of/IN cIMT/NN in/IN 
93_93_6_7_22_23::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN 
1061_1061_2_3_25_27::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
355_355_12_13_16_17::POS_ACTION_BIND::mutant/JJ form/NN of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD 
769586_0_7_8_1_2::None::Subclinical/JJ atherosclerosis/NN has/VBZ been/VBN recently/RB detected/VBN in/IN adolescents/NNS with/IN a/DT family/NN 
361641_4_11_12_13_14::None::+/CC )/) ,/, cells/NNS were/VBD exposed/VBN to/TO the/DT calcium/NN 
238_238_23_24_0_1::POS_ACTION_SIMILAR::MSH3/NN appears/VBZ to/TO be/VB more/RBR closely/RB related/JJ to/TO the/DT mouse/NN Rep-3/NN gene/NN and/CC other/JJ similar/JJ eukaryotic/JJ mutS/NN homologues/NNS than/IN to/TO the/DT yeast/NN gene/NN MSH2/NN and/CC other/JJ mutS/NN 
844136_3_5_6_23_24::None::current/JJ methods/NNS ,/, gene/NN therapy/NN ,/, which/WDT targets/VBZ cancer/NN -/: specific/JJ expression/NN and/CC limits/NNS toxicity/NN ,/, is/VBZ a/DT new/JJ strategy/NN for/IN treating/VBG cancers/NNS ./. 
996_996_31_34_5_7::None::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
591167_7_30_31_22_23::None::and/CC very/RB elderly/JJ participants/NNS ,/, although/IN the/DT risk/NN of/IN heart/NN failure/NN hospitalization/NN was/VBD increased/VBN irrespective/RB 
1616_1616_34_35_20_21::None::protein/NN gene/NN ;/: 4a/NN and/CC 4b/NN are/VBP two/CD genes/NNS ,/, one/CD of/IN which/WDT codes/VBZ for/IN the/DT proposed/VBN phosphoprotein/NN P/NN and/CC the/DT 
814130_0_6_7_16_17::None::pathology/NN ,/, pancreatic/JJ cystic/JJ tumors/NNS stand/VBP nowadays/RB for/IN 25/CD %/NN of/IN all/DT pancreatic/JJ surgical/JJ diseases/NNS ./. 
393131_1_19_20_0_1::None::Factors/NNS thought/VBD to/TO be/VB important/JJ for/IN colonization/NN include/VBP the/DT ability/NN of/IN the/DT mycoplasma/NN to/TO form/VB a/DT biofilm/NN on/IN epithelial/JJ surfaces/NNS and/CC the/DT production/NN 
490079_2_3_4_8_9::None::We/PRP sought/VBD to/TO determine/VB whether/IN statin/NN treatment/NN after/IN cancer/NN diagnosis/NN is/VBZ associated/VBN 
467441_4_18_19_12_13::medicine.drug_ingredient.active_moiety_of_drug::enzyme/NN activities/NNS of/IN Copper/NN //: Zinc/NNP Superoxide/NN dismutase/NN (/( Cu/NN //: Zn/NN -/: 
90_90_3_4_5_6::POS_ACTION_COLOCALIZE::Although/IN co-localization/NN of/IN glucokinase/NN with/IN actin/NN filaments/NNS was/VBD not/RB 
229532_2_45_46_42_44::medicine.drug.active_moieties::well/RB as/IN reduced/VBN prostaglandin/NN E2/NN (/( PGE2/NN )/) secretion/NN ./. 
1164_1164_42_43_33_34::POS_ACTION_ATTACH:::/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN ./. 
1957_1957_36_37_10_11::None::with/IN association/NN of/IN beta-catenin/NN with/IN EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ cells/NNS at/IN confluence/NN were/VBD dissociated/VBN into/IN single/JJ cells/NNS by/IN tryptic/JJ digestion/NN ,/, being/VBG accompanied/VBN by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
326118_0_34_35_30_31::None::powered/VBN intranasal/JJ delivery/NN system/NN containing/VBG low/JJ -/: dose/NN (/( 22/CD mg/NN 
2222_2222_17_18_11_12::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, 
12271_2_60_61_9_10::None::(/( Lys/SYM -/: Trp/SYM -/: Tyr/SYM -/: Lys/SYM -/: Asp/NN -/: Gly/SYM -/: Asp/NN )/) coupled/VBN to/TO a/DT biotin/NN molecule/NN through/IN the/DT N/NN -/: terminal/JJ amino/NN group/NN and/CC e/SYM -/: amino/NN group/NN of/IN N/NN -/: terminus/NN Lys/NNP ,/, (/( Btn/NNP )/) KP6/NN and/CC K/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, and/CC heir/NN their/PRP$ biotinylated/VBN peptides/NNS substituted/VBN with/IN 
119342_0_8_9_6_7::medicine.disease.treatments::exoskeleton/NN for/IN gait/NN rehabilitation/NN after/IN stroke/NN :/: early/JJ findings/NNS 
26717_2_48_49_16_18::medicine.risk_factor.diseases::definite/JJ or/CC probable/JJ myocardial/JJ infarction/NN )/) and/CC acute/JJ CHD/NN death/NN ,/, adjusting/VBG for/IN age/NN ,/, age/NN at/IN last/JJ menstrual/JJ period/NN &/CC lt/NN ;/: 45/CD years/NNS ,/, region/NN ,/, education/NN level/NN ,/, income/NN ,/, diabetes/NN ,/, smoking/NN ,/, systolic/JJ blood/NN 
456259_11_9_10_0_1::None::They/PRP can/MD be/VB used/VBN for/IN distinguishing/VBG benign/JJ from/IN malignant/JJ tumors/NNS ./. 
580543_2_28_29_20_22::None::preeclampsia/NN ,/, emergency/NN cesarean/NN delivery/NN ,/, postpartum/NN depression/NN and/CC inadequate/JJ breastfeeding/VBG initiation/NN ./. 
346_346_24_25_7_8::POS_ACTION_BIND::that/IN beta-catenin/NN and/CC plakoglobin/NN bind/VBP to/TO the/DT same/JJ region/NN of/IN alpha-catenin/NN ,/, beta-catenin/NN competed/VBD with/IN the/DT binding/NN of/IN plakoglobin/NN to/TO alpha-catenin/NN and/CC vice/NN versa/RB 
566758_0_11_12_0_1::None::Accelerometer/SYM -/: derived/VBN sedentary/JJ and/CC physical/JJ activity/NN time/NN in/IN overweight/JJ //: obese/JJ adults/NNS with/IN type/NN 
718366_2_27_28_0_1::medicine.disease.symptoms::Pica/NNP was/VBD identified/VBN in/IN four/CD percent/NN of/IN cases/NNS of/IN TSC/NNP It/PRP was/VBD associated/VBN with/IN adult/JJ onset/NN or/CC persistence/NN into/IN adulthood/NN ,/, epilepsy/NN ,/, severe/JJ learning/NN difficulties/NNS and/CC anaemia/NN ./. 
856_856_22_23_37_38::None::,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN 
735_735_11_12_3_4::None::In/IN contrast/NN ,/, act1-159/NN partially/RB suppresses/VBZ the/DT temperature/NN sensitivity/NN of/IN a/DT tropomyosin/NN mutant/NN ,/, and/CC 
211495_10_40_42_10_11::medicine.disease.symptoms::in/IN neutrophils/NNS and/CC tumor/NN -/: associated/JJ fibroblasts/NNS promotes/VBZ colon/NN tumorigenesis/NN by/IN amplifying/VBG inflammation/NN and/CC shaping/VBG tumor/NN microenvironment/NN ,/, and/CC suggests/VBZ that/IN EP2/NN antagonists/NNS are/VBP promising/JJ candidates/NNS of/IN aspirin/NN -/: alternative/NN for/IN chemoprevention/NN of/IN colorectal/JJ cancer/NN ./. 
247970_0_22_23_20_21::medicine.drug.active_moieties::mice/NNS treated/VBN with/IN methotrexate/NN (/( MTX/NN )/) ./. 
991_991_4_5_17_18::None::known/VBN to/TO link/VB actin/NN filaments/NNS to/TO membrane/NN were/VBD also/RB examined/VBN ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN 
638398_10_8_9_6_7::None::tumor/NN model/NN ,/, PA/NN -/: MSHA/NNP prolonged/VBD mice/NNS survival/NN 
1479_1479_13_15_21_22::POS_REG(0)_CONTROL::the/DT effects/NNS of/IN LIM/NN kinase/NN and/CC cofilin/NN in/IN the/DT control/NN of/IN actin/NN dynamics/NNS ./. 
753851_0_6_7_3_5::None::Differential/JJ impact/NN of/IN risk/NN factors/NNS for/IN tumor/NN recurrence/NN in/IN hepatitis/NN 
1289_1289_13_14_4_6::None::interactions/NNS between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN bovine/JJ 
1434_1434_7_8_11_12::None::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN 
301320_2_27_28_29_30::None::whosewhat/NN disease/NN ,/, cocaine/NN and/CC cannabis/NN addiction/NN ,/, bipolar/JJ 
2064_2064_40_41_8_9::None::of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN 
173493_0_1_2_0_1::None::Budesonide/NN formoterol/NN (/( BF/NN )/) 
243_243_27_28_0_2::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN 
93_93_4_5_24_26::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
613549_0_1_2_8_9::None::Postmastectomy/NNP radiotherapy/NN is/VBZ increasingly/RB common/JJ for/IN patients/NNS with/IN advanced/JJ breast/NN cancer/NN ./. 
567_567_18_19_10_11::POS_ACTION_ACTIVATE::acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
573489_1_15_16_4_5::None::is/VBZ currently/RB considerable/JJ variability/NN in/IN the/DT timing/NN of/IN consultation/NN with/IN a/DT plastic/NN and/CC reconstructive/JJ surgeon/NN after/IN the/DT initial/JJ 
119_119_33_34_12_13::None::fit/NN show/VBP that/IN vinculin/NN has/VBZ a/DT negligible/JJ influence/NN on/IN internal/JJ actin/NN filament/NN dynamics/NNS and/CC actin/NN bending/VBG stiffness/NN which/WDT contrasts/VBZ with/IN our/PRP$ previous/JJ observations/NNS with/IN talin/NN ,/, another/DT actin/NN 
710476_3_22_23_2_3::None::Participants/NNS completed/VBD measures/NNS of/IN global/JJ mental/JJ health/NN ,/, depression/NN ,/, anxiety/NN ,/, stress/NN ,/, alcohol/NN -/: related/JJ problems/NNS at/IN up/RB to/TO four/CD time/NN points/NNS in/IN their/PRP$ 
374_374_12_13_4_5::POS_REG(0)_INACTIVATE::of/IN SIR4/NN enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC deletion/NN of/IN SIR1/NN or/CC SIR3/NN did/VBD 
1082_1082_31_34_38_39::POS_ACTION_BIND::a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ./. 
1047_1047_17_18_7_8::None::pro-apoptotic/JJ adapter/NN proteins/NNS TRADD/NN and/CC FADD/NN are/VBP also/RB involved/VBN in/IN the/DT activation/NN of/IN A-SMase/NN ./. 
367_367_26_27_5_7::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
670852_3_16_17_13_14::None::ER/NN )/) positive/JJ tumors/NNS ,/, who/WP referred/VBD for/IN surgery/NN ,/, 
383627_0_11_12_13_14::people.cause_of_death.includes_causes_of_death::-/: stage/NN gynecological/JJ cancers/NNS (/( ovarian/JJ //: endometrial/JJ malignancies/NNS 
157_157_14_15_1_2::None::Archaeal/NNP histones/NNS are/VBP most/RBS similar/JJ to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT 
112_112_0_1_18_19::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN epithelial/JJ cells/NNS and/CC forms/VBZ a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN localized/JJ to/TO the/DT 
311864_8_2_3_17_18::None::Low/JJ dose/NN immunoglobulin/NN infusion/NN is/VBZ the/DT only/RB effective/JJ way/NN to/TO reach/VB successful/JJ pregnancy/NN ,/, despite/IN previous/JJ habitual/JJ abortions/NNS in/IN patients/NNS suffering/VBG 
491928_0_10_11_5_6::None::premorbid/JJ childhood/NN and/CC adolescent/JJ functioning/VBG in/IN schizophrenia/NN -/: spectrum/NN psychoses/NNS :/: A/DT 
322970_7_25_26_52_53::None::(/( in/IN all/DT indicators/NNS )/) had/VBD lower/JJR current/JJ smoking/NN levels/NNS and/CC higher/JJR cessation/NN ratios/NNS than/IN those/DT of/IN middle/JJ or/CC low/JJ SES/NNP Inequalities/NNS in/IN current/JJ smoking/NN increased/VBD significantly/RB in/IN poorly/RB educated/VBN adults/NNS of/IN 45/CD -/: 
833393_2_16_17_7_8::None::source/NN of/IN energy/NN generation/NN for/IN malaria/NN parasite/NN Plasmodium/NN falciparum/NN ,/, hence/RB a/DT potential/JJ pathway/NN for/IN therapeutic/JJ 
671_671_5_7_16_17::POS_ACTION_MEMBER::revealed/VBD that/IN two/CD actin-binding/JJ proteins/NNS of/IN low/JJ molecular/JJ weight/NN with/IN different/JJ functional/JJ activity/NN ,/, ADF/NN and/CC cofilin/NN ,/, 
179835_3_30_31_9_10::None::discuss/VB cutting/VBG -/: edge/NN cardiovascular/JJ imaging/NN techniques/NNS and/CC potential/JJ clinical/JJ applications/NNS and/CC limitations/NNS of/IN those/DT techniques/NNS for/IN the/DT evaluation/NN of/IN major/JJ SLE/NN -/: related/JJ heart/NN disorders/NNS ./. 
372023_9_18_19_2_3::None::No/DT significant/JJ correlation/NN was/VBD observed/VBN between/IN identical/JJ in/IN -/: clinic/NN and/CC in/IN -/: home/NN parameters/NNS in/IN the/DT PD/NN group/NN (/( R/NN =/JJ 
881655_2_14_15_21_22::None::catechins/NNS and/CC anticancer/JJ drugs/NNS has/VBZ the/DT potential/JJ to/TO enhance/VB the/DT efficacy/NN of/IN the/DT drugs/NNS 
183829_5_15_16_5_6::None::of/IN its/PRP$ juvenile/JJ nature/NN ,/, the/DT tail/NN plumage/NN resembles/VBZ the/DT feathering/NN of/IN adult/JJ individuals/NNS of/IN modern/JJ birds/NNS 
468819_2_78_79_31_32::None::arteries/NNS ,/, concomitant/JJ presence/NN of/IN unruptured/JJ intracranial/JJ aneurysms/NNS ,/, arteriovenous/JJ malformations/NNS and/CC dural/JJ fistulas/NNS ,/, co/SYM -/: existing/VBG brain/NN tumors/NNS as/RB well/RB as/IN in/IN conditions/NNS mimicking/VBG AIS/NNP The/DT review/NN systematically/RB evaluates/VBZ the/DT safety/NN of/IN off/JJ -/: label/NN use/NN of/IN IVT/NNP and/CC summarizes/VBZ data/NNS from/IN case/NN reports/NNS of/IN uncommon/JJ complications/NNS of/IN systemic/JJ thrombolysis/NN administration/NN in/IN 
241096_2_5_6_16_17::medicine.drug.active_moieties::were/VBD immobilized/VBN with/IN silver/NN -/: indole/NN -/: 3/CD acetic/JJ acid/NN hydrazide/NN (/( IAAH/NN -/: Ag/NN )/) complexes/NNS via/IN 
71991_0_5_7_9_10::None::the/DT relationship/NN between/IN musculoskeletal/JJ disorders/NNS and/CC comorbid/NN health/NN problems/NNS ,/, including/VBG 
1337_1337_9_10_7_8::None::talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN 
1052_1052_34_35_27_28::None::acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN 
256031_1_64_65_26_27::medicine.risk_factor.diseases::absolute/JJ risk/NN of/IN cardiovascular/JJ outcomes/NNS and/CC the/DT relative/JJ risk/NN reduction/NN associated/VBN with/IN screening/NN and/CC intensive/JJ treatment/NN ,/, screening/NN and/CC routine/JJ treatment/NN ,/, and/CC no/DT screening/NN with/IN a/DT 3/LS -/: or/CC 6/CD -/: year/NN delay/NN in/IN the/DT diagnosis/NN and/CC routine/JJ treatment/NN of/IN diabetes/NN and/CC cardiovascular/JJ risk/NN 
565841_0_11_12_9_10::medicine.symptom.symptom_of::an/DT association/NN between/IN endometriosis/NN and/CC infertility/NN ./. 
672_672_19_20_16_17::POS_ACTION_LOCALIZE-TO::distributed/VBN in/IN cortical/JJ actin/NN patches/NNS where/WRB cofilin/NN was/VBD also/RB co-localized/VBN 
154850_0_16_17_8_9::None::dicer/NN -/: dependent/JJ microRNAs/NNS abrogates/VBZ the/DT response/NN of/IN the/DT parathyroid/JJ to/TO acute/JJ and/CC chronic/JJ hypocalcemia/NN 
389319_8_24_25_13_14::None::-/: induced/VBN SEC/NNP injury/NN based/VBN on/IN serum/NN hyaluronic/JJ acid/NN (/( HA/NN )/) level/NN ,/, apoptosis/NN and/CC ultrastructural/JJ and/CC 
1052_1052_37_38_12_13::None::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
1069_1069_33_35_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) 
1502_1502_18_19_6_7::None::virus/NN type/NN 1/CD UL8/NN protein/NN influences/VBZ the/DT intracellular/JJ localization/NN of/IN the/DT UL52/NN but/CC not/RB the/DT ICP8/NN or/CC POL/NN replication/NN 
865150_0_5_6_24_25::None::small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) remains/VBZ the/DT most/RBS common/JJ cause/NN of/IN cancer/NN death/NN worldwide/RB due/JJ its/PRP$ resistance/NN to/TO chemotherapy/NN and/CC aggressive/JJ tumor/NN growth/NN ./. 
1061_1061_19_20_15_16::None::but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO 
432219_9_28_29_12_13::people.cause_of_death.includes_causes_of_death::,/, and/CC severe/JJ dehydration/NN were/VBD found/VBN to/TO have/VB the/DT following/VBG respective/JJ gains/NNS in/IN percent/NN weight/NN at/IN the/DT end/NN of/IN illness/NN :/: 2.44/CD !/. 
954_954_6_7_9_10::None::LIMKs/NNS )/) phosphorylate/VBP cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
1380_1380_24_25_36_37::POS_ACTION_BIND::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, 
2107_2107_24_26_5_7::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, 
800922_2_10_11_7_8::None::that/IN the/DT irreversible/JJ MAO/NNP -/: B/NN inhibitors/NNS selegiline/NN and/CC rasagiline/NN 
275967_6_19_20_1_2::medicine.symptom.symptom_of::When/WRB OSA/NN patients/NNS stay/VBP at/IN altitudes/NNS above/IN 1600/CD m/NN ,/, corresponding/VBG to/TO that/DT of/IN many/JJ tourist/NN destinations/NNS ,/, hypobaric/JJ hypoxia/NN promotes/VBZ frequent/JJ central/JJ 
26283_1_16_17_22_24::None::in/IN addition/NN to/TO marked/JJ tachycardia/NN with/IN atrial/JJ fibrillation/NN and/CC heart/NN failure/NN associated/VBN with/IN a/DT 
500377_1_12_13_4_5::medicine.medical_treatment.used_to_treat::patients/NNS with/IN essential/JJ hypertension/NN were/VBD treated/VBN with/IN the/DT beta/NN -/: blocker/NN metoprolol/NN and/CC followed/VBD up/RP 
382707_7_33_34_19_20::None::neuroticism/NN ,/, current/JJ depression/NN ,/, and/CC tendencies/NNS toward/IN catastrophic/JJ and/CC anxiety/NN -/: provoking/VBG appraisals/NNS of/IN pain/NN among/IN persons/NNS seeking/VBG treatment/NN for/IN 
776_776_24_26_28_29::None::the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT 
237202_1_31_32_26_28::medicine.disease.treatments::administered/VBN to/TO 6/CD liver/NN transplant/NN recipients/NNS with/IN recurrent/JJ hepatitis/NN C/NN ,/, one/CD 
553693_0_12_13_10_11::None::characterized/VBN by/IN abdominal/JJ pain/NN and/CC changed/VBD bowel/NN habits/NNS ./. 
408257_14_17_19_18_19::people.cause_of_death.includes_causes_of_death::role/NN in/IN active/JJ multiple/JJ myeloma/NN or/CC is/VBZ more/RBR 
1782_1782_27_28_1_6::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
1486_1486_32_33_4_5::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ 
1553_1553_45_46_32_33::None::daltons/NNS )/) ,/, fimbrin/NN (/( 68,000/CD daltons/NNS )/) ,/, actin/NN (/( 43,000/CD daltons/NNS )/) ,/, and/CC calmodulin/NN (/( 17,000/CD daltons/NNS 
594353_0_13_14_14_15::None::endometrial/JJ cancers/NNS in/IN mutation/NN carriers/NNS from/IN hereditary/JJ breast/NN 
380111_3_42_43_9_10::None::)/) -/: H2/NN presents/VBZ a/DT H/NN -/: Au/SYM -/: H/NN insertion/NN minimum/NN attributed/VBD to/TO the/DT stabilization/NN of/IN the/DT LUMO/NNP 3b2/NN orbital/NN ,/, which/WDT can/MD be/VB considered/VBN as/IN the/DT preamble/NN of/IN the/DT chemisorption/NN well/RB appearing/VBG in/IN larger/JJR gold/NN clusters/NNS ./. 
1381_1381_33_34_30_31::None::nucleation/NN by/IN the/DT actin/NN monomer-binding/JJ protein/NN profilin/NN ,/, giving/VBG active/JJ 
106335_13_17_18_37_38::None::predictive/JJ tools/NNS in/IN multifactorial/JJ intervention/NN such/JJ as/IN ERAS/NNS Compliance/NN with/IN ERAS/NNS can/MD reliably/RB predict/VB both/DT delayed/VBN discharge/NN and/CC 30/CD -/: day/NN readmission/NN following/VBG laparoscopic/JJ colorectal/JJ cancer/NN surgery/NN 
514561_0_24_25_14_15::None::through/IN high/JJ -/: density/NN lipoprotein/NN (/( HDL/NN )/) is/VBZ only/RB associated/VBN with/IN its/PRP$ serum/NN concentration/NN ./. 
553693_0_0_3_9_11::medicine.disease.symptoms::Irritable/JJ bowel/NN syndrome/NN (/( IBS/NN )/) is/VBZ characterized/VBN by/IN abdominal/JJ pain/NN and/CC changed/VBD bowel/NN 
205_205_2_3_4_5::None::BACKGROUND/NN :/: p27/NN (/( Kip1/NN )/) ,/, a/DT 
924463_2_6_7_8_9::None::case/NN of/IN a/DT patient/NN with/IN acute/JJ ischemic/JJ stroke/NN who/WP 
95037_9_21_22_11_12::None::55/CD //: 136/CD control/NN elderly/JJ (/( 40.0/CD %/NN )/) ,/, 21/CD //: 29/CD AD/NN (/( 72.4/CD %/NN 
1069_1069_33_35_42_45::None::)/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
346_346_7_8_16_17::None::that/IN beta-catenin/NN and/CC plakoglobin/NN bind/VBP to/TO the/DT same/JJ region/NN of/IN alpha-catenin/NN ,/, beta-catenin/NN competed/VBD with/IN the/DT 
556_556_7_9_10_11::None::to/TO be/VB a/DT nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, 
1405_1405_8_9_1_2::None::The/DT talin/NN dimer/NN ,/, which/WDT is/VBZ crucial/JJ for/IN actin/NN and/CC lipid/NN binding/NN 
1399_1399_55_57_3_4::None::The/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN (/( VSV/NN )/) serotypes/NNS New/NNP Jersey/NNP [/( P/NN (/( NJ/NNP )/) ]/) and/CC Indiana/NNP [/( P/NN (/( I/NN )/) ]/) contains/VBZ a/DT highly/RB conserved/VBN carboxy-terminal/JJ domain/NN which/WDT is/VBZ required/VBN for/IN binding/VBG to/TO the/DT cognate/JJ N-RNA/NN template/NN as/RB well/RB as/IN to/TO form/VB a/DT soluble/JJ complex/NN with/IN the/DT nucleocapsid/JJ protein/NN N/NN in/FW vivo/FW 
571439_1_4_5_11_12::None::-/: TNF/NN agents/NNS improve/VBP the/DT clinical/JJ picture/NN of/IN severe/JJ RA/NN patients/NNS ,/, inhibit/VBP joint/JJ 
865_865_33_35_17_18::None::(/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
523349_15_8_9_6_7::None::involved/VBN in/IN the/DT onset/NN of/IN preeclampsia/NN by/IN regulating/VBG proliferation/NN 
484109_1_2_3_11_12::None::For/IN penile/JJ cancer/NN surgical/JJ treatment/NN ,/, radiotherapy/NN ,/, chemotherapy/NN ,/, and/CC combined/VBN modality/NN treatment/NN are/VBP 
247832_2_53_54_6_7::None::studies/NNS suggest/VBP that/IN inflammatory/JJ processes/NNS have/VBP emerged/VBN critical/JJ in/IN the/DT pathogenesis/NN of/IN CVD/NNP in/IN OSAS/NNP A/NNP range/NN of/IN circulating/VBG inflammatory/JJ molecules/NNS has/VBZ been/VBN identified/VBN and/CC measured/VBN ,/, with/IN a/DT view/NN to/TO assess/VB inflammation/NN and/CC predict/VBP vascular/JJ damage/NN risk/NN ,/, such/JJ as/IN plasma/NN cytokines/NNS ,/, adhesion/NN molecules/NNS ,/, and/CC C/NN -/: reactive/JJ protein/NN (/( CRP/NN 
32713_5_1_2_16_17::None::Current/JJ evidence/NN suggests/VBZ that/IN impaired/JJ insulin/NN signalling/NN in/IN the/DT vasculature/NN may/MD be/VB a/DT common/JJ link/NN between/IN metabolic/JJ and/CC cardiovascular/JJ diseases/NNS 
739076_0_5_6_9_12::None::of/IN non/JJ -/: surgical/JJ treatment/NN for/IN childhood/NN obstructive/JJ sleep/NN apnea/NN (/( OSA/NN )/) 
544373_0_5_6_23_24::None::concentration/NN of/IN cardiac/JJ troponin/NN T/NN (/( ie/FW ,/, high/JJ -/: sensitivity/NN cardiac/JJ troponin/NN T/NN [/( hs/SYM -/: cTnT/NN ]/) )/) ,/, measured/VBN using/VBG a/DT highly/RB 
1052_1052_34_35_12_13::None::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN 
749205_0_12_13_4_5::None::,/, SLC6A2/NN ,/, SLC6A3/NN ,/, DRD2/NN and/CC DRD4/NN Polymorphisms/NNS and/CC Neuroendocrine/JJ Factors/NNS Predict/VB SSRIs/NNS Treatment/NN 
776_776_24_26_29_30::None::the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
485087_11_12_13_14_16::None::remains/VBZ difficult/JJ to/TO control/VB with/IN antiarrhythmic/JJ drugs/NNS ,/, RFA/NN should/MD 
211991_5_14_15_0_1::None::Twenty/CD -/: eight/CD obese/JJ women/NNS were/VBD recruited/VBN with/IN the/DT diagnosis/NN of/IN PCOS/NN ,/, mean/VB age/NN 27/CD !/. 
980_980_14_15_12_13::None::the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN 
848984_1_0_1_2_3::None::Methods/NNS :/: We/PRP calculated/VBD the/DT polygenic/JJ 
1037_1037_9_11_21_22::POS_ACTION_INTERACT::exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ 
237_237_9_10_5_6::None::causes/VBZ phosphorylation/NN of/IN talin/NN and/CC redistribution/NN of/IN actin/NN microfilaments/NNS in/IN fibroblasts/NNS 
159605_0_27_29_30_31::medicine.drug_ingredient.active_moiety_of_drug::organic/JJ dyes/NNS with/IN hydrogen/NN peroxide/NN (/( H2O2/NN )/) ./. 
1162_1162_6_8_12_13::POS_ACTION_BIND::cysteine/NN 374/CD of/IN muscle/NN actin/NN reduces/VBZ the/DT affinity/NN for/IN profilin/NN 10-fold/RB ./. 
1667_1667_3_4_5_6::POS_ACTION_LOCALIZE::The/DT role/NN of/IN profilin/NN in/IN actin/NN polymerization/NN and/CC nucleotide/NN 
418321_2_17_18_25_26::None::be/VB influenced/VBN by/IN OSA/NN Patients/NNS with/IN this/DT syndrome/NN exhibit/VBP a/DT high/JJ prevalence/NN of/IN non/JJ -/: 
294085_3_4_5_5_6::None::indicate/VBP that/IN parenting/NN stress/NN moderates/NNS the/DT association/NN between/IN 
411_411_15_16_20_21::None::including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ./. 
36424_0_30_31_34_36::None::Calculation/NN in/IN Stereotactic/JJ Body/NN Radiation/NNP Therapy/NN for/IN Lung/NN Cancer/NN ./. 
131579_0_17_19_7_8::medicine.disease.treatments::of/IN adding/VBG neoadjuvant/JJ chemotherapy/NN to/TO surgery/NN and/CC radiation/NN therapy/NN for/IN locally/RB advanced/JJ resectable/JJ oral/JJ cavity/NN squamous/JJ cell/NN carcinoma/NN 
1486_1486_4_5_60_61::POS_ACTION_STIMULATE::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
1701_1701_11_12_6_7::None::that/IN this/DT novel/JJ RhoGAP/NN is/VBZ involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, 
295269_3_18_19_25_27::None::role/NN across/IN a/DT range/NN of/IN prevalent/JJ human/JJ diseases/NNS ,/, including/VBG diabetes/NN mellitus/NN ,/, cardiovascular/JJ disease/NN 
234343_0_7_8_8_11::None::anticoagulant/JJ therapy/NN during/IN primary/JJ percutaneous/JJ coronary/JJ intervention/NN for/IN acute/JJ myocardial/JJ 
1957_1957_10_11_15_16::POS_ACTION_BIND::with/IN association/NN of/IN beta-catenin/NN with/IN EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ 
255381_4_8_9_7_8::people.cause_of_death.includes_causes_of_death::was/VBD searched/VBN for/IN esophageal/NN cancers/NNS from/IN 1986/CD to/TO 
333054_4_20_21_30_31::None::depending/VBG on/IN the/DT genotype/NN ,/, a/DT higher/JJR lignin/NN accumulation/NN may/MD occur/VB in/IN the/DT stem/NN ,/, thus/RB implying/VBG 
1775_1775_3_4_21_22::None::The/DT structure/NN of/IN Ykt6pN/NN differed/VBD entirely/RB from/IN that/DT of/IN syntaxin/NN and/CC resembled/VBD the/DT overall/JJ fold/NN of/IN the/DT actin/NN regulatory/JJ protein/NN ,/, profilin/NN ./. 
1782_1782_25_26_27_28::POS_ACTION_INTERACT::,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
1850_1850_10_11_8_9::POS_ACTION_Causal::directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN 
241804_0_3_4_8_9::None::Hemorrhagic/JJ transformation/NN (/( HT/NN )/) is/VBZ a/DT major/JJ complication/NN of/IN delayed/VBN tissue/NN 
487559_4_32_33_0_1::None::This/DT case/NN raises/VBZ the/DT possibility/NN that/IN cerebral/JJ vasoconstriction/NN may/MD be/VB related/VBN to/TO the/DT cause/NN of/IN GDI/NNP A/NNP high/JJ index/NN of/IN suspicion/NN of/IN GDI/NNP should/MD be/VB maintained/VBN in/IN patients/NNS who/WP present/VBP with/IN typical/JJ signs/NNS and/CC symptoms/NNS ,/, 
491928_0_0_1_2_3::None::Trajectories/NNS of/IN premorbid/JJ childhood/NN and/CC adolescent/JJ 
2055_2055_28_29_21_22::POS_ACTION_BIND::the/DT recombinant/JJ viral/JJ profilin/NN ,/, and/CC characterized/VBD its/PRP$ interactions/NNS with/IN actin/NN and/CC polyphosphoinositides/NNS ./. 
1798_1798_33_34_41_42::None::integrin/NN receptors/NNS ,/, actin/NN and/CC cytoskeletal/JJ proteins/NNS such/JJ as/IN vinculin/NN and/CC talin/NN ./. 
604261_0_21_22_25_26::None::express/VBP the/DT metabotropic/JJ glutamate/NN receptor/NN 1/CD (/( GRM1/NN )/) and/CC that/IN 
2013_2013_0_1_7_9::None::WASp/NN contains/VBZ a/DT binding/NN motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB 
414579_11_0_1_27_28::medicine.drug.active_moieties::Norepinephrine/NN was/VBD used/VBN more/RBR frequently/RB and/CC in/IN higher/JJR amounts/NNS ,/, during/IN cardiopulmonary/JJ bypass/NN ,/, in/IN patients/NNS who/WP developed/VBD AKI/NNP These/DT differences/NNS in/IN arterial/JJ pressures/NNS and/CC use/NN of/IN norepinephrine/NN between/IN the/DT groups/NNS 
1439_1439_16_17_24_25::POS_ACTION_BIND::for/IN association/NN of/IN TNFR1/NN and/CC other/JJ death/NN domain-containing/JJ proteins/NNS such/JJ as/IN FADD/NN and/CC RIP/NN ./. 
365_365_15_16_12_15::None::D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN 
544373_0_5_6_39_41::None::concentration/NN of/IN cardiac/JJ troponin/NN T/NN (/( ie/FW ,/, high/JJ -/: sensitivity/NN cardiac/JJ troponin/NN T/NN [/( hs/SYM -/: cTnT/NN ]/) )/) ,/, measured/VBN using/VBG a/DT highly/RB sensitive/JJ assay/NN ,/, represents/VBZ a/DT useful/JJ biomarker/NN for/IN evaluating/VBG the/DT pathogenesis/NN of/IN heart/NN failure/NN or/CC predicting/VBG cardiovascular/JJ 
1008_1008_8_9_2_3::None::Mutants/NNS of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB 
93033_7_4_5_27_28::None::,/, all/DT three/CD TEs/NNS were/VBD found/VBN in/IN only/RB one/CD of/IN the/DT two/CD main/JJ lineages/NNS leading/VBG to/TO the/DT modern/JJ sugarcane/NN cultivars/NNS and/CC are/VBP therefore/RB the/DT first/JJ TEs/NN identified/VBD that/DT could/MD potentially/RB 
552813_1_22_23_48_49::None::-/: 30/CD years/NNS post/NN -/: MS/NN symptom/NN onset/NN for/IN :/: EDSS/NNS ,/, HRQoL/NN (/( MSQoL/NN -/: 54/CD )/) ,/, depression/NN (/( Beck/NNP Depression/NNP Inventory/NNP -/: II/CD )/) ,/, and/CC fatigue/NN (/( Modified/VBN Fatigue/NNP 
2108_2108_8_11_18_19::POS_ACTION_MEMBER::proteins/NNS are/VBP indeed/RB nuclear/JJ basic/JJ proteins/NNS :/: the/DT 14/CD kd/NN is/VBZ the/DT histone/NN H4/NN ,/, the/DT 19/CD 
614185_6_18_19_0_1::None::These/DT procedures/NNS can/MD be/VB typically/RB completed/VBN within/IN ~/CD 30/CD min/NN ,/, and/CC they/PRP are/VBP highly/RB adaptable/JJ to/TO other/JJ strains/NNS of/IN rats/NNS ,/, 
88435_3_0_1_26_27::None::Patients/NNS with/IN stable/JJ or/CC progressing/VBG metastatic/JJ solid/JJ tumours/NNS ,/, on/IN single/JJ -/: agent/NN chemotherapy/NN or/CC hormonal/JJ therapy/NN ,/, with/IN at/IN least/JJS three/CD distinct/JJ measurable/JJ sites/NNS of/IN disease/NN ,/, were/VBD treated/VBN 
425469_7_45_46_20_21::None::relationship/NN between/IN treatment/NN condition/NN and/CC change/NN in/IN eating/VBG concerns/NNS ,/, where/WRB younger/JJR adolescents/NNS and/CC individuals/NNS with/IN high/JJ baseline/NN purging/VBG had/VBD greater/JJR change/NN when/WRB treated/VBN with/IN FBT/NN relative/JJ to/TO SPT/NNP Age/NNP and/CC purging/VBG 
1069_1069_26_27_46_47::None::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
316251_0_17_18_19_20::biology.organism_classification.lower_classifications::,/, 1854/CD (/( Myliobatiformes/NNPS :/: Myliobatidae/NNP )/) from/IN the/DT 
780438_1_23_24_33_34::None::HAV/NN and/CC assess/VB reasons/NNS why/WRB travelers/NNS had/VBD not/RB received/VBN hepatitis/NN A/NN vaccine/NN before/IN traveling/VBG ./. 
93_93_4_5_6_7::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT 
10441_0_13_14_1_2::None::Distal/JJ symmetric/JJ peripheral/JJ polyneuropathy/NN (/( DSPN/NN )/) is/VBZ a/DT highly/RB prevalent/JJ complication/NN of/IN diabetes/NN ./. 
670_670_12_13_16_17::None::post-TGF-beta1/NN showed/VBD that/IN beta-catenin/NN ,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, and/CC cadherin-5/NN 
236807_0_2_3_12_13::None::The/DT nonsteroidal/JJ antiinflammatory/JJ drug/NN piroxicam/NN reverses/VBZ the/DT onset/NN of/IN depressive/JJ -/: like/IN behavior/NN in/IN 6/CD -/: 
149017_0_17_18_21_22::None::,/, characterized/VBN by/IN progressive/JJ cognitive/JJ impairment/NN ,/, dementia/NN and/CC atrophy/NN of/IN 
919_919_12_13_14_15::None::E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT 
459561_0_3_4_11_12::None::To/TO assess/VB the/DT efficacy/NN and/CC safety/NN of/IN dapagliflozin/NN ,/, a/DT selective/JJ sodium/NN -/: glucose/NN cotransporter/NN 
2013_2013_20_21_0_1::None::WASp/NN contains/VBZ a/DT binding/NN motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN verprolin/cofilin-like/JJ actin-regulatory/JJ domains/NNS ,/, but/CC no/DT specific/JJ actin/NN structure/NN regulated/VBN by/IN 
761186_8_23_24_20_21::None::including/VBG MI/NNP ,/, angina/NN ,/, and/CC stroke/NN ./. 
379013_1_15_17_50_51::None::high/JJ -/: fructose/NN corn/NN syrup/NN (/( HFCS/NN )/) at/IN zero/CD ,/, low/JJ ,/, medium/NN ,/, and/CC high/JJ proportions/NNS of/IN energy/NN requirements/NNS (/( Ereq/NN )/) on/IN circulating/VBG lipid/NN //: lipoprotein/NN risk/NN factors/NNS for/IN CVD/NN anduric/JJ acid/NN in/IN adults/NNS [/( age/NN :/: 18/CD -/: 
1507_1507_19_20_22_23::None::the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS ./. 
117943_0_4_5_22_23::None::thrombus/NN aspiration/NN (/( TA/NNP )/) during/IN primary/JJ percutaneous/JJ coronary/JJ intervention/NN (/( PCI/NN )/) was/VBD reported/VBN to/TO promote/VB better/JJR coronary/JJ and/CC myocardial/JJ reperfusion/NN ./. 
456903_0_3_4_20_21::None::Lixisenatide/NNP is/VBZ a/DT potent/JJ ,/, selective/JJ and/CC short/JJ -/: acting/VBG once/RB daily/JJ prandial/JJ glucagon/NN -/: like/IN peptide/NN -/: 1/CD receptor/NN agonist/NN which/WDT lowers/VBZ glycohemoglobin/NN 
828493_2_10_11_15_17::None::,/, was/VBD to/TO investigate/VB associations/NNS between/IN obesity/NN and/CC gene/NN methylation/NN in/IN breast/NN tumors/NNS 
607039_6_22_23_21_22::None::corticosteroids/NNS ,/, and/CC identifies/VBZ areas/NNS where/WRB further/JJ study/NN 
1652_1652_45_46_20_21::None::with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
784_784_8_9_12_13::None::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, 
549_549_11_12_9_10::None::was/VBD due/JJ to/TO msh6-F337A/NN sequestering/NN MSH2/NN and/CC preventing/VBG it/PRP 
1726_1726_16_17_16_17::None::of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ 
513_513_7_8_17_19::POS_REG(+)_Assembly::(/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO promote/VB U2/NN snRNP/NN binding/NN to/TO pre-mRNA/NN 
1850_1850_8_9_2_3::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ 
2222_2222_37_38_23_24::NEG_ACTION_COLOCALIZE::,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
1274_1274_9_12_29_30::None::a/DT full/JJ length/NN myosin/NN heavy/JJ chain/NN and/CC a/DT tagged/VBN tail/NN ,/, was/VBD isolated/VBN on/IN the/DT basis/NN of/IN the/DT affinities/NNS for/IN Nickel/NN agarose/NN and/CC actin/NN ./. 
1417_1417_4_5_9_10::None::cellular/JJ transcription/NN co-activators/NNS p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS 
431465_3_22_23_20_21::None::,/, representing/VBG a/DT Mn/NN -/: catalyzed/VBN enantioselective/JJ aliphatic/JJ C/NN 
2064_2064_6_7_8_9::None::the/DT down-regulation/NN of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN 
1505_1505_28_29_33_34::None::of/IN the/DT virus-coded/JJ UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN proteins/NNS ./. 
1633_1633_32_33_26_27::None::,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC two/CD histone/NN H2b/NN genes/NNS ./. 
423_423_2_4_5_6::POS_ACTION_AFFECT::Effects/NNS of/IN macrophage/NN profilin/NN on/IN actin/NN in/IN the/DT presence/NN 
170709_1_19_20_17_18::medicine.drug.active_moieties::Her2/NN receptor/NN ,/, trastuzumab/NN (/( Herceptin/NN )/) was/VBD used/VBN 
919_919_14_15_12_13::None::E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT 
938_938_9_11_14_15::None::cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ actin/NN cytoskeletal/JJ reorganization/NN ./. 
1502_1502_18_19_14_15::None::localization/NN of/IN the/DT UL52/NN but/CC not/RB the/DT ICP8/NN or/CC POL/NN replication/NN 
627_627_24_25_19_20::POS_ACTION_MEMBER::up-regulation/NN of/IN the/DT p27/NN cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CKI/NN )/) ,/, and/CC 
2131_2131_7_8_23_24::POS_ACTION_LOCALIZE::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
1633_1633_26_27_32_33::None::,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC two/CD histone/NN H2b/NN genes/NNS ./. 
1560_1560_39_40_17_18::None::versus/CC acetylation/NN of/IN histone/NN H3/NN :/: with/IN the/DT purified/VBN acetylase/NN ,/, histone/NN H4/NN in/IN nucleosomes/NNS was/VBD acetylated/VBN to/TO a/DT much/RB greater/JJR extent/NN than/IN was/VBD histone/NN H3/NN ,/, whereas/IN the/DT 
242294_6_31_32_10_11::None::,/, inter/NN -/: molecular/JJ O/NN -/: H/NN O/NN ,/, C/NN -/: H/NN O/NN and/CC C/NN -/: Hpi/NN inter/NN -/: actions/NNS link/VBP the/DT independent/JJ benzoates/NNS alternately/RB ,/, forming/VBG a/DT 
652874_0_23_24_22_23::biology.organism_classification.lower_classifications::egg/NN laying/VBG in/IN squamate/NN reptiles/NNS (/( lizards/NNS and/CC 
1147_1147_17_18_22_23::POS_ACTION_BIND::ligands/NNS which/WDT localize/VBP profilin/NN to/TO sites/NNS requiring/VBG extensive/JJ actin/NN filament/NN accumulation/NN ./. 
350670_24_13_14_1_2::None::Atherogenic/JJ dyslipidemia/NN is/VBZ associated/VBN with/IN higher/JJR risk/NN of/IN stroke/NN recurrence/NN in/IN ischemic/JJ stroke/NN patients/NNS ./. 
1284_1284_6_7_13_14::POS_ACTION_BIND::three/CD ligands/NNS for/IN profilin/NN have/VBP been/VBN well-characterized/VBN in/FW vitro/FW :/: actin/NN monomers/NNS ,/, membrane/NN 
93_93_57_58_54_55::None::,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
322602_4_7_9_18_19::people.cause_of_death.includes_causes_of_death::diseases/NNS were/VBD congenital/JJ heart/NN disease/NN (/( n/NN =/JJ 65/CD ,/, 53.3/CD %/NN )/) and/CC arrhythmia/NN (/( n/NN =/JJ 
390913_0_3_4_5_8::medicine.drug.active_moieties::Because/IN lapatinib/NN and/CC vorinostat/NN [/( suberoylanilide/NN hydroxamic/JJ acid/NN (/( SAHA/NN )/) 
318370_0_2_3_6_7::None::Black/JJ titania/NN spheres/NNS (/( H/NN -/: TiO2/NN -/: x/NN )/) 
439403_7_6_7_9_10::medicine.disease.symptoms::patients/NNS classified/VBN as/IN depressed/JJ showed/VBD greater/JJR pain/NN interference/NN ,/, lower/JJR 
538077_4_39_40_0_1::None::Lead/JJ compounds/NNS 4e/NN (/( CWHM/NN -/: 123/CD )/) and/CC 12k/NN (/( CWHM/NN -/: 505/CD )/) are/VBP potent/JJ antimalarials/NNS with/IN IC50/NN values/NNS against/IN Plasmodium/NN falciparum/NN 3D7/NN of/IN 0.310/CD muM/NN and/CC 0.099/CD muM/NN ,/, respectively/RB ,/, and/CC the/DT former/JJ features/NNS equivalent/JJ potency/NN on/IN the/DT chloroquine/NN 
736874_8_14_15_18_19::None::streptococci/NNS )/) and/CC Actinobacteria/NN (/( mainly/RB Actinomyces/NNP species/NNS )/) ./. 
648_648_1_3_6_9::None::Human/JJ platelet/NN P-235/NN ,/, a/DT talin-like/JJ actin/NN binding/NN protein/NN ,/, binds/VBZ selectively/RB 
380111_3_3_4_42_43::medicine.drug_ingredient.active_moiety_of_drug::We/PRP found/VBD that/IN Au/NN (/( -/: )/) -/: H2/NN presents/VBZ a/DT H/NN -/: Au/SYM -/: H/NN insertion/NN minimum/NN attributed/VBD to/TO the/DT stabilization/NN of/IN the/DT LUMO/NNP 3b2/NN orbital/NN ,/, which/WDT can/MD be/VB considered/VBN as/IN the/DT preamble/NN of/IN the/DT chemisorption/NN well/RB appearing/VBG in/IN larger/JJR gold/NN clusters/NNS ./. 
323448_0_20_21_6_7::None::early/JJ experience/NN with/IN carbon/NN ion/NN irradiation/NN in/IN the/DT treatment/NN of/IN gross/JJ residual/JJ or/CC unresectable/JJ malignant/JJ peripheral/JJ nerve/NN sheath/NN tumors/NNS (/( MPNST/NN 
755_755_9_10_20_21::None::as/RB well/RB as/IN ADF/NN ,/, translocates/VBZ from/IN the/DT cytoplasm/NN into/IN the/DT nucleus/NN together/RB with/IN actin/NN and/CC forms/NNS rod-like/JJ 
268127_0_1_3_10_11::None::Many/JJ malignant/JJ tumors/NNS express/VBP high/JJ levels/NNS of/IN the/DT chemokine/NN receptor/NN CXCR4/NN ,/, and/CC the/DT 
275967_6_32_33_25_26::None::central/JJ apneas/NNS in/IN addition/NN to/TO obstructive/JJ events/NNS ,/, resulting/VBG in/IN combined/VBN intermittent/JJ and/CC sustained/JJ 
264127_3_16_19_20_23::medicine.symptom.symptom_of::non/JJ -/: fatal/JJ acute/JJ myocardial/JJ infarction/NN or/CC coronary/JJ heart/NN disease/NN death/NN (/( primary/JJ 
381796_0_22_23_18_22::None::or/CC Intolerant/JJ of/IN Continuous/JJ Positive/JJ Airway/NNP Pressure/NN Ventilation/NN ./. 
1094_1094_14_15_22_23::None::three/CD subunits/NNS ,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT eIF3/NN complex/NN ./. 
1560_1560_17_18_17_18::None::versus/CC acetylation/NN of/IN histone/NN H3/NN :/: with/IN 
930063_2_14_15_2_3::None::While/IN IV/CD thrombolysis/NN has/VBZ been/VBN shown/VBN to/TO decrease/VB morbidity/NN and/CC mortality/NN from/IN acute/JJ ischemic/JJ stroke/NN ,/, it/PRP is/VBZ 
574337_0_0_1_5_6::None::Infection/NN by/IN human/JJ papillomavirus/NN (/( HPV/NN )/) is/VBZ among/IN 
1782_1782_23_24_1_6::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC 
678566_0_27_28_16_17::medicine.disease.treatments::the/DT target/NN for/IN levetiracetam/NN (/( LEV/NN )/) ,/, which/WDT is/VBZ a/DT successful/JJ anti/JJ -/: epileptic/JJ drug/NN ./. 
597121_2_22_23_2_3::None::Several/JJ pathophysiologic/JJ mechanisms/NNS have/VBP been/VBN demonstrated/VBN and/CC evaluated/VBN among/IN hypertensives/NNS and/CC the/DT conglomeration/NN of/IN genetics/NNS ,/, environmental/JJ ,/, and/CC personal/JJ lifestyle/NN activities/NNS concurrently/RB impact/VBP the/DT progression/NN 
1075_1075_8_9_20_21::None::as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) 
763530_0_9_10_29_30::None::index/NN are/VBP risk/NN factors/NNS for/IN esophageal/NN adenocarcinoma/NN and/CC its/PRP$ main/JJ precursor/NN ,/, Barrett/NNP whosewhat/NN esophagus/NN ;/: however/RB ,/, there/EX are/VBP no/DT known/JJ biological/JJ mechanisms/NNS for/IN these/DT associations/NNS 
311810_6_7_8_6_7::None::inhibitors/NNS that/WDT raise/VBP cAMP/NN levels/NNS in/IN P/NN falciparum/NN 
1507_1507_22_23_6_7::None::virus/NN type/NN 1/CD primosome/NN consists/VBZ of/IN three/CD subunits/NNS that/WDT are/VBP the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS ./. 
1989_1989_11_12_32_33::POS_ACTION_BIND::actin-binding/JJ domain/NN of/IN fimbrin/NN ,/, these/DT results/NNS have/VBP enabled/VBN us/PRP to/TO determine/VB the/DT likely/JJ orientation/NN of/IN the/DT utrophin/NN actin-binding/JJ domain/NN with/IN respect/NN to/TO the/DT actin/NN filament/NN ./. 
78_78_20_21_17_18::POS_ACTION_BIND::1:1/CD complex/NN between/IN profilin/NN and/CC monomeric/JJ actin/NN with/IN a/DT Kr/NN 
1303_1303_5_6_7_8::None::the/DT interaction/NN between/IN actin/NN and/CC cofilin/NN purified/VBN by/IN a/DT 
1061_1061_2_3_15_16::NEG_ACTION_BIND::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, 
1094_1094_16_17_18_19::POS_ACTION_BIND::,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT 
249535_0_12_14_6_8::medicine.risk_factor.diseases::serum/NN microRNAs/NNS in/IN pancreatic/JJ cancer/NN associated/VBN new/JJ -/: onset/NN diabetes/NN mellitus/NN ./. 
856_856_24_25_40_41::None::the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
944835_4_0_1_0_2::biology.organism_classification.lower_classifications::Plasmodium/NN falciparum/NN eta/NN -/: CA/NNP 
1701_1701_48_49_43_46::None::which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
597121_2_34_37_27_28::medicine.disease.risk_factors::the/DT progression/NN of/IN hypertension/NN -/: related/JJ comorbidities/NNS (/( ie/FW ,/, chronic/JJ renal/JJ disease/NN ,/, CVD/NNP ,/, 
1486_1486_35_40_41_44::None::MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
1380_1380_24_25_40_41::POS_ACTION_BIND::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN 
850254_13_0_1_8_9::None::HbA1c/NN and/CC fructosamine/NN were/VBD significantly/RB increased/VBN in/IN diabetic/JJ patients/NNS with/IN acute/JJ infection/NN 
87_87_16_20_37_38::POS_ACTION_COLOCALIZE::,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN 
1637_1637_7_8_27_29::POS_ACTION_BIND::similar/JJ to/TO authentic/JJ profilin/NN from/IN Acanthamoeba-based/JJ on/IN fluorescence/NN monitored/VBD urea/NN denaturation/NN ,/, circular/JJ dichroism/NN ,/, actin-nucleotide/JJ exchange/NN rate/NN and/CC the/DT Kd/NN for/IN rabbit/NN skeletal/JJ actin/NN ./. 
144491_1_25_26_52_54::None::serum/NN albumin/NN (/( HSA/NN )/) and/CC immunoglobulin/NN G/NN (/( IgG/NN )/) in/IN their/PRP$ native/JJ and/CC partially/RB unfolded/VBD states/NNS using/VBG steady/JJ state/NN and/CC time/NN resolved/VBD fluorescence/NN spectroscopy/NN ,/, molecular/JJ docking/NN and/CC circular/JJ dichroism/NN (/( CD/NN )/) 
1758_1758_19_20_22_23::None::,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ,/, and/CC TNF-induced/JJ 
1337_1337_9_10_12_13::None::to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN ./. 
172257_0_29_30_19_20::medicine.risk_factor.diseases::and/CC treatment/NN of/IN anemia/NN in/IN 349/CD lung/NN cancer/NN patients/NNS undergoing/VBG first/JJ -/: line/NN chemotherapy/NN ./. 
369325_1_33_34_4_5::medicine.disease.risk_factors::total/NN of/IN 3178/CD black/JJ and/CC white/JJ women/NNS and/CC men/NNS in/IN the/DT Coronary/JJ Artery/NN Risk/NN Development/NN in/IN Young/NNP Adults/NNS study/NN were/VBD assessed/VBN to/TO identify/VB the/DT order/NN in/IN which/WDT cardiovascular/JJ disease/NN risk/NN factors/NNS including/VBG diabetes/NN ,/, hypertension/NN ,/, 
1889_1889_0_2_11_13::None::TNF/NN receptor/NN death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN acid/NN sphingomyelinase/NN ./. 
132437_10_38_39_59_60::None::,/, diabetes/NN and/CC concurrent/JJ aspirin/NN therapy/NN ;/: 1.8/CD -/: 2.3/CD in/IN patients/NNS with/IN congestive/JJ heart/NN failure/NN ;/: 1.9/CD -/: 2.4/CD in/IN patients/NNS with/IN previous/JJ stroke/NN or/CC thromboembolism/NN ;/: 
1758_1758_19_20_4_5::POS_ACTION_MEDIATE::results/NNS suggest/VBP that/IN TNF-alpha/NN can/MD cause/VB apoptosis/NN in/IN pancreatic/JJ beta/NN cells/NNS through/IN TNFR1-linked/JJ apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP 
784_784_12_13_18_19::None::,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN 
684974_3_9_10_45_46::None::cluster/NN of/IN bd/NN oxidase/NN might/MD have/VB occurred/VBN in/IN the/DT ancestors/NNS of/IN extant/JJ alpha/NN -/: proteobacteria/NN of/IN the/DT Rhodospirillales/NNP order/NN ,/, such/JJ as/IN Acidocella/NNP ,/, from/IN which/WDT the/DT bd/NN -/: I/PRP type/NN of/IN the/DT oxidase/NN might/MD have/VB diffused/VBN to/TO other/JJ proteobacterial/JJ lineages/NNS ./. 
938_938_14_15_6_7::None::LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ actin/NN cytoskeletal/JJ reorganization/NN ./. 
126724_0_9_10_6_7::None::Future/NNP :/: Are/VBP Tumor/NN -/: Targeting/NN Bacteria/NNS the/DT Next/JJ -/: 
1069_1069_21_22_33_35::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) 
337732_11_47_48_42_43::None::task/NN designed/VBN to/TO assess/VB phasic/JJ alertness/NN in/IN healthy/JJ adult/JJ volunteers/NNS ;/: these/DT 
328070_0_5_6_13_14::None::have/VBP been/VBN frequently/RB involved/VBN in/IN many/JJ Cu/NN -/: mediated/JJ carbon/NN -/: hydrogen/NN halogenation/NN reactions/NNS ./. 
1069_1069_36_37_33_35::None::)/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC 
270415_4_1_2_15_17::medicine.risk_factor.diseases::Global/JJ stress/NN and/CC rest/NN MFR/NN were/VBD automatically/RB derived/VBN from/IN PET/NNP Patient/NNP age/NN ,/, sex/NN ,/, cardiovascular/JJ risk/NN factors/NNS ,/, coronary/JJ 
1170_1170_5_6_30_31::POS_ACTION_BIND::we/PRP characterized/VBD several/JJ profilin/NN isoforms/NNS from/IN maize/NN pollen/NN for/IN their/PRP$ ability/NN to/TO alter/VB cytoarchitecture/NN when/WRB microinjected/VBN into/IN living/NN plant/NN cells/NNS and/CC for/IN their/PRP$ association/NN with/IN poly-L-proline/NN and/CC monomeric/JJ actin/NN from/IN maize/NN pollen/NN 
401885_4_6_7_2_3::None::Exposed/VBN elderly/JJ persons/NNS had/VBD a/DT significantly/RB higher/JJR prevalence/NN of/IN chronic/JJ 
363545_0_59_60_41_42::None::disorders/NNS such/JJ as/IN depression/NN and/CC anxiety/NN ,/, thus/RB MAOs/NNS may/MD be/VB considered/VBN as/IN targets/NNS for/IN the/DT treatment/NN of/IN these/DT multi/NNS -/: factorial/JJ diseases/NNS ./. 
164887_1_43_44_42_43::None::sleep/NN apnea/NN during/IN overnight/JJ polygraphy/NN ;/: to/TO determine/VB 
676_676_9_10_5_6::None::of/IN actin-anchoring/JJ proteins/NNS vinculin/NN ,/, talin/NN and/CC paxillin/NN in/IN rat/NN brain/NN 
605_605_8_9_23_24::POS_ACTION_CONTAIN::encodes/VBZ a/DT heterotrimeric/JJ helicase-primase/NN complex/NN that/WDT is/VBZ composed/VBN of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN genes/NNS ./. 
405799_1_0_1_30_33::None::Inflammation/NN is/VBZ supposed/VBN to/TO participate/VB in/IN the/DT development/NN of/IN DR/NN This/DT study/NN aimed/VBN to/TO investigate/VB whether/IN genetic/JJ variants/NNS of/IN CRP/NN are/VBP associated/VBN with/IN DR/NN A/NN total/NN of/IN 1,018/CD patients/NNS with/IN type/NN 2/CD diabetes/NNS were/VBD recruited/VBN in/IN 
736878_5_15_17_5_6::medicine.disease.symptoms::frequent/JJ causes/NNS of/IN vaginitis/NN were/VBD unspecific/JJ bacterial/JJ infections/NNS (/( 42.4/CD %/NN )/) and/CC vaginal/JJ candidiasis/NN (/( 44.8/CD %/NN 
1037_1037_4_5_27_28::None::disclosed/VBN interactions/NNS between/IN gephyrin/NN ,/, exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
87_87_37_38_41_45::None::the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN alpha/NN v/LS beta/NN 5/CD shows/VBZ a/DT distinct/JJ 
1052_1052_27_28_18_20::None::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) 
292_292_11_14_19_21::None::also/RB known/VBN as/IN dipeptidyl/NN peptidase/NN IV/CD ,/, is/VBZ directly/RB associated/VBN with/IN adenosine/NN deaminase/NN (/( ADA/NN )/) 
544721_14_10_11_9_10::medicine.symptom.symptom_of::benignity/NN of/IN palpable/JJ breast/NN masses/NNS had/VBD been/VBN used/VBN 
1321_1321_26_27_9_11::None::)/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN testicular/JJ germ/NN cells/NNS and/CC has/VBZ the/DT potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
1737_1737_58_59_39_40::None::the/DT polymerization/NN of/IN actin/NN in/IN RBL/NN cells/NNS ,/, possibly/RB through/IN the/DT interaction/NN of/IN the/DT polyphosphoinositides/NNS with/IN actin-binding/JJ proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
76427_8_31_32_4_5::medicine.drug_ingredient.active_moiety_of_drug::recent/JJ studies/NNS on/IN copper/NN -/: based/VBN catalysts/NNS are/VBP presented/VBN here/RB as/IN an/DT example/NN of/IN the/DT application/NN of/IN these/DT complementary/JJ model/NN systems/NNS ,/, starting/VBG from/IN the/DT creation/NN of/IN undercoordinated/JJ sites/NNS on/IN Cu/NN (/( 111/CD )/) 
95125_0_9_10_0_2::None::Aedes/NNS aegypti/NNS is/VBZ a/DT primary/JJ vector/NN of/IN dengue/NN and/CC chikungunya/NN ./. 
292034_0_15_16_5_8::people.cause_of_death.includes_causes_of_death::Clear/JJ Cell/NN Type/NN Squamous/JJ Cell/NN Carcinoma/NN that/WDT Required/NNP Differential/JJ Diagnosis/NN from/IN Metastatic/JJ Ureter/NN Cancer/NN ;/: Report/NNP of/IN 
908550_0_19_20_31_32::medicine.risk_factor.diseases::in/IN modestly/RB severely/RB obese/JJ African/JJ Americans/NNPS and/CC White/NNP Americans/NNPS with/IN prediabetes/NNS :/: implications/NNS for/IN the/DT metabolic/JJ paradoxes/NNS ./. 
1711_1711_16_19_7_8::None::predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN 
1008_1008_8_9_4_5::None::of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB 
374_374_6_7_4_5::None::of/IN SIR4/NN enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC 
174565_5_43_44_54_55::None::striatum/NN from/IN various/JJ environments/NNS generated/VBN by/IN different/JJ doses/NNS of/IN dopaminergic/JJ (/( DA/NN )/) neuron/NN toxin/NN ./. 
454283_3_1_2_4_5::None::At/IN pH/NN 6.0/CD ,/, arsenate/NN inhibits/VBZ the/DT formation/NN 
322972_6_26_27_16_17::None::distribution/NN ,/, and/CC elimination/NN of/IN MPA/NNP in/IN lung/NN transplant/NN recipients/NNS with/IN or/CC without/IN CF/NN disease/NN ./. 
1069_1069_24_25_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, 
1380_1380_40_41_36_37::POS_ACTION_BIND::,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN 
968089_0_8_9_21_22::medicine.disease.treatments::)/) -/: related/JJ cirrhosis/NN and/CC hepatocellular/JJ carcinoma/NN account/NN for/IN approximately/RB 40/CD %/NN of/IN the/DT 6,000/CD adult/JJ liver/NN transplantations/NNS performed/VBN each/DT 
229532_2_33_34_10_12::None::fatty/JJ acids/NNS ,/, arachidonic/JJ acid/NN (/( AA/NN )/) or/CC decosahexaenoic/JJ acid/NN (/( DHA/NN )/) ,/, resulted/VBD in/IN down/RB -/: regulation/NN of/IN cell/NN signaling/NN pathway/NN genes/NNS and/CC specific/JJ fatty/JJ acid/NN metabolism/NN 
1071_1071_21_22_32_33::POS_REG(0)_ASSEMBLE::each/DT other/JJ :/: profilin/NN has/VBZ different/JJ effects/NNS on/IN elongation/NN at/IN the/DT two/CD ends/NNS of/IN actin/NN filaments/NNS ;/: profilin/NN 
243_243_3_4_0_2::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT 
767824_2_28_29_19_20::None::predictor/NN of/IN reduced/VBN depression/NN symptoms/NNS in/IN obese/JJ adolescents/NNS during/IN long/JJ -/: term/NN interdisciplinary/JJ weight/NN loss/NN therapy/NN 
234343_0_4_5_0_1::None::What/WP is/VBZ the/DT best/JJS anticoagulant/JJ therapy/NN during/IN primary/JJ 
365_365_30_31_12_15::None::D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN in/IN subversion/NN of/IN the/DT G1/S/NN traverse/NN by/IN signaling/NN pathways/NNS activated/VBN by/IN HER-2/NN function/NN ./. 
772940_6_5_6_4_5::None::patients/NNS with/IN chronic/JJ HBV/NN infection/NN ,/, fourteen/CD sphingolipids/NNS 
2222_2222_17_18_37_38::None::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
257215_0_7_8_15_16::None::a/DT redox/NN and/CC enzyme/NN dual/JJ -/: stimuli/NNS responsive/JJ delivery/NN system/NN (/( MSN/NNP -/: SS/NN -/: 
93_93_24_26_54_55::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
254148_6_22_23_13_14::medicine.disease.symptoms::set/NN of/IN chronic/JJ delusional/JJ psychoses/NNS (/( CDPs/NNS )/) ,/, including/VBG chronic/JJ hallucinatory/JJ psychosis/NN ./. 
240658_2_14_16_17_19::biology.organism_classification.lower_classifications::SNC/NN trait/NN in/IN fruit/NN flies/NNS (/( Drosophila/FW melanogaster/FW )/) ,/, but/CC 
1168_1168_29_30_16_18::None::recombinant/JJ Arabidopsis/NNP thaliana/NN fimbrin/NN 1/CD (/( AtFim1/NN )/) is/VBZ a/DT member/NN of/IN the/DT fimbrin/plastin/NN family/NN of/IN actin/NN filament/NN bundling/VBG or/CC 
53_53_17_18_5_7::None::modulating/VBG domain/NN in/IN glucocorticoid/NN receptor/NN monomers/NNS in/IN the/DT repression/NN of/IN activity/NN of/IN the/DT transcription/NN factor/NN AP-1/NN ./. 
749205_0_14_15_2_3::None::TPH/NN ,/, SLC6A2/NN ,/, SLC6A3/NN ,/, DRD2/NN and/CC DRD4/NN Polymorphisms/NNS and/CC Neuroendocrine/JJ Factors/NNS Predict/VB SSRIs/NNS Treatment/NN Outcome/NN in/IN 
497715_6_14_15_21_22::None::and/CC Health/NNP at/IN Every/DT Size/NN (/( HAES/NN )/) ,/, we/PRP highlight/VBP pedagogical/JJ approaches/NNS to/TO 
1686_1686_25_28_47_48::None::at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP 
264127_3_30_32_37_38::None::)/) ,/, major/JJ cardiovascular/JJ events/NNS (/( acute/JJ myocardial/JJ infarction/NN ,/, stroke/NN )/) or/CC all/DT 
359239_0_21_22_3_4::people.cause_of_death.includes_causes_of_death::The/DT balance/NN between/IN tumor/NN -/: promoting/VBG and/CC tumor/NN -/: suppressing/VBG immune/JJ responses/NNS and/CC the/DT difference/NN between/IN them/PRP ultimately/RB determine/VBP whether/IN a/DT cancer/NN escapes/VBZ immune/JJ recognition/NN 
649052_1_5_6_9_11::None::while/IN dogs/NNS and/CC wolves/NNS show/VBP a/DT similar/JJ social/JJ organization/NN ,/, they/PRP differ/VBP 
129749_7_12_13_0_1::None::Subclinical/JJ hypothyroidism/NN risk/NN for/IN DM/NN was/VBD prominent/JJ only/RB upon/IN statin/NN use/NN (/( RR/NN 1.94/CD [/( 1.13/CD 
365_365_30_31_8_10::None::that/IN the/DT G1/NN cyclin/NN D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN in/IN subversion/NN of/IN the/DT G1/S/NN traverse/NN by/IN signaling/NN pathways/NNS activated/VBN by/IN HER-2/NN function/NN ./. 
422301_6_9_10_24_25::None::of/IN the/DT turtle/NN shell/NN are/VBP an/DT evolutionary/JJ novelty/NN ,/, whereas/IN the/DT tubercles/NNS found/VBN on/IN the/DT shells/NNS of/IN some/DT turtles/NNS are/VBP homologous/JJ to/TO 
81377_14_11_12_0_1::None::Being/VBG obese/JJ before/IN pregnancy/NN and/CC frequently/RB consuming/JJ fruit/NN drinks/NNS were/VBD important/JJ determinants/NNS of/IN excessive/JJ GWG/NN 
93_93_6_7_4_5::POS_ACTION_MEMBER::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT 
1580_1580_18_19_25_26::POS_ACTION_BIND::protein/NN complex/NN containing/VBG E-cadherin/NN and/CC its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
188913_0_113_114_38_39::None::Zn/NN )/) ,/, iodine/NN (/( I/NN )/) ,/, selenium/NN (/( Se/NN )/) ,/, molybdenum/NN (/( Mo/NN )/) ,/, and/CC chromium/NN (/( Cr/NN )/) ]/) ,/, the/DT energy/NN metabolic/JJ indicators/NNS [/( triglyceride/NN (/( TG/NN )/) ,/, glucose/NN (/( Glu/NN )/) ,/, total/JJ cholesterol/NN (/( CHO/NN )/) ,/, nonesterified/JJ fatty/JJ acids/NNS (/( NEFA/NN )/) ,/, beta/NN -/: hydroxybutyrate/NN (/( BHBA/NN )/) ,/, lactate/NN (/( LA/NNP )/) ,/, and/CC blood/NN urea/NN nitrogen/NN (/( BUN/NN )/) ]/) ,/, and/CC inflammatory/JJ indexes/NNS [/( bovine/JJ haptoglobin/NN (/( BoHp/NN 
1052_1052_18_20_21_22::None::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG 
607_607_21_22_19_20::None::by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS 
776470_0_18_20_33_35::None::diabetes/NN mellitus/NN induced/VBD kidney/NN failure/NN ,/, glomerulosclerosis/NN and/CC nephritis/NN resulting/VBG in/IN chronic/JJ kidney/NN disease/NN or/CC end/NN -/: stage/NN renal/JJ disease/NN ./. 
984_984_20_21_9_10::None::different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, 
862710_1_51_52_37_38::None::the/DT only/JJ agent/NN approved/VBN for/IN treating/VBG ALS/NNP However/RB ,/, several/JJ promising/JJ nanocarrier/NN approaches/NNS are/VBP surfacing/VBG that/IN can/MD provide/VB more/RBR efficient/JJ drug/NN 
149877_5_17_18_23_24::medicine.disease.symptoms::better/JJR post/NN -/: diagnosis/NN survival/NN than/IN those/DT cases/NNS whose/WP$ tumours/NNS lost/VBD p16/NN expression/NN 
245220_2_9_10_10_11::medicine.risk_factor.diseases::-/: 195/CD reduces/VBZ diabetic/JJ cardiomyopathy/NN in/IN a/DT mouse/NN 
326684_5_12_14_12_13::medicine.drug.active_moieties::tolerable/JJ as/IN liposomal/JJ amphotericin/NN B/NN The/DT most/RBS 
212_212_31_32_24_25::None::the/DT ectodomain/NN of/IN E-cadherin/NN and/CC the/DT actin/NN binding/NN site/NN of/IN alpha-catenin/NN ./. 
435_435_15_16_4_5::None::domains/NNS of/IN the/DT PRP21/NN splicing/NN factor/NN are/VBP implicated/VBN in/IN the/DT binding/NN to/TO PRP9/NN and/CC PRP11/NN proteins/NNS and/CC are/VBP 
770512_2_40_41_5_6::None::the/DT woman/NN presented/VBD high/JJ fever/NN ,/, myalgia/NN ,/, muscular/JJ weakness/NN ,/, mild/JJ headache/NN ,/, polyarthralgia/NN and/CC thrombocytopenia/NN reminding/VBG a/DT lupus/NN flare/NN ,/, but/CC since/IN the/DT number/NN of/IN people/NNS infected/VBN by/IN dengue/NN at/IN that/DT time/NN was/VBD high/JJ and/CC the/DT symptoms/NNS from/IN both/DT conditions/NNS 
1580_1580_25_26_23_24::None::its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
626703_0_15_17_24_25::None::with/IN decompensated/VBN alcoholic/JJ liver/NN cirrhosis/NN and/CC poorly/RB controlled/VBN non/JJ -/: insulin/NN -/: dependent/JJ diabetes/NN mellitus/NN who/WP 
626703_0_22_23_43_44::None::controlled/VBN non/JJ -/: insulin/NN -/: dependent/JJ diabetes/NN mellitus/NN who/WP was/VBD admitted/VBN with/IN a/DT 1/CD day/NN history/NN of/IN altered/JJ mental/JJ status/NN ,/, high/JJ -/: grade/NN fevers/NNS ,/, worsening/VBG jaundice/NN 
865_865_7_8_15_16::None::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) 
1114_1114_17_18_13_16::None::binding/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, p21/NN (/( Cip1/WAF1/NN )/) 
138_138_5_6_1_4::None::Another/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, p27KIP1/NN ,/, and/CC cyclin/NN 
430599_3_9_10_3_4::None::proteinuria/NN ,/, diminished/VBD GFR/NN )/) are/VBP more/RBR pronounced/JJ in/IN group/NN SP/NN than/IN normotensive/JJ 
2146_2146_9_10_6_7::None::that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN 
1777_1777_8_9_27_29::POS_REG(0)_LOCALIZE::the/DT Listeria/NN monocytogenes/NNS ActA/NN protein/NN controls/VBZ the/DT rate/NN of/IN actin-based/JJ motility/NN ,/, the/DT percentage/NN of/IN moving/VBG bacteria/NNS ,/, and/CC the/DT localization/NN of/IN vasodilator-stimulated/JJ phosphoprotein/NN and/CC profilin/NN ./. 
807498_0_23_25_29_30::medicine.disease.treatments::patients/NNS affected/VBN by/IN oral/JJ cancer/NN treated/VBN with/IN or/CC without/IN radiotherapy/NN ./. 
1534_1534_34_35_12_13::None::TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) are/VBP controversial/JJ 
1486_1486_60_61_35_40::None::MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
322_322_19_20_0_1::None::Cofilin/NNP and/CC profilin/NN may/MD also/RB be/VB involved/VBN in/IN the/DT redistribution/NN of/IN actin/NN during/IN myofibrillogenesis/NN and/CC in/IN the/DT process/NN of/IN actin/NN disassembly/NN in/IN degenerating/VBG 
98643_2_34_35_55_56::None::diary/NN ,/, the/DT Functional/JJ Living/VBG Index/NN -/: Emesis/NN (/( flie/NN )/) ,/, and/CC the/DT European/JJ Organisation/NNP for/IN Research/NNP and/CC Treatment/NN of/IN Cancer/NN Quality/NNP of/IN Life/NNP Questionnaire/NNP -/: C15/NNP 
372_372_9_10_30_31::POS_ACTION_INTERACT::virus/NN type/NN 1/CD UL8/NN protein/NN :/: effect/NN on/IN DNA/NN synthesis/NN and/CC ability/NN to/TO interact/VB with/IN and/CC influence/VB the/DT intracellular/JJ localization/NN of/IN the/DT UL5/NN and/CC UL52/NN proteins/NNS ./. 
225720_6_5_6_17_18::medicine.symptom.symptom_of::show/VBP that/IN primary/JJ tumors/NNS can/MD be/VB modeled/VBN in/IN immunocompetent/JJ mice/NNS by/IN microinjecting/VBG CCR9/NN -/: expressing/VBG cancer/NN cell/NN lines/NNS into/IN 
459561_0_24_27_18_19::None::2/CD inhibitor/NN ,/, compared/VBN with/IN placebo/NN in/IN patients/NNS with/IN type/NN 2/CD diabetes/NN (/( T2D/NN )/) 
2222_2222_21_22_19_20::None::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
422533_4_14_15_11_12::None::-/: hodgkin/NN whosewhat/NN lymphomas/NNS ,/, 21/CD patients/NNS (/( aged/JJ 35/CD 
191115_5_72_73_92_93::medicine.medical_treatment.used_to_treat::and/CC //: or/CC surgical/JJ staging/NN (/( Recommendation/NN grade/NN C/NN )/) 3/CD In/IN patients/NNS with/IN suspected/VBN or/CC proven/VBN &/CC lt/VBN ;/: 3/CD cm/NN peripheral/JJ NSCLC/NN with/IN normal/JJ mediastinal/JJ 
1701_1701_6_7_48_49::None::that/IN this/DT novel/JJ RhoGAP/NN is/VBZ involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
453075_8_29_30_22_23::people.cause_of_death.includes_causes_of_death::such/JJ as/IN decreased/VBN necrosis/NN and/CC resistance/NN to/TO contraction/NN -/: induced/VBN injury/NN ./. 
383627_0_35_37_2_3::None::Despite/IN adequate/JJ surgery/NN ,/, women/NNS affected/VBN by/IN advanced/JJ -/: stage/NN gynecological/JJ cancers/NNS (/( ovarian/JJ //: endometrial/JJ malignancies/NNS )/) carry/VBP an/DT extremely/RB poor/JJ prognosis/NN ;/: an/DT improved/VBN oncological/JJ prognosis/NN could/MD largely/RB depend/VB upon/IN the/DT enhancement/NN of/IN adjuvant/JJ treatment/NN ./. 
373923_0_86_87_31_33::medicine.risk_factor.diseases::to/TO asymptomatic/JJ structural/JJ heart/NN disease/NN (/( stage/NN B/NN )/) ,/, to/TO clinical/JJ manifestations/NNS of/IN heart/NN failure/NN (/( stage/NN C/NN )/) and/CC finally/RB end/NN -/: stage/NN or/CC refractory/JJ heart/NN failure/NN (/( stage/NN D/NN )/) This/DT review/NN outlines/VBZ the/DT key/JJ role/NN of/IN diabetes/NN mellitus/NN as/IN a/DT stage/NN A/DT risk/NN factor/NN for/IN heart/NN failure/NN with/IN preserved/JJ ejection/NN fraction/NN ,/, and/CC asymptomatic/JJ diabetic/JJ cardiomyopathy/NN ,/, referring/VBG 
268127_0_26_27_21_22::None::its/PRP$ ligand/NN ,/, SDF/NN -/: 1/CD ,/, promotes/VBZ migration/NN ,/, invasion/NN ,/, 
1061_1061_36_37_24_25::None::binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
88435_3_13_14_71_72::None::single/JJ -/: agent/NN chemotherapy/NN or/CC hormonal/JJ therapy/NN ,/, with/IN at/IN least/JJS three/CD distinct/JJ measurable/JJ sites/NNS of/IN disease/NN ,/, were/VBD treated/VBN with/IN concurrent/JJ radiotherapy/NN (/( 35/CD Gy/NN in/IN ten/CD fractions/NNS ,/, over/IN 2/CD weeks/NNS )/) to/TO one/CD metastatic/JJ site/NN and/CC granulocyte/NN -/: macrophage/NN colony/NN -/: stimulating/VBG factor/NN (/( 125/CD mug/NN //: m/NN (/( 2/CD )/) subcutaneously/RB injected/VBD daily/JJ for/IN 2/CD weeks/NNS ,/, starting/VBG during/IN the/DT second/JJ 
352038_4_0_1_12_13::None::Proteobacteria/NNP was/VBD the/DT most/RBS abundant/JJ ,/, followed/VBN by/IN Firmicutes/NNP ,/, Bacteroidetes/NNP and/CC Actinobacteria/NNP ./. 
254148_6_0_2_22_23::None::The/DT main/JJ examples/NNS are/VBP Bouffee/NNP Delirante/NNP ,/, and/CC the/DT complex/NN set/NN of/IN chronic/JJ delusional/JJ psychoses/NNS (/( CDPs/NNS )/) ,/, including/VBG chronic/JJ hallucinatory/JJ psychosis/NN ./. 
882908_0_10_11_6_7::biology.organism_classification.lower_classifications::of/IN the/DT Sharpnose/NN stingray/NN Himantura/NN gerrardi/NNS (/( Myliobatiformes/NNS :/: Dasyatidae/NNP )/) 
774440_0_16_18_24_25::None::diseases/NNS that/WDT include/VBP insulin/NN resistance/NN ,/, type/NN 2/CD diabetes/NN ,/, and/CC steatosis/NN of/IN the/DT liver/NN 
397285_3_7_8_11_12::people.cause_of_death.includes_causes_of_death::an/DT anti/JJ -/: inflammatory/JJ cytokine/NN associated/VBN with/IN tumour/NN malignancy/NN ,/, causes/VBZ 
1726_1726_14_15_23_24::POS_ACTION_MODIFY::increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
1498_1498_8_9_4_5::POS_ACTION_BIND::head/NN domain/NN of/IN talin/NN thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT 
1599_1599_29_30_22_23::None::that/DT of/IN a/DT talin/NN mediated/VBD mechanism/NN for/IN the/DT attachment/NN of/IN actin/NN filaments/NNS to/TO the/DT 
1782_1782_27_28_23_24::None::RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
307_307_12_13_12_13::POS_ACTION_INHIBIT::severing/VBG activity/NN of/IN gelsolin/NN and/CC cofilin/NN ./. 
1857_1857_17_18_9_11::None::quantitative/JJ conversion/NN of/IN platelet/NN profilin/NN and/CC gelsolin/NN to/TO high-affinity/JJ complexes/NNS with/IN actin/NN ,/, but/CC these/DT 
2222_2222_15_16_13_14::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, 
793106_10_25_26_46_47::None::,/, gender/NN ,/, disease/NN duration/NN ,/, tumor/NN size/NN ,/, basal/JJ hormone/NN levels/NNS ,/, relevant/JJ treatment/NN modalities/NNS ,/, and/CC relevant/JJ comorbidities/NNS )/) ,/, with/IN a/DT higher/JJR degree/NN of/IN psychopathology/NN 
1246_1246_29_31_31_32::POS_ACTION_MEMBER::IV/CD collagen/NN ,/, actin-binding/JJ protein/NN cofilin/NN ,/, profilin/NN and/CC 
1373_1373_4_5_11_12::NEG_ACTION_RELATE::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
483865_3_3_4_10_11::None::Here/RB we/PRP present/VBP measurements/NNS of/IN ocean/NN -/: derived/VBN particles/NNS containing/VBG reduced/VBN sulfur/NN ,/, detected/VBN 
597523_1_6_7_4_5::None::impact/NN of/IN UV/NN radiation/NN and/CC carbaryl/NN singly/RB and/CC in/IN 
1834_1834_15_17_6_7::POS_ACTION_BIND::three/CD structures/NNS of/IN actin/NN complexed/VBN with/IN different/JJ monomer-binding/JJ proteins/NNS ,/, namely/RB with/IN DNase/NN I/CD ,/, gelsolin/NN segment/NN 
639297_0_6_10_14_15::None::onset/NN sepsis/NN following/VBG peripherally/RB inserted/VBN central/JJ catheter/NN removal/NN :/: association/NN with/IN antibiotic/JJ use/NN and/CC adverse/JJ 
712_712_27_28_11_12::POS_ACTION_BIND::to/TO suggest/VB that/IN HRG/NN stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN ./. 
573489_1_14_15_22_23::None::a/DT plastic/NN and/CC reconstructive/JJ surgeon/NN after/IN the/DT initial/JJ diagnosis/NN of/IN breast/NN cancer/NN ./. 
801582_5_28_29_1_2::None::A/DT fresh/JJ full/JJ thickness/NN biopsy/NN sample/NN was/VBD taken/VBN from/IN the/DT center/NN of/IN the/DT burn/VBP wound/NN ,/, the/DT burn/VBP wound/NN edge/NN ,/, and/CC the/DT graft/NN donor/NN site/NN in/IN 7/CD patients/NNS (/( n/NN =/JJ 
412955_2_16_17_22_23::None::higher/JJR risk/NN of/IN pregnancy/NN complications/NNS compared/VBN with/IN spontaneously/RB conceived/VBN pregnancies/NNS ./. 
928918_0_3_4_5_6::None::Long/JJ -/: term/NN consequences/NNS of/IN anesthetic/JJ technique/NN after/IN cancer/NN 
212_212_27_28_27_28::None::E-cadherin/NN and/CC the/DT actin/NN binding/NN site/NN of/IN 
1052_1052_21_22_37_38::POS_ACTION_INITIATE::oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
367_367_26_27_32_33::None::as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
2107_2107_24_26_27_28::POS_ACTION_MEMBER::bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
93_93_50_51_57_58::POS_ACTION_DOWNREGULATE::as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
8_8_2_3_13_14::None::Abundance/NN of/IN actin/NN ,/, talin/NN ,/, alpha/NN 5/CD and/CC beta/NN 1/CD integrins/NNS ,/, pp125/CD focal/JJ adhesion/NN kinase/NN 
315964_1_10_11_4_5::None::pieces/NNS of/IN evidence/NN support/VBP the/DT idea/NN that/IN exposure/NN to/TO trace/NN and/CC toxic/JJ metals/NNS 
768_768_24_27_13_14::None::of/IN the/DT parental/JJ profilin/NN ,/, and/CC the/DT Kd/NN value/NN of/IN its/PRP$ interaction/NN with/IN rabbit/NN skeletal/JJ muscle/NN actin/NN ,/, as/IN determined/VBN 
1486_1486_41_44_4_5::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
537465_2_10_11_16_17::medicine.symptom.symptom_of::of/IN T/NN cell/NN exhaustion/NN ,/, placing/VBG recent/JJ findings/NNS on/IN PD/NN -/: 1/CD blockade/NN 
489059_5_0_1_12_13::medicine.drug_ingredient.active_moiety_of_drug::Silver/NN nanoparticles/NNS were/VBD not/RB detected/VBN in/IN food/NN simulants/NNS ,/, suggesting/VBG that/IN the/DT silver/JJ migration/NN may/MD be/VB 
2131_2131_10_11_7_8::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN 
1534_1534_9_10_12_13::None::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ 
331938_2_24_25_26_27::None::improve/VB ischemic/JJ myocardial/JJ metabolism/NN ,/, scavenge/VB free/JJ radicals/NNS and/CC 
1227_1227_2_3_10_11::None::Saccharomyces/FW cerevisiae/FW RAD14/NN was/VBD identified/VBN in/IN a/DT two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN 
607_607_23_24_8_9::POS_ACTION_ENCODE::expresses/VBZ a/DT heterotrimeric/JJ helicase-primase/NN ,/, the/DT subunits/NNS of/IN which/WDT are/VBP encoded/VBN by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS ./. 
415007_0_27_28_23_24::None::-/: cholesterol/NN (/( LDL/NN -/: C/NN )/) concentration/NN ,/, causing/VBG premature/JJ 
959107_3_15_17_6_9::biology.organism_classification.lower_classifications::effective/JJ vaccine/NN against/IN influenza/NN A/NN viruses/NNS ,/, a/DT chimerical/JJ DNA/NN plasmid/NN encoding/VBG Influenza/NN virus/NN M2/NN protein/NN and/CC 
510261_8_11_12_24_25::None::used/VBN as/IN an/DT adjunct/NN to/TO chemotherapy/NN had/VBD a/DT benefit/NN in/IN the/DT management/NN of/IN dialysisdependent/JJ multiple/JJ myeloma/NN patients/NNS with/IN renal/JJ failure/NN 
309692_18_29_30_22_23::None::restricted/JJ to/TO the/DT acute/JJ effect/NN of/IN these/DT LAMAs/NNS and/CC the/DT inhaled/VBN doses/NNS were/VBD not/RB 
616400_0_8_9_9_10::None::mexicanum/NN ,/, the/DT Mexican/JJ axolotl/NN ./. 
63_63_25_26_49_50::None::electrophoresis/NN :/: histone/NN H1/NN (/( 0/CD )/) ,/, four/CD histone/NN H1/NN subfractions/NNS ,/, histone/NN H2A/NN .1/NN ,/, histone/NN H2A/NN .2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN 
1522_1522_15_16_10_11::POS_ACTION_INTERACT::virus/NN phosphoprotein/NN (/( P/NN )/) and/CC nucleocapsid/NN (/( N/NN )/) protein/NN has/VBZ 
1515_1515_21_22_26_27::None::focal/JJ adhesion/NN protein/NN talin/NN and/CC the/DT yeast/NN protein/NN Sla2p/NN ./. 
865_865_21_24_33_35::POS_ACTION_BIND::)/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
214438_2_21_23_1_2::None::Forty/CD SD/NN rats/NNS were/VBD randomly/RB divided/VBN into/IN sham/NN group/NN (/( A/DT group/NN )/) and/CC hypoxia/NN //: reoxygenation/NN group/NN (/( H/NN //: R/NN group/NN )/) ./. 
488875_3_7_8_10_12::None::suggest/VBP a/DT hybrid/NN confirmed/VBN by/IN the/DT ancient/JJ DNA/NN analyses/NNS resulting/VBG in/IN 
431_431_6_7_0_1::None::END5/NN encodes/VBZ a/DT proline-rich/JJ protein/NN (/( End5p/NN or/CC verprolin/NN )/) 
176735_0_48_49_45_47::None::-/: photon/NN emission/NN computed/VBD tomography/NN (/( SPECT/NN )/) brain/NN images/NNS 
245_245_2_3_10_11::POS_ACTION_BIND::Neuropilin-1/NN (/( NRP1/NN )/) is/VBZ a/DT 130-kDa/JJ transmembrane/NN receptor/NN for/IN semaphorins/NNS ,/, mediators/NNS of/IN 
1850_1850_0_1_8_9::POS_ACTION_BIND::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ 
405799_1_19_20_28_29::None::genetic/JJ variants/NNS of/IN CRP/NN are/VBP associated/VBN with/IN DR/NN A/NN total/NN of/IN 1,018/CD patients/NNS with/IN type/NN 2/CD 
1793_1793_4_5_14_15::None::viscoelasticity/NN of/IN entangled/JJ actin/NN networks/NNS :/: the/DT influence/NN of/IN defects/NNS and/CC modulation/NN by/IN talin/NN and/CC vinculin/NN ./. 
194621_0_7_8_9_10::None::lifestyle/NN ,/, the/DT technology/NN of/IN active/JJ and/CC biodegradable/JJ packaging/NN 
550981_1_4_5_11_12::None::results/VBZ from/IN increased/VBN resistance/NN to/TO portal/JJ blood/NN flow/NN through/IN the/DT cirrhotic/JJ liver/NN ./. 
355_355_12_13_25_26::POS_ACTION_BIND::mutant/JJ form/NN of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD form/VB a/DT structural/JJ complex/NN with/IN E-cadherin/NN via/IN these/DT interactions/NNS 
360_360_8_9_13_14::None::of/IN the/DT N-terminal/JJ actin/NN binding/NN domain/NN of/IN human/JJ fimbrin/NN ./. 
728820_2_11_12_6_7::None::outcomes/NNS in/IN elderly/JJ men/NNS undergoing/VBG LVP/NN for/IN lower/JJR urinary/JJ tract/NN symptoms/NNS secondary/JJ 
725268_1_23_24_5_6::None::results/NNS indicated/VBD a/DT linear/JJ relationship/NN ,/, it/PRP is/VBZ not/RB clear/JJ what/WP role/NN the/DT observed/VBN bias/NN toward/IN the/DT time/NN -/: left/VBD option/NN plays/NNS in/IN this/DT procedure/NN 
1871_1871_10_11_16_17::None::the/DT association/NN between/IN E-cadherin/NN and/CC alpha-catenin/NN is/VBZ mediated/VBN by/IN beta-catenin/NN ,/, and/CC that/IN 
1486_1486_4_5_24_25::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN 
93_93_6_7_57_58::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
768572_0_21_22_4_7::medicine.disease.treatments::utility/NN of/IN intravenous/JJ tissue/NN plasminogen/NN activator/NN (/( IV/CD t/NN -/: PA/NN )/) in/IN improving/VBG the/DT clinical/JJ outcomes/NNS after/IN acute/JJ ischemic/JJ stroke/NN has/VBZ been/VBN well/RB 
773440_1_41_42_0_1::None::All/DT five/CD TNF/NN inhibitors/NNS currently/RB available/JJ on/IN the/DT market/NN (/( ie/FW ,/, etanercept/NN ,/, infliximab/NN ,/, adalimumab/NN ,/, certolizumab/NN and/CC golimumab/NN )/) are/VBP top/JJ sellers/NNS ,/, although/IN indicated/VBN only/RB in/IN autoimmune/JJ diseases/NNS ,/, including/VBG rheumatoid/JJ arthritis/NN ,/, Crohn/NN whosewhat/NN disease/NN and/CC psoriasis/NN ./. 
1508_1508_16_18_5_6::None::simplex/NN virus/NN type-1/NN UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS encode/VBP an/DT essential/JJ heterotrimeric/JJ DNA/NN helicase-primase/NN that/WDT is/VBZ responsible/JJ 
1380_1380_26_27_24_25::None::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD 
239458_5_41_43_32_33::None::2/CD )/) ,/, panic/NN disorder/NN (/( n/NN =/JJ 2/CD )/) ,/, and/CC social/JJ phobia/NN (/( n/NN =/JJ 
373723_3_0_1_6_7::None::We/PRP performed/VBD a/DT systematic/JJ review/NN to/TO determine/VB the/DT current/JJ worldwide/JJ 
712_712_11_12_15_16::POS_ACTION_UPREGULATE::to/TO suggest/VB that/IN HRG/NN stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN 
1289_1289_11_12_13_14::None::)/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN bovine/JJ 
245220_2_1_2_13_15::None::We/PRP investigated/VBD whether/IN silencing/NN of/IN miR/NN -/: 195/CD reduces/VBZ diabetic/JJ cardiomyopathy/NN in/IN a/DT mouse/NN model/NN of/IN streptozotocin/NN (/( 
322750_1_36_37_4_5::None::addition/NN ,/, we/PRP investigated/VBD detrimental/JJ side/JJ effects/NNS in/IN terms/NNS of/IN the/DT release/NN of/IN nitrite/NN (/( NO2/NN -/: N/NN )/) ,/, ammonium/NN (/( NH4/NN -/: N/NN )/) ,/, phosphate/NN (/( PO4/NN -/: P/NN )/) ,/, dissolved/VBN organic/JJ carbon/NN (/( DOC/NN 
143793_11_38_39_17_19::None::(/( 95/CD %/NN confidence/NN interval/NN =/JJ 1.55/CD -/: 1.96/CD )/) in/IN patients/NNS with/IN COPD/NN compared/VBN with/IN patients/NNS without/IN COPD/NNP after/IN adjusting/VBG for/IN age/NN ,/, gender/NN ,/, and/CC comorbidities/NNS 
119767_6_31_32_26_27::None::angiogenic/JJ ability/NN of/IN PB/NN -/: ECFCs/NNS in/IN fibrin/JJ matrices/NNS ./. 
755_755_9_10_4_5::None::cultured/VBN cells/NNS ,/, cofilin/NN ,/, as/RB well/RB as/IN ADF/NN ,/, translocates/VBZ from/IN 
334920_0_20_21_3_4::biology.organism_classification.lower_classifications::Studies/NNS of/IN the/DT retroviruses/NNS have/VBP focused/VBN on/IN the/DT specific/JJ interaction/NN of/IN the/DT nucleocapsid/JJ protein/NN with/IN a/DT packaging/NN signal/NN in/IN the/DT viral/JJ RNA/NN as/IN important/JJ 
1486_1486_32_33_60_61::POS_ACTION_STIMULATE::protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
1055_1055_22_23_0_1::POS_REG(+)_PHOSPHORYLATE::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC E2F/NN 
757758_7_23_25_27_28::medicine.disease.symptoms::often/RB have/VBP preexisting/VBG gastrointestinal/JJ illness/NN and/CC longer/JJR duration/NN of/IN time/NN from/IN 
123245_6_53_54_38_39::None::transport/NN and/CC membrane/NN organization/NN proteins/NNS (/( FABP5/NN ,/, GC/NN ,/, and/CC EHD2/NN )/) ,/, chaperons/NNS (/( FKBP4/NN and/CC HSPD1/NN )/) and/CC known/VBN 
72723_0_7_10_6_7::medicine.risk_factor.diseases::a/DT consequence/NN of/IN chronic/JJ high/JJ blood/NN pressure/NN ,/, is/VBZ increasingly/RB 
948941_3_10_11_16_17::medicine.disease.treatments::on/IN anti/JJ -/: epileptic/JJ medication/NN use/NN :/: those/DT taking/VBG carbamazepine/NN //: oxcarbazepine/NN (/( 
324666_0_16_18_9_10::None::of/IN the/DT most/RBS common/JJ causes/NNS of/IN hereditary/JJ non/JJ -/: spherocytic/JJ hemolytic/JJ anemias/NNS ./. 
2146_2146_6_7_14_15::POS_ACTION_PHOSPHORYLATE::that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
72_72_19_20_0_1::POS_ACTION_SUPPRESS::Aip1p/NN localizes/VBZ to/TO cortical/JJ actin/NN patches/NNS in/IN yeast/NN cells/NNS ,/, and/CC this/DT localization/NN is/VBZ disrupted/VBN by/IN specific/JJ actin/NN and/CC cofilin/NN mutations/NNS ./. 
393131_1_16_17_9_10::None::colonization/NN include/VBP the/DT ability/NN of/IN the/DT mycoplasma/NN to/TO form/VB a/DT biofilm/NN on/IN epithelial/JJ surfaces/NNS 
638398_10_2_3_10_11::biology.organism_classification.lower_classifications::In/IN the/DT murine/JJ tumor/NN model/NN ,/, PA/NN -/: MSHA/NNP prolonged/VBD mice/NNS survival/NN and/CC reduced/VBN 
439403_7_34_35_9_10::None::depressed/JJ showed/VBD greater/JJR pain/NN interference/NN ,/, lower/JJR quality/NN of/IN life/NN ,/, more/JJR sleep/NN problems/NNS ,/, and/CC greater/JJR functional/JJ disability/NN than/IN nondepressed/JJ patients/NNS ;/: the/DT two/CD groups/NNS did/VBD not/RB differ/VB in/IN pain/NN severity/NN 
1657_1657_8_9_12_13::POS_ACTION_BIND::with/IN respect/NN to/TO cofilin/NN binding/NN to/TO filamentous/JJ actin/NN which/WDT may/MD be/VB 
822180_0_28_29_23_24::None::without/IN the/DT major/JJ immunological/JJ complications/NNS associated/VBN with/IN allogeneic/JJ transplantation/NN ./. 
72_72_0_1_19_20::None::Aip1p/NN localizes/VBZ to/TO cortical/JJ actin/NN patches/NNS in/IN yeast/NN cells/NNS ,/, and/CC this/DT localization/NN is/VBZ disrupted/VBN by/IN specific/JJ actin/NN and/CC cofilin/NN mutations/NNS ./. 
907653_2_35_36_54_55::None::Web/NN -/: based/VBN illness/NN management/NN system/NN for/IN breast/NN cancer/NN patients/NNS (/( IPPC/NN included/VBN )/) ,/, and/CC (/( 3/LS )/) usual/JJ care/NN on/IN symptom/NN distress/NN ,/, anxiety/NN 
670852_3_13_14_3_5::medicine.symptom.symptom_of::86/CD newly/RB diagnosed/VBN breast/NN cancer/NN patients/NNS with/IN estrogen/NN receptor/NN (/( ER/NN )/) positive/JJ tumors/NNS ,/, who/WP referred/VBD 
1095_1095_35_36_11_12::POS_ACTION_MODIFY::adhesion/NN pattern/NN ,/, actin/NN organization/NN ,/, and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ proteins/NNS are/VBP dependent/JJ on/IN the/DT supramolecular/JJ organization/NN of/IN the/DT collagens/NNS ./. 
1380_1380_38_39_40_41::POS_ACTION_BIND::,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN 
1055_1055_22_23_2_3::POS_REG(+)_PHOSPHORYLATE::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC E2F/NN 
389675_10_10_11_8_9::people.cause_of_death.includes_causes_of_death::in/IN patients/NNS with/IN blunt/JJ head/NN trauma/NN is/VBZ important/JJ ./. 
668570_12_25_26_21_22::None::depressive/JJ symptoms/NNS run/VBP counter/RB to/TO other/JJ available/JJ evidence/NN ,/, potentially/RB attributable/JJ 
215150_5_13_14_1_3::None::A/DT multiple/JJ regression/NN analysis/NN for/IN within/IN -/: subject/JJ mediation/NN indicated/VBD that/IN improvements/NNS in/IN depressive/JJ symptoms/NNS were/VBD partially/RB 
745266_0_10_11_25_26::None::patients/NNS diagnosed/VBN with/IN type/NN -/: 2/CD diabetes/NN ;/: however/RB ,/, the/DT impact/NN of/IN different/JJ treatment/NN escalation/NN strategies/NNS after/IN metformin/JJ failure/NN has/VBZ thus/RB 
266669_0_28_29_13_14::None::(/( AF/NN )/) treated/VBN with/IN warfarin/NN had/VBD a/DT cortical/JJ left/JJ middle/JJ cerebral/JJ artery/NN (/( MCA/NNP )/) stroke/NN (/( October/NNP 2009/CD ,/, international/JJ 
157_157_24_25_1_2::None::Archaeal/NNP histones/NNS are/VBP most/RBS similar/JJ to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN 
93_93_4_5_22_23::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN 
1860_1860_21_22_2_3::None::Thus/RB ,/, alpha-syntrophin/NN has/VBZ an/DT important/JJ role/NN in/IN synapse/NN formation/NN and/CC in/IN the/DT organization/NN of/IN utrophin/NN ,/, acetylcholine/NN receptor/NN ,/, and/CC acetylcholinesterase/NN at/IN the/DT neuromuscular/JJ 
16153_0_14_15_16_17::None::in/IN trials/NNS evaluating/VBG fludarabine/NN ,/, cyclophosphamide/NN ,/, and/CC rituximab/NN 
240152_0_66_67_68_69::medicine.drug.active_moieties::Ni/NN )/) ,/, chromium/NN (/( Cr/NN )/) and/CC arsenic/NN 
358_358_25_26_20_21::None::for/IN the/DT HSV/NN helicase-primase/JJ complex/NN (/( UL5/NN ,/, UL8/NN ,/, UL52/NN )/) 
1074_1074_10_11_7_8::None::including/VBG vinculin/NN ,/, talin/NN ,/, and/CC ezrin/NN ,/, are/VBP not/RB 
332030_3_9_10_19_20::medicine.disease.symptoms::blood/NN pressure/NN and/CC cardiovascular/JJ remodeling/NN in/IN rats/NNS with/IN DOCA/NN -/: salt/NN -/: induced/VBN hypertension/NN were/VBD investigated/VBN ./. 
490714_0_3_4_9_10::None::Species/NNP richness/NN and/CC macronutrient/JJ content/NN of/IN wawo/NN worms/NNS (/( Polychaeta/NN ,/, Annelida/NN )/) 
497715_6_38_39_36_39::people.cause_of_death.includes_causes_of_death::of/IN type/NN 2/CD diabetes/NN -/: related/JJ stigma/NN 
243_243_0_2_27_28::POS_ACTION_BIND::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN 
374_374_14_15_12_13::None::but/CC deletion/NN of/IN SIR1/NN or/CC SIR3/NN did/VBD not/RB affect/VB 
1782_1782_23_24_11_12::None::)/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC 
442979_9_5_6_14_15::medicine.medical_treatment.used_to_treat::demonstrate/VBP firstly/RB that/IN cocaine/NN may/MD not/RB be/VB the/DT most/RBS suitable/JJ agent/NN for/IN assessing/VBG direct/JJ versus/CC indirect/JJ 
25905_6_2_3_27_28::medicine.drug.active_moieties::Subsequently/RB ,/, nitrate/JJ concentration/NN in/IN the/DT feed/NN was/VBD increased/VBN in/IN a/DT step/NN -/: wise/JJ manner/NN to/TO establish/VB complete/JJ denitrification/NN of/IN 5420/CD mg/NN L/NN (/( -/: 1/LS )/) NO3/NN -/: N/NN at/IN 
459829_1_16_17_7_8::None::the/DT surface/NN of/IN mesoporous/JJ TiO/NN (/( 2/CD )/) by/IN the/DT decomposition/NN of/IN magnesium/NN acetate/NN and/CC ,/, 
873835_0_10_11_43_46::medicine.medical_treatment.used_to_treat::a/DT relatively/RB new/JJ procedure/NN that/WDT has/VBZ gained/VBN popularity/NN in/IN the/DT last/JJ couple/NN of/IN decades/NNS as/IN a/DT possible/JJ alternative/NN to/TO a/DT meniscectomy/NN to/TO provide/VB significant/JJ pain/NN relief/NN ,/, improve/VB function/NN ,/, and/CC prevent/VB the/DT early/JJ onset/NN of/IN degenerative/JJ joint/JJ disease/NN (/( DJD/NN )/) 
176735_0_9_10_7_8::medicine.drug.active_moieties::of/IN heroin/NN and/CC methamphetamine/NN (/( METH/NN )/) addiction/NN on/IN 
410_410_11_12_11_12::None::histone/NN H3/NN and/CC histone/NN H4/NN were/VBD inviable/JJ 
14901_2_11_12_32_33::None::cysteine/NN substitutions/NNS on/IN alpha/NN -/: helix/NN regions/NNS of/IN 2/LS -/: Cys/NN Prx/NN A/NN in/IN Arabidopsis/NNP mutants/NNS and/CC the/DT effects/NNS they/PRP have/VBP on/IN the/DT dual/JJ function/NN of/IN the/DT protein/NN 
93_93_6_7_50_51::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
1782_1782_23_24_25_26::POS_ACTION_MUTUALCOMPLEX::RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: 
1052_1052_18_20_34_35::POS_REG(+)_DISASSEMBLE::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN 
2076_2076_42_43_42_43::POS_ACTION_SQSIMILAR::identical/JJ to/TO porcine/NN Cof/NN ./. 
1069_1069_24_25_46_47::None::helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
132437_10_2_3_5_6::None::The/DT optimal/JJ therapeutic/JJ ranges/NNS of/IN INR/NN in/IN the/DT stratified/JJ 
1233_1233_30_31_19_24::None::,/, desmin/NN and/CC smooth/VB muscle/NN myosin/NN heavy/JJ chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
436129_1_10_11_17_18::None::that/IN ASA/NN use/NN reduces/VBZ the/DT risk/NN of/IN different/JJ cancers/NNS including/VBG breast/NN cancer/NN (/( BC/NN 
38849_2_21_22_2_3::None::1/CD are/VBP rare/JJ in/IN human/JJ acute/JJ myeloid/JJ leukemia/NN (/( AML/NN )/) ,/, they/PRP are/VBP common/JJ in/IN murine/JJ models/NNS of/IN radiation/NN -/: induced/VBN AML/NN ,/, and/CC 
1748_1748_19_20_27_28::None::in/IN reorganization/NN of/IN actin/NN filaments/NNS and/CC membrane/NN structures/NNS ,/, by/IN phosphorylating/VBG cofilin/ADF/NN proteins/NNS ./. 
713526_5_0_1_13_14::medicine.medical_treatment.used_to_treat::Carbamazepine/NNP was/VBD found/VBN to/TO have/VB strong/JJ preclinical/JJ data/NNS for/IN the/DT treatment/NN of/IN comorbid/JJ bipolar/JJ mood/NN disorder/NN and/CC 
814864_2_12_13_0_1::None::To/TO our/PRP$ knowledge/NN ,/, however/RB ,/, sensitization/NN profiles/NNS among/IN children/NNS hospitalized/VBN for/IN asthma/NN are/VBP unknown/JJ ./. 
73717_0_57_58_32_33::None::OARs/NNS )/) in/IN patients/NNS with/IN high/JJ -/: risk/NN prostate/NN cancer/NN (/( PCa/NN )/) to/TO be/VB treated/VBN with/IN whole/JJ pelvic/JJ radiation/NN therapy/NN (/( WPRT/NN )/) in/IN an/DT attempt/NN to/TO define/VB the/DT hostile/JJ pelvis/NN 
345363_0_15_17_0_1::None::Factor/NN structure/NN and/CC psychometric/JJ properties/NNS of/IN the/DT TFEQ/NN in/IN morbid/JJ obese/JJ patients/NNS ,/, candidates/NNS to/TO bariatric/JJ surgery/NN ./. 
402511_2_17_18_24_25::None::malaria/NN parasite/NN -/: specific/JJ metabolites/NNS in/IN Plasmodium/NN falciparum/NN in/FW vitro/FW culture/NN samples/NNS ./. 
398_398_8_9_20_21::POS_ACTION_BIND::acids/NNS )/) of/IN PRT1/NN and/CC TIF35/NN were/VBD found/VBN to/TO be/VB responsible/JJ for/IN their/PRP$ binding/NN to/TO TIF34/NN ./. 
491928_0_10_11_11_12::None::in/IN schizophrenia/NN -/: spectrum/NN psychoses/NNS :/: A/DT first/JJ 
735_735_11_12_24_25::None::sensitivity/NN of/IN a/DT tropomyosin/NN mutant/NN ,/, and/CC the/DT loss/NN of/IN cytoplasmic/JJ cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, and/CC tropomyosin/NN 
1652_1652_43_44_18_19::None::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, 
1994_1994_8_9_10_11::POS_ACTION_BIND::we/PRP show/VBP that/IN verprolin/NN binds/VBZ actin/NN ./. 
1052_1052_34_35_29_30::None::with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN 
394127_6_0_1_32_33::None::The/DT most/RBS common/JJ primary/JJ malignancy/NN sites/NNS were/VBD colon/NN (/( 33.2/CD %/NN )/) ,/, endometrium/NN (/( 17.1/CD %/NN )/) ,/, breast/NN (/( 14.3/CD %/NN )/) ,/, appendix/NN (/( 7.3/CD %/NN )/) ,/, and/CC stomach/NN (/( 4.5/CD %/NN 
505690_0_2_3_2_4::biology.organism_classification.lower_classifications::Distribution/NN of/IN Candida/NN albicans/NNS and/CC non/JJ -/: 
712_712_15_16_23_24::None::stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN 
1866_1866_7_8_3_4::POS_ACTION_Change::Thus/RB ,/, both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, 
1889_1889_7_8_11_13::POS_ACTION_ACTIVATE::proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN acid/NN sphingomyelinase/NN ./. 
326118_0_51_52_61_63::None::acute/JJ treatment/NN of/IN migraine/NN in/IN a/DT double/JJ -/: dummy/NN ,/, randomized/VBN comparative/JJ efficacy/NN clinical/JJ trial/NN allowing/VBG treatment/NN across/IN 
323448_0_7_9_21_22::None::experience/NN with/IN carbon/NN ion/NN irradiation/NN in/IN the/DT treatment/NN of/IN gross/JJ residual/JJ or/CC unresectable/JJ malignant/JJ peripheral/JJ nerve/NN sheath/NN tumors/NNS (/( MPNST/NN )/) 
402845_14_13_14_25_26::people.cause_of_death.includes_causes_of_death::efficiently/RB reproduces/VBZ the/DT inflammatory/JJ ,/, US/NNP ,/, SF/NNP and/CC histopathological/JJ changes/NNS of/IN the/DT human/JJ acute/JJ gouty/JJ attack/NN ./. 
254148_6_9_10_0_2::None::The/DT main/JJ examples/NNS are/VBP Bouffee/NNP Delirante/NNP ,/, and/CC the/DT complex/NN set/NN of/IN chronic/JJ 
854528_1_15_16_17_19::biology.organism_classification.lower_classifications::collected/VBN from/IN 51/CD camels/NNS (/( Camelus/JJ dromedarius/NN )/) in/IN Kano/NNP 
113665_4_82_83_91_92::medicine.drug.active_moieties::of/IN serial/JJ inhibitory/JJ GABAergic/NN circuitry/NN rather/RB than/IN a/DT direct/JJ facilitatory/JJ effect/NN on/IN GABA/NN release/NN onto/IN rod/NN 
1052_1052_12_13_6_8::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT 
1095_1095_17_18_35_36::None::and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ proteins/NNS are/VBP dependent/JJ on/IN the/DT supramolecular/JJ organization/NN of/IN the/DT collagens/NNS ./. 
373757_6_37_40_24_26::None::,/, hypertension/NN ,/, atrial/JJ fibrillation/NN ,/, hyperlipidaemia/NN ,/, chronic/JJ kidney/NN disease/NN ,/, ischaemic/JJ heart/NN disease/NN ,/, peripheral/JJ arterial/JJ disease/NN and/CC left/VBD ventricular/JJ 
151_151_6_7_0_1::None::Aprotinin/NN inhibited/VBD platelet/NN aggregation/NN induced/VBN by/IN thrombin/NN (/( 0.25/CD U.ml-1/NN 
499291_35_20_21_14_15::None::be/VB significantly/RB different/JJ depending/VBG on/IN ethnicity/NN ,/, obesity/NN and/CC age/NN ./. 
813_813_23_24_27_28::POS_ACTION_BIND::of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN P/NN is/VBZ essential/JJ for/IN 
373923_0_128_129_63_64::None::)/) This/DT review/NN outlines/VBZ the/DT key/JJ role/NN of/IN diabetes/NN mellitus/NN as/IN a/DT stage/NN A/DT risk/NN factor/NN for/IN heart/NN failure/NN with/IN preserved/JJ ejection/NN fraction/NN ,/, and/CC asymptomatic/JJ diabetic/JJ cardiomyopathy/NN ,/, referring/VBG to/TO the/DT presence/NN of/IN left/JJ ventricular/JJ diastolic/JJ dysfunction/NN in/IN diabetic/JJ patients/NNS without/IN coronary/JJ artery/NN disease/NN ,/, hypertension/NN or/CC other/JJ potential/JJ aetiologies/NNS ,/, as/IN an/DT expression/NN of/IN stage/NN B/NN heart/NN failure/NN with/IN preserved/JJ ejection/NN fraction/NN at/IN high/JJ risk/NN of/IN transitioning/VBG to/TO symptomatic/JJ stage/NN 
1861_1861_12_13_10_11::None::containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
1344_1344_22_23_20_21::None::helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, indicates/VBZ that/IN 
583_583_4_5_10_11::None::we/PRP report/VBP that/IN p120/NN associates/NNS with/IN a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, 
238_238_0_1_23_24::None::MSH3/NN appears/VBZ to/TO be/VB more/RBR closely/RB related/JJ to/TO the/DT mouse/NN Rep-3/NN gene/NN and/CC other/JJ similar/JJ eukaryotic/JJ mutS/NN homologues/NNS than/IN to/TO the/DT yeast/NN gene/NN MSH2/NN and/CC other/JJ mutS/NN 
1008_1008_4_5_2_3::None::Mutants/NNS of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP 
831553_2_24_26_5_7::None::are/VBP associated/VBN with/IN morbid/JJ obesity/NN ,/, including/VBG psychological/JJ (/( eg/FW ,/, depression/NN )/) ,/, physiological/JJ (/( eg/FW ,/, hypothyroidism/NN )/) mechanisms/NNS ,/, sleep/VB disorders/NNS (/( eg/FW ,/, 
856_856_24_25_22_23::None::,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT 
427379_2_21_22_7_8::None::the/DT chronic/JJ intermittent/JJ hypoxia/NN (/( CIH/NN )/) of/IN OSAS/NN patients/NNS may/MD per/FW se/FW trigger/NN liver/NN injury/NN ,/, inflammation/NN ,/, and/CC fibrogenesis/NN 
452997_6_5_6_21_22::None::Klotho/NNP augmented/VBD the/DT Epo/NN -/: triggered/JJ phosphorylation/NN of/IN Jak2/NN and/CC Stat5/NN and/CC protected/VBD H19/NN -/: 7/CD cells/NNS from/IN hydrogen/NN peroxide/NN cytotoxicity/NN ./. 
726738_8_14_16_20_22::None::,/, breast/NN and/CC colorectal/JJ cancers/NNS than/IN for/IN those/DT treating/VBG hematological/JJ malignancies/NNS (/( all/DT p/NN 
398_398_10_11_8_9::None::acids/NNS )/) of/IN PRT1/NN and/CC TIF35/NN were/VBD found/VBN to/TO 
763530_0_40_43_1_2::medicine.disease.risk_factors::Abdominal/JJ obesity/NN and/CC increasing/VBG body/NN mass/NN index/NN are/VBP risk/NN factors/NNS for/IN esophageal/NN adenocarcinoma/NN and/CC its/PRP$ main/JJ precursor/NN ,/, Barrett/NNP whosewhat/NN esophagus/NN ;/: however/RB ,/, there/EX are/VBP no/DT known/JJ biological/JJ mechanisms/NNS for/IN these/DT associations/NNS or/CC regarding/VBG why/WRB only/RB some/DT patients/NNS with/IN gastroesophageal/NN reflux/NN disease/NN develop/VBP Barrett/NNP whosewhat/NN 
492_492_25_27_17_19::None::that/IN ,/, like/IN beta/NN 1-syntrophin/NN ,/, both/CC beta/NN 2/CD -/: and/CC alpha/NN 1-syntrophin/JJ interact/NN with/IN peptides/NNS 
240510_12_0_1_10_11::None::In/IN contrast/NN ,/, four/CD of/IN the/DT more/RBR recently/RB named/VBN gastropod/NN clades/NNS (/( Vetigastropoda/NNP ,/, 
13_13_1_2_14_15::POS_REG(-)_POLYMERIZE::Acanthamoeba/NN profilin/NN strongly/RB inhibits/VBZ in/IN a/DT concentration-dependent/JJ fashion/NN the/DT rate/NN and/CC extent/NN of/IN Acanthamoeba/NN actin/NN polymerization/NN in/IN 50/CD 
30174_0_0_1_23_24::None::Effect/NN of/IN 23/CD -/: Valent/NNP Pneumococcal/NNP Polysaccharide/NNP Vaccine/NNP Inoculated/NNP During/IN Anti/NNP -/: Cancer/NNP Treatment/NNP Period/NN in/IN Elderly/NNP Lung/NN Cancer/NN Patients/NNS on/IN Community/NN -/: Acquired/VBN Pneumonia/NNP Hospitalization/NNP :/: 
890409_7_1_2_23_24::None::The/DT Data/NNP collected/VBN were/VBD demographic/JJ information/NN about/IN the/DT patients/NNS (/( age/NN and/CC sex/NN )/) ,/, clinical/JJ condition/NN (/( diagnosis/NN and/CC the/DT length/NN of/IN hospital/NN stay/NN )/) and/CC 
432927_5_15_16_0_2::None::Animal/NN models/NNS ,/, imaging/NN and/CC pharmacological/JJ studies/NNS concur/VBP in/IN pointing/VBG out/RP dopaminergic/JJ denervation/NN in/IN the/DT aetiology/NN of/IN parkinsonian/JJ apathy/NN 
116203_2_16_17_44_45::None::view/NN in/IN colorectal/JJ ESD/NN From/IN April/NNP 2009/CD to/TO December/NNP 2013/CD ,/, 130/CD colorectal/JJ tumors/NNS were/VBD examined/VBN in/IN 128/CD patients/NNS treated/VBN with/IN ESD/NN A/NN total/NN of/IN 119/CD patients/NNS with/IN a/DT mean/JJ tumor/NN size/NN of/IN 27.2/CD mm/NN 
531305_1_4_5_0_1::None::It/PRP is/VBZ associated/VBN with/IN hallucination/NN ,/, psychosis/NN and/CC 
267813_3_6_7_1_2::None::,/, Text/VB Revision/NNP (/( DSM/NNP -/: IV/CD -/: TR/NN )/) 
544373_0_4_5_5_6::None::blood/NN concentration/NN of/IN cardiac/JJ troponin/NN T/NN (/( ie/FW 
461685_1_5_6_1_2::None::Impaired/JJ glucagon/NN secretion/NN predisposes/VBZ some/DT patients/NNS with/IN type/NN 1/CD 
768572_0_8_9_11_12::None::plasminogen/NN activator/NN (/( IV/CD t/NN -/: PA/NN )/) in/IN improving/VBG 
471565_0_13_14_3_4::None::It/PRP is/VBZ the/DT object/NN of/IN debate/NN whether/IN a/DT low/JJ or/CC high/JJ dialysate/NN sodium/NN concentration/NN (/( DNa/NN (/( 
1373_1373_1_2_4_5::NEG_ACTION_RELATE::The/DT APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC 
124453_5_40_42_6_7::None::that/IN modifying/VBG the/DT endogenous/JJ Tre/NN content/NN by/IN Tre/NNP pretreatment/NN improved/VBD Cu/NN tolerance/NN in/IN rice/NN plants/NNS by/IN inhibiting/VBG Cu/NN uptake/NN and/CC regulating/VBG the/DT antioxidant/JJ and/CC glyoxalase/NN systems/NNS ,/, and/CC thereby/RB demonstrated/VBD the/DT important/JJ role/NN of/IN Tre/NNP in/IN mitigating/VBG heavy/JJ metal/NN toxicity/NN ./. 
710476_3_8_9_5_7::None::measures/NNS of/IN global/JJ mental/JJ health/NN ,/, depression/NN ,/, anxiety/NN ,/, 
382707_7_13_14_4_5::None::findings/NNS represent/VBP an/DT early/JJ but/CC important/JJ step/NN towards/IN the/DT clarification/NN of/IN complex/JJ associations/NNS between/IN trait/NN neuroticism/NN 
562_562_8_9_6_7::POS_ACTION_INTERACT::interactions/NNS between/IN human/JJ RAD51/NN and/CC RAD52/NN proteins/NNS are/VBP demonstrated/VBN 
566758_0_14_17_11_12::None::in/IN overweight/JJ //: obese/JJ adults/NNS with/IN type/NN 2/CD diabetes/NN :/: cross/NN -/: 
191783_4_11_12_9_10::medicine.drug_ingredient.active_moiety_of_drug::-/: 300/CD nm/NN polydimethylsiloxane/NN (/( PDMS/NN )/) on/IN the/DT 
1861_1861_15_16_12_13::POS_ACTION_MUTUALCOMPLEX::of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN which/WDT are/VBP independent/JJ 
467137_1_1_2_11_13::None::Varroa/NNP destructor/NN has/VBZ been/VBN a/DT major/JJ factor/NN in/IN global/JJ honeybee/NN (/( Apis/NN mellifera/NN )/) declines/VBZ since/IN 
670_670_16_17_14_15::None::that/IN beta-catenin/NN ,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, and/CC cadherin-5/NN 
1889_1889_5_6_0_2::None::TNF/NN receptor/NN death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN 
306064_4_18_19_29_30::None::is/VBZ only/RB one/CD report/NN of/IN its/PRP$ effect/NN on/IN GCRG/NNP Moreover/RB ,/, the/DT effect/NN of/IN denosumab/NN on/IN GCRG/NN of/IN 
2148_2148_44_45_52_53::None::the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ 
2137_2137_19_20_4_5::None::previously/RB showed/VBD that/IN actin/NN is/VBZ transported/VBN in/IN an/DT unassembled/JJ form/NN with/IN its/PRP$ associated/JJ proteins/NNS actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
722712_7_12_13_1_2::None::Tumor/NN resection/NN after/IN preoperative/JJ drainage/NN was/VBD effective/JJ in/IN the/DT management/NN of/IN a/DT patient/NN with/IN dyspnea/NN induced/VBN 
489_489_20_21_9_10::None::of/IN three/CD putative/JJ PCAF/NN substrates/NNS ,/, histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP 
317242_0_9_10_0_2::None::Pituitary/JJ adenomas/NNS have/VBP to/TO be/VB studied/VBN in/IN detail/NN for/IN structural/JJ characteristics/NNS ,/, especially/RB 
350044_5_0_1_10_11::None::These/DT findings/NNS have/VBP interdisciplinary/JJ implications/NNS for/IN practice/NN with/IN women/NNS with/IN heart/NN disease/NN ./. 
329598_0_2_3_11_12::None::Doxorubicin/NN -/: induced/VBN cardiomyopathy/NN (/( DOX/NN -/: CM/NN )/) is/VBZ a/DT severe/JJ complication/NN of/IN doxorubicin/NN 
205_205_2_3_8_11::None::BACKGROUND/NN :/: p27/NN (/( Kip1/NN )/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, negatively/RB regulates/VBZ 
820342_0_45_46_19_20::None::(/( 3D/NN -/: CRT/NNP )/) ,/, intensity/NN -/: modulated/VBN radiotherapy/NN (/( IMRT/NN )/) ,/, volumetric/JJ modulated/VBD arc/NN therapy/NN (/( VMAT/NN )/) ,/, flattening/VBG filter/NN free/JJ (/( FFF/NN )/) and/CC stereotactic/JJ ablative/JJ radiotherapy/NN (/( 
567_567_20_21_15_16::None::through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
609813_2_36_38_33_34::biology.organism_classification.lower_classifications::invasive/JJ plant/NN species/NNS Phragmites/NNP australis/NNP (/( common/JJ reed/NN )/) as/IN an/DT 
785586_0_15_16_0_1::None::Pancreaticoduodenectomy/NN (/( PD/NN )/) is/VBZ one/CD of/IN the/DT most/RBS difficult/JJ and/CC dangerous/JJ operations/NNS in/IN general/JJ surgery/NN ./. 
1069_1069_33_35_29_30::None::UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) 
1052_1052_37_38_27_28::None::acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
1075_1075_6_7_22_23::None::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
1321_1321_26_27_23_24::None::potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
2222_2222_15_16_21_22::POS_ACTION_COLOCALIZE::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
154850_0_8_9_14_15::None::dicer/NN -/: dependent/JJ microRNAs/NNS abrogates/VBZ the/DT response/NN of/IN the/DT parathyroid/JJ to/TO acute/JJ and/CC 
500377_1_1_2_12_13::None::Chinese/JJ patients/NNS with/IN essential/JJ hypertension/NN were/VBD treated/VBN with/IN the/DT beta/NN -/: blocker/NN metoprolol/NN and/CC followed/VBD up/RP 
102783_0_42_44_37_38::None::radical/JJ traps/NNS and/CC detected/VBN by/IN room/NN -/: temperature/NN EPR/NN spectroscopy/NN ./. 
18729_3_0_1_2_5::None::In/IN a/DT retrospective/JJ cohort/NN study/NN of/IN children/NNS with/IN 
776470_0_23_24_21_22::medicine.disease.risk_factors::kidney/NN failure/NN ,/, glomerulosclerosis/NN and/CC nephritis/NN resulting/VBG in/IN chronic/JJ 
314_314_12_13_15_18::None::sequestered/VBD more/JJR monomeric/JJ actin/NN than/IN did/VBD class/NN I/CD profilins/NNS ./. 
159_159_33_34_31_33::None::the/DT small/JJ soluble/JJ actin-binding/JJ protein/NN profilin/NN ./. 
492455_9_15_16_17_18::None::among/IN a/DT highly/RB comorbid/JJ inpatient/JJ sample/NN of/IN severely/RB affected/VBN 
996_996_5_7_8_9::None::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT 
227834_1_19_22_9_10::None::leukocytic/JJ DNA/NN and/CC enhancement/NN of/IN homocysteine/NN (/( Hcy/NN )/) level/NN in/IN sera/NNS of/IN type/NN 2/CD diabetic/JJ patients/NNS ./. 
1652_1652_31_32_18_19::POS_ACTION_BIND::and/CC complexing/VBG with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( 
436129_1_4_5_29_30::None::studies/NNS and/CC other/JJ experimental/JJ studies/NNS suggest/VBP that/IN ASA/NN use/NN reduces/VBZ the/DT risk/NN of/IN different/JJ cancers/NNS including/VBG breast/NN cancer/NN (/( BC/NN )/) and/CC may/MD be/VB used/VBN as/IN a/DT chemopreventive/JJ agent/NN against/IN BC/NNP and/CC 
339_339_10_11_15_16::None::modulation/NN of/IN the/DT actin/NN cytoskeleton/NN by/IN cofilin/NN and/CC Aip1/NN ./. 
769586_0_13_14_7_8::None::recently/RB detected/VBN in/IN adolescents/NNS with/IN a/DT family/NN history/NN of/IN premature/JJ atherosclerosis/NN ./. 
106335_13_38_40_40_41::medicine.disease.treatments::readmission/NN following/VBG laparoscopic/JJ colorectal/JJ cancer/NN surgery/NN ./. 
569500_0_7_8_24_25::None::activity/NN patterns/NNS after/IN Roux/NNP -/: en/IN Y/NN gastric/JJ bypass/NN surgery/NN compared/VBN with/IN non/JJ -/: operated/VBN obese/JJ and/CC non/JJ -/: obese/JJ control/NN women/NNS ./. 
1672_1672_8_9_10_11::POS_ACTION_MEMBER::belongs/VBZ to/TO the/DT RAD17/NN ,/, MEC3/NN and/CC RAD24/NN epistasis/NN 
26717_2_48_49_15_16::None::(/( definite/JJ or/CC probable/JJ myocardial/JJ infarction/NN )/) and/CC acute/JJ CHD/NN death/NN ,/, adjusting/VBG for/IN age/NN ,/, age/NN at/IN last/JJ menstrual/JJ period/NN &/CC lt/NN ;/: 45/CD years/NNS ,/, region/NN ,/, education/NN level/NN ,/, income/NN ,/, diabetes/NN ,/, smoking/NN ,/, systolic/JJ blood/NN 
429997_1_34_36_8_9::None::US/NNP Food/NNP and/CC Drug/NNP Administration/NNP analysis/NN have/VBP documented/VBN uncommon/JJ persistent/JJ sexual/JJ and/CC nonsexual/JJ side/NN -/: effects/NNS in/IN a/DT subset/NN of/IN younger/JJR men/NNS who/WP have/VBP taken/VBN finasteride/NN 1/CD mg/NN for/IN androgenic/JJ alopecia/NN ./. 
528491_0_3_4_37_38::None::Chronic/JJ pain/NN is/VBZ common/JJ during/IN childhood/NN and/CC adolescence/NN and/CC is/VBZ associated/VBN with/IN negative/JJ outcomes/NNS such/JJ as/IN increased/VBN severity/NN of/IN pain/NN ,/, reduced/VBD function/NN (/( eg/FW missing/VBG school/NN )/) ,/, and/CC low/JJ mood/NN (/( eg/FW high/JJ levels/NNS of/IN depression/NN and/CC anxiety/NN )/) 
322590_4_16_17_0_1::None::Pre/SYM -/: eclampsia/NN was/VBD defined/VBN as/IN per/IN the/DT International/NNP Society/NNP for/IN the/DT Study/NN of/IN Hypertension/NN in/IN Pregnancy/NNP guidelines/NNS ./. 
267_267_24_25_26_27::POS_ACTION_COLOCALIZE::on/IN patches/NNS containing/VBG vinculin/NN and/CC talin/NN ;/: thus/RB the/DT 
1061_1061_36_37_15_16::POS_ACTION_BIND::but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
594019_6_15_16_17_18::None::to/TO report/VB a/DT diagnosis/NN of/IN hypothyroidism/NN versus/CC those/DT who/WP 
938_938_6_7_9_11::None::LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ 
476691_1_3_4_21_22::None::Advanced/NNP age/NN and/CC severe/JJ surgical/JJ trauma/NN are/VBP two/CD main/JJ risk/NN factors/NNS for/IN POCD/NNP Lithium/NNP ,/, a/DT neuroprotective/JJ agent/NN ,/, can/MD alleviate/VB peripheral/JJ surgery/NN -/: induced/VBN 
452997_6_21_22_20_22::medicine.drug.active_moieties::cells/NNS from/IN hydrogen/NN peroxide/NN cytotoxicity/NN ./. 
770512_2_49_50_43_44::None::symptoms/NNS from/IN both/DT conditions/NNS are/VBP similar/JJ ,/, a/DT dengue/JJ serology/NN was/VBD requested/VBN ./. 
322_322_19_20_2_3::None::Cofilin/NNP and/CC profilin/NN may/MD also/RB be/VB involved/VBN in/IN the/DT redistribution/NN of/IN actin/NN during/IN myofibrillogenesis/NN and/CC in/IN the/DT process/NN of/IN actin/NN disassembly/NN in/IN degenerating/VBG 
470116_0_14_15_2_3::None::A/DT Mixed/JJ Phenotype/NN of/IN Airway/NNP Wall/NNP Thickening/NNP and/CC Emphysema/NNP Is/VBZ Associated/VBN with/IN Dyspnea/NN and/CC Hospitalization/NN for/IN Chronic/JJ Obstructive/JJ 
1593_1593_4_5_22_25::None::potentiating/NN effect/NN of/IN insulin/NN appears/VBZ to/TO involve/VB increases/NNS in/IN the/DT expression/NN of/IN cyclin/NN E/NN and/CC decreases/VBZ in/IN the/DT expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( Kip1/NN 
93_93_4_5_28_29::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
865_865_33_35_15_16::None::related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
779_779_21_24_49_52::None::accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
515725_7_8_9_36_37::None::physical/JJ conditions/NNS (/( fatigue/NN ,/, insomnia/NN ,/, anxiety/NN ,/, depression/NN ,/, diabetes/NN ,/, breathing/NN problems/NNS ,/, high/JJ blood/NN pressure/NN ,/, heart/NN disease/NN ,/, stroke/NN and/CC cancer/NN )/) were/VBD more/RBR likely/JJ to/TO report/VB the/DT lowest/JJS levels/NNS 
314756_0_26_27_7_9::None::)/) ,/, an/DT active/JJ metabolite/NN of/IN vitamin/NN A/NN (/( retinol/NN )/) ,/, has/VBZ been/VBN implicated/VBN in/IN the/DT regulation/NN of/IN lipid/NN metabolism/NN and/CC hepatic/JJ steatosis/NN in/IN animal/NN 
311030_10_14_15_10_11::None::which/WDT activated/VBD P2X2/NN channels/NNS specifically/RB expressed/VBN in/IN dopaminergic/JJ neurons/NNS ./. 
484109_1_8_9_1_3::None::For/IN penile/JJ cancer/NN surgical/JJ treatment/NN ,/, radiotherapy/NN ,/, chemotherapy/NN ,/, and/CC combined/VBN 
1171_1171_9_10_5_6::POS_ACTION_BIND::have/VBP identified/VBN an/DT alpha-catenin/NN binding/NN site/NN in/IN beta-catenin/NN and/CC plakoglobin/NN and/CC 
861_861_9_11_5_6::POS_ACTION_MEMBER::actin/NN clustering/NN ,/, profilin/NN ,/, a/DT monomeric/JJ actin-binding/JJ protein/NN that/WDT has/VBZ been/VBN 
2076_2076_42_43_16_18::None::(/( r/NN )/) actin-binding/JJ protein/NN of/IN 143/CD amino/NN acid/NN (/( aa/NN )/) residues/NNS (/( yeast/NN cofilin/NN ;/: Cof/NN )/) ;/: its/PRP$ aa/NN sequence/NN is/VBZ 35/CD %/NN identical/JJ to/TO porcine/NN Cof/NN ./. 
959107_3_18_19_8_9::None::against/IN influenza/NN A/NN viruses/NNS ,/, a/DT chimerical/JJ DNA/NN plasmid/NN encoding/VBG Influenza/NN virus/NN M2/NN protein/NN and/CC Leishmania/NN major/JJ 
237_237_9_10_17_18::None::and/CC redistribution/NN of/IN actin/NN microfilaments/NNS in/IN fibroblasts/NNS :/: possible/JJ role/NN for/IN PKC-delta/NN ./. 
2052_2052_20_21_6_7::POS_ACTION_BIND::axonal/JJ transport/NN of/IN actin/NN and/CC its/PRP$ monomer/NN binding/NN proteins/NNS ,/, actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ,/, in/IN the/DT 
1380_1380_43_44_40_41::None::,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN (/( Machesky/NNP et/FW 
289843_2_11_12_25_26::medicine.disease.symptoms::diseases/NNS such/JJ as/IN arthritis/NN ,/, inflammatory/JJ bowel/NN diseases/NNS ,/, hematological/JJ disorders/NNS ,/, hepatic/JJ disease/NN ,/, and/CC necrotizing/JJ vasculitis/NN ./. 
357978_8_28_29_14_15::None::markers/NNS indicated/VBD low/JJ genetic/JJ variation/NN in/IN Sundarbans/NNP tigers/NNS (/( He/PRP =/JJ 0.58/CD )/) as/IN compared/VBN to/TO other/JJ mainland/NN populations/NNS ,/, such/JJ 
217_217_27_28_7_8::None::shown/VBN that/IN the/DT RAD51/NN and/CC RAD52/NN proteins/NNS interact/VBP ,/, RAD51/NN on/IN a/DT high/JJ copy/NN number/NN plasmid/NN was/VBD tested/VBN and/CC found/VBN to/TO suppress/VB the/DT rad52-20/NN allele/NN ,/, but/CC 
326684_5_0_1_16_17::None::Miltefosine/NNP is/VBZ equally/RB efficacious/JJ to/TO and/CC may/MD be/VB as/IN tolerable/JJ as/IN liposomal/JJ amphotericin/NN B/NN The/DT most/RBS common/JJ adverse/JJ effects/NNS of/IN 
436497_1_15_16_3_4::None::We/PRP investigated/VBD the/DT correlations/NNS between/IN impulsivity/NN and/CC bulimic/JJ symptoms/NNS ,/, and/CC tested/VBN impulsivity/NN as/IN a/DT moderator/NN of/IN the/DT body/NN 
1834_1834_23_24_6_7::POS_ACTION_BIND::three/CD structures/NNS of/IN actin/NN complexed/VBN with/IN different/JJ monomer-binding/JJ proteins/NNS ,/, namely/RB with/IN DNase/NN I/CD ,/, gelsolin/NN segment/NN 1/CD ,/, and/CC profilin/NN ./. 
1701_1701_48_49_50_51::None::proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
628556_0_13_14_14_15::None:::/: Implications/NNS for/IN Adaptive/JJ Radiotherapy/NN ./. 
159983_7_6_8_7_8::medicine.drug.active_moieties::the/DT affinity/NN of/IN methyl/NN eugenol/NN for/IN the/DT resting/VBG 
2_2_11_13_0_1::None::alpha-catenin/NN inhibits/VBZ beta-catenin/NN signaling/NN by/IN preventing/VBG formation/NN of/IN a/DT beta-catenin/NN */SYM T-cell/NN factor/NN */SYM DNA/NN complex/NN 
807498_0_10_11_16_18::None::to/TO evaluate/VB the/DT survival/NN of/IN dental/JJ implants/NNS placed/VBN after/IN ablative/JJ surgery/NN ,/, in/IN patients/NNS 
810075_0_0_1_6_7::None::Regular/JJ atrial/JJ tachycardias/NNS following/VBG pulmonary/JJ vein/NN isolation/NN for/IN paroxysmal/JJ atrial/JJ 
513_513_5_6_7_8::None::spliceosomal/JJ proteins/NNS (/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, 
191783_4_8_9_29_30::None::200/CD -/: 300/CD nm/NN polydimethylsiloxane/NN (/( PDMS/NN )/) on/IN the/DT zeolite/NN -/: polymer/NN composite/NN ,/, transport/NN data/NNS for/IN CO2/NN //: N2/NN separation/NN indicate/VBP separation/NN factors/NNS of/IN 35/CD -/: 
1119_1119_5_6_11_12::POS_REG(-)_INCREASE::LIM-kinase/NN 1/CD inactivates/VBZ cofilin/NN ,/, leading/VBG to/TO accumulation/NN of/IN actin/NN filaments/NNS ./. 
527579_4_72_73_26_27::None::stoke/VB and/CC 11/CD VBS/NNS )/) A/DT multivariate/JJ model/NN with/IN adjustment/NN for/IN age/NN ,/, baseline/NN stroke/NN severity/NN (/( National/NNP Institutes/NNPS of/IN Health/NNP Stroke/NNP Scale/NNP [/( NIHSS/NNP ]/) )/) ,/, and/CC CTA/NNP -/: based/VBN modified/VBN clot/NNS burden/NN score/NN (/( mCBS/NN )/) was/VBD used/VBN to/TO determine/VB independent/JJ predictors/NNS of/IN short/JJ -/: and/CC long/JJ -/: term/NN clinical/JJ 
1940_1940_7_11_11_12::POS_ACTION_MEMBER::in/IN activation/NN of/IN extracellular/JJ signal-regulated/JJ protein/NN kinases/NNS ERK1/NN and/CC ERK2/NN ,/, 
322_322_0_1_2_3::None::Cofilin/NNP and/CC profilin/NN may/MD also/RB be/VB 
240658_2_0_1_11_12::None::In/IN earlier/JJR work/NN ,/, we/PRP demonstrated/VBD that/IN aggression/NN acts/VBZ as/IN an/DT SNC/NN trait/NN in/IN fruit/NN 
590053_1_21_23_19_20::None::,/, such/JJ as/IN fever/NN and/CC joint/JJ pain/NN ./. 
331938_2_21_22_17_18::None::,/, increase/VBP the/DT coronary/JJ blood/NN supply/NN ,/, improve/VB ischemic/JJ myocardial/JJ metabolism/NN 
219974_13_16_17_7_8::None::of/IN death/NN are/VBP responsible/JJ for/IN almost/RB half/DT of/IN later/JJ deaths/NNS in/IN cardiac/JJ patients/NNS ./. 
372_372_28_29_30_31::None::localization/NN of/IN the/DT UL5/NN and/CC UL52/NN proteins/NNS ./. 
1266_1266_4_5_2_3::POS_ACTION_COLOCALIZE::Since/IN both/DT caldesmon/NN and/CC profilin/NN have/VBP been/VBN found/VBN 
933691_0_19_20_4_5::medicine.disease.treatments::behavior/NN therapy/NN (/( CBT/NN )/) leads/VBZ to/TO a/DT reduction/NN of/IN fatigue/NN and/CC pain/NN in/IN chronic/JJ fatigue/NN syndrome/NN (/( CFS/NN )/) ./. 
21613_1_33_34_32_33::None::according/VBG to/TO the/DT injection/NN route/NN ./. 
532193_6_11_12_0_1::None::There/EX was/VBD no/DT significant/JJ association/NN of/IN codon/NN 248/CD polymorphisms/NNS with/IN bladder/NN cancer/NN in/IN the/DT study/NN 
2146_2146_11_13_14_15::None::both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
1850_1850_8_9_8_9::None::directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ 
607_607_8_9_21_22::None::expresses/VBZ a/DT heterotrimeric/JJ helicase-primase/NN ,/, the/DT subunits/NNS of/IN which/WDT are/VBP encoded/VBN by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS 
9_9_12_13_12_13::None::acid/NN 364/CD of/IN actin/NN and/CC lysine/NN 115/CD 
480543_0_16_17_11_12::None::is/VBZ produced/VBN by/IN proton/NN irradiation/NN of/IN a/DT gallium/NN metal/NN target/NN ,/, purified/VBN 
565_565_4_7_39_40::None::we/PRP demonstrate/VBP that/IN type/NN XIII/CD collagen/NN is/VBZ concentrated/VBN in/IN cultured/VBN skin/NN fibroblasts/NNS and/CC several/JJ other/JJ human/JJ mesenchymal/JJ cell/NN lines/NNS in/IN the/DT focal/JJ adhesions/NNS at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS ,/, co-localizing/VBG with/IN the/DT known/JJ focal/JJ adhesion/NN components/NNS talin/NN and/CC vinculin/NN ./. 
449335_7_6_7_2_3::None::Those/DT recent/JJ findings/NNS suggest/VBP possible/JJ alternative/JJ ways/NNS of/IN modulating/VBG the/DT 
549_549_20_21_9_10::None::was/VBD due/JJ to/TO msh6-F337A/NN sequestering/NN MSH2/NN and/CC preventing/VBG it/PRP from/IN interacting/VBG with/IN MSH3/NN and/CC MSH6/NN ./. 
652_652_11_12_13_14::None::alpha-catenin/NN ,/, and/CC p120/NN (/( Cas/NNS )/) and/CC caused/VBD 
422533_4_38_39_2_3::None::Among/IN 1100/CD adrenal/JJ tumors/NNS and/CC 1/CD 002/CD non/JJ -/: hodgkin/NN whosewhat/NN lymphomas/NNS ,/, 21/CD patients/NNS (/( aged/JJ 35/CD to/TO 80/CD years/NNS ,/, mean/VB 56/CD years/NNS )/) were/VBD diagnosed/VBN as/IN having/VBG adrenal/JJ non/JJ -/: Hodgkin/NN whosewhat/NN lymphoma/NN with/IN 14/CD males/NNS and/CC 7/CD females/NNS 
143595_7_3_4_32_33::None::In/IN the/DT chronic/JJ bioassay/NN ,/, larvae/NNS were/VBD exposed/VBN to/TO nitrate/VB concentrations/NNS of/IN 50/CD ,/, 100/CD ,/, 200/CD ,/, and/CC 400/CD mg/NN //: L/NN NO3/NN (/( -/: )/) -/: N/NN during/IN the/DT entire/JJ larval/JJ period/NN (/( 23/CD 
596699_0_10_11_12_13::None::are/VBP growing/VBG in/IN prevalence/NN as/IN major/JJ causal/JJ factors/NNS of/IN 
1820_1820_12_13_5_6::POS_ACTION_RELATE::profilin/NN I/PRP suppresses/VBZ actin/NN polymerization/NN in/IN microspike/NN formation/NN induced/VBN by/IN N-WASP/NN ,/, the/DT essential/JJ 
116331_2_7_8_1_2::None::Cumulative/JJ incidence/NN of/IN anemia/NN 7/CD years/NNS post/JJ procedure/NN was/VBD 58/CD %/NN 
854528_1_10_11_52_53::None::(/( Ixodida/NNP :/: Ixodidae/NNP )/) collected/VBN from/IN 51/CD camels/NNS (/( Camelus/JJ dromedarius/NN )/) in/IN Kano/NNP ,/, northern/JJ Nigeria/NNP ,/, were/VBD screened/VBN by/IN amplification/NN and/CC sequencing/NN of/IN the/DT citrate/NN synthase/NN (/( gltA/NN )/) ,/, outer/JJ membrane/NN protein/NN A/NN (/( ompA/NN )/) and/CC 17/CD -/: kDa/NN antigen/NN gene/NN fragments/NNS ./. 
776_776_26_27_29_30::None::of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
260299_3_14_15_15_16::medicine.disease.risk_factors::-/: old/JJ ,/, chronic/JJ smoker/NN ,/, who/WP incidentally/RB 
251166_0_6_7_3_4::None::There/EX is/VBZ growing/VBG evidence/NN that/IN the/DT predictive/JJ value/NN of/IN HDL/NN 
426927_1_31_32_6_7::None::of/IN a/DT hexane/NN extract/NN of/IN Lithospermum/NN erythrorhizon/NN root/NN (/( LEH/NN )/) was/VBD investigated/VBN in/IN Beagle/NNP dogs/NNS by/IN using/VBG single/JJ escalating/VBG doses/NNS ,/, two/CD -/: week/NN dose/NN range/NN -/: finding/NN ,/, and/CC 4/LS 
267813_3_59_60_20_21::None::hypomanic/JJ ,/, or/CC mixed/JJ episode/NN ,/, were/VBD recruited/VBN over/IN a/DT 6/CD year/NN period/NN from/IN two/CD academic/JJ outpatient/NN programs/NNS for/IN a/DT double/JJ -/: blinded/VBN ,/, placebo/NN -/: controlled/JJ trial/NN in/IN which/WDT subjects/NNS were/VBD randomized/VBN in/IN a/DT 2/CD :/: 2/CD :/: 1/CD ratio/NN to/TO risperidone/NN solution/NN ,/, valproic/JJ 
1726_1726_8_9_14_15::POS_REG(+)_PHOSPHORYLATE::of/IN LIM-kinase/NN by/IN ROCK/NN and/CC consequently/RB increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP 
639297_0_4_5_14_15::medicine.disease.treatments::late/JJ -/: onset/NN sepsis/NN following/VBG peripherally/RB inserted/VBN central/JJ catheter/NN removal/NN :/: association/NN with/IN antibiotic/JJ use/NN and/CC adverse/JJ 
1591_1591_19_20_21_22::POS_ACTION_CROSS-LINK::a/DT crosslinker/NN between/IN myosin/NN and/CC actin/NN ./. 
302982_3_17_18_7_8::None::(/( 1/LS )/) Glucagon/NNP ,/, glucagon/NNP //: insulin/NN ratio/NN and/CC AUCG/NN were/VBD significantly/RB higher/JJR (/( P/NN &/CC 
2222_2222_11_12_23_24::POS_ACTION_COLOCALIZE::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
784_784_4_5_8_9::None::normal/JJ livers/NNS ,/, E-cad/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB 
185_185_6_7_4_5::None::of/IN UBE2I/NN with/IN RAD52/NN ,/, UBL1/NN ,/, p53/NN ,/, 
238332_6_27_29_14_15::None::primary/JJ goal/NN in/IN T1D/NN Provision/NN of/IN pain/NN relief/NN from/IN chronic/JJ pancreatitis/NN is/VBZ the/DT primary/JJ goal/NN of/IN total/JJ pancreatectomy/NN in/IN TPIAT/NNP ,/, 
591167_7_15_16_6_7::None::TIMI/NNP 53/CD trial/NN supports/VBZ the/DT overall/JJ CV/NN safety/NN of/IN saxagliptin/NN in/IN a/DT robust/JJ number/NN of/IN elderly/JJ 
1580_1580_28_29_23_24::None::its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
93_93_24_26_11_12::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
68_68_12_13_16_17::None::of/IN expression/NN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB 
563809_10_11_12_58_59::None::all/DT -/: cause/VB mortality/NN (/( hazard/NN ratio/NN 1.14/CD [/( 95/CD %/NN confidence/NN interval/NN 1.05/CD -/: 1.24/CD ]/) )/) and/CC CVD/NN mortality/NN (/( hazard/NN ratio/NN 1.24/CD [/( 95/CD %/NN confidence/NN interval/NN 1.09/CD -/: 1.41/CD ]/) )/) adjusted/VBN for/IN age/NN ,/, body/NN mass/NN index/NN ,/, education/NN ,/, smoking/NN ,/, health/NN status/NN ,/, diabetes/NN ,/, and/CC stroke/NN 
1486_1486_24_25_35_40::None::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ 
1754_1754_7_8_32_33::None::the/DT dysfunction/NN of/IN E-cadherin/NN in/IN these/DT cell/NN lines/NNS is/VBZ due/JJ primarily/RB to/TO its/PRP$ failure/NN to/TO interact/VB with/IN alpha-catenin/NN ,/, and/CC that/IN this/DT defect/NN results/VBZ from/IN the/DT mutation/NN in/IN beta-catenin/NN ./. 
756738_0_16_17_17_20::medicine.disease.treatments::in/IN patients/NNS on/IN chronic/JJ renal/JJ replacement/NN therapy/NN (/( RRT/NN )/) 
204277_6_47_48_3_4::None::Testosterone/NN level/NN correlated/VBD positively/RB with/IN RHI/NN (/( r/NN =/JJ 0.24/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD )/) and/CC inversely/RB with/IN AIX/NNP (/( r/NN =/SYM -/: 0.14/CD ,/, p/NN =/JJ 0.033/CD )/) but/CC not/RB with/IN FMD/NN or/CC PWV/NN ,/, indicating/VBG impaired/JJ microvascular/JJ hyperemia/NN and/CC arterial/JJ elasticity/NN with/IN lower/JJR testosterone/NN levels/NNS ./. 
539_539_18_19_15_16::None::protein/NN that/WDT links/VBZ integrins/NNS to/TO the/DT actin/NN cytoskeleton/NN ,/, is/VBZ 
2146_2146_4_5_14_15::POS_ACTION_PHOSPHORYLATE::report/VBP here/RB that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
412_412_10_13_15_16::POS_ACTION_MEMBER::,/, expression/NN of/IN cyclin-dependent/JJ kinase/NN inhibitors/NNS p21/NN and/CC p27/NN increased/VBD ,/, whereas/IN 
2108_2108_17_18_8_11::None::proteins/NNS are/VBP indeed/RB nuclear/JJ basic/JJ proteins/NNS :/: the/DT 14/CD kd/NN is/VBZ the/DT histone/NN H4/NN ,/, the/DT 
1819_1819_13_14_10_11::POS_ACTION_BIND::--/: one/CD for/IN profilin/NN bound/VBD to/TO actin/NN monomers/NNS and/CC one/CD 
112_112_0_1_3_4::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN 
865150_0_24_25_4_5::None::-/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) remains/VBZ the/DT most/RBS common/JJ cause/NN of/IN cancer/NN death/NN worldwide/RB due/JJ its/PRP$ resistance/NN to/TO chemotherapy/NN and/CC aggressive/JJ tumor/NN growth/NN ./. 
1219_1219_11_12_0_1::None::RIPc/NN ,/, one/CD of/IN the/DT cleavage/NN products/NNS ,/, enhanced/VBD interaction/NN between/IN TRADD/NN and/CC FADD/MORT1/NN and/CC 
260299_3_23_24_3_4::None::Herein/RB ,/, we/PRP report/VBP the/DT case/NN of/IN a/DT 49/CD -/: year/NN -/: old/JJ ,/, chronic/JJ smoker/NN ,/, who/WP incidentally/RB had/VBD a/DT laryngeal/JJ growth/NN detected/VBN during/IN flexible/JJ bronchoscopy/NN 
198729_8_18_19_28_29::None::may/MD support/VB the/DT hypothesis/NN of/IN C/NN neoformans/NNS as/IN a/DT risk/NN factor/NN for/IN the/DT development/NN of/IN asthma/NN in/IN 
1926_1926_26_27_13_14::None::as/IN that/DT of/IN FLICE/NNP ,/, Fas/NN ,/, FADD/NN ,/, DR3/NN ,/, FAF/NN ,/, TRADD/NN ,/, and/CC RIP/NN was/VBD similar/JJ in/IN 
1064_1064_15_16_8_9::POS_ACTION_SIMILAR::yeast/NN actin-binding/JJ protein/NN Sac6p/NN ,/, which/WDT is/VBZ homologous/JJ to/TO vertebrate/JJ fimbrin/NN (/( Adams/NNP ,/, 
2131_2131_7_8_10_11::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN 
476387_6_7_9_3_4::None::The/DT absence/NN of/IN pyruvate/NN groups/NNS renders/VBZ the/DT xanthan/JJ gum/NN less/RBR sensitive/JJ to/TO 
1420_1420_11_12_4_7::None::characteristics/NNS of/IN the/DT vitamin/NN D-binding/JJ protein/NN and/CC profilin/NN interactions/NNS with/IN actin/NN are/VBP similar/JJ ./. 
1957_1957_15_16_38_39::None::EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ cells/NNS at/IN confluence/NN were/VBD dissociated/VBN into/IN single/JJ cells/NNS by/IN tryptic/JJ digestion/NN ,/, being/VBG accompanied/VBN by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
1144_1144_17_18_17_18::None::although/IN it/PRP inhibits/VBZ actin/NN polymerization/NN more/RBR strongly/RB 
685_685_30_31_14_15::None::to/TO E-cadherin/NN ,/, alpha-catenin/NN ,/, and/CC gamma-catenin/NN and/CC a/DT 79-kDa/JJ band/NN which/WDT was/VBD apparently/RB smaller/JJR than/IN that/DT of/IN normal/JJ beta-catenin/NN ,/, indicating/VBG truncated/VBN 
157_157_1_2_33_34::None::Archaeal/NNP histones/NNS are/VBP most/RBS similar/JJ to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN formed/VBN by/IN eukaryal/JJ histone/NN (/( H3/NN +/CC H4/NN )/) 
1164_1164_33_34_5_6::POS_ACTION_ATTACH::the/DT appearance/NN of/IN X22/NN banding/NN in/IN primary/JJ cultures/NNS of/IN myotubes/NNS indicates/VBZ that/IN it/PRP precedes/VBZ that/IN of/IN other/JJ myofibrillar/NN proteins/NNS and/CC that/IN assembly/NN takes/VBZ place/NN in/IN the/DT following/VBG order/NN :/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ 
408257_14_16_17_13_14::None::BMMSCs/NNS plays/VBZ a/DT pathological/JJ role/NN in/IN active/JJ multiple/JJ myeloma/NN or/CC 
420079_6_3_6_26_27::None::During/IN pregnancy/NN ,/, acute/JJ kidney/NN injury/NN (/( 5/CD //: 8/CD )/) ,/, anemia/NN (/( 5/CD //: 8/CD )/) ,/, hematuria/NN (/( 8/CD //: 8/CD )/) and/CC proteinuria/NN (/( 8/CD //: 
22_22_0_1_36_37::POS_REG(0)_Change::ActA/NN appears/VBZ to/TO control/VB at/IN least/JJS four/CD functions/NNS that/WDT collectively/RB lead/VBP to/TO actin-based/JJ motility/NN :/: (/( 1/LS )/) initiation/NN of/IN actin/NN polymerization/NN ,/, (/( 2/LS )/) polarization/NN of/IN ActA/NN function/NN ,/, (/( 3/LS )/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT 
369325_1_6_7_35_36::None::3178/CD black/JJ and/CC white/JJ women/NNS and/CC men/NNS in/IN the/DT Coronary/JJ Artery/NN Risk/NN Development/NN in/IN Young/NNP Adults/NNS study/NN were/VBD assessed/VBN to/TO identify/VB the/DT order/NN in/IN which/WDT cardiovascular/JJ disease/NN risk/NN factors/NNS including/VBG diabetes/NN ,/, hypertension/NN ,/, dyslipidemia/NN (/( 
452997_6_22_23_21_22::None::cells/NNS from/IN hydrogen/NN peroxide/NN cytotoxicity/NN ./. 
2222_2222_21_22_15_16::None::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD 
106581_3_43_45_41_42::None::diverse/JJ disorders/NNS as/IN cancer/NN ,/, pulmonary/JJ disease/NN and/CC cognition/NN defects/NNS 
31738_0_2_3_5_7::None::Variation/NN in/IN Medicare/NNP Payments/NNS for/IN Colorectal/JJ Cancer/NN Surgery/NN ./. 
96855_6_9_10_14_15::people.cause_of_death.includes_causes_of_death::life/NN -/: threatening/VBG injuries/NNS ,/, all/DT five/CD underwent/VBD burn/VBP excision/NN and/CC microsurgical/JJ 
2076_2076_16_18_8_9::None::cerevisiae/FW gene/NN (/( COF1/NN )/) encoding/VBG a/DT low-M/NN (/( r/NN )/) actin-binding/JJ protein/NN of/IN 143/CD amino/NN 
347064_0_29_30_8_9::None::(/( SCs/NNS )/) holds/VBZ considerable/JJ promise/NN as/IN a/DT therapy/NN for/IN spinal/JJ cord/NN injury/NN ,/, but/CC the/DT optimal/JJ source/NN of/IN these/DT cells/NNS and/CC the/DT best/JJS timing/NN for/IN intervention/NN remains/VBZ 
305802_4_31_32_0_1::None::Dantrolene/NN reduced/VBD the/DT number/NN of/IN premature/JJ ventricular/JJ complexes/NNS (/( PVCs/NNS )/) on/IN average/NN by/IN 74/CD %/NN (/( range/NN 33/CD -/: 97/CD )/) in/IN four/CD patients/NNS with/IN N/NN -/: terminal/JJ or/CC central/JJ mutations/NNS in/IN the/DT cytosolic/JJ 
583303_11_22_23_19_20::medicine.disease.treatments::untreated/JJ uncomplicated/JJ acute/JJ tympanostomy/NN -/: tube/NN otorrhea/NN ./. 
567_567_10_11_14_15::None::acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS 
18_18_21_22_6_7::None::the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) ./. 
1380_1380_40_41_34_35::POS_ACTION_BIND::novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN 
813_813_27_28_23_24::None::of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN P/NN is/VBZ essential/JJ for/IN 
1052_1052_21_22_6_8::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG 
416067_10_13_14_23_24::None:://: -/: )/) mice/NNS was/VBD significantly/RB lower/JJR than/IN in/IN wild/JJ -/: type/NN 20/CD weeks/NNS after/IN AOM/NNP -/: 
240152_0_21_22_61_62::None::soil/NN profiles/NNS were/VBD collected/VBN from/IN the/DT Shenyang/NNP industrial/JJ district/NN in/IN northeast/JJ China/NNP and/CC were/VBD analyzed/VBN for/IN contents/NNS of/IN titanium/NN (/( Ti/NN )/) ,/, copper/NN (/( Cu/NN )/) ,/, lead/NN (/( Pb/NN )/) ,/, zinc/NN (/( Zn/NN )/) ,/, cobalt/NN (/( Co/NNP )/) ,/, nickel/NN (/( Ni/NN )/) 
2222_2222_23_24_21_22::None::,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
1686_1686_51_53_15_18::None::domains/NNS of/IN all/DT myosin/JJ heavy/JJ chains/NNS ,/, and/CC light/JJ chains/NNS at/IN least/JJS of/IN class/NN II/CD myosins/NNS ,/, have/VBP coevolved/VBN and/CC are/VBP likely/JJ to/TO be/VB functionally/RB interdependent/JJ ,/, consistent/JJ with/IN biochemical/JJ evidence/NN showing/VBG that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP myosin/NN II/CD requires/VBZ isoform/NN specific/JJ 
576_576_22_23_9_10::None::the/DT regulation/NN of/IN cofilin/NN ,/, a/DT ubiquitous/JJ actin-binding/JJ protein/NN that/WDT is/VBZ essential/JJ for/IN effective/JJ depolymerization/NN of/IN actin/NN filaments/NNS ./. 
1701_1701_48_49_11_12::None::involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
95125_0_0_1_0_2::biology.organism_classification.lower_classifications::Aedes/NNS aegypti/NNS is/VBZ a/DT primary/JJ 
565_565_39_40_4_7::POS_ACTION_COLOCALIZE::we/PRP demonstrate/VBP that/IN type/NN XIII/CD collagen/NN is/VBZ concentrated/VBN in/IN cultured/VBN skin/NN fibroblasts/NNS and/CC several/JJ other/JJ human/JJ mesenchymal/JJ cell/NN lines/NNS in/IN the/DT focal/JJ adhesions/NNS at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS ,/, co-localizing/VBG with/IN the/DT known/JJ focal/JJ adhesion/NN components/NNS talin/NN and/CC vinculin/NN ./. 
1803_1803_32_34_27_28::None::is/VBZ distinct/JJ from/IN FADD/NNP 's/POS functions/NNS at/IN activated/VBN death/NN receptors/NNS ./. 
513747_5_116_117_113_115::None::role/NN of/IN cardiac/JJ computerized/JJ tomography/NN in/IN cardiovascular/JJ screening/NN )/) ./. 
164393_5_2_3_31_32::medicine.drug_ingredient.active_moiety_of_drug::Participants/NNS reported/VBD nicotine/NN craving/NN ,/, nicotine/NN withdrawal/NN symptoms/NNS ,/, and/CC substance/NN use/NN in/IN the/DT week/NN following/VBG a/DT uniform/JJ quit/VBD attempt/NN of/IN the/DT TAU/NN +/CC SCT/NN group/NN ,/, and/CC self/NN -/: reported/VBN smoking/NN 7/CD -/: day/NN 
510261_8_0_1_1_2::None::Our/PRP$ meta/NN -/: analysis/NN results/NNS 
1095_1095_11_12_17_18::None::adhesion/NN pattern/NN ,/, actin/NN organization/NN ,/, and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN 
442063_4_37_38_9_12::medicine.medical_treatment.used_to_treat::statin/NN therapy/NN in/IN acute/JJ myocardial/JJ infarction/NN (/( ALPS/NN -/: AMI/NNP )/) study/NN was/VBD a/DT multi/JJ -/: center/NN study/NN that/WDT enrolled/VBD 508/CD AMI/NNP patients/NNS to/TO compare/VB the/DT efficacy/NN of/IN hydrophilic/JJ and/CC lipophilic/JJ statins/NNS in/IN secondary/JJ prevention/NN 
1710_1710_16_18_18_19::POS_ACTION_MEMBER::region/NN of/IN the/DT actin-binding/JJ protein/NN profilin/NN ./. 
637206_9_10_11_6_7::None::leading/VBG cause/NN of/IN ESRD/NNP The/DT prevalence/NN and/CC incidence/NN of/IN RRT/NNP continues/VBZ 
449_449_19_20_17_18::NEG_ACTION_Change::with/IN both/CC the/DT UL5/NN and/CC UL52/NN proteins/NNS ./. 
932_932_3_4_1_2::None::Like/IN TESK1/NN ,/, TESK2/NN phosphorylated/VBN cofilin/NN specifically/RB 
397679_0_8_9_17_19::medicine.risk_factor.diseases::novel/JJ treatments/NNS for/IN elderly/JJ (/( gtgt/NN =/JJ 66/CD yr/NN )/) patients/NNS with/IN multiple/JJ myeloma/NN (/( MM/NN )/) 
398949_5_24_25_1_2::None::A/DT mixture/NN of/IN antioxidants/NNS (/( vitamin/NN C/NN ,/, vitamin/NN E/NN ,/, N/NN -/: acetyl/NN -/: l/NN -/: cysteine/NN )/) provided/VBD partial/JJ protection/NN against/IN cell/NN loss/NN but/CC also/RB promoted/VBD 
290049_2_11_12_24_25::None::for/IN influenza/NN A/NN viruses/NNS raises/VBZ questions/NNS about/IN the/DT role/NN of/IN this/DT mammalian/JJ taxon/NN in/IN influenza/NN A/NN virus/NN ecology/NN and/CC possible/JJ 
855088_0_17_18_6_7::None::the/DT Arndt/NNP endobronchial/JJ blocker/NN has/VBZ not/RB gained/VBN widespread/JJ acceptance/NN during/IN video/NN -/: assisted/VBN thoracoscopic/JJ surgery/NN (/( VATS/NNS )/) 
1858_1858_2_3_8_9::None::Thus/RB ,/, actin/NN was/VBD found/VBN in/IN association/NN with/IN fimbrin/NN in/IN the/DT mechanoreceptive/JJ 
984_984_0_1_33_34::None::MLL/NN is/VBZ fused/VBN in-frame/RB to/TO a/DT different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, and/CC transcriptional/JJ repression/NN domain/NN of/IN MLL/NN fused/VBN to/TO the/DT CREB/NN binding/NN domain/NN or/CC 
1227_1227_26_27_2_3::None::Saccharomyces/FW cerevisiae/FW RAD14/NN was/VBD identified/VBN in/IN a/DT two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN ,/, ''/'' and/CC pairwise/JJ interactions/NNS between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, RAD3/NN ,/, RAD10/NN ,/, 
515959_4_3_4_14_15::None::We/PRP have/VBP previously/RB reported/VBN that/IN breast/NN tumors/NNS highly/RB express/VBP functional/JJ muscarinic/JJ acetylcholine/NN receptors/NNS (/( mAChRs/NNS )/) that/WDT regulate/VBP 
1866_1866_12_13_5_6::POS_ACTION_RELATE::both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN in/IN their/PRP$ signal/NN 
178051_0_3_5_17_18::None::The/DT Scandinavian/JJ Candesartan/NNP Acute/JJ Stroke/NNP Trial/NN (/( SCAST/NN )/) indicated/VBD that/IN blood/NN pressure/NN -/: lowering/VBG treatment/NN with/IN candesartan/NN in/IN the/DT acute/JJ 
769684_3_29_30_64_65::None::,/, Chinese/NNP mainland/NN version/NN )/) ,/, Pittsburgh/NNP Sleep/NNP Quality/NNP Index/NNP (/( PSQI/NNP )/) ,/, Family/NNP APGAR/NNP Index/NNP (/( PAGAR/NNP )/) ,/, Family/NNP Adaptability/NNP and/CC Cohesion/NNP Evaluation/NN Scale/NNP (/( FACES/NNP II/NNP ,/, Chinese/NNP version/NN )/) and/CC the/DT Social/NNP Functioning/NNP Questionnaire/NNP (/( SFQ/NNP )/) 
590437_1_26_27_28_29::medicine.disease.risk_factors::used/VBN to/TO treat/VB depression/NN in/IN PD/NN patients/NNS ./. 
349514_1_10_11_25_26::None::be/VB associated/VBN with/IN greater/JJR cardiovascular/JJ risk/NN in/IN prehypertensives/NNS ,/, it/PRP is/VBZ important/JJ to/TO investigate/VB whether/IN heart/NN rate/NN variability/NN biofeedback/NN (/( HRV/NN -/: 
311826_8_0_1_3_4::medicine.drug.active_moieties::Bleomycin/NN ,/, and/CC bleomycin/NN -/: induced/VBN Fas/NN 
758838_26_44_45_2_3::None::We/PRP report/VBP variable/JJ prevalence/NN of/IN obesity/NN ,/, cholesterol/NN ,/, hypertension/NN and/CC diabetes/NN in/IN the/DT OA/NN in/IN contrast/NN to/TO the/DT larger/JJR ethnic/JJ majorities/NNS such/JJ as/IN Malays/NNP ,/, Chinese/NNP and/CC Indians/NNPS in/IN Malaysia/NNP These/DT differences/NNS are/VBP likely/JJ to/TO be/VB due/JJ to/TO socio/NN -/: economic/JJ effects/NNS and/CC lifestyle/NN changes/NNS ./. 
1692_1692_33_34_28_29::None::the/DT effect/NN of/IN profilin/NN on/IN the/DT assembly/NN of/IN actin/NN that/WDT had/VBD been/VBN 
271641_1_39_41_10_11::medicine.disease.symptoms::the/DT effects/NNS of/IN tumor/NN growth/NN following/VBG radiotherapy/NN and/CC G/NN -/: CSF/NN administration/NN in/IN a/DT murine/JJ xenograft/NN model/NN of/IN colon/NN cancer/NN ,/, female/JJ BALB/NN //: c/NN mice/NNS were/VBD injected/VBN with/IN cells/NNS of/IN a/DT colon/NN carcinoma/NN cell/NN line/NN (/( 
363177_0_13_14_20_21::None::and/CC deposition/NN of/IN fibrinogen/NN in/IN the/DT central/JJ nervous/JJ system/NN (/( CNS/NN )/) ./. 
1233_1233_28_29_30_31::None:::/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
33757_12_25_26_13_14::None::multi/NNS -/: parametric/JJ MRI/NNP combined/VBN with/IN supervised/JJ learning/VBG to/TO be/VB able/JJ to/TO accurately/RB detect/VB cancer/NN foci/NNS and/CC its/PRP$ aggressiveness/NN 
664393_0_6_7_4_5::None::radiotherapy/NN of/IN the/DT breast/NN for/IN early/JJ -/: stage/NN breast/NN 
418321_2_21_22_25_26::None::Patients/NNS with/IN this/DT syndrome/NN exhibit/VBP a/DT high/JJ prevalence/NN of/IN non/JJ -/: 
162957_0_16_17_32_33::None::and/CC protease/NN -/: activated/VBN receptor/NN -/: 2/CD (/( PAR2/NN )/) in/IN the/DT pathogenesis/NN of/IN itch/NN using/VBG a/DT recently/RB developed/VBN murine/JJ model/NN of/IN atopic/JJ 
2064_2064_40_41_40_41::None::,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN 
532193_6_11_12_10_12::people.cause_of_death.includes_causes_of_death::polymorphisms/NNS with/IN bladder/NN cancer/NN in/IN the/DT study/NN 
394419_6_42_45_61_62::None::,/, FGF2/NN (/( fibroblast/NN growth/NN factor/NN 2/CD )/) ,/, FGF21/NN ,/, FSTL1/NN (/( follistatin/NN -/: related/JJ protein/NN 1/CD )/) ,/, irisin/NN ,/, EPO/NN (/( erythropoetin/NN )/) 
1726_1726_23_24_16_17::None::of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
318680_2_21_22_17_20::medicine.drug_ingredient.active_moiety_of_drug::their/PRP$ affinities/NNS for/IN human/JJ serum/NN albumin/NN (/( HSA/NN )/) by/IN a/DT 
393131_1_18_19_27_28::None::a/DT biofilm/NN on/IN epithelial/JJ surfaces/NNS and/CC the/DT production/NN of/IN hydrogen/NN peroxide/NN to/TO damage/VB host/NN tissue/NN ./. 
2053_2053_17_19_11_12::None::sequestering/NN protein/NN ,/, profilin/NN ,/, in/IN the/DT regulation/NN of/IN PMN/NN actin/NN filament/NN assembly/NN during/IN 
550981_1_11_12_12_13::None::flow/NN through/IN the/DT cirrhotic/JJ liver/NN ./. 
90241_0_3_4_19_20::None::In/IN LUX/NN -/: Lung/NN 3/CD ,/, afatinib/NN significantly/RB improved/VBD progression/NN -/: free/JJ survival/NN (/( PFS/NN )/) versus/CC cisplatin/NN //: pemetrexed/VBN in/IN EGFR/NN mutation/NN 
590_590_21_22_33_34::None::ability/NN to/TO inhibit/VB p300/NN (/( and/CC the/DT highly/RB related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN 
226308_2_1_2_7_8::None::Initially/RB slime/NN production/NN was/VBD assessed/VBN on/IN CRA/NNP agar/NN and/CC hydrophobicity/NN of/IN 
521445_4_22_23_3_4::None::During/IN the/DT recent/JJ Musculoskeletal/JJ Infection/NN symposium/NN ,/, specific/JJ issues/NNS were/VBD discussed/VBN with/IN regard/NN to/TO the/DT treatment/NN of/IN periprosthetic/JJ joint/JJ infection/NN ,/, including/VBG medical/JJ optimization/NN ,/, systematic/JJ 
1052_1052_34_35_6_8::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN 
144491_1_50_51_45_46::None::state/NN and/CC time/NN resolved/VBD fluorescence/NN spectroscopy/NN ,/, molecular/JJ docking/NN and/CC circular/JJ dichroism/NN 
63_63_44_45_44_45::None::.2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, 
1866_1866_12_13_9_10::None::use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN in/IN their/PRP$ signal/NN 
2148_2148_44_45_4_5::None::report/VBP here/RB that/IN tropomyosin/NN ,/, which/WDT is/VBZ found/VBN in/IN the/DT rootlet/NN but/CC not/RB in/IN the/DT microvillus/JJ core/NN ,/, can/MD bind/VB to/TO and/CC saturate/VB the/DT actin/NN of/IN isolated/VBN cores/NNS ,/, and/CC can/MD cause/VB the/DT dissociation/NN of/IN up/RB to/TO 30/CD %/NN of/IN the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS 
13_13_14_15_1_2::None::Acanthamoeba/NN profilin/NN strongly/RB inhibits/VBZ in/IN a/DT concentration-dependent/JJ fashion/NN the/DT rate/NN and/CC extent/NN of/IN Acanthamoeba/NN actin/NN polymerization/NN in/IN 50/CD 
855088_0_30_31_37_41::medicine.medical_treatment.used_to_treat::longer/JJR time/NN to/TO operative/JJ lung/NN collapse/NN especially/RB in/IN patients/NNS with/IN chronic/JJ obstructive/JJ pulmonary/JJ disease/NN (/( COPD/NN )/) 
140351_4_4_5_6_7::None::treatment/NN efficacy/NN studies/NNS exist/VBP in/IN elderly/JJ IBD/NN as/IN most/JJS 
225_225_4_5_2_3::POS_ACTION_BIND::Binding/NN of/IN talin/NN to/TO actin/NN occurs/VBZ at/IN a/DT 
2148_2148_56_57_52_53::POS_ACTION_BIND::does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ calmodulin/NN ./. 
1831_1831_11_14_14_15::POS_ACTION_MEMBER::expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN in/IN 44/CD %/NN 
1233_1233_26_27_30_31::None::chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
415007_0_10_11_15_16::None::autosomal/JJ co/NN -/: dominant/JJ disorder/NN that/WDT markedly/RB raises/VBZ plasma/NN low/JJ -/: density/NN 
649052_1_26_27_17_18::None::in/IN their/PRP$ intraspecific/JJ cooperation/NN tendencies/NNS in/IN that/DT wolves/NNS rely/VBP more/RBR heavily/RB on/IN group/NN coordination/NN in/IN regard/NN 
119767_6_18_19_5_6::None::of/IN uPA/NN (/( urokinase/NN -/: type/NN plasminogen/NN activator/NN )/) or/CC uPAR/NN (/( uPA/NN receptor/NN )/) by/IN siRNA/NN technology/NN completely/RB abolished/VBD 
401885_4_9_10_13_14::None::higher/JJR prevalence/NN of/IN chronic/JJ respiratory/JJ symptoms/NNS and/CC diseases/NNS than/IN those/DT who/WP 
367_367_5_7_32_33::None::belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
910_910_9_11_3_4::POS_ACTION_BIND::Isolation/NN of/IN human/JJ delta-catenin/NN and/CC its/PRP$ binding/NN specificity/NN with/IN presenilin/NN 1/CD ./. 
1407_1407_15_16_21_22::POS_ACTION_BIND::polymerizability/NN of/IN the/DT actin/NN ,/, abolished/VBD its/PRP$ binding/NN to/TO profilin/NN ,/, and/CC filaments/NNS 
1726_1726_16_17_23_24::POS_ACTION_MODIFY::of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
447089_0_14_15_12_13::None::(/( ACTH/NN )/) promoted/VBD erythroblast/NN differentiation/NN and/CC increased/VBD the/DT 
1288_1288_11_12_13_14::None::)/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ 
322602_4_7_9_2_3::None::The/DT most/RBS common/JJ heart/NN diseases/NNS were/VBD congenital/JJ heart/NN disease/NN (/( n/NN =/JJ 
76705_14_5_6_22_23::None::a/DT recent/JJ -/: onset/NN AF/NN and/CC troponin/NN -/: rise/NN showed/VBD a/DT high/JJ prevalence/NN of/IN CVE/NN but/CC not/RB stroke/NN ,/, thus/RB CAD/NN might/MD have/VB a/DT 
467695_7_4_5_11_12::None::,/, mixtures/NNS of/IN equimolar/JJ amounts/NNS of/IN PhSiH3/NN and/CC the/DT zinc/NN bis/NN (/( amide/NN )/) 
121583_0_6_7_39_40::biology.organism_classification.lower_classifications::believed/VBN that/IN the/DT archaeal/JJ ancestor/NN was/VBD hyperthermophilic/JJ ,/, but/CC during/IN archaeal/NN evolution/NN ,/, several/JJ lineages/NNS -/: including/VBG haloarchaea/NN and/CC their/PRP$ sister/NN methanogens/NNS ,/, the/DT Thaumarchaeota/NNP ,/, and/CC the/DT uncultured/JJ Marine/NNP Group/NNP II/NNP and/CC Marine/NNP Group/NNP III/NNP Euryarchaeota/NNP (/( MGII/NNP //: 
1672_1672_3_4_10_11::None::The/DT Saccharomyces/FW cerevisiae/FW DDC1/NN gene/NN belongs/VBZ to/TO the/DT RAD17/NN ,/, MEC3/NN and/CC RAD24/NN epistasis/NN 
1380_1380_34_35_24_25::None::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, 
75_75_17_18_1_2::None::A/DT LIMK2/NN mutant/NN with/IN replacement/NN of/IN threonine/NN 505/CD by/IN valine/NN abolished/VBD LIMK2/NN activities/NNS for/IN cofilin/NN phosphorylation/NN and/CC actin/NN cytoskeletal/JJ changes/NNS ,/, 
386606_0_5_6_3_5::medicine.medical_treatment.used_to_treat::Resection/NN margins/NNS in/IN oral/JJ cancer/NN surgery/NN :/: Room/NN for/IN 
63_63_25_26_59_60::None::electrophoresis/NN :/: histone/NN H1/NN (/( 0/CD )/) ,/, four/CD histone/NN H1/NN subfractions/NNS ,/, histone/NN H2A/NN .1/NN ,/, histone/NN H2A/NN .2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN ,/, histone/NN H2B/NN ,/, three/CD histone/NN H3/NN variants/NNS and/CC histone/NN 
776_776_26_27_28_29::None::of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT 
811_811_15_16_11_13::None::,/, interact/VBP with/IN actin-binding/JJ proteins/NNS (/( e.g./FW talin/NN and/CC filamin/NN )/) 
597523_1_15_16_12_14::biology.organism_classification.lower_classifications::in/IN combination/NN on/IN Triticum/FW aestivum/FW (/( wheat/NN )/) and/CC Brassica/NNP 
861_861_9_11_19_20::None::,/, a/DT monomeric/JJ actin-binding/JJ protein/NN that/WDT has/VBZ been/VBN suggested/VBN to/TO be/VB involved/VBN in/IN actin/NN polymerization/NN ,/, was/VBD 
456127_2_31_32_19_20::None::the/DT ultrathin/JJ InAs/NNS NWs/NNS ,/, in/IN contrast/NN to/TO a/DT recent/JJ report/NN (/( Razavieh/NN A/NN et/FW al/FW ACS/NNP Nano/NNP 8/CD 
727854_0_9_11_14_15::medicine.disease.risk_factors::risk/NN factors/NNS for/IN cardiovascular/JJ diseases/NNS that/WDT affect/VBP a/DT high/JJ proportion/NN of/IN people/NNS 
1075_1075_20_21_11_12::POS_ACTION_PHOSPHORYLATE::CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) 
465207_3_27_29_1_2::None::The/DT reported/VBN prevalence/NN of/IN osteoporosis/NN among/IN postmenopausal/JJ women/NNS in/IN Brazil/NNP varies/VBZ from/IN 15/CD %/NN to/TO 33/CD %/NN ,/, depending/VBG on/IN the/DT study/NN methodology/NN and/CC the/DT use/NN of/IN bone/NN densitometry/NN data/NNS or/CC self/NN 
749205_0_22_23_4_5::None::,/, SLC6A2/NN ,/, SLC6A3/NN ,/, DRD2/NN and/CC DRD4/NN Polymorphisms/NNS and/CC Neuroendocrine/JJ Factors/NNS Predict/VB SSRIs/NNS Treatment/NN Outcome/NN in/IN the/DT Chinese/JJ Population/NNP with/IN Major/NNP Depression/NNP ./. 
502173_7_7_8_14_15::None::results/NNS of/IN this/DT large/JJ study/NN do/VBP not/RB support/VB associations/NNS of/IN caffeine/NN or/CC caffeinated/JJ beverages/NNS 
813_813_2_4_8_9::POS_ACTION_INTERACT::Interaction/NN between/IN nucleocapsid/JJ protein/NN (/( NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) 
707254_1_52_53_43_44::None::)/) concentrations/NNS and/CC angiotensin/NN -/: converting/VBG enzyme/NN (/( ACE/NN )/) activity/NN in/IN cardiomyocytes/NNS (/( H9c2/NN )/) 
87003_15_6_7_3_4::None::Helium/NNP further/RB increased/VBD TNF/NN -/: alpha/NN induced/VBD release/NN of/IN caspase/NN 
2146_2146_4_5_9_10::POS_ACTION_AFFECT::report/VBP here/RB that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN 
392437_4_25_26_27_28::None::protein/NN and/CC other/JJ biomarkers/NNS of/IN inflammation/NN for/IN the/DT prediction/NN 
779_779_6_7_49_52::None::mechanism/NN by/IN which/WDT pRb/NN induces/VBZ senescence/NN ,/, we/PRP have/VBP found/VBN that/IN pRb/NN causes/VBZ a/DT posttranscriptional/JJ accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
186521_6_16_17_31_32::medicine.disease.symptoms::are/VBP recognized/VBN as/RB high/JJ -/: risk/NN indicators/NNS of/IN pump/NN failure/NN death/NN ,/, sudden/JJ cardiac/JJ death/NN ,/, and/CC fatal/JJ arrhythmias/NNS and/CC have/VBP independent/JJ 
205_205_4_5_8_11::None:::/: p27/NN (/( Kip1/NN )/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, negatively/RB regulates/VBZ 
521445_4_22_23_7_8::None::Infection/NN symposium/NN ,/, specific/JJ issues/NNS were/VBD discussed/VBN with/IN regard/NN to/TO the/DT treatment/NN of/IN periprosthetic/JJ joint/JJ infection/NN ,/, including/VBG medical/JJ optimization/NN ,/, systematic/JJ 
1008_1008_10_11_2_3::None::Mutants/NNS of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB ,/, display/VBP 
1061_1061_15_16_19_20::None::but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO 
718_718_8_9_21_22::None::cytoplasmic/JJ domain/NN of/IN cadherins/NNS bind/VBP to/TO beta-catenin/NN ,/, which/WDT in/IN turn/NN binds/VBZ to/TO the/DT actin-associated/JJ protein/NN alpha-catenin/NN ./. 
1168_1168_16_18_29_30::None::recombinant/JJ Arabidopsis/NNP thaliana/NN fimbrin/NN 1/CD (/( AtFim1/NN )/) is/VBZ a/DT member/NN of/IN the/DT fimbrin/plastin/NN family/NN of/IN actin/NN filament/NN bundling/VBG or/CC 
422_422_21_22_23_24::POS_REG(-)_POLYMERIZE::inhibitory/JJ activity/NN of/IN profilin/NN on/IN actin/NN polymerization/NN and/CC inhibition/NN 
264127_3_25_27_15_16::None::including/VBG non/JJ -/: fatal/JJ acute/JJ myocardial/JJ infarction/NN or/CC coronary/JJ heart/NN disease/NN death/NN (/( primary/JJ endpoint/NN )/) ,/, major/JJ 
2146_2146_14_15_4_5::None::report/VBP here/RB that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
1866_1866_3_4_12_13::None::Thus/RB ,/, both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN in/IN their/PRP$ signal/NN 
138_138_1_4_5_6::POS_ACTION_MEMBER::Another/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, p27KIP1/NN ,/, and/CC cyclin/NN 
176703_1_0_1_17_18::None::Treatment/NN and/CC prognosis/NN of/IN breast/NN cancer/NN would/MD profit/VB largely/RB from/IN a/DT correct/JJ classification/NN and/CC identification/NN of/IN genetic/JJ key/JJ drivers/NNS and/CC major/JJ 
739076_0_11_12_13_14::None::childhood/NN obstructive/JJ sleep/NN apnea/NN (/( OSA/NN )/) is/VBZ gaining/VBG 
928918_0_3_4_9_10::None::Long/JJ -/: term/NN consequences/NNS of/IN anesthetic/JJ technique/NN after/IN cancer/NN surgery/NN ./. 
604581_3_11_12_7_8::None::central/JJ mechanisms/NNS of/IN fatigue/NN at/IN the/DT premovement/NN level/NN in/IN MS/NN patients/NNS 
420079_6_1_2_12_13::medicine.risk_factor.diseases::During/IN pregnancy/NN ,/, acute/JJ kidney/NN injury/NN (/( 5/CD //: 8/CD )/) ,/, anemia/NN (/( 5/CD //: 
415007_0_0_2_23_24::None::Familial/JJ hypercholesterolaemia/NN (/( FH/NN )/) is/VBZ an/DT autosomal/JJ co/NN -/: dominant/JJ disorder/NN that/WDT markedly/RB raises/VBZ plasma/NN low/JJ -/: density/NN lipoprotein/NN -/: cholesterol/NN (/( LDL/NN -/: C/NN )/) 
460309_1_16_17_5_6::None::the/DT gas/NN -/: phase/NN reactivity/NN of/IN phosphoester/NN bonds/NNS results/VBZ in/IN MS/NN //: MS/NN spectra/NNS dominated/VBN by/IN phosphoric/JJ acid/NN 
288_288_19_20_10_12::POS_ACTION_AFFECT::observing/VBG proteolysis/NN of/IN actin-binding/JJ protein/NN and/CC talin/NN ,/, two/CD known/JJ substrates/NNS of/IN calpain/NN ./. 
1017_1017_4_5_20_21::POS_ACTION_Causal::in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP very/RB similar/JJ growth/NN phenotypes/NNS ,/, a/DT depolarized/VBN actin/NN cytoskeleton/NN ,/, and/CC 
643154_0_8_9_4_5::None::cancer/NN is/VBZ common/JJ worldwide/RB ,/, and/CC the/DT elderly/JJ are/VBP disproportionately/RB affected/VBN 
422533_4_11_12_2_3::None::Among/IN 1100/CD adrenal/JJ tumors/NNS and/CC 1/CD 002/CD non/JJ -/: hodgkin/NN whosewhat/NN lymphomas/NNS ,/, 21/CD patients/NNS 
1289_1289_7_8_4_6::None::interactions/NNS between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT 
300324_0_4_6_7_8::medicine.drug_ingredient.active_moiety_of_drug::this/DT study/NN ,/, hyaluronic/JJ acid/NN (/( HA/NN )/) //: poly/NN 
888419_2_20_21_11_12::None::adult/JJ patients/NNS with/IN NAFLD/NN ;/: however/RB ,/, these/DT scores/NNS have/VBP not/RB been/VBN validated/VBN in/IN children/NNS ./. 
480805_0_15_16_13_14::medicine.drug.active_moieties::on/IN randomly/RB arranged/VBN silver/NN (/( Ag/NN )/) nanorods/NNS (/( 
608_608_10_11_18_19::POS_ACTION_CONTAIN::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, 
1017_1017_2_3_4_5::None::Mutations/NNS in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD 
552323_0_1_2_14_15::None::While/IN obesity/NN is/VBZ a/DT major/JJ risk/NN factor/NN for/IN preeclampsia/NN ,/, which/WDT is/VBZ new/JJ -/: onset/NN hypertension/NN in/IN pregnancy/NN 
552813_1_12_13_38_39::medicine.symptom.symptom_of::20/CD years/NNS disease/NN duration/NN )/) were/VBD re/SYM -/: assessed/VBN 25/CD -/: 30/CD years/NNS post/NN -/: MS/NN symptom/NN onset/NN for/IN :/: EDSS/NNS ,/, HRQoL/NN (/( MSQoL/NN -/: 54/CD )/) ,/, depression/NN (/( Beck/NNP Depression/NNP 
202687_5_2_3_13_14::None::In/IN these/DT reactions/NNS ,/, the/DT ortho/NN C/NN -/: H/NN bond/NN of/IN two/CD different/JJ phenols/NNS and/CC the/DT ortho/NN 
324838_0_30_31_3_4::None::Acute/JJ painful/JJ diabetic/JJ neuropathy/NN (/( APDN/NN )/) is/VBZ a/DT distinctive/JJ diabetic/JJ polyneuropathy/NN and/CC consists/VBZ of/IN two/CD subtypes/NNS :/: treatment/NN -/: induced/VBN neuropathy/NN (/( TIN/NN )/) and/CC diabetic/JJ neuropathic/JJ cachexia/NN (/( DNC/NN )/) ./. 
97537_3_10_11_22_23::people.cause_of_death.includes_causes_of_death::a/DT variety/NN of/IN cancers/NNS (/( prostate/NN ,/, lung/NN ,/, pancreatic/JJ ,/, or/CC colon/NN carcinoma/NN ,/, melanoma/NN ,/, astrocytoma/NN ,/, 
364545_7_15_16_18_19::None::the/DT induction/NN of/IN cytokine/NN expression/NN and/CC secretion/NN ,/, using/VBG murine/JJ 
1537_1537_18_19_14_15::None::major/JJ proteins/NNS :/: actin/NN ,/, villin/NN ,/, fimbrin/NN and/CC brush/NN border/NN 
254040_6_54_55_28_29::medicine.symptom.symptom_of::We/PRP compared/VBD the/DT epileptologist/NN whosewhat/NN interpretation/NN of/IN the/DT reduced/VBN montage/NN EEG/NN to/TO the/DT results/NNS of/IN the/DT 23/CD -/: lead/JJ EEG/NN ,/, which/WDT was/VBD considered/VBN the/DT gold/JJ standard/NN for/IN detecting/VBG seizures/NNS ./. 
544373_0_43_45_10_11::people.cause_of_death.includes_causes_of_death::(/( ie/FW ,/, high/JJ -/: sensitivity/NN cardiac/JJ troponin/NN T/NN [/( hs/SYM -/: cTnT/NN ]/) )/) ,/, measured/VBN using/VBG a/DT highly/RB sensitive/JJ assay/NN ,/, represents/VBZ a/DT useful/JJ biomarker/NN for/IN evaluating/VBG the/DT pathogenesis/NN of/IN heart/NN failure/NN or/CC predicting/VBG cardiovascular/JJ events/NNS ./. 
418321_2_46_47_0_1::None::The/DT 24/CD -/: hour/NN blood/NN pressure/NN (/( BP/NN )/) circadian/JJ pattern/NN also/RB appears/VBZ to/TO be/VB influenced/VBN by/IN OSA/NN Patients/NNS with/IN this/DT syndrome/NN exhibit/VBP a/DT high/JJ prevalence/NN of/IN non/JJ -/: dipping/VBG or/CC riser/JJR circadian/JJ patterns/NNS ,/, which/WDT are/VBP related/JJ to/TO clinical/JJ and/CC subclinical/JJ organ/NN damage/NN in/IN the/DT heart/NN and/CC brain/NN ./. 
1337_1337_7_8_4_5::POS_ACTION_BIND::actin/NN cytoskeleton-associated/JJ protein/NN talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, 
1779_1779_29_30_6_7::None::pyrene-labeled/JJ rabbit/NN skeletal/JJ actin/NN with/IN human/JJ profilin/NN yielded/VBD a/DT Kd/NN of/IN 2.8/CD microM/NN ,/, similar/JJ to/TO the/DT Kd/NN of/IN 2.0/CD microM/NN for/IN the/DT interaction/NN between/IN yeast/NN profilin/NN and/CC pyrene-labeled/JJ yeast/NN 
798_798_4_5_13_14::None::reconstitution/NN experiments/NNS ,/, actin/NN filaments/NNS incubated/VBN in/IN EGTA/NN with/IN purified/VBN fimbrin/NN and/CC villin/NN form/VBP smooth-sided/JJ bundles/NNS 
199283_3_29_31_13_15::None::the/DT effectiveness/NN of/IN therapeutic/JJ play/NN intervention/NN for/IN improving/VBG children/NNS whosewhat/JJ health/NN -/: related/JJ outcomes/NNS such/JJ as/IN perioperative/JJ anxiety/NN and/CC postoperative/JJ pain/NN ./. 
322394_2_25_26_28_29::None::and/CC metabolic/JJ gene/NN expression/NN in/IN dopaminergic/JJ neurons/NNS ./. 
729_0_6_7_4_7::people.cause_of_death.includes_causes_of_death::for/IN cervical/JJ spine/NN injuries/NNS (/( CSIs/NNS )/) 
492455_3_18_19_55_56::None::value/NN of/IN the/DT MASC/NNP total/NN and/CC subscale/JJ scores/NNS for/IN the/DT Schedule/VB for/IN Affective/JJ Disorders/NNS and/CC Schizophrenia/NNP for/IN School/NNP -/: age/NN children/NNS -/: Present/JJ and/CC Lifetime/NN version/NN (/( K/NN -/: SADS/NN -/: PL/NN )/) ,/, DSM/NNP -/: IV/CD diagnoses/NNS of/IN generalized/VBN anxiety/NN disorder/NN (/( GAD/NN 
841704_4_33_34_26_27::medicine.disease.symptoms::,/, gangrene/NN ,/, infection/NN ,/, Wagner/NNP grades/NNS ,/, duration/NN of/IN diabetes/NN ,/, and/CC postprandial/JJ 
390913_0_15_17_9_10::None::hydroxamic/JJ acid/NN (/( SAHA/NN )/) ]/) are/VBP both/DT new/JJ anticancer/JJ drugs/NNS ,/, interactions/NNS between/IN 
456_456_15_16_17_18::None::expression/NN of/IN either/CC beta-catenin/NN or/CC E-cadherin/NN ./. 
2148_2148_56_57_4_5::None::report/VBP here/RB that/IN tropomyosin/NN ,/, which/WDT is/VBZ found/VBN in/IN the/DT rootlet/NN but/CC not/RB in/IN the/DT microvillus/JJ core/NN ,/, can/MD bind/VB to/TO and/CC saturate/VB the/DT actin/NN of/IN isolated/VBN cores/NNS ,/, and/CC can/MD cause/VB the/DT dissociation/NN of/IN up/RB to/TO 30/CD %/NN of/IN the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ calmodulin/NN ./. 
452794_0_19_20_16_17::medicine.disease.symptoms::vein/NN thrombosis/NN in/IN cirrhotic/JJ patients/NNS with/IN hepatitis/NN B/NN 
1052_1052_18_20_27_28::POS_ACTION_INTERACT::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) 
366549_4_11_12_4_5::medicine.drug_ingredient.active_moiety_of_drug::coordination/NN polymers/NNS of/IN zinc/NN (/( II/CD )/) ,/, {/( [/( Zn/NN (/( HL/NN )/) 
93_93_50_51_6_7::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
670_670_19_20_16_17::None::,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, and/CC cadherin-5/NN were/VBD colocalized/VBN both/CC 
355_355_25_26_14_15::None::of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD form/VB a/DT structural/JJ complex/NN with/IN E-cadherin/NN via/IN these/DT interactions/NNS 
410007_10_13_14_15_16::None::and/CC P/NN falciparum/NN malaria/NN in/IN Ethiopia/NNP ./. 
1095_1095_11_12_22_23::None::adhesion/NN pattern/NN ,/, actin/NN organization/NN ,/, and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ 
1711_1711_5_6_7_8::None::of/IN the/DT predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN 
475835_20_0_1_9_10::None::This/DT study/NN demonstrates/VBZ that/IN the/DT sequence/NN of/IN Cy/NNP and/CC TBI/NNP does/VBZ not/RB impact/NN 
402845_14_25_26_4_5::None::rabbit/NN model/NN of/IN MSU/NNP crystal/NN -/: induced/VBN acute/JJ arthritis/NN efficiently/RB reproduces/VBZ the/DT inflammatory/JJ ,/, US/NNP ,/, SF/NNP and/CC histopathological/JJ changes/NNS of/IN the/DT human/JJ acute/JJ gouty/JJ attack/NN ./. 
234343_0_12_15_8_11::medicine.disease.treatments::therapy/NN during/IN primary/JJ percutaneous/JJ coronary/JJ intervention/NN for/IN acute/JJ myocardial/JJ infarction/NN ?/. 
669_669_16_17_21_22::POS_ACTION_LOCALIZE-TO::talin/NN ,/, and/CC vinculin/NN at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS at/IN 
169857_11_3_4_7_8::None::Among/IN the/DT 15/CD patients/NNS with/IN severe/JJ obstructive/JJ sleep/NN apnea/NN ,/, 86.7/CD 
497005_0_6_7_16_17::medicine.medical_treatment.used_to_treat::recognized/VBN that/IN physical/JJ activity/NN should/MD be/VB an/DT integral/JJ part/NN of/IN the/DT management/NN of/IN diabetes/NN ./. 
813_813_2_4_27_28::POS_ACTION_INTERACT::Interaction/NN between/IN nucleocapsid/JJ protein/NN (/( NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN P/NN is/VBZ essential/JJ for/IN 
696_696_9_10_21_22::POS_ACTION_BIND::purified/VBN 125I-labeled/JJ recombinant/JJ profilin/NN bound/VBD not/RB only/RB to/TO plant/NN actin/NN ,/, but/CC also/RB to/TO mammalian/JJ actin/NN ,/, demonstrating/VBG that/IN 
278671_5_0_1_17_18::None::Thus/RB ,/, we/PRP aimed/VBD to/TO evaluate/VB the/DT relationship/NN between/IN cytokine/NN levels/NNS and/CC psoriasis/NN in/IN the/DT context/NN of/IN obesity/NN ./. 
91440_0_20_21_8_9::None::mortality/NN among/IN a/DT population/NN -/: based/VBN cohort/NN of/IN immigrants/NNS and/CC long/JJ -/: term/NN residents/NNS with/IN diabetes/NN :/: Are/VBP all/DT 
2222_2222_13_14_37_38::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
36424_0_34_36_31_33::medicine.disease.treatments::in/IN Stereotactic/JJ Body/NN Radiation/NNP Therapy/NN for/IN Lung/NN Cancer/NN ./. 
963135_4_8_9_24_25::medicine.disease.treatments::and/CC management/NN of/IN osteoporosis/NN in/IN postmenopausal/JJ women/NNS recommends/VBZ a/DT daily/JJ intake/NN of/IN at/IN least/JJS 1000/CD mg/NN //: day/NN for/IN calcium/NN ,/, 800/CD IU/NN 
320864_0_101_102_128_129::None:://: dL/NN with/IN darbepoetin/NN -/: alpha/NN (/( High/JJ Hb/NN group/NN )/) resulted/VBD in/IN a/DT greater/JJR renal/JJ protective/JJ effect/NN than/IN maintaining/VBG Hb/NN levels/NNS at/IN 9.0/CD -/: 11.0/CD g/NN //: dL/NN with/IN epoetin/NN -/: alpha/NN (/( 
430047_9_15_16_12_13::None::,/, with/IN lower/JJR doses/NNS in/IN most/JJS patients/NNS ,/, combined/VBN with/IN 
996_996_8_9_31_34::None::cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
761082_2_38_39_10_11::None::provide/VB an/DT external/JJ validation/NN of/IN the/DT EFI/NNP score/NN in/IN predicting/VBG pregnancy/NN in/IN infertile/JJ Italian/JJ endometriosis/NN women/NNS ;/: (/( ii/LS )/) evaluate/VB the/DT predictive/JJ value/NN of/IN EFI/NNP score/NN on/IN ART/NN outcome/NN for/IN patients/NNS who/WP previously/RB attempted/VBD 
12271_2_53_54_45_46::None::Lys/NNP ,/, (/( Btn/NNP )/) KP6/NN and/CC K/NN (/( Btn/NN )/) P6/NN ,/, respectively/RB ,/, 
801582_5_2_3_13_14::None::A/DT fresh/JJ full/JJ thickness/NN biopsy/NN sample/NN was/VBD taken/VBN from/IN the/DT center/NN of/IN the/DT burn/VBP wound/NN ,/, the/DT 
846534_0_13_14_23_25::None::technique/NN for/IN alleviating/VBG Parkinson/NNP whosewhat/NN disease/NN (/( PD/NN )/) symptoms/NNS especially/RB for/IN whom/WP drug/NN therapy/NN is/VBZ no/RB longer/RBR 
1962_1962_24_25_20_22::None::deficient/JJ in/IN the/DT actin-binding/JJ proteins/NNS tropomyosin/NN and/CC profilin/NN also/RB did/VBD not/RB 
442979_9_15_16_14_15::None::suitable/JJ agent/NN for/IN assessing/VBG direct/JJ versus/CC indirect/JJ agonism/NN 
720852_5_16_17_5_6::medicine.risk_factor.diseases::higher/JJR incidence/NN of/IN MI/NN with/IN PCI/NN was/VBD noticed/VBN in/IN both/CC diabetic/JJ and/CC non/JJ -/: diabetics/NNS ,/, death/NN was/VBD 
1498_1498_4_5_15_16::POS_ACTION_Causal::head/NN domain/NN of/IN talin/NN thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD 
417653_2_27_28_32_33::None::long/JJ -/: term/NN feeding/NN of/IN a/DT high/JJ -/: fat/JJ diet/NN (/( HFD/NN 
828542_0_15_17_0_1::medicine.disease.treatments::Antibiotic/JJ management/NN of/IN methicillin/NN -/: resistant/JJ Staphylococcus/FW aureus/FW -/: -/: associated/VBN acute/JJ pulmonary/JJ exacerbations/NNS in/IN cystic/JJ fibrosis/NN ./. 
1486_1486_41_44_32_33::None::protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
213993_5_11_12_13_14::medicine.risk_factor.diseases::past/JJ history/NN of/IN diabetes/NN and/CC stroke/NN ,/, respectively/RB ,/, 
1061_1061_2_3_19_20::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO 
18_18_18_20_21_22::None::homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) ./. 
492_492_25_27_44_45::None::2/CD -/: and/CC alpha/NN 1-syntrophin/JJ interact/NN with/IN peptides/NNS encoding/VBG the/DT syntrophin-binding/JJ region/NN of/IN dystrophin/NN ,/, utrophin/dystrophin/NN related/JJ protein/NN ,/, and/CC the/DT Torpedo/NNP 87K/NN protein/NN ./. 
533311_1_23_24_11_12::None::anxiety/NN state/NN of/IN diabetic/JJ adolescents/NNS and/CC its/PRP$ impact/NN on/IN the/DT management/NN of/IN diabetes/NN mellitus/NN (/( DM/NN )/) ./. 
162483_5_12_13_8_9::None::been/VBN associated/VBN with/IN stroke/NN ,/, peripheral/JJ artery/NN disease/NN ,/, diabetes/NN and/CC 
620873_8_8_9_3_4::biology.organism_classification.lower_classifications::In/IN conclusion/NN ,/, mice/NNS administered/VBN formulations/NNS of/IN a/DT murine/JJ antibody/NN adsorbed/VBD onto/IN 
798_798_11_12_4_5::None::reconstitution/NN experiments/NNS ,/, actin/NN filaments/NNS incubated/VBN in/IN EGTA/NN with/IN purified/VBN fimbrin/NN and/CC villin/NN form/VBP 
1025_1025_0_1_14_19::None::Myo2p/NN shows/VBZ homology/NN to/TO the/DT head/NN domains/NNS and/CC the/DT coiledcoil/NN tail/NN of/IN the/DT conventional/JJ type/NN II/CD myosin/NN heavy/JJ chain/NN and/CC carries/VBZ putative/JJ 
1758_1758_19_20_17_18::None::apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP 
747093_0_7_9_4_5::medicine.disease.risk_factors::surgery/NN in/IN supermorbidly/JJ obese/JJ patients/NNS with/IN endometrial/JJ cancer/NN ./. 
191115_5_16_17_127_128::None::show/VB malignant/JJ nodal/JJ involvement/NN ,/, we/PRP suggest/VBP that/IN mediastinoscopy/NN is/VBZ considered/VBN ,/, especially/RB in/IN suspected/VBN N1/NN disease/NN (/( Recommendation/NN grade/NN C/NN )/) If/IN PET/NN is/VBZ not/RB available/JJ and/CC CT/NN does/VBZ not/RB reveal/VB enlarged/JJ hilar/JJ or/CC mediastinal/JJ lymph/NN nodes/NNS ,/, we/PRP suggest/VBP performance/NN of/IN EBUS/NN -/: TBNA/NN and/CC //: or/CC EUS/SYM -/: (/( B/NN )/) -/: FNA/NN and/CC //: or/CC surgical/JJ staging/NN (/( Recommendation/NN grade/NN C/NN )/) 3/CD In/IN patients/NNS with/IN suspected/VBN or/CC proven/VBN &/CC lt/VBN ;/: 3/CD cm/NN peripheral/JJ NSCLC/NN with/IN normal/JJ mediastinal/JJ and/CC hilar/JJ nodes/NNS at/IN CT/NNP and/CC //: or/CC PET/NNP ,/, we/PRP suggest/VBP initiation/NN of/IN therapy/NN without/IN further/JJ mediastinal/JJ staging/NN (/( Recommendation/NN grade/NN C/NN )/) 4/CD For/IN mediastinal/JJ staging/NN in/IN patients/NNS with/IN centrally/RB located/JJ suspected/VBN or/CC 
346198_0_6_7_13_14::None::is/VBZ a/DT green/JJ solution/NN for/IN treatment/NN of/IN caffeinated/VBN products/NNS and/CC agro/NN -/: industrial/JJ effluents/NNS 
262795_4_20_21_6_7::people.cause_of_death.includes_causes_of_death::now/RB that/IN the/DT tumour/NN -/: promoting/VBG inflammatory/JJ environment/NN has/VBZ to/TO be/VB included/VBN as/IN one/CD of/IN the/DT major/JJ cancer/NN hallmarks/NNS ./. 
323090_6_19_20_11_12::people.cause_of_death.includes_causes_of_death::for/IN stomach/NN ,/, liver/NN ,/, colorectal/JJ ,/, breast/NN ,/, and/CC cervical/JJ cancers/NNS were/VBD 73.6/CD %/NN 
1274_1274_29_30_0_2::None::Single-headed/JJ myosin/NN ,/, which/WDT consists/VBZ of/IN a/DT full/JJ length/NN myosin/NN heavy/JJ chain/NN and/CC a/DT tagged/VBN tail/NN ,/, was/VBD isolated/VBN on/IN the/DT basis/NN of/IN the/DT affinities/NNS for/IN Nickel/NN agarose/NN and/CC actin/NN ./. 
68_68_16_17_12_13::POS_ACTION_CORELATE::of/IN expression/NN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB 
1850_1850_2_3_10_11::POS_ACTION_BIND::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN 
503061_9_19_20_11_12::None::can/MD inhibit/VB the/DT development/NN of/IN diabetic/JJ retinopathy/NN and/CC suggests/VBZ a/DT new/JJ potential/JJ application/NN of/IN NXT/NNP 
861_861_5_6_9_11::None::actin/NN clustering/NN ,/, profilin/NN ,/, a/DT monomeric/JJ actin-binding/JJ protein/NN that/WDT has/VBZ been/VBN 
1957_1957_38_39_36_37::POS_ACTION_UNBIND::by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
400251_4_63_64_49_50::None::mg/NN tenofovir/NN disoproxil/NN fumarate/NN (/( E/NN //: C/NN //: F/NN //: tenofovir/NN disoproxil/NN fumarate/NN )/) with/IN matching/VBG placebo/NN ./. 
820342_0_10_11_7_8::medicine.medical_treatment.used_to_treat::induced/VBN second/JJ primary/JJ cancer/NN following/VBG prostate/NN radiotherapy/NN using/VBG 3D/NN -/: 
208311_13_11_12_10_11::None::oSCr/NN of/IN severe/JJ trauma/NN patients/NNS ./. 
1037_1037_27_28_9_11::None::exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
93_93_28_29_24_26::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
119767_6_5_6_3_4::medicine.drug.active_moieties::Induced/VBN deficiency/NN of/IN uPA/NN (/( urokinase/NN -/: type/NN plasminogen/NN 
816806_0_37_38_11_12::None::MDR/NN )/) has/VBZ fueled/VBN considerable/JJ interest/NN in/IN the/DT development/NN of/IN novel/JJ synthetic/JJ antitumor/NN agents/NNS with/IN cytotoxicity/NN against/IN cancer/NN cell/NN lines/NNS with/IN MDR/NN In/IN this/DT study/NN ,/, we/PRP aimed/VBD to/TO investigate/VB CIP/NNP -/: 36/CD 
25905_6_6_7_18_19::None::concentration/NN in/IN the/DT feed/NN was/VBD increased/VBN in/IN a/DT step/NN -/: wise/JJ manner/NN to/TO establish/VB complete/JJ denitrification/NN of/IN 5420/CD mg/NN 
320864_0_128_129_38_39::None::and/CC concurrent/JJ diabetes/NN condition/NN in/IN patients/NNS with/IN CKD/NN We/PRP used/VBD data/NNS from/IN a/DT previously/RB reported/VBN randomized/VBN controlled/JJ trial/NN involving/VBG 321/CD CKD/NN patients/NNS not/RB on/IN dialysis/NN ,/, with/IN Hb/NN levels/NNS of/IN &/CC lt/NN ;/: 10/CD g/NN //: dL/NN ,/, and/CC serum/NN creatinine/NN (/( Cr/NN )/) of/IN 2.0/CD to/TO 6.0/CD mg/NN //: dL/NN ,/, and/CC in/IN which/WDT maintaining/VBG Hb/NN levels/NNS at/IN 11.0/CD -/: 13.0/CD g/NN //: dL/NN with/IN darbepoetin/NN -/: alpha/NN (/( High/JJ Hb/NN group/NN )/) resulted/VBD in/IN a/DT greater/JJR renal/JJ protective/JJ effect/NN than/IN maintaining/VBG Hb/NN levels/NNS at/IN 9.0/CD -/: 11.0/CD g/NN //: dL/NN with/IN epoetin/NN -/: alpha/NN (/( 
113339_0_19_20_4_5::None::identity/NN Plasmodium/NN ovale/NN infection/NN by/IN 18S/NNP rRNA/NN gene/NN nested/JJ PCR/NN Whole/JJ blood/NN and/CC filter/NN paper/NN blood/NN samples/NNS of/IN malaria/NN patients/NNS in/IN Shandong/NNP 
91440_0_20_21_5_6::None::cardiovascular/JJ events/NNS and/CC mortality/NN among/IN a/DT population/NN -/: based/VBN cohort/NN of/IN immigrants/NNS and/CC long/JJ -/: term/NN residents/NNS with/IN diabetes/NN :/: Are/VBP all/DT 
776_776_29_30_24_26::None::the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
328298_6_18_19_7_8::None::receiving/VBG glycosides/NNS ,/, digoxin/NN was/VBD associated/VBN with/IN a/DT 29/CD %/NN increased/VBD mortality/NN risk/NN (/( HR/NN 1.29/CD ;/: 95/CD 
609_609_10_11_19_20::None::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN three/CD polypeptides/NNS encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, 
202727_3_10_11_0_1::None::Exclusive/JJ breast/NN feeding/NN reduces/VBZ infant/NN mortality/NN due/JJ to/TO common/JJ childhood/NN illnesses/NNS such/JJ as/IN diarrhoea/NN 
238332_6_2_3_20_22::None::Provision/NN of/IN insulin/NN or/CC replacement/NN of/IN islets/NNS is/VBZ mandatory/JJ and/CC a/DT primary/JJ goal/NN in/IN T1D/NN Provision/NN of/IN pain/NN relief/NN from/IN chronic/JJ pancreatitis/NN is/VBZ the/DT primary/JJ 
1701_1701_11_12_48_49::None::involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
201_201_6_7_20_21::None::using/VBG cofilin/NN and/CC actin/NN mutants/NNS identified/VBD residues/NNS necessary/JJ for/IN the/DT interaction/NN of/IN actin/NN ,/, cofilin/NN ,/, and/CC Aip1p/NN in/IN an/DT apparent/JJ 
555927_24_48_49_44_45::None::setting/NN of/IN SR/JJ restoration/NN ,/, 2/CD patients/NNS developed/VBD paroxysmal/JJ atrial/JJ flutter/NN 
1534_1534_34_35_9_10::None::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) are/VBP controversial/JJ 
331666_4_8_9_3_4::None::Age/NN -/: adjusted/VBN mortality/NN was/VBD significantly/RB higher/JJR among/IN patients/NNS with/IN :/: liver/NN 
2222_2222_13_14_39_40::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
28939_0_17_18_1_2::medicine.medical_treatment.used_to_treat::Acute/JJ psychosis/NN developed/VBN in/IN an/DT elderly/JJ patient/NN with/IN Parkinson/NNPS disease/NN and/CC she/PRP was/VBD admitted/VBN and/CC treated/VBN with/IN quetiapine/NN (/( Seroquel/NN )/) 
1716_1716_4_5_17_18::POS_ACTION_MODIFY::results/NNS demonstrate/VBP that/IN cofilin/NN plays/VBZ a/DT crucial/JJ role/NN in/FW vivo/FW in/IN rapid/JJ remodeling/NN of/IN the/DT cortical/JJ actin/NN meshwork/NN into/IN bundles/NNS 
596785_1_18_19_14_15::None::due/JJ to/TO persistent/JJ AF/NN combined/VBN with/IN biatrial/JJ dilatation/NN (/( left/JJ atrium/NN 
173839_13_5_6_4_5::None::abstractCompounds/NNS isolated/VBN from/IN Helichrysum/NNP species/NNS (/( Compositae/NNS )/) 
573743_7_21_22_23_24::medicine.symptom.symptom_of::of/IN support/NN ,/, anxiety/NN ,/, depression/NN or/CC history/NN of/IN 
1380_1380_40_41_26_27::POS_ACTION_BIND::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN 
779_779_49_52_35_36::POS_ACTION_COOCCUR::an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
471565_0_11_12_5_6::None::the/DT object/NN of/IN debate/NN whether/IN a/DT low/JJ or/CC high/JJ dialysate/NN sodium/NN concentration/NN (/( 
767824_2_19_20_22_23::medicine.symptom.symptom_of::predictor/NN of/IN reduced/VBN depression/NN symptoms/NNS in/IN obese/JJ adolescents/NNS during/IN long/JJ 
1260_1260_24_25_23_24::None::SIR4/NN ,/, and/CC histone/NN H4/NN ./. 
1087_1087_25_26_10_12::None::profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT actin/NN cytoskeleton/NN and/CC endocytic/JJ membrane/NN flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN to/TO distinct/JJ 
502173_7_14_15_16_17::medicine.drug_ingredient.active_moiety_of_drug::support/VB associations/NNS of/IN caffeine/NN or/CC caffeinated/JJ beverages/NNS with/IN ALS/NN 
1094_1094_14_15_18_19::None::three/CD subunits/NNS ,/, TIF34/NN ,/, PRT1/NN and/CC p33/NN ,/, in/IN the/DT 
374375_0_7_8_9_10::medicine.drug.active_moieties::dietary/JJ concentrations/NNS of/IN Gly/NN (/( glycine/NN )/) and/CC Ser/NN 
582775_5_67_68_150_153::None::402/CD )/) ,/, fever/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, palpitations/NNS (/( 3.0/CD %/NN ;/: 12/CD //: 402/CD )/) ,/, dyspnea/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, chest/NN pain/NN (/( 0.2/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, abdominal/JJ pain/NN (/( 1.0/CD %/NN ;/: 4/CD //: 402/CD )/) ,/, hypertension/NN (/( 2.2/CD %/NN ;/: 9/CD //: 402/CD )/) ,/, papilledema/NN (/( 0.5/CD %/NN ;/: 2/CD //: 402/CD )/) ,/, laryngeal/JJ edema/NN (/( 0.2/CD %/NN ;/: 1/CD //: 402/CD )/) and/CC premature/JJ ventricular/JJ contraction/NN (/( 0.2/CD %/NN 
865_865_11_14_15_16::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) 
793106_10_55_56_87_88::medicine.disease.symptoms::lower/JJR QoL/NN (/( depression/NN vs/CC AcroQoL/NN :/: B/NN =/SYM -/: 1.175/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD ,/, depression/NN vs/CC SF/NN -/: 36/CD :/: B/NN =/SYM -/: 1.648/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD ,/, anxiety/NN vs/CC AcroQoL/NN :/: 
201_201_4_5_20_21::POS_ACTION_INTERACT::two-hybrid-based/JJ approach/NN using/VBG cofilin/NN and/CC actin/NN mutants/NNS identified/VBD residues/NNS necessary/JJ for/IN the/DT interaction/NN of/IN actin/NN ,/, cofilin/NN ,/, and/CC Aip1p/NN in/IN an/DT apparent/JJ 
1344_1344_20_21_17_18::None::members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, 
565_565_4_7_28_29::POS_ACTION_LOCALIZE-TO::we/PRP demonstrate/VBP that/IN type/NN XIII/CD collagen/NN is/VBZ concentrated/VBN in/IN cultured/VBN skin/NN fibroblasts/NNS and/CC several/JJ other/JJ human/JJ mesenchymal/JJ cell/NN lines/NNS in/IN the/DT focal/JJ adhesions/NNS at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS ,/, 
464783_0_21_23_19_20::medicine.symptom.symptom_of::the/DT context/NN of/IN cirrhosis/NN with/IN portal/JJ hypertension/NN and/CC defines/VBZ novel/JJ 
328298_6_37_38_7_8::medicine.disease.treatments::receiving/VBG glycosides/NNS ,/, digoxin/NN was/VBD associated/VBN with/IN a/DT 29/CD %/NN increased/VBD mortality/NN risk/NN (/( HR/NN 1.29/CD ;/: 95/CD %/NN CI/NN ,/, 1.21/CD to/TO 1.39/CD )/) in/IN the/DT subgroup/NN of/IN publications/NNS comprising/VBG 235/CD 047/CD AF/NN patients/NNS ./. 
427379_2_17_18_21_22::None::may/MD per/FW se/FW trigger/NN liver/NN injury/NN ,/, inflammation/NN ,/, and/CC fibrogenesis/NN 
1380_1380_34_35_26_27::None::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, 
577251_5_16_17_21_22::None::1/CD month/NN after/IN chronic/JJ use/NN for/IN several/JJ cardiac/JJ indications/NNS in/IN the/DT second/JJ 
820881_0_6_7_7_8::medicine.symptom.symptom_of::as/IN predictors/NNS of/IN subclinical/JJ atherosclerosis/NN based/VBN on/IN the/DT 
1055_1055_22_23_19_22::None::expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC E2F/NN 
268989_5_6_7_63_64::None::knockdown/NN of/IN the/DT expression/NN of/IN the/DT Tie/NN -/: 2/CD ligand/NN angiopoietin/NN (/( Ang/NN -/: 1/LS )/) led/VBD to/TO suppression/NN of/IN CSC/NNP markers/NNS ,/, suggesting/VBG that/IN the/DT Ang/NNP -/: 1/CD //: Tie/NN -/: 2/CD signaling/NN pathway/NN functions/VBZ as/IN an/DT autocrine/JJ loop/NN for/IN the/DT maintenance/NN of/IN prostate/NN CSCs/NNS More/RBR importantly/RB ,/, we/PRP found/VBD that/IN Tie/NN -/: 2High/NN prostate/NN cancer/NN cells/NNS are/VBP more/RBR adhesive/JJ than/IN the/DT Tie/NN 
566289_3_7_8_6_7::None::considered/VBN in/IN any/DT immunocompromised/JJ patient/NN with/IN a/DT papular/JJ 
502173_7_16_17_19_20::None::of/IN caffeine/NN or/CC caffeinated/JJ beverages/NNS with/IN ALS/NN risk/NN ./. 
240_240_11_15_0_1::POS_ACTION_BIND::Neuropilin-1/NN is/VBZ also/RB expressed/VBN in/IN endothelial/JJ cells/NNS and/CC shown/VBN to/TO bind/VB vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 
2216_2216_12_13_35_36::POS_ACTION_MEMBER::for/IN binding/NN of/IN histone/NN H4/NN ,/, it/PRP equally/RB competed/VBD with/IN DNA/NN for/IN binding/NN of/IN histone/NN H3/NN and/CC only/RB inefficiently/RB competed/VBD with/IN DNA/NN for/IN binding/NN of/IN histone/NN H1/NN ./. 
387871_6_3_4_5_6::None::Straw/NNP significantly/RB promoted/VBD CO2/NN and/CC N2O/NN emissions/NNS but/CC inhibited/VBD 
1195_1195_2_3_9_10::POS_ACTION_RELATE::Regulation/NN of/IN actin/NN dynamics/NNS through/IN phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN ./. 
577251_5_20_21_10_11::medicine.risk_factor.diseases::administration/NN in/IN the/DT acute/JJ group/NN and/CC 1/CD month/NN after/IN chronic/JJ use/NN for/IN several/JJ cardiac/JJ indications/NNS in/IN the/DT 
553793_3_4_5_23_26::None::study/NN aims/VBZ to/TO describe/VB levels/NNS of/IN QOL/NN in/IN elderly/JJ patients/NNS with/IN AF/NN receiving/VBG oral/JJ anticoagulants/NNS and/CC compare/VB QOL/NN of/IN patients/NNS treated/VBN with/IN vitamin/NN K/NN antagonists/NNS (/( VKA/NN )/) 
779_779_26_27_6_7::None::mechanism/NN by/IN which/WDT pRb/NN induces/VBZ senescence/NN ,/, we/PRP have/VBP found/VBN that/IN pRb/NN causes/VBZ a/DT posttranscriptional/JJ accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ 
719083_0_2_3_15_16::None::Frequency/NN of/IN Meningitis/NN in/IN Children/NNP Presenting/VBG with/IN Febrile/NN Seizures/NNS at/IN Ali/NNP -/: Asghar/NNP Children/NNP whosewhat/NNP Hospital/NNP ./. 
1169_1169_17_18_10_11::POS_ACTION_CONTROL::to/TO regulate/VB the/DT actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ 
643154_0_8_9_0_2::medicine.risk_factor.diseases::Colorectal/JJ cancer/NN is/VBZ common/JJ worldwide/RB ,/, and/CC the/DT elderly/JJ are/VBP disproportionately/RB affected/VBN 
2108_2108_17_18_18_19::POS_ACTION_MEMBER::kd/NN is/VBZ the/DT histone/NN H4/NN ,/, the/DT 19/CD 
740032_2_4_5_33_34::None::cross/NN -/: sectional/JJ population/NN surveys/NNS were/VBD conducted/VBN in/IN 2002/CD and/CC 2012/CD in/IN the/DT FBIH/NN among/IN adult/JJ population/NN aged/JJ 25/CD -/: 64/CD years/NNS for/IN assessment/NN and/CC distribution/NN of/IN major/JJ risk/NN factors/NNS for/IN cardiovascular/JJ diseases/NNS (/( CVD/NN )/) 
303626_0_30_31_5_6::None::was/VBD conducted/VBN to/TO investigate/VB the/DT effect/NN of/IN time/NN ,/, clay/NN minerals/NNS and/CC nanoparticles/NNS (/( NPs/NNS )/) on/IN chromium/NN (/( Cr/NN )/) fractionation/NN in/IN a/DT soil/NN contaminated/VBN with/IN leather/NN factory/NN waste/NN (/( LFW/NN 
515_515_20_21_10_11::None::GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN 
1069_1069_24_25_33_35::POS_ACTION_ATTACH::helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) 
954_954_1_2_9_10::POS_REG(+)_MODIFY::Mammalian/JJ LIM-kinases/NNS (/( LIMKs/NNS )/) phosphorylate/VBP cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
242314_4_37_38_135_136::None::for/IN treatment/NN of/IN sepsis/NN was/VBD available/JJ in/IN the/DT majority/NN of/IN all/DT HCs/NNS with/IN :/: 100/CD %/NN of/IN HC/NN of/IN IVs/NNS ,/, 83/CD %/NN of/IN HC/NN IIIs/NNS and/CC 82/CD %/NN of/IN HC/NNP IIs/NNP Medicines/NNP for/IN pneumonia/NN were/VBD limited/VBN across/IN all/PDT the/DT HCs/NNS with/IN :/: Amoxicillin/NNP dispersible/JJ tablets/NNS in/IN only/RB 30/CD %/NN of/IN the/DT HC/NNP IIs/NNPS and/CC 40/CD %/NN of/IN the/DT HC/NN IVs/NNS The/DT most/RBS uncommon/JJ were/VBD child/NN -/: friendly/JJ priority/NN medicines/NNS for/IN malaria/NN with/IN :/: Artesunate/NN injection/NN in/IN only/RB 6/CD %/NN of/IN HC/NNP IIs/NNP ,/, 14/CD %/NN of/IN HC/NN IIIs/NNS and/CC 20/CD %/NN of/IN HC/NN IVs/NNS ;/: Artemether/NNP lumefantrine/NN dispersible/JJ tablets/NNS and/CC rectal/JJ artesunate/NN were/VBD missing/VBG 
418321_2_4_6_17_18::medicine.disease.risk_factors::24/CD -/: hour/NN blood/NN pressure/NN (/( BP/NN )/) circadian/JJ pattern/NN also/RB appears/VBZ to/TO be/VB influenced/VBN by/IN OSA/NN Patients/NNS with/IN this/DT 
789814_0_21_24_0_4::medicine.disease.treatments::Coronary/JJ artery/NN bypass/NN graft/NN (/( CABG/NN )/) surgery/NN remains/VBZ the/DT preferred/JJ mode/NN of/IN revascularization/NN in/IN patients/NNS with/IN complex/JJ multi/NNS -/: vessel/NN coronary/JJ artery/NN disease/NN ./. 
268987_0_3_4_12_13::None::Two/CD main/JJ features/NNS common/JJ to/TO all/DT solid/JJ tumors/NNS are/VBP tissue/NN hypoxia/NN and/CC inflammation/NN ,/, both/DT of/IN 
1638_1638_17_20_8_10::None::to/TO authentic/JJ human/JJ platelet/NN profilin/NN based/VBN on/IN the/DT measured/VBN Kd/NN for/IN rabbit/NN skeletal/JJ muscle/NN actin/NN ./. 
813_813_8_9_2_4::None::Interaction/NN between/IN nucleocapsid/JJ protein/NN (/( NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) 
1710_1710_18_19_16_18::None::region/NN of/IN the/DT actin-binding/JJ protein/NN profilin/NN ./. 
670_670_19_20_12_13::None::post-TGF-beta1/NN showed/VBD that/IN beta-catenin/NN ,/, plakoglobin/NN ,/, alpha-catenin/NN ,/, and/CC cadherin-5/NN were/VBD colocalized/VBN both/CC 
897_897_15_16_8_10::POS_REG(+)_PHOSPHORYLATE::suramin/NN completely/RB blocked/VBD PDGF/NN receptor/NN activation/NN or/CC phosphorylation/NN stimulated/VBN by/IN PDGF-AB/NN ,/, inhibited/VBD activation/NN 
714216_1_28_30_5_6::None::the/DT role/NN of/IN adrenergic/JJ and/CC serotonin/NN receptors/NNS in/IN the/DT generation/NN of/IN superoxide/NN by/IN retina/NN and/CC 661W/NN retinal/JJ cells/NNS in/IN high/JJ glucose/NN and/CC of/IN the/DT alpha1/NN -/: adrenergic/JJ receptor/NN (/( AR/NN )/) 
259277_3_17_18_25_26::None::,/, hypertension/NN and/CC diabetes/NN in/IN patients/NNS with/IN lacunar/NN stroke/NN ,/, and/CC vascular/JJ peripheral/JJ disease/NN ,/, 
2107_2107_27_28_39_40::POS_REG(0)_MODIFY::actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
687516_9_7_8_4_5::None::approach/NN has/VBZ the/DT potential/JJ to/TO dramatically/RB reduce/VB the/DT cost/NN of/IN 
295269_3_25_27_4_5::None::research/NN suggests/VBZ that/IN loss/NN ,/, rather/RB than/IN mutation/NN ,/, of/IN mtDNA/NN plays/VBZ a/DT major/JJ role/NN across/IN a/DT range/NN of/IN prevalent/JJ human/JJ diseases/NNS ,/, including/VBG diabetes/NN mellitus/NN ,/, cardiovascular/JJ disease/NN 
963135_4_10_11_4_5::None::guidance/NN for/IN the/DT diagnosis/NN and/CC management/NN of/IN osteoporosis/NN in/IN postmenopausal/JJ women/NNS recommends/VBZ a/DT 
956369_1_16_17_52_53::None::anticoagulant/NN therapy/NN for/IN patients/NNS who/WP had/VBD undergone/VBN catheter/NN ablation/NN (/( CA/NNP )/) for/IN AF/NN We/PRP evaluated/VBD 342/CD consecutive/JJ patients/NNS who/WP underwent/VBD CA/NNP for/IN AF/NN between/IN April/NNP 2013/CD and/CC March/NNP 2014/CD and/CC received/VBD apixaban/NN (/( n/NN =/JJ 105/CD )/) and/CC warfarin/NN (/( n/NN =/JJ 
341530_0_0_1_2_5::None::Patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN (/( SLE/NN )/) 
233540_0_33_34_12_13::None::,/, measured/VBN as/IN glycated/JJ haemoglobin/NN (/( HbA1c/NN )/) ,/, influences/VBZ the/DT role/NN of/IN leisure/NN time/NN physical/JJ activity/NN on/IN the/DT increased/VBN risk/NN of/IN death/NN from/IN cardiovascular/JJ disease/NN ./. 
116217_7_4_5_12_13::None::was/VBD found/VBN that/IN sirolimus/NN treatment/NN was/VBD given/VBN to/TO 9/CD of/IN 20/CD patients/NNS because/IN of/IN different/JJ 
1755_1755_26_27_13_14::None::the/DT interaction/NN with/IN actin/NN and/CC ,/, therefore/RB ,/, may/MD constitute/VB part/NN of/IN the/DT actin-binding/JJ domain/NN of/IN cofilin/NN ./. 
189032_0_0_1_2_3::None::Alcohol/NN -/: Related/JJ Consequences/NNS Mediating/VBG PTSD/NN 
427379_2_6_7_19_20::None::that/IN the/DT chronic/JJ intermittent/JJ hypoxia/NN (/( CIH/NN )/) of/IN OSAS/NN patients/NNS may/MD per/FW se/FW trigger/NN liver/NN injury/NN ,/, inflammation/NN ,/, 
515_515_7_8_5_6::None::work/NN ,/, the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN 
626703_0_14_15_56_58::None::woman/NN with/IN decompensated/VBN alcoholic/JJ liver/NN cirrhosis/NN and/CC poorly/RB controlled/VBN non/JJ -/: insulin/NN -/: dependent/JJ diabetes/NN mellitus/NN who/WP was/VBD admitted/VBN with/IN a/DT 1/CD day/NN history/NN of/IN altered/JJ mental/JJ status/NN ,/, high/JJ -/: grade/NN fevers/NNS ,/, worsening/VBG jaundice/NN and/CC generalised/JJ malaise/NN with/IN subsequent/JJ development/NN of/IN hypotension/NN requiring/VBG intensive/JJ care/NN ./. 
710476_3_8_9_12_13::medicine.disease.risk_factors::mental/JJ health/NN ,/, depression/NN ,/, anxiety/NN ,/, stress/NN ,/, alcohol/NN -/: 
2107_2107_39_40_9_10::None::proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
16_16_32_33_28_29::POS_ACTION_BIND::expected/VBN ,/, since/IN beta-catenin/NN binding/NN disrupts/VBZ the/DT alpha-catenin/NN dimer/NN ./. 
631121_4_11_12_17_18::medicine.disease.treatments::majority/NN of/IN borderline/JJ ovarian/JJ tumours/NNS should/MD be/VB managed/VBN with/IN surgery/NN alone/RB ./. 
387237_8_25_26_11_12::None::from/IN dogs/NNS and/CC cats/NNS in/IN the/DT current/JJ study/NN and/CC phylogeny/NN revealed/VBD that/IN C/NN canis/JJ forms/NNS a/DT sister/NN clade/NN to/TO the/DT oriental/JJ 
361641_4_0_1_11_12::None::To/TO deplete/VB extracellular/JJ and/CC cytosolic/JJ Ca/NN (/( 2/CD +/CC )/) ,/, cells/NNS were/VBD exposed/VBN to/TO 
1539_1539_13_14_1_3::POS_ACTION_BIND::The/DT K114E/NN profilin/NN exhibited/VBD a/DT profound/JJ decrease/NN in/IN its/PRP$ ability/NN to/TO interact/VB with/IN actin/NN ,/, whereas/IN binding/VBG 
1334_1334_17_18_30_31::POS_REG(-)_Change::suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN growth/NN ,/, and/CC fluid-phase/JJ endocytosis/NN of/IN pfy1-4/NN ,/, a/DT profilin/NN mutant/NN defective/JJ in/IN 
555927_24_34_35_32_33::None::9/CD patients/NNS still/RB presented/VBN paroxymal/JJ rapid/JJ firing/NN within/IN the/DT 
199283_3_26_27_13_15::None::the/DT effectiveness/NN of/IN therapeutic/JJ play/NN intervention/NN for/IN improving/VBG children/NNS whosewhat/JJ health/NN -/: related/JJ outcomes/NNS such/JJ as/IN perioperative/JJ anxiety/NN and/CC postoperative/JJ 
367_367_32_33_26_27::None::as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
1274_1274_9_12_0_2::None::Single-headed/JJ myosin/NN ,/, which/WDT consists/VBZ of/IN a/DT full/JJ length/NN myosin/NN heavy/JJ chain/NN and/CC a/DT tagged/VBN 
1284_1284_13_14_6_7::None::three/CD ligands/NNS for/IN profilin/NN have/VBP been/VBN well-characterized/VBN in/FW vitro/FW :/: actin/NN monomers/NNS ,/, membrane/NN 
573743_7_25_26_13_14::None::mechanisms/NNS including/VBG maternal/JJ illness/NN ,/, exhaustion/NN ,/, lack/NN of/IN support/NN ,/, anxiety/NN ,/, depression/NN or/CC history/NN of/IN abuse/NN ./. 
198729_8_12_13_13_14::None::neoformans/NNS infection/NN in/IN male/JJ asthmatics/NNS and/CC may/MD support/VB 
591709_2_27_28_24_25::biology.organism_classification.lower_classifications::in/IN Mollusca/NNP ,/, Crustacea/NNP ,/, and/CC Insecta/NNP ,/, assessing/VBG COX/NNP 
718_718_21_22_8_9::None::cytoplasmic/JJ domain/NN of/IN cadherins/NNS bind/VBP to/TO beta-catenin/NN ,/, which/WDT in/IN turn/NN binds/VBZ to/TO the/DT actin-associated/JJ protein/NN alpha-catenin/NN ./. 
114029_26_3_4_48_49::None::After/IN four/CD cycles/NNS chemotherapy/NN ,/, the/DT incidence/NN rates/NNS of/IN ventricular/JJ arrhythmia/NN greater/JJR than/IN Lown/JJ grade/NN 3/CD (/( 30/CD %/NN vs/CC 2.5/CD %/NN )/) ,/, QTc/NN (/( 20/CD %/NN vs/CC 0/CD )/) elongation/NN and/CC ST/JJ -/: T/NN (/( 40/CD %/NN vs/CC 5/CD %/NN )/) changes/NNS in/IN HRG/NNP were/VBD significantly/RB higher/JJR than/IN those/DT observed/VBN 
2013_2013_7_9_0_1::None::WASp/NN contains/VBZ a/DT binding/NN motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB 
346_346_16_17_16_17::None::of/IN alpha-catenin/NN ,/, beta-catenin/NN competed/VBD with/IN the/DT 
154535_13_18_19_13_14::None::obesity/NN ,/, and/CC depression/NN in/IN PCOS/NN ,/, warranting/VBG additional/JJ investigation/NN ./. 
583_583_10_11_4_5::POS_ACTION_BIND::we/PRP report/VBP that/IN p120/NN associates/NNS with/IN a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, 
9_9_12_13_17_18::None::acid/NN 364/CD of/IN actin/NN and/CC lysine/NN 115/CD of/IN profilin/NN ./. 
213993_5_22_23_11_12::None::past/JJ history/NN of/IN diabetes/NN and/CC stroke/NN ,/, respectively/RB ,/, whereas/IN 15/CD %/NN had/VBD a/DT positive/JJ family/NN history/NN of/IN 
87529_17_7_8_3_4::medicine.disease.risk_factors::Advanced/NNP age/NN ,/, hypertension/NN ,/, and/CC prior/RB stroke/NN were/VBD associated/VBN with/IN 
443_443_6_7_11_12::None::conformational/JJ change/NN in/IN actin/NN induced/VBN by/IN fimbrin/NN (/( N375/NN )/) binding/NN ./. 
1534_1534_12_13_9_10::None::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ 
22_22_54_55_36_37::POS_REG(+)_Change::)/) transformation/NN of/IN actin/NN polymerization/NN into/IN a/DT motile/JJ force/NN and/CC (/( 4/LS )/) acceleration/NN of/IN movement/NN mediated/VBN by/IN the/DT host/NN protein/NN profilin/NN ./. 
609221_0_4_5_13_14::None::is/VBZ characterized/VBN by/IN spontaneous/JJ recurrent/JJ seizures/NNS and/CC represents/VBZ one/CD of/IN the/DT most/RBS frequent/JJ neurological/JJ diseases/NNS ,/, 
63_63_59_60_44_45::None::.2/NN ,/, oxidized/VBN histone/NN H2A/NN .2/NN ,/, histone/NN H2A.X/NN ,/, histone/NN H2A.Z/NN ,/, histone/NN H2B/NN ,/, three/CD histone/NN H3/NN variants/NNS and/CC histone/NN 
162721_4_16_18_19_20::medicine.drug.active_moieties::with/IN vehicle/NN (/( dimethyl/JJ sulfoxide/NN ,/, DMSO/NN )/) or/CC different/JJ 
1917_1917_14_15_27_28::POS_REG(0)_MODIFY::profilin/NN gene/NN (/( PFY1/NN )/) and/CC examined/VBD the/DT consequences/NNS of/IN specific/JJ point/NN mutations/NNS on/IN growth/NN and/CC actin/NN organization/NN ./. 
280_280_13_14_14_15::POS_ACTION_MEMBER::we/PRP observed/VBD that/IN histone/NN H4/NN ,/, and/CC not/RB 
328298_6_5_6_15_16::None::subjects/NNS not/RB receiving/VBG glycosides/NNS ,/, digoxin/NN was/VBD associated/VBN with/IN a/DT 29/CD %/NN increased/VBD mortality/NN risk/NN (/( HR/NN 
547287_4_8_9_2_3::None::The/DT overall/JJ incidence/NN of/IN the/DT 4/CD types/NNS of/IN gynecological/JJ cancer/NN was/VBD 39.0/CD 
206151_6_15_16_23_24::people.cause_of_death.includes_causes_of_death::children/NNS with/IN any/DT injury/NN ,/, and/CC 88/CD %/NN of/IN those/DT with/IN severe/JJ traumatic/JJ brain/NN injury/NN 
264127_4_35_36_35_37::people.cause_of_death.includes_causes_of_death::)/) and/CC major/JJ cardiovascular/JJ events/NNS or/CC all/DT -/: 
872_872_8_9_6_7::POS_ACTION_BIND::the/DT role/NN of/IN MSH2/NN ,/, MSH3/NN ,/, and/CC MSH6/NN 
567_567_7_9_14_15::None::TNF-dependent/JJ activation/NN of/IN acid/NN SMase/NN (/( A-SMase/NN )/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS 
2107_2107_15_16_7_8::POS_ACTION_AFFECT::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ 
1957_1957_38_39_15_16::None::EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ cells/NNS at/IN confluence/NN were/VBD dissociated/VBN into/IN single/JJ cells/NNS by/IN tryptic/JJ digestion/NN ,/, being/VBG accompanied/VBN by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
2076_2076_28_29_16_18::None::(/( r/NN )/) actin-binding/JJ protein/NN of/IN 143/CD amino/NN acid/NN (/( aa/NN )/) residues/NNS (/( yeast/NN cofilin/NN ;/: Cof/NN )/) 
1375_1375_14_15_7_8::POS_REG(+)_POLYMERIZE::for/IN polymerization/NN of/IN actin/NN is/VBZ increased/VBN by/IN the/DT addition/NN of/IN profilin/NN ./. 
370565_0_34_35_39_40::medicine.symptom.symptom_of::of/IN severe/JJ neck/NN pain/NN ,/, rigidity/NN ,/, and/CC high/JJ fever/NN ./. 
714216_1_31_32_29_30::None::alpha1/NN -/: adrenergic/JJ receptor/NN (/( AR/NN )/) on/IN vascular/JJ 
1156_1156_10_11_5_6::None::form/VBP complexes/NNS with/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN ,/, all/DT components/NNS 
241096_2_10_12_21_22::None::indole/NN -/: 3/CD acetic/JJ acid/NN hydrazide/NN (/( IAAH/NN -/: Ag/NN )/) complexes/NNS via/IN a/DT pH/NN -/: sensitive/JJ hydrazone/NN 
761186_8_7_8_23_24::None::interest/NN was/VBD the/DT presence/NN of/IN any/DT CAD/NN (/( n/NN =/JJ 176/CD )/) ,/, including/VBG MI/NNP ,/, angina/NN ,/, and/CC stroke/NN ./. 
1373_1373_4_5_16_17::None::APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
828542_0_1_2_11_12::None::Antibiotic/JJ management/NN of/IN methicillin/NN -/: resistant/JJ Staphylococcus/FW aureus/FW -/: -/: associated/VBN acute/JJ pulmonary/JJ exacerbations/NNS in/IN 
960_960_9_10_5_6::None::the/DT previously/RB identified/VBN VRP1/NN ,/, which/WDT encodes/VBZ verprolin/NN ,/, required/VBN for/IN 
410591_0_20_21_18_19::None::is/VBZ characterized/VBN by/IN edema/NN ,/, hypoalbuminemia/NN ,/, hyperlipidemia/NN ,/, 
1861_1861_2_3_12_13::POS_ACTION_MUTUALCOMPLEX::Thus/RB ,/, APC/NN forms/NNS distinct/JJ heteromeric/JJ complexes/NNS containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
1701_1701_50_51_43_46::None::which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
356156_0_10_11_18_19::None::Drug/NNP Administration/NNP (/( FDA/NNP )/) mandated/VBD a/DT label/NN change/NN for/IN leukotriene/NN inhibitors/NNS (/( LTIs/NNS )/) 
1289_1289_7_8_13_14::POS_ACTION_INTERACT::nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN bovine/JJ 
318680_2_3_4_8_9::None::This/DT study/NN therefore/RB investigated/VBD the/DT relationship/NN between/IN the/DT structural/JJ properties/NNS of/IN nine/CD 
1652_1652_31_32_43_44::POS_ACTION_RELATE::preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( c/LS )/) the/DT cytoplasmic/JJ partners/NNS of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, 
433781_3_2_3_13_14::None::Circulating/VBG Tc17/NN cells/NNS were/VBD significantly/RB more/RBR numerous/JJ in/IN gastric/JJ cancer/NN patients/NNS than/IN in/IN controls/NNS ,/, and/CC significantly/RB 
97537_3_10_11_24_25::None::a/DT variety/NN of/IN cancers/NNS (/( prostate/NN ,/, lung/NN ,/, pancreatic/JJ ,/, or/CC colon/NN carcinoma/NN ,/, melanoma/NN ,/, astrocytoma/NN ,/, glioblastoma/NN ,/, 
76427_8_49_50_51_52::None::of/IN mixed/JJ -/: metal/NN copper/NN oxides/NNS ,/, the/DT synthesis/NN 
205283_0_22_23_25_26::medicine.disease.symptoms::cardiovascular/JJ disease/NN (/( CVD/NN )/) remains/VBZ high/JJ ./. 
292_292_11_14_0_1::None::CD26/NN ,/, a/DT T/NN cell/NN activation/NN Ag/NN ,/, also/RB known/VBN as/IN dipeptidyl/NN peptidase/NN IV/CD ,/, is/VBZ directly/RB 
162957_0_35_37_27_28::medicine.disease.symptoms::the/DT pathogenesis/NN of/IN itch/NN using/VBG a/DT recently/RB developed/VBN murine/JJ model/NN of/IN atopic/JJ dermatitis/NN (/( AD/NN )/) 
1052_1052_27_28_6_8::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) 
996_996_27_28_31_34::None::coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
406221_0_7_8_23_25::None::prescribing/VBG rate/NN in/IN patients/NNS suffering/VBG from/IN acute/JJ exacerbations/NNS of/IN chronic/JJ obstructive/JJ pulmonary/JJ disease/NN (/( COPD/NN )/) or/CC asthma/NN in/IN general/JJ practice/NN are/VBP only/RB sparsely/RB 
980_980_18_19_14_15::None::of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN beta-catenin/NN to/TO the/DT cytoplasm/NN 
735_735_24_25_11_12::None::sensitivity/NN of/IN a/DT tropomyosin/NN mutant/NN ,/, and/CC the/DT loss/NN of/IN cytoplasmic/JJ cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, and/CC tropomyosin/NN 
296153_6_5_7_0_2::medicine.risk_factor.diseases::Major/JJ depression/NN ,/, fibromyalgia/NNP ,/, Alzheimer/NNP disease/NN ,/, psoriasis/NN ,/, 
1616_1616_20_21_34_35::None::protein/NN gene/NN ;/: 4a/NN and/CC 4b/NN are/VBP two/CD genes/NNS ,/, one/CD of/IN which/WDT codes/VBZ for/IN the/DT proposed/VBN phosphoprotein/NN P/NN and/CC the/DT 
1105_1105_6_9_20_24::None::)/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, induces/VBZ G1/NN arrest/NN and/CC can/MD inhibit/VB the/DT activity/NN of/IN the/DT proliferating/VBG cell/NN nuclear/JJ antigen/NN (/( PCNA/NN )/) 
25753_2_26_27_11_12::None::to/TO chronic/JJ kidney/NN disease/NN (/( CKD/NN )/) ,/, which/WDT can/MD progress/VB to/TO end/VB -/: stage/NN renal/JJ disease/NN (/( ESRD/NN )/) with/IN a/DT 
1486_1486_4_5_41_44::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
324774_0_4_5_0_1::None::Components/NNP of/IN nicotine/NN reward/NN system/NN can/MD potentially/RB influence/VB 
1532_1532_31_33_17_18::POS_ACTION_BIND::association/NN of/IN the/DT Munc18-2/NN variants/NNS with/IN syntaxin/NN 3/CD correlated/VBD well/RB with/IN their/PRP$ ability/NN to/TO displace/VB SNAP-23/NN from/IN syntaxin/NN 3/CD complexes/NNS when/WRB overexpressed/VBN 
1507_1507_19_20_6_7::None::virus/NN type/NN 1/CD primosome/NN consists/VBZ of/IN three/CD subunits/NNS that/WDT are/VBP the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
1081_1081_5_6_39_40::POS_ACTION_CONTROL::indicate/VBP that/IN even/RB profilins/NNS of/IN highly/RB distant/JJ evolutionary/JJ origin/NN can/MD functionally/RB substitute/VB for/IN each/DT other/JJ and/CC support/VBP the/DT hypothesis/NN that/IN in/IN animal/NN cells/NNS ,/, profilins/NNS are/VBP engaged/VBN in/IN regulating/VBG either/CC the/DT stability/NN or/CC the/DT kinetic/JJ properties/NNS of/IN actin/NN filaments/NNS ./. 
841704_4_15_16_18_19::None::rest/NN pain/NN ,/, ulcer/NN history/NN ,/, revascularization/NN history/NN ,/, amputation/NN 
212_212_31_32_27_28::POS_ACTION_BIND::E-cadherin/NN and/CC the/DT actin/NN binding/NN site/NN of/IN alpha-catenin/NN ./. 
1427_1427_32_33_27_28::None::and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
1457_1457_28_30_56_57::None::(/( 1/LS )/) profilin/NN I/PRP functions/VBZ predominantly/RB as/IN an/DT actin/NN monomer-binding/JJ protein/NN ;/: (/( 2/LS )/) profilin/NN II/CD regulates/VBZ ,/, or/CC is/VBZ regulated/VBN by/IN ,/, PIP2/NN ;/: and/CC (/( 3/LS )/) actobindin/NN inhibits/VBZ nucleation/NN of/IN 
1427_1427_32_33_3_4::None::The/DT comparison/NN of/IN E-CD/NN proteins/NNS synthesized/VBN by/IN E62/NN and/CC E24/NN cell/NN lines/NNS revealed/VBD no/DT structural/JJ or/CC functional/JJ differences/NNS because/IN both/DT localized/JJ at/IN cell-cell/JJ contacts/NNS and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
373757_6_19_21_29_32::medicine.risk_factor.diseases::and/CC to/TO have/VB diabetes/NN mellitus/NN ,/, hypertension/NN ,/, atrial/JJ fibrillation/NN ,/, hyperlipidaemia/NN ,/, chronic/JJ kidney/NN disease/NN ,/, ischaemic/JJ heart/NN 
1069_1069_29_30_33_35::POS_ACTION_ATTACH::UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) 
93_93_50_51_11_12::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
714216_1_18_20_21_22::None::retina/NN and/CC 661W/NN retinal/JJ cells/NNS in/IN high/JJ glucose/NN and/CC of/IN 
173_173_12_13_3_4::None::As/IN expected/VBN ,/, C/ATF/NN was/VBD found/VBN to/TO interact/VB with/IN three/CD domains/NNS of/IN CBP/NN including/VBG CREB/NN binding/NN 
1379_1379_27_28_11_12::None::of/IN the/DT human/JJ RAD52/NN protein/NN shows/VBZ no/DT homology/NN with/IN the/DT yeast/NN RAD52/NN protein/NN ,/, indicating/VBG that/IN the/DT interaction/NN between/IN RAD51/NN and/CC RAD52/NN is/VBZ 
71_71_3_4_6_7::POS_ACTION_DEPOLYMERIZE::Aip1p/NN interacts/VBZ with/IN cofilin/NN to/TO disassemble/VB actin/NN filaments/NNS ./. 
1205_1205_4_5_6_7::None::of/IN the/DT yeast/NN MSH3/NN and/CC MSH6/NN genes/NNS for/IN MSH2-dependent/JJ 
1434_1434_72_73_75_76::POS_ACTION_MEMBER::histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
476691_1_9_11_4_5::medicine.disease.treatments::age/NN and/CC severe/JJ surgical/JJ trauma/NN are/VBP two/CD main/JJ risk/NN factors/NNS for/IN POCD/NNP Lithium/NNP 
1341_1341_1_2_4_5::POS_ACTION_Causal::The/DT alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC 
228362_4_51_52_29_30::None::whole/JJ murine/JJ IVD/NN Trypsin/NN treatment/NN resulted/VBD in/IN a/DT decrease/NN of/IN proteoglycans/NNS and/CC loss/NN of/IN disc/NN height/NN ,/, while/IN ribosylation/NN had/VBD no/DT effect/NN on/IN structure/NN or/CC proteoglycan/NN composition/NN ./. 
735_735_22_23_11_12::None::sensitivity/NN of/IN a/DT tropomyosin/NN mutant/NN ,/, and/CC the/DT loss/NN of/IN cytoplasmic/JJ cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, 
191783_4_21_22_3_4::None::With/IN a/DT thin/JJ coating/NN of/IN 200/CD -/: 300/CD nm/NN polydimethylsiloxane/NN (/( PDMS/NN )/) on/IN the/DT zeolite/NN -/: polymer/NN composite/NN ,/, transport/NN data/NNS for/IN CO2/NN //: 
162483_5_28_29_2_4::medicine.risk_factor.diseases::Furthermore/RB ,/, erectile/JJ dysfunction/NN has/VBZ been/VBN associated/VBN with/IN stroke/NN ,/, peripheral/JJ artery/NN disease/NN ,/, diabetes/NN and/CC chronic/JJ kidney/NN disease/NN as/RB well/RB as/IN with/IN several/JJ CHD/NN risk/NN factors/NNS including/VBG hypertension/NN ,/, dyslipidaemia/NN ,/, 
1169_1169_10_11_13_16::None::to/TO regulate/VB the/DT actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) 
98_98_31_32_29_30::POS_ACTION_BIND::the/DT affinity/NN of/IN profilin/NN for/IN actin/NN may/MD be/VB under/IN 
718_718_21_22_11_12::None::cadherins/NNS bind/VBP to/TO beta-catenin/NN ,/, which/WDT in/IN turn/NN binds/VBZ to/TO the/DT actin-associated/JJ protein/NN alpha-catenin/NN ./. 
873835_0_1_2_31_33::None::Meniscal/JJ allograft/NN transplantation/NN (/( MAT/NN )/) is/VBZ a/DT relatively/RB new/JJ procedure/NN that/WDT has/VBZ gained/VBN popularity/NN in/IN the/DT last/JJ couple/NN of/IN decades/NNS as/IN a/DT possible/JJ alternative/NN to/TO a/DT meniscectomy/NN to/TO provide/VB significant/JJ pain/NN relief/NN ,/, improve/VB function/NN 
2107_2107_9_10_24_26::None::proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, 
205283_0_4_5_19_21::None::there/EX has/VBZ been/VBN great/JJ progress/NN achieved/VBN by/IN the/DT use/NN of/IN intensive/JJ statin/NN therapy/NN ,/, the/DT burden/NN of/IN atherosclerotic/JJ cardiovascular/JJ disease/NN (/( CVD/NN )/) 
1850_1850_0_1_2_3::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB 
1850_1850_0_1_23_24::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN and/CC serves/VBZ to/TO link/VB the/DT cadherin/catenin/NN complex/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
543881_0_0_2_24_25::None::Rheumatoid/JJ arthritis/NN (/( RA/NN )/) is/VBZ a/DT chronic/JJ autoimmune/JJ inflammatory/JJ disease/NN of/IN unknown/JJ aetiology/NN ,/, leading/VBG to/TO progressive/JJ damage/NN of/IN bone/NN and/CC cartilage/NN with/IN functional/JJ impairment/NN and/CC disability/NN 
881_881_25_26_15_16::None::the/DT domains/NNS on/IN alpha-catenin/NN that/WDT allow/VBP it/PRP to/TO associate/VB with/IN beta-catenin/plakoglobin/NN and/CC with/IN alpha-actinin/NN ./. 
1546_1546_5_6_8_11::None::inhibitory/JJ action/NN of/IN p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) 
1616_1616_35_36_20_21::None::protein/NN gene/NN ;/: 4a/NN and/CC 4b/NN are/VBP two/CD genes/NNS ,/, one/CD of/IN which/WDT codes/VBZ for/IN the/DT proposed/VBN phosphoprotein/NN P/NN and/CC the/DT other/JJ 
223084_8_10_11_13_15::None::diabetes/NN and/CC hypertension/NN predicted/VBD AMI/NNP in/IN multivariate/JJ analysis/NN ./. 
442063_4_28_29_1_2::None::The/DT assessment/NN of/IN lipophilic/JJ vs/CC hydrophilic/JJ statin/NN therapy/NN in/IN acute/JJ myocardial/JJ infarction/NN (/( ALPS/NN -/: AMI/NNP )/) study/NN was/VBD a/DT multi/JJ -/: center/NN study/NN that/WDT enrolled/VBD 508/CD AMI/NNP patients/NNS to/TO compare/VB the/DT 
446387_0_30_31_13_14::None::-/: resistant/JJ prostate/NN cancer/NN (/( CRPC/NN )/) was/VBD successfully/RB treated/VBN for/IN two/CD years/NNS with/IN in/FW situ/FW gene/NN therapy/NN using/VBG an/DT adenovirus/NN vector/NN carrying/VBG the/DT 
176735_0_16_17_36_37::None::dopamine/NN transporters/NNS (/( DATs/NNS )/) in/IN the/DT same/JJ dose/NN and/CC duration/NN ,/, we/PRP assessed/VBD DAT/NNP levels/NNS in/IN the/DT striatum/NN by/IN (/( 99m/CD )/) Tc/SYM -/: TRODAT/NN -/: 
1301_1301_18_19_10_11::None::both/CC alpha-catenin/NN and/CC plakoglobin/NN are/VBP important/JJ for/IN the/DT adhesive/JJ function/NN of/IN cadherins/NNS ./. 
244414_9_9_10_23_24::None::with/IN IMRT/NN and/CC chemotherapy/NN ,/, survival/NN and/CC locoregional/JJ disease/NN control/NN rates/NNS have/VBP improved/VBN ,/, however/RB late/JJ treatment/NN toxicity/NN remains/VBZ a/DT concern/NN 
1037_1037_21_22_9_11::None::exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ 
761082_2_19_20_35_36::medicine.disease.treatments::predicting/VBG pregnancy/NN in/IN infertile/JJ Italian/JJ endometriosis/NN women/NNS ;/: (/( ii/LS )/) evaluate/VB the/DT predictive/JJ value/NN of/IN EFI/NNP score/NN on/IN ART/NN outcome/NN for/IN patients/NNS 
119342_0_10_11_14_16::None::after/IN stroke/NN :/: early/JJ findings/NNS from/IN a/DT clinical/JJ study/NN ./. 
514561_0_9_10_12_13::people.cause_of_death.includes_causes_of_death::the/DT concept/NN that/IN cardiovascular/JJ protection/NN through/IN high/JJ -/: density/NN lipoprotein/NN 
1523_1523_4_5_7_8::None::interaction/NN of/IN Acanthamoeba/NN actin/NN and/CC Acanthamoeba/NN profilin/NN was/VBD evaluated/VBN as/IN 
807975_0_14_15_9_10::None::inhibitor/NN amitifadine/NN on/IN pain/NN -/: related/JJ depression/NN of/IN behavior/NN and/CC mesolimbic/JJ dopamine/NN 
1417_1417_4_5_17_18::None::cellular/JJ transcription/NN co-activators/NNS p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS for/IN transformation/NN by/IN the/DT E1A/NN proteins/NNS of/IN non-oncogenic/JJ 
217765_0_5_7_9_10::None::arthrosis/NN of/IN the/DT glenohumeral/JJ joint/NN :/: From/IN partial/JJ resurfacing/NN to/TO reverse/VB 
279969_6_26_27_14_16::None::patient/NN whosewhat/NN plasma/NN viral/JJ load/NN was/VBD high/JJ just/RB after/IN transplantation/NN ,/, although/IN the/DT subject/NN was/VBD asymptomatic/JJ ,/, and/CC the/DT 
373109_2_32_33_28_31::medicine.drug.active_moieties::proteins/NNS such/JJ as/IN human/JJ serum/NN albumin/NN (/( HSA/NN )/) and/CC human/JJ 
311702_2_27_28_28_29::medicine.disease.risk_factors::inflammation/NN -/: mediated/VBN acute/JJ cardiac/JJ events/NNS that/WDT may/MD 
76427_8_26_27_40_41::None::starting/VBG from/IN the/DT creation/NN of/IN undercoordinated/JJ sites/NNS on/IN Cu/NN (/( 111/CD )/) and/CC Cu2O/NN (/( 111/CD )/) surfaces/NNS ,/, continuing/VBG with/IN 
639297_0_1_2_17_18::None::Neonatal/JJ late/JJ -/: onset/NN sepsis/NN following/VBG peripherally/RB inserted/VBN central/JJ catheter/NN removal/NN :/: association/NN with/IN antibiotic/JJ use/NN and/CC adverse/JJ line/NN events/NNS ./. 
900398_7_6_7_4_5::None::OSA/NN -/: obesity/NN associations/NNS were/VBD robust/JJ and/CC evident/JJ for/IN 
567_567_18_19_14_15::None::)/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
2_2_0_1_9_10::POS_ACTION_SUPPRESS::alpha-catenin/NN inhibits/VBZ beta-catenin/NN signaling/NN by/IN preventing/VBG formation/NN of/IN a/DT beta-catenin/NN */SYM T-cell/NN factor/NN 
1701_1701_6_7_43_46::None::that/IN this/DT novel/JJ RhoGAP/NN is/VBZ involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN 
658012_2_32_33_17_18::medicine.symptom.symptom_of::undergone/VBN PD/NN for/IN pancreatic/JJ head/NN adenocarcinoma/NN 10/CD months/NNS previously/RB and/CC who/WP presented/VBD at/IN our/PRP$ hospital/NN with/IN fever/NN and/CC jaundice/NN due/JJ to/TO afferent/JJ 
367_367_0_2_26_27::POS_ACTION_LOCALIZE::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS 
429251_0_4_5_26_27::None::evidence/NN suggests/VBZ that/IN dopamine/NN (/( DA/NN )/) is/VBZ involved/VBN in/IN altering/VBG neural/JJ activity/NN and/CC gene/NN expression/NN in/IN a/DT zebra/NN finch/NN cortical/JJ -/: basal/JJ ganglia/NN circuit/NN specialized/VBN for/IN singing/NN ,/, 
556761_3_39_40_5_6::None::last/JJ urethral/JJ catheterisation/NN performed/VBN for/IN a/DT male/JJ cat/NN with/IN UO/NN ,/, the/DT VS/NNP was/VBD asked/VBN about/IN the/DT use/NN of/IN antibiotics/NNS while/IN the/DT catheter/NN was/VBD in/FW situ/FW ,/, whether/IN a/DT closed/JJ urinary/JJ collection/NN system/NN was/VBD used/VBN ,/, whether/IN aseptic/JJ skin/NN preparation/NN of/IN 
497005_0_10_11_0_1::None::It/PRP is/VBZ well/RB recognized/VBN that/IN physical/JJ activity/NN should/MD be/VB an/DT integral/JJ part/NN of/IN the/DT 
1373_1373_4_5_1_2::None::The/DT APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC 
563809_10_61_62_58_59::medicine.disease.risk_factors::health/NN status/NN ,/, diabetes/NN ,/, and/CC stroke/NN ./. 
264127_4_34_35_28_29::None::,/, 95/CD %/NN CI/NN 0.78/CD -/: 1.01/CD )/) and/CC major/JJ cardiovascular/JJ events/NNS or/CC 
172875_8_28_30_9_10::None::data/NNS from/IN the/DT Atherosclerosis/NNP Risk/NN in/IN Communities/NNP Study/NNP (/( n/NN =/JJ 12779/CD )/) demonstrated/VBD that/IN serum/NN sodium/NN is/VBZ a/DT significant/JJ predictor/NN of/IN 10/CD Years/NNS Risk/NN of/IN coronary/JJ 
1321_1321_9_11_0_4::POS_ACTION_MEMBER::Testicular/JJ protein/NN kinase/NN 1/CD (/( TESK1/NN )/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN 
301320_2_27_28_50_51::None::whosewhat/NN disease/NN ,/, cocaine/NN and/CC cannabis/NN addiction/NN ,/, bipolar/JJ disorder/NN ,/, depression/NN ,/, trichotillomania/NN ,/, nail/NN biting/VBG ,/, skin/NN picking/NN ,/, obsessive/JJ -/: compulsive/JJ disorder/NN ,/, schizophrenia/NN ,/, drug/NN -/: 
1633_1633_32_33_25_26::None::identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC two/CD histone/NN H2b/NN genes/NNS ./. 
91851_7_3_4_4_5::None::2/CD months/NNS after/IN CA/NNP induction/NN ,/, surgically/RB treated/VBN 
1726_1726_14_15_8_9::None::of/IN LIM-kinase/NN by/IN ROCK/NN and/CC consequently/RB increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP 
331666_4_67_68_58_59::people.cause_of_death.includes_causes_of_death::)/) ,/, and/CC pancreatic/JJ (/( 1.63/CD [/( 1.6/CD -/: 1.7/CD ]/) )/) cancers/NNS ./. 
571439_1_2_3_3_4::None::Anti/SYM -/: TNF/NN agents/NNS improve/VBP the/DT clinical/JJ 
88435_3_26_27_55_56::None::measurable/JJ sites/NNS of/IN disease/NN ,/, were/VBD treated/VBN with/IN concurrent/JJ radiotherapy/NN (/( 35/CD Gy/NN in/IN ten/CD fractions/NNS ,/, over/IN 2/CD weeks/NNS )/) to/TO one/CD metastatic/JJ site/NN and/CC granulocyte/NN -/: macrophage/NN colony/NN -/: stimulating/VBG factor/NN (/( 125/CD mug/NN 
1052_1052_21_22_12_13::None::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG 
865_865_7_8_17_18::None::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 
1782_1782_27_28_20_22::None::the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
450_450_28_29_45_46::POS_ACTION_BIND::binding/NN surface/NN between/IN actin/NN and/CC thymosin/NN beta/NN (/( 4/CD )/) ,/, and/CC explain/VB why/WRB thymosin/NN beta/NN (/( 4/CD )/) and/CC profilin/NN can/MD bind/VB simultaneously/RB 
201815_2_24_25_9_12::medicine.medical_treatment.used_to_treat::silkworm/NN model/NN of/IN type/NN II/CD diabetes/NNS for/IN the/DT evaluation/NN of/IN anti/JJ -/: diabetic/JJ drugs/NNS such/JJ as/IN pioglitazone/NN and/CC metformin/NN ./. 
123245_6_57_58_66_67::people.cause_of_death.includes_causes_of_death::)/) and/CC known/VBN cancer/NN marker/NN (/( NME1/NN )/) have/VBP been/VBN associated/VBN with/IN prostate/NN and/CC other/JJ cancers/NNS 
106487_0_26_27_13_14::None::for/IN perioperative/JJ cardiovascular/JJ complications/NNS ;/: however/RB its/PRP$ whosewhat/NN impact/NN at/IN the/DT time/NN of/IN kidney/NN transplantation/NN (/( KTX/NN )/) is/VBZ not/RB 
1415_1415_32_33_12_13::None::are/VBP consistent/JJ with/IN profilin/NN being/VBG a/DT negative/JJ regulator/NN of/IN the/DT phosphoinositide/NN signaling/NN pathway/NN in/IN addition/NN to/TO its/PRP$ established/JJ function/NN as/IN an/DT inhibitor/NN of/IN actin/NN polymerization/NN ./. 
1546_1546_26_27_5_6::POS_ACTION_Change::inhibitory/JJ action/NN of/IN p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ from/IN its/PRP$ binding/NN with/IN the/DT cyclin/NN E/cyclin-dependent/JJ kinase/NN 2/CD (/( Cdk2/NN )/) complex/NN that/WDT 
659_659_14_15_26_27::POS_ACTION_COOCCUR::a/DT subpopulation/NN of/IN alpha-catenin/NN joined/VBD the/DT complex/NN at/IN a/DT time/NN coincident/JJ with/IN the/DT arrival/NN of/IN E-cadherin/NN at/IN the/DT plasma/NN 
919_919_14_15_20_21::POS_ACTION_BIND::either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT can/MD assemble/VB alpha-catenin/NN into/IN the/DT complex/NN 
1095_1095_11_12_35_36::None::adhesion/NN pattern/NN ,/, actin/NN organization/NN ,/, and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ proteins/NNS are/VBP dependent/JJ on/IN the/DT supramolecular/JJ organization/NN of/IN the/DT collagens/NNS ./. 
787228_4_23_24_24_25::None::with/IN COPD/NN were/VBD corticosteroid/NN users/NNS and/CC irrespective/RB of/IN 
553943_2_9_11_21_22::None::the/DT analysis/NN of/IN dynamic/JJ contrast/NN -/: enhanced/VBN magnetic/JJ resonance/NN imaging/NN data/NNS from/IN bevacizumab/NN -/: treated/VBN glioblastoma/NN patients/NNS in/IN less/JJR 
605_605_20_21_8_9::None::encodes/VBZ a/DT heterotrimeric/JJ helicase-primase/NN complex/NN that/WDT is/VBZ composed/VBN of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN 
402511_2_11_12_6_7::None::,/, high/JJ resolution/NN metabolomics/NNS (/( HRM/NN )/) was/VBD employed/VBN to/TO identify/VB malaria/NN 
485087_11_8_9_28_29::medicine.symptom.symptom_of::,/, if/IN the/DT tachyarrhythmia/NN remains/VBZ difficult/JJ to/TO control/VB with/IN antiarrhythmic/JJ drugs/NNS ,/, RFA/NN should/MD be/VB strongly/RB considered/VBN ,/, to/TO avoid/VB the/DT risk/NN of/IN tachycardia/NN recurrence/NN following/VBG ECMO/NN 
307_307_12_13_6_7::POS_REG(+)_DEPOLYMERIZE::truncates/VBZ that/IN inhibit/VBP actin/NN depolymerization/NN by/IN severing/VBG activity/NN of/IN gelsolin/NN and/CC cofilin/NN ./. 
758270_7_5_6_32_33::None::cigarette/NN smoke/NN related/JJ lung/NN disease/NN ,/, the/DT PGP/NN pathway/NN can/MD become/VB a/DT self/NN -/: propagating/VBG cycle/NN of/IN inflammation/NN through/IN cigarette/NN -/: smoke/NN mediated/VBD inhibition/NN of/IN leukotriene/NN A4/NN hydrolase/NN ,/, the/DT enzyme/NN responsible/JJ for/IN degrading/VBG 
345363_0_10_11_15_17::medicine.disease.treatments::TFEQ/NN in/IN morbid/JJ obese/JJ patients/NNS ,/, candidates/NNS to/TO bariatric/JJ surgery/NN ./. 
865_865_15_16_17_18::None::related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 
394419_6_40_41_31_32::None::factor/NN )/) ,/, IGF1/NN (/( insulin/NN -/: like/IN growth/NN factor/NN )/) ,/, FGF2/NN (/( fibroblast/NN growth/NN 
774440_0_16_18_9_10::None::a/DT spectrum/NN of/IN metabolic/JJ syndrome/NN -/: related/JJ diseases/NNS that/WDT include/VBP insulin/NN resistance/NN ,/, type/NN 2/CD 
366549_4_6_7_13_14::None::of/IN zinc/NN (/( II/CD )/) ,/, {/( [/( Zn/NN (/( HL/NN )/) 2/CD ]/) 
473887_5_13_14_15_16::None::improves/VBZ quality/NN of/IN life/NN for/IN patients/NNS and/CC their/PRP$ families/NNS 
616400_0_0_1_2_3::None::Housing/NN and/CC maintenance/NN of/IN Ambystoma/NN mexicanum/NN 
452763_3_31_33_29_30::medicine.disease.symptoms::types/NNS of/IN human/JJ tumors/NNS including/VBG breast/NN cancer/NN ,/, prostate/NN cancer/NN 
686_686_13_14_33_34::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
169759_4_4_5_24_25::None::-/: to/TO -/: serine/NN substitutions/NNS at/IN the/DT other/JJ sites/NNS lead/VBP to/TO the/DT loss/NN of/IN expression/NN and/CC //: or/CC activity/NN ,/, consistent/JJ with/IN their/PRP$ involvement/NN in/IN the/DT disulfide/NN 
374_374_4_5_12_13::None::of/IN SIR4/NN enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC deletion/NN of/IN SIR1/NN or/CC SIR3/NN did/VBD 
1164_1164_33_34_39_40::None:::/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN 
865_865_21_24_15_16::None::related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ 
515_515_5_6_23_24::POS_ACTION_Causal::work/NN ,/, the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
1653_1653_42_43_42_43::POS_ACTION_Change::and/CC MSH6/NN or/CC MSH2/NN and/CC MSH3/NN ./. 
237_237_17_18_5_6::POS_ACTION_PHOSPHORYLATE::causes/VBZ phosphorylation/NN of/IN talin/NN and/CC redistribution/NN of/IN actin/NN microfilaments/NNS in/IN fibroblasts/NNS :/: possible/JJ role/NN for/IN PKC-delta/NN ./. 
316251_0_24_25_13_14::None::and/CC M/NN tobijei/NNS Bleeker/NNP ,/, 1854/CD (/( Myliobatiformes/NNPS :/: Myliobatidae/NNP )/) from/IN the/DT East/NNP Indo/NNP -/: West/NNP Pacific/NNP 
352442_4_28_30_28_29::medicine.drug.active_moieties::1/LS )/) (/( sodium/NN chloride/NN )/) ;/: 
1334_1334_0_1_27_28::POS_REG(-)_Change::act1-157/NN ,/, an/DT actin/NN mutant/NN with/IN an/DT increased/VBN intrinsic/JJ rate/NN of/IN nucleotide/NN exchange/NN ,/, suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN growth/NN ,/, and/CC fluid-phase/JJ endocytosis/NN of/IN pfy1-4/NN ,/, a/DT profilin/NN 
295839_4_33_35_13_14::None::using/VBG the/DT STAT3/NN inhibitor/NN LY5/NN and/CC MEK/NN inhibitor/NN Trametinib/NN exerts/VBZ significant/JJ anti/JJ -/: tumor/NN cell/NN efficacy/NN in/IN K/NN -/: Ras/NN mutant/NN pancreatic/JJ and/CC colon/NN cancer/NN cells/NNS in/FW vitro/FW 
322750_1_21_22_23_24::medicine.drug_ingredient.active_moiety_of_drug::N/NN )/) ,/, ammonium/NN (/( NH4/NN -/: N/NN )/) 
980_980_5_6_14_15::POS_REG(+)_DECREASE::stable/JJ expression/NN of/IN V12Ras/NNS into/IN keratinocytes/NNS promotes/VBZ the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN 
1069_1069_42_45_29_30::None::UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
372_372_30_31_9_10::None::virus/NN type/NN 1/CD UL8/NN protein/NN :/: effect/NN on/IN DNA/NN synthesis/NN and/CC ability/NN to/TO interact/VB with/IN and/CC influence/VB the/DT intracellular/JJ localization/NN of/IN the/DT UL5/NN and/CC UL52/NN proteins/NNS ./. 
317242_0_43_44_19_20::None::of/IN granulation/NN and/CC immunohistochemical/JJ hormone/NN expression/NN ,/, such/JJ as/IN growth/NN hormone/NN (/( GH/NN )/) ,/, prolactin/NN ,/, adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) ,/, thyroid/NN stimulating/NN hormone/NN (/( TSH/NN )/) ,/, follicle/NN 
513_513_9_10_7_8::None::(/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN 
769684_3_40_41_23_24::None::-/: Fatigue/NN (/( FACIT/NN -/: Fatigue/NNP ,/, Chinese/NNP mainland/NN version/NN )/) ,/, Pittsburgh/NNP Sleep/NNP Quality/NNP Index/NNP (/( PSQI/NNP )/) ,/, Family/NNP APGAR/NNP Index/NNP (/( 
1647_1647_13_15_17_18::POS_REG(-)_ASSEMBLE::thymosin/NN beta4/NN and/CC profilin/NN II/CD to/TO inhibit/VB actin/NN nucleation/NN and/CC restores/VBZ 
1052_1052_37_38_18_20::None::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
862710_1_44_45_0_2::None::The/DT complex/NN neuro/NN -/: etiology/NN and/CC the/DT restrictive/JJ nature/NN of/IN the/DT blood/NN -/: brain/NN barrier/NN (/( BBB/NNP )/) have/VBP significantly/RB hindered/VBN the/DT drug/NN therapy/NN of/IN ALS/NNP Riluzole/NNP ,/, a/DT moderately/RB performing/VBG drug/NN ,/, is/VBZ the/DT only/JJ agent/NN approved/VBN for/IN treating/VBG ALS/NNP However/RB ,/, several/JJ promising/JJ nanocarrier/NN approaches/NNS are/VBP 
1047_1047_9_10_7_8::None::pro-apoptotic/JJ adapter/NN proteins/NNS TRADD/NN and/CC FADD/NN are/VBP also/RB involved/VBN 
932_932_3_4_5_6::POS_ACTION_PHOSPHORYLATE::Like/IN TESK1/NN ,/, TESK2/NN phosphorylated/VBN cofilin/NN specifically/RB at/IN Ser-3/NN 
1464_1464_3_4_22_23::None::The/DT domains/NNS in/IN CBP/NN that/WDT are/VBP involved/VBN in/IN CREB/NN binding/NN and/CC transcriptional/JJ activation/NN are/VBP highly/RB related/VBN to/TO the/DT adenoviral/JJ E1A-associated/JJ cellular/JJ protein/NN p300/NN (/( refs/NNS 2/CD 
491599_4_8_10_3_4::None::In/IN addition/NN ,/, positive/JJ effects/NNS of/IN TQ/NN in/IN cardiovascular/JJ disorders/NNS ,/, diabetes/NN ,/, 
1341_1341_6_7_4_5::None::alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS 
459829_1_27_28_14_15::None::)/) by/IN the/DT decomposition/NN of/IN magnesium/NN acetate/NN and/CC ,/, therefore/RB ,/, could/MD block/VB contact/NN between/IN the/DT perovskite/NN and/CC TiO/NN (/( 
157_157_1_2_8_9::POS_ACTION_STSIMILAR::Archaeal/NNP histones/NNS are/VBP most/RBS similar/JJ to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN 
18085_7_16_17_34_35::medicine.medical_treatment.used_to_treat::after/IN ICSI/NN -/: IVF/NN with/IN PGS/NN using/VBG ejaculated/VBN sperm/NN from/IN a/DT man/NN with/IN non/JJ -/: mosaic/JJ trisomy/NN 21/CD and/CC male/JJ factor/NN infertility/NN ./. 
245350_6_5_6_83_84::None::the/DT refeeding/VBG diets/NNS contained/VBD VitD/NN We/PRP concluded/VBD that/IN :/: i/LS )/) food/NN restriction/NN led/VBD to/TO the/DT upregulation/NN of/IN insulin/NN receptor/NN in/IN liver/NN and/CC adipose/NN tissue/NN accompanied/VBN by/IN increased/VBN Tnfalpha/NN in/IN the/DT hypothalamus/NN ;/: ii/LS )/) in/IN all/DT of/IN the/DT refed/JJ groups/NNS ,/, refeeding/VBG led/VBN to/TO similar/JJ body/NN weight/NN gain/NN during/IN the/DT refeeding/JJ period/NN ;/: and/CC iii/LS )/) refeeding/VBG with/IN MSP/NN and/CC MRD/NN diets/NNS induced/VBD higher/JJR food/NN intake/NN on/IN the/DT fourth/JJ week/NN of/IN refeeding/NN ,/, and/CC this/DT increase/NN was/VBD associated/VBN with/IN reduced/VBN hypothalamic/JJ interleukin/NN 6/CD expression/NN 
600_600_0_1_8_9::None::alpha-SNAP/NN binds/VBZ to/TO predicted/VBN alpha-helical/JJ coiled-coil/JJ regions/NNS of/IN syntaxin/NN and/CC SNAP-25/NN ,/, 
534857_3_53_54_51_52::None::randomly/RB assigned/VBN to/TO losartan/NN or/CC atenolol/NN -/: based/VBN treatment/NN 
465207_3_1_2_6_7::None::The/DT reported/VBN prevalence/NN of/IN osteoporosis/NN among/IN postmenopausal/JJ women/NNS in/IN Brazil/NNP 
237_237_17_18_9_10::POS_ACTION_LOCALIZE::and/CC redistribution/NN of/IN actin/NN microfilaments/NNS in/IN fibroblasts/NNS :/: possible/JJ role/NN for/IN PKC-delta/NN ./. 
1128_1128_0_2_11_14::None::Platelet/NN talin/NN binds/VBZ to/TO actin/NN in/FW vitro/FW and/CC hence/RB is/VBZ an/DT actin/NN binding/NN protein/NN ./. 
1069_1069_33_35_24_25::None::helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) 
1037_1037_24_26_9_11::None::exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD 
426927_1_18_19_17_18::biology.organism_classification.lower_classifications::was/VBD investigated/VBN in/IN Beagle/NNP dogs/NNS by/IN using/VBG single/JJ 
1633_1633_15_16_32_33::None::;/: four/CD histone/NN H2a/NN genes/NNS ,/, two/CD of/IN which/WDT are/VBP identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC two/CD histone/NN H2b/NN genes/NNS ./. 
479_479_2_4_21_22::None::Expressions/NNS of/IN cyclin/NN E/NN ,/, A/NN ,/, and/CC B1/NN in/IN Hodgkin/NN and/CC Reed-Sternberg/NN cells/NNS :/: not/RB suppressed/VBN by/IN cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN expression/NN ./. 
1787_1787_11_12_14_15::None::their/PRP$ interaction/NN with/IN actin/NN ,/, like/IN destrin/NN and/CC cofilin/NN isolated/VBN 
2146_2146_11_13_6_7::None::that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) 
566289_3_15_17_10_11::medicine.disease.symptoms::patient/NN with/IN a/DT papular/JJ facial/JJ eruption/NN reminiscent/NN of/IN acne/NN vulgaris/NN and/CC with/IN keratotic/JJ 
266669_0_26_27_18_19::None::warfarin/NN had/VBD a/DT cortical/JJ left/JJ middle/JJ cerebral/JJ artery/NN (/( MCA/NNP )/) stroke/NN (/( October/NNP 2009/CD 
1957_1957_15_16_36_37::None::EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ cells/NNS at/IN confluence/NN were/VBD dissociated/VBN into/IN single/JJ cells/NNS by/IN tryptic/JJ digestion/NN ,/, being/VBG accompanied/VBN by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
370565_0_16_17_32_33::None::the/DT atlantoaxial/JJ junction/NN induced/VBN by/IN ''/'' crown/NN -/: like/IN ''/'' calcifications/NNS around/IN the/DT dens/NNS ,/, present/JJ with/IN symptoms/NNS of/IN severe/JJ neck/NN pain/NN ,/, 
721_721_15_16_13_14::POS_ACTION_INTERACT::to/TO DNA/NN were/VBD PRP21/NN and/CC PRP9/NN or/CC PRP21/NN and/CC 
2131_2131_10_11_9_10::None::,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN 
1344_1344_20_21_6_7::None::these/DT three/CD mutant/JJ UL5/NN proteins/NNS to/TO form/VB specific/JJ interactions/NNS with/IN other/JJ members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, 
654472_6_37_38_23_24::medicine.disease.symptoms::non/JJ -/: ocular/JJ pain/NN measures/NNS (/( numerical/JJ rating/NN scale/NN and/CC pain/NN history/NN )/) ,/, (/( B/NN )/) depression/NN and/CC (/( C/NN 
102783_0_19_20_32_33::None::copper/NN -/: based/VBN carbene/NN radical/NN and/CC alpha/NN -/: carbonyl/NN diazomethane/NN radical/JJ intermediates/NNS ,/, which/WDT could/MD be/VB captured/VBN by/IN radical/JJ traps/NNS 
406187_0_34_35_37_38::None::A/NN Ophthalmoscopy/NN demonstrated/VBD findings/NNS of/IN confluent/JJ ischemic/JJ retinopathy/NN ./. 
387603_2_38_39_45_46::None::composed/VBN of/IN a/DT hydrophobic/JJ PLGA/NNP head/NN and/CC a/DT hydrophilic/JJ HA/NNP segment/NN linked/VBN by/IN a/DT 
172875_8_21_23_22_23::medicine.drug.active_moieties::)/) demonstrated/VBD that/IN serum/NN sodium/NN is/VBZ a/DT significant/JJ 
1338_1338_5_6_23_24::POS_ACTION_BIND::monomer-binding/JJ protein/NN ,/, profilin/NN ,/, influences/VBZ the/DT dynamics/NNS of/IN actin/NN filaments/NNS in/FW vitro/FW by/IN suppressing/VBG nucleation/NN ,/, enhancing/VBG nucleotide/NN exchange/NN on/IN actin/NN ,/, and/CC promoting/VBG 
398_398_10_11_20_21::POS_ACTION_BIND::of/IN PRT1/NN and/CC TIF35/NN were/VBD found/VBN to/TO be/VB responsible/JJ for/IN their/PRP$ binding/NN to/TO TIF34/NN ./. 
834587_19_27_28_32_33::None::distribution/NN with/IN a/DT reduction/NN in/IN the/DT dose/NN to/TO lung/NN and/CC heart/NN ./. 
367_367_0_2_32_33::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN ./. 
1052_1052_29_30_27_28::None::acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
1672_1672_8_9_3_4::POS_ACTION_MEMBER::The/DT Saccharomyces/FW cerevisiae/FW DDC1/NN gene/NN belongs/VBZ to/TO the/DT RAD17/NN ,/, MEC3/NN and/CC 
2131_2131_10_11_21_22::POS_ACTION_LOCALIZE::UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
411693_2_18_19_10_11::None::value/NN of/IN maximum/NN standardized/JJ uptake/NN value/NN (/( SUVmax/NN )/) determined/VBN by/IN pancreatic/JJ ductal/JJ cancers/NNS is/VBZ 
315603_0_26_27_2_3::None::[/( Clinical/JJ Efficacy/NN of/IN Dasatinib/NNP ,/, Nilotinib/NNP and/CC Imatinib/NNP in/IN Newly/RB Diagnosed/VBN Patients/NNS with/IN Chronic/JJ -/: Phase/NN Chronic/JJ Myeloid/JJ Leukemia/NN :/: A/DT Three/CD -/: year/NN Retrospective/JJ Analysis/NN ]/) ./. 
1580_1580_23_24_28_29::POS_ACTION_BIND::its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
178297_11_42_43_34_35::medicine.disease.symptoms::)/) ,/, including/VBG cirrhosis/NN (/( 24.4/CD %/NN )/) ,/, acute/JJ toxic/JJ hepatitis/NN (/( 12/CD %/NN 
122457_3_43_44_7_8::None::sequencing/NN technologies/NNS have/VBP identified/VBN several/JJ genetic/JJ variants/NNS that/WDT may/MD regulate/VB the/DT development/NN and/CC progression/NN of/IN T2DM/NN ,/, little/JJ is/VBZ known/VBN about/IN whether/IN or/CC not/RB the/DT variants/NNS are/VBP involved/VBN in/IN disease/NN progression/NN and/CC how/WRB these/DT genetic/JJ variants/NNS are/VBP associated/VBN with/IN diabetic/JJ neuropathy/NN specifically/RB ./. 
933691_0_17_18_15_17::None::and/CC pain/NN in/IN chronic/JJ fatigue/NN syndrome/NN (/( CFS/NN )/) 
374_374_6_7_12_13::None::enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC deletion/NN of/IN SIR1/NN or/CC SIR3/NN did/VBD 
88_88_1_2_30_31::POS_ACTION_AFFECT::Although/IN profilin/NN released/VBN actin/NN at/IN the/DT appropriate/JJ time/NN to/TO stimulate/VB actin/NN assembly/NN during/IN exposure/NN to/TO chemoattractants/NNS ,/, the/DT concentration/NN of/IN profilin/NN in/IN PMN/NN was/VBD insufficient/JJ to/TO explain/VB the/DT high/JJ unpolymerized/JJ actin/NN content/NN in/IN unstimulated/JJ 
594019_6_0_1_17_18::medicine.risk_factor.diseases::Females/NNS who/WP began/VBD running/VBG at/IN or/CC before/IN age/NN 10/CD were/VBD more/RBR likely/JJ to/TO report/VB a/DT diagnosis/NN of/IN hypothyroidism/NN versus/CC those/DT who/WP 
1850_1850_2_3_0_1::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB 
515725_7_3_4_12_13::None::Individuals/NNS with/IN chronic/JJ mental/JJ and/CC physical/JJ conditions/NNS (/( fatigue/NN ,/, insomnia/NN ,/, anxiety/NN ,/, depression/NN ,/, 
1169_1169_41_42_13_16::None::actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD found/VBN to/TO possess/VB short/JJ peptide/NN motifs/NNS homologous/JJ to/TO one/CD part/NN of/IN verprolin/NN ./. 
352038_4_10_11_0_1::None::Proteobacteria/NNP was/VBD the/DT most/RBS abundant/JJ ,/, followed/VBN by/IN Firmicutes/NNP ,/, Bacteroidetes/NNP and/CC Actinobacteria/NNP ./. 
86_86_28_29_14_15::None::all/DT sera/NNS caused/VBD IgG/NN binding/NN to/TO platelet/NN components/NNS of/IN 87-90/CD kD/NN ,/, 140/CD kD/NN (/( identified/VBN as/IN vinculin/NN )/) and/CC 220-240/CD 
1777_1777_27_29_8_9::None::the/DT Listeria/NN monocytogenes/NNS ActA/NN protein/NN controls/VBZ the/DT rate/NN of/IN actin-based/JJ motility/NN ,/, the/DT percentage/NN of/IN moving/VBG bacteria/NNS ,/, and/CC the/DT localization/NN of/IN vasodilator-stimulated/JJ phosphoprotein/NN and/CC profilin/NN ./. 
533311_1_6_7_8_9::medicine.disease.symptoms::to/TO identify/VB the/DT depression/NN and/CC anxiety/NN state/NN of/IN diabetic/JJ 
1546_1546_8_11_26_27::None::p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ from/IN its/PRP$ binding/NN with/IN the/DT cyclin/NN E/cyclin-dependent/JJ kinase/NN 2/CD (/( Cdk2/NN )/) complex/NN that/WDT 
410_410_11_12_9_10::POS_ACTION_MEMBER::of/IN both/DT histone/NN H3/NN and/CC histone/NN H4/NN were/VBD inviable/JJ 
367_367_5_7_0_2::POS_ACTION_MEMBER::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP 
605_605_8_9_18_19::POS_ACTION_CONTAIN::encodes/VBZ a/DT heterotrimeric/JJ helicase-primase/NN complex/NN that/WDT is/VBZ composed/VBN of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, 
2222_2222_19_20_23_24::POS_ACTION_COLOCALIZE::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
408887_9_18_22_34_35::None::chronic/JJ illnesses/NNS :/: type/NN 2/CD diabetes/NN mellitus/NN ,/, cardiovascular/JJ disease/NN ,/, and/CC some/DT cancers/NNS ;/: which/WDT are/VBP associated/VBN with/IN overweight/JJ //: obesity/NN ,/, 
322769_0_1_2_21_22::None::Selenate/NNP removal/NN by/IN zero/CD -/: valent/JJ iron/NN in/IN oxic/JJ condition/NN :/: the/DT role/NN of/IN Fe/NNP (/( II/NNP )/) and/CC selenate/NN removal/NN mechanism/NN ./. 
1105_1105_20_24_6_9::None::)/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, induces/VBZ G1/NN arrest/NN and/CC can/MD inhibit/VB the/DT activity/NN of/IN the/DT proliferating/VBG cell/NN nuclear/JJ antigen/NN (/( PCNA/NN )/) 
229532_2_7_9_11_12::None::cells/NNS to/TO single/JJ fatty/JJ acids/NNS ,/, arachidonic/JJ acid/NN (/( AA/NN )/) 
1560_1560_17_18_39_40::POS_ACTION_MEMBER::versus/CC acetylation/NN of/IN histone/NN H3/NN :/: with/IN the/DT purified/VBN acetylase/NN ,/, histone/NN H4/NN in/IN nucleosomes/NNS was/VBD acetylated/VBN to/TO a/DT much/RB greater/JJR extent/NN than/IN was/VBD histone/NN H3/NN ,/, whereas/IN the/DT 
761082_2_20_21_43_44::None::pregnancy/NN in/IN infertile/JJ Italian/JJ endometriosis/NN women/NNS ;/: (/( ii/LS )/) evaluate/VB the/DT predictive/JJ value/NN of/IN EFI/NNP score/NN on/IN ART/NN outcome/NN for/IN patients/NNS who/WP previously/RB attempted/VBD to/TO spontaneously/RB conceive/VB after/IN surgery/NN 
458615_4_42_43_9_10::None::,/, besides/IN P/NN starvation/NN responsive/JJ genes/NNS ,/, the/DT expression/NN of/IN a/DT number/NN of/IN genes/NNS involved/VBN in/IN iron/NN (/( Fe/NNP )/) ,/, potassium/NN (/( K/NN )/) ,/, sodium/NN (/( Na/NN )/) ,/, and/CC calcium/NN (/( Ca/NN )/) absorption/NN was/VBD dramatically/RB up/RB 
736874_8_17_18_7_8::None::belonged/VBN to/TO the/DT phyla/NN Firmicutes/NNS (/( mainly/RB streptococci/NNS )/) and/CC Actinobacteria/NN (/( mainly/RB Actinomyces/NNP species/NNS )/) ./. 
531305_1_0_1_6_7::medicine.disease.symptoms::It/PRP is/VBZ associated/VBN with/IN hallucination/NN ,/, psychosis/NN and/CC hearing/NN impairments/NNS 
996_996_8_9_12_13::POS_ACTION_UPREGULATE::cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT 
226276_6_45_46_15_16::None::)/) individuals/NNS with/IN higher/JJR levels/NNS of/IN sub/NN -/: psychotic/JJ pre/JJ -/: delusional/JJ symptoms/NNS that/WDT acutely/RB worsen/VBP in/IN the/DT ramp/NN -/: up/IN to/TO full/JJ -/: blown/VBN psychosis/NN ,/, and/CC as/IN such/JJ may/MD reflect/VB pathophysiological/JJ processes/NNS driving/VBG emergence/NN of/IN 
1726_1726_8_9_16_17::POS_ACTION_PHOSPHORYLATE::of/IN LIM-kinase/NN by/IN ROCK/NN and/CC consequently/RB increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ 
258_258_8_9_6_7::None::and/CC association/NN of/IN beta-catenin/NN with/IN EGFR/NN were/VBD inhibited/VBN by/IN 
955511_15_22_23_3_4::None::For/IN example/NN ,/, Proteobacterial/JJ species/NNS are/VBP important/JJ for/IN electricity/NN generation/NN in/IN the/DT anode/NN biofilms/NNS and/CC Firmicutes/NNS phylum/NN was/VBD predominant/JJ on/IN anolyte/NN to/TO transfer/VB electron/NN ./. 
140351_4_12_13_15_17::None::most/JJS authors/NNS have/VBP focused/VBN on/IN the/DT adverse/JJ events/NNS related/JJ to/TO therapy/NN 
388589_2_12_13_17_19::people.cause_of_death.includes_causes_of_death::reporting/VBG information/NN on/IN cardiovascular/JJ disease/NN (/( defined/VBN as/IN myocardial/JJ infarction/NN ,/, stroke/NN ,/, 
2131_2131_9_10_21_22::POS_ACTION_LOCALIZE::,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
143595_7_3_4_23_24::None::In/IN the/DT chronic/JJ bioassay/NN ,/, larvae/NNS were/VBD exposed/VBN to/TO nitrate/VB concentrations/NNS of/IN 50/CD ,/, 100/CD ,/, 200/CD ,/, and/CC 400/CD mg/NN //: L/NN NO3/NN (/( -/: )/) 
747093_0_7_9_0_2::None::Robotic/JJ surgery/NN in/IN supermorbidly/JJ obese/JJ patients/NNS with/IN endometrial/JJ cancer/NN ./. 
412955_2_20_21_4_5::None::resulting/VBG from/IN assisted/VBN reproductive/JJ treatments/NNS (/( ART/NN )/) are/VBP associated/VBN with/IN a/DT higher/JJR risk/NN of/IN pregnancy/NN complications/NNS compared/VBN with/IN spontaneously/RB conceived/VBN pregnancies/NNS ./. 
1061_1061_24_25_25_27::None::binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
856_856_13_14_37_38::None::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN 
643154_0_0_2_3_4::None::Colorectal/JJ cancer/NN is/VBZ common/JJ worldwide/RB ,/, and/CC 
529506_0_0_3_9_13::None::Diffuse/JJ alveolar/JJ hemorrhage/NN from/IN systemic/JJ lupus/NN erythematosus/NN misdiagnosed/JJ as/RB high/JJ altitude/NN pulmonary/JJ edema/NN ./. 
578166_0_15_16_13_14::biology.organism_classification.lower_classifications::antioxidant/JJ capacity/NN of/IN almond/NN (/( Amygdalus/JJ communisL/NN ./. 
228216_0_19_20_4_5::medicine.disease.risk_factors::cells/NNS to/TO folding/JJ stress/NN causes/VBZ a/DT subset/NN of/IN their/PRP$ proteins/NNS to/TO misfold/VB and/CC accumulate/VB in/IN inclusion/NN bodies/NNS (/( IBs/NNS )/) ./. 
71991_0_18_19_15_16::medicine.symptom.symptom_of::including/VBG depression/NN //: anxiety/NN disorder/NN ,/, insomnia/NN //: sleep/VB disorder/NN 
1061_1061_19_20_24_25::POS_ACTION_BIND::;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
1546_1546_5_6_12_13::None::inhibitory/JJ action/NN of/IN p27/NN ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ 
1061_1061_24_25_15_16::None::but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
174613_5_16_17_18_19::medicine.disease.symptoms::,/, more/RBR severe/JJ hypertension/NN ,/, proteinuria/NN ,/, placental/JJ pathology/NN 
2212_2212_9_10_1_2::None::While/IN alpha-catenin/NN has/VBZ been/VBN demonstrated/VBN to/TO be/VB crucial/JJ for/IN cadherin/NN function/NN ,/, the/DT 
1337_1337_4_5_9_10::POS_ACTION_BIND::actin/NN cytoskeleton-associated/JJ protein/NN talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN 
488205_3_5_6_69_70::None::molybdenum/NN -/: rich/JJ anions/NNS ,/, PMo/NN (/( 12/CD -/: n/NN )/) W/NN (/( n/NN )/) O/NN (/( 40/CD )/) (/( 3/LS -/: )/) (/( n/NN =/JJ 0/CD -/: 2/CD )/) ,/, generates/VBZ an/DT abundant/JJ doubly/RB charged/VBN fragment/NN containing/VBG seven/CD metal/NN atoms/NNS (/( M/NN )/) and/CC 22/CD oxygen/NN atoms/NNS (/( M/NN (/( 7/CD )/) O/NN (/( 22/CD )/) (/( 2/LS -/: )/) )/) and/CC its/PRP$ complementary/JJ singly/RB charged/VBN PM/NNP (/( 5/CD )/) 
257215_0_39_41_24_25::None::based/VBN on/IN mesoporous/JJ silica/NN nanoparticles/NNS (/( MSN/NNP )/) for/IN targeted/VBN drug/NN delivery/NN has/VBZ been/VBN developed/VBN ,/, in/IN which/WDT hyaluronic/JJ acid/NN (/( HA/NN )/) 
394127_6_25_26_7_8::None::malignancy/NN sites/NNS were/VBD colon/NN (/( 33.2/CD %/NN )/) ,/, endometrium/NN (/( 17.1/CD %/NN )/) ,/, breast/NN (/( 14.3/CD %/NN )/) ,/, appendix/NN (/( 7.3/CD %/NN 
2022_2022_8_9_11_12::None::potential/JJ sequestration/NN of/IN actin/NN monomers/NNS by/IN profilin/NN ,/, when/WRB present/JJ 
231380_9_19_20_20_21::medicine.risk_factor.diseases::are/VBP related/JJ to/TO postmenopausal/JJ osteoporotic/JJ phenotype/NN ./. 
1160_1160_22_23_8_10::None::21,000/CD molecular/JJ weight/NN actin-binding/JJ protein/NN ,/, from/IN porcine/NN kidney/NN and/CC identification/NN of/IN the/DT cofilin-binding/JJ site/NN in/IN the/DT actin/NN sequence/NN ./. 
221936_3_2_5_33_34::None::Measurements/NNS on/IN systolic/JJ blood/NN pressure/NN ,/, HOMA/NNP index/NN ,/, triglycerides/NNS ,/, TC/NN //: HDL/SYM -/: c/NN ,/, VO2max/NN and/CC the/DT sum/NN of/IN four/CD skinfolds/NNS were/VBD obtained/VBN ,/, and/CC a/DT clustered/VBN cardiovascular/JJ disease/NN (/( CVD/NN )/) risk/NN index/NN 
1478_1478_4_5_9_10::POS_ACTION_ASSEMBLE::essential/JJ role/NN of/IN profilin/NN in/IN the/DT assembly/NN of/IN actin/NN for/IN microspike/NN formation/NN 
1434_1434_72_73_11_12::POS_ACTION_MEMBER::,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN 
2146_2146_4_5_6_7::None::report/VBP here/RB that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN 
814130_0_16_17_6_7::None::pathology/NN ,/, pancreatic/JJ cystic/JJ tumors/NNS stand/VBP nowadays/RB for/IN 25/CD %/NN of/IN all/DT pancreatic/JJ surgical/JJ diseases/NNS ./. 
117943_0_9_10_1_2::None::Adjunctive/JJ thrombus/NN aspiration/NN (/( TA/NNP )/) during/IN primary/JJ percutaneous/JJ coronary/JJ intervention/NN (/( PCI/NN 
79843_0_20_24_8_9::medicine.disease.treatments::the/DT psychostimulant/NN ,/, methylphenidate/NN (/( MPD/NN )/) the/DT drug/NN of/IN choice/NN in/IN the/DT treatment/NN of/IN attention/NN deficit/NN hyperactivity/NN disorder/NN (/( ADHD/NN )/) 
574065_1_35_37_9_11::medicine.medical_treatment.used_to_treat::,/, renal/JJ and/CC bladder/NN cancer/NN presented/VBN at/IN the/DT 2014/CD congresses/NNS (/( European/JJ Association/NNP of/IN Urology/NNP ,/, American/NNP Urological/NNP Association/NNP ,/, American/NNP Society/NNP of/IN Clinical/JJ Oncology/NN and/CC American/JJ Society/NNP for/IN Radiation/NNP Oncology/NNP )/) that/WDT received/VBD 
2107_2107_15_16_39_40::None::targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
1095_1095_22_23_17_18::None::and/CC distribution/NN of/IN integrin/NN subunits/NNS ,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ 
933691_0_19_20_17_18::None::in/IN chronic/JJ fatigue/NN syndrome/NN (/( CFS/NN )/) ./. 
799053_0_3_4_15_16::None::Clinical/JJ observations/NNS on/IN chemotherapy/NN curable/JJ malignancies/NNS :/: unique/JJ genetic/JJ events/NNS ,/, frozen/JJ development/NN and/CC enduring/VBG apoptotic/JJ potential/NN ./. 
444311_5_86_87_42_43::None::,/, supporting/VBG the/DT function/NN of/IN PrP/NN (/( C/NN )/) as/IN a/DT plasma/NN membrane/NN FR/NN Coexpression/NN of/IN PrP/NN (/( C/NN )/) with/IN ZIP14/NN and/CC DMT1/NN in/IN HepG2/NN cells/NNS increased/VBD uptake/NN of/IN Fe/NNP (/( 3/CD +/CC )/) significantly/RB ,/, and/CC surprisingly/RB ,/, increased/VBD the/DT ratio/NN of/IN N/NN -/: terminally/RB truncated/VBN PrP/NN (/( C/NN 
1711_1711_7_8_19_20::None::predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN ,/, 
1798_1798_41_42_33_34::None::integrin/NN receptors/NNS ,/, actin/NN and/CC cytoskeletal/JJ proteins/NNS such/JJ as/IN vinculin/NN and/CC talin/NN ./. 
1486_1486_60_61_60_61::None::receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
322972_6_0_1_16_17::None::The/DT population/NN PK/NN model/NN developed/VBD from/IN our/PRP$ study/NN successfully/RB characterizes/VBZ the/DT absorption/NN ,/, distribution/NN ,/, and/CC elimination/NN of/IN MPA/NNP in/IN 
1103_1103_9_10_5_8::None::cyclin/NN E/NN and/CC cyclin-dependent/JJ kinase/NN inhibitor/NN (/( p27Kip1/NN )/) :/: effect/NN 
1164_1164_33_34_35_38::None:::/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, 
773440_1_8_9_39_40::None::available/JJ on/IN the/DT market/NN (/( ie/FW ,/, etanercept/NN ,/, infliximab/NN ,/, adalimumab/NN ,/, certolizumab/NN and/CC golimumab/NN )/) are/VBP top/JJ sellers/NNS ,/, although/IN indicated/VBN only/RB in/IN autoimmune/JJ diseases/NNS ,/, including/VBG rheumatoid/JJ arthritis/NN ,/, Crohn/NN whosewhat/NN disease/NN and/CC psoriasis/NN ./. 
984_984_33_34_9_10::POS_ACTION_BIND::different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS producing/VBG chimeric/JJ proteins/NNS containing/VBG the/DT AT-hooks/NNPS ,/, methyltransferase/NN homology/NN domain/NN ,/, and/CC transcriptional/JJ repression/NN domain/NN of/IN MLL/NN fused/VBN to/TO the/DT CREB/NN binding/NN domain/NN or/CC 
686_686_31_32_31_32::None::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
243_243_32_35_36_37::None::through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) ./. 
1726_1726_16_17_8_9::None::of/IN LIM-kinase/NN by/IN ROCK/NN and/CC consequently/RB increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ 
1818_1818_11_12_9_10::POS_ACTION_COLOCALIZE::the/DT coexistence/NN of/IN profilin/NN with/IN actin/NN filaments/NNS in/IN the/DT 
1672_1672_3_4_8_9::None::The/DT Saccharomyces/FW cerevisiae/FW DDC1/NN gene/NN belongs/VBZ to/TO the/DT RAD17/NN ,/, MEC3/NN and/CC 
1061_1061_19_20_6_7::None::(/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO 
419773_1_34_35_9_10::None::18/CD %/NN of/IN nursing/NN home/NN residents/NNS suffer/VBP from/IN pressure/NN ulcers/NNS and/CC the/DT resulting/VBG hospital/NN costs/NNS can/MD account/VB for/IN up/RB to/TO 4/CD %/NN of/IN a/DT nation/NN whosewhat/NN health/NN care/NN budget/NN ./. 
148500_0_3_5_12_13::None::Gap/NN Junctions/NNS as/IN Common/JJ Cause/NN of/IN High/JJ -/: Frequency/NN Oscillations/NNS and/CC Epileptic/JJ Seizures/NNS in/IN a/DT Computational/JJ 
556_556_12_13_10_11::None::nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ 
784_784_21_22_18_19::None::,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
1874_1874_17_18_3_4::None::Thus/RB ,/, like/IN verprolin/NN ,/, WIP/NNP functions/VBZ in/IN yeast/NN to/TO link/VB the/DT polarity/NN development/NN pathway/NN and/CC the/DT actin/NN cytoskeleton/NN to/TO generate/VB 
1617_1617_21_22_2_3::POS_ACTION_BIND::The/DT protein/NN profilin/NN binds/VBZ to/TO both/DT actin/NN and/CC the/DT head/NN groups/NNS of/IN poly/NN )/) phosphoinositide/NN )/) s/NNS and/CC may/MD regulate/VB both/DT actin/NN assembly/NN and/CC the/DT 
265345_3_4_5_12_13::None::persistent/JJ impairment/NN of/IN renal/JJ function/NN has/VBZ been/VBN also/RB reported/VBN following/VBG macroscopic/JJ haematuria/NN -/: associated/VBN acute/JJ 
897_897_8_10_15_16::None::suramin/NN completely/RB blocked/VBD PDGF/NN receptor/NN activation/NN or/CC phosphorylation/NN stimulated/VBN by/IN PDGF-AB/NN ,/, inhibited/VBD activation/NN 
779_779_26_27_49_52::None::inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
2146_2146_14_15_6_7::None::that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
703552_5_23_24_24_25::None::IL/NN -/: 1/CD family/NN members/NNS in/IN retinal/JJ layers/NNS 
1052_1052_6_8_27_28::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) 
374_374_6_7_14_15::None::enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC deletion/NN of/IN SIR1/NN or/CC SIR3/NN did/VBD not/RB affect/VB 
1341_1341_12_13_1_2::None::The/DT alpha-catenin/NN molecule/NN links/NNS E-cadherin/NN //: beta-catenin/NN or/CC E-cadherin/plakoglobin/NN complexes/NNS to/TO the/DT actin/NN cytoskeleton/NN ./. 
747093_0_0_2_7_9::None::Robotic/JJ surgery/NN in/IN supermorbidly/JJ obese/JJ patients/NNS with/IN endometrial/JJ cancer/NN ./. 
399_399_2_3_23_24::POS_ACTION_MODIFY::Dispersal/NN of/IN profilin/NN from/IN such/JJ sites/NNS by/IN oligoproline-rich/JJ peptide/NN inhibitors/NNS suggests/VBZ that/IN profilin/NN is/VBZ directly/RB involved/VBN in/IN intracellular/JJ pathogen/NN locomotion/NN and/CC reorganization/NN of/IN actin/NN cytoskeleton/NN of/IN the/DT 
2146_2146_11_13_9_10::None::LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) 
686_686_33_34_29_30::POS_ACTION_BIND::the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
813_813_27_28_8_9::None::NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN P/NN is/VBZ essential/JJ for/IN 
435_435_15_16_13_14::None::the/DT binding/NN to/TO PRP9/NN and/CC PRP11/NN proteins/NNS and/CC are/VBP 
740032_2_28_29_14_15::None::2012/CD in/IN the/DT FBIH/NN among/IN adult/JJ population/NN aged/JJ 25/CD -/: 64/CD years/NNS for/IN assessment/NN and/CC distribution/NN of/IN major/JJ risk/NN factors/NNS for/IN 
776_776_4_6_29_30::None::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT were/VBD 
1486_1486_60_61_32_33::None::protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
432219_9_8_9_28_29::None::or/CC mild/JJ ,/, moderate/JJ ,/, and/CC severe/JJ dehydration/NN were/VBD found/VBN to/TO have/VB the/DT following/VBG respective/JJ gains/NNS in/IN percent/NN weight/NN at/IN the/DT end/NN of/IN illness/NN :/: 2.44/CD !/. 
1160_1160_8_10_22_23::None::21,000/CD molecular/JJ weight/NN actin-binding/JJ protein/NN ,/, from/IN porcine/NN kidney/NN and/CC identification/NN of/IN the/DT cofilin-binding/JJ site/NN in/IN the/DT actin/NN sequence/NN ./. 
89_89_1_2_17_18::POS_ACTION_Assembly::Although/IN talin/NN has/VBZ been/VBN suggested/VBN to/TO act/VB as/IN a/DT linkage/NN protein/NN mediating/VBG the/DT attachment/NN of/IN GPIIb-IIIa/NN to/TO actin/NN filaments/NNS ,/, direct/JJ 
165_165_12_15_23_24::POS_ACTION_BIND::beta/NN 4/CD (/( T/NN beta/NN 4/CD )/) ,/, low/JJ amounts/NNS of/IN profilin/NN promote/VBP extensive/JJ actin/NN assembly/NN off/IN of/IN 
10363_2_9_10_12_13::None::diabetic/JJ by/IN a/DT single/JJ high/JJ dose/NN injection/NN of/IN streptozotocin/NN (/( 
387871_6_22_24_3_4::medicine.drug.active_moieties::Straw/NNP significantly/RB promoted/VBD CO2/NN and/CC N2O/NN emissions/NNS but/CC inhibited/VBD CH4/NN emission/NN ,/, while/IN interactions/NNS between/IN nematodes/NNS and/CC nitrogen/NN fertilization/NN on/IN emissions/NNS of/IN greenhouse/NN gases/NNS were/VBD obvious/JJ ./. 
323444_1_54_55_56_57::medicine.drug_ingredient.active_moiety_of_drug::a/DT patient/NN with/IN adrenocorticotropin/NN (/( ACTH/NN )/) -/: dependent/JJ 
591709_2_6_7_19_20::None::ease/NN in/IN generating/VBG genomic/JJ data/NNS ,/, as/RB well/RB as/IN recent/JJ ,/, although/IN incomplete/JJ descriptions/NNS of/IN potential/JJ COX/NNP sequences/NNS in/IN Mollusca/NNP 
159983_7_6_8_4_5::None::estimation/NN of/IN the/DT affinity/NN of/IN methyl/NN eugenol/NN for/IN the/DT resting/VBG 
956369_1_26_27_52_53::medicine.disease.treatments::CA/NNP )/) for/IN AF/NN We/PRP evaluated/VBD 342/CD consecutive/JJ patients/NNS who/WP underwent/VBD CA/NNP for/IN AF/NN between/IN April/NNP 2013/CD and/CC March/NNP 2014/CD and/CC received/VBD apixaban/NN (/( n/NN =/JJ 105/CD )/) and/CC warfarin/NN (/( n/NN =/JJ 
295269_3_28_30_25_27::medicine.disease.risk_factors::diseases/NNS ,/, including/VBG diabetes/NN mellitus/NN ,/, cardiovascular/JJ disease/NN ,/, and/CC aging/NN 
431_431_0_1_6_7::POS_ACTION_ENCODE::END5/NN encodes/VBZ a/DT proline-rich/JJ protein/NN (/( End5p/NN or/CC verprolin/NN )/) 
549_549_11_12_20_21::POS_ACTION_INTERACT::to/TO msh6-F337A/NN sequestering/NN MSH2/NN and/CC preventing/VBG it/PRP from/IN interacting/VBG with/IN MSH3/NN and/CC MSH6/NN ./. 
313728_4_1_2_36_37::None::Research/NNP investigating/VBG the/DT unique/JJ metabolic/JJ needs/NNS of/IN tumor/NN cells/NNS has/VBZ led/VBN to/TO the/DT proposal/NN of/IN a/DT new/JJ metabolic/JJ treatment/NN for/IN various/JJ cancers/NNS including/VBG GBMs/NNS that/WDT may/MD enhance/VB the/DT effectiveness/NN of/IN the/DT SOC/NNP The/DT goal/NN of/IN metabolic/JJ cancer/NN therapy/NN is/VBZ to/TO 
671_671_16_17_5_7::None::revealed/VBD that/IN two/CD actin-binding/JJ proteins/NNS of/IN low/JJ molecular/JJ weight/NN with/IN different/JJ functional/JJ activity/NN ,/, ADF/NN and/CC cofilin/NN ,/, 
2414_0_0_1_22_23::None::Amino/NN -/: Terminal/JJ Pro/FW -/: B/NN -/: Type/NN Natriuretic/JJ Peptide/NN Improves/VBZ Discrimination/NN for/IN Incident/NNP Atherosclerotic/JJ Cardiovascular/NNP Disease/NNP Beyond/NNP Ambulatory/NNP Blood/NNP Pressure/NN in/IN Elderly/NNP Men/NNP 
1140_1140_20_21_22_23::None::the/DT interaction/NN of/IN gelsolin/NN and/CC profilin/NN with/IN actin/NN ./. 
1779_1779_6_7_5_7::None::pyrene-labeled/JJ rabbit/NN skeletal/JJ actin/NN with/IN human/JJ profilin/NN 
605_605_18_19_8_9::None::encodes/VBZ a/DT heterotrimeric/JJ helicase-primase/NN complex/NN that/WDT is/VBZ composed/VBN of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, 
443_443_9_10_6_7::None::conformational/JJ change/NN in/IN actin/NN induced/VBN by/IN fimbrin/NN (/( N375/NN )/) 
217765_0_9_10_14_15::None::joint/NN :/: From/IN partial/JJ resurfacing/NN to/TO reverse/VB shoulder/NN arthroplasty/NN ]/) ./. 
241_241_0_1_13_17::POS_ACTION_BIND::Neuropilin-1/NN is/VBZ expressed/VBN by/IN endothelial/JJ and/CC tumor/NN cells/NNS as/IN an/DT isoform-specific/JJ receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN ./. 
489059_5_12_13_23_24::None::suggesting/VBG that/IN the/DT silver/JJ migration/NN may/MD be/VB due/JJ solely/RB to/TO ionic/JJ silver/NN released/VBN into/IN solution/NN from/IN oxidation/NN of/IN 
438089_4_26_27_13_14::None::months/NNS that/WDT included/VBD jaundice/NN patients/NNS admitted/VBN in/IN the/DT General/NNP Surgery/NNP Department/NNP of/IN ''/'' Coltea/NNP ''/'' Clinical/JJ Hospital/NN ./. 
2146_2146_9_10_4_5::None::report/VBP here/RB that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN 
193027_2_32_33_14_15::None::affinity/NN -/: enhanced/VBN version/NN of/IN JO/NNP -/: 1/CD ,/, which/WDT we/PRP call/VBP JO/SYM -/: 4/CD ,/, in/IN combination/NN with/IN PEGylated/VBN liposomal/JJ doxorubicin/NN (/( PLD/NN )/) 
118239_0_10_11_6_7::None::efficient/JJ catalytic/JJ system/NN based/VBN on/IN a/DT mesostructured/JJ ceria/NN -/: supported/VBN gold/NN 
112_112_3_4_18_19::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN epithelial/JJ cells/NNS and/CC forms/VBZ a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN localized/JJ to/TO the/DT 
1646_1646_2_3_8_9::NEG_ACTION_BIND::The/DT resulting/VBG beta-catenin/NN product/NN is/VBZ unable/JJ to/TO bind/VB alpha-catenin/NN that/WDT is/VBZ responsible/JJ 
279969_6_26_27_17_18::medicine.symptom.symptom_of::viral/JJ load/NN was/VBD high/JJ just/RB after/IN transplantation/NN ,/, although/IN the/DT subject/NN was/VBD asymptomatic/JJ ,/, and/CC the/DT 
605_605_8_9_20_21::POS_ACTION_CONTAIN::encodes/VBZ a/DT heterotrimeric/JJ helicase-primase/NN complex/NN that/WDT is/VBZ composed/VBN of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL52/NN ,/, and/CC UL8/NN 
102233_0_9_11_0_4::None::Complex/JJ regional/JJ pain/NN syndrome/NN (/( CRPS/NN )/) is/VBZ a/DT chronic/JJ pain/NN condition/NN typically/RB involving/VBG 
805_805_10_11_5_9::None::factor/NN I/PRP stimulates/VBZ cardiac/JJ myosin/NN heavy/JJ chain/NN and/CC actin/NN synthesis/NN in/IN the/DT 
1901_1901_31_32_29_30::None::kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, 
143793_11_6_7_8_9::people.cause_of_death.includes_causes_of_death::ratio/NN of/IN developing/VBG dementia/NN (/( AD/NN or/CC PD/NN )/) 
112017_4_4_5_8_9::None::patients/NNS had/VBD situational/JJ disorders/NNS ,/, with/IN a/DT slight/JJ prevalence/NN of/IN situational/JJ 
1593_1593_22_25_4_5::None::potentiating/NN effect/NN of/IN insulin/NN appears/VBZ to/TO involve/VB increases/NNS in/IN the/DT expression/NN of/IN cyclin/NN E/NN and/CC decreases/VBZ in/IN the/DT expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( Kip1/NN 
2222_2222_21_22_39_40::None::,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
652874_0_6_7_14_15::None::large/JJ -/: scale/NN phylogenies/NNS suggest/VBP a/DT radically/RB different/JJ history/NN for/IN the/DT evolution/NN of/IN live/JJ birth/NN 
513_513_12_13_7_8::POS_ACTION_INTERACT::(/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO 
140351_4_4_5_12_13::None::treatment/NN efficacy/NN studies/NNS exist/VBP in/IN elderly/JJ IBD/NN as/IN most/JJS authors/NNS have/VBP focused/VBN on/IN the/DT adverse/JJ 
1156_1156_5_6_7_8::None::form/VBP complexes/NNS with/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN 
196539_13_0_1_6_7::None::The/DT association/NN between/IN cardiovascular/JJ fitness/NN and/CC adverse/JJ cardiovascular/JJ outcomes/NNS may/MD 
491599_4_11_12_8_10::medicine.risk_factor.diseases::of/IN TQ/NN in/IN cardiovascular/JJ disorders/NNS ,/, diabetes/NN ,/, reproductive/JJ disorders/NNS 
416_416_1_2_5_6::None::Dynamic/NNP actin/NN structures/NNS stabilized/VBN by/IN profilin/NN ./. 
591379_13_20_21_15_16::None::heart/NN disease/NN and/CC raise/VB the/DT possibility/NN that/IN pulmonary/JJ hypertension/NN contributes/VBZ to/TO the/DT 
632_632_4_5_16_17::POS_REG(0)_POLYMERIZE::,/, regulation/NN of/IN profilin/NN function/NN is/VBZ generally/RB unknown/JJ and/CC controversy/NN exists/VBZ regarding/VBG profilin/NN effects/NNS on/IN actin/NN polymerization/NN ./. 
410007_10_13_14_12_13::biology.organism_classification.lower_classifications::vivax/NN and/CC P/NN falciparum/NN malaria/NN in/IN Ethiopia/NNP ./. 
763423_0_6_7_0_1::None::Evaluation/NN of/IN proton/NN pump/NN inhibitor/NN -/: resistant/JJ nonerosive/JJ reflux/NN disease/NN 
1502_1502_14_15_6_7::None::virus/NN type/NN 1/CD UL8/NN protein/NN influences/VBZ the/DT intracellular/JJ localization/NN of/IN the/DT UL52/NN but/CC not/RB the/DT 
591379_13_12_14_19_21::None::and/CC preclinical/JJ metabolic/JJ heart/NN disease/NN and/CC raise/VB the/DT possibility/NN that/IN pulmonary/JJ hypertension/NN contributes/VBZ to/TO the/DT 
278424_0_4_5_11_13::medicine.medical_treatment.used_to_treat::kinase/NN signaling/NN :/: tamoxifen/NN response/NN and/CC prognostic/JJ indication/NN in/IN two/CD breast/NN cancer/NN cohorts/NNS ./. 
1075_1075_8_9_22_23::None::as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN are/VBP similar/JJ targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
400251_26_26_29_28_29::None:://: F/NN //: tenofovir/NN disoproxil/NN fumarate/NN had/VBD virological/JJ success/NN 
938_938_9_11_0_2::None::LIM-kinase/NN 1/CD (/( LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ 
259065_5_2_3_12_13::None::Correlations/NNS between/IN FFI/NNP -/: BPD/NN and/CC relevant/JJ measures/NNS of/IN psychiatric/JJ symptomatology/NN and/CC etiology/NN (/( eg/FW ,/, 
638398_10_4_5_3_4::None::In/IN the/DT murine/JJ tumor/NN model/NN ,/, PA/NN -/: 
312_312_35_36_33_34::POS_ACTION_SUPPRESS::inhibiting/JJ effect/NN of/IN profilin/NN on/IN actin/NN polymerization/NN ./. 
583_583_4_5_14_15::None::we/PRP report/VBP that/IN p120/NN associates/NNS with/IN a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
489059_5_0_1_19_20::None::Silver/NN nanoparticles/NNS were/VBD not/RB detected/VBN in/IN food/NN simulants/NNS ,/, suggesting/VBG that/IN the/DT silver/JJ migration/NN may/MD be/VB due/JJ solely/RB to/TO ionic/JJ silver/NN released/VBN into/IN 
1075_1075_8_9_6_7::None::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN 
208311_13_7_8_0_1::None::The/DT eSCr75/NN -/: MDRD/NN equation/NN systematically/RB overestimates/VBZ oSCr/NN of/IN severe/JJ trauma/NN 
210955_0_29_30_17_18::None::characterized/VBN by/IN elevated/JJ serum/NN IgG4/NN and/CC infiltration/NN of/IN IgG4/NN (/( +/CC )/) plasma/NN cells/NNS into/IN multiple/JJ organs/NNS ./. 
930_930_6_7_8_9::None::the/DT actin-associated/JJ proteins/NNS filamin/NN ,/, talin/NN and/CC the/DT beta/NN 
122457_3_1_2_4_6::None::Although/IN advances/NNS in/IN gene/NN sequencing/NN technologies/NNS have/VBP identified/VBN several/JJ 
927981_0_31_32_11_12::medicine.disease.treatments::determination/NN of/IN nine/CD antidepressants/NNS in/IN traditional/JJ Chinese/JJ medicines/NNS and/CC health/NN food/NN by/IN ultra/NN performance/NN liquid/JJ chromatography/NN -/: tandem/JJ mass/NN spectrometry/NN (/( UPLC/NN -/: MS/NN //: MS/NN )/) 
843828_6_25_26_3_4::None::Factors/NNS associated/VBN with/IN higher/JJR mortality/NN (/( HR/NN ,/, 95/CD %/NN CI/NN )/) were/VBD older/JJR age/NN at/IN diagnosis/NN (/( 1.06/CD ,/, 1.03/CD -/: 1.08/CD )/) ,/, male/JJ gender/NN (/( 2.29/CD 
406187_0_30_32_25_26::medicine.disease.symptoms::hours/NNS of/IN having/VBG fever/NN and/CC myalgias/NNS heralding/VBG H1N1/NN influenza/NN A/NN Ophthalmoscopy/NN demonstrated/VBD findings/NNS 
478731_4_15_16_8_9::None::change/NN suggests/VBZ the/DT action/NN of/IN fluoride/NN and/CC magnesium/NN at/IN different/JJ steps/NNS of/IN the/DT E2Mg/NN 
2117_2117_2_3_18_19::POS_ACTION_BIND::We/PRP investigated/VBD actin/NN filament/NN turnover/NN rates/NNS ,/, length/NN ,/, number/NN ,/, barbed/VBN end/NN exposure/NN ,/, and/CC binding/NN of/IN cofilin/NN in/IN bovine/JJ arterial/JJ 
1258_1258_34_35_3_4::None::Significantly/RB ,/, those/DT actin/NN mutants/NNS exhibiting/VBG the/DT most/RBS severe/JJ phenotypes/NNS in/IN all/DT three/CD processes/NNS have/VBP altered/VBN residues/NNS that/WDT cluster/VBP to/TO a/DT small/JJ region/NN of/IN the/DT actin/NN crystal/NN structure/NN previously/RB defined/VBN as/IN the/DT fimbrin/NN (/( Sac6p/NN )/) -/: binding/VBG 
1534_1534_12_13_32_33::POS_ACTION_Change::TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
130735_2_16_17_1_2::None::The/DT fluorescence/NN (/( FL/NN )/) of/IN the/DT QD/NN bioconjugates/VBZ changes/NNS as/IN a/DT function/NN of/IN the/DT structure/NN transformation/NN during/IN the/DT interaction/NN 
573581_3_64_65_67_68::biology.organism_classification.lower_classifications::in/IN neutralizing/VBG the/DT virus/NN and/CC inhibiting/VBG Env/NN -/: mediated/VBN cell/NN 
1593_1593_27_28_4_5::None::potentiating/NN effect/NN of/IN insulin/NN appears/VBZ to/TO involve/VB increases/NNS in/IN the/DT expression/NN of/IN cyclin/NN E/NN and/CC decreases/VBZ in/IN the/DT expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( Kip1/NN )/) ./. 
206273_1_25_26_27_28::None::CHD/NN patients/NNS with/IN uremic/JJ accelerated/VBN atherosclerosis/NN (/( UAAS/NN )/) 
448173_0_11_12_10_12::None::rats/NNS and/CC transgenic/JJ mice/NNS ./. 
722712_7_14_15_19_21::medicine.symptom.symptom_of::a/DT patient/NN with/IN dyspnea/NN induced/VBN by/IN a/DT giant/JJ ovarian/JJ tumor/NN ./. 
2131_2131_23_24_13_14::None::UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
174_174_6_7_8_9::None::immunofluorescence/NN experiments/NNS ,/, Abp1p/NN ,/, cofilin/NN ,/, and/CC actin/NN 
908550_0_0_2_11_12::None::comparative/JJ study/NN of/IN glucose/NN homeostasis/NN ,/, lipids/NNS and/CC lipoproteins/NNS ,/, HDL/NN functionality/NN ,/, and/CC cardiometabolic/JJ 
1105_1105_0_1_20_24::POS_ACTION_INHIBIT::p21/NN (/( p21WAF1/Cip1/NN )/) ,/, a/DT cyclin-dependent/JJ kinase/NN inhibitor/NN ,/, induces/VBZ G1/NN arrest/NN and/CC can/MD inhibit/VB the/DT activity/NN of/IN the/DT proliferating/VBG cell/NN nuclear/JJ antigen/NN (/( PCNA/NN )/) 
123245_6_0_1_21_22::None::Thirteen/CD of/IN the/DT identified/VBN proteins/NNS ,/, namely/RB ,/, constituents/NNS of/IN the/DT intermediate/JJ filaments/NNS (/( KRT8/NN ,/, KRT18/NN ,/, DES/NNP )/) ,/, potential/JJ tumor/NN suppressors/NNS (/( 
236148_4_0_1_20_22::medicine.risk_factor.diseases::Diabetic/NNP patients/NNS with/IN CKD/NN were/VBD more/RBR likely/JJ to/TO have/VB a/DT higher/JJR prevalence/NN of/IN previously/RB diagnosed/VBN comorbidities/NNS ,/, to/TO have/VB developed/VBN heart/NN failure/NN acutely/RB ,/, and/CC 
1164_1164_35_38_42_43::None::,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN ./. 
1348_1348_4_5_15_17::POS_ACTION_BIND::cellular/JJ tumor/NN antigen/NN p53/NN is/VBZ bound/VBN to/TO the/DT simian/JJ virus/NN 40/CD (/( SV40/NN )/) large/JJ T-antigen/NN in/IN SV40-infected/JJ and/CC 
306632_3_43_44_0_1::None::In/IN this/DT study/NN ,/, we/PRP found/VBD that/IN the/DT diabetes/NN resolution/NN after/IN LSG/NNP occurred/VBD in/IN 40/CD %/NN of/IN patients/NNS ;/: in/IN the/DT other/JJ 60/CD %/NN ,/, even/RB if/IN they/PRP showed/VBD a/DT normal/JJ fasting/NN glycemia/NN and/CC A1c/NN ,/, patients/NNS spent/VBD a/DT lot/NN of/IN time/NN in/IN hyperglycemia/NN ./. 
1871_1871_12_13_10_11::POS_ACTION_BIND::the/DT association/NN between/IN E-cadherin/NN and/CC alpha-catenin/NN is/VBZ mediated/VBN by/IN 
1957_1957_38_39_10_11::None::with/IN association/NN of/IN beta-catenin/NN with/IN EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ cells/NNS at/IN confluence/NN were/VBD dissociated/VBN into/IN single/JJ cells/NNS by/IN tryptic/JJ digestion/NN ,/, being/VBG accompanied/VBN by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
117943_0_21_22_7_8::None::TA/NNP )/) during/IN primary/JJ percutaneous/JJ coronary/JJ intervention/NN (/( PCI/NN )/) was/VBD reported/VBN to/TO promote/VB better/JJR coronary/JJ and/CC myocardial/JJ reperfusion/NN ./. 
2074_2074_18_19_16_17::None::)/) protein/NN and/CC phosphoprotein/NN (/( P/NN )/) of/IN sonchus/NN 
2072_2072_14_15_11_14::None::of/IN the/DT mammalian/JJ actin/NN binding/NN protein/NN cofilin/NN ./. 
91441_7_8_9_2_3::medicine.disease.risk_factors::Immigrants/NNS with/IN diabetes/NNS are/VBP at/IN lower/JJR risk/NN for/IN cardiovascular/JJ events/NNS and/CC mortality/NN 
237_237_5_6_17_18::None::causes/VBZ phosphorylation/NN of/IN talin/NN and/CC redistribution/NN of/IN actin/NN microfilaments/NNS in/IN fibroblasts/NNS :/: possible/JJ role/NN for/IN PKC-delta/NN ./. 
426593_3_16_17_13_14::medicine.symptom.symptom_of::MIBG/NN could/MD achieve/VB high/JJ -/: probability/NN pain/NN reduction/NN ,/, the/DT 
1701_1701_43_46_6_7::None::that/IN this/DT novel/JJ RhoGAP/NN is/VBZ involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN 
229284_0_4_5_17_18::medicine.medical_treatment.used_to_treat::to/TO methotrexate/NN (/( MTX/NN )/) ,/, the/DT ''/'' anchor/NN drug/NN ''/'' for/IN treating/VBG rheumatoid/JJ arthritis/NN (/( RA/NN )/) ,/, varies/VBZ 
1517_1517_15_16_4_5::None::influence/NN of/IN these/DT collagens/NNS on/IN cell/NN morphology/NN and/CC the/DT distribution/NN pattern/NN of/IN actin/NN ,/, vimentin/NN ,/, talin/NN ,/, 
350044_5_1_2_10_12::None::These/DT findings/NNS have/VBP interdisciplinary/JJ implications/NNS for/IN practice/NN with/IN women/NNS with/IN heart/NN disease/NN ./. 
87529_17_0_1_3_4::None::Advanced/NNP age/NN ,/, hypertension/NN ,/, and/CC prior/RB 
410591_0_12_13_9_11::None::leading/VBG causes/NNS of/IN nephrotic/JJ syndrome/NN in/IN adults/NNS ,/, which/WDT is/VBZ 
2222_2222_39_40_37_38::NEG_ACTION_COLOCALIZE::contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
1648_1648_44_45_7_8::POS_ACTION_ATTACH::that/IN the/DT mutated/VBN cofilin/NN possessing/VBG KTLKK/NNP instead/RB of/IN KKRKK/NNP did/VBD not/RB translocate/VB into/IN the/DT nuclei/NNS in/IN response/NN to/TO heat/NN shock/NN whereas/IN a/DT recombinant/JJ cofilin/NN with/IN the/DT unaltered/JJ sequence/NN of/IN KKRKK/NNP responded/VBD to/TO heat/NN shock/NN and/CC formed/VBD intranuclear/JJ rods/NNS together/RB with/IN actin/NN ./. 
712_712_23_24_11_12::None::to/TO suggest/VB that/IN HRG/NN stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN 
563809_10_27_28_11_12::None::all/DT -/: cause/VB mortality/NN (/( hazard/NN ratio/NN 1.14/CD [/( 95/CD %/NN confidence/NN interval/NN 1.05/CD -/: 1.24/CD ]/) )/) and/CC CVD/NN mortality/NN (/( hazard/NN 
661306_5_15_16_10_11::medicine.disease.symptoms::,/, frustration/NN ,/, anger/NN ,/, and/CC sadness/NN //: depression/NN ./. 
95037_9_4_5_45_46::None::-/: 43/CD immunoreactive/JJ structures/NNS were/VBD observed/VBN in/IN 55/CD //: 136/CD control/NN elderly/JJ (/( 40.0/CD %/NN )/) ,/, 21/CD //: 29/CD AD/NN (/( 72.4/CD %/NN )/) ,/, 8/CD //: 11/CD LBD/NN (/( 72.7/CD %/NN )/) ,/, and/CC 6/CD //: 11/CD AGD/NN (/( 54.5/CD %/NN )/) brains/NNS ./. 
890409_7_42_43_47_49::medicine.disease.treatments::and/CC exposure/NN to/TO invasive/JJ devices/NNS or/CC exposure/NN to/TO surgical/JJ procedures/NNS ./. 
176703_1_17_18_4_6::None::and/CC prognosis/NN of/IN breast/NN cancer/NN would/MD profit/VB largely/RB from/IN a/DT correct/JJ classification/NN and/CC identification/NN of/IN genetic/JJ key/JJ drivers/NNS and/CC major/JJ 
553693_0_10_11_14_15::None::characterized/VBN by/IN abdominal/JJ pain/NN and/CC changed/VBD bowel/NN habits/NNS ./. 
776470_0_21_22_33_34::None::kidney/NN failure/NN ,/, glomerulosclerosis/NN and/CC nephritis/NN resulting/VBG in/IN chronic/JJ kidney/NN disease/NN or/CC end/NN -/: stage/NN renal/JJ disease/NN ./. 
265468_0_0_1_5_7::medicine.symptom.symptom_of::Constipation/NN is/VBZ not/RB associated/VBN with/IN diverticular/JJ disease/NN -/: Analysis/NN of/IN 
1037_1037_24_26_27_28::POS_ACTION_MEMBER::RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
779_779_35_36_49_52::None::an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
1344_1344_17_18_22_23::POS_ACTION_CONTAIN::members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, indicates/VBZ that/IN 
671_671_5_7_35_36::None::revealed/VBD that/IN two/CD actin-binding/JJ proteins/NNS of/IN low/JJ molecular/JJ weight/NN with/IN different/JJ functional/JJ activity/NN ,/, ADF/NN and/CC cofilin/NN ,/, are/VBP transported/VBN into/IN nuclei/NNS of/IN cultured/VBN myogenic/JJ cells/NNS to/TO form/VB rod/NN structures/NNS there/RB together/RB with/IN actin/NN ,/, when/WRB the/DT 
900999_12_13_14_11_12::None::longer/JJR survivals/NNS in/IN patients/NNS with/IN clinical/JJ characters/NNS of/IN smaller/JJR 
337732_11_32_34_62_63::None::,/, and/CC slower/JJR reaction/NN times/NNS in/IN specific/JJ runs/NNS of/IN a/DT task/NN designed/VBN to/TO assess/VB phasic/JJ alertness/NN in/IN healthy/JJ adult/JJ volunteers/NNS ;/: these/DT findings/NNS are/VBP consistent/JJ with/IN previous/JJ evidence/NN that/IN links/NNS phasic/JJ alertness/NN with/IN dopaminergic/JJ neurotransmission/NN ./. 
295839_4_21_22_34_36::None::Trametinib/NN exerts/VBZ significant/JJ anti/JJ -/: tumor/NN cell/NN efficacy/NN in/IN K/NN -/: Ras/NN mutant/NN pancreatic/JJ and/CC colon/NN cancer/NN cells/NNS in/FW vitro/FW ./. 
2107_2107_39_40_5_7::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
489_489_9_10_26_27::None::of/IN three/CD putative/JJ PCAF/NN substrates/NNS ,/, histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP determined/VBN that/IN histone/NN H3/NN is/VBZ significantly/RB 
170773_3_9_10_47_48::None::in/IN unraveling/NN genetic/JJ factors/NNS that/WDT predispose/VBP to/TO sudden/JJ cardiac/JJ death/NN in/IN the/DT setting/NN of/IN sequela/NN of/IN coronary/JJ artery/NN disease/NN and/CC present/VB the/DT genome/NN -/: wide/JJ association/NN studies/NNS conducted/VBN in/IN recent/JJ years/NNS on/IN electrocardiographic/JJ parameters/NNS ,/, highlighting/VBG their/PRP$ potential/NN in/IN uncovering/VBG new/JJ biological/JJ insights/NNS into/IN cardiac/JJ 
356086_0_1_3_6_7::None::Cancer/NN stem/NN cells/NNS (/( CSCs/NNS )/) play/VBP an/DT important/JJ role/NN 
379013_1_44_45_12_13::medicine.disease.symptoms::beverages/NNS sweetened/VBN with/IN high/JJ -/: fructose/NN corn/NN syrup/NN (/( HFCS/NN )/) at/IN zero/CD ,/, low/JJ ,/, medium/NN ,/, and/CC high/JJ proportions/NNS of/IN energy/NN requirements/NNS (/( Ereq/NN )/) on/IN circulating/VBG lipid/NN //: lipoprotein/NN risk/NN factors/NNS for/IN CVD/NN anduric/JJ acid/NN in/IN 
309_309_6_8_9_10::POS_REG(0)_POLYMERIZE::action/NN of/IN porcine/NN brain/NN profilin/NN on/IN actin/NN polymerization/NN ./. 
604313_0_31_33_21_22::None::diseases/NNS ,/, especially/RB hypertension/NN and/CC atherosclerosis/NN ,/, and/CC that/DT are/VBP commonly/RB prescribed/VBN after/IN cardiac/JJ surgery/NN ./. 
350981_0_19_20_2_3::medicine.symptom.symptom_of::A/DT Novel/JJ Anxiety/NN and/CC Affective/JJ Spectrum/NN Disorder/NN of/IN Mind/NNP and/CC Body/NNP -/: The/NNP ALPIM/NNP (/( Anxiety/NN -/: Laxity/NN -/: Pain/NN -/: Immune/JJ -/: 
1052_1052_12_13_18_20::None::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) 
856_856_40_41_22_23::POS_ACTION_UPREGULATE::,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
245350_6_4_5_5_6::None::of/IN the/DT refeeding/VBG diets/NNS contained/VBD VitD/NN We/PRP concluded/VBD 
187563_7_8_9_14_15::None::44/CD %/NN )/) patients/NNS (/( death/NN -/: 3/CD ,/, device/NN embolization/NN -/: 1/CD 
441793_0_42_43_67_68::None::traditional/JJ cardiovascular/JJ risk/NN factors/NNS ;/: 2/LS )/) stronger/JJR among/IN whites/NNS than/IN blacks/NNS ;/: and/CC 3/LS )/) stronger/JJR among/IN those/DT genetically/RB predisposed/VBN to/TO having/VBG high/JJ levels/NNS of/IN vitamin/NN D/NN binding/NN protein/NN (/( DBP/NN 
829573_1_29_30_21_22::medicine.symptom.symptom_of::trigeminal/JJ neuralgia/NN ,/, TMJ/NNP dysfunction/NN ,/, thalamic/JJ syndrome/NN ,/, and/CC primary/JJ headache/NN syndromes/NNS ./. 
186443_2_0_1_25_26::None::Patients/NNS diagnosed/VBD with/IN diabetes/NN mellitus/NN type/NN 1/CD or/CC 2/CD ,/, or/CC using/VBG antidiabetic/JJ drugs/NNS (/( ADDs/NNS )/) ,/, were/VBD compared/VBN to/TO matched/VBN non/JJ -/: diabetic/JJ controls/NNS ./. 
189032_0_0_1_20_21::None::Alcohol/NN -/: Related/JJ Consequences/NNS Mediating/VBG PTSD/NN Symptoms/NNS and/CC Mental/NNP Health/NNP -/: Related/JJ Quality/NNP of/IN Life/NNP in/IN OEF/NNP //: OIF/NNP Combat/NNP Veterans/NNP ./. 
311030_10_6_7_3_4::None::Dopamine/NN release/NN was/VBD stimulated/VBN by/IN applying/VBG ATP/NN which/WDT activated/VBD P2X2/NN 
805_805_0_4_5_9::POS_ACTION_STIMULATE::Insulin-like/JJ growth/NN factor/NN I/PRP stimulates/VBZ cardiac/JJ myosin/NN heavy/JJ chain/NN and/CC actin/NN synthesis/NN 
198729_8_13_14_32_34::medicine.disease.risk_factors::infection/NN in/IN male/JJ asthmatics/NNS and/CC may/MD support/VB the/DT hypothesis/NN of/IN C/NN neoformans/NNS as/IN a/DT risk/NN factor/NN for/IN the/DT development/NN of/IN asthma/NN in/IN urban/JJ areas/NNS ./. 
18729_3_15_16_20_22::None::referred/VBN for/IN possible/JJ surgical/JJ intervention/NN ,/, we/PRP compared/VBD direct/JJ costs/NNS of/IN those/DT treated/VBN 
331938_2_12_13_17_18::medicine.disease.risk_factors::higenamine/NN ,/, enhance/VBP heart/NN contractility/NN ,/, increase/VBP the/DT coronary/JJ blood/NN supply/NN ,/, 
1851_1851_21_22_17_18::None::been/VBN identified/VBN :/: Armadillo/NN (/( homolog/NN of/IN beta-catenin/NN )/) ,/, Drosophila/FW 
1248_1248_19_20_12_13::None::beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB associated/VBN with/IN these/DT cadherins/NNS and/CC serve/VB to/TO 
1420_1420_4_7_11_12::POS_ACTION_SIMILAR::characteristics/NNS of/IN the/DT vitamin/NN D-binding/JJ protein/NN and/CC profilin/NN interactions/NNS with/IN actin/NN are/VBP similar/JJ ./. 
1861_1861_15_16_10_11::None::containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN which/WDT are/VBP independent/JJ 
136045_10_16_17_6_7::medicine.medical_treatment.used_to_treat::independent/JJ predictor/NN of/IN cancer/NN -/: specific/JJ and/CC overall/JJ survival/NN in/IN patients/NNS who/WP underwent/VBD surgery/NN for/IN RCC/NN Also/RB 
264127_4_5_6_19_21::None::complex/JJ patients/NNS ,/, early/JJ endocrinologist/NN care/NN was/VBD associated/VBN with/IN a/DT lower/JJR 3/LS -/: year/NN incidence/NN of/IN the/DT primary/JJ endpoint/NN (/( hazard/NN ratio/NN 
553793_3_9_10_60_61::medicine.risk_factor.diseases::of/IN QOL/NN in/IN elderly/JJ patients/NNS with/IN AF/NN receiving/VBG oral/JJ anticoagulants/NNS and/CC compare/VB QOL/NN of/IN patients/NNS treated/VBN with/IN vitamin/NN K/NN antagonists/NNS (/( VKA/NN )/) and/CC DOAC/NN This/DT prospective/JJ study/NN included/VBD patients/NNS of/IN 65/CD years/NNS and/CC over/IN ,/, receiving/VBG anticoagulants/NNS for/IN AF/NN (/( VKA/NN or/CC DOAC/NN )/) from/IN general/JJ practice/NN (/( n/NN =/JJ 70/CD )/) or/CC cardiac/JJ practice/NN (/( n/NN 
22703_5_50_51_14_15::None::adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) -/: mediated/VBN stimulation/NN of/IN adrenal/JJ steroidogenesis/NN (/( P/NN &/CC lt/NN ;/: 0.001/CD )/) ,/, with/IN plasma/NN corticosterone/NN levels/NNS that/WDT were/VBD respectively/RB 44/CD -/: 59/CD %/NN lower/JJR (/( P/NN &/CC lt/NN ;/: 0.01/CD )/) as/IN compared/VBN to/TO adrenal/JJ LDL/NN 
671_671_35_36_5_7::None::revealed/VBD that/IN two/CD actin-binding/JJ proteins/NNS of/IN low/JJ molecular/JJ weight/NN with/IN different/JJ functional/JJ activity/NN ,/, ADF/NN and/CC cofilin/NN ,/, are/VBP transported/VBN into/IN nuclei/NNS of/IN cultured/VBN myogenic/JJ cells/NNS to/TO form/VB rod/NN structures/NNS there/RB together/RB with/IN actin/NN ,/, when/WRB the/DT 
825_825_7_9_10_11::None::Arp2/3/NN complex/NN ,/, capping/VBG protein/NN and/CC profilin/NN in/IN remodeling/NN of/IN 
992_992_10_11_12_13::POS_ACTION_DISRUPT::C-terminal/JJ regions/NNS of/IN talin/NN disrupt/VBP actin/NN stress/NN fibers/NNS when/WRB 
1678_1678_1_2_13_14::POS_ACTION_MEMBER::These/DT histone/NN H3/NN and/CC H2a/NN genes/NNS encode/VBP approximately/RB 40/CD %/NN of/IN the/DT total/JJ H3/NN and/CC H2a/NN mRNA/NN 
488205_3_80_81_38_39::None::abundant/JJ doubly/RB charged/VBN fragment/NN containing/VBG seven/CD metal/NN atoms/NNS (/( M/NN )/) and/CC 22/CD oxygen/NN atoms/NNS (/( M/NN (/( 7/CD )/) O/NN (/( 22/CD )/) (/( 2/LS -/: )/) )/) and/CC its/PRP$ complementary/JJ singly/RB charged/VBN PM/NNP (/( 5/CD )/) O/NN (/( 18/CD )/) (/( -/: )/) ion/NN ./. 
112_112_0_1_14_16::None::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN epithelial/JJ cells/NNS and/CC forms/VBZ a/DT complex/NN with/IN syntaxin/NN 3/CD ,/, a/DT t-SNARE/NN 
566931_0_11_12_0_1::None::In/IN the/DT treatment/NN of/IN polymyositis/NN (/( PM/NN )/) and/CC dermatomyositis/NN (/( DM/NN )/) ,/, muscle/NN 
1434_1434_7_8_75_76::None::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
669734_0_48_49_30_31::medicine.risk_factor.diseases::depressive/JJ disorder/NN (/( MDD/NN )/) during/IN the/DT same/JJ period/NN and/CC if/IN it/PRP prospectively/RB predicted/VBD MDD/NN onset/NN between/IN mid/JJ -/: and/CC late/JJ adolescence/NN ./. 
609976_0_10_11_16_17::None::dementia/NN :/: A/DT secondary/JJ post/NN -/: hoc/FW analysis/NN from/IN north/NN -/: west/JJ India/NNP 
569500_0_3_5_19_20::medicine.medical_treatment.used_to_treat::Subjective/JJ and/CC objective/JJ physical/JJ activity/NN patterns/NNS after/IN Roux/NNP -/: en/IN Y/NN gastric/JJ bypass/NN surgery/NN compared/VBN with/IN non/JJ -/: operated/VBN obese/JJ and/CC non/JJ -/: 
317242_0_36_37_33_35::medicine.drug_ingredient.active_moiety_of_drug::,/, prolactin/NN ,/, adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) ,/, thyroid/NN 
127291_4_42_43_25_27::None::part/NN of/IN the/DT splenic/JJ artery/NN in/IN 1/CD case/NN ;/: the/DT artificial/JJ vessel/NN bypass/NN was/VBD done/VBN between/IN the/DT infra/NN -/: renal/JJ aorta/NN and/CC distal/JJ portion/NN 
531305_1_0_1_4_5::None::It/PRP is/VBZ associated/VBN with/IN hallucination/NN ,/, psychosis/NN and/CC 
406187_0_27_28_16_17::None::loss/NN to/TO the/DT level/NN of/IN light/JJ perception/NN within/IN 24/CD hours/NNS of/IN having/VBG fever/NN and/CC myalgias/NNS heralding/VBG H1N1/NN influenza/NN 
374375_0_14_15_7_8::None::dietary/JJ concentrations/NNS of/IN Gly/NN (/( glycine/NN )/) and/CC Ser/NN (/( serine/NN )/) in/IN broiler/NN 
451755_0_33_34_11_12::None::are/VBP important/JJ radiological/JJ clues/NNS to/TO the/DT diagnosis/NN of/IN multiple/JJ sclerosis/NN (/( MS/NN )/) ,/, but/CC may/MD also/RB occur/VB in/IN other/JJ neuroinflammatory/JJ and/CC non/JJ -/: neuroinflammatory/JJ conditions/NNS ./. 
1047_1047_7_8_17_18::POS_ACTION_ACTIVATE::pro-apoptotic/JJ adapter/NN proteins/NNS TRADD/NN and/CC FADD/NN are/VBP also/RB involved/VBN in/IN the/DT activation/NN of/IN A-SMase/NN ./. 
513_513_5_6_12_13::None::spliceosomal/JJ proteins/NNS (/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO 
566289_3_6_7_0_1::None::TS/NN should/MD be/VB considered/VBN in/IN any/DT immunocompromised/JJ patient/NN with/IN a/DT 
328070_0_8_9_0_1::medicine.drug.active_moieties::Copper/NN complexes/NNS have/VBP been/VBN frequently/RB involved/VBN in/IN many/JJ Cu/NN -/: mediated/JJ carbon/NN 
25_25_0_2_4_5::POS_ACTION_MEMBER::Actin-binding/JJ proteins/NNS such/JJ as/IN profilin/NN and/CC gelsolin/NN bind/VBP 
588835_2_26_27_24_25::biology.organism_classification.lower_classifications::and/CC baleen/NN (/( mysticete/NN )/) whales/NNS ,/, using/VBG X/NN 
188127_4_3_4_11_12::None::We/PRP included/VBD 34/CD patients/NNS with/IN DP/NN allergy/NN that/WDT received/VBD sub/SYM -/: cutaneous/JJ immunotherapy/NN (/( SCIT/NN 
1901_1901_31_32_33_34::None::(/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, and/CC markers/NNS 
1748_1748_19_20_4_5::None::results/NNS suggest/VBP that/IN LIMK2/NN functions/NNS downstream/RB of/IN the/DT Rho-ROCK/JJ signalling/NN pathway/NN and/CC plays/VBZ a/DT role/NN in/IN reorganization/NN of/IN actin/NN filaments/NNS and/CC membrane/NN 
759_759_20_24_17_19::None::increases/NNS in/IN immunoreactive/JJ sarcomeric/JJ actin/NN and/CC sarcomeric/JJ myosin/NN heavy/JJ chain/NN (/( SMHC/NN )/) 
373723_3_16_17_12_13::medicine.disease.risk_factors::worldwide/JJ status/NN of/IN fat/JJ grafting/VBG for/IN aesthetic/JJ breast/NN augmentation/NN ./. 
458615_4_14_15_38_39::None::genes/NNS ,/, the/DT expression/NN of/IN a/DT number/NN of/IN genes/NNS involved/VBN in/IN iron/NN (/( Fe/NNP )/) ,/, potassium/NN (/( K/NN )/) ,/, sodium/NN (/( Na/NN )/) ,/, and/CC calcium/NN (/( Ca/NN )/) 
1786_1786_23_25_20_21::None::exhibits/VBZ higher/JJR actin-activated/JJ ATPase/NN than/IN does/VBZ beta/NN myosin/NN ,/, and/CC hearts/NNS 
1782_1782_1_6_23_24::POS_ACTION_LOCALIZE::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC 
1773_1773_10_11_4_5::POS_ACTION_SIMILAR::structural/JJ homology/NN between/IN cofilin/NN and/CC gelsolin/NN segment-1/NN binding/NN to/TO actin/NN was/VBD confirmed/VBN experimentally/RB 
510403_0_1_2_10_11::None::In/IN subjects/NNS without/IN kidney/NN disease/NN ,/, adiponectin/NN appears/VBZ to/TO have/VB anti/JJ -/: inflammatory/JJ ,/, 
93_93_6_7_11_12::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD 
288_288_13_14_19_20::None::actin-binding/JJ protein/NN and/CC talin/NN ,/, two/CD known/JJ substrates/NNS of/IN calpain/NN ./. 
2198_2198_5_6_20_21::POS_ACTION_COLOCALIZE::-/: or/CC islet-type/JJ glucokinase/NN was/VBD transiently/RB expressed/VBN in/IN COS-7/NN cells/NNS ,/, the/DT expressed/VBN glucokinase/NN was/VBD also/RB co-localized/VBN with/IN actin/NN filaments/NNS in/IN the/DT 
1367_1367_4_5_17_20::None::amount/NN of/IN unassembled/JJ actin/NN (/( 12/CD microM/NN )/) is/VBZ accounted/VBN for/IN by/IN the/DT sequestering/VBG functions/NNS of/IN T/NN beta/NN 4Xen/NN (/( 20/CD microM/NN 
71_71_0_1_6_7::POS_ACTION_DEPOLYMERIZE::Aip1p/NN interacts/VBZ with/IN cofilin/NN to/TO disassemble/VB actin/NN filaments/NNS ./. 
241386_9_25_26_18_19::medicine.disease.treatments::for/IN monitoring/NN and/CC treating/VBG mesothelioma/NN and/CC other/JJ mesothelin/NN -/: expressing/VBG cancers/NNS ./. 
739338_5_15_16_6_7::medicine.risk_factor.diseases::than/IN men/NNS at/IN stroke/NN onset/NN and/CC more/JJR men/NNS had/VBD a/DT history/NN of/IN smoking/NN and/CC diabetes/NN ,/, 
1248_1248_19_20_9_10::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB associated/VBN with/IN these/DT cadherins/NNS and/CC serve/VB to/TO 
579913_0_14_15_7_8::None::)/) is/VBZ a/DT cluster/NN of/IN cardiovascular/JJ risk/NN factors/NNS that/WDT includes/VBZ obesity/NN ,/, diabetes/NN ,/, 
784_784_18_19_4_5::NEG_ACTION_COLOCALIZE::normal/JJ livers/NNS ,/, E-cad/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN 
204277_6_47_48_0_1::medicine.drug_ingredient.active_moiety_of_drug::Testosterone/NN level/NN correlated/VBD positively/RB with/IN RHI/NN (/( r/NN =/JJ 0.24/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD )/) and/CC inversely/RB with/IN AIX/NNP (/( r/NN =/SYM -/: 0.14/CD ,/, p/NN =/JJ 0.033/CD )/) but/CC not/RB with/IN FMD/NN or/CC PWV/NN ,/, indicating/VBG impaired/JJ microvascular/JJ hyperemia/NN and/CC arterial/JJ elasticity/NN with/IN lower/JJR testosterone/NN levels/NNS ./. 
467441_4_18_19_27_28::None::Superoxide/NN dismutase/NN (/( Cu/NN //: Zn/NN -/: SOD/NN )/) ,/, catalase/NN (/( CAT/NN )/) ,/, and/CC 
26_26_11_12_0_2::None::Actin-binding/JJ proteins/NNS such/JJ as/IN profilins/NNS participate/VBP in/IN the/DT restructuration/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN plant/NN 
1248_1248_12_13_9_10::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB 
2131_2131_21_22_9_10::None::,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
778878_10_10_11_8_9::None::CF/NN bronchiectasis/NN ,/, long/JJ -/: term/NN inhaled/VBD antibiotics/NNS can/MD 
1274_1274_0_2_29_30::POS_ACTION_BIND::Single-headed/JJ myosin/NN ,/, which/WDT consists/VBZ of/IN a/DT full/JJ length/NN myosin/NN heavy/JJ chain/NN and/CC a/DT tagged/VBN tail/NN ,/, was/VBD isolated/VBN on/IN the/DT basis/NN of/IN the/DT affinities/NNS for/IN Nickel/NN agarose/NN and/CC actin/NN ./. 
1498_1498_4_5_21_22::POS_ACTION_MODULATE::head/NN domain/NN of/IN talin/NN thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD thus/RB regulate/VB integrin/NN function/NN ./. 
980_980_12_13_18_19::None::the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN beta-catenin/NN to/TO the/DT cytoplasm/NN 
458193_0_21_22_25_26::None::area/NN and/CC surrounding/VBG environment/NN ,/, of/IN Ika/NNP land/NN in/IN the/DT Delta/NNP 
865_865_15_16_33_35::POS_ACTION_BIND::related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ organ/NN ,/, also/RB bind/VBP to/TO translated/VBN beta/NN 1-syntrophin/NN ./. 
1782_1782_23_24_7_8::None::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC 
125951_3_11_12_34_36::None::used/VBN in/IN multimodal/JJ analgesia/NN (/( ie/FW ,/, COX/NNP inhibitors/NNS ,/, local/JJ analgesics/NNS and/CC dexamethasone/NN )/) can/MD induce/VB apoptosis/NN in/IN cancer/NN cells/NNS and/CC //: or/CC diminish/VB the/DT inflammatory/JJ response/NN during/IN surgery/NN which/WDT 
1219_1219_11_12_20_21::None::enhanced/VBD interaction/NN between/IN TRADD/NN and/CC FADD/MORT1/NN and/CC increased/VBN cells/NNS '/POS sensitivity/NN to/TO TNF/NN ./. 
515_515_10_11_23_24::POS_ACTION_Causal::GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB appear/VBP to/TO be/VB involved/VBN in/IN linking/VBG Cdc42p/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
381889_8_29_30_31_32::medicine.symptom.symptom_of::Survey/NN )/) and/CC anxiety/NN //: depression/NN (/( Hospital/NN Anxiety/NN 
759_759_12_13_17_19::POS_REG(-)_INCREASE::cell/NN strain/NN ,/, EGF/NN inhibited/VBD increases/NNS in/IN immunoreactive/JJ sarcomeric/JJ actin/NN and/CC sarcomeric/JJ myosin/NN 
1061_1061_25_27_19_20::None::;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO 
101_101_24_25_22_23::None::the/DT influence/NN of/IN talin/NN and/CC vinculin/NN on/IN the/DT structure/NN 
395_395_9_10_7_8::POS_ACTION_BIND::verprolin-homology/JJ domain/NN in/IN N-WASP/NN to/TO actin/NN is/VBZ essential/JJ for/IN 
1450_1450_23_24_4_5::None::data/NNS suggest/VBP that/IN profilin/NN binding/NN to/TO actin/NN weakens/VBZ nucleotide/NN binding/NN to/TO actin/NN by/IN disrupting/VBG Mg/NN (/( 2/CD +/CC )/) coordination/NN in/IN the/DT actin/NN central/JJ cleft/NN ./. 
113339_0_25_26_11_13::None::gene/NN nested/JJ PCR/NN Whole/JJ blood/NN and/CC filter/NN paper/NN blood/NN samples/NNS of/IN malaria/NN patients/NNS in/IN Shandong/NNP Province/NNP were/VBD collected/VBN during/IN 2012/CD -/: 
322_322_2_3_0_1::None::Cofilin/NNP and/CC profilin/NN may/MD also/RB be/VB 
660282_0_10_11_5_6::None::the/DT influence/NN of/IN timing/NN of/IN salvage/NN and/CC adjuvant/JJ radiation/NN therapy/NN on/IN outcomes/NNS 
691_691_6_9_13_14::POS_ACTION_COLOCALIZE::APBs/NNS also/RB contain/VBP replication/NN factor/NN A/NN ,/, RAD51/NN ,/, and/CC RAD52/NN ,/, proteins/NNS involved/VBN 
179564_0_0_1_9_10::None::Combining/VBG three/CD antibodies/NNS nullifies/VBZ feedback/NN -/: mediated/VBN resistance/NN to/TO erlotinib/NN in/IN lung/NN cancer/NN 
113845_3_19_20_11_12::None::coagulation/NN properties/NNS ,/, precise/JJ incision/NN margin/NN ,/, lack/NN of/IN swelling/VBG ,/, bleeding/VBG ,/, pain/NN ,/, 
429997_1_34_36_30_31::medicine.disease.treatments::who/WP have/VBP taken/VBN finasteride/NN 1/CD mg/NN for/IN androgenic/JJ alopecia/NN ./. 
1289_1289_4_6_11_12::None::interactions/NNS between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) 
1008_1008_2_3_10_11::None::Mutants/NNS of/IN cdc3/NN and/CC cdc8/NN ,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB ,/, display/VBP 
127291_4_4_5_1_2::medicine.disease.treatments::Upon/IN resection/NN of/IN the/DT aneurysm/NN ,/, the/DT auto/NN 
1479_1479_16_17_13_15::None::the/DT effects/NNS of/IN LIM/NN kinase/NN and/CC cofilin/NN in/IN the/DT control/NN 
367649_3_9_10_21_22::medicine.medical_treatment.used_to_treat::has/VBZ various/JJ pharmacological/JJ activities/NNS ,/, including/VBG lowering/VBG blood/NN glucose/NN ,/, regulating/VBG blood/NN lipids/NNS and/CC reducing/VBG inflammation/NN in/IN addition/NN to/TO 
532193_6_15_16_0_1::None::There/EX was/VBD no/DT significant/JJ association/NN of/IN codon/NN 248/CD polymorphisms/NNS with/IN bladder/NN cancer/NN in/IN the/DT study/NN population/NN ./. 
461685_1_7_11_29_30::people.cause_of_death.includes_causes_of_death::some/DT patients/NNS with/IN type/NN 1/CD diabetes/NN mellitus/NN (/( T1DM/NN )/) to/TO hypoglycaemia/NN ;/: whereas/IN hyperglycaemia/NN in/IN patients/NNS with/IN T1DM/NN or/CC type/NN 2/CD diabetes/NN mellitus/NN (/( T2DM/NN )/) is/VBZ often/RB 
433781_3_13_14_8_9::None::more/RBR numerous/JJ in/IN gastric/JJ cancer/NN patients/NNS than/IN in/IN controls/NNS ,/, and/CC significantly/RB 
138079_4_5_6_25_26::medicine.disease.treatments::remaining/VBG 100/CD Mycobacterium/NN tuberculosis/NN isolates/NNS ,/, the/DT resistance/NN rates/NNS were/VBD 7/CD %/NN ,/, 7/CD %/NN ,/, 3/CD %/NN ,/, and/CC 9/CD %/NN against/IN isoniazid/NN ,/, rifampin/NN ,/, 
710191_0_26_27_24_26::None::advanced/JJ head/NN and/CC neck/NN cancer/NN patients/NNS ./. 
452211_4_8_9_7_8::None::-/: 2/CD //: survivin/NN siRNAs/NNS loaded/VBN in/IN the/DT 
212_212_27_28_31_32::POS_ACTION_BIND::E-cadherin/NN and/CC the/DT actin/NN binding/NN site/NN of/IN alpha-catenin/NN ./. 
1510_1510_5_6_17_18::None::affinity/NN of/IN vaccinia/NN profilin/NN for/IN polyphosphoinositides/NNS (/( Kd/NN =/JJ 0.2-8/CD .5/CD microM/NN )/) than/IN for/IN actin/NN or/CC poly/NN (/( 
324666_0_12_13_16_18::medicine.risk_factor.diseases::common/JJ causes/NNS of/IN hereditary/JJ non/JJ -/: spherocytic/JJ hemolytic/JJ anemias/NNS ./. 
318370_0_1_2_26_28::None::Black/JJ titania/NN spheres/NNS (/( H/NN -/: TiO2/NN -/: x/NN )/) were/VBD synthesized/VBN via/IN a/DT simple/JJ green/JJ method/NN assisted/VBN by/IN water/NN plasma/NN at/IN a/DT low/JJ temperature/NN and/CC atmospheric/JJ pressure/NN ./. 
356904_0_4_5_12_13::None::is/VBZ a/DT chronic/JJ inflammatory/JJ disorder/NN of/IN the/DT airway/NN characterized/VBN by/IN the/DT episodic/JJ symptoms/NNS of/IN breathlessness/NN 
750_750_21_22_7_8::POS_ACTION_Change::integrin/NN with/IN the/DT actin/NN cytoskeleton/NN is/VBZ consistent/JJ with/IN and/CC might/MD be/VB mediated/VBN by/IN its/PRP$ enhanced/VBN binding/NN to/TO talin/NN ./. 
1927_1927_27_28_19_20::POS_ACTION_RELATE::regulatory/JJ protein/NN ,/, GAL4/NN ,/, and/CC a/DT negative/JJ regulatory/JJ protein/NN ,/, GAL80/NN ./. 
537405_0_18_20_0_1::None::In/IN recent/JJ years/NNS ,/, evidence/NN supporting/VBG multimodality/JJ treatment/NN for/IN oesophageal/NN ,/, oesophagogastric/JJ junction/NN (/( OGJ/NN )/) ,/, and/CC gastric/JJ cancer/NN has/VBZ accumulated/VBN ./. 
287681_8_33_34_12_13::None::and/CC Cx36/NN remained/VBD resistant/JJ certain/JJ time/NN after/IN OGD/NNP and/CC were/VBD able/JJ to/TO modulate/VB CA1/NN neuron/NN survival/NN through/IN GABAARs/NNS ,/, alpha7nAChRs/NN and/CC Cx36/NN -/: channels/NNS activity/NN ./. 
116217_7_4_5_0_1::None::It/PRP was/VBD found/VBN that/IN sirolimus/NN treatment/NN was/VBD given/VBN 
214618_2_10_11_13_14::None::of/IN troponin/NN are/VBP essential/JJ to/TO the/DT diagnosis/NN of/IN acute/JJ MI/NNP 
1696_1696_7_8_18_19::POS_ACTION_Causal::first/JJ evidence/NN that/IN profilin/NN is/VBZ a/DT key/JJ molecule/NN linking/VBG a/DT signaling/NN network/NN to/TO rapid/JJ actin/NN polymerization/NN in/IN microspike/NN 
212_212_31_32_31_32::None::binding/NN site/NN of/IN alpha-catenin/NN ./. 
1686_1686_47_48_51_53::None::that/IN regulated/VBN actin-dependent/JJ MgATPase/NN activity/NN of/IN Dictyostelium/NNP myosin/NN II/CD requires/VBZ isoform/NN specific/JJ 
93_93_24_26_6_7::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
443637_7_44_45_12_13::None::tumorigenic/JJ model/NN of/IN HCC/NNP These/DT findings/NNS provide/VBP in/FW vitro/FW evidence/NN that/IN sorafenib/NN suppresses/VBZ HGF/NN -/: induced/VBN EMT/NN and/CC cell/NN migration/NN //: invasion/NN ,/, as/RB well/RB as/IN HGF/NN -/: induced/VBN c/SYM -/: MET/NN and/CC MEK/NN //: ERK/NN pathways/NNS ./. 
963135_4_8_9_27_28::None::and/CC management/NN of/IN osteoporosis/NN in/IN postmenopausal/JJ women/NNS recommends/VBZ a/DT daily/JJ intake/NN of/IN at/IN least/JJS 1000/CD mg/NN //: day/NN for/IN calcium/NN ,/, 800/CD IU/NN //: day/NN for/IN 
996_996_12_13_8_9::None::cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT 
2222_2222_17_18_13_14::None::,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, 
387237_8_29_30_28_30::biology.organism_classification.lower_classifications::to/TO the/DT oriental/JJ cat/NN flea/NN Ctenocephalides/NNS orientis/NN 
1055_1055_19_22_22_23::POS_ACTION_MEMBER::expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC E2F/NN 
727854_0_0_1_14_15::None::Hypertension/NN is/VBZ one/CD of/IN the/DT major/JJ risk/NN factors/NNS for/IN cardiovascular/JJ diseases/NNS that/WDT affect/VBP a/DT high/JJ proportion/NN of/IN people/NNS 
25753_2_30_32_4_5::None::kidney/NN injury/NN (/( AKI/NN )/) may/MD lead/VB to/TO chronic/JJ kidney/NN disease/NN (/( CKD/NN )/) ,/, which/WDT can/MD progress/VB to/TO end/VB -/: stage/NN renal/JJ disease/NN (/( ESRD/NN )/) with/IN a/DT mortality/NN rate/NN ./. 
575_575_17_18_11_12::POS_ACTION_INTERACT::binding/NN site/NN in/IN alpha-catenin/NN which/WDT mediates/VBZ its/PRP$ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
488205_3_0_1_5_6::None::CID/NN of/IN molybdenum/NN -/: rich/JJ anions/NNS ,/, PMo/NN (/( 
1818_1818_9_10_11_12::None::the/DT coexistence/NN of/IN profilin/NN with/IN actin/NN filaments/NNS in/IN the/DT 
171_171_21_22_12_13::POS_ACTION_BIND::C/NN terminus/NN of/IN profilin/NN ,/, a/DT region/NN that/WDT has/VBZ been/VBN implicated/VBN in/IN actin/NN binding/NN ./. 
685_685_6_7_14_15::POS_ACTION_COPRECIPITATE::labeled/VBN proteins/NNS with/IN HECD-1/NN revealed/VBD three/CD bands/NNS corresponding/VBG to/TO E-cadherin/NN ,/, alpha-catenin/NN ,/, and/CC gamma-catenin/NN 
684974_3_20_21_18_19::None::ancestors/NNS of/IN extant/JJ alpha/NN -/: proteobacteria/NN of/IN the/DT Rhodospirillales/NNP 
34897_2_36_37_1_2::None::A/DT solid/JJ water/NN phantom/JJ with/IN iodine/NN (/( 2.0/CD -/: 20.0/CD mg/NN I/PRP //: ml/NN )/) and/CC calcium/NN (/( 50.0/CD -/: 600.0/CD mg/NN Ca/NN //: ml/NN )/) rod/NN inserts/NNS was/VBD used/VBN to/TO evaluate/VB effective/JJ energy/NN estimate/NN (/( EEE/NN )/) and/CC iodine/NN 
352442_4_7_9_28_29::None::,/, the/DT calculated/JJ association/NN constants/NNS are/VBP 10.1/CD M/NN (/( -/: 1/LS )/) (/( lidocainium/NN docusate/NN )/) ;/: 0.77/CD M/NN (/( -/: 1/LS )/) (/( sodium/NN chloride/NN )/) ;/: 
1923_1923_21_22_52_53::POS_ACTION_BIND::actin/NN that/WDT bound/VBD profilin/NN ,/, a/DT protein/NN that/WDT interacts/VBZ with/IN phosphoinositides/NNS and/CC actin-monomers/NNS in/IN a/DT mutually/RB exclusive/JJ manner/NN ,/, with/IN an/DT order/NN of/IN magnitude/NN greater/JJR affinity/NN (/( Kd/NN =/JJ 3.6/CD microM/NN )/) than/IN cys-374-labeled/JJ actin/NN (/( Kd/NN >/JJR 
237860_0_6_7_12_13::biology.organism_classification.lower_classifications::the/DT baby/NN woolly/JJ mammoth/JJ (/( Mammuthus/JJ primigenius/NN )/) named/VBN Lyuba/NNP was/VBD found/VBN frozen/VBN 
476387_6_7_8_7_9::medicine.drug.active_moieties::groups/NNS renders/VBZ the/DT xanthan/JJ gum/NN less/RBR sensitive/JJ to/TO 
275901_0_42_43_36_37::None::to/TO manage/VB antiviral/JJ resistance/NN or/CC insufficient/JJ suppression/NN of/IN HBV/NN DNA/NN Very/RB limited/JJ data/NNS 
438089_4_13_14_18_20::medicine.disease.treatments::months/NNS that/WDT included/VBD jaundice/NN patients/NNS admitted/VBN in/IN the/DT General/NNP Surgery/NNP Department/NNP of/IN ''/'' 
1474_1474_9_10_21_24::POS_ACTION_Dynamics::(/( serum/NN and/CC laminin/NN )/) and/CC time/NN in/IN culture/NN on/IN the/DT expression/NN of/IN genes/NNS encoding/VBG myosin/NN heavy/JJ chain/NN (/( MHC/NN )/) 
2222_2222_15_16_39_40::None::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
489_489_26_27_15_16::POS_ACTION_MEMBER::histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP determined/VBN that/IN histone/NN H3/NN is/VBZ significantly/RB 
267813_3_49_50_33_34::None::from/IN two/CD academic/JJ outpatient/NN programs/NNS for/IN a/DT double/JJ -/: blinded/VBN ,/, placebo/NN -/: controlled/JJ trial/NN in/IN which/WDT subjects/NNS were/VBD randomized/VBN in/IN a/DT 2/CD 
1233_1233_28_29_26_27::None::chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
1144_1144_17_18_0_2::None::Profilin/NN II/CD binds/VBZ actin/NN with/IN a/DT similar/JJ affinity/NN to/TO that/DT of/IN profilin/NN I/CD ,/, although/IN it/PRP inhibits/VBZ actin/NN polymerization/NN more/RBR strongly/RB 
583_583_12_13_17_18::None::containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
850254_13_7_8_11_12::medicine.risk_factor.diseases::significantly/RB increased/VBN in/IN diabetic/JJ patients/NNS with/IN acute/JJ infection/NN ./. 
302982_3_9_10_17_18::None::)/) Glucagon/NNP ,/, glucagon/NNP //: insulin/NN ratio/NN and/CC AUCG/NN were/VBD significantly/RB higher/JJR (/( P/NN &/CC 
312_312_35_36_35_36::POS_REG(+)_POLYMERIZE::of/IN profilin/NN on/IN actin/NN polymerization/NN ./. 
433781_3_20_21_8_10::None::more/RBR numerous/JJ in/IN gastric/JJ cancer/NN patients/NNS than/IN in/IN controls/NNS ,/, and/CC significantly/RB more/RBR numerous/JJ before/IN surgery/NN than/IN after/IN surgery/NN 
1498_1498_21_22_15_16::None::link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD thus/RB regulate/VB integrin/NN function/NN ./. 
488875_3_0_1_6_7::None::Anatomical/JJ and/CC morphometrical/JJ analyses/NNS suggest/VBP a/DT hybrid/NN confirmed/VBN by/IN the/DT 
92775_0_11_12_28_29::None::of/IN Alzheimer/NN whosewhat/NN disease/NN (/( AD/NN )/) may/MD be/VB optimal/JJ for/IN clinical/JJ trials/NNS to/TO test/VB potential/JJ treatments/NNS for/IN preventing/VBG or/CC delaying/VBG decline/NN to/TO dementia/NN 
489359_3_16_17_7_8::None::apnea/NN syndrome/NN (/( OSAS/NN )/) was/VBD defined/VBN as/IN reporting/VBG both/CC snoring/VBG and/CC daytime/JJ sleepiness/NN ./. 
816_816_2_3_11_12::POS_REG(0)_Assembly::Interaction/NN of/IN Munc-18-2/NN with/IN syntaxin/NN 3/CD controls/VBZ the/DT association/NN of/IN apical/JJ SNAREs/NNS in/IN epithelial/JJ cells/NNS 
2107_2107_9_10_15_16::None::proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ 
792678_1_16_17_11_12::None::according/VBG to/TO The/DT Diagnostic/JJ and/CC Statistical/JJ Manual/NN of/IN Mental/JJ Disorders/NNS (/( 5th/NN 
820881_0_8_9_6_7::None::as/IN predictors/NNS of/IN subclinical/JJ atherosclerosis/NN based/VBN on/IN the/DT coronary/JJ 
1321_1321_26_27_0_4::None::Testicular/JJ protein/NN kinase/NN 1/CD (/( TESK1/NN )/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN testicular/JJ germ/NN cells/NNS and/CC has/VBZ the/DT potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
1760_1760_1_3_13_14::None::The/DT serine/NN phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC activate/VB the/DT actin-binding/JJ protein/NN cofilin/NN in/IN human/JJ T/NN 
311864_8_48_49_50_51::medicine.drug.active_moieties::deficiency/NN (/( mostly/RB IgG1/NN and/CC IgG3/NN )/) may/MD help/VB 
393_393_12_15_16_17::None::the/DT degradation/NN of/IN myosin/NN heavy/JJ chain/NN and/CC actin/NN ./. 
417823_9_12_13_32_33::None::this/DT study/NN were/VBD lumbar/JJ arthrosis/NN (/( 14/CD %/NN )/) ,/, dementia/NN (/( Alzheimer/NN whosewhat/NN type/NN ,/, vascular/JJ )/) (/( 12.4/CD %/NN )/) ,/, Parkinson/NNP whosewhat/NN disease/NN (/( 
882908_0_10_11_12_13::None::Himantura/NN gerrardi/NNS (/( Myliobatiformes/NNS :/: Dasyatidae/NNP )/) ./. 
231976_9_34_35_20_21::None::Day/NN 5/CD thawed/VBD FFP/NNP Thrombin/NN generation/NN assays/NNS revealed/VBD that/IN the/DT total/NN ,/, lag/NN time/NN to/TO ,/, and/CC peak/NN thrombin/NN formation/NN were/VBD 
483185_4_29_30_2_3::medicine.disease.risk_factors::Genome/NNP -/: wide/JJ association/NN studies/NNS based/VBN on/IN adequate/JJ population/NN samples/NNS have/VBP shown/VBN a/DT higher/JJR frequency/NN of/IN genetic/JJ polymorphisms/NNS of/IN the/DT LHCGR/NNP ,/, THADA/NNP and/CC DENND1A/NN genes/NNS in/IN women/NNS with/IN PCOS/NN Genetic/JJ studies/NNS of/IN 
2064_2064_6_7_49_50::NEG_ACTION_CORELATE::the/DT down-regulation/NN of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
516597_4_1_2_6_7::None::We/PRP identified/VBD 647/CD children/NNS with/IN severe/JJ isolated/VBN head/NN injuries/NNS :/: 
53_53_5_7_17_18::POS_ACTION_INHIBIT::modulating/VBG domain/NN in/IN glucocorticoid/NN receptor/NN monomers/NNS in/IN the/DT repression/NN of/IN activity/NN of/IN the/DT transcription/NN factor/NN AP-1/NN ./. 
324838_0_0_1_11_12::None::Acute/JJ painful/JJ diabetic/JJ neuropathy/NN (/( APDN/NN )/) is/VBZ a/DT distinctive/JJ diabetic/JJ polyneuropathy/NN and/CC consists/VBZ of/IN 
339_339_15_16_13_14::POS_ACTION_RELATE::actin/NN cytoskeleton/NN by/IN cofilin/NN and/CC Aip1/NN ./. 
865_865_17_18_21_24::None::(/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ 
1047_1047_17_18_9_10::None::proteins/NNS TRADD/NN and/CC FADD/NN are/VBP also/RB involved/VBN in/IN the/DT activation/NN of/IN A-SMase/NN ./. 
313724_3_10_12_11_12::None::presenting/VBG acutely/RB with/IN intracranial/JJ hemorrhage/NN in/IN adult/JJ patients/NNS 
452979_10_10_12_15_17::medicine.risk_factor.diseases::apnea/NN risk/NN and/CC diabetes/NN mellitus/NN among/IN blacks/NNS with/IN metabolic/JJ syndrome/NN ./. 
1427_1427_3_4_29_30::POS_ACTION_BIND::The/DT comparison/NN of/IN E-CD/NN proteins/NNS synthesized/VBN by/IN E62/NN and/CC E24/NN cell/NN lines/NNS revealed/VBD no/DT structural/JJ or/CC functional/JJ differences/NNS because/IN both/DT localized/JJ at/IN cell-cell/JJ contacts/NNS and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
93177_0_15_16_8_9::None::is/VBZ an/DT inflammatory/JJ CNS/NN syndrome/NN distinct/JJ from/IN multiple/JJ sclerosis/NN (/( MS/NN )/) that/WDT is/VBZ 
665172_5_5_6_10_11::None::was/VBD evident/JJ in/IN male/JJ NK1R/NN -/: //: -/: mice/NNS ,/, only/RB ,/, 
1144_1144_0_2_17_18::POS_ACTION_BIND::Profilin/NN II/CD binds/VBZ actin/NN with/IN a/DT similar/JJ affinity/NN to/TO that/DT of/IN profilin/NN I/CD ,/, although/IN it/PRP inhibits/VBZ actin/NN polymerization/NN more/RBR strongly/RB 
435_435_13_14_15_16::None::the/DT binding/NN to/TO PRP9/NN and/CC PRP11/NN proteins/NNS and/CC are/VBP 
799053_0_5_6_3_4::medicine.disease.treatments::Clinical/JJ observations/NNS on/IN chemotherapy/NN curable/JJ malignancies/NNS :/: unique/JJ genetic/JJ 
3197_0_16_19_15_16::None::HIV/NN -/: 1/CD nucleotide/NN reverse/JJ transcriptase/NN inhibitor/NN tenofovir/NN (/( TFV/NN 
93_93_11_12_22_23::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN 
813_813_8_9_27_28::None::NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN P/NN is/VBZ essential/JJ for/IN 
720852_5_3_4_16_17::None::While/IN the/DT higher/JJR incidence/NN of/IN MI/NN with/IN PCI/NN was/VBD noticed/VBN in/IN both/CC diabetic/JJ and/CC non/JJ -/: diabetics/NNS ,/, death/NN was/VBD 
93177_0_21_22_22_23::None::is/VBZ associated/VBN with/IN serum/NN aquaporin/NN -/: 4/CD immunoglobulin/NN 
1373_1373_16_17_13_14::POS_ACTION_MUTUALCOMPLEX::with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
231772_0_42_43_39_41::medicine.drug.active_moieties::ZnO/NN )/) and/CC titanium/NN dioxide/NN (/( TiO2/NN )/) as/IN photocatalysts/NNS 
28939_0_8_10_6_7::None::in/IN an/DT elderly/JJ patient/NN with/IN Parkinson/NNPS disease/NN and/CC she/PRP was/VBD 
235710_2_17_18_4_5::medicine.disease.treatments::investigate/VB the/DT adjuvant/JJ cabergoline/NN therapy/NN effects/NNS on/IN menstrual/JJ irregularity/NN and/CC androgen/NN system/NN in/IN PCOS/NN women/NNS with/IN hyperprolactinemia/NN ./. 
1069_1069_42_45_24_25::None::helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
1380_1380_34_35_38_39::None::novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, 
1417_1417_7_9_9_10::POS_ACTION_MEMBER::p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS 
1578_1578_9_10_5_6::None::assembly/NN of/IN the/DT talin/NN homologue/NN together/RB with/IN actin/NN and/CC a/DT series/NN 
442063_4_37_38_28_29::None::enrolled/VBD 508/CD AMI/NNP patients/NNS to/TO compare/VB the/DT efficacy/NN of/IN hydrophilic/JJ and/CC lipophilic/JJ statins/NNS in/IN secondary/JJ prevention/NN 
2107_2107_39_40_15_16::None::targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
2108_2108_18_19_8_11::None::proteins/NNS are/VBP indeed/RB nuclear/JJ basic/JJ proteins/NNS :/: the/DT 14/CD kd/NN is/VBZ the/DT histone/NN H4/NN ,/, the/DT 19/CD 
249535_0_3_4_11_12::None::Altered/JJ profile/NN of/IN serum/NN microRNAs/NNS in/IN pancreatic/JJ cancer/NN associated/VBN new/JJ -/: onset/NN diabetes/NN mellitus/NN ./. 
1427_1427_29_30_3_4::None::The/DT comparison/NN of/IN E-CD/NN proteins/NNS synthesized/VBN by/IN E62/NN and/CC E24/NN cell/NN lines/NNS revealed/VBD no/DT structural/JJ or/CC functional/JJ differences/NNS because/IN both/DT localized/JJ at/IN cell-cell/JJ contacts/NNS and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
456_456_17_18_15_16::None::expression/NN of/IN either/CC beta-catenin/NN or/CC E-cadherin/NN ./. 
566931_0_4_5_27_28::None::the/DT treatment/NN of/IN polymyositis/NN (/( PM/NN )/) and/CC dermatomyositis/NN (/( DM/NN )/) ,/, muscle/NN inflammation/NN and/CC underlying/VBG autoimmunity/NN need/NN to/TO be/VB suppressed/VBN promptly/RB ;/: however/RB ,/, catabolic/JJ effects/NNS of/IN corticosteroids/NNS 
217765_0_14_15_12_13::None::partial/JJ resurfacing/NN to/TO reverse/VB shoulder/NN arthroplasty/NN ]/) ./. 
793106_10_87_88_23_24::None::variables/NNS age/NN ,/, gender/NN ,/, disease/NN duration/NN ,/, tumor/NN size/NN ,/, basal/JJ hormone/NN levels/NNS ,/, relevant/JJ treatment/NN modalities/NNS ,/, and/CC relevant/JJ comorbidities/NNS )/) ,/, with/IN a/DT higher/JJR degree/NN of/IN psychopathology/NN indicating/VBG a/DT lower/JJR QoL/NN (/( depression/NN vs/CC AcroQoL/NN :/: B/NN =/SYM -/: 1.175/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD ,/, depression/NN vs/CC SF/NN -/: 36/CD :/: B/NN =/SYM -/: 1.648/CD ,/, p/NN &/CC lt/NN ;/: 0.001/CD ,/, anxiety/NN vs/CC AcroQoL/NN :/: 
1503_1503_5_7_13_14::None::simplex/NN virus/NN type-1/NN DNA/NN helicase-primase/NN is/VBZ a/DT heterotrimer/NN encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, 
129749_7_0_1_1_2::medicine.symptom.symptom_of::Subclinical/JJ hypothyroidism/NN risk/NN for/IN DM/NN 
240510_12_12_13_1_2::None::In/IN contrast/NN ,/, four/CD of/IN the/DT more/RBR recently/RB named/VBN gastropod/NN clades/NNS (/( Vetigastropoda/NNP ,/, Neritimorpha/NNP ,/, 
25905_6_2_3_13_14::None::Subsequently/RB ,/, nitrate/JJ concentration/NN in/IN the/DT feed/NN was/VBD increased/VBN in/IN a/DT step/NN -/: wise/JJ manner/NN to/TO establish/VB 
1782_1782_20_22_1_6::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, 
151063_0_5_6_19_23::medicine.medical_treatment.used_to_treat::PTX/NN )/) and/CC carboplatin/NN (/( CBP/NN )/) are/VBP widely/RB used/VBN for/IN the/DT combined/JJ chemotherapy/NN of/IN non/JJ -/: small/JJ cell/NN lung/NN cancer/NN (/( NSCLC/NN )/) 
672_672_16_17_19_20::None::distributed/VBN in/IN cortical/JJ actin/NN patches/NNS where/WRB cofilin/NN was/VBD also/RB co-localized/VBN 
378211_8_34_35_30_31::medicine.disease.risk_factors::in/IN non/JJ -/: smokers/NNS ,/, smokers/NNS and/CC COPD/NN patients/NNS ./. 
243_243_27_28_3_4::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN 
242622_9_23_24_0_1::None::These/DT findings/NNS indicate/VBP that/IN beta/NN -/: blocker/NN use/NN was/VBD associated/VBN with/IN reduced/VBN cancer/NN -/: specific/JJ mortality/NN among/IN prostate/NN cancer/NN patients/NNS taking/VBG beta/NN -/: blockers/NNS ./. 
452211_4_8_9_9_10::None::2/CD //: survivin/NN siRNAs/NNS loaded/VBN in/IN the/DT anti/JJ 
549899_0_7_8_26_27::None::that/IN breast/NN cancer/NN stem/NN cells/NNS may/MD be/VB closely/RB associated/VBN with/IN tumor/NN metastasis/NN ,/, recurrence/NN ,/, and/CC even/RB the/DT failure/NN of/IN chemotherapy/NN and/CC radiotherapy/NN ./. 
610_610_27_28_22_23::POS_ACTION_BIND::DNA/NN replication-specific/JJ genes/NNS UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN (/( Crute/NN ,/, 
178051_0_17_18_2_3::medicine.drug_ingredient.active_moiety_of_drug::The/DT Scandinavian/JJ Candesartan/NNP Acute/JJ Stroke/NNP Trial/NN (/( SCAST/NN )/) indicated/VBD that/IN blood/NN pressure/NN -/: lowering/VBG treatment/NN with/IN candesartan/NN in/IN the/DT acute/JJ 
526397_0_12_13_10_11::None::-/: term/NN work/NN disability/NN and/CC absenteeism/NN between/IN anxiety/NN and/CC 
795722_1_2_3_0_1::None::One/CD hundred/CD forty/CD -/: one/CD patients/NNS 
930_930_6_7_11_15::None::the/DT actin-associated/JJ proteins/NNS filamin/NN ,/, talin/NN and/CC the/DT beta/NN 1/CD integrin/NN subunit/NN were/VBD also/RB found/VBN 
882908_0_6_7_10_11::None::of/IN the/DT Sharpnose/NN stingray/NN Himantura/NN gerrardi/NNS (/( Myliobatiformes/NNS :/: Dasyatidae/NNP )/) 
755_755_4_5_20_21::None::cultured/VBN cells/NNS ,/, cofilin/NN ,/, as/RB well/RB as/IN ADF/NN ,/, translocates/VBZ from/IN the/DT cytoplasm/NN into/IN the/DT nucleus/NN together/RB with/IN actin/NN and/CC forms/NNS rod-like/JJ 
225_225_2_3_4_5::None::Binding/NN of/IN talin/NN to/TO actin/NN occurs/VBZ at/IN a/DT 
221316_7_5_6_0_1::None::There/EX was/VBD symmetrical/JJ polyarthritis/NN with/IN high/JJ tender/NN and/CC swollen/JJ 
236807_0_0_1_22_23::None::The/DT nonsteroidal/JJ antiinflammatory/JJ drug/NN piroxicam/NN reverses/VBZ the/DT onset/NN of/IN depressive/JJ -/: like/IN behavior/NN in/IN 6/CD -/: OHDA/NN animal/NN model/NN of/IN Parkinson/NNP whosewhat/NN disease/NN ./. 
177255_4_10_11_14_15::None::from/IN diabetic/JJ foot/NN infection/NN with/IN modified/VBN cotton/NN socks/NNS ./. 
494835_0_1_2_36_39::None::To/TO report/VB the/DT secondary/JJ analyses/NNS of/IN treatment/NN satisfaction/NN and/CC clinically/RB meaningful/JJ improvements/NNS in/IN a/DT randomized/VBN study/NN comparing/VBG coadministration/NN of/IN tadalafil/NN 5/CD mg/NN with/IN finasteride/NN 5/CD mg/NN versus/CC finasteride/NN alone/RB in/IN men/NNS with/IN prostatic/JJ enlargement/NN secondary/JJ to/TO benign/JJ prostatic/JJ hyperplasia/NN ./. 
242294_6_0_1_36_37::None::In/IN the/DT crystal/NN of/IN (/( A/NN )/) ,/, inter/NN -/: molecular/JJ O/NN -/: H/NN O/NN ,/, C/NN -/: H/NN O/NN and/CC C/NN -/: Hpi/NN inter/NN -/: actions/NNS link/VBP the/DT independent/JJ benzoates/NNS alternately/RB ,/, forming/VBG a/DT chain/NN structure/NN ./. 
1871_1871_12_13_16_17::None::between/IN E-cadherin/NN and/CC alpha-catenin/NN is/VBZ mediated/VBN by/IN beta-catenin/NN ,/, and/CC that/IN 
253162_8_4_5_1_2::medicine.drug_ingredient.active_moiety_of_drug::All/DT IgG/NN subclasses/NNS (/( IgG1/NN //: IgG2a/NN //: 
170709_1_11_12_1_2::None::In/IN order/NN to/TO target/VB SkBr3/NN ,/, which/WDT is/VBZ a/DT breast/NN cancer/NN cell/NN overexpressing/VBG the/DT Her2/NN 
139515_2_39_40_24_25::None::SBP/NN and/CC later/RB HSP/NN In/IN this/DT patient/NN ,/, the/DT diagnosis/NN of/IN HSP/NN was/VBD demonstrated/VBN clinically/RB by/IN his/PRP$ palpable/JJ purpura/NN ,/, diarrhea/NN ,/, 
1523_1523_7_8_4_5::POS_ACTION_INTERACT::interaction/NN of/IN Acanthamoeba/NN actin/NN and/CC Acanthamoeba/NN profilin/NN was/VBD evaluated/VBN as/IN 
768458_5_30_31_29_30::None::against/IN PAAC/NN -/: induced/VBN cardiac/JJ remodelling/NN ./. 
245220_2_24_25_1_2::None::We/PRP investigated/VBD whether/IN silencing/NN of/IN miR/NN -/: 195/CD reduces/VBZ diabetic/JJ cardiomyopathy/NN in/IN a/DT mouse/NN model/NN of/IN streptozotocin/NN (/( STZ/NN )/) -/: induced/VBN type/NN 1/CD diabetes/NN ./. 
747_747_30_31_25_26::None::and/CC association/NN of/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN relative/JJ to/TO Apc/NN 
473229_16_5_6_25_26::None::of/IN extended/JJ -/: spectrum/NN beta/NN -/: lactamase/NN (/( ESBL/NN )/) was/VBD noted/VBN in/IN 12.8/CD %/NN of/IN pediatric/JJ Enterobacteria/NNP vs/CC 22.6/CD %/NN of/IN the/DT neonatal/JJ strains/NNS ./. 
2064_2064_6_7_40_41::None::the/DT down-regulation/NN of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN 
460309_1_21_22_18_20::medicine.drug_ingredient.active_moiety_of_drug::spectra/NNS dominated/VBN by/IN phosphoric/JJ acid/NN (/( H3PO4/NN )/) neutral/JJ loss/NN 
231123_0_10_12_21_22::None::analysis/NN of/IN the/DT phase/NN 2/CD ,/, open/JJ -/: label/NN ,/, single/JJ -/: arm/NN nilotinib/JJ registration/NN study/NN ./. 
379000_0_1_3_9_10::None::Nerve/NN conduction/NN block/NN in/IN diabetic/JJ rats/NNS using/VBG high/JJ -/: intensity/NN focused/VBD ultrasound/NN for/IN 
1386_1386_1_2_20_21::POS_ACTION_Assembly::The/DT UL8/NN component/NN of/IN the/DT herpes/NN simplex/NN virus/NN helicase-primase/JJ complex/NN stimulates/VBZ primer/NN synthesis/NN by/IN a/DT subassembly/NN of/IN the/DT UL5/NN and/CC UL52/NN components/NNS ./. 
755_755_20_21_4_5::POS_ACTION_COLOCALIZE::cultured/VBN cells/NNS ,/, cofilin/NN ,/, as/RB well/RB as/IN ADF/NN ,/, translocates/VBZ from/IN the/DT cytoplasm/NN into/IN the/DT nucleus/NN together/RB with/IN actin/NN and/CC forms/NNS rod-like/JJ 
1017_1017_9_10_20_21::None::the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP very/RB similar/JJ growth/NN phenotypes/NNS ,/, a/DT depolarized/VBN actin/NN cytoskeleton/NN ,/, and/CC 
938_938_6_7_0_2::None::LIM-kinase/NN 1/CD (/( LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ 
814864_2_12_13_2_3::None::To/TO our/PRP$ knowledge/NN ,/, however/RB ,/, sensitization/NN profiles/NNS among/IN children/NNS hospitalized/VBN for/IN asthma/NN are/VBP unknown/JJ ./. 
275849_11_10_11_14_15::None::coli/NN O157/NN :/: H7/NN was/VBD treated/VBN with/IN acetic/JJ acid/NN and/CC salt/NN 
268987_0_6_8_27_28::None::common/JJ to/TO all/DT solid/JJ tumors/NNS are/VBP tissue/NN hypoxia/NN and/CC inflammation/NN ,/, both/DT of/IN which/WDT cause/VBP tumor/NN progression/NN ,/, metastasis/NN ,/, therapy/NN resistance/NN and/CC increased/VBD mortality/NN ./. 
225032_8_23_25_23_24::medicine.drug.active_moieties::up/RB -/: regulated/VBN insulin/NN gene/NN expression/NN ./. 
428759_1_6_7_1_3::None::For/IN cervical/JJ cancer/NN ,/, several/JJ therapeutic/JJ agents/NNS showed/VBD viable/JJ antitumor/NN 
954_954_6_7_1_2::None::Mammalian/JJ LIM-kinases/NNS (/( LIMKs/NNS )/) phosphorylate/VBP cofilin/NN and/CC induce/VB actin/NN 
1866_1866_5_6_7_8::None::both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, 
2100_2100_12_13_18_19::POS_REG(-)_POLYMERIZE::to/TO Trp104-Met115/NN of/IN cofilin/NN is/VBZ a/DT potent/JJ inhibitor/NN of/IN actin/NN polymerization/NN (/( Yonezawa/NN 
479_479_21_22_2_4::NEG_ACTION_DOWNREGULATE::Expressions/NNS of/IN cyclin/NN E/NN ,/, A/NN ,/, and/CC B1/NN in/IN Hodgkin/NN and/CC Reed-Sternberg/NN cells/NNS :/: not/RB suppressed/VBN by/IN cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN expression/NN ./. 
938_938_14_15_0_2::None::LIM-kinase/NN 1/CD (/( LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ actin/NN cytoskeletal/JJ reorganization/NN ./. 
410019_0_0_1_21_22::None::Neo/SYM -/: adjuvant/JJ breast/NN cancer/NN clinical/JJ trials/NNS of/IN zoledronic/JJ acid/NN (/( ZOL/NN )/) have/VBP shown/VBN that/IN patients/NNS with/IN oestrogen/NN negative/JJ (/( ER/NN -/: ve/NN )/) 
1474_1474_29_31_21_24::None::of/IN genes/NNS encoding/VBG myosin/NN heavy/JJ chain/NN (/( MHC/NN )/) isoforms/NNS and/CC alpha-skeletal/JJ actin/NN were/VBD analysed/VBN in/IN 
483865_3_11_12_32_33::medicine.drug.active_moieties::particles/NNS containing/VBG reduced/VBN sulfur/NN ,/, detected/VBN as/IN elemental/JJ sulfur/NN ions/NNS (/( eg/FW ,/, (/( 32/CD )/) S/NN (/( +/CC )/) ,/, (/( 64/CD )/) S2/NN (/( +/CC )/) 
1260_1260_23_24_24_25::POS_ACTION_MEMBER::SIR4/NN ,/, and/CC histone/NN H4/NN ./. 
503817_10_12_13_14_15::None::and/CC repopulation/NN in/IN rats/NNS with/IN acute/JJ liver/NN injury/NN ./. 
130_130_6_7_4_5::None::assembly/NN of/IN the/DT UL5/NN and/CC UL52/NN subunits/NNS retains/VBZ both/CC 
1591_1591_21_22_19_20::None::a/DT crosslinker/NN between/IN myosin/NN and/CC actin/NN ./. 
264127_4_1_2_28_29::None::Among/IN medically/RB complex/JJ patients/NNS ,/, early/JJ endocrinologist/NN care/NN was/VBD associated/VBN with/IN a/DT lower/JJR 3/LS -/: year/NN incidence/NN of/IN the/DT primary/JJ endpoint/NN (/( hazard/NN ratio/NN 0.89/CD ,/, 95/CD %/NN CI/NN 0.78/CD -/: 1.01/CD 
686_686_13_14_31_32::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
908550_0_20_22_18_19::None::parameters/NNS in/IN modestly/RB severely/RB obese/JJ African/JJ Americans/NNPS and/CC White/NNP Americans/NNPS 
106487_0_23_25_23_24::None::the/DT time/NN of/IN kidney/NN transplantation/NN (/( KTX/NN 
1128_1128_0_2_4_5::None::Platelet/NN talin/NN binds/VBZ to/TO actin/NN in/FW vitro/FW and/CC 
343970_4_118_119_89_90::None::reactive/JJ phosphate/NN (/( PO4/NN (/( 3/CD -/: )/) -/: P/NN )/) ,/, TDN/NN ;/: PO4/NN (/( 3/CD -/: )/) -/: P/NN ,/, total/JJ dissolved/VBN phosphorus/NN (/( TDP/NN )/) and/CC nitrite/JJ nitrogen/NN (/( NO2/NN (/( -/: )/) 
575_575_11_12_17_18::POS_ACTION_Change::binding/NN site/NN in/IN alpha-catenin/NN which/WDT mediates/VBZ its/PRP$ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
526387_8_12_13_0_1::None::These/DT results/NNS suggest/VBP that/IN DcEV/NN is/VBZ a/DT novel/JJ species/NNS of/IN the/DT genus/NN Enterovirus/NN in/IN Picornaviridae/NNP ./. 
410_410_12_13_9_10::None::of/IN both/DT histone/NN H3/NN and/CC histone/NN H4/NN were/VBD inviable/JJ ./. 
1199_1199_5_6_8_9::None::the/DT inhibition/NN of/IN actin/NN polymerization/NN by/IN profilin/NN ./. 
1373_1373_13_14_1_2::None::The/DT APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
225720_6_4_6_24_25::None::also/RB show/VBP that/IN primary/JJ tumors/NNS can/MD be/VB modeled/VBN in/IN immunocompetent/JJ mice/NNS by/IN microinjecting/VBG CCR9/NN -/: expressing/VBG cancer/NN cell/NN lines/NNS into/IN early/JJ -/: stage/NN mouse/NN blastocysts/NNS ,/, which/WDT 
320906_2_15_16_6_7::None::to/TO better/RBR understand/VB consumer/NN antimalarial/JJ prices/NNS by/IN documenting/VBG and/CC exploring/VBG the/DT pricing/NN behaviour/NN of/IN retailers/NNS and/CC 
230298_6_19_21_0_1::medicine.disease.risk_factors::Management/NN strategies/NNS include/VBP cognitive/JJ behavioral/JJ therapy/NN ,/, mindfulness/NN -/: based/VBN cognitive/JJ therapy/NN ,/, and/CC sex/NN therapy/NN and/CC ,/, for/IN erectile/JJ dysfunction/NN and/CC premature/JJ ejaculation/NN 
968089_0_0_3_23_24::None::Hepatitis/NNP C/NNP virus/NN (/( HCV/NN )/) -/: related/JJ cirrhosis/NN and/CC hepatocellular/JJ carcinoma/NN account/NN for/IN approximately/RB 40/CD %/NN of/IN the/DT 6,000/CD adult/JJ liver/NN transplantations/NNS performed/VBN each/DT year/NN in/IN 
149877_5_30_31_1_2::None::Those/DT cases/NNS with/IN intermediate/JJ or/CC high/JJ p16/NN //: INK4A/NN tumour/NN expression/NN had/VBD a/DT significantly/RB better/JJR post/NN -/: diagnosis/NN survival/NN than/IN those/DT cases/NNS whose/WP$ tumours/NNS lost/VBD p16/NN expression/NN (/( log/NN -/: rank/NN P/NN &/CC lt/NN 
441567_0_9_10_6_8::medicine.drug_ingredient.active_moiety_of_drug::use/NN of/IN combined/JJ ursodeoxycholic/JJ acid/NN (/( UDCA/NN )/) and/CC rifampicin/NN 
243_243_3_4_30_32::None::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD 
340516_1_54_57_11_12::None::2011/CD ,/, we/PRP estimated/VBD the/DT frequency/NN of/IN antibiotics/NNS prescribing/VBG for/IN URI/NNP in/IN pediatric/JJ outpatients/NNS with/IN diagnoses/NNS of/IN acute/JJ nasopharyngitis/NN (/( common/JJ cold/NN )/) ,/, acute/JJ sinusitis/NN ,/, acute/JJ pharyngitis/NN ,/, acute/JJ tonsillitis/NN ,/, acute/JJ laryngitis/NN //: tracheitis/NN ,/, acute/JJ obstructive/JJ laryngitis/NN //: epiglottitis/NN ,/, and/CC acute/JJ upper/JJ respiratory/JJ infections/NNS of/IN multiple/JJ and/CC 
28939_0_19_20_6_7::None::in/IN an/DT elderly/JJ patient/NN with/IN Parkinson/NNPS disease/NN and/CC she/PRP was/VBD admitted/VBN and/CC treated/VBN with/IN quetiapine/NN (/( Seroquel/NN )/) ./. 
693466_12_9_10_12_15::None::effective/JJ regimen/NN for/IN Philadelphia/NNP -/: positive/JJ acute/JJ lymphoblastic/JJ leukemia/NN ./. 
95307_0_8_9_0_1::None::The/DT safety/NN pharmacology/NN testing/NN for/IN anticancer/JJ agents/NNS has/VBZ historically/RB differed/VBN for/IN small/JJ 
32713_5_16_17_18_20::None::common/JJ link/NN between/IN metabolic/JJ and/CC cardiovascular/JJ diseases/NNS ,/, including/VBG glycaemic/JJ 
205283_0_11_12_22_23::None::the/DT use/NN of/IN intensive/JJ statin/NN therapy/NN ,/, the/DT burden/NN of/IN atherosclerotic/JJ cardiovascular/JJ disease/NN (/( CVD/NN )/) remains/VBZ high/JJ 
1373_1373_13_14_11_12::POS_ACTION_SIMILAR::independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
193027_2_32_33_22_23::None::,/, which/WDT we/PRP call/VBP JO/SYM -/: 4/CD ,/, in/IN combination/NN with/IN PEGylated/VBN liposomal/JJ doxorubicin/NN (/( PLD/NN )/) 
433927_4_6_7_14_15::medicine.drug.active_moieties::cells/NNS in/IN a/DT sodium/NN -/: free/JJ medium/NN (/( made/VBN by/IN substituting/VBG Na/NN +/CC with/IN K/NN 
227834_1_21_22_19_22::people.cause_of_death.includes_causes_of_death::of/IN type/NN 2/CD diabetic/JJ patients/NNS ./. 
1248_1248_12_13_19_20::None::beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB associated/VBN with/IN these/DT cadherins/NNS and/CC serve/VB to/TO 
608_608_10_11_20_21::POS_ACTION_CONTAIN::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
968089_0_28_30_20_21::None::of/IN the/DT 6,000/CD adult/JJ liver/NN transplantations/NNS performed/VBN each/DT year/NN in/IN the/DT United/NNP States/NNPS ./. 
494835_0_36_39_3_4::None::To/TO report/VB the/DT secondary/JJ analyses/NNS of/IN treatment/NN satisfaction/NN and/CC clinically/RB meaningful/JJ improvements/NNS in/IN a/DT randomized/VBN study/NN comparing/VBG coadministration/NN of/IN tadalafil/NN 5/CD mg/NN with/IN finasteride/NN 5/CD mg/NN versus/CC finasteride/NN alone/RB in/IN men/NNS with/IN prostatic/JJ enlargement/NN secondary/JJ to/TO benign/JJ prostatic/JJ hyperplasia/NN ./. 
476195_1_13_14_0_1::None::In/IN this/DT study/NN we/PRP investigated/VBD the/DT effects/NNS of/IN Cu/NN -/: NPs/NNS and/CC soluble/JJ Cu/NN in/IN the/DT intestines/NNS 
322970_7_19_20_30_31::medicine.disease.risk_factors::both/DT periods/NNS ,/, high/JJ SES/NN respondents/NNS (/( in/IN all/DT indicators/NNS )/) had/VBD lower/JJR current/JJ smoking/NN levels/NNS and/CC higher/JJR 
183879_18_16_17_14_15::None::reversed/VBD the/DT depressive/JJ mood/NN of/IN patients/NNS with/IN severe/JJ MDD/NN 
1360_1360_4_5_7_8::POS_ACTION_BIND::affinity/NN of/IN yeast/NN profilin/NN for/IN rabbit/NN actin/NN (/( 2.9/CD microM/NN 
341530_0_22_23_11_12::None::are/VBP at/IN a/DT high/JJ risk/NN for/IN cardiovascular/JJ disease/NN (/( CVD/NN )/) due/JJ to/TO increased/VBN prevalence/NN of/IN traditional/JJ and/CC 
1052_1052_6_8_21_22::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG 
495841_5_10_11_24_26::None::equipotent/JJ activities/NNS against/IN vemurafenib/NN -/: resistant/JJ SK/NN -/: Mel2/NN melanoma/NN cells/NNS and/CC p53/NN -/: deficient/JJ H1299/NN lung/NN cancer/NN cells/NNS as/RB well/RB ,/, 
428_428_32_33_34_35::POS_ACTION_COLOCALIZE::with/IN substrate/NN containing/VBG actin/NN and/CC talin/NN ./. 
711_711_14_15_22_23::POS_ACTION_INCREASE::,/, stimulation/NN with/IN TNF-alpha/NN led/VBD to/TO a/DT 2.4-fold/JJ increase/NN in/IN net/JJ actin/NN protein/NN synthesis/NN and/CC 
151533_0_27_28_32_33::None::rifampicin/NN use/NN (/( Intensive/JJ phase/NN only/RB versus/CC both/DT phases/NNS )/) have/VBP not/RB 
1889_1889_11_13_0_2::None::TNF/NN receptor/NN death/NN domain-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN acid/NN sphingomyelinase/NN ./. 
1164_1164_5_6_35_38::None::the/DT appearance/NN of/IN X22/NN banding/NN in/IN primary/JJ cultures/NNS of/IN myotubes/NNS indicates/VBZ that/IN it/PRP precedes/VBZ that/IN of/IN other/JJ myofibrillar/NN proteins/NNS and/CC that/IN assembly/NN takes/VBZ place/NN in/IN the/DT following/VBG order/NN :/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, 
2052_2052_6_7_20_21::None::axonal/JJ transport/NN of/IN actin/NN and/CC its/PRP$ monomer/NN binding/NN proteins/NNS ,/, actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ,/, in/IN the/DT 
1969_1969_20_21_18_19::POS_ACTION_BIND::motility/NN complex/NN containing/VBG VASP/NN and/CC profilin/NN ./. 
814130_0_16_17_5_6::medicine.medical_treatment.used_to_treat::infrequent/JJ pathology/NN ,/, pancreatic/JJ cystic/JJ tumors/NNS stand/VBP nowadays/RB for/IN 25/CD %/NN of/IN all/DT pancreatic/JJ surgical/JJ diseases/NNS ./. 
2222_2222_15_16_11_12::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, 
1761_1761_13_15_23_25::None::,/, the/DT HPIV3/NN nucleocapsid/NN protein/NN N/NN ,/, the/DT phosphoprotein/NN P/NN ,/, and/CC the/DT polymerase/NN protein/NN L./NN 
443015_2_12_13_15_16::None::two/CD standard/JJ experimental/JJ murine/JJ models/NNS of/IN asthma/NN ,/, where/WRB the/DT 
178116_0_15_16_14_15::None::metabolism/NN ,/, and/CC flowering/NN time/NN -/: -/: joint/JJ 
1486_1486_41_44_24_25::None::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB 
73717_0_57_58_37_39::None::high/JJ -/: risk/NN prostate/NN cancer/NN (/( PCa/NN )/) to/TO be/VB treated/VBN with/IN whole/JJ pelvic/JJ radiation/NN therapy/NN (/( WPRT/NN )/) in/IN an/DT attempt/NN to/TO define/VB the/DT hostile/JJ pelvis/NN 
552323_0_21_22_8_9::None::risk/NN factor/NN for/IN preeclampsia/NN ,/, which/WDT is/VBZ new/JJ -/: onset/NN hypertension/NN in/IN pregnancy/NN ,/, the/DT mechanisms/NNS linking/VBG obesity/NN and/CC hypertension/NN 
2022_2022_11_12_8_9::POS_ACTION_LOCALIZE::potential/JJ sequestration/NN of/IN actin/NN monomers/NNS by/IN profilin/NN ,/, when/WRB present/JJ 
221936_3_17_18_13_14::None::,/, TC/NN //: HDL/SYM -/: c/NN ,/, VO2max/NN and/CC the/DT sum/NN 
220528_2_11_12_50_51::medicine.drug_ingredient.active_moiety_of_drug::the/DT effect/NN of/IN fluoride/NN treatments/NNS on/IN in/FW vivo/FW maturation/NN and/CC developmental/JJ potential/NN of/IN mouse/NN oocytes/NNS ,/, in/IN which/WDT female/JJ ICR/NN mice/NNS were/VBD treated/VBN with/IN a/DT range/NN of/IN doses/NNS (/( 0/CD ,/, 30/CD ,/, 60/CD ,/, and/CC 150/CD mg/NN //: L/NN )/) of/IN NaF/NN After/IN treatment/NN ,/, 
438998_0_14_16_16_17::None::of/IN everolimus/NN on/IN renal/JJ cancer/NN cells/NNS ./. 
1417_1417_17_18_7_9::None::p300/NN and/CC the/DT CREB-binding/JJ protein/NN CBP/NN are/VBP cellular/JJ targets/NNS for/IN transformation/NN by/IN the/DT E1A/NN proteins/NNS of/IN non-oncogenic/JJ 
458615_4_24_25_32_33::None::in/IN iron/NN (/( Fe/NNP )/) ,/, potassium/NN (/( K/NN )/) ,/, sodium/NN (/( Na/NN )/) 
1672_1672_12_13_10_11::POS_ACTION_MEMBER::the/DT RAD17/NN ,/, MEC3/NN and/CC RAD24/NN epistasis/NN group/NN which/WDT 
23235_3_51_53_50_53::medicine.drug_ingredient.active_moiety_of_drug::and/CC functional/JJ activated/VBN protein/NN C/NN -/: resistance/NN ./. 
1464_1464_3_4_8_9::POS_ACTION_Assembly::The/DT domains/NNS in/IN CBP/NN that/WDT are/VBP involved/VBN in/IN CREB/NN binding/NN and/CC transcriptional/JJ 
313728_4_7_8_49_50::None::metabolic/JJ needs/NNS of/IN tumor/NN cells/NNS has/VBZ led/VBN to/TO the/DT proposal/NN of/IN a/DT new/JJ metabolic/JJ treatment/NN for/IN various/JJ cancers/NNS including/VBG GBMs/NNS that/WDT may/MD enhance/VB the/DT effectiveness/NN of/IN the/DT SOC/NNP The/DT goal/NN of/IN metabolic/JJ cancer/NN therapy/NN is/VBZ to/TO restrict/VB GBM/NN cells/NNS of/IN glucose/NN ,/, their/PRP$ main/JJ energy/NN substrate/NN ./. 
1386_1386_18_19_20_21::POS_ACTION_BIND::subassembly/NN of/IN the/DT UL5/NN and/CC UL52/NN components/NNS ./. 
387871_6_5_6_6_7::None::promoted/VBD CO2/NN and/CC N2O/NN emissions/NNS but/CC inhibited/VBD CH4/NN 
25979_5_19_20_5_6::None::60,211/CD participants/NNS without/IN cardiovascular/JJ disease/NN at/IN baseline/NN with/IN available/JJ data/NNS on/IN ethnicity/NN (/( White/NNP ,/, Black/NNP ,/, Asian/NNP or/CC Hispanic/NNP )/) 
779_779_49_52_6_7::None::mechanism/NN by/IN which/WDT pRb/NN induces/VBZ senescence/NN ,/, we/PRP have/VBP found/VBN that/IN pRb/NN causes/VBZ a/DT posttranscriptional/JJ accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN )/) that/WDT is/VBZ accompanied/VBN by/IN an/DT increase/NN in/IN p27/NN (/( KIP1/NN )/) specifically/RB bound/VBD to/TO cyclin/NN E/NN and/CC a/DT concomitant/JJ decrease/NN in/IN cyclin/NN E-associated/JJ kinase/NN activity/NN ./. 
583_583_4_5_12_13::None::we/PRP report/VBP that/IN p120/NN associates/NNS with/IN a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, 
1037_1037_21_22_4_5::None::disclosed/VBN interactions/NNS between/IN gephyrin/NN ,/, exchange/NN factors/NNS for/IN G/NN proteins/NNS of/IN the/DT Rho/NN and/CC Rac/NN families/NNS ,/, the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ 
75337_1_18_19_19_21::None::small/JJ HER2/NN -/: positive/JJ breast/NN cancer/NN in/IN routine/JJ clinical/JJ 
2222_2222_15_16_23_24::POS_ACTION_COLOCALIZE::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
1240_1240_7_8_18_19::None::coding/VBG region/NN for/IN RAD51/NN protein/NN share/NN homology/NN with/IN the/DT damage/NN response/NN sequence/NN element/NN of/IN RAD54/NN ,/, an/DT upstream/JJ 
28_28_3_4_11_13::None::Actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) and/CC cofilin/NN define/VBP a/DT family/NN of/IN actin-binding/JJ proteins/NNS essential/JJ for/IN the/DT 
1061_1061_15_16_2_3::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ to/TO Fas/APO1/NN but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, 
467695_7_29_30_25_26::None::hexane/NN )/) afforded/VBD monomeric/JJ heteroleptic/JJ hydride/NN (/( HMDS/NN )/) ZnH/NN !/. 
1169_1169_13_16_26_27::POS_ACTION_SIMILAR::actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ homolog/NN expressed/VBN in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD 
411_411_13_14_17_18::POS_ACTION_BIND::signaling/VBG molecules/NNS including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP 
1321_1321_23_24_0_4::None::Testicular/JJ protein/NN kinase/NN 1/CD (/( TESK1/NN )/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN testicular/JJ germ/NN cells/NNS and/CC has/VBZ the/DT potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN 
2222_2222_23_24_15_16::None::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
311810_6_5_6_7_8::None::phosphodiesterase/NN inhibitors/NNS that/WDT raise/VBP cAMP/NN levels/NNS in/IN P/NN falciparum/NN 
1782_1782_7_8_11_12::None::receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS 
1786_1786_20_21_23_25::POS_ACTION_FNSIMILAR::exhibits/VBZ higher/JJR actin-activated/JJ ATPase/NN than/IN does/VBZ beta/NN myosin/NN ,/, and/CC hearts/NNS 
102233_0_24_25_28_29::None::neuropathic/JJ pain/NN ,/, sensory/JJ abnormalities/NNS and/CC neurovascular/JJ findings/NNS ./. 
608_608_18_19_20_21::None::products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
631121_4_0_1_10_11::None::It/PRP has/VBZ been/VBN quite/RB clearly/RB established/VBN that/IN the/DT majority/NN of/IN borderline/JJ ovarian/JJ tumours/NNS should/MD 
596699_0_16_18_2_3::medicine.disease.risk_factors::Diabetes/NNP and/CC hypertension/NN are/VBP chronic/JJ conditions/NNS that/WDT are/VBP growing/VBG in/IN prevalence/NN as/IN major/JJ causal/JJ factors/NNS of/IN cardiovascular/JJ disease/NN (/( CVD/NN )/) 
1534_1534_16_17_26_29::POS_ACTION_Change::and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( 
333090_0_3_4_8_9::None::Prevalence/NN estimates/NNS for/IN depression/NN and/CC anxiety/NN in/IN individuals/NNS post/NN -/: stroke/NN are/VBP 
1834_1834_15_17_23_24::None::,/, namely/RB with/IN DNase/NN I/CD ,/, gelsolin/NN segment/NN 1/CD ,/, and/CC profilin/NN ./. 
309_309_9_10_6_8::None::action/NN of/IN porcine/NN brain/NN profilin/NN on/IN actin/NN polymerization/NN ./. 
2131_2131_9_10_23_24::POS_ACTION_LOCALIZE::,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
703552_5_23_24_8_12::None::Western/NN blot/NN and/CC confocal/JJ laser/NN scanning/NN microscopy/NN analysis/NN the/DT effect/NN of/IN hyperglycemia/NN on/IN expression/NN of/IN IL/NN -/: 1/CD family/NN members/NNS in/IN retinal/JJ 
459829_1_0_1_16_17::medicine.drug.active_moieties::MgO/NN was/VBD coated/JJ onto/IN the/DT surface/NN of/IN mesoporous/JJ TiO/NN (/( 2/CD )/) by/IN the/DT decomposition/NN of/IN magnesium/NN acetate/NN and/CC ,/, 
397033_2_7_9_40_41::None::carrion/NN crows/NNS ,/, Corvus/NN corone/NN ,/, common/JJ ravens/NNS ,/, Corvus/NNP corax/NN ,/, Goffin/NNP cockatoos/NNS ,/, Cacatua/NN goffiniana/NN )/) performed/VBD comparably/RB to/TO primates/NNS in/IN an/DT exchange/NN task/NN ,/, contradicting/VBG previous/JJ notions/NNS that/WDT birds/NNS may/MD lack/VB any/DT impulse/NN control/NN ./. 
95871_5_26_27_8_9::None::was/VBD assessed/VBN for/IN norepinephrine/NN (/( NE/NN )/) levels/NNS ,/, blood/NN for/IN EPO/NN and/CC hemoglobin/NN (/( Hgb/NN )/) ,/, and/CC BM/NN for/IN erythroid/JJ progenitor/NN growth/NN ./. 
339_339_10_11_13_14::POS_ACTION_RELATE::modulation/NN of/IN the/DT actin/NN cytoskeleton/NN by/IN cofilin/NN and/CC Aip1/NN ./. 
91441_7_25_27_9_10::None::risk/NN for/IN cardiovascular/JJ events/NNS and/CC mortality/NN compared/VBN with/IN long/JJ -/: term/NN residents/NNS ,/, an/DT effect/NN that/WDT persists/VBZ more/JJR than/IN 10/CD years/NNS after/IN arrival/NN ./. 
619_619_21_22_26_29::POS_ACTION_ACTIVATE::of/IN Ras/NN with/IN Myc/NN allows/VBZ the/DT generation/NN of/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN and/CC the/DT 
896731_2_8_10_1_2::None::An/DT acute/JJ MI/NNP model/NN was/VBD induced/VBN in/IN male/JJ Wistar/NNP rats/NNS by/IN subcutaneous/JJ injection/NN 
292034_0_13_14_17_18::None::Differential/JJ Diagnosis/NN from/IN Metastatic/JJ Ureter/NN Cancer/NN ;/: Report/NNP of/IN a/DT Case/NN 
702304_0_16_19_7_9::None::risk/NN for/IN atherosclerotic/JJ cardiovascular/JJ disease/NN (/( ASCVD/NN )/) and/CC are/VBP considered/VBN a/DT coronary/JJ heart/NN disease/NN risk/NN equivalent/NN ./. 
2222_2222_17_18_19_20::None::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC 
471043_1_14_15_12_13::None::radical/JJ cystectomy/NN to/TO lyse/VB cancer/NN cells/NNS that/WDT might/MD have/VB 
1713_1713_10_11_12_13::POS_ACTION_BIND::relevant/JJ ligands/NNS of/IN profilin/NN ,/, actin/NN and/CC proline-rich/JJ peptides/NNS 
95605_9_11_12_24_25::None::correlated/VBN with/IN a/DT higher/JJR risk/NN of/IN adverse/JJ effects/NNS induced/VBN by/IN head/NN and/CC neck/NN area/NN irradiation/NN (/( OR/NN =/JJ 2.41/CD ,/, 
2146_2146_6_7_4_5::None::report/VBP here/RB that/IN LIMK1/NN and/CC LIMK2/NN phosphorylate/VBP both/DT cofilin/NN 
30174_0_24_25_17_19::medicine.symptom.symptom_of::Period/NN in/IN Elderly/NNP Lung/NN Cancer/NN Patients/NNS on/IN Community/NN -/: Acquired/VBN Pneumonia/NNP Hospitalization/NNP :/: A/NNP 
440638_0_13_14_1_2::None::Systematic/JJ review/NN with/IN network/NN meta/NN -/: analysis/NN :/: comparative/JJ efficacy/NN and/CC safety/NN of/IN budesonide/NN and/CC mesalazine/NN (/( 
138079_4_25_26_27_28::None::9/CD %/NN against/IN isoniazid/NN ,/, rifampin/NN ,/, ethambutol/NN ,/, 
596639_0_15_17_0_1::None::Competition/NN for/IN pollinators/NNS occurs/VBZ when/WRB ,/, in/IN a/DT community/NN of/IN flowering/NN plants/NNS ,/, several/JJ simultaneously/RB flowering/VBG plant/NN species/NNS depend/VBP on/IN 
1069_1069_42_45_36_37::POS_ACTION_ATTACH::origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
1508_1508_10_11_5_6::None::simplex/NN virus/NN type-1/NN UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN genes/NNS encode/VBP an/DT 
669_669_11_12_21_22::POS_ACTION_LOCALIZE-TO::the/DT presence/NN of/IN paxillin/NN ,/, talin/NN ,/, and/CC vinculin/NN at/IN the/DT ends/NNS of/IN actin/NN stress/NN fibers/NNS at/IN 
204981_8_11_12_15_16::None::of/IN pharmacological/JJ TLR4/NN blockade/NN ,/, providing/VBG converging/VBG lines/NNS of/IN evidence/NN of/IN 
770512_2_6_7_21_22::medicine.symptom.symptom_of::woman/NN presented/VBD high/JJ fever/NN ,/, myalgia/NN ,/, muscular/JJ weakness/NN ,/, mild/JJ headache/NN ,/, polyarthralgia/NN and/CC thrombocytopenia/NN reminding/VBG a/DT lupus/NN flare/NN ,/, but/CC 
748_748_10_11_20_21::None::binding/NN proposed/VBN for/IN fimbrin/NN ,/, the/DT utrophin/NN actin-binding/JJ domain/NN appears/VBZ to/TO associate/VB with/IN actin/NN in/IN an/DT extended/JJ 
76585_4_1_2_13_14::None::Exclusion/NN criteria/NNS were/VBD :/: tobacco/NN consumption/NN ,/, hypercholesterolemia/NN ,/, diabetes/NN ,/, aspirin/NN or/CC statin/NN treatment/NN ./. 
1457_1457_56_57_28_30::None::(/( 1/LS )/) profilin/NN I/PRP functions/VBZ predominantly/RB as/IN an/DT actin/NN monomer-binding/JJ protein/NN ;/: (/( 2/LS )/) profilin/NN II/CD regulates/VBZ ,/, or/CC is/VBZ regulated/VBN by/IN ,/, PIP2/NN ;/: and/CC (/( 3/LS )/) actobindin/NN inhibits/VBZ nucleation/NN of/IN 
443637_7_0_1_20_21::medicine.drug_ingredient.active_moiety_of_drug::Sorafenib/NNP reduced/VBD MMP/NN activity/NN in/IN this/DT HGF/NN -/: induced/VBN tumorigenic/JJ model/NN of/IN HCC/NNP These/DT findings/NNS provide/VBP in/FW vitro/FW evidence/NN that/IN sorafenib/NN suppresses/VBZ HGF/NN -/: 
1037_1037_27_28_21_22::None::the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD integrate/VB activity-dependent/JJ 
294475_2_58_60_33_34::medicine.medical_treatment.used_to_treat::,/, or/CC a/DT high/JJ -/: fat/NN (/( HF/NN )/) diet/NN consisting/VBG of/IN the/DT regular/JJ diet/NN supplemented/VBN with/IN an/DT additional/JJ amount/NN of/IN 3.5/CD %/NN soybean/NN oil/NN and/CC 1/CD %/NN fish/NN oil/NN at/IN the/DT expense/NN 
1025_1025_27_28_14_19::None::of/IN the/DT conventional/JJ type/NN II/CD myosin/NN heavy/JJ chain/NN and/CC carries/VBZ putative/JJ binding/NN sites/NNS for/IN ATP/NN and/CC actin/NN ./. 
1399_1399_57_58_55_57::None::complex/NN with/IN the/DT nucleocapsid/JJ protein/NN N/NN in/FW vivo/FW ./. 
1521_1521_7_8_4_6::POS_ACTION_Change::interaction/NN between/IN calf/NN spleen/NN profilin/NN and/CC actin/NN depends/VBZ critically/RB on/IN 
449335_7_5_6_11_12::None::findings/NNS suggest/VBP possible/JJ alternative/JJ ways/NNS of/IN modulating/VBG the/DT cannabinoid/NN system/NN that/WDT could/MD have/VB 
1337_1337_7_8_12_13::None::talin/NN binds/VBZ to/TO integrins/NNS ,/, vinculin/NN ,/, and/CC actin/NN ./. 
753851_0_3_5_9_10::None::Differential/JJ impact/NN of/IN risk/NN factors/NNS for/IN tumor/NN recurrence/NN in/IN hepatitis/NN B/NN and/CC hepatitis/NN 
1061_1061_15_16_24_25::None::but/CC not/RB to/TO p55-R/NN ;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC 
358_358_20_21_25_26::POS_ACTION_CONTAIN::for/IN the/DT HSV/NN helicase-primase/JJ complex/NN (/( UL5/NN ,/, UL8/NN ,/, UL52/NN )/) 
1069_1069_24_25_29_30::None::helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT 
1534_1534_32_33_26_29::None::the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
881131_8_18_19_12_13::None::its/PRP$ interactions/NNS with/IN alcohol/NN drinking/NN and/CC //: or/CC smoking/NN highlights/VBZ the/DT significance/NN of/IN 
356904_0_17_18_0_1::medicine.symptom.symptom_of::Asthma/NN is/VBZ a/DT chronic/JJ inflammatory/JJ disorder/NN of/IN the/DT airway/NN characterized/VBN by/IN the/DT episodic/JJ symptoms/NNS of/IN breathlessness/NN ,/, wheezes/VBZ and/CC cough/NN ./. 
736878_5_0_1_15_16::None::The/DT most/RBS frequent/JJ causes/NNS of/IN vaginitis/NN were/VBD unspecific/JJ bacterial/JJ infections/NNS (/( 42.4/CD %/NN )/) and/CC vaginal/JJ candidiasis/NN (/( 44.8/CD 
2076_2076_42_43_8_9::None::cerevisiae/FW gene/NN (/( COF1/NN )/) encoding/VBG a/DT low-M/NN (/( r/NN )/) actin-binding/JJ protein/NN of/IN 143/CD amino/NN acid/NN (/( aa/NN )/) residues/NNS (/( yeast/NN cofilin/NN ;/: Cof/NN )/) ;/: its/PRP$ aa/NN sequence/NN is/VBZ 35/CD %/NN identical/JJ to/TO porcine/NN Cof/NN ./. 
1169_1169_10_11_17_18::None::to/TO regulate/VB the/DT actin/NN cytoskeleton/NN ,/, Wiskott-Aldrich/NNP Syndrome/NN Protein/NN (/( WASP/NNP )/) and/CC its/PRP$ 
905933_12_29_30_31_33::medicine.medical_treatment.used_to_treat::risk/NN in/IN combined/JJ radiotherapy/NN for/IN cervical/JJ cancer/NN under/IN pre/JJ -/: 
397285_3_8_9_15_16::None::anti/JJ -/: inflammatory/JJ cytokine/NN associated/VBN with/IN tumour/NN malignancy/NN ,/, causes/VBZ escape/NN from/IN immune/JJ surveillance/NN 
87_87_16_20_41_45::None::,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN alpha/NN v/LS beta/NN 5/CD shows/VBZ a/DT distinct/JJ 
687548_0_1_2_7_8::None::Diabetic/NNP polyneuropathy/NN (/( DPN/NN )/) is/VBZ a/DT devastating/JJ complication/NN of/IN diabetes/NN 
980_980_18_19_12_13::None::the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN beta-catenin/NN to/TO the/DT cytoplasm/NN 
1380_1380_40_41_38_39::None::,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN 
1052_1052_18_20_37_38::POS_ACTION_INITIATE::the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
2064_2064_40_41_28_29::NEG_ACTION_CORELATE::,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN 
1701_1701_43_46_48_49::POS_ACTION_MEMBER::which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
34_34_19_20_13_14::None::the/DT effect/NN of/IN profilin/NN on/IN the/DT thermal/JJ stability/NN of/IN actin/NN was/VBD studied/VBN ./. 
357978_8_6_7_14_15::None::found/VBN stronger/JJR for/IN mtDNA/NN than/IN nuclear/JJ DNA/NN Microsatellite/NN markers/NNS indicated/VBD low/JJ genetic/JJ variation/NN in/IN Sundarbans/NNP 
33757_12_28_29_5_6::medicine.symptom.symptom_of::a/DT sophisticated/JJ while/IN user/NN -/: friendly/JJ platform/NN using/VBG multi/NNS -/: parametric/JJ MRI/NNP combined/VBN with/IN supervised/JJ learning/VBG to/TO be/VB able/JJ to/TO accurately/RB detect/VB cancer/NN foci/NNS and/CC its/PRP$ aggressiveness/NN ./. 
254040_6_53_54_30_31::None::the/DT epileptologist/NN whosewhat/NN interpretation/NN of/IN the/DT reduced/VBN montage/NN EEG/NN to/TO the/DT results/NNS of/IN the/DT 23/CD -/: lead/JJ EEG/NN ,/, which/WDT was/VBD considered/VBN the/DT gold/JJ standard/NN for/IN detecting/VBG seizures/NNS ./. 
1498_1498_8_9_15_16::POS_ACTION_RELATE::thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD 
231123_0_20_21_0_1::medicine.drug.active_moieties::Nilotinib/NNP in/IN patients/NNS with/IN systemic/JJ mastocytosis/NN :/: analysis/NN of/IN the/DT phase/NN 2/CD ,/, open/JJ -/: label/NN ,/, single/JJ -/: arm/NN nilotinib/JJ registration/NN study/NN ./. 
510001_0_9_10_8_10::biology.organism_classification.lower_classifications::phylogenetically/RB diverse/JJ flowering/NN plant/NN lineages/NNS ./. 
25753_2_13_14_18_19::None::kidney/NN disease/NN (/( CKD/NN )/) ,/, which/WDT can/MD progress/VB to/TO end/VB -/: 
166_166_10_11_14_15::POS_ACTION_LOCALIZE::in/IN cofilin/NN and/CC ADF/NN but/CC not/RB in/IN actin/NN ,/, ADF/NN and/or/CC 
367649_3_23_24_13_15::None::,/, including/VBG lowering/VBG blood/NN glucose/NN ,/, regulating/VBG blood/NN lipids/NNS and/CC reducing/VBG inflammation/NN in/IN addition/NN to/TO its/PRP$ antioxidant/JJ 
1168_1168_16_18_26_27::None::recombinant/JJ Arabidopsis/NNP thaliana/NN fimbrin/NN 1/CD (/( AtFim1/NN )/) is/VBZ a/DT member/NN of/IN the/DT fimbrin/plastin/NN family/NN of/IN actin/NN 
1380_1380_43_44_24_25::None::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN (/( Machesky/NNP et/FW 
391631_1_9_10_8_9::None::a/DT double/JJ -/: antibody/NN sandwich/NN format/NN and/CC employs/VBZ 
848984_1_18_19_12_14::medicine.risk_factor.diseases::on/IN 66/CD known/JJ prostate/NN cancer/NN susceptibility/NN variants/NNS for/IN 17,012/CD men/NNS aged/JJ 50/CD -/: 
14_14_1_2_5_6::POS_ACTION_CROSS-LINK::Acanthamoeba/NN profilin/NN was/VBD cross-linked/VBN to/TO actin/NN via/IN a/DT zero-length/JJ 
784_784_12_13_8_9::NEG_ACTION_COLOCALIZE::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, 
3836_0_0_1_11_12::None::Management/NN of/IN Idiopathic/JJ Pulmonary/JJ Fibrosis/NN in/IN the/DT Elderly/NNP Patient/NN :/: Addressing/VBG Key/NN Questions/NNS ./. 
1380_1380_36_37_24_25::None::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, 
2107_2107_24_26_15_16::None::targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, 
162581_4_12_13_7_8::people.cause_of_death.includes_causes_of_death::,/, gastric/JJ ,/, pancreatic/JJ ,/, liver/NN and/CC colorectal/JJ cancers/NNS ./. 
1580_1580_28_29_18_19::None::protein/NN complex/NN containing/VBG E-cadherin/NN and/CC its/PRP$ cytoplasmic/JJ cofactors/NNS alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
590437_1_14_15_25_26::None::(/( trifluoromethyl/NN )/) phenoxy/NN ]/) benzenepropanamine/NN hydrochloride/NN ;/: FLX/NNP )/) are/VBP frequently/RB used/VBN to/TO treat/VB depression/NN in/IN PD/NN 
245_245_2_3_0_1::None::Neuropilin-1/NN (/( NRP1/NN )/) is/VBZ a/DT 
1793_1793_4_5_16_17::None::viscoelasticity/NN of/IN entangled/JJ actin/NN networks/NNS :/: the/DT influence/NN of/IN defects/NNS and/CC modulation/NN by/IN talin/NN and/CC vinculin/NN ./. 
695_695_15_17_9_10::None::concentrations/NNS of/IN Acanthamoeba/NN profilin/NN inhibit/VBP the/DT elongation/NN rate/NN of/IN muscle/NN actin/NN filaments/NNS measured/VBN directly/RB 
513_513_17_19_5_6::None::spliceosomal/JJ proteins/NNS (/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO promote/VB U2/NN snRNP/NN binding/NN to/TO pre-mRNA/NN 
3836_0_2_5_12_13::None::Management/NN of/IN Idiopathic/JJ Pulmonary/JJ Fibrosis/NN in/IN the/DT Elderly/NNP Patient/NN :/: Addressing/VBG Key/NN Questions/NNS ./. 
241510_0_0_1_28_29::None::In/IN patients/NNS with/IN ischemic/JJ cardiomyopathy/NN the/DT size/NN of/IN bipolar/JJ low/JJ voltage/NN areas/NNS (/( LVA/NN )/) in/IN electroanatomical/JJ maps/NNS (/( EAM/NN )/) was/VBD associated/VBN with/IN poorer/JJR outcomes/NNS after/IN catheter/NN ablation/NN (/( CA/NNP )/) 
699_699_24_25_19_22::None::inactivation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN (/( INK4A/NN )/) and/or/CC up-regulation/NN 
567_567_15_16_18_19::None::through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
503817_10_12_13_2_3::None::Differential/JJ hepatocyte/NN transfusion/NN rates/NNS contributed/VBD to/TO accelerated/VBN early/JJ engraftment/NN and/CC repopulation/NN in/IN rats/NNS with/IN acute/JJ liver/NN 
430047_9_26_28_24_25::medicine.disease.risk_factors::to/TO reduction/NN of/IN smoking/NN ,/, blood/NN pressure/NN and/CC weight/NN ,/, 
556761_3_32_33_21_22::medicine.disease.treatments::the/DT use/NN of/IN antibiotics/NNS while/IN the/DT catheter/NN was/VBD in/FW situ/FW ,/, whether/IN a/DT closed/JJ urinary/JJ collection/NN system/NN was/VBD 
1878_1878_5_6_17_18::POS_ACTION_Change::poly-L-proline/NN binding/NN ,/, actin/NN binding/NN ,/, and/CC actin/NN nucleotide/NN exchange/NN are/VBP each/DT independent/JJ requirements/NNS for/IN profilin/NN function/NN in/IN fission/NN 
1075_1075_20_21_22_23::None::targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
88_88_30_31_30_31::POS_ACTION_RELATE::the/DT high/JJ unpolymerized/JJ actin/NN content/NN in/IN unstimulated/JJ 
675416_11_28_30_21_22::None::care/NN decisions/NNS ,/, cardiac/JJ troponin/NN for/IN acute/JJ myocardial/JJ infarction/NN ,/, natriuretic/JJ peptides/NNS for/IN acute/JJ heart/NN 
1344_1344_6_7_17_18::None::these/DT three/CD mutant/JJ UL5/NN proteins/NNS to/TO form/VB specific/JJ interactions/NNS with/IN other/JJ members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN 
408257_14_16_17_6_7::None::is/VBZ questionable/JJ whether/IN senescence/NN of/IN MM/NN -/: BMMSCs/NNS plays/VBZ a/DT pathological/JJ role/NN in/IN active/JJ multiple/JJ myeloma/NN or/CC 
278671_5_9_10_17_18::None::the/DT relationship/NN between/IN cytokine/NN levels/NNS and/CC psoriasis/NN in/IN the/DT context/NN of/IN obesity/NN ./. 
1782_1782_25_26_11_12::None::)/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: 
1344_1344_22_23_6_7::None::these/DT three/CD mutant/JJ UL5/NN proteins/NNS to/TO form/VB specific/JJ interactions/NNS with/IN other/JJ members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, indicates/VBZ that/IN 
230298_6_5_6_7_8::None::include/VBP cognitive/JJ behavioral/JJ therapy/NN ,/, mindfulness/NN -/: based/VBN cognitive/JJ 
580543_2_0_1_15_16::None::Young/NNP maternal/JJ age/NN is/VBZ associated/VBN with/IN an/DT increased/VBN risk/NN of/IN maternal/JJ anemia/NN ,/, infections/NNS ,/, eclampsia/NN and/CC preeclampsia/NN ,/, 
1434_1434_14_15_72_73::None::H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN 
157_157_24_25_8_9::None::to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN 
1087_1087_23_24_23_24::POS_ACTION_ASSEMBLE::flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN 
1652_1652_31_32_20_21::None::with/IN LEF-1/NN and/CC vinculin/NN ;/: (/( b/LS )/) LEF-1-dependent/JJ transactivation/NN is/VBZ preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( 
405531_0_2_3_3_4::None::Tamiflu/NNP (/( oseltamivir/JJ phosphate/NN ester/NN ,/, OE/NN 
1082_1082_38_39_31_34::None::a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ./. 
1771_1771_15_16_19_20::POS_ACTION_BIND::I/CD myosin/NN ,/, Myo5p/NN ,/, binds/VBZ to/TO verprolin/VB and/CC is/VBZ required/VBN 
400251_26_17_18_9_10::None::90/CD %/NN of/IN patients/NNS given/VBN E/NN //: C/NN //: F/NN //: tenofovir/NN alafenamide/NN or/CC E/NN 
131_131_5_6_7_8::None::was/VBD seen/VBN between/IN E-cadherin/NN and/CC alpha-catenin/NN expression/NN ,/, in/IN 
1957_1957_10_11_38_39::None::with/IN association/NN of/IN beta-catenin/NN with/IN EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ cells/NNS at/IN confluence/NN were/VBD dissociated/VBN into/IN single/JJ cells/NNS by/IN tryptic/JJ digestion/NN ,/, being/VBG accompanied/VBN by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
670852_3_3_5_5_6::None::86/CD newly/RB diagnosed/VBN breast/NN cancer/NN patients/NNS with/IN estrogen/NN receptor/NN 
226276_6_24_25_45_46::None::pre/JJ -/: delusional/JJ symptoms/NNS that/WDT acutely/RB worsen/VBP in/IN the/DT ramp/NN -/: up/IN to/TO full/JJ -/: blown/VBN psychosis/NN ,/, and/CC as/IN such/JJ may/MD reflect/VB pathophysiological/JJ processes/NNS driving/VBG emergence/NN of/IN 
445671_0_31_32_4_5::None::muscular/JJ dystrophy/NN (/( DMD/NN )/) ,/, the/DT most/RBS common/JJ form/NN of/IN muscular/JJ dystrophy/NN ,/, is/VBZ characterized/VBN by/IN muscular/JJ wasting/NN caused/VBN by/IN dystrophin/NN deficiency/NN that/WDT ultimately/RB ends/VBZ in/IN force/NN reduction/NN and/CC premature/JJ death/NN ./. 
728764_2_2_3_12_13::None::Causes/NNS of/IN chronic/JJ kidney/NN disease/NN included/VBD diabetes/NN mellitus/NN (/( n/NN =/JJ 9/CD patients/NNS )/) ,/, hypertensive/JJ 
856_856_40_41_37_38::None::PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
553693_0_9_11_10_11::None::is/VBZ characterized/VBN by/IN abdominal/JJ pain/NN and/CC changed/VBD bowel/NN 
474123_0_12_13_4_5::None::cancer/NN is/VBZ the/DT sixth/JJ leading/VBG cause/NN of/IN cancer/NN -/: related/JJ death/NN worldwide/RB ./. 
906557_3_34_35_31_32::None::stress/NN ,/, cell/NN ageing/NN and/CC a/DT large/JJ range/NN of/IN pathologies/NNS 
119767_6_19_20_23_24::None::)/) by/IN siRNA/NN technology/NN completely/RB abolished/VBD the/DT angiogenic/JJ ability/NN of/IN PB/NN 
295269_3_11_12_20_21::None::mutation/NN ,/, of/IN mtDNA/NN plays/VBZ a/DT major/JJ role/NN across/IN a/DT range/NN of/IN prevalent/JJ human/JJ diseases/NNS ,/, 
631669_5_14_15_10_12::None::in/IN patients/NNS with/IN varicose/NN veins/NNS of/IN pelvic/JJ origin/NN ./. 
329598_0_5_6_2_3::None::Doxorubicin/NN -/: induced/VBN cardiomyopathy/NN (/( DOX/NN -/: CM/NN )/) 
1167_1167_12_13_3_4::None::Recent/JJ evidence/NN that/IN profilin/NN inhibits/VBZ phospholipase/NN C/NN and/CC enhances/VBZ nucleotide/NN exchange/NN of/IN actin/NN has/VBZ led/VBN some/DT 
556_556_10_11_24_25::NEG_ACTION_INTERACT::nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ protein/NN based/VBN on/IN the/DT lack/NN of/IN reactivity/NN of/IN antigravin/NN with/IN these/DT polypeptides/NNS 
1052_1052_27_28_21_22::None::oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) 
604313_0_6_7_17_19::None::are/VBP a/DT heterogeneous/JJ class/NN of/IN agents/NNS that/WDT are/VBP used/VBN in/IN the/DT treatment/NN of/IN many/JJ cardiovascular/JJ diseases/NNS ,/, especially/RB hypertension/NN 
1870_1870_16_17_8_9::None::that/IN the/DT both/DT cofilin/NN isoforms/NNS are/VBP involved/VBN in/IN the/DT regulation/NN of/IN actin/NN assembly/NN during/IN myofibrillogenesis/NN 
1334_1334_27_28_30_31::None::fluid-phase/JJ endocytosis/NN of/IN pfy1-4/NN ,/, a/DT profilin/NN mutant/NN defective/JJ in/IN 
122457_3_44_45_19_20::medicine.symptom.symptom_of::and/CC progression/NN of/IN T2DM/NN ,/, little/JJ is/VBZ known/VBN about/IN whether/IN or/CC not/RB the/DT variants/NNS are/VBP involved/VBN in/IN disease/NN progression/NN and/CC how/WRB these/DT genetic/JJ variants/NNS are/VBP associated/VBN with/IN diabetic/JJ neuropathy/NN specifically/RB ./. 
314_314_15_18_12_13::POS_ACTION_LOCALIZE::sequestered/VBD more/JJR monomeric/JJ actin/NN than/IN did/VBD class/NN I/CD profilins/NNS ./. 
745266_0_0_1_10_11::None::Metformin/NNP is/VBZ the/DT first/JJ line/NN drug/NN for/IN patients/NNS diagnosed/VBN with/IN type/NN -/: 2/CD diabetes/NN 
1142_1142_27_28_0_2::None::Profilin/NN I/NN and/CC profilin/NN II/CD have/VBP similar/JJ affinities/NNS for/IN PtdIns/NN (/( 4,5/CD )/) P2/NN and/CC poly/NN (/( L-proline/NN )/) ,/, and/CC both/DT accelerate/VBP nucleotide/NN exchange/NN on/IN monomeric/JJ actin/NN to/TO the/DT same/JJ 
328070_0_8_9_1_2::None::Copper/NN complexes/NNS have/VBP been/VBN frequently/RB involved/VBN in/IN many/JJ Cu/NN -/: mediated/JJ carbon/NN 
402511_2_15_16_14_15::biology.organism_classification.lower_classifications::employed/VBN to/TO identify/VB malaria/NN parasite/NN -/: specific/JJ metabolites/NNS 
76365_0_30_32_5_6::medicine.disease.symptoms::anxiety/NN disorders/NNS is/VBZ high/JJ in/IN the/DT elderly/JJ (/( between/IN 3.2/CD and/CC 14.2/CD %/NN of/IN the/DT subjects/NNS )/) with/IN ,/, by/IN order/NN of/IN frequency/NN ,/, phobic/JJ disorders/NNS and/CC generalized/VBN anxiety/NN disorder/NN rank/NN ahead/RB of/IN 
1850_1850_23_24_2_3::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN and/CC serves/VBZ to/TO link/VB the/DT cadherin/catenin/NN complex/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
685990_8_19_20_29_31::None::of/IN having/VBG OSA/NN compared/VBN with/IN only/RB 19/CD (/( 24.1/CD %/NN )/) in/IN the/DT control/NN group/NN (/( OR/NN 2.9/CD 
331666_4_3_4_37_38::None::Age/NN -/: adjusted/VBN mortality/NN was/VBD significantly/RB higher/JJR among/IN patients/NNS with/IN :/: liver/NN (/( RR/NN ,/, 29.6/CD [/( 95/CD %/NN CI/NN ,/, 29.1/CD -/: 30.1/CD ]/) )/) ,/, oral/JJ (/( 5.2/CD [/( 5.1/CD -/: 5.4/CD ]/) )/) ,/, rectum/NN (/( 2.6/CD [/( 
1337_1337_12_13_12_13::None::vinculin/NN ,/, and/CC actin/NN ./. 
1782_1782_25_26_23_24::None::RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: 
186521_6_21_22_16_17::None::are/VBP recognized/VBN as/RB high/JJ -/: risk/NN indicators/NNS of/IN pump/NN failure/NN death/NN ,/, 
960_960_17_18_5_6::None::the/DT previously/RB identified/VBN VRP1/NN ,/, which/WDT encodes/VBZ verprolin/NN ,/, required/VBN for/IN proper/JJ organization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
93_93_4_5_11_12::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD 
1546_1546_26_27_12_13::None::kinase/NN inhibitor/NN (/( CDKI/NN )/) ,/, arises/VBZ from/IN its/PRP$ binding/NN with/IN the/DT cyclin/NN E/cyclin-dependent/JJ kinase/NN 2/CD (/( Cdk2/NN )/) complex/NN that/WDT 
444311_5_18_19_9_10::None::)/) in/IN HepG2/NN cells/NNS increased/VBD uptake/NN and/CC storage/NN of/IN ferric/JJ iron/NN (/( Fe/NNP (/( 3/CD +/CC 
1096_1096_14_15_9_10::POS_ACTION_BIND::pool/NN of/IN polymerizable/JJ actin/NN monomers/NNS is/VBZ complexed/VBN with/IN profilin/NN and/CC spread/NN throughout/IN 
272493_8_24_25_39_40::medicine.disease.symptoms::as/IN follows/VBZ :/: depressive/JJ (/( 9/CD )/) ,/, catatonic/JJ (/( 9/CD )/) ,/, disorganized/JJ (/( 8/CD )/) ,/, anxious/JJ (/( 8/CD )/) 
576_576_22_23_13_15::None::,/, a/DT ubiquitous/JJ actin-binding/JJ protein/NN that/WDT is/VBZ essential/JJ for/IN effective/JJ depolymerization/NN of/IN actin/NN filaments/NNS ./. 
739076_0_9_12_13_14::medicine.disease.symptoms::treatment/NN for/IN childhood/NN obstructive/JJ sleep/NN apnea/NN (/( OSA/NN )/) is/VBZ gaining/VBG 
428759_1_1_2_9_10::medicine.disease.treatments::For/IN cervical/JJ cancer/NN ,/, several/JJ therapeutic/JJ agents/NNS showed/VBD viable/JJ antitumor/NN clinical/JJ response/NN in/IN 
1380_1380_34_35_43_44::None::novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN (/( Machesky/NNP et/FW 
1854_1854_8_9_14_15::None::fluorescent/JJ analog/NN of/IN actin/NN with/IN a/DT high/JJ affinity/NN for/IN profilin/NN revealed/VBD that/IN it/PRP 
113339_0_20_21_7_8::None::infection/NN by/IN 18S/NNP rRNA/NN gene/NN nested/JJ PCR/NN Whole/JJ blood/NN and/CC filter/NN paper/NN blood/NN samples/NNS of/IN malaria/NN patients/NNS in/IN Shandong/NNP Province/NNP 
117451_0_39_40_11_12::medicine.disease.risk_factors::iron/NN following/VBG prolonged/JJ high/JJ dose/NN of/IN oral/JJ supplementation/NN for/IN treatment/NN of/IN iron/NN deficiency/NN anemia/NN (/( IDA/NN )/) leads/VBZ to/TO body/NN iron/NN overload/NN and/CC oxidative/JJ stress/NN ,/, which/WDT starts/VBZ the/DT process/NN of/IN atherosclerosis/NN ./. 
638398_10_11_12_2_3::None::In/IN the/DT murine/JJ tumor/NN model/NN ,/, PA/NN -/: MSHA/NNP prolonged/VBD mice/NNS survival/NN and/CC reduced/VBN tumor/NN 
491771_3_34_35_46_47::None::Fe3O4/NN NPs/NNS @/IN SiO2/NN and/CC AuNC/NN structure/NN were/VBD broken/VBN in/IN favor/NN of/IN the/DT gold/NN -/: thiol/NN bonds/NNS ./. 
78_78_17_18_20_21::None::1:1/CD complex/NN between/IN profilin/NN and/CC monomeric/JJ actin/NN with/IN a/DT Kr/NN 
996_996_27_28_12_13::None::can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) 
124453_5_20_21_14_15::None::pretreatment/NN improved/VBD Cu/NN tolerance/NN in/IN rice/NN plants/NNS by/IN inhibiting/VBG Cu/NN uptake/NN and/CC regulating/VBG 
1373_1373_1_2_16_17::NEG_ACTION_RELATE::The/DT APC/NN protein/NN and/CC E-cadherin/NN form/NN similar/JJ but/CC independent/JJ complexes/NNS with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
685_685_14_15_6_7::None::labeled/VBN proteins/NNS with/IN HECD-1/NN revealed/VBD three/CD bands/NNS corresponding/VBG to/TO E-cadherin/NN ,/, alpha-catenin/NN ,/, and/CC gamma-catenin/NN 
1782_1782_20_22_11_12::None::)/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, 
372_372_9_10_28_29::POS_ACTION_INTERACT::virus/NN type/NN 1/CD UL8/NN protein/NN :/: effect/NN on/IN DNA/NN synthesis/NN and/CC ability/NN to/TO interact/VB with/IN and/CC influence/VB the/DT intracellular/JJ localization/NN of/IN the/DT UL5/NN and/CC UL52/NN proteins/NNS 
8_8_13_14_26_27::None::1/CD integrins/NNS ,/, pp125/CD focal/JJ adhesion/NN kinase/NN ,/, and/CC alpha-catenin/NN is/VBZ not/RB affected/VBN by/IN the/DT differential/JJ calreticulin/NN expression/NN ./. 
2052_2052_17_18_20_21::None::depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ,/, in/IN the/DT 
659_659_26_27_14_15::None::a/DT subpopulation/NN of/IN alpha-catenin/NN joined/VBD the/DT complex/NN at/IN a/DT time/NN coincident/JJ with/IN the/DT arrival/NN of/IN E-cadherin/NN at/IN the/DT plasma/NN 
109645_7_11_12_31_32::None::the/DT non/JJ -/: BRCA/NN families/NNS with/IN a/DT 6.36/CD %/NN proportion/NN (/( CI/NN 4.67/CD -/: 8.2/CD )/) compared/VBN to/TO the/DT proportion/NN in/IN the/DT general/JJ population/NN in/IN the/DT reference/NN 
2222_2222_39_40_17_18::NEG_ACTION_COLOCALIZE::,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, did/VBD not/RB 
1442_1442_4_5_23_24::None::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN can/MD not/RB directly/RB associate/JJ with/IN alpha-catenin/NN but/CC interacts/VBZ with/IN high/JJ affinity/NN with/IN beta-catenin/NN ,/, whereas/IN the/DT binding/NN of/IN gamma-catenin/NN (/( plakoglobin/NN )/) 
470116_0_4_5_1_2::None::A/DT Mixed/JJ Phenotype/NN of/IN Airway/NNP Wall/NNP Thickening/NNP and/CC 
699_699_22_23_24_25::None::cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN (/( INK4A/NN )/) and/or/CC up-regulation/NN 
1889_1889_11_13_7_8::None::proteins/NNS TRADD/NN and/CC FADD/NN signal/NN activation/NN of/IN acid/NN sphingomyelinase/NN ./. 
208311_13_10_11_9_10::people.cause_of_death.includes_causes_of_death::overestimates/VBZ oSCr/NN of/IN severe/JJ trauma/NN patients/NNS ./. 
2148_2148_52_53_44_45::None::the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ 
502173_7_12_13_14_15::None::do/VBP not/RB support/VB associations/NNS of/IN caffeine/NN or/CC caffeinated/JJ beverages/NNS 
256031_1_18_19_59_60::None::the/DT ADDITION/NNP -/: Europe/NNP study/NN to/TO estimate/VB the/DT absolute/JJ risk/NN of/IN cardiovascular/JJ outcomes/NNS and/CC the/DT relative/JJ risk/NN reduction/NN associated/VBN with/IN screening/NN and/CC intensive/JJ treatment/NN ,/, screening/NN and/CC routine/JJ treatment/NN ,/, and/CC no/DT screening/NN with/IN a/DT 3/LS -/: or/CC 6/CD -/: year/NN delay/NN in/IN the/DT diagnosis/NN and/CC routine/JJ treatment/NN 
631121_4_10_11_8_9::None::established/VBN that/IN the/DT majority/NN of/IN borderline/JJ ovarian/JJ tumours/NNS should/MD 
95_95_5_6_9_10::POS_REG(0)_ASSEMBLE::contain/VBP only/RB 1/CD profilin/NN for/IN every/DT 5-10/CD actin/NN molecules/NNS ,/, these/DT 
1052_1052_12_13_29_30::POS_ACTION_INTERACT::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
2107_2107_15_16_27_28::None::targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
996_996_12_13_27_28::None::can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) 
174_174_8_9_6_7::POS_ACTION_COLOCALIZE::immunofluorescence/NN experiments/NNS ,/, Abp1p/NN ,/, cofilin/NN ,/, and/CC actin/NN 
221936_3_2_5_30_31::None::Measurements/NNS on/IN systolic/JJ blood/NN pressure/NN ,/, HOMA/NNP index/NN ,/, triglycerides/NNS ,/, TC/NN //: HDL/SYM -/: c/NN ,/, VO2max/NN and/CC the/DT sum/NN of/IN four/CD skinfolds/NNS were/VBD obtained/VBN ,/, and/CC a/DT clustered/VBN cardiovascular/JJ disease/NN (/( CVD/NN 
236038_0_9_10_4_5::None::is/VBZ the/DT major/JJ surface/NN hyaluronan/NN (/( HA/NN )/) receptor/NN implicated/VBN in/IN intercellular/JJ 
288_288_13_14_10_12::None::observing/VBG proteolysis/NN of/IN actin-binding/JJ protein/NN and/CC talin/NN ,/, two/CD known/JJ 
179564_0_11_13_6_7::None::nullifies/VBZ feedback/NN -/: mediated/VBN resistance/NN to/TO erlotinib/NN in/IN lung/NN cancer/NN ./. 
479157_1_20_21_41_42::None::cytoplasmic/JJ membrane/NN ,/, peptidoglycan/NN layer/NN and/CC outer/JJ membrane/NN ,/, whereas/IN its/PRP$ 16S/NN rRNA/NN -/: based/VBN taxonomy/NN shows/VBZ that/IN the/DT bacteria/NNS belongs/VBZ to/TO Gram/NN -/: positive/JJ Firmicutes/NNS ./. 
1095_1095_22_23_35_36::None::,/, talin/NN ,/, vinculin/NN ,/, and/CC phosphotyrosine-containing/JJ proteins/NNS are/VBP dependent/JJ on/IN the/DT supramolecular/JJ organization/NN of/IN the/DT collagens/NNS ./. 
655566_1_0_1_42_43::None::There/EX have/VBP been/VBN great/JJ changes/NNS in/IN the/DT clinical/JJ manifestation/NN of/IN severe/JJ falciparum/NN malaria/NN over/IN the/DT past/JJ couple/NN of/IN decades/NNS ,/, with/IN a/DT shift/NN from/IN cerebral/JJ malaria/NN to/TO fever/NN with/IN jaundice/NN ,/, renal/JJ failure/NN ,/, bleeding/VBG diathesis/NN ,/, and/CC multi/NNS -/: organ/NN dysfunction/NN syndrome/NN ./. 
750_750_3_5_21_22::None::Increased/VBN interaction/NN of/IN beta1D/NN integrin/NN with/IN the/DT actin/NN cytoskeleton/NN is/VBZ consistent/JJ with/IN and/CC might/MD be/VB mediated/VBN by/IN its/PRP$ enhanced/VBN binding/NN to/TO talin/NN ./. 
125415_10_6_7_12_13::None::hyperglycemia/NN coexisted/VBD with/IN hyperinsulinemia/NN (/( in/IN general/JJ on/IN the/DT HP/NNP diet/NN ;/: postprandially/RB 
583303_11_18_19_11_12::None::are/VBP the/DT most/RBS common/JJ microorganisms/NNS in/IN children/NNS with/IN untreated/JJ uncomplicated/JJ acute/JJ tympanostomy/NN -/: tube/NN 
97678_0_10_11_0_1::medicine.risk_factor.diseases::Parkinson/NNP whosewhat/NN Disease/NN and/CC Home/NN Healthcare/NNP Use/NNP and/CC Expenditures/NNS among/IN Elderly/NNP Medicare/NNP Beneficiaries/NNS ./. 
520523_1_17_18_7_8::None::host/NN preference/NN and/CC reproductive/JJ potential/NN of/IN S/NN amygdali/NNS on/IN four/CD tree/NN species/NNS :/: almond/NN (/( Prunus/FW dulcis/FW 
957_957_23_24_8_11::None::mutation/NN in/IN the/DT myosin/NN heavy/JJ chain/NN (/( Myh/NN )/) predicted/VBD to/TO interfere/VB strongly/RB with/IN myosin/NN 's/POS binding/NN to/TO actin/NN was/VBD designed/VBN and/CC 
412_412_15_16_10_13::None::,/, expression/NN of/IN cyclin-dependent/JJ kinase/NN inhibitors/NNS p21/NN and/CC p27/NN increased/VBD ,/, whereas/IN 
520523_1_31_33_17_18::None::tree/NN species/NNS :/: almond/NN (/( Prunus/FW dulcis/FW )/) ,/, apricot/NN (/( Prunus/FW armeniaca/FW )/) ,/, peach/NN (/( Prunus/FW persica/FW )/) ,/, and/CC 
1748_1748_27_28_19_20::POS_ACTION_MODIFY::in/IN reorganization/NN of/IN actin/NN filaments/NNS and/CC membrane/NN structures/NNS ,/, by/IN phosphorylating/VBG cofilin/ADF/NN proteins/NNS ./. 
93_93_11_12_6_7::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD 
662630_5_13_14_30_31::None::with/IN Black/JJ adolescents/NNS reporting/VBG lower/JJR withdrawal/NN discomfort/NN scores/NNS and/CC experiencing/VBG less/RBR severe/JJ depressed/JJ mood/NN ,/, difficulty/NN sleeping/VBG ,/, nervousness/NN //: anxiety/NN ,/, and/CC strange/JJ 
444311_5_40_41_0_1::None::Expression/NN of/IN exogenous/JJ PrP/NN (/( C/NN )/) in/IN HepG2/NN cells/NNS increased/VBD uptake/NN and/CC storage/NN of/IN ferric/JJ iron/NN (/( Fe/NNP (/( 3/CD +/CC )/) )/) ,/, not/RB ferrous/JJ iron/NN (/( Fe/NNP (/( 2/CD +/CC )/) )/) ,/, from/IN the/DT medium/NN ,/, supporting/VBG the/DT function/NN of/IN 
303_303_23_24_5_6::POS_ACTION_BIND::beta-catenin/NN binding/NN to/TO cadherin/NN or/CC APC/NN protein/NN ,/, and/CC the/DT ensuing/VBG effects/NNS on/IN cell/NN morphology/NN and/CC adhesion/NN ,/, are/VBP independent/JJ of/IN beta-catenin/NN binding/NN to/TO alpha-catenin/NN 
693828_2_7_8_16_17::None::was/VBD conducted/VBN on/IN studies/NNS assessing/VBG the/DT clinical/JJ characteristics/NNS and/CC correlates/VBZ of/IN unipolar/JJ MDD/NN and/CC bipolar/JJ MDD/NN 
813_813_27_28_2_4::None::Interaction/NN between/IN nucleocapsid/JJ protein/NN (/( NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN P/NN is/VBZ essential/JJ for/IN 
1103_1103_5_8_9_10::POS_ACTION_MEMBER::cyclin/NN E/NN and/CC cyclin-dependent/JJ kinase/NN inhibitor/NN (/( p27Kip1/NN )/) :/: effect/NN 
637036_2_22_23_4_5::None::to/TO a/DT tertiary/JJ epilepsy/NN center/NN early/RB in/IN the/DT course/NN of/IN disease/NN is/VBZ recommended/VBN ;/: however/RB ,/, patients/NNS live/VBP with/IN disabling/VBG and/CC life/NN -/: threatening/VBG seizures/NNS 
1029_1029_12_13_0_4::POS_ACTION_COLOCALIZE::Myosin/NN heavy/JJ chain/NN A/DT staining/NN was/VBD dimmer/JJR and/CC its/PRP$ colocalization/NN with/IN filamentous/JJ actin/NN bundles/NNS in/IN growth/NN 
1810_1810_0_1_2_3::None::beta-catenin/NN and/CC plakoglobin/NN possibly/RB play/VB more/JJR 
924463_2_16_17_10_11::medicine.medical_treatment.used_to_treat::with/IN acute/JJ ischemic/JJ stroke/NN who/WP was/VBD deemed/VBN ineligible/JJ for/IN intravenous/JJ recombinant/JJ tissue/NN plasminogen/NN 
1075_1075_11_12_6_7::None::proteins/NNS such/JJ as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN 
322394_2_23_24_24_26::None::dopamine/NN transport/NN and/CC metabolic/JJ gene/NN expression/NN in/IN dopaminergic/JJ neurons/NNS 
191115_5_44_45_73_74::None::CT/NN does/VBZ not/RB reveal/VB enlarged/JJ hilar/JJ or/CC mediastinal/JJ lymph/NN nodes/NNS ,/, we/PRP suggest/VBP performance/NN of/IN EBUS/NN -/: TBNA/NN and/CC //: or/CC EUS/SYM -/: (/( B/NN )/) -/: FNA/NN and/CC //: or/CC surgical/JJ staging/NN (/( Recommendation/NN grade/NN 
1528_1528_10_11_4_5::POS_ACTION_INTERACT::interactions/NNS of/IN the/DT UL52/NN protein/NN with/IN the/DT UL8/NN and/CC UL5/NN proteins/NNS were/VBD analysed/VBN 
380111_3_26_27_16_17::None::Au/SYM -/: H/NN insertion/NN minimum/NN attributed/VBD to/TO the/DT stabilization/NN of/IN the/DT LUMO/NNP 3b2/NN orbital/NN ,/, which/WDT can/MD 
753851_0_19_21_16_17::medicine.medical_treatment.used_to_treat::C/NN virus/NN -/: infected/JJ patients/NNS undergoing/VBG liver/NN transplantation/NN for/IN hepatocellular/JJ carcinoma/NN 
422_422_23_24_21_22::None::inhibitory/JJ activity/NN of/IN profilin/NN on/IN actin/NN polymerization/NN and/CC inhibition/NN 
1434_1434_7_8_72_73::None::Physarum/NNP ,/, histones/NNS H2A/NN ,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN 
159605_0_24_26_30_31::None::for/IN degradation/NN of/IN organic/JJ dyes/NNS with/IN hydrogen/NN peroxide/NN (/( H2O2/NN )/) ./. 
428759_7_14_16_9_10::None::effectiveness/NN of/IN adjuvant/JJ ovarian/JJ suppression/NN in/IN premenopausal/JJ early/JJ breast/NN cancer/NN have/VBP been/VBN selected/VBN 
1711_1711_19_20_7_8::None::predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN ,/, 
1834_1834_23_24_15_17::None::,/, namely/RB with/IN DNase/NN I/CD ,/, gelsolin/NN segment/NN 1/CD ,/, and/CC profilin/NN ./. 
718_718_11_12_8_9::POS_ACTION_BIND::cytoplasmic/JJ domain/NN of/IN cadherins/NNS bind/VBP to/TO beta-catenin/NN ,/, which/WDT in/IN 
250192_5_32_33_9_10::medicine.medical_treatment.used_to_treat::in/IN reducing/VBG OA/NN pain/NN (/( least/JJS squares/NNS mean/VBP change/NN from/IN baseline/NN in/IN visual/JJ analogue/NN scale/NN score/NN [/( standard/JJ error/NN ]/) -/: 37.1/CD [/( 2.0/CD ]/) for/IN celecoxib/NN and/CC -/: 37.5/CD 
1017_1017_20_21_2_3::None::Mutations/NNS in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP very/RB similar/JJ growth/NN phenotypes/NNS ,/, a/DT depolarized/VBN actin/NN cytoskeleton/NN ,/, and/CC 
1321_1321_9_11_23_24::None::)/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN testicular/JJ germ/NN cells/NNS and/CC has/VBZ the/DT potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN 
162581_4_11_13_3_4::None::We/PRP focused/VBD on/IN esophageal/NN ,/, gastric/JJ ,/, pancreatic/JJ ,/, liver/NN and/CC colorectal/JJ cancers/NNS ./. 
443_443_11_12_6_7::POS_REG(+)_MODIFY::conformational/JJ change/NN in/IN actin/NN induced/VBN by/IN fimbrin/NN (/( N375/NN )/) binding/NN ./. 
278671_5_12_13_17_18::medicine.disease.risk_factors::cytokine/NN levels/NNS and/CC psoriasis/NN in/IN the/DT context/NN of/IN obesity/NN ./. 
773440_1_16_17_34_36::medicine.medical_treatment.used_to_treat::,/, infliximab/NN ,/, adalimumab/NN ,/, certolizumab/NN and/CC golimumab/NN )/) are/VBP top/JJ sellers/NNS ,/, although/IN indicated/VBN only/RB in/IN autoimmune/JJ diseases/NNS ,/, including/VBG rheumatoid/JJ arthritis/NN ,/, Crohn/NN whosewhat/NN 
1248_1248_9_10_12_13::None::including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ,/, are/VBP tightly/RB 
856_856_22_23_40_41::None::,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT molecular/JJ mechanism/NN of/IN transcriptional/JJ activation/NN by/IN PU/NN .1/NN ,/, IRF1/NN ,/, and/CC ICSBP/NN ./. 
311030_10_10_11_8_9::None::applying/VBG ATP/NN which/WDT activated/VBD P2X2/NN channels/NNS specifically/RB expressed/VBN in/IN 
71_71_6_7_3_4::None::Aip1p/NN interacts/VBZ with/IN cofilin/NN to/TO disassemble/VB actin/NN filaments/NNS ./. 
393_393_5_7_12_15::POS_ACTION_CORELATE::isolated/VBN myofibrils/NNS with/IN alkaline/NN proteinase/NN resulted/VBD in/IN the/DT degradation/NN of/IN myosin/NN heavy/JJ chain/NN and/CC actin/NN ./. 
828542_0_5_6_0_1::None::Antibiotic/JJ management/NN of/IN methicillin/NN -/: resistant/JJ Staphylococcus/FW aureus/FW -/: 
103419_1_27_28_39_40::None::,/, Cu/NN -/: Field/NN ,/, Cu/NN -/: Nwires/NNS and/CC Cu/NN -/: NPs/NNS ;/: AgNO3/NN ,/, Ag/NN NM300K/NN ,/, Ag/NN 
629883_0_33_34_16_17::medicine.risk_factor.diseases::adipose/NN tissue/NN (/( AD/NN -/: MSC/NN )/) into/IN rabbit/NN models/NNS of/IN corneal/NN allograft/NN rejection/NN with/IN either/CC normal/JJ -/: risk/NN or/CC high/JJ -/: risk/NN vascularized/VBN 
1024_1024_32_33_32_33::None::RNA-binding/JJ surfaces/NNS of/IN HSH49/NN are/VBP not/RB required/VBN 
92775_0_31_32_29_30::None::preventing/VBG or/CC delaying/VBG decline/NN to/TO dementia/NN ./. 
128715_9_63_64_19_20::None::function/NN of/IN splenic/JJ DCs/NNS Captopril/NN treatment/NN also/RB promoted/VBD IL/NN -/: 10/CD &/CC amp/NN ;/: TGF/NN -/: beta/NN production/NN while/IN decreasing/VBG that/DT of/IN IL/NN -/: 6/CD &/CC amp/NN ;/: IL/NN -/: 12/CD in/IN splenic/JJ DCs/NNS Finally/RB ,/, the/DT results/NNS of/IN flow/NN cytometry/NN indicated/VBD that/IN captopril/NN obviously/RB inhibited/VBD DC/NN maturation/NN and/CC promoted/VBD Treg/NNP 
244614_0_48_49_2_3::None::The/DT conventional/JJ Phillips/NNP ethylene/NN trimerization/NN catalyst/NN prepared/VBN by/IN reacting/VBG Cr/NN (/( EH/NN )/) 3/CD (/( EH/NN =/JJ 2/CD -/: ethylhexanoate/NN )/) ,/, 2,5/CD -/: dimethylpyrrole/NN (/( Me2C4H2NH/NN )/) ,/, Et3Al/NN ,/, and/CC Et2AlCl/NN in/IN an/DT aromatic/JJ hydrocarbon/NN solvent/JJ was/VBD improved/VBN to/TO obtain/VB a/DT congener/NN composed/VBN of/IN a/DT new/JJ chromium/NN precursor/NN (/( EH/NN 
1164_1164_5_6_39_40::None::the/DT appearance/NN of/IN X22/NN banding/NN in/IN primary/JJ cultures/NNS of/IN myotubes/NNS indicates/VBZ that/IN it/PRP precedes/VBZ that/IN of/IN other/JJ myofibrillar/NN proteins/NNS and/CC that/IN assembly/NN takes/VBZ place/NN in/IN the/DT following/VBG order/NN :/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN 
125639_3_6_7_21_22::None::UV/NN -/: visible/JJ absorption/NN and/CC electron/NN paramagnetic/JJ resonance/NN (/( EPR/NN )/) analysis/NN suggested/VBD that/IN the/DT enzyme/NN had/VBD the/DT typical/JJ copper/NN sites/NNS ,/, 
467441_4_0_1_18_19::None::Further/JJ studies/NNS revealed/VBD that/IN TBBPA/NN did/VBD not/RB alter/VB the/DT enzyme/NN activities/NNS of/IN Copper/NN //: Zinc/NNP Superoxide/NN dismutase/NN (/( Cu/NN //: Zn/NN -/: 
121583_0_46_47_32_33::None::and/CC the/DT uncultured/JJ Marine/NNP Group/NNP II/NNP and/CC Marine/NNP Group/NNP III/NNP Euryarchaeota/NNP (/( MGII/NNP //: III/NNP )/) -/: independently/RB adapted/VBN to/TO lower/JJR 
1500_1500_11_12_16_17::None::heterotrimer/NN of/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN proteins/NNS ,/, displays/VBZ 
430599_3_0_1_16_17::medicine.symptom.symptom_of::proteinuria/NN ,/, diminished/VBD GFR/NN )/) are/VBP more/RBR pronounced/JJ in/IN group/NN SP/NN than/IN normotensive/JJ group/NN WKY/NN and/CC hypertensive/JJ group/NN SC/NN without/IN 
831385_3_58_59_16_17::None::effect/NN on/IN P/NN falciparum/NN and/CC recent/JJ studies/NNS have/VBP provided/VBN evidence/NN that/IN the/DT parasite/NN with/IN this/DT mutation/NN is/VBZ more/RBR susceptible/JJ to/TO CPA/NNP Here/RB ,/, we/PRP characterized/VBD ,/, for/IN the/DT first/JJ time/NN ,/, the/DT interaction/NN of/IN CPA/NN with/IN PfATP6/NN and/CC its/PRP$ mammalian/JJ counterpart/NN to/TO understand/VB similarities/NNS and/CC differences/NNS in/IN the/DT mode/NN 
637036_2_25_26_33_34::medicine.disease.treatments::life/NN -/: threatening/VBG seizures/NNS for/IN an/DT average/NN of/IN 22years/NNS before/IN considering/VBG surgical/JJ treatment/NN ./. 
26717_2_0_2_5_6::None::Cox/NN regression/NN modelswere/NN used/VBN to/TO calculate/VB the/DT hazard/NN of/IN 
1423_1423_36_37_28_30::None::overlap/VBP to/TO animal/NN actin-depolymerizing/JJ factors/NNS (/( ADF/NN )/) ,/, cofilin/NN and/CC destrin/NN ./. 
116203_2_25_27_36_37::None::2013/CD ,/, 130/CD colorectal/JJ tumors/NNS were/VBD examined/VBN in/IN 128/CD patients/NNS treated/VBN with/IN ESD/NN A/NN total/NN of/IN 119/CD patients/NNS 
430047_9_8_9_24_25::None::on/IN the/DT pharmacodynamic/JJ evidence/NN ,/, with/IN lower/JJR doses/NNS in/IN most/JJS patients/NNS ,/, combined/VBN with/IN close/JJ attention/NN to/TO reduction/NN of/IN smoking/NN ,/, blood/NN pressure/NN 
1140_1140_24_25_20_21::POS_ACTION_INTERACT::the/DT interaction/NN of/IN gelsolin/NN and/CC profilin/NN with/IN actin/NN ./. 
735_735_24_25_3_4::None::In/IN contrast/NN ,/, act1-159/NN partially/RB suppresses/VBZ the/DT temperature/NN sensitivity/NN of/IN a/DT tropomyosin/NN mutant/NN ,/, and/CC the/DT loss/NN of/IN cytoplasmic/JJ cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, and/CC tropomyosin/NN 
2107_2107_27_28_7_8::POS_ACTION_BIND::the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ proteins/NNS and/CC bind/VBP to/TO an/DT actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ 
1087_1087_23_24_7_9::None::that/IN in/IN brain/NN profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT actin/NN cytoskeleton/NN and/CC endocytic/JJ membrane/NN flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN 
865_865_17_18_11_14::None::relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 
336146_1_23_25_27_28::medicine.disease.risk_factors::association/NN with/IN subsequent/JJ endometrial/JJ cancer/NN risk/NN among/IN tamoxifen/NN -/: treated/JJ breast/NN 
93_93_24_26_57_58::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
123245_6_74_75_35_36::None::MFAP4/NN )/) ,/, transport/NN and/CC membrane/NN organization/NN proteins/NNS (/( FABP5/NN ,/, GC/NN ,/, and/CC EHD2/NN )/) ,/, chaperons/NNS (/( FKBP4/NN and/CC HSPD1/NN )/) and/CC known/VBN cancer/NN marker/NN (/( NME1/NN )/) have/VBP been/VBN associated/VBN with/IN prostate/NN and/CC other/JJ cancers/NNS by/IN numerous/JJ proteomics/NNS ,/, genomics/NNS or/CC functional/JJ studies/NNS 
1069_1069_33_35_46_47::None::)/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
1782_1782_11_12_1_6::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS 
411_411_17_18_15_16::None::including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP 
1434_1434_75_76_72_73::None::histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
350670_24_13_14_8_9::None::higher/JJR risk/NN of/IN stroke/NN recurrence/NN in/IN ischemic/JJ stroke/NN patients/NNS ./. 
2074_2074_16_17_18_19::None::)/) protein/NN and/CC phosphoprotein/NN (/( P/NN )/) of/IN sonchus/NN 
1386_1386_20_21_1_2::None::The/DT UL8/NN component/NN of/IN the/DT herpes/NN simplex/NN virus/NN helicase-primase/JJ complex/NN stimulates/VBZ primer/NN synthesis/NN by/IN a/DT subassembly/NN of/IN the/DT UL5/NN and/CC UL52/NN components/NNS ./. 
637206_9_6_7_0_1::medicine.disease.risk_factors::Diabetes/NNP remained/VBD the/DT leading/VBG cause/NN of/IN ESRD/NNP The/DT prevalence/NN and/CC 
954_954_1_2_6_7::POS_ACTION_PHOSPHORYLATE::Mammalian/JJ LIM-kinases/NNS (/( LIMKs/NNS )/) phosphorylate/VBP cofilin/NN and/CC induce/VB actin/NN 
1668_1668_8_9_3_4::None::The/DT role/NN of/IN profilin/NN in/IN the/DT regulation/NN of/IN actin/NN assembly/NN has/VBZ been/VBN 
549899_0_5_7_26_27::medicine.disease.risk_factors::have/VBP reported/VBN that/IN breast/NN cancer/NN stem/NN cells/NNS may/MD be/VB closely/RB associated/VBN with/IN tumor/NN metastasis/NN ,/, recurrence/NN ,/, and/CC even/RB the/DT failure/NN of/IN chemotherapy/NN and/CC radiotherapy/NN ./. 
960_960_17_18_9_10::None::,/, which/WDT encodes/VBZ verprolin/NN ,/, required/VBN for/IN proper/JJ organization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
369325_1_23_24_15_16::None::Coronary/JJ Artery/NN Risk/NN Development/NN in/IN Young/NNP Adults/NNS study/NN were/VBD assessed/VBN to/TO identify/VB the/DT order/NN in/IN 
763423_0_6_7_11_12::None::pump/NN inhibitor/NN -/: resistant/JJ nonerosive/JJ reflux/NN disease/NN by/IN esophageal/NN manometry/NN and/CC 24/CD 
660282_0_10_11_17_19::medicine.medical_treatment.used_to_treat::salvage/NN and/CC adjuvant/JJ radiation/NN therapy/NN on/IN outcomes/NNS after/IN prostatectomy/NN for/IN prostate/NN cancer/NN ./. 
1678_1678_13_14_1_2::None::These/DT histone/NN H3/NN and/CC H2a/NN genes/NNS encode/VBP approximately/RB 40/CD %/NN of/IN the/DT total/JJ H3/NN and/CC H2a/NN mRNA/NN 
1866_1866_3_4_7_8::None::Thus/RB ,/, both/DT DR5/NN and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, 
1164_1164_5_6_42_43::None::the/DT appearance/NN of/IN X22/NN banding/NN in/IN primary/JJ cultures/NNS of/IN myotubes/NNS indicates/VBZ that/IN it/PRP precedes/VBZ that/IN of/IN other/JJ myofibrillar/NN proteins/NNS and/CC that/IN assembly/NN takes/VBZ place/NN in/IN the/DT following/VBG order/NN :/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, and/CC desmin/NN ./. 
609976_0_7_8_4_6::None::and/CC diabetes/NN as/IN risk/NN factors/NNS for/IN dementia/NN :/: A/DT secondary/JJ 
1017_1017_20_21_4_5::None::in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP very/RB similar/JJ growth/NN phenotypes/NNS ,/, a/DT depolarized/VBN actin/NN cytoskeleton/NN ,/, and/CC 
991_991_17_18_20_21::None::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN ,/, but/CC none/NN 
411_411_17_18_20_21::None::,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NNP ./. 
620872_0_11_12_7_8::None::-/: Containing/NNP Formulations/NNPS Impact/NNP Anti/NNP -/: drug/NN Antibody/NN Responses/NNS to/TO Murine/JJ 
151537_7_11_12_28_29::None::we/PRP discuss/VBP include/VBP sarcoma/NN (/( osteosarcoma/NN ,/, soft/JJ tissue/NN sarcoma/NN ,/, histiocytic/JJ sarcoma/NN ,/, hemangiosarcoma/NN )/) ,/, haematological/JJ malignancies/NNS (/( lymphoma/NN ,/, leukaemia/NN )/) 
102233_0_12_13_0_4::None::Complex/JJ regional/JJ pain/NN syndrome/NN (/( CRPS/NN )/) is/VBZ a/DT chronic/JJ pain/NN condition/NN typically/RB involving/VBG a/DT limb/NN 
202451_1_45_46_40_41::None::)/) has/VBZ been/VBN solved/VBN (/( P21/NN //: c/NN monoclinic/JJ space/NN group/NN )/) 
591379_13_13_14_20_21::None::preclinical/JJ metabolic/JJ heart/NN disease/NN and/CC raise/VB the/DT possibility/NN that/IN pulmonary/JJ hypertension/NN contributes/VBZ to/TO the/DT 
512095_3_23_24_29_30::None::no/DT improvement/NN of/IN wash/NN -/: out/RP on/IN post/NN -/: operative/JJ MAG/NN -/: 3/CD 
523643_0_1_2_25_27::None::Our/PRP$ objective/NN is/VBZ to/TO explore/VB the/DT correlation/NN between/IN the/DT mouth/NN diameter/NN of/IN left/JJ atrial/JJ appendage/NN (/( LAA/NN )/) and/CC stroke/NN risk/NN score/NN in/IN patients/NNS with/IN atrial/JJ fibrillation/NN (/( AF/NN )/) 
1251_1251_42_43_32_33::POS_ACTION_BIND::and/CC bind/VBP to/TO actin/NN in/IN the/DT same/JJ way/NN as/IN native/JJ ,/, conventionally/RB purified/VBN profilin/NN without/IN urea/NN treatment/NN 
119342_0_2_3_8_9::None::The/DT H2/NN robotic/JJ exoskeleton/NN for/IN gait/NN rehabilitation/NN after/IN stroke/NN :/: early/JJ findings/NNS 
800292_15_33_35_11_13::None::,/, the/DT increased/VBN relative/JJ risk/NN of/IN mortality/NN associated/VBN with/IN male/JJ sex/NN ,/, diabetes/NN ,/, congestive/JJ heart/NN failure/NN ,/, and/CC open/JJ surgical/JJ access/NN could/MD influence/VB clinical/JJ decision/NN making/NN ./. 
511797_2_23_24_6_7::medicine.symptom.symptom_of::63/CD persons/NNS with/IN MS/NN (/( 75/CD %/NN relapsing/NN -/: remitting/VBG MS/NN ,/, median/JJ EDSS/NN =/JJ 4.0/CD ,/, and/CC mean/VB MS/NN duration/NN =/JJ 13.1/CD years/NNS 
1372_1372_18_19_18_19::None::amino-terminal/JJ halves/NNS of/IN beta-catenin/NN will/MD independently/RB associate/VB 
93177_0_31_32_25_27::medicine.drug_ingredient.active_moiety_of_drug::aquaporin/NN -/: 4/CD immunoglobulin/NN G/NN antibodies/NNS (/( AQP4/NN -/: IgG/NN )/) ./. 
217765_0_14_15_2_3::medicine.medical_treatment.used_to_treat::[/( Posttraumatic/JJ arthrosis/NN of/IN the/DT glenohumeral/JJ joint/NN :/: From/IN partial/JJ resurfacing/NN to/TO reverse/VB shoulder/NN arthroplasty/NN ]/) ./. 
776470_0_17_18_18_20::None::,/, diabetes/NN mellitus/NN induced/VBD kidney/NN failure/NN ,/, glomerulosclerosis/NN and/CC 
185_185_2_3_6_7::None::Associations/NNS of/IN UBE2I/NN with/IN RAD52/NN ,/, UBL1/NN ,/, p53/NN ,/, 
356904_0_13_14_4_5::None::is/VBZ a/DT chronic/JJ inflammatory/JJ disorder/NN of/IN the/DT airway/NN characterized/VBN by/IN the/DT episodic/JJ symptoms/NNS of/IN breathlessness/NN ,/, 
215150_5_34_35_13_14::medicine.risk_factor.diseases::that/IN improvements/NNS in/IN depressive/JJ symptoms/NNS were/VBD partially/RB mediated/VBN by/IN improvements/NNS in/IN parent/NN -/: youth/NN conflict/NN ;/: however/RB ,/, family/NN process/NN changes/NNS did/VBD not/RB mediate/VB diabetes/NN health/NN outcomes/NNS ./. 
718366_2_2_3_19_20::None::Pica/NNP was/VBD identified/VBN in/IN four/CD percent/NN of/IN cases/NNS of/IN TSC/NNP It/PRP was/VBD associated/VBN with/IN adult/JJ onset/NN or/CC persistence/NN into/IN adulthood/NN ,/, epilepsy/NN ,/, 
151533_0_15_16_32_33::None::is/VBZ effective/JJ but/CC intensity/NN (/( daily/JJ versus/CC intermittent/JJ )/) and/CC duration/NN of/IN rifampicin/NN use/NN (/( Intensive/JJ phase/NN only/RB versus/CC both/DT phases/NNS )/) have/VBP not/RB 
1055_1055_0_1_19_22::None::p130/NN and/CC pRb/NN were/VBD phosphorylated/VBN before/IN the/DT infected/JJ myotubes/NNS entered/VBD S/NN phase/NN ,/, despite/IN the/DT high/JJ expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN ,/, and/CC 
235_235_1_2_11_12::None::Birch/NNP profilin/NN increased/VBD the/DT critical/JJ concentration/NN required/VBN for/IN muscle/NN and/CC brain/NN actin/NN polymerization/NN in/IN a/DT 
246590_2_11_12_19_20::None::the/DT role/NN of/IN local/JJ coordination/NN and/CC covalency/NN of/IN the/DT aluminate/JJ host/NN lattice/NN ,/, related/JJ to/TO 
400251_26_26_29_17_18::medicine.drug_ingredient.active_moiety_of_drug:://: F/NN //: tenofovir/NN alafenamide/NN or/CC E/NN //: C/NN //: F/NN //: tenofovir/NN disoproxil/NN fumarate/NN had/VBD virological/JJ success/NN 
243_243_36_37_27_28::POS_ACTION_ACTIVATE::coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) ./. 
1288_1288_4_6_13_14::None::interaction/NN between/IN the/DT nucleocapsid/JJ protein/NN (/( N/NN )/) and/CC the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ 
292_292_0_1_19_21::None::CD26/NN ,/, a/DT T/NN cell/NN activation/NN Ag/NN ,/, also/RB known/VBN as/IN dipeptidyl/NN peptidase/NN IV/CD ,/, is/VBZ directly/RB associated/VBN with/IN adenosine/NN deaminase/NN (/( ADA/NN )/) 
1860_1860_2_3_21_22::POS_ACTION_MODIFY::Thus/RB ,/, alpha-syntrophin/NN has/VBZ an/DT important/JJ role/NN in/IN synapse/NN formation/NN and/CC in/IN the/DT organization/NN of/IN utrophin/NN ,/, acetylcholine/NN receptor/NN ,/, and/CC acetylcholinesterase/NN at/IN the/DT neuromuscular/JJ 
479157_1_42_43_6_7::None::strictly/RB anaerobic/JJ ruminal/JJ bacterium/NN ,/, possesses/VBZ typical/JJ Gram/NN -/: negative/JJ cell/NN surface/NN structure/NN comprising/VBG cytoplasmic/JJ membrane/NN ,/, peptidoglycan/NN layer/NN and/CC outer/JJ membrane/NN ,/, whereas/IN its/PRP$ 16S/NN rRNA/NN -/: based/VBN taxonomy/NN shows/VBZ that/IN the/DT bacteria/NNS belongs/VBZ to/TO Gram/NN -/: positive/JJ Firmicutes/NNS ./. 
81377_14_1_2_6_7::None::Being/VBG obese/JJ before/IN pregnancy/NN and/CC frequently/RB consuming/JJ fruit/NN drinks/NNS were/VBD 
626703_0_14_15_15_17::medicine.risk_factor.diseases::woman/NN with/IN decompensated/VBN alcoholic/JJ liver/NN cirrhosis/NN and/CC poorly/RB controlled/VBN 
1017_1017_2_3_9_10::None::Mutations/NNS in/IN RVS161/NN and/CC RVS167/NN ,/, the/DT two/CD yeast/NN amphiphysin/JJ homologs/NNS ,/, cause/VBP 
1560_1560_13_14_17_18::None::acetylation/NN of/IN histone/NN H4/NN versus/CC acetylation/NN of/IN histone/NN H3/NN :/: with/IN 
243_243_27_28_30_32::None::coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD 
965433_2_3_4_0_1::None::HPLC/NN )/) with/IN heart/NN -/: cutting/VBG and/CC 
103419_1_39_40_37_38::medicine.drug_ingredient.active_moiety_of_drug::-/: NPs/NNS ;/: AgNO3/NN ,/, Ag/NN NM300K/NN ,/, Ag/NN 
296153_6_15_16_0_2::None::Major/JJ depression/NN ,/, fibromyalgia/NNP ,/, Alzheimer/NNP disease/NN ,/, psoriasis/NN ,/, arthritis/NN ,/, allergies/NNS ,/, and/CC asthma/NN are/VBP all/DT associated/VBN 
2222_2222_15_16_19_20::None::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC 
363177_0_9_10_16_19::None::characterized/VBN by/IN inflammatory/JJ demyelination/NN and/CC deposition/NN of/IN fibrinogen/NN in/IN the/DT central/JJ nervous/JJ system/NN (/( CNS/NN )/) 
406599_4_14_15_0_1::None::We/PRP also/RB observed/VBD that/IN human/JJ ovarian/JJ cancer/NN cells/NNS proliferate/VBP better/JJR if/IN exposed/VBN to/TO cell/NN debris/NN harvested/VBN from/IN irradiated/JJ 
1787_1787_11_12_16_17::None::their/PRP$ interaction/NN with/IN actin/NN ,/, like/IN destrin/NN and/CC cofilin/NN isolated/VBN from/IN porcine/NN 
373757_6_37_40_29_32::None::,/, hyperlipidaemia/NN ,/, chronic/JJ kidney/NN disease/NN ,/, ischaemic/JJ heart/NN disease/NN ,/, peripheral/JJ arterial/JJ disease/NN and/CC left/VBD ventricular/JJ 
475835_20_13_14_20_22::medicine.medical_treatment.used_to_treat::does/VBZ not/RB impact/NN transplantation/NN outcomes/NNS and/CC complications/NNS in/IN patients/NNS with/IN acute/JJ leukemia/NN undergoing/VBG hematopoietic/JJ cell/NN 
1164_1164_35_38_5_6::POS_ACTION_ATTACH::the/DT appearance/NN of/IN X22/NN banding/NN in/IN primary/JJ cultures/NNS of/IN myotubes/NNS indicates/VBZ that/IN it/PRP precedes/VBZ that/IN of/IN other/JJ myofibrillar/NN proteins/NNS and/CC that/IN assembly/NN takes/VBZ place/NN in/IN the/DT following/VBG order/NN :/: X22/NN ,/, titin/NN ,/, myosin/NN heavy/JJ chain/NN ,/, actin/NN ,/, 
290049_2_24_25_20_21::None::of/IN this/DT mammalian/JJ taxon/NN in/IN influenza/NN A/NN virus/NN ecology/NN and/CC possible/JJ 
1793_1793_16_17_14_15::None::and/CC modulation/NN by/IN talin/NN and/CC vinculin/NN ./. 
236038_0_7_8_5_6::medicine.drug_ingredient.active_moiety_of_drug::the/DT major/JJ surface/NN hyaluronan/NN (/( HA/NN )/) receptor/NN implicated/VBN 
170709_1_17_18_0_1::None::In/IN order/NN to/TO target/VB SkBr3/NN ,/, which/WDT is/VBZ a/DT breast/NN cancer/NN cell/NN overexpressing/VBG the/DT Her2/NN receptor/NN ,/, trastuzumab/NN (/( Herceptin/NN )/) 
1917_1917_27_28_2_3::None::To/TO study/VB profilin/NN function/NN ,/, we/PRP extensively/RB mutagenized/VBD the/DT Saccharomyces/FW cerevisiae/FW profilin/NN gene/NN (/( PFY1/NN )/) and/CC examined/VBD the/DT consequences/NNS of/IN specific/JJ point/NN mutations/NNS on/IN growth/NN and/CC actin/NN organization/NN ./. 
803668_11_6_7_12_13::None::MS/NN who/WP report/VBP high/JJ levels/NNS of/IN chronic/JJ pain/NN and/CC depressive/JJ symptoms/NNS may/MD benefit/VB 
257913_10_39_40_43_45::None::damage/NN ,/, thereby/RB reducing/VBG the/DT incidence/NN of/IN cardiovascular/JJ events/NNS ./. 
229532_2_34_36_28_30::None::-/: regulation/NN of/IN cell/NN signaling/NN pathway/NN genes/NNS and/CC specific/JJ fatty/JJ acid/NN metabolism/NN genes/NNS as/RB 
550981_1_7_9_11_12::None::resistance/NN to/TO portal/JJ blood/NN flow/NN through/IN the/DT cirrhotic/JJ liver/NN ./. 
149493_0_11_12_35_36::None::Hypertension/NN Guideline/NN was/VBD developed/VBN to/TO assist/VB primary/JJ care/NN physicians/NNS and/CC other/JJ health/NN care/NN professionals/NNS in/IN the/DT outpatient/NN treatment/NN of/IN uncomplicated/JJ hypertension/NN in/IN adult/JJ men/NNS and/CC nonpregnant/JJ women/NNS aged/VBN 18/CD years/NNS and/CC 
110211_10_8_9_7_8::None::and/CC validated/VBN with/IN service/NN users/NNS with/IN a/DT diagnosis/NN 
608_608_18_19_10_11::None::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN the/DT products/NNS of/IN the/DT UL5/NN ,/, UL8/NN ,/, 
614185_6_18_19_15_16::None::they/PRP are/VBP highly/RB adaptable/JJ to/TO other/JJ strains/NNS of/IN rats/NNS ,/, 
18729_3_0_1_19_20::None::In/IN a/DT retrospective/JJ cohort/NN study/NN of/IN children/NNS with/IN drug/NN -/: resistant/JJ epilepsy/NN referred/VBN for/IN possible/JJ surgical/JJ intervention/NN ,/, we/PRP compared/VBD direct/JJ costs/NNS of/IN 
1169_1169_41_42_26_27::None::in/IN neurons/NNS (/( N-WASP/NN )/) ,/, were/VBD found/VBN to/TO possess/VB short/JJ peptide/NN motifs/NNS homologous/JJ to/TO one/CD part/NN of/IN verprolin/NN ./. 
571439_1_20_21_14_15::None::patients/NNS ,/, inhibit/VBP joint/JJ destruction/NN and/CC improve/VB quality/NN of/IN life/NN ./. 
954_954_9_10_1_2::None::Mammalian/JJ LIM-kinases/NNS (/( LIMKs/NNS )/) phosphorylate/VBP cofilin/NN and/CC induce/VB actin/NN cytoskeletal/JJ reorganization/NN ./. 
784_784_18_19_12_13::None::,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN 
1498_1498_15_16_21_22::None::link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD thus/RB regulate/VB integrin/NN function/NN ./. 
26283_1_19_21_17_18::medicine.disease.symptoms::addition/NN to/TO marked/JJ tachycardia/NN with/IN atrial/JJ fibrillation/NN and/CC heart/NN failure/NN 
220528_2_33_34_30_31::None::ICR/NN mice/NNS were/VBD treated/VBN with/IN a/DT range/NN of/IN doses/NNS (/( 
172257_0_14_15_4_5::None::aim/NN of/IN the/DT Anaemia/NN in/IN Lung/NN Cancer/NN in/IN Spain/NNP study/NN was/VBD to/TO provide/VB epidemiological/JJ data/NNS and/CC treatment/NN 
1380_1380_24_25_24_25::POS_ACTION_BIND::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: 
26283_1_19_21_27_28::None::marked/JJ tachycardia/NN with/IN atrial/JJ fibrillation/NN and/CC heart/NN failure/NN associated/VBN with/IN a/DT reduced/VBN left/VBD ventricular/JJ function/NN 
184609_0_4_5_8_9::medicine.drug.active_moieties::of/IN l/NN -/: arginine/NN (/( l/NN -/: Arg/NN )/) to/TO nitric/JJ 
144_144_34_36_39_40::POS_ACTION_MEMBER::)/) ,/, and/CC capping/VBG protein/NN (/( CAP1/NN and/CC CAP2/NN )/) genes/NNS have/VBP 
428759_1_6_7_15_17::None::,/, several/JJ therapeutic/JJ agents/NNS showed/VBD viable/JJ antitumor/NN clinical/JJ response/NN in/IN recurrent/JJ and/CC metastatic/JJ disease/NN :/: bevacizumab/NN ,/, 
332464_0_6_7_18_20::None::lipoprotein/NN cholesterol/NN (/( LDL/NN -/: C/NN )/) reduction/NN with/IN statins/NNS is/VBZ the/DT cornerstone/NN of/IN atherosclerotic/JJ cardiovascular/JJ disease/NN (/( CVD/NN )/) 
179835_3_30_31_10_11::people.cause_of_death.includes_causes_of_death::cutting/VBG -/: edge/NN cardiovascular/JJ imaging/NN techniques/NNS and/CC potential/JJ clinical/JJ applications/NNS and/CC limitations/NNS of/IN those/DT techniques/NNS for/IN the/DT evaluation/NN of/IN major/JJ SLE/NN -/: related/JJ heart/NN disorders/NNS ./. 
1170_1170_30_31_5_6::None::we/PRP characterized/VBD several/JJ profilin/NN isoforms/NNS from/IN maize/NN pollen/NN for/IN their/PRP$ ability/NN to/TO alter/VB cytoarchitecture/NN when/WRB microinjected/VBN into/IN living/NN plant/NN cells/NNS and/CC for/IN their/PRP$ association/NN with/IN poly-L-proline/NN and/CC monomeric/JJ actin/NN from/IN maize/NN pollen/NN 
1082_1082_35_36_31_34::None::a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
1524_1524_18_19_12_13::None::)/) and/CC birch/VB profilin/NN ,/, a/DT structurally/RB well/RB conserved/VBN actin/NN -/: and/CC phosphoinositide-binding/JJ 
219974_13_15_16_2_3::people.cause_of_death.includes_causes_of_death::Non/SYM -/: cardiovascular/JJ causes/NNS of/IN death/NN are/VBP responsible/JJ for/IN almost/RB half/DT of/IN later/JJ deaths/NNS in/IN cardiac/JJ patients/NNS ./. 
798_798_11_12_13_14::None::EGTA/NN with/IN purified/VBN fimbrin/NN and/CC villin/NN form/VBP smooth-sided/JJ bundles/NNS 
95037_9_6_7_3_4::None::TDP/SYM -/: 43/CD immunoreactive/JJ structures/NNS were/VBD observed/VBN in/IN 55/CD //: 
322590_4_0_1_12_13::None::Pre/SYM -/: eclampsia/NN was/VBD defined/VBN as/IN per/IN the/DT International/NNP Society/NNP for/IN the/DT Study/NN of/IN Hypertension/NN in/IN 
856_856_13_14_24_25::POS_ACTION_UPREGULATE::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT 
106581_3_17_19_11_12::medicine.disease.risk_factors::of/IN MD/NN for/IN obesity/NN ,/, diabetes/NN type/NN II/CD ,/, metabolic/JJ syndrome/NN and/CC fatty/NN liver/NN 
76975_8_18_19_17_18::None::high/JJ -/: risk/NN hypertensive/JJ patients/NNS ,/, and/CC it/PRP 
763530_0_20_21_18_19::None::main/JJ precursor/NN ,/, Barrett/NNP whosewhat/NN esophagus/NN ;/: however/RB ,/, 
905933_12_4_5_19_20::None::results/NNS suggest/VBP that/IN DIR/NN -/: based/VBN dose/NN accumulation/NN may/MD be/VB acceptable/JJ for/IN assessing/VBG cumulative/JJ dose/NN distributions/NNS to/TO assess/VB doses/NNS to/TO the/DT tumor/NN 
565841_0_11_12_5_6::None::and/CC epidemiological/JJ studies/NNS demonstrated/VBD an/DT association/NN between/IN endometriosis/NN and/CC infertility/NN ./. 
549899_0_6_9_8_9::None::reported/VBN that/IN breast/NN cancer/NN stem/NN cells/NNS may/MD be/VB closely/RB 
1761_1761_23_25_13_15::None::,/, the/DT HPIV3/NN nucleocapsid/NN protein/NN N/NN ,/, the/DT phosphoprotein/NN P/NN ,/, and/CC the/DT polymerase/NN protein/NN L./NN 
363177_0_20_21_0_2::None::Multiple/JJ sclerosis/NN (/( MS/NN )/) is/VBZ characterized/VBN by/IN inflammatory/JJ demyelination/NN and/CC deposition/NN of/IN fibrinogen/NN in/IN the/DT central/JJ nervous/JJ system/NN (/( CNS/NN )/) ./. 
236_236_27_29_2_3::POS_ACTION_BIND::Birch/NNP pollen/NN profilin/NN and/CC actin/NN can/MD be/VB copurified/VBN as/IN a/DT complex/NN ,/, and/CC purified/VBN recombinant/JJ birch/NN profilin/NN can/MD be/VB used/VBN as/IN an/DT affinity/NN matrix/NN to/TO obtain/VB birch/JJ pollen/NN actin/NN ./. 
881655_2_13_15_13_14::None::tea/NN catechins/NNS and/CC anticancer/JJ drugs/NNS has/VBZ the/DT 
416817_3_43_44_4_5::None::feasibility/NN study/NN was/VBD conducted/VBN to/TO test/VB the/DT reliability/NN of/IN the/DT NWEH/NN -/: LDB/NN to/TO support/VB longitudinal/JJ data/NN analysis/NN and/CC pragmatic/JJ clinical/JJ trials/NNS in/IN asthma/NN and/CC COPD/NNP This/DT involved/VBD a/DT retrospective/JJ extraction/NN of/IN data/NNS from/IN all/DT registered/VBN practices/NNS in/IN Salford/NNP to/TO identify/VB a/DT cohort/NN of/IN patients/NNS with/IN 
449335_7_17_19_8_9::None::alternative/JJ ways/NNS of/IN modulating/VBG the/DT cannabinoid/NN system/NN that/WDT could/MD have/VB implication/NN for/IN nicotine/NN dependence/NN treatment/NN ./. 
387603_2_38_39_5_6::None::study/NN ,/, we/PRP describe/VBP the/DT synthesis/NN and/CC characterization/NN of/IN a/DT new/JJ amphiphilic/JJ polymer/NN ,/, hyaluronic/JJ acid/NN -/: cystamine/NN -/: polylactic/NN -/: co/SYM -/: glycolic/JJ acid/NN (/( HA/SYM -/: SS/NN -/: PLGA/NN )/) ,/, composed/VBN of/IN a/DT hydrophobic/JJ PLGA/NNP head/NN and/CC 
1782_1782_25_26_1_6::None::The/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) and/CC the/DT Fas/NN receptor/NN recruit/VB complexes/NNS formed/VBN by/IN the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: 
1787_1787_16_17_11_12::POS_ACTION_INTERACT::their/PRP$ interaction/NN with/IN actin/NN ,/, like/IN destrin/NN and/CC cofilin/NN isolated/VBN from/IN porcine/NN 
1994_1994_10_11_8_9::None::we/PRP show/VBP that/IN verprolin/NN binds/VBZ actin/NN ./. 
1957_1957_10_11_36_37::None::with/IN association/NN of/IN beta-catenin/NN with/IN EGF/NN receptor/NN (/( EGFR/NN )/) when/WRB quiescent/JJ cells/NNS at/IN confluence/NN were/VBD dissociated/VBN into/IN single/JJ cells/NNS by/IN tryptic/JJ digestion/NN ,/, being/VBG accompanied/VBN by/IN dissociation/NN of/IN alpha-catenin/NN from/IN E-cadherin/NN ./. 
144491_1_21_24_25_26::medicine.drug.active_moieties::serum/NN proteins/NNS namely/RB human/JJ serum/NN albumin/NN (/( HSA/NN )/) and/CC immunoglobulin/NN 
386745_4_25_26_27_28::None::)/) ,/, an/DT Internet/NN -/: based/VBN sports/NNS injury/NN surveillance/NN 
783888_0_22_24_38_39::None::mg/NN IV/CD (/( control/NN group/NN )/) among/IN adult/JJ ambulatory/JJ surgery/NN patients/NNS to/TO control/VB established/JJ postoperative/JJ nausea/NN or/CC vomiting/NN (/( PONV/NN )/) ./. 
151533_0_24_25_6_8::medicine.medical_treatment.used_to_treat::suggest/VBP that/IN intermittent/JJ pulmonary/JJ tuberculosis/NN (/( TB/NN )/) chemotherapy/NN is/VBZ effective/JJ but/CC intensity/NN (/( daily/JJ versus/CC intermittent/JJ )/) and/CC duration/NN of/IN rifampicin/NN use/NN (/( Intensive/JJ 
1004_1004_3_4_21_22::POS_ACTION_RELATE::Most/JJS of/IN these/DT integrins/NNS ,/, with/IN their/PRP$ intracellular/JJ domains/NNS ,/, interact/VBP with/IN the/DT actin-containing/JJ cytoskeleton/NN ,/, via/IN linking/VBG proteins/NNS such/JJ as/IN vinculin/NN and/CC talin/NN ,/, 
206273_1_23_24_0_1::None::In/IN this/DT study/NN ,/, we/PRP further/RB investigate/VBP the/DT relationship/NN between/IN H/NN 2/CD S/NN and/CC conventional/JJ protein/NN kinase/NN CbetaII/NN (/( cPKCbetaII/NN )/) in/IN CHD/NN patients/NNS with/IN uremic/JJ accelerated/VBN 
662630_5_19_20_33_34::None::discomfort/NN scores/NNS and/CC experiencing/VBG less/RBR severe/JJ depressed/JJ mood/NN ,/, difficulty/NN sleeping/VBG ,/, nervousness/NN //: anxiety/NN ,/, and/CC strange/JJ //: wild/JJ dreams/NNS 
391631_1_21_22_15_16::None::employs/VBZ two/CD distinct/JJ anti/JJ -/: LMoV/NN polyclonal/JJ antibodies/NNS (/( IgG3/NN and/CC IgG4/NN )/) 
1227_1227_2_3_26_27::None::Saccharomyces/FW cerevisiae/FW RAD14/NN was/VBD identified/VBN in/IN a/DT two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN ,/, ''/'' and/CC pairwise/JJ interactions/NNS between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, RAD3/NN ,/, RAD10/NN ,/, 
671014_4_21_22_43_44::None::responses/NNS ,/, a/DT paradigm/NN is/VBZ needed/VBN that/IN (/( a/DT )/) reliably/RB induces/VBZ high/JJ levels/NNS of/IN social/JJ -/: evaluative/JJ threat/NN and/CC (/( b/LS )/) is/VBZ extremely/RB adaptable/JJ to/TO the/DT needs/NNS 
938_938_9_11_6_7::POS_ACTION_MEMBER::LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ 
405577_1_13_15_4_5::None::the/DT plasma/NN ,/, PCI/NN physiologically/RB inhibits/VBZ an/DT anticoagulant/JJ serine/NN protease/NN ,/, activated/VBN protein/NN C/NN (/( APC/NN )/) 
1052_1052_6_8_34_35::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN 
489_489_15_16_26_27::None::histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP determined/VBN that/IN histone/NN H3/NN is/VBZ significantly/RB 
1926_1926_13_14_19_20::None::as/IN that/DT of/IN FLICE/NNP ,/, Fas/NN ,/, FADD/NN ,/, DR3/NN ,/, FAF/NN ,/, 
988_988_20_21_26_27::None::homologous/JJ to/TO human/JJ plakoglobin/NN and/CC the/DT Drosophila/NN gene/NN product/NN armadillo/NN ./. 
280859_11_22_24_3_4::medicine.medical_treatment.used_to_treat::In/IN overfat/NN and/CC obese/JJ participants/NNS fat/JJ mass/NN was/VBD reduced/VBN with/IN increasing/VBG resistance/NN exercise/NN (/( p/NN ltlt/NN =/JJ 0.02/CD )/) but/CC not/RB with/IN aerobic/JJ exercise/NN (/( p/NN gtgt/NN 
1464_1464_8_9_3_4::None::The/DT domains/NNS in/IN CBP/NN that/WDT are/VBP involved/VBN in/IN CREB/NN binding/NN and/CC transcriptional/JJ 
687516_9_34_35_21_22::None::tumors/NNS ,/, while/IN maintaining/VBG detection/NN of/IN tumors/NNS for/IN which/WDT treatment/NN has/VBZ been/VBN proven/VBN to/TO reduce/VB prostate/NN cancer/NN mortality/NN ./. 
68_68_20_21_16_17::NEG_ACTION_CORELATE::,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB beta-catenin/NN ,/, with/IN increased/VBN 
729_0_27_28_24_25::None::unresponsive/JJ because/IN of/IN severe/JJ traumatic/JJ brain/NN injury/NN ./. 
515959_4_18_19_3_4::None::We/PRP have/VBP previously/RB reported/VBN that/IN breast/NN tumors/NNS highly/RB express/VBP functional/JJ muscarinic/JJ acetylcholine/NN receptors/NNS (/( mAChRs/NNS )/) that/WDT regulate/VBP tumor/NN progression/NN ./. 
315432_4_19_20_17_18::None::negative/JJ reinforcement/NN and/CC NAc/NN dopaminergic/JJ transmission/NN ./. 
938_938_6_7_14_15::None::LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ actin/NN cytoskeletal/JJ reorganization/NN ./. 
1633_1633_25_26_32_33::POS_ACTION_MEMBER::identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC two/CD histone/NN H2b/NN genes/NNS ./. 
1069_1069_42_45_46_47::None::and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) assemble/VBP together/RB 
1782_1782_25_26_20_22::POS_ACTION_INTERACT::the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: 
523349_15_13_14_17_18::None::regulating/VBG proliferation/NN ,/, invasion/NN and/CC apoptosis/NN of/IN trophoblast/NN cells/NNS ./. 
91905_5_25_26_13_15::None::assay/NN )/) for/IN perennial/JJ ryegrass/NN (/( Lolium/NN perenne/NN )/) was/VBD created/VBN and/CC validated/VBN in/IN a/DT broad/JJ ecotype/JJ collection/NN of/IN 
526397_0_35_36_0_1::None::This/DT longitudinal/JJ study/NN aims/VBZ to/TO compare/VB long/JJ -/: term/NN work/NN disability/NN and/CC absenteeism/NN between/IN anxiety/NN and/CC depressive/JJ disorders/NNS focusing/VBG on/IN the/DT effects/NNS of/IN different/JJ course/NN trajectories/NNS (/( remission/NN ,/, recurrence/NN and/CC chronic/JJ course/NN )/) and/CC specific/JJ symptom/NN dimensions/NNS (/( 
1052_1052_6_8_29_30::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB 
268989_5_36_38_58_60::None::Tie/NN -/: 2/CD signaling/NN pathway/NN functions/VBZ as/IN an/DT autocrine/JJ loop/NN for/IN the/DT maintenance/NN of/IN prostate/NN CSCs/NNS More/RBR importantly/RB ,/, we/PRP found/VBD that/IN Tie/NN -/: 2High/NN prostate/NN cancer/NN cells/NNS are/VBP more/RBR 
1381_1381_30_31_33_34::POS_ACTION_BIND::nucleation/NN by/IN the/DT actin/NN monomer-binding/JJ protein/NN profilin/NN ,/, giving/VBG active/JJ 
341530_0_17_18_11_12::medicine.disease.symptoms::are/VBP at/IN a/DT high/JJ risk/NN for/IN cardiovascular/JJ disease/NN (/( CVD/NN )/) due/JJ to/TO 
2131_2131_10_11_23_24::POS_ACTION_LOCALIZE::UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
2131_2131_21_22_10_11::None::UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ for/IN the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) 
789814_0_17_18_21_24::None::in/IN patients/NNS with/IN complex/JJ multi/NNS -/: vessel/NN coronary/JJ artery/NN disease/NN ./. 
813_813_23_24_2_4::None::Interaction/NN between/IN nucleocapsid/JJ protein/NN (/( NP/NN )/) and/CC phosphoprotein/NN (/( P/NN )/) of/IN human/JJ parainfluenza/NN virus/NN type/NN 2/CD :/: one/CD of/IN the/DT two/CD NP/NN binding/NN sites/NNS on/IN 
1380_1380_38_39_24_25::POS_ACTION_BIND::actin-related/JJ proteins/NNS ,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, 
1052_1052_6_8_37_38::None::determine/VB whether/IN other/JJ glycoprotein/NN 130/CD (/( gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
750_750_21_22_3_5::POS_ACTION_BIND::Increased/VBN interaction/NN of/IN beta1D/NN integrin/NN with/IN the/DT actin/NN cytoskeleton/NN is/VBZ consistent/JJ with/IN and/CC might/MD be/VB mediated/VBN by/IN its/PRP$ enhanced/VBN binding/NN to/TO talin/NN ./. 
1005_1005_6_7_13_14::POS_ACTION_BIND::have/VBP focused/VBN on/IN profilin/NN itself/PRP rather/RB than/IN its/PRP$ complex/NN with/IN actin/NN ./. 
121781_2_0_1_13_14::medicine.risk_factor.diseases::Diabetes/NNP is/VBZ associated/VBN with/IN various/JJ nervous/JJ disorders/NNS ,/, such/JJ as/IN cognitive/JJ deficits/NNS ,/, depression/NN ,/, and/CC Alzheimer/NN 
1465_1465_6_7_8_9::POS_REG(0)_ASSEMBLE::of/IN the/DT exogenous/JJ cofilin/NN on/IN actin/NN assembly/NN were/VBD suppressed/VBN 
2213_2213_18_19_15_18::None::D1/NN and/CC the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p21/NN Cip1/WAF1/NN is/VBZ observed/VBN 
564_564_20_21_22_23::None::of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN ,/, enhanced/VBD association/NN 
128715_9_18_19_33_34::None::immunostimulatory/JJ function/NN of/IN splenic/JJ DCs/NNS Captopril/NN treatment/NN also/RB promoted/VBD IL/NN -/: 10/CD &/CC amp/NN ;/: TGF/NN -/: beta/NN production/NN while/IN decreasing/VBG that/DT 
727854_0_14_15_0_1::None::Hypertension/NN is/VBZ one/CD of/IN the/DT major/JJ risk/NN factors/NNS for/IN cardiovascular/JJ diseases/NNS that/WDT affect/VBP a/DT high/JJ proportion/NN of/IN people/NNS 
763423_0_18_19_11_12::None::reflux/NN disease/NN by/IN esophageal/NN manometry/NN and/CC 24/CD -/: hour/NN esophageal/NN impedance/NN and/CC pH/NN monitoring/NN 
294085_3_12_13_4_5::medicine.disease.risk_factors::indicate/VBP that/IN parenting/NN stress/NN moderates/NNS the/DT association/NN between/IN bullying/VBG victimization/NN and/CC anxiety/NN ./. 
245350_6_20_22_20_21::medicine.drug_ingredient.active_moiety_of_drug::the/DT upregulation/NN of/IN insulin/NN receptor/NN in/IN liver/NN 
522582_0_14_15_8_9::None::,/, and/CC rumination/NN predict/VBP depressive/JJ and/CC anxiety/NN symptoms/NNS in/IN young/JJ adolescents/NNS ./. 
2064_2064_40_41_49_50::NEG_ACTION_CORELATE::,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
420079_6_33_34_1_2::None::During/IN pregnancy/NN ,/, acute/JJ kidney/NN injury/NN (/( 5/CD //: 8/CD )/) ,/, anemia/NN (/( 5/CD //: 8/CD )/) ,/, hematuria/NN (/( 8/CD //: 8/CD )/) and/CC proteinuria/NN (/( 8/CD //: 8/CD )/) were/VBD common/JJ ./. 
374_374_14_15_6_7::POS_REG(0)_INACTIVATE::enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC deletion/NN of/IN SIR1/NN or/CC SIR3/NN did/VBD not/RB affect/VB 
576_576_9_10_22_23::POS_ACTION_DEPOLYMERIZE::the/DT regulation/NN of/IN cofilin/NN ,/, a/DT ubiquitous/JJ actin-binding/JJ protein/NN that/WDT is/VBZ essential/JJ for/IN effective/JJ depolymerization/NN of/IN actin/NN filaments/NNS ./. 
315432_4_19_20_14_16::None::used/VBN to/TO assess/VB negative/JJ reinforcement/NN and/CC NAc/NN dopaminergic/JJ transmission/NN ./. 
95125_0_4_5_0_1::None::Aedes/NNS aegypti/NNS is/VBZ a/DT primary/JJ vector/NN of/IN dengue/NN 
322972_6_26_27_27_28::medicine.disease.symptoms::with/IN or/CC without/IN CF/NN disease/NN ./. 
2222_2222_37_38_19_20::None::,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB at/IN cell-cell/JJ borders/NNS ,/, whereas/IN the/DT focal/JJ contact/NN proteins/NNS ,/, paxillin/NN and/CC talin/NN ,/, 
253162_8_32_33_1_2::None::All/DT IgG/NN subclasses/NNS (/( IgG1/NN //: IgG2a/NN //: IgG2b/NN //: IgG3/NN )/) were/VBD elicited/VBN by/IN omvPV/NN and/CC in/IN a/DT lower/JJR magnitude/NN by/IN wPV/NN ,/, but/CC not/RB by/IN aPV/NN (/( IgG1/NN )/) or/CC infection/NN (/( IgG2a/NN //: 
553793_3_52_54_15_16::None::AF/NN receiving/VBG oral/JJ anticoagulants/NNS and/CC compare/VB QOL/NN of/IN patients/NNS treated/VBN with/IN vitamin/NN K/NN antagonists/NNS (/( VKA/NN )/) and/CC DOAC/NN This/DT prospective/JJ study/NN included/VBD patients/NNS of/IN 65/CD years/NNS and/CC over/IN ,/, receiving/VBG anticoagulants/NNS for/IN AF/NN (/( VKA/NN or/CC DOAC/NN )/) from/IN general/JJ practice/NN (/( n/NN =/JJ 
313724_3_7_8_13_14::None::of/IN these/DT tumors/NNS presenting/VBG acutely/RB with/IN intracranial/JJ hemorrhage/NN in/IN adult/JJ patients/NNS ./. 
315964_1_17_18_19_20::medicine.drug.active_moieties::,/, such/JJ as/IN aluminum/NN (/( Al/NNP )/) and/CC manganese/NN 
365_365_30_31_15_16::None::cyclin-dependent/JJ kinase/NN inhibitor/NN p27KIP1/NN may/MD be/VB involved/VBN in/IN subversion/NN of/IN the/DT G1/S/NN traverse/NN by/IN signaling/NN pathways/NNS activated/VBN by/IN HER-2/NN function/NN ./. 
113665_4_81_82_25_26::None::adaptation/NN by/IN suppressing/VBG GABAA/NNP R/NN -/: mediated/VBN serial/NN inhibition/NN onto/IN rod/NN DBC/NNP GABAC/NNP Rs/NN Block/NN of/IN D1/NN receptors/NNS does/VBZ not/RB suppress/VB rod/NN -/: driven/VBN DBC/NN sensitivity/NN when/WRB GABAA/NNP -/: mediated/VBN serial/NN inhibition/NN is/VBZ blocked/VBN by/IN gabazine/NN ,/, suggesting/VBG that/IN the/DT reduction/NN in/IN rod/NN -/: driven/VBN DBC/NN sensitivity/NN in/IN the/DT absence/NN of/IN D1/NN receptors/NNS is/VBZ due/JJ to/TO disinhibition/NN of/IN serial/JJ inhibitory/JJ GABAergic/NN circuitry/NN rather/RB 
2081_2081_30_31_18_19::POS_REG(0)_CONTROL::pool/NN of/IN unpolymerized/JJ actin/NN and/CC the/DT flux/NN of/IN actin/NN subunits/NNS through/IN filaments/NNS are/VBP controlled/VBN by/IN profilin/NN and/CC free/JJ filament/NN 
250070_2_85_88_52_53::None::Kidney/NN Disease/NN Epidemiology/NNP Collaboration/NNP (/( CKD/NNP -/: EPI/NN )/) creatinine/NN and/CC cystatin/NN C/NN -/: creatinine/NN ]/) were/VBD associated/VBN with/IN markers/NNS of/IN systemic/JJ inflammation/NN [/( high/JJ -/: sensitivity/NN C/NN -/: reactive/JJ protein/NN ,/, interleukin/NN -/: 6/CD ,/, tumour/NN necrosis/NN factor/NN (/( TNF/NN )/) 
492455_9_17_18_9_10::None::limited/JJ function/NN in/IN screening/VBG for/IN AD/NN among/IN a/DT highly/RB comorbid/JJ inpatient/JJ sample/NN of/IN severely/RB affected/VBN 
223084_8_10_11_3_4::None::Hypercholesterolaemia/NN ,/, chronic/JJ coronary/JJ artery/NN disease/NN ,/, diabetes/NN and/CC hypertension/NN predicted/VBD AMI/NNP in/IN multivariate/JJ 
567_567_14_15_18_19::POS_ACTION_BIND::)/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC FADD/NN ./. 
92623_1_0_1_4_5::None::It/PRP is/VBZ the/DT largest/JJS genus/NN of/IN Actinobacteria/NNP comprising/VBG 
996_996_31_34_8_9::None::cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) cyclin-dependent/JJ kinase/NN inhibitor/NN ./. 
1866_1866_7_8_12_13::None::and/CC DR4/NN use/VBP FADD/NN ,/, TRADD/NN ,/, and/CC RIP/NN in/IN their/PRP$ signal/NN 
1553_1553_38_39_45_46::POS_ACTION_COLOCALIZE::daltons/NNS )/) ,/, actin/NN (/( 43,000/CD daltons/NNS )/) ,/, and/CC calmodulin/NN (/( 17,000/CD daltons/NNS 
685990_8_3_4_19_20::None::Fifty/CD of/IN the/DT cases/NNS (/( 61.7/CD %/NN )/) were/VBD classified/VBN as/IN being/VBG at/IN a/DT high/JJ risk/NN of/IN having/VBG OSA/NN compared/VBN with/IN only/RB 19/CD 
241386_9_16_17_24_25::None::promising/JJ candidates/NNS for/IN monitoring/NN and/CC treating/VBG mesothelioma/NN and/CC other/JJ mesothelin/NN -/: expressing/VBG cancers/NNS ./. 
607039_6_6_7_8_9::medicine.medical_treatment.used_to_treat::an/DT overview/NN of/IN arthroplasty/NN in/IN RA/NN ,/, summarizes/VBZ the/DT 
761772_0_13_14_11_12::biology.organism_classification.lower_classifications::to/TO the/DT order/NN Passeriformes/NN of/IN bird/NN species/NNS and/CC is/VBZ 
807975_0_17_18_0_1::None::Effects/NNS of/IN the/DT triple/JJ monoamine/NN uptake/NN inhibitor/NN amitifadine/NN on/IN pain/NN -/: related/JJ depression/NN of/IN behavior/NN and/CC mesolimbic/JJ dopamine/NN release/NN in/IN rats/NNS 
938_938_0_2_14_15::POS_REG(0)_MODIFY::LIM-kinase/NN 1/CD (/( LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ factor/NN ,/, and/CC regulates/VBZ actin/NN cytoskeletal/JJ reorganization/NN ./. 
707254_1_48_49_26_27::medicine.medical_treatment.used_to_treat::by/IN testosterone/NN in/IN high/JJ concentrations/NNS involves/VBZ increments/NNS in/IN tumor/NN necrosis/NN factor/NN -/: alpha/NN (/( TNF/NN -/: alpha/NN )/) concentrations/NNS and/CC angiotensin/NN -/: converting/VBG enzyme/NN (/( ACE/NN )/) activity/NN in/IN 
620872_0_14_15_18_19::biology.organism_classification.lower_classifications::Antibody/NN Responses/NNS to/TO Murine/JJ Monoclonal/JJ Antibody/NN in/IN Mice/NNS 
410007_10_3_4_12_13::None::Geographical/JJ and/CC age/NN differences/NNS influence/VBP the/DT distribution/NN of/IN P/NN vivax/NN and/CC P/NN falciparum/NN malaria/NN in/IN Ethiopia/NNP 
1296_1296_3_4_9_10::None::Stimulus-dependent/JJ disorganization/NN of/IN actin/NN filaments/NNS induced/VBN by/IN overexpression/NN of/IN cofilin/NN in/IN C2/NN myoblasts/NNS 
215150_5_17_18_14_15::None::improvements/NNS in/IN depressive/JJ symptoms/NNS were/VBD partially/RB mediated/VBN by/IN improvements/NNS in/IN 
1861_1861_15_16_2_3::POS_ACTION_MUTUALCOMPLEX::Thus/RB ,/, APC/NN forms/NNS distinct/JJ heteromeric/JJ complexes/NNS containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN which/WDT are/VBP independent/JJ 
725268_1_38_39_11_12::medicine.symptom.symptom_of::it/PRP is/VBZ not/RB clear/JJ what/WP role/NN the/DT observed/VBN bias/NN toward/IN the/DT time/NN -/: left/VBD option/NN plays/NNS in/IN this/DT procedure/NN and/CC there/EX are/VBP no/DT reports/NNS of/IN how/WRB variability/NN changes/NNS with/IN predicted/VBN indifference/NN ./. 
395871_8_22_23_6_7::None::mass/NN loss/NN during/IN neoadjuvant/JJ chemoradiotherapy/NN may/MD provide/VB a/DT readily/RB available/JJ and/CC inexpensive/JJ assessment/NN to/TO identify/VB patients/NNS at/IN risk/NN for/IN developing/VBG unfavorable/JJ postoperative/JJ outcome/NN 
2137_2137_4_5_19_20::POS_ACTION_BIND::previously/RB showed/VBD that/IN actin/NN is/VBZ transported/VBN in/IN an/DT unassembled/JJ form/NN with/IN its/PRP$ associated/JJ proteins/NNS actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
784_784_4_5_21_22::None::normal/JJ livers/NNS ,/, E-cad/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN ,/, were/VBD expressed/VBN 
406221_0_7_8_8_9::None::prescribing/VBG rate/NN in/IN patients/NNS suffering/VBG from/IN acute/JJ exacerbations/NNS 
553943_2_16_17_13_16::None::contrast/NN -/: enhanced/VBN magnetic/JJ resonance/NN imaging/NN data/NNS from/IN bevacizumab/NN -/: 
429997_1_30_31_26_27::None::subset/NN of/IN younger/JJR men/NNS who/WP have/VBP taken/VBN finasteride/NN 1/CD mg/NN for/IN 
364545_7_18_19_7_8::None::the/DT role/NN of/IN MS/NN type/NN 1/CD fimbriae/NN in/IN the/DT induction/NN of/IN cytokine/NN expression/NN and/CC secretion/NN ,/, using/VBG murine/JJ 
367_367_28_30_26_27::None::as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
1486_1486_32_33_24_25::None::the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ 
379222_0_4_7_12_13::None::diagnosis/NN of/IN critical/JJ congenital/JJ heart/NN disease/NN reduces/VBZ risk/NN of/IN death/NN from/IN cardiovascular/JJ compromise/NN prior/RB to/TO 
607_607_19_20_8_9::POS_ACTION_ENCODE::expresses/VBZ a/DT heterotrimeric/JJ helicase-primase/NN ,/, the/DT subunits/NNS of/IN which/WDT are/VBP encoded/VBN by/IN the/DT viral/JJ UL5/NN ,/, UL8/NN and/CC 
279_279_19_20_30_31::POS_ACTION_CONTAIN::a/DT previously/RB characterized/VBN eIF3/NN subunit/NN ,/, and/CC a/DT novel/JJ protein/NN of/IN 33/CD kDa/NN (/( eIF3-p33/NN )/) which/WDT is/VBZ 
510403_0_0_1_1_2::None::In/IN subjects/NNS without/IN kidney/NN disease/NN 
1858_1858_8_9_2_3::POS_ACTION_BIND::Thus/RB ,/, actin/NN was/VBD found/VBN in/IN association/NN with/IN fimbrin/NN in/IN the/DT mechanoreceptive/JJ 
163_163_8_9_5_6::None::from/IN Acanthamoeba/NN binds/VBZ profilin/NN and/CC cross-links/NNS actin/NN filaments/NNS ./. 
2181_2181_25_26_17_18::None::determine/VB how/WRB much/JJ profilin/NN is/VBZ bound/VBN to/TO its/PRP$ known/JJ ligands/NNS :/: actin/NN ,/, membrane/NN PIP/NN 
174613_5_15_16_0_1::None::Further/JJ challenge/NN by/IN increasing/VBG AngII/NN results/NNS in/IN preeclampsia/NN -/: like/IN symptoms/NNS ,/, namely/RB ,/, more/RBR severe/JJ hypertension/NN ,/, proteinuria/NN 
1578_1578_5_6_9_10::POS_ACTION_BIND::assembly/NN of/IN the/DT talin/NN homologue/NN together/RB with/IN actin/NN and/CC a/DT series/NN 
1423_1423_28_30_36_37::POS_ACTION_MEMBER::overlap/VBP to/TO animal/NN actin-depolymerizing/JJ factors/NNS (/( ADF/NN )/) ,/, cofilin/NN and/CC destrin/NN ./. 
515725_7_25_27_21_24::medicine.disease.symptoms::breathing/NN problems/NNS ,/, high/JJ blood/NN pressure/NN ,/, heart/NN disease/NN ,/, stroke/NN and/CC 
528491_0_39_40_26_27::None::(/( eg/FW missing/VBG school/NN )/) ,/, and/CC low/JJ mood/NN (/( eg/FW high/JJ levels/NNS of/IN depression/NN and/CC anxiety/NN )/) ./. 
355_355_16_17_12_13::POS_ACTION_Causal::mutant/JJ form/NN of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD 
72_72_0_1_17_18::POS_ACTION_LOCALIZE-TO::Aip1p/NN localizes/VBZ to/TO cortical/JJ actin/NN patches/NNS in/IN yeast/NN cells/NNS ,/, and/CC this/DT localization/NN is/VBZ disrupted/VBN by/IN specific/JJ actin/NN and/CC cofilin/NN mutations/NNS 
108257_1_3_4_2_3::medicine.symptom.symptom_of::Expectations/NNS of/IN high/JJ pain/NN can/MD exacerbate/VB pain/NN 
109645_7_3_5_4_5::medicine.disease.risk_factors::We/PRP found/VBD that/IN endometrial/JJ cancer/NN was/VBD overrepresented/VBN in/IN 
243_243_30_32_32_35::POS_ACTION_MEMBER::VEGF165/NN function/NN through/IN tyrosine/NN kinase/NN VEGF/NN receptor/NN 2/CD (/( VEGFR-2/NN )/) 
1303_1303_7_8_5_6::POS_ACTION_INTERACT::the/DT interaction/NN between/IN actin/NN and/CC cofilin/NN purified/VBN by/IN a/DT 
185_185_4_5_2_3::POS_ACTION_BIND::Associations/NNS of/IN UBE2I/NN with/IN RAD52/NN ,/, UBL1/NN ,/, 
1233_1233_28_29_19_24::None::,/, desmin/NN and/CC smooth/VB muscle/NN myosin/NN heavy/JJ chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC SMemb/NN ./. 
71991_0_26_27_13_14::None::problems/NNS ,/, including/VBG depression/NN //: anxiety/NN disorder/NN ,/, insomnia/NN //: sleep/VB disorder/NN ,/, fatigue/NN ,/, and/CC injury/NN by/IN accident/NN ,/, 
336146_1_17_18_9_11::None::prevalence/NN of/IN Chinese/JJ herbal/JJ products/NNS containing/VBG coumestrol/NN ,/, genistein/NN ,/, or/CC daidzein/NN and/CC their/PRP$ association/NN 
245220_2_0_1_16_17::None::We/PRP investigated/VBD whether/IN silencing/NN of/IN miR/NN -/: 195/CD reduces/VBZ diabetic/JJ cardiomyopathy/NN in/IN a/DT mouse/NN model/NN of/IN streptozotocin/NN (/( STZ/NN )/) 
1227_1227_10_11_26_27::None::two-hybrid/JJ screen/NN using/VBG MSH2/NN as/IN ``/`` bait/NN ,/, ''/'' and/CC pairwise/JJ interactions/NNS between/IN MSH2/NN and/CC RAD1/NN ,/, RAD2/NN ,/, RAD3/NN ,/, RAD10/NN ,/, 
268989_5_59_61_47_48::people.cause_of_death.includes_causes_of_death::the/DT maintenance/NN of/IN prostate/NN CSCs/NNS More/RBR importantly/RB ,/, we/PRP found/VBD that/IN Tie/NN -/: 2High/NN prostate/NN cancer/NN cells/NNS are/VBP more/RBR adhesive/JJ 
214438_2_1_2_4_5::None::Forty/CD SD/NN rats/NNS were/VBD randomly/RB divided/VBN into/IN sham/NN 
12641_5_51_52_14_15::None::(/( RC/NN )/) subjects/NNS experienced/JJ 268/CD %/NN (/( 3.14/CD //: 1.17/CD )/) more/RBR total/JJ mood/NN episodes/NNS //: year/NN ,/, and/CC 293/CD %/NN (/( 1.29/CD //: 0.44/CD )/) more/RBR depressive/JJ episodes/NNS //: year/NN ,/, compared/VBN with/IN non/JJ -/: rapid/JJ cycling/NN (/( NRC/NNP )/) subjects/NNS (/( 
515_515_5_6_10_11::None::work/NN ,/, the/DT BNI1/NN ,/, GIC1/NN ,/, and/CC GIC2/NN gene/NN products/NNS also/RB 
776_776_28_29_4_6::None::infected/JJ cells/NNS ,/, C/NN protein/NN was/VBD detected/VBN exclusively/RB in/IN the/DT cytoplasm/NN as/IN granular/JJ fluorescence/NN ,/, which/WDT coincided/VBD very/RB well/RB with/IN the/DT distribution/NN of/IN nucleocapsid/JJ protein/NN NP/NN and/CC phosphoprotein/NN P/NN ,/, which/WDT 
2064_2064_49_50_6_7::None::the/DT down-regulation/NN of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
372_372_30_31_28_29::None::localization/NN of/IN the/DT UL5/NN and/CC UL52/NN proteins/NNS ./. 
93_93_54_55_6_7::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN 
1427_1427_3_4_27_28::POS_ACTION_BIND::The/DT comparison/NN of/IN E-CD/NN proteins/NNS synthesized/VBN by/IN E62/NN and/CC E24/NN cell/NN lines/NNS revealed/VBD no/DT structural/JJ or/CC functional/JJ differences/NNS because/IN both/DT localized/JJ at/IN cell-cell/JJ contacts/NNS and/CC associated/VBN with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
881131_8_29_30_10_11::None::ESCC/NN and/CC its/PRP$ interactions/NNS with/IN alcohol/NN drinking/NN and/CC //: or/CC smoking/NN highlights/VBZ the/DT significance/NN of/IN reducing/VBG salted/JJ meat/NN intake/NN among/IN smokers/NNS and/CC drinkers/NNS with/IN respect/NN to/TO 
2146_2146_9_10_14_15::None::LIMK2/NN phosphorylate/VBP both/DT cofilin/NN and/CC actin-depolymerizing/JJ factor/NN (/( ADF/NN )/) specifically/RB at/IN 
510403_0_21_22_1_2::None::In/IN subjects/NNS without/IN kidney/NN disease/NN ,/, adiponectin/NN appears/VBZ to/TO have/VB anti/JJ -/: inflammatory/JJ ,/, anti/JJ -/: diabetic/JJ ,/, and/CC anti/JJ -/: atherogenic/JJ effects/NNS ./. 
1850_1850_2_3_23_24::None::beta-catenin/NN or/CC plakoglobin/NN is/VBZ associated/VBN directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN and/CC serves/VBZ to/TO link/VB the/DT cadherin/catenin/NN complex/NN to/TO the/DT actin/NN cytoskeleton/NN ./. 
2131_2131_10_11_13_14::None::UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ 
637206_9_10_11_12_13::None::The/DT prevalence/NN and/CC incidence/NN of/IN RRT/NNP continues/VBZ to/TO increase/VB 
1234_1234_15_16_34_35::POS_ACTION_BIND::used/VBN to/TO extract/VB gelsolin/NN and/CC profilin/NN ,/, respectively/RB ,/, from/IN EGTA-containing/JJ platelet/NN extracts/NNS and/CC determine/VB the/DT proportion/NN of/IN these/DT molecules/NNS bound/VBD to/TO actin/NN with/IN sufficient/JJ affinity/NN 
202451_1_3_4_26_27::None::The/DT X/NN -/: ray/NN crystal/NN structure/NN of/IN the/DT host/NN N2/NN ,/, N5/NN -/: bis/NN (/( 6/CD -/: methylpyridin/NN -/: 2/LS -/: yl/NN )/) -/: 3,4/SYM -/: diphenyl/NN -/: 1H/NN -/: 
489_489_9_10_20_21::POS_ACTION_AFFECT::of/IN three/CD putative/JJ PCAF/NN substrates/NNS ,/, histones/NNS H3/NN and/CC H4/NN and/CC the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP 
1069_1069_36_37_21_22::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC 
2030_2030_18_19_3_4::None::We/PRP conclude/VBP that/IN Aip1p/NN is/VBZ a/DT cofilin-associated/JJ protein/NN that/WDT enhances/VBZ the/DT filament/NN disassembly/NN activity/NN of/IN cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ 
761186_8_7_8_20_21::None::interest/NN was/VBD the/DT presence/NN of/IN any/DT CAD/NN (/( n/NN =/JJ 176/CD )/) ,/, including/VBG MI/NNP ,/, angina/NN ,/, and/CC stroke/NN 
1814_1814_18_19_11_12::POS_ACTION_BIND::storage/NN pool/NN of/IN actin/NN bound/VBD to/TO the/DT sequestering/NN protein/NN ,/, profilin/NN ./. 
1486_1486_60_61_4_5::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB via/IN p38/NN MAPK/NN ,/, may/MD be/VB involved/VBN in/IN the/DT muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
856_856_22_23_13_14::None::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN 
774440_0_0_1_24_25::medicine.risk_factor.diseases::Obesity/NN is/VBZ a/DT major/JJ cause/NN for/IN a/DT spectrum/NN of/IN metabolic/JJ syndrome/NN -/: related/JJ diseases/NNS that/WDT include/VBP insulin/NN resistance/NN ,/, type/NN 2/CD diabetes/NN ,/, and/CC steatosis/NN of/IN the/DT liver/NN 
379013_1_31_32_15_17::None::high/JJ -/: fructose/NN corn/NN syrup/NN (/( HFCS/NN )/) at/IN zero/CD ,/, low/JJ ,/, medium/NN ,/, and/CC high/JJ proportions/NNS of/IN energy/NN requirements/NNS (/( Ereq/NN 
234343_0_0_1_7_8::None::What/WP is/VBZ the/DT best/JJS anticoagulant/JJ therapy/NN during/IN primary/JJ percutaneous/JJ coronary/JJ intervention/NN 
2064_2064_40_41_6_7::None::the/DT down-regulation/NN of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN 
450_450_45_46_28_29::None::binding/NN surface/NN between/IN actin/NN and/CC thymosin/NN beta/NN (/( 4/CD )/) ,/, and/CC explain/VB why/WRB thymosin/NN beta/NN (/( 4/CD )/) and/CC profilin/NN can/MD bind/VB simultaneously/RB 
235710_2_17_18_9_10::None::effects/NNS on/IN menstrual/JJ irregularity/NN and/CC androgen/NN system/NN in/IN PCOS/NN women/NNS with/IN hyperprolactinemia/NN ./. 
1082_1082_11_12_38_39::POS_ACTION_COLOCALIZE::mobile/JJ form/NN of/IN actin/NN in/IN slow/JJ transport/NN is/VBZ soluble/JJ and/CC that/IN a/DT substantial/JJ amount/NN of/IN this/DT actin/NN may/MD travel/VB as/IN a/DT complex/NN with/IN actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ./. 
386606_0_9_10_5_6::None::in/IN oral/JJ cancer/NN surgery/NN :/: Room/NN for/IN improvement/NN ./. 
1782_1782_27_28_25_26::None::,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: adaptor/NN proteins/NNS 
76365_0_30_32_24_25::None::by/IN order/NN of/IN frequency/NN ,/, phobic/JJ disorders/NNS and/CC generalized/VBN anxiety/NN disorder/NN rank/NN ahead/RB of/IN 
132031_1_10_12_47_48::None::diabetes/NN and/CC high/JJ cardiovascular/JJ risk/NN were/VBD enrolled/VBN during/IN a/DT run/NN -/: in/IN period/NN on/IN basal/JJ -/: bolus/NN insulin/NN (/( BBI/NN )/) ,/, and/CC 102/CD were/VBD randomized/VBN to/TO continued/VBN BBI/NNP or/CC to/TO basal/JJ insulin/NN with/IN a/DT prandial/JJ GLP/NN -/: 1/CD receptor/NN agonist/NN (/( GLIPULIN/NN )/) 
1534_1534_9_10_26_29::POS_ACTION_Change::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( 
491933_11_8_9_7_8::None::importance/NN of/IN alcohol/NN consumption/NN measures/NNS in/IN public/JJ health/NN 
747_747_30_31_27_28::None::of/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN relative/JJ to/TO Apc/NN 
1069_1069_36_37_24_25::None::helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC 
1037_1037_21_22_24_26::None::the/DT translational/JJ regulator/NN RAFT1/NN ,/, and/CC actin-binding/JJ proteins/NNS like/IN profilin/NN might/MD 
14211_8_23_24_12_13::None::that/IN in/FW vitro/FW drug/NN sensitivity/NN test/NN ,/, which/WDT is/VBZ easy/JJ to/TO perform/VB ,/, may/MD predict/VB the/DT outcome/NN of/IN 
756738_0_21_22_6_7::None::are/VBP the/DT most/RBS common/JJ non/JJ -/: cardiovascular/JJ causes/NNS of/IN death/NN in/IN patients/NNS on/IN chronic/JJ renal/JJ replacement/NN therapy/NN (/( RRT/NN )/) ./. 
540626_0_14_15_3_4::None::C/NN -/: peptide/NN immunoreactivity/NN index/NN is/VBZ associated/VBN with/IN improvement/NN of/IN HbA1c/NN :/: 2/LS -/: Year/NN follow/VBP -/: up/IN 
712_712_23_24_24_25::POS_ACTION_MEMBER::interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN 
967935_1_14_15_17_18::None::Triatominae/FW genomes/NNS by/IN Genomic/JJ in/FW situ/FW Hybridization/NN using/VBG Triatoma/NN delpontei/NN 
243_243_3_4_27_28::POS_ACTION_BIND::Neuropilin/NNP 1/CD (/( NP-1/NN )/) is/VBZ a/DT receptor/NN for/IN vascular/JJ endothelial/JJ growth/NN factor/NN (/( VEGF/NN )/) 165/CD (/( VEGF165/NN )/) and/CC acts/VBZ as/IN a/DT coreceptor/NN that/WDT enhances/VBZ VEGF165/NN function/NN through/IN tyrosine/NN 
1344_1344_6_7_20_21::POS_ACTION_BIND::these/DT three/CD mutant/JJ UL5/NN proteins/NNS to/TO form/VB specific/JJ interactions/NNS with/IN other/JJ members/NNS of/IN the/DT helicase-primase/JJ complex/NN ,/, UL8/NN and/CC UL52/NN ,/, 
122457_3_3_4_7_8::None::Although/IN advances/NNS in/IN gene/NN sequencing/NN technologies/NNS have/VBP identified/VBN several/JJ genetic/JJ variants/NNS 
307348_1_31_32_19_20::medicine.risk_factor.diseases::lead/VBP to/TO a/DT wide/JJ spectrum/NN of/IN symptoms/NNS and/CC disabilities/NNS ,/, such/JJ as/IN cognitive/JJ deficits/NNS ,/, mood/NN or/CC anxiety/NN disorders/NNS 
2013_2013_0_1_0_1::None::WASp/NN contains/VBZ a/DT binding/NN 
2222_2222_11_12_13_14::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, 
138079_4_9_10_5_6::None::remaining/VBG 100/CD Mycobacterium/NN tuberculosis/NN isolates/NNS ,/, the/DT resistance/NN rates/NNS were/VBD 7/CD 
822180_0_19_20_28_29::medicine.disease.treatments::to/TO treat/VB this/DT illness/NN without/IN the/DT major/JJ immunological/JJ complications/NNS associated/VBN with/IN allogeneic/JJ transplantation/NN ./. 
397285_3_8_9_0_1::None::IL/NN -/: 10/CD ,/, an/DT anti/JJ -/: inflammatory/JJ cytokine/NN associated/VBN with/IN tumour/NN 
846_846_12_13_16_17::None::the/DT polymerization/NN of/IN actin/NN from/IN A/DT :/: Tbeta4/NN ./. 
441567_0_12_13_15_16::None::UDCA/NN )/) and/CC rifampicin/NN treatment/NN in/IN intrahepatic/JJ cholestasis/NN of/IN pregnancy/NN 
2064_2064_8_9_28_29::None::of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN 
427379_2_12_13_33_34::medicine.risk_factor.diseases::CIH/NN )/) of/IN OSAS/NN patients/NNS may/MD per/FW se/FW trigger/NN liver/NN injury/NN ,/, inflammation/NN ,/, and/CC fibrogenesis/NN ,/, promoting/VBG NAFLD/NNP development/NN and/CC the/DT progression/NN from/IN steatosis/NN to/TO steatohepatitis/NN ,/, 
1633_1633_32_33_15_16::None::;/: four/CD histone/NN H2a/NN genes/NNS ,/, two/CD of/IN which/WDT are/VBP identical/JJ ,/, one/CD histone/NN H4/NN gene/NN ;/: and/CC two/CD histone/NN H2b/NN genes/NNS ./. 
259277_3_13_14_25_26::None::patients/NNS with/IN cardioembolic/JJ infarction/NN ,/, hypertension/NN and/CC diabetes/NN in/IN patients/NNS with/IN lacunar/NN stroke/NN ,/, and/CC vascular/JJ peripheral/JJ disease/NN ,/, 
537_537_6_7_18_19::None::inactivating/VBG effect/NN of/IN calmodulin/NN can/MD be/VB prevented/VBN by/IN coexpressing/VBG a/DT region/NN of/IN the/DT cytoskeletal/JJ protein/NN alpha-actinin2/NN known/VBN to/TO interact/VB 
664393_0_9_11_14_15::None::early/JJ -/: stage/NN breast/NN cancer/NN :/: ready/JJ for/IN primetime/NN ./. 
888419_2_6_7_9_10::None::scores/NNS have/VBP been/VBN developed/VBN for/IN adult/JJ patients/NNS with/IN NAFLD/NN ;/: 
231976_9_21_22_4_5::medicine.drug_ingredient.active_moiety_of_drug::results/VBZ demonstrated/VBD similar/JJ thrombin/NN ,/, fibrinogen/NN ,/, and/CC platelet/NN function/NN on/IN Day/NN 28/CD LP/NN compared/VBN with/IN Day/NN 5/CD thawed/VBD FFP/NNP Thrombin/NN generation/NN assays/NNS revealed/VBD 
1008_1008_8_9_10_11::None::,/, which/WDT encode/VBP profilin/NN and/CC tropomyosin/NN respectively/RB ,/, display/VBP 
68_68_16_17_14_15::None::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB 
301320_2_50_51_52_53::medicine.disease.risk_factors::compulsive/JJ disorder/NN ,/, schizophrenia/NN ,/, drug/NN -/: induced/VBN neuropathy/NN 
34_34_13_14_19_20::POS_ACTION_Physical::the/DT effect/NN of/IN profilin/NN on/IN the/DT thermal/JJ stability/NN of/IN actin/NN was/VBD studied/VBN ./. 
394705_2_79_80_49_50::None::B/NN Death/NN -/: censored/VBN graft/NN survivals/NNS were/VBD 93/CD %/NN for/IN group/NN A/NN and/CC 95/CD %/NN for/IN group/NN B/NN Graft/NN function/NN was/VBD significantly/RB better/JJR at/IN 8/CD years/NNS ,/, with/IN 91/CD %/NN of/IN group/NN A/NN patients/NNS compared/VBN with/IN 50/CD 
513_513_9_10_17_19::POS_REG(+)_Assembly::,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO promote/VB U2/NN snRNP/NN binding/NN to/TO pre-mRNA/NN 
1926_1926_13_14_26_27::None::as/IN that/DT of/IN FLICE/NNP ,/, Fas/NN ,/, FADD/NN ,/, DR3/NN ,/, FAF/NN ,/, TRADD/NN ,/, and/CC RIP/NN was/VBD similar/JJ in/IN 
132031_1_46_47_56_57::None::GLP/NN -/: 1/CD receptor/NN agonist/NN (/( GLIPULIN/NN )/) group/NN ,/, each/DT seeking/VBG to/TO maintain/VB HbA1c/NN levels/NNS between/IN 
112987_0_34_35_35_36::None::investigate/VB the/DT acid/NN dissociation/NN equilibrium/NN of/IN HN3/NN in/IN 
423761_7_30_33_17_18::None::IgG3/NN ,/, and/CC total/JJ IgG/NN in/IN female/JJ mice/NNS ,/, indicating/VBG negative/JJ regulation/NN of/IN antibody/NN production/NN by/IN female/JJ sex/NN hormones/NNS ./. 
770_770_11_12_8_11::None::or/CC induction/NN of/IN cyclin-dependent/JJ kinase/NN inhibitor/NN p21WAF1/NN expression/NN was/VBD found/VBN 
1061_1061_2_3_6_7::None::One/CD ,/, MORT1/NN (/( also/RB called/VBN FADD/NN )/) ,/, binds/VBZ 
416_416_5_6_1_2::POS_ACTION_AFFECT::Dynamic/NNP actin/NN structures/NNS stabilized/VBN by/IN profilin/NN ./. 
2030_2030_18_19_18_19::None::cofilin/NN and/CC restricts/VBZ cofilin/NN localization/NN to/TO cortical/JJ 
872597_0_13_14_2_4::None::Coyotes/NNS (/( Canis/NN latrans/NNS )/) are/VBP an/DT important/JJ species/NNS in/IN human/JJ -/: inhabited/VBN areas/NNS ./. 
2013_2013_0_1_20_21::POS_ACTION_MODULATE::WASp/NN contains/VBZ a/DT binding/NN motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN verprolin/cofilin-like/JJ actin-regulatory/JJ domains/NNS ,/, but/CC no/DT specific/JJ actin/NN structure/NN regulated/VBN by/IN 
257215_0_39_41_19_20::medicine.drug.active_moieties::-/: SS/NN -/: HA/NN )/) based/VBN on/IN mesoporous/JJ silica/NN nanoparticles/NNS (/( MSN/NNP )/) for/IN targeted/VBN drug/NN delivery/NN has/VBZ been/VBN developed/VBN ,/, in/IN which/WDT hyaluronic/JJ acid/NN (/( HA/NN )/) 
825_825_15_16_10_11::None::capping/VBG protein/NN and/CC profilin/NN in/IN remodeling/NN of/IN branched/VBN actin/NN filament/NN networks/NNS ./. 
872_872_8_9_11_12::None::of/IN MSH2/NN ,/, MSH3/NN ,/, and/CC MSH6/NN in/IN mismatch/NN repair/NN 
2003_2003_26_27_33_34::POS_ACTION_MODULATE::]/) for/IN binding/VBG profilin/NN ,/, an/DT actin-regulatory/JJ protein/NN that/WDT stimulates/VBZ actin/NN filament/NN assembly/NN ./. 
856_856_24_25_13_14::None::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN is/VBZ the/DT 
322_322_2_3_19_20::POS_ACTION_LOCALIZE::Cofilin/NNP and/CC profilin/NN may/MD also/RB be/VB involved/VBN in/IN the/DT redistribution/NN of/IN actin/NN during/IN myofibrillogenesis/NN and/CC in/IN the/DT process/NN of/IN actin/NN disassembly/NN in/IN degenerating/VBG 
589175_4_6_7_0_1::None::Thus/RB ,/, 79/CD %/NN of/IN lung/NN adenocarcinomas/NNS from/IN never/RB -/: 
1334_1334_27_28_17_18::NEG_ACTION_BIND::suppressed/VBD defects/NNS in/IN actin/NN organization/NN ,/, cell/NN growth/NN ,/, and/CC fluid-phase/JJ endocytosis/NN of/IN pfy1-4/NN ,/, a/DT profilin/NN 
93_93_22_23_6_7::None::of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN 
1652_1652_45_46_43_44::None::of/IN beta-catenin/NN ,/, cadherin/NN and/CC alpha-catenin/NN ,/, can/MD sequester/VB 
1380_1380_36_37_40_41::None::,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN 
428759_1_8_9_23_24::None::therapeutic/JJ agents/NNS showed/VBD viable/JJ antitumor/NN clinical/JJ response/NN in/IN recurrent/JJ and/CC metastatic/JJ disease/NN :/: bevacizumab/NN ,/, cediranib/NN ,/, and/CC immunotherapies/NNS including/VBG human/JJ papillomavirus/NN 
337142_1_25_27_28_29::medicine.drug.active_moieties::)/) ,/, and/CC adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) in/IN chum/NN 
514561_0_17_18_12_13::None::cardiovascular/JJ protection/NN through/IN high/JJ -/: density/NN lipoprotein/NN (/( HDL/NN )/) is/VBZ only/RB 
92775_0_23_24_19_21::None::be/VB optimal/JJ for/IN clinical/JJ trials/NNS to/TO test/VB potential/JJ treatments/NNS for/IN preventing/VBG 
686_686_31_32_23_24::POS_ACTION_BIND::,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT other/JJ of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC plakoglobin/NN ./. 
93_93_57_58_4_5::None::neither/CC activation/NN of/IN BCK1/NN (/( MEKK/NN )/) by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
367_367_28_30_0_2::None::Death/NN receptors/NNS belong/VBP to/TO the/DT TNF/NN receptor/NN family/NN and/CC are/VBP characterised/VBN by/IN an/DT intracellular/JJ death/NN domain/NN that/WDT serves/VBZ to/TO recruit/VB adapter/NN proteins/NNS such/JJ as/IN TRADD/NN and/CC FADD/NN and/CC cysteine/NN proteases/NNS such/JJ as/IN Caspase-8/NN 
346562_11_7_8_13_15::None::GSK1838705A/NN is/VBZ a/DT promising/JJ compound/NN for/IN the/DT treatment/NN of/IN prostate/NN cancer/NN ,/, especially/RB for/IN 
661306_5_2_3_13_14::None::Commonly/RB occurring/VBG strains/NNS included/VBD apprehension/NN //: anxiety/NN ,/, frustration/NN ,/, anger/NN ,/, and/CC sadness/NN //: depression/NN ./. 
676_676_5_6_9_10::None::of/IN actin-anchoring/JJ proteins/NNS vinculin/NN ,/, talin/NN and/CC paxillin/NN in/IN rat/NN brain/NN 
1052_1052_34_35_21_22::None::oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN 
436497_1_11_12_15_16::None::symptoms/NNS ,/, and/CC tested/VBN impulsivity/NN as/IN a/DT moderator/NN of/IN the/DT body/NN 
740032_2_32_34_18_19::medicine.disease.risk_factors::among/IN adult/JJ population/NN aged/JJ 25/CD -/: 64/CD years/NNS for/IN assessment/NN and/CC distribution/NN of/IN major/JJ risk/NN factors/NNS for/IN cardiovascular/JJ diseases/NNS (/( CVD/NN )/) 
468565_7_6_7_8_9::None::the/DT heat/NN waves/NNS ended/VBD ,/, indicating/VBG rapid/JJ physiological/JJ recovery/NN 
393_393_16_17_12_15::None::the/DT degradation/NN of/IN myosin/NN heavy/JJ chain/NN and/CC actin/NN ./. 
198817_2_39_40_8_9::None::with/IN surgically/RB treated/VBN CRC/NN (/( Group/NN A/NN =/JJ 22/CD patients/NNS )/) and/CC non/JJ -/: colorectal/JJ carcinomas/NNS (/( Group/NN B/NN =/JJ 19/CD patients/NNS )/) ,/, who/WP developed/VBD matachronous/JJ LMs/NNS and/CC underwent/VBD pulmonary/JJ metastasectomy/NN with/IN curative/JJ intent/NN ,/, were/VBD analyzed/VBN 
28475_4_2_3_88_89::None::This/DT purification/NN revealed/VBD absence/NN of/IN conventional/JJ TR/NN and/CC GR/NN The/DT glutathione/NN reductase/NN activity/NN of/IN the/DT purified/VBN TGR/NN exhibits/VBZ a/DT hysteretic/JJ behavior/NN typical/JJ of/IN flatworm/NN TGRs/NNS Consistently/RB ,/, M/NN vogae/FW genome/NN analysis/NN revealed/VBD the/DT presence/NN of/IN a/DT selenocysteine/NN -/: containing/VBG TGR/NN and/CC absenceof/JJ conventional/JJ TR/NN and/CC GR/NN M/NN vogae/FW thioredoxin/NN and/CC glutathione/NN reductase/NN activities/NNS were/VBD inhibited/VBN by/IN 3,4/CD -/: bis/NN (/( phenylsulfonyl/NN )/) -/: 1,2,5/CD -/: oxadiazole/NN N2/NN -/: oxide/NN (/( VL16E/NN )/) ,/, an/DT oxadiazole/NN N/NN -/: oxide/NN previously/RB identified/VBN as/IN an/DT inhibitor/NN of/IN fluke/NN and/CC tapeworm/NN TGRs/NNS Finally/RB ,/, we/PRP show/VBP 
991_991_17_18_4_5::POS_ACTION_Causal::known/VBN to/TO link/VB actin/NN filaments/NNS to/TO membrane/NN were/VBD also/RB examined/VBN ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, and/CC zyxin/NN 
1843_1843_31_33_12_13::None::the/DT lack/NN of/IN talin/NN ,/, a/DT protein/NN that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD ,/, 
768458_5_30_31_14_15::medicine.disease.treatments::of/IN irbesartan/NN and/CC spironolactone/NN both/CC in/IN low/JJ -/: and/CC conventional/JJ -/: dose/NN exhibited/VBD additional/JJ cardioprotection/NN against/IN PAAC/NN -/: induced/VBN cardiac/JJ remodelling/NN ./. 
583_583_12_13_14_15::POS_ACTION_BIND::containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN 
1234_1234_15_16_17_18::None::used/VBN to/TO extract/VB gelsolin/NN and/CC profilin/NN ,/, respectively/RB ,/, 
2107_2107_5_7_15_16::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ 
270415_4_52_53_13_14::None::Patient/NNP age/NN ,/, sex/NN ,/, cardiovascular/JJ risk/NN factors/NNS ,/, coronary/JJ calcium/NN score/NN (/( CCS/NN )/) ,/, and/CC EFVi/NNS were/VBD combined/VBN by/IN boosted/VBN ensemble/NN machine/NN learning/VBG algorithm/NN into/IN a/DT novel/JJ composite/JJ risk/NN score/NN ,/, using/VBG 10/CD -/: fold/JJ cross/NN -/: validation/NN ,/, to/TO predict/VB impaired/JJ global/JJ MFR/NN 
112_112_3_4_0_1::POS_ACTION_SIMILAR::Munc18-2/NN is/VBZ a/DT Sec1/NN homologue/NN enriched/VBN in/IN 
301018_1_23_24_16_18::None::,/, starfish/NN ,/, sea/NN cucumbers/NNS ,/, etc/FW )/) can/MD switch/VB reversibly/RB between/IN stiff/JJ and/CC 
178297_11_49_51_40_41::None::%/NN )/) ,/, acute/JJ toxic/JJ hepatitis/NN (/( 12/CD %/NN )/) ,/, and/CC hepatocellular/JJ carcinoma/NN (/( 6.1/CD %/NN 
443_443_11_12_9_10::None::actin/NN induced/VBN by/IN fimbrin/NN (/( N375/NN )/) binding/NN ./. 
12641_5_4_5_15_16::None::those/DT continued/VBN on/IN antidepressants/NNS (/( AD/NN )/) ,/, rapid/JJ cycling/NN (/( RC/NN )/) subjects/NNS experienced/JJ 268/CD %/NN (/( 
198131_1_22_23_9_10::None::of/IN long/JJ -/: term/NN users/NNS ,/, their/PRP$ smoking/NN behaviour/NN ,/, attachment/NN to/TO smoking/NN ,/, experience/NN of/IN nicotine/NN withdrawal/NN symptoms/NNS ,/, 
821060_0_19_20_41_42::None::role/NN in/IN the/DT beneficial/JJ graft/NN -/: versus/CC -/: leukemia/NN (/( GVL/NN )/) effect/NN of/IN allogeneic/JJ stem/NN cell/NN transplantation/NN (/( allo/NN -/: SCT/NN )/) but/CC also/RB mediates/VBZ serious/JJ GVH/NN complications/NNS 
907653_2_59_60_57_58::medicine.disease.symptoms::symptom/NN distress/NN ,/, anxiety/NN ,/, depression/NN ,/, (/( primary/JJ 
164887_1_33_35_29_30::None::monitoring/NN in/IN an/DT adult/JJ population/NN identified/VBD obstructive/JJ sleep/NN apnea/NN //: non/JJ -/: 
1142_1142_0_2_27_28::POS_REG(+)_LOCALIZE::Profilin/NN I/NN and/CC profilin/NN II/CD have/VBP similar/JJ affinities/NNS for/IN PtdIns/NN (/( 4,5/CD )/) P2/NN and/CC poly/NN (/( L-proline/NN )/) ,/, and/CC both/DT accelerate/VBP nucleotide/NN exchange/NN on/IN monomeric/JJ actin/NN to/TO the/DT same/JJ 
828493_2_13_14_15_17::None::investigate/VB associations/NNS between/IN obesity/NN and/CC gene/NN methylation/NN in/IN breast/NN tumors/NNS 
248756_2_45_46_28_29::None::Prunus/NNP persica/NN (/( peach/NN )/) ,/, and/CC unitegmic/JJ species/NNS ,/, such/JJ as/IN Prunus/NNP incisa/NNP ,/, analyzing/VBG the/DT expression/NN pattern/NN of/IN genes/NNS that/WDT are/VBP involved/VBN 
71991_0_18_19_13_14::medicine.symptom.symptom_of::problems/NNS ,/, including/VBG depression/NN //: anxiety/NN disorder/NN ,/, insomnia/NN //: sleep/VB disorder/NN 
649052_1_5_6_3_4::biology.organism_classification.lower_classifications::Interestingly/RB ,/, while/IN dogs/NNS and/CC wolves/NNS show/VBP a/DT similar/JJ 
240510_12_14_15_1_2::None::In/IN contrast/NN ,/, four/CD of/IN the/DT more/RBR recently/RB named/VBN gastropod/NN clades/NNS (/( Vetigastropoda/NNP ,/, Neritimorpha/NNP ,/, Caenogastropoda/NNP ,/, 
919_919_20_21_9_10::None::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT can/MD assemble/VB alpha-catenin/NN into/IN the/DT complex/NN 
98643_2_55_56_31_32::None::-/: specific/JJ daily/JJ diary/NN ,/, the/DT Functional/JJ Living/VBG Index/NN -/: Emesis/NN (/( flie/NN )/) ,/, and/CC the/DT European/JJ Organisation/NNP for/IN Research/NNP and/CC Treatment/NN of/IN Cancer/NN Quality/NNP of/IN Life/NNP Questionnaire/NNP -/: C15/NNP 
132031_1_9_10_10_12::medicine.risk_factor.diseases::2/CD diabetes/NN and/CC high/JJ cardiovascular/JJ risk/NN were/VBD enrolled/VBN during/IN 
93_93_57_58_57_58::None::MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
843828_6_37_38_6_7::None::higher/JJR mortality/NN (/( HR/NN ,/, 95/CD %/NN CI/NN )/) were/VBD older/JJR age/NN at/IN diagnosis/NN (/( 1.06/CD ,/, 1.03/CD -/: 1.08/CD )/) ,/, male/JJ gender/NN (/( 2.29/CD ,/, 1.57/CD -/: 3.35/CD )/) ,/, Hoehn/NNP &/CC amp/NNP ;/: Yahr/NNP (/( 
128605_11_4_5_23_24::None::data/NNS indicate/VBP that/IN disturbance/NN of/IN the/DT XIAP/NN //: Smac/JJ balance/NN may/MD be/VB a/DT driver/NN of/IN radio/NN chemotherapy/NN resistance/NN ,/, and/CC hence/RB high/JJ levels/NNS of/IN XIAP/NN may/MD 
157_157_24_25_14_15::POS_ACTION_SIMILAR::of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN 
176703_1_16_17_4_6::None::and/CC prognosis/NN of/IN breast/NN cancer/NN would/MD profit/VB largely/RB from/IN a/DT correct/JJ classification/NN and/CC identification/NN of/IN genetic/JJ key/JJ drivers/NNS and/CC 
619459_0_37_38_54_57::None::lymphoblastic/JJ leukemia/NN (/( ALL/NN )/) ,/, subtypes/NNS of/IN myeloid/JJ leukemia/NN and/CC T/NN -/: cell/NN lymphomas/NNS ,/, whereas/IN the/DT anti/JJ -/: chronic/JJ myeloid/JJ leukemia/NN (/( CML/NN )/) 
2148_2148_56_57_44_45::None::the/DT villin/NN and/CC fimbrin/NN from/IN the/DT cores/NNS but/CC does/VBZ not/RB affect/VB actin/NN binding/NN by/IN 110-kD/JJ calmodulin/NN ./. 
93_93_28_29_22_23::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
702752_2_34_35_16_19::None::inhibitor/NN ,/, in/IN T/NN cell/NN activation/NN ,/, proliferation/NN ,/, and/CC differentiation/NN using/VBG isolated/VBN murine/JJ splenic/JJ T/NN cells/NNS from/IN C57BL/NN //: 6/CD mice/NNS ./. 
607039_6_12_13_16_17::None::,/, summarizes/VBZ the/DT evidence/NN supporting/VBG perioperative/JJ medication/NN management/NN including/VBG corticosteroids/NNS ,/, 
434205_2_3_4_9_10::None::Specifically/RB ,/, the/DT neurotransmitters/NNS dopamine/NN (/( DA/NN )/) and/CC norepinephrine/NN (/( NE/NN )/) 
1399_1399_3_4_55_57::None::The/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN (/( VSV/NN )/) serotypes/NNS New/NNP Jersey/NNP [/( P/NN (/( NJ/NNP )/) ]/) and/CC Indiana/NNP [/( P/NN (/( I/NN )/) ]/) contains/VBZ a/DT highly/RB conserved/VBN carboxy-terminal/JJ domain/NN which/WDT is/VBZ required/VBN for/IN binding/VBG to/TO the/DT cognate/JJ N-RNA/NN template/NN as/RB well/RB as/IN to/TO form/VB a/DT soluble/JJ complex/NN with/IN the/DT nucleocapsid/JJ protein/NN N/NN in/FW vivo/FW 
275947_1_10_11_7_8::None::of/IN coxsackie/NN and/CC adenovirus/NN receptor/NN (/( CAR/NN )/) and/CC alphanu/NN 
117451_0_3_4_15_16::None::Numerous/JJ studies/NNS have/VBP demonstrated/VBN that/IN tissue/NN deposition/NN of/IN iron/NN following/VBG prolonged/JJ high/JJ dose/NN of/IN oral/JJ supplementation/NN for/IN treatment/NN of/IN 
95307_0_5_7_19_20::None::pharmacology/NN testing/NN for/IN anticancer/JJ agents/NNS has/VBZ historically/RB differed/VBN for/IN small/JJ molecule/NN pharmaceutical/JJ drugs/NNS versus/CC large/JJ -/: molecule/NN biopharmaceuticals/NNS ./. 
76765_3_0_1_95_96::None::We/PRP examined/VBD cross/NN -/: sectional/JJ associations/NNS between/IN high/JJ -/: sensitivity/NN cardiac/JJ troponin/NN T/NN (/( hsTnT/NN )/) and/CC FPG/NNP categorized/VBD as/IN normal/JJ fasting/NN glucose/NN (/( NFG/NN :/: FPG/NNP &/CC lt/NN ;/: //: =/JJ 6.0/CD mmol/NN //: L/NN )/) ,/, impaired/JJ fasting/NN glucose/NN (/( IFG/NN :/: FPG/NNP 6.1/CD -/: 6.9/CD mmol/NN //: L/NN )/) ,/, and/CC diabetes/NN mellitus/NN (/( DM/NN :/: FPG/NNP &/CC gt/NN ;/: //: =/JJ 7.0/CD mmol/NN //: L/NN )/) ,/, in/IN 535/CD men/NNS and/CC 226/CD women/NNS aged/JJ 56/CD -/: 79/CD years/NNS without/IN overt/JJ cardiovascular/JJ disease/NN who/WP received/VBD no/DT cardiovascular/JJ ,/, antidiabetic/JJ or/CC lipid/NN lowering/NN drugs/NNS ,/, using/VBG multiple/JJ 
410_410_9_10_12_13::None::of/IN both/DT histone/NN H3/NN and/CC histone/NN H4/NN were/VBD inviable/JJ ./. 
352442_4_29_30_28_29::None::1/LS )/) (/( sodium/NN chloride/NN )/) ;/: 0.086/CD 
404541_2_6_7_4_5::None::,/, the/DT ATG6/NN functions/VBZ in/IN wheat/NN (/( Triticum/FW aestivum/FW 
240152_0_51_52_17_18::None::samples/NNS and/CC six/CD typical/JJ soil/NN profiles/NNS were/VBD collected/VBN from/IN the/DT Shenyang/NNP industrial/JJ district/NN in/IN northeast/JJ China/NNP and/CC were/VBD analyzed/VBN for/IN contents/NNS of/IN titanium/NN (/( Ti/NN )/) ,/, copper/NN (/( Cu/NN )/) ,/, lead/NN (/( Pb/NN )/) ,/, zinc/NN (/( Zn/NN )/) 
1005_1005_13_14_6_7::None::have/VBP focused/VBN on/IN profilin/NN itself/PRP rather/RB than/IN its/PRP$ complex/NN with/IN actin/NN ./. 
640_640_25_26_29_30::None::can/MD not/RB increase/VB profilin/NN 's/POS affinity/NN for/IN actin/NN ./. 
865_865_15_16_7_8::POS_ACTION_SIMILAR::system/NN ,/, the/DT dystrophin/NN relatives/NNS ,/, human/JJ dystrophin/NN related/JJ protein/NN (/( DRP/NN or/CC utrophin/NN )/) 
345914_6_17_18_22_23::None::nanoparticles/NNS indicate/VBP the/DT enhancement/NN of/IN a/DT ferric/JJ over/IN ferrous/JJ pathway/NN supporting/VBG the/DT 
271641_1_17_18_10_11::None::the/DT effects/NNS of/IN tumor/NN growth/NN following/VBG radiotherapy/NN and/CC G/NN -/: CSF/NN administration/NN in/IN a/DT 
609813_2_33_34_53_54::None::invasive/JJ plant/NN species/NNS Phragmites/NNP australis/NNP (/( common/JJ reed/NN )/) as/IN an/DT example/NN of/IN how/WRB development/NN of/IN microbial/JJ -/: based/VBN control/NN strategies/NNS can/MD be/VB enhanced/VBN using/VBG a/DT collective/JJ 
257913_10_2_3_13_14::None::In/IN hypertensive/JJ patients/NNS ,/, a/DT strategy/NN based/VBN on/IN ACE/NN inhibitors/NNS with/IN dose/NN -/: dependent/JJ efficacy/NN such/JJ as/IN 
1618_1618_23_24_9_10::POS_ACTION_BIND::domains/NNS identified/VBD as/IN actin/NN and/CC phosphatidylinositol/NN 4,5-biphosphate/NN (/( PIP2/NN )/) binding/NN sites/NNS found/VBN in/IN members/NNS of/IN the/DT cofilin/NN family/NN ./. 
2107_2107_15_16_9_10::POS_ACTION_AFFECT::proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP potential/JJ targets/NNS of/IN the/DT Rho/NN family/NN small/JJ GTP-binding/JJ 
157_157_8_9_1_2::None::Archaeal/NNP histones/NNS are/VBP most/RBS similar/JJ to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN 
113845_3_3_4_2_3::None::Our/PRP$ preliminary/JJ clinical/JJ findings/NNS include/VBP sufficient/JJ hemostasis/NN 
1529_1529_10_13_7_8::None::and/CC human/JJ platelet/NN profilins/NNS with/IN rabbit/NN skeletal/JJ muscle/NN actin/NN were/VBD characterized/VBN by/IN 
741231_0_14_17_8_9::None::and/CC renal/JJ //: cardiovascular/JJ outcomes/NNS in/IN Japanese/JJ patients/NNS with/IN chronic/JJ kidney/NN disease/NN under/IN nephrologist/NN care/NN 
467137_1_27_28_9_10::None::factor/NN in/IN global/JJ honeybee/NN (/( Apis/NN mellifera/NN )/) declines/VBZ since/IN shifting/VBG hosts/NNS from/IN the/DT Asian/JJ honeybee/NN (/( Apis/NN cerana/NN )/) &/CC gt/NN ;/: 50/CD years/NNS 
417653_2_21_22_20_22::medicine.disease.symptoms::exhibit/VBP chronic/JJ vascular/JJ inflammation/NN ,/, and/CC long/JJ 
161_161_0_1_11_12::POS_ACTION_Assembly::Armadillo/NN (/( Arm/NN )/) repeat/NN 10/CD to/TO the/DT COOH/NN terminus/NN of/IN beta-catenin/NN is/VBZ involved/VBN in/IN 
984_984_0_1_9_10::None::MLL/NN is/VBZ fused/VBN in-frame/RB to/TO a/DT different/JJ exon/NN of/IN CBP/NN in/IN two/CD patients/NNS 
2052_2052_6_7_17_18::None::axonal/JJ transport/NN of/IN actin/NN and/CC its/PRP$ monomer/NN binding/NN proteins/NNS ,/, actin/NN depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN 
268989_5_38_39_1_2::None::In/IN addition/NN ,/, knockdown/NN of/IN the/DT expression/NN of/IN the/DT Tie/NN -/: 2/CD ligand/NN angiopoietin/NN (/( Ang/NN -/: 1/LS )/) led/VBD to/TO suppression/NN of/IN CSC/NNP markers/NNS ,/, suggesting/VBG that/IN the/DT Ang/NNP -/: 1/CD //: Tie/NN -/: 2/CD signaling/NN pathway/NN functions/VBZ as/IN an/DT autocrine/JJ 
546055_2_20_21_15_16::None::was/VBD employed/VBN to/TO develop/VB a/DT urinarypeptide/NN -/: based/VBN high/JJ -/: dimensional/JJ classifier/NN 
394419_6_13_14_1_2::None::The/DT identified/VBN myokines/NNS include/VBP eg/FW IL4/NN ,/, IL6/NN ,/, IL7/NN ,/, IL15/NN ,/, myostatin/NN ,/, LIF/NN (/( 
186521_6_10_11_21_22::None::1.8/CD and/CC an/DT accelerated/VBN washout/NN rate/NN are/VBP recognized/VBN as/RB high/JJ -/: risk/NN indicators/NNS of/IN pump/NN failure/NN death/NN ,/, 
562_562_6_7_8_9::None::interactions/NNS between/IN human/JJ RAD51/NN and/CC RAD52/NN proteins/NNS are/VBP demonstrated/VBN 
125145_4_16_17_9_10::medicine.symptom.symptom_of::rFVIIa/NN achieves/VBZ consistently/RB high/JJ efficacy/NN rates/NNS in/IN the/DT management/NN of/IN acute/JJ (/( including/VBG joint/NN 
607039_6_1_2_22_23::None::This/DT article/NN provides/VBZ an/DT overview/NN of/IN arthroplasty/NN in/IN RA/NN ,/, summarizes/VBZ the/DT evidence/NN supporting/VBG perioperative/JJ medication/NN management/NN including/VBG corticosteroids/NNS ,/, and/CC identifies/VBZ areas/NNS where/WRB further/JJ study/NN 
1069_1069_42_45_33_35::POS_ACTION_ATTACH::)/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
546055_2_13_14_31_32::None::mass/NN spectrometry/NN was/VBD employed/VBN to/TO develop/VB a/DT urinarypeptide/NN -/: based/VBN high/JJ -/: dimensional/JJ classifier/NN ,/, namely/RB CKD273/NN ,/, for/IN predicting/VBG CKD/NNP progression/NN ./. 
604261_0_10_11_53_54::None::majority/NN of/IN human/JJ melanomas/NNS (/( &/CC gt/NN ;/: 60/CD %/NN )/) express/VBP the/DT metabotropic/JJ glutamate/NN receptor/NN 1/CD (/( GRM1/NN )/) and/CC that/IN the/DT glutamate/NN release/NN inhibitor/NN riluzole/NN ,/, a/DT drug/NN currently/RB used/VBN to/TO treat/VB amyotrophic/JJ lateral/JJ sclerosis/NN ,/, can/MD induce/VB apoptosis/NN in/IN GRM1/NN -/: expressing/VBG melanoma/NN cells/NNS ./. 
445433_1_3_4_8_9::None::Indeed/RB ,/, a/DT neuronal/JJ pathway/NN for/IN histamine/NN -/: induced/VBN itch/NN in/IN the/DT 
1274_1274_29_30_9_12::None::a/DT full/JJ length/NN myosin/NN heavy/JJ chain/NN and/CC a/DT tagged/VBN tail/NN ,/, was/VBD isolated/VBN on/IN the/DT basis/NN of/IN the/DT affinities/NNS for/IN Nickel/NN agarose/NN and/CC actin/NN ./. 
162483_5_30_31_44_47::None::including/VBG hypertension/NN ,/, dyslipidaemia/NN ,/, smoking/NN ,/, obesity/NN ,/, metabolic/JJ syndrome/NN ,/, hyperuricaemia/NN ,/, arterial/JJ stiffness/NN and/CC obstructive/JJ sleep/NN apnea/NN syndrome/NN ./. 
2064_2064_49_50_49_50::None::was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
465207_3_9_10_29_30::None::postmenopausal/JJ women/NNS in/IN Brazil/NNP varies/VBZ from/IN 15/CD %/NN to/TO 33/CD %/NN ,/, depending/VBG on/IN the/DT study/NN methodology/NN and/CC the/DT use/NN of/IN bone/NN densitometry/NN data/NNS or/CC self/NN -/: 
142623_1_29_30_8_9::None::stress/NN conditions/NNS in/IN response/NN to/TO aluminum/NN (/( Al/NNP )/) ,/, a/DT metal/NN known/VBN to/TO limit/VB agricultural/JJ productivity/NN in/IN acidic/JJ soils/NNS primarily/RB due/JJ to/TO reduced/VBN root/NN elongation/NN ./. 
307348_1_22_23_19_20::None::lead/VBP to/TO a/DT wide/JJ spectrum/NN of/IN symptoms/NNS and/CC disabilities/NNS ,/, 
829573_1_30_31_10_11::None::dysregulation/NN of/IN sympathetic/JJ outflow/NN ,/, upper/JJ cervical/JJ pathology/NN ,/, glossopharyngeal/NN and/CC trigeminal/JJ neuralgia/NN ,/, TMJ/NNP dysfunction/NN ,/, thalamic/JJ syndrome/NN ,/, and/CC primary/JJ headache/NN syndromes/NNS ./. 
1025_1025_14_19_27_28::None::of/IN the/DT conventional/JJ type/NN II/CD myosin/NN heavy/JJ chain/NN and/CC carries/VBZ putative/JJ binding/NN sites/NNS for/IN ATP/NN and/CC actin/NN ./. 
1854_1854_14_15_8_9::POS_ACTION_BIND::fluorescent/JJ analog/NN of/IN actin/NN with/IN a/DT high/JJ affinity/NN for/IN profilin/NN revealed/VBD that/IN it/PRP 
230298_6_14_16_5_6::None::include/VBP cognitive/JJ behavioral/JJ therapy/NN ,/, mindfulness/NN -/: based/VBN cognitive/JJ therapy/NN ,/, and/CC sex/NN therapy/NN and/CC ,/, for/IN 
14211_8_14_15_33_34::None::vitro/FW drug/NN sensitivity/NN test/NN ,/, which/WDT is/VBZ easy/JJ to/TO perform/VB ,/, may/MD predict/VB the/DT outcome/NN of/IN fludarabine/NN -/: based/VBN chemotherapy/NN in/IN CLL/NN patients/NNS ./. 
151_151_0_1_64_65::NEG_ACTION_Amount::Aprotinin/NN inhibited/VBD platelet/NN aggregation/NN induced/VBN by/IN thrombin/NN (/( 0.25/CD U.ml-1/NN )/) with/IN IC50/NN 200/CD kIU.ml-1/NN ,/, and/CC inhibited/VBD the/DT rise/NN of/IN cytosolic/JJ free/JJ calcium/NN concentration/NN in/IN platelets/NNS stimulated/VBN by/IN thrombin/NN (/( 0.1/CD U.ml-1/NN )/) in/IN the/DT absence/NN and/CC in/IN the/DT presence/NN of/IN Ca2/NN +/CC 0.5/CD mmol.L-1/NN (/( IC50/NN 117/CD and/CC 50/CD kIU.ml-1/NN ,/, respectively/RB )/) ,/, but/CC had/VBD no/DT effect/NN on/IN the/DT amounts/NNS of/IN actin/NN and/CC myosin/NN heavy/JJ 
260299_3_5_6_23_24::None::we/PRP report/VBP the/DT case/NN of/IN a/DT 49/CD -/: year/NN -/: old/JJ ,/, chronic/JJ smoker/NN ,/, who/WP incidentally/RB had/VBD a/DT laryngeal/JJ growth/NN detected/VBN during/IN flexible/JJ bronchoscopy/NN 
2107_2107_39_40_27_28::None::actin-binding/JJ protein/NN ,/, profilin/NN ,/, at/IN their/PRP$ proline-rich/JJ FH1/NN domains/NNS to/TO regulate/VB reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN in/IN the/DT 
1773_1773_4_5_10_11::None::structural/JJ homology/NN between/IN cofilin/NN and/CC gelsolin/NN segment-1/NN binding/NN to/TO actin/NN was/VBD confirmed/VBN experimentally/RB 
128_128_4_5_18_19::None::of/IN various/JJ truncated/VBN alpha-catenin/NN molecules/NNS revealed/VBD that/IN amino-terminal/JJ residues/NNS 48-163/CD are/VBP able/JJ to/TO bind/VB to/TO beta-catenin/NN and/CC plakoglobin/NN ./. 
861_861_5_6_19_20::POS_ACTION_ASSEMBLE::actin/NN clustering/NN ,/, profilin/NN ,/, a/DT monomeric/JJ actin-binding/JJ protein/NN that/WDT has/VBZ been/VBN suggested/VBN to/TO be/VB involved/VBN in/IN actin/NN polymerization/NN ,/, was/VBD 
616_616_17_18_17_18::None::six/CD sites/NNS and/CC histone/NN H4/NN had/VBD five/CD 
1653_1653_42_43_44_45::None::and/CC MSH6/NN or/CC MSH2/NN and/CC MSH3/NN ./. 
322590_4_14_15_2_3::medicine.risk_factor.diseases::Pre/SYM -/: eclampsia/NN was/VBD defined/VBN as/IN per/IN the/DT International/NNP Society/NNP for/IN the/DT Study/NN of/IN Hypertension/NN in/IN Pregnancy/NNP guidelines/NNS 
1069_1069_21_22_26_27::POS_ACTION_CONTAIN::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
1940_1940_7_11_13_14::POS_ACTION_MEMBER::in/IN activation/NN of/IN extracellular/JJ signal-regulated/JJ protein/NN kinases/NNS ERK1/NN and/CC ERK2/NN ,/, induction/NN of/IN 
547287_4_27_28_15_16::None::%/NN higher/JJR in/IN colorectal/JJ cancer/NN patients/NNS than/IN in/IN comparisons/NNS (/( 2.99/CD vs/CC 2.14/CD per/IN 1000/CD person/NN -/: years/NNS )/) 
355_355_16_17_25_26::POS_ACTION_Assembly::binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, and/CC can/MD form/VB a/DT structural/JJ complex/NN with/IN E-cadherin/NN via/IN these/DT interactions/NNS 
98427_7_4_5_3_4::None::Also/RB ,/, a/DT higher/JJR proportion/NN of/IN those/DT with/IN 
401885_4_11_12_10_11::None::prevalence/NN of/IN chronic/JJ respiratory/JJ symptoms/NNS and/CC diseases/NNS than/IN 
2107_2107_7_8_5_7::None::shown/VBN that/IN the/DT FH/NN proteins/NNS Bni1p/NN and/CC Bnr1p/NN are/VBP 
508103_4_15_16_36_37::None::body/NN weights/NNS in/IN STZ/NN -/: induced/VBN diabetic/JJ rats/NNS ,/, but/CC normalized/VBD myocardial/JJ steatosis/NN ,/, expression/NN of/IN PKC/NN ,/, NAD/NNP (/( P/NN )/) H/NN oxidase/NN activity/NN ,/, oxidative/JJ stress/NN 
938_938_0_2_6_7::POS_ACTION_PHOSPHORYLATE::LIM-kinase/NN 1/CD (/( LIMK1/NN )/) phosphorylates/VBZ cofilin/NN ,/, an/DT actin-depolymerizing/JJ 
513_513_17_19_7_8::None::(/( PRP5/NN ,/, PRP9/NN ,/, PRP11/NN ,/, and/CC PRP21/NN )/) interact/VBP to/TO promote/VB U2/NN snRNP/NN binding/NN to/TO pre-mRNA/NN 
540781_2_6_8_19_20::None::HIV/NN -/: 1/CD drug/NN resistance/NN is/VBZ therefore/RB of/IN great/JJ importance/NN to/TO evaluate/VB the/DT current/JJ sensitivity/NN of/IN antiretroviral/JJ agents/NNS and/CC is/VBZ 
810075_0_8_9_19_20::None::vein/NN isolation/NN for/IN paroxysmal/JJ atrial/JJ fibrillation/NN :/: a/DT retrospective/JJ comparison/NN between/IN the/DT cryoballoon/NN and/CC conventional/JJ focal/JJ tip/NN radiofrequency/NN 
930_930_8_9_1_2::POS_ACTION_COLOCALIZE::Like/IN actin/NN ,/, the/DT actin-associated/JJ proteins/NNS filamin/NN ,/, talin/NN and/CC the/DT beta/NN 
1992_1992_10_11_19_20::POS_REG(+)_DISASSEMBLE::reports/NNS that/IN intact/JJ talin/NN induces/VBZ cross-linking/NN as/RB well/RB as/IN filament/NN shortening/VBG on/IN actin/NN networks/NNS ./. 
311864_8_44_45_41_42::None::network/NN ;/: showing/VBG evidence/NN of/IN IgG/NN subclasses/NNS deficiency/NN (/( mostly/RB 
1728_1728_15_16_9_11::POS_REG(0)_ASSEMBLE::of/IN cytoskeletal/JJ and/CC sarcomeric/JJ actins/NNS is/VBZ regulated/VBN differently/RB by/IN profilin/NN in/IN the/DT developing/VBG 
189641_0_10_11_13_14::medicine.risk_factor.diseases::energy/NN intake/NN ,/, sedentary/JJ habits/NNS and/CC obesity/NN ,/, type/NN 2/CD 
522582_0_2_3_9_10::None::Stressful/JJ life/NN events/NNS ,/, worry/NN ,/, and/CC rumination/NN predict/VBP depressive/JJ and/CC anxiety/NN symptoms/NNS 
1977_1977_22_23_24_25::None::molecular/JJ interaction/NN with/IN beta-catenin/NN and/CC plakoglobin/NN ./. 
159463_2_27_28_18_19::None::women/NNS or/CC age/NN matched/VBD males/NNS while/IN the/DT incidence/NN of/IN cardiovascular/JJ disease/NN is/VBZ greater/JJR in/IN postmenopausal/JJ than/IN 
324774_0_9_10_4_5::None::of/IN nicotine/NN reward/NN system/NN can/MD potentially/RB influence/VB smoking/NN behavior/NN ./. 
350196_12_10_11_0_1::None::Cervical/JJ ,/, uterine/JJ and/CC ovary/JJ cancers/NNS remain/VBP to/TO be/VB a/DT focus/NN of/IN treatment/NN ./. 
204277_6_38_39_47_48::None::or/CC PWV/NN ,/, indicating/VBG impaired/JJ microvascular/JJ hyperemia/NN and/CC arterial/JJ elasticity/NN with/IN lower/JJR testosterone/NN levels/NNS ./. 
294085_3_3_4_4_5::None::Findings/NNS indicate/VBP that/IN parenting/NN stress/NN moderates/NNS the/DT association/NN 
452763_3_26_27_28_29::None::progression/NN of/IN various/JJ types/NNS of/IN human/JJ tumors/NNS including/VBG breast/NN 
490714_0_9_10_19_20::None::wawo/NN worms/NNS (/( Polychaeta/NN ,/, Annelida/NN )/) from/IN Ambonese/JJ waters/NNS ,/, Maluku/NNP ,/, Indonesia/NNP ./. 
9_9_17_18_17_18::None::lysine/NN 115/CD of/IN profilin/NN ./. 
556_556_10_11_7_9::None::to/TO be/VB a/DT nonerythroid/JJ spectrin/NN ,/, talin/NN ,/, myosin/NN ,/, 
2222_2222_19_20_11_12::POS_ACTION_COLOCALIZE::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC 
7137_13_29_30_23_24::None::breast/NN cancers/NNS (/( RR/NN ,/, 1.25/CD ;/: 95/CD %/NN CI/NN ,/, 1.18/CD -/: 
996_996_5_7_27_28::None::ectopic/JJ expression/NN of/IN cyclin/NN D1/NN and/CC Cdk4/NN can/MD stimulate/VB the/DT Brca1/NN promoter/NN in/IN an/DT E2F-dependent/JJ manner/NN ,/, and/CC this/DT is/VBZ inhibited/VBN by/IN coexpression/NN of/IN the/DT p16/NN (/( INK4a/NN )/) 
589175_4_10_11_6_7::None::%/NN of/IN lung/NN adenocarcinomas/NNS from/IN never/RB -/: smoker/NN females/NNS harbored/VBD well/RB 
248192_9_13_14_15_16::medicine.symptom.symptom_of::benign/JJ paroxysmal/JJ positional/JJ vertigo/NN (/( BPPV/NN )/) ,/, 23/CD 
1219_1219_0_1_20_21::POS_ACTION_INCREASE::RIPc/NN ,/, one/CD of/IN the/DT cleavage/NN products/NNS ,/, enhanced/VBD interaction/NN between/IN TRADD/NN and/CC FADD/MORT1/NN and/CC increased/VBN cells/NNS '/POS sensitivity/NN to/TO TNF/NN ./. 
443_443_6_7_9_10::None::conformational/JJ change/NN in/IN actin/NN induced/VBN by/IN fimbrin/NN (/( N375/NN )/) 
2013_2013_20_21_7_9::None::motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN verprolin/cofilin-like/JJ actin-regulatory/JJ domains/NNS ,/, but/CC no/DT specific/JJ actin/NN structure/NN regulated/VBN by/IN 
93_93_11_12_57_58::NEG_ACTION_DOWNREGULATE::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
399_399_23_24_2_3::None::Dispersal/NN of/IN profilin/NN from/IN such/JJ sites/NNS by/IN oligoproline-rich/JJ peptide/NN inhibitors/NNS suggests/VBZ that/IN profilin/NN is/VBZ directly/RB involved/VBN in/IN intracellular/JJ pathogen/NN locomotion/NN and/CC reorganization/NN of/IN actin/NN cytoskeleton/NN of/IN the/DT 
189447_0_9_10_1_2::None::Breast/NN cancer/NN incidence/NN is/VBZ increasing/VBG in/RB low/JJ -/: and/CC middle/JJ -/: income/NN countries/NNS 
322_322_0_1_19_20::POS_ACTION_LOCALIZE::Cofilin/NNP and/CC profilin/NN may/MD also/RB be/VB involved/VBN in/IN the/DT redistribution/NN of/IN actin/NN during/IN myofibrillogenesis/NN and/CC in/IN the/DT process/NN of/IN actin/NN disassembly/NN in/IN degenerating/VBG 
691_691_13_14_6_9::None::APBs/NNS also/RB contain/VBP replication/NN factor/NN A/NN ,/, RAD51/NN ,/, and/CC RAD52/NN ,/, proteins/NNS involved/VBN 
2052_2052_20_21_17_18::None::depolymerizing/NN factor/NN ,/, cofilin/NN ,/, and/CC profilin/NN ,/, in/IN the/DT 
169857_11_7_8_16_17::None::with/IN severe/JJ obstructive/JJ sleep/NN apnea/NN ,/, 86.7/CD %/NN experienced/VBD a/DT significant/JJ AHI/NNP reduction/NN to/TO moderate/JJ or/CC 
172257_0_4_5_6_8::None::aim/NN of/IN the/DT Anaemia/NN in/IN Lung/NN Cancer/NN in/IN Spain/NNP study/NN 
1652_1652_31_32_31_32::None::preferentially/RB driven/VBN by/IN beta-catenin/NN ;/: and/CC (/( 
307552_0_4_5_8_9::None::animals/NNS are/VBP constantly/RB faced/VBN with/IN various/JJ environmental/JJ stresses/NNS that/WDT challenge/VBP normal/JJ 
394127_6_19_20_4_5::None::most/RBS common/JJ primary/JJ malignancy/NN sites/NNS were/VBD colon/NN (/( 33.2/CD %/NN )/) ,/, endometrium/NN (/( 17.1/CD %/NN )/) ,/, breast/NN (/( 14.3/CD %/NN 
322750_1_6_8_49_50::None::we/PRP investigated/VBD detrimental/JJ side/JJ effects/NNS in/IN terms/NNS of/IN the/DT release/NN of/IN nitrite/NN (/( NO2/NN -/: N/NN )/) ,/, ammonium/NN (/( NH4/NN -/: N/NN )/) ,/, phosphate/NN (/( PO4/NN -/: P/NN )/) ,/, dissolved/VBN organic/JJ carbon/NN (/( DOC/NN )/) ,/, methane/NN (/( CH4/NN )/) ,/, and/CC dinitrogen/NN oxide/NN (/( N2O/NN )/) 
198817_2_30_31_32_33::None::)/) ,/, who/WP developed/VBD matachronous/JJ LMs/NNS and/CC underwent/VBD pulmonary/JJ 
28475_4_23_24_84_85::biology.organism_classification.lower_classifications::behavior/NN typical/JJ of/IN flatworm/NN TGRs/NNS Consistently/RB ,/, M/NN vogae/FW genome/NN analysis/NN revealed/VBD the/DT presence/NN of/IN a/DT selenocysteine/NN -/: containing/VBG TGR/NN and/CC absenceof/JJ conventional/JJ TR/NN and/CC GR/NN M/NN vogae/FW thioredoxin/NN and/CC glutathione/NN reductase/NN activities/NNS were/VBD inhibited/VBN by/IN 3,4/CD -/: bis/NN (/( phenylsulfonyl/NN )/) -/: 1,2,5/CD -/: oxadiazole/NN N2/NN -/: oxide/NN (/( VL16E/NN )/) ,/, an/DT oxadiazole/NN N/NN -/: oxide/NN previously/RB identified/VBN as/IN an/DT inhibitor/NN of/IN fluke/NN and/CC tapeworm/NN TGRs/NNS 
379013_1_1_2_0_1::None::We/PRP determined/VBD the/DT dose/NN -/: 
676724_2_35_36_47_48::medicine.symptom.symptom_of::1/CD -/: like/IN disease/NN (/( D1/NN )/) was/VBD provoked/VBN by/IN STZ/NN without/IN NA/NNP Non/NNP -/: diabetic/JJ mice/NNS received/VBD vehicle/NN 
609_609_21_22_19_20::None::encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN 
235372_5_2_4_10_12::None::Race/NN ,/, family/NN history/NN of/IN osteoporosis/NN ,/, BMI/NN ,/, current/JJ physical/JJ activity/NN ,/, osteoporosis/NN knowledge/NN 
957_957_8_11_12_13::None::mutation/NN in/IN the/DT myosin/NN heavy/JJ chain/NN (/( Myh/NN )/) predicted/VBD to/TO 
93_93_22_23_24_26::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
1052_1052_12_13_37_38::POS_ACTION_INITIATE::gp130/NN )/) binding/NN cytokines/NNS can/MD mimic/VB the/DT effects/NNS of/IN oncostatin/NN M/NN (/( OSM/NN )/) in/IN acting/VBG synergistically/RB with/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) to/TO induce/VB cartilage/NN collagen/NN breakdown/NN and/CC collagenase/NN expression/NN ,/, and/CC 
271641_1_0_1_25_27::None::In/IN the/DT present/JJ study/NN ,/, to/TO investigate/VB the/DT effects/NNS of/IN tumor/NN growth/NN following/VBG radiotherapy/NN and/CC G/NN -/: CSF/NN administration/NN in/IN a/DT murine/JJ xenograft/NN model/NN of/IN colon/NN cancer/NN ,/, female/JJ BALB/NN 
667084_2_13_14_7_8::None::with/IN an/DT increased/VBN prevalence/NN of/IN mental/JJ health/NN disorders/NNS including/VBG anxiety/NN ,/, depression/NN ,/, 
489_489_26_27_20_21::None::the/DT transcription/NN factor/NN p53/NN ,/, and/CC have/VBP determined/VBN that/IN histone/NN H3/NN is/VBZ significantly/RB 
125647_5_3_4_5_6::None::There/EX were/VBD more/JJR frequent/JJ hospital/NN admissions/NNS in/IN nonallergic/JJ and/CC 
374375_0_17_18_12_13::None::glycine/NN )/) and/CC Ser/NN (/( serine/NN )/) in/IN broiler/NN diets/NNS may/MD be/VB 
87529_17_11_12_7_8::None::,/, and/CC prior/RB stroke/NN were/VBD associated/VBN with/IN deep/JJ WMLs/NNS (/( P/NN 
378211_8_24_25_26_27::None::-/: alpha/NN )/) release/NN from/IN PBMCs/NNS in/IN non/JJ -/: 
527579_4_55_56_52_53::None::)/) ,/, and/CC CTA/NNP -/: based/VBN modified/VBN clot/NNS burden/NN score/NN 
604313_0_21_22_23_24::medicine.risk_factor.diseases::diseases/NNS ,/, especially/RB hypertension/NN and/CC atherosclerosis/NN ,/, and/CC that/DT 
191783_4_3_4_17_18::None::With/IN a/DT thin/JJ coating/NN of/IN 200/CD -/: 300/CD nm/NN polydimethylsiloxane/NN (/( PDMS/NN )/) on/IN the/DT zeolite/NN -/: polymer/NN composite/NN ,/, transport/NN 
724990_11_28_29_20_21::medicine.symptom.symptom_of::in/IN patients/NNS with/IN epilepsy/NN may/MD not/RB be/VB detrimental/JJ with/IN regard/NN to/TO seizure/NN control/NN ./. 
511797_2_4_5_35_37::None::sample/NN included/VBD 63/CD persons/NNS with/IN MS/NN (/( 75/CD %/NN relapsing/NN -/: remitting/VBG MS/NN ,/, median/JJ EDSS/NN =/JJ 4.0/CD ,/, and/CC mean/VB MS/NN duration/NN =/JJ 13.1/CD years/NNS )/) who/WP underwent/VBD measurements/NNS of/IN aerobic/JJ fitness/NN and/CC muscular/JJ strength/NN (/( ie/FW impairment/NN 
431465_3_6_7_20_21::medicine.drug.active_moieties::with/IN a/DT chiral/JJ manganese/NN salen/NN catalyst/NN afforded/VBD the/DT azide/NN product/NN in/IN 70/CD %/NN ee/NN ,/, representing/VBG a/DT Mn/NN -/: catalyzed/VBN enantioselective/JJ 
519_519_32_33_33_34::None::)/) -/: specific/JJ Act88F/NN actin/NN gene/NN ./. 
476195_1_4_5_19_20::None::this/DT study/NN we/PRP investigated/VBD the/DT effects/NNS of/IN Cu/NN -/: NPs/NNS and/CC soluble/JJ Cu/NN in/IN the/DT intestines/NNS of/IN juvenile/JJ Epinephelus/NN coioides/NNS ./. 
76365_0_17_18_8_9::None::high/JJ in/IN the/DT elderly/JJ (/( between/IN 3.2/CD and/CC 14.2/CD %/NN of/IN the/DT subjects/NNS )/) with/IN ,/, 
301018_1_22_23_1_2::None::In/IN contrast/NN to/TO this/DT ,/, the/DT connective/JJ tissues/NNS of/IN echinoderms/NNS (/( sea/NN urchins/NNS ,/, starfish/NN ,/, sea/NN cucumbers/NNS ,/, etc/FW )/) can/MD switch/VB reversibly/RB between/IN stiff/JJ 
93_93_11_12_24_26::None::by/IN the/DT dominant/JJ BCK1-20/NN mutation/NN nor/CC increased/VBD dosage/NN of/IN MKK1/NN (/( MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN 
1486_1486_4_5_35_40::None::findings/NNS suggest/VBP that/IN M1/NN muscarinic/JJ receptors/NNS are/VBP involved/VBN in/IN muscarinic/JJ receptor-mediated/JJ enhancement/NN of/IN IL-2/NN production/NN in/IN Jurkat/NN cells/NNS and/CC that/IN the/DT transcription/NN factor/NN AP-1/NN and/CC pathways/NNS via/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) //: extracellular/JJ signal/NN regulated/VBN protein/NN kinase/NN and/CC c-Jun/NN N-terminal/JJ 
377_377_10_11_12_13::None::bands/NNS corresponding/VBG to/TO actin/NN and/CC fimbrin/NN and/CC several/JJ proteins/NNS 
119_119_12_13_33_34::POS_ACTION_BIND::fit/NN show/VBP that/IN vinculin/NN has/VBZ a/DT negligible/JJ influence/NN on/IN internal/JJ actin/NN filament/NN dynamics/NNS and/CC actin/NN bending/VBG stiffness/NN which/WDT contrasts/VBZ with/IN our/PRP$ previous/JJ observations/NNS with/IN talin/NN ,/, another/DT actin/NN 
607_607_23_24_21_22::None::viral/JJ UL5/NN ,/, UL8/NN and/CC UL52/NN genes/NNS ./. 
18_18_21_22_4_5::None::domain/NN of/IN the/DT phosphoprotein/NN (/( P/NN )/) of/IN vesicular/JJ stomatitis/NN virus/NN differentially/RB interacts/VBZ with/IN homologous/JJ and/CC heterologous/JJ nucleocapsid/NN protein/NN (/( N/NN )/) ./. 
583_583_12_13_10_11::None::a/DT complex/NN containing/VBG E-cadherin/NN ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, 
722712_7_9_10_18_19::None::effective/JJ in/IN the/DT management/NN of/IN a/DT patient/NN with/IN dyspnea/NN induced/VBN by/IN a/DT giant/JJ ovarian/JJ tumor/NN ./. 
117451_0_12_13_6_7::None::demonstrated/VBN that/IN tissue/NN deposition/NN of/IN iron/NN following/VBG prolonged/JJ high/JJ dose/NN of/IN oral/JJ supplementation/NN 
372023_9_17_18_48_49::medicine.disease.symptoms::parameters/NNS in/IN the/DT PD/NN group/NN (/( R/NN =/JJ 0.10/CD -/: 0.25/CD ;/: p/NN &/CC gt/NN ;/: 0.40/CD )/) ,/, while/IN the/DT healthy/JJ showed/VBD stronger/JJR correlation/NN in/IN gait/NN speed/NN ,/, sit/VBP -/: to/TO -/: stand/VB duration/NN ,/, and/CC stand/VB 
72969_0_43_44_41_42::None::symptoms/NNS within/IN the/DT spectrum/NN of/IN post/NN -/: traumatic/JJ stress/NN 
805_805_0_4_10_11::POS_ACTION_STIMULATE::Insulin-like/JJ growth/NN factor/NN I/PRP stimulates/VBZ cardiac/JJ myosin/NN heavy/JJ chain/NN and/CC actin/NN synthesis/NN in/IN the/DT 
616_616_18_19_17_18::None::six/CD sites/NNS and/CC histone/NN H4/NN had/VBD five/CD sites/NNS 
1345_1345_6_7_12_13::None::WIP/NNP to/TO replace/VB verprolin/NN is/VBZ dependent/JJ on/IN its/PRP$ WH2/NN actin/NN binding/NN domain/NN and/CC 
228362_4_49_50_51_52::None::no/DT effect/NN on/IN structure/NN or/CC proteoglycan/NN composition/NN ./. 
960_960_9_10_17_18::POS_ACTION_MODIFY::,/, which/WDT encodes/VBZ verprolin/NN ,/, required/VBN for/IN proper/JJ organization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
930_930_11_15_8_9::None::proteins/NNS filamin/NN ,/, talin/NN and/CC the/DT beta/NN 1/CD integrin/NN subunit/NN were/VBD also/RB found/VBN 
381796_0_22_23_7_8::None::auto/NN Treatment/NN in/IN Patients/NNS with/IN Obstructive/JJ Sleep/NNP Apnea/NNP Not/RB Responsive/JJ to/TO or/CC Intolerant/JJ of/IN Continuous/JJ Positive/JJ Airway/NNP Pressure/NN Ventilation/NN ./. 
212_212_24_25_31_32::POS_ACTION_CROSS-LINK::the/DT ectodomain/NN of/IN E-cadherin/NN and/CC the/DT actin/NN binding/NN site/NN of/IN alpha-catenin/NN ./. 
218394_4_27_29_8_11::medicine.symptom.symptom_of::prehospital/JJ thrombolysis/NN for/IN acute/JJ ischemic/JJ stroke/NN administered/VBN in/IN specialized/VBN ambulances/NNS on/IN delay/NN in/IN thrombolytic/JJ administration/NN ,/, thrombolysis/NN rate/NN ,/, post/NN -/: thrombolysis/NN intracerebral/JJ hemorrhage/NN ,/, and/CC 7/CD 
350196_12_5_6_10_11::None::uterine/JJ and/CC ovary/JJ cancers/NNS remain/VBP to/TO be/VB a/DT focus/NN of/IN treatment/NN ./. 
846534_0_23_25_9_10::None::has/VBZ been/VBN a/DT successful/JJ technique/NN for/IN alleviating/VBG Parkinson/NNP whosewhat/NN disease/NN (/( PD/NN )/) symptoms/NNS especially/RB for/IN whom/WP drug/NN therapy/NN is/VBZ no/RB longer/RBR 
1534_1534_32_33_16_17::None::and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) 
1628_1628_27_28_31_33::POS_ACTION_BIND::the/DT ability/NN of/IN Munc-18-2/NN to/TO associate/VB with/IN syntaxin/NN 3/CD in/FW vitro/FW ./. 
464783_0_28_29_29_30::None::novel/JJ strategies/NNS and/CC potential/JJ targets/NNS for/IN therapy/NN ./. 
483865_3_32_33_49_50::None::(/( 64/CD )/) S2/NN (/( +/CC )/) )/) ,/, in/IN seven/CD different/JJ marine/JJ environments/NNS using/VBG real/JJ -/: time/NN ,/, single/JJ particle/NN mass/NN spectrometry/NN ;/: 
712_712_27_28_23_24::None::interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN ./. 
991_991_4_5_15_16::None::known/VBN to/TO link/VB actin/NN filaments/NNS to/TO membrane/NN were/VBD also/RB examined/VBN ,/, including/VBG alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, 
1380_1380_36_37_38_39::None::,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, 
452794_0_0_1_4_5::None::Efficacy/NN and/CC safety/NN of/IN anticoagulation/NN therapy/NN with/IN different/JJ 
787228_4_4_5_28_29::None::results/NNS revealed/VBD that/IN COPD/NNP was/VBD significantly/RB associated/VBN with/IN a/DT high/JJ risk/NN of/IN osteoporosis/NN ,/, regardless/RB of/IN whether/IN the/DT patients/NNS with/IN COPD/NN were/VBD corticosteroid/NN users/NNS and/CC irrespective/RB of/IN age/NN and/CC sex/NN ./. 
428759_7_15_16_14_16::people.cause_of_death.includes_causes_of_death::premenopausal/JJ early/JJ breast/NN cancer/NN have/VBP been/VBN selected/VBN 
1102_1102_2_3_6_7::POS_REG(+)_ASSEMBLE::Overexpression/NN of/IN cofilin/NN stimulates/VBZ bundling/VBG of/IN actin/NN filaments/NNS ,/, membrane/NN 
697_697_23_25_2_3::POS_REG(+)_POLYMERIZE::In/IN Acanthamoeba/NN actin/NN polymerization/NN is/VBZ regulated/VBN ,/, at/IN least/JJS in/IN part/NN ,/, by/IN profilin/NN ,/, which/WDT binds/VBZ to/TO actin/NN monomers/NNS ,/, and/CC by/IN capping/VBG protein/NN ,/, which/WDT both/DT 
1258_1258_3_4_34_35::POS_ACTION_BIND::Significantly/RB ,/, those/DT actin/NN mutants/NNS exhibiting/VBG the/DT most/RBS severe/JJ phenotypes/NNS in/IN all/DT three/CD processes/NNS have/VBP altered/VBN residues/NNS that/WDT cluster/VBP to/TO a/DT small/JJ region/NN of/IN the/DT actin/NN crystal/NN structure/NN previously/RB defined/VBN as/IN the/DT fimbrin/NN (/( Sac6p/NN )/) -/: binding/VBG 
342702_0_7_8_15_16::medicine.symptom.symptom_of::understanding/NN of/IN the/DT inflammatory/JJ and/CC immune/JJ mechanisms/NNS in/IN rheumatoid/JJ arthritis/NN (/( RA/NN )/) have/VBP fuelled/VBN 
1361_1361_3_4_6_7::None::The/DT affinity/NN of/IN ZmPRO4/NN for/IN monomeric/JJ actin/NN ,/, which/WDT was/VBD 
609_609_19_20_10_11::POS_ACTION_ENCODE::)/) encodes/VBZ a/DT helicase-primase/NN that/WDT consists/VBZ of/IN three/CD polypeptides/NNS encoded/VBN by/IN the/DT UL5/NN ,/, UL8/NN ,/, 
320864_0_16_17_38_39::None::target/NN range/NN through/IN erythropoiesis/NN -/: stimulating/VBG agent/NN therapy/NN on/IN the/DT renal/JJ outcome/NN with/IN respect/NN to/TO chronic/JJ kidney/NN disease/NN (/( CKD/NN )/) stage/NN and/CC concurrent/JJ diabetes/NN condition/NN in/IN patients/NNS with/IN 
772940_6_0_1_5_6::None::In/IN patients/NNS with/IN chronic/JJ HBV/NN infection/NN ,/, fourteen/CD sphingolipids/NNS 
814864_2_12_13_6_7::medicine.symptom.symptom_of::,/, however/RB ,/, sensitization/NN profiles/NNS among/IN children/NNS hospitalized/VBN for/IN asthma/NN are/VBP unknown/JJ ./. 
201_201_6_7_4_5::None::two-hybrid-based/JJ approach/NN using/VBG cofilin/NN and/CC actin/NN mutants/NNS identified/VBD residues/NNS 
75337_1_23_25_10_11::None::adjuvant/JJ regimens/NNS with/IN trastuzumab/NN for/IN the/DT treatment/NN of/IN small/JJ HER2/NN -/: positive/JJ breast/NN cancer/NN in/IN routine/JJ clinical/JJ practice/NN ./. 
856_856_16_18_13_14::None::coactivator/NN protein/NN ,/, CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO 
236148_4_11_12_3_4::None::Diabetic/NNP patients/NNS with/IN CKD/NN were/VBD more/RBR likely/JJ to/TO have/VB a/DT higher/JJR prevalence/NN of/IN previously/RB diagnosed/VBN 
116217_7_16_17_24_26::None::because/IN of/IN different/JJ reasons/NNS ,/, 7/CD of/IN these/DT 9/CD patients/NNS had/VBD epileptic/JJ seizures/NNS and/CC sirolimus/NN treatment/NN 
152333_0_17_18_12_15::biology.organism_classification.lower_classifications::poultry/NN caused/VBN by/IN influenza/NN A/NN viruses/NNS ,/, family/NN Orthomyxoviridae/NNP ./. 
2222_2222_17_18_15_16::POS_ACTION_COLOCALIZE::,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, 
1678_1678_33_34_33_34::POS_ACTION_ENCODE::of/IN the/DT total/JJ H4/NN and/CC H2b/NN mRNA/NN 
30983_5_6_7_8_9::None::significantly/RB lower/JJR mean/NN concentration/NN of/IN estradiol/NN and/CC higher/JJR intensity/NN 
906557_3_3_4_10_11::None::As/IN can/MD be/VB inferred/VBN from/IN all/DT these/DT functions/NNS ,/, TXNDC5/NN plays/VBZ an/DT important/JJ role/NN 
742394_1_0_1_20_21::None::It/PRP is/VBZ suggested/VBN that/IN cardiovascular/JJ diseases/NNS (/( CVD/NN )/) occur/VBP earlier/JJR among/IN HIV/NN -/: positive/JJ patients/NNS compared/VBN with/IN HIV/NN -/: negative/JJ patients/NNS ,/, and/CC 
785586_0_0_1_14_16::None::Pancreaticoduodenectomy/NN (/( PD/NN )/) is/VBZ one/CD of/IN the/DT most/RBS difficult/JJ and/CC dangerous/JJ operations/NNS in/IN general/JJ surgery/NN ./. 
1726_1726_23_24_14_15::None::increased/VBD phosphorylation/NN of/IN cofilin/NN by/IN LIM-kinase/NN contribute/VBP to/TO Rho-induced/JJ reorganization/NN of/IN the/DT actin/NN cytoskeleton/NN ./. 
2222_2222_23_24_11_12::None::calcium/NN ions/NNS ,/, integrins/NNS ,/, cadherins/NNS ,/, alpha-catenin/NN ,/, beta-catenin/NN ,/, plakoglobin/NN ,/, vinculin/NN and/CC alpha-actinin/NN appeared/VBD to/TO accumulate/VB 
431_431_0_1_15_16::None::END5/NN encodes/VBZ a/DT proline-rich/JJ protein/NN (/( End5p/NN or/CC verprolin/NN )/) required/VBN for/IN a/DT polarised/JJ cortical/JJ actin/NN cytoskeleton/NN and/CC endocytosis/NN 
266602_0_6_7_18_19::None::acid/NN levels/NNS in/IN young/JJ people/NNS at/IN ultra/NN -/: high/JJ risk/NN for/IN psychotic/JJ disorder/NN and/CC healthy/JJ adolescent/JJ controls/NNS ./. 
2131_2131_9_10_10_11::None::,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN 
2131_2131_13_14_7_8::None::replication/NN proteins/NNS ,/, UL5/NN ,/, UL8/NN UL52/NN ,/, and/CC UL9/NN ,/, are/VBP necessary/JJ 
1831_1831_14_15_11_14::None::expression/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p16/NN in/IN 44/CD %/NN 
292034_0_20_21_5_8::None::Clear/JJ Cell/NN Type/NN Squamous/JJ Cell/NN Carcinoma/NN that/WDT Required/NNP Differential/JJ Diagnosis/NN from/IN Metastatic/JJ Ureter/NN Cancer/NN ;/: Report/NNP of/IN a/DT Case/NN ]/) ./. 
1570_1570_2_3_6_7::POS_ACTION_DISRUPT::The/DT N-terminal/JJ talin/NN polypeptide/NN eventually/RB disrupted/VBD actin/NN stress/NN fibres/NNS whereas/IN 
305802_4_31_32_42_43::None::terminal/JJ or/CC central/JJ mutations/NNS in/IN the/DT cytosolic/JJ region/NN of/IN the/DT RyR2/NN protein/NN ,/, while/IN dantrolene/NN had/VBD no/DT effect/NN 
1773_1773_6_7_4_5::None::structural/JJ homology/NN between/IN cofilin/NN and/CC gelsolin/NN segment-1/NN binding/NN to/TO 
157_157_33_34_14_15::None::of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN formed/VBN by/IN eukaryal/JJ histone/NN (/( H3/NN +/CC H4/NN )/) 
767_767_2_3_17_18::None::Inhibition/NN of/IN actin/NN polymerization/NN by/IN a/DT synthetic/JJ dodecapeptide/NN patterned/VBN on/IN the/DT sequence/NN around/IN the/DT actin-binding/JJ site/NN of/IN cofilin/NN ./. 
1075_1075_11_12_8_9::None::as/IN profilin/NN and/CC CapG/NN but/CC also/RB fragmin/NN from/IN Physarum/NN polycephalum/NN 
410591_0_18_19_27_28::None::is/VBZ characterized/VBN by/IN edema/NN ,/, hypoalbuminemia/NN ,/, hyperlipidemia/NN ,/, lipiduria/NN ,/, and/CC proteinuria/NN ./. 
294475_2_8_9_2_3::None::Therefore/RB ,/, sows/VBZ were/VBD fed/VBN either/CC a/DT regular/JJ diet/NN ,/, based/VBN on/IN 
590_590_35_36_29_31::None::related/JJ molecule/NN ,/, CREB-binding/JJ protein/NN ,/, or/CC CBP/NN )/) histone/NN acetylation/NN activity/NN ./. 
524639_5_22_23_16_17::medicine.disease.symptoms::,/, diclofenac/NN and/CC high/JJ -/: dose/NN ibuprofen/NN cause/NN adverse/JJ cardiovascular/JJ effects/NNS to/TO a/DT 
337142_1_28_29_37_40::None::adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) in/IN chum/NN salmon/NN Oncorhynchus/NNP keta/NN using/VBG quantitative/JJ polymerase/NN chain/NN reaction/NN (/( QPCR/NN )/) 
1434_1434_11_12_75_76::None::,/, H2B/NN ,/, H3/NN ,/, and/CC H4/NN ,/, are/VBP rapidly/RB acetylated/VBN ;/: histone/NN H4/NN shows/VBZ five/CD subfractions/NNS ,/, analogous/JJ to/TO the/DT five/CD subfractions/NNS of/IN mammalian/JJ histone/NN H4/NN (/( containing/VBG zero/CD to/TO four/CD acetyllysine/NN residues/NNS per/IN molecule/NN )/) ;/: histone/NN H3/NN has/VBZ a/DT more/RBR complex/JJ pattern/NN that/IN we/PRP interpret/VBP as/IN zero/CD to/TO four/CD acetyllysine/NN residues/NNS on/IN each/DT of/IN two/CD sequence/NN variants/NNS of/IN histone/NN H3/NN ;/: histones/NNS H2A/NN and/CC H2B/NN show/VBP less/JJR heterogeneity/NN 
15883_8_14_15_16_17::medicine.medical_treatment.used_to_treat::effects/NNS of/IN biologic/JJ DMARDs/NNS in/IN RA/NN 
1075_1075_22_23_20_21::None::targets/NNS for/IN PIP2-stimulated/JJ pp60/NN (/( c-src/NN )/) phosphorylation/NN ./. 
265539_2_29_31_5_6::people.cause_of_death.includes_causes_of_death::an/DT inflammatory/JJ ,/, demyelinating/JJ ,/, neurodegenerative/JJ disease/NN of/IN the/DT CNS/NN During/IN the/DT last/JJ several/JJ decades/NNS ,/, experimental/JJ models/NNS of/IN MS/NN have/VBP contributed/VBN to/TO our/PRP$ understanding/NN of/IN the/DT inflammatory/JJ disease/NN mechanisms/NNS and/CC have/VBP 
373109_2_13_14_25_26::None::analysis/NN using/VBG a/DT quartz/NN -/: crystal/NN microbalance/NN (/( QCM/NN )/) revealed/VBD that/IN the/DT amounts/NNS of/IN proteins/NNS such/JJ as/IN human/JJ 
136045_10_0_1_11_12::None::DM/NN is/VBZ an/DT independent/JJ predictor/NN of/IN cancer/NN -/: specific/JJ and/CC overall/JJ survival/NN in/IN patients/NNS who/WP 
1608_1608_24_25_26_27::None::protein/NN to/TO bind/VB actin/NN or/CC vinculin/NN ./. 
71991_0_26_27_20_22::None::,/, insomnia/NN //: sleep/VB disorder/NN ,/, fatigue/NN ,/, and/CC injury/NN by/IN accident/NN ,/, 
198817_2_4_5_8_9::None::data/NNS of/IN 41/CD patients/NNS with/IN surgically/RB treated/VBN CRC/NN (/( Group/NN A/NN 
303_303_5_6_23_24::None::beta-catenin/NN binding/NN to/TO cadherin/NN or/CC APC/NN protein/NN ,/, and/CC the/DT ensuing/VBG effects/NNS on/IN cell/NN morphology/NN and/CC adhesion/NN ,/, are/VBP independent/JJ of/IN beta-catenin/NN binding/NN to/TO alpha-catenin/NN 
456127_2_0_1_2_3::medicine.drug.active_moieties::Chromium/NNP (/( Cr/NNP )/) and/CC nickel/NN 
655566_1_18_19_29_30::None::past/JJ couple/NN of/IN decades/NNS ,/, with/IN a/DT shift/NN from/IN cerebral/JJ malaria/NN to/TO fever/NN with/IN jaundice/NN ,/, renal/JJ failure/NN 
2064_2064_49_50_8_9::NEG_ACTION_CORELATE::of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN labeling/NN ,/, or/CC c-erbB2/NN expression/NN ,/, except/IN for/IN beta-catenin/NN ,/, the/DT down-regulation/NN of/IN which/WDT was/VBD associated/VBN with/IN c-erbB2/NN down-regulation/NN ./. 
159605_0_20_21_13_14::None::delaminated/VBN two/CD dimensional/JJ titanate/NN nanosheets/NNS (/( TNSs/NNS )/) has/VBZ been/VBN explored/VBN for/IN degradation/NN of/IN 
374_374_14_15_4_5::POS_REG(0)_INACTIVATE::of/IN SIR4/NN enhanced/VBD mURA3/NN and/CC MET15/NN silencing/NN ,/, but/CC deletion/NN of/IN SIR1/NN or/CC SIR3/NN did/VBD not/RB affect/VB 
410019_0_3_5_8_10::None::Neo/SYM -/: adjuvant/JJ breast/NN cancer/NN clinical/JJ trials/NNS of/IN zoledronic/JJ acid/NN (/( ZOL/NN )/) 
833154_0_2_3_4_5::medicine.symptom.symptom_of::Management/NN of/IN angioedema/NN without/IN urticaria/NN in/IN the/DT emergency/NN 
1701_1701_50_51_6_7::None::that/IN this/DT novel/JJ RhoGAP/NN is/VBZ involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN and/CC profilin/NN ./. 
2064_2064_28_29_6_7::None::the/DT down-regulation/NN of/IN E-cad/NN ,/, alpha-catenin/NN ,/, and/CC beta-catenin/NN expression/NN significantly/RB correlated/VBD with/IN tumor/NN high/JJ grade/NN ,/, but/CC not/RB with/IN vascular/JJ invasion/NN ,/, metastasis/NN ,/, p53/NN expression/NN ,/, Ki-67/NN 
350044_5_1_2_0_1::None::These/DT findings/NNS have/VBP interdisciplinary/JJ implications/NNS 
1758_1758_17_18_19_20::None::apoptotic/JJ factors/NNS ,/, TRADD/NN ,/, FADD/NN ,/, and/CC FLICE/NNP 
1321_1321_23_24_9_11::None::)/) is/VBZ a/DT serine/threonine/NN kinase/NN highly/RB expressed/VBN in/IN testicular/JJ germ/NN cells/NNS and/CC has/VBZ the/DT potential/JJ to/TO phosphorylate/VB cofilin/NN and/CC induce/VB actin/NN 
469705_8_8_9_34_35::None::determine/VB effective/JJ depression/NN screening/NN and/CC evidence/NN -/: based/VBN interventions/NNS for/IN depressive/JJ symptoms/NNS in/IN RA/NN patients/NNS in/IN this/DT socio/NN -/: cultural/JJ context/NN ,/, as/IN intervening/VBG in/IN depression/NN may/MD decrease/VB pain/NN perception/NN ./. 
653700_25_8_9_22_23::None::to/TO treat/VB a/DT vaginal/JJ colonisation/NN of/IN Candida/NN in/IN healthy/JJ women/NNS ,/, vaginal/JJ administration/NN of/IN antimycotics/NNS is/VBZ often/RB recommended/VBN in/IN the/DT third/JJ 
2065_2065_50_51_37_38::None::PCNA/NN )/) ,/, histone/NN H1/NN ,/, histone/NN H2A/NN +/CC 2B/NN ,/, histone/NN H3/NN ,/, and/CC histone/NN H4/NN ,/, was/VBD induced/VBN 
1843_1843_31_33_19_20::None::that/WDT couples/VBZ the/DT actin/NN network/NN to/TO the/DT plasma/NN membrane/NN ,/, or/CC by/IN the/DT lack/NN of/IN cortexillin/NN I/CD or/CC II/CD ,/, 
102783_0_2_3_32_33::None::Poly/NN (/( imidazole/NN -/: Cu/NN )/) -/: mediated/VBN C1/NN //: C1N2/NN copolymerization/NN of/IN ethyl/NN diazoacetate/NN involved/VBN copper/NN -/: based/VBN carbene/NN radical/NN and/CC alpha/NN -/: carbonyl/NN diazomethane/NN radical/JJ intermediates/NNS ,/, which/WDT could/MD be/VB captured/VBN by/IN radical/JJ traps/NNS 
440638_0_17_18_15_16::medicine.drug_ingredient.active_moiety_of_drug::of/IN budesonide/NN and/CC mesalazine/NN (/( mesalamine/NN )/) for/IN Crohn/NN 
290049_2_9_10_22_25::biology.organism_classification.lower_classifications::additional/JJ reservoir/NN for/IN influenza/NN A/NN viruses/NNS raises/VBZ questions/NNS about/IN the/DT role/NN of/IN this/DT mammalian/JJ taxon/NN in/IN influenza/NN A/NN virus/NN ecology/NN and/CC possible/JJ 
1538_1538_11_12_12_13::None::partner/NN of/IN the/DT Rap1A/NN GTPase/NN and/CC associates/VBZ with/IN 
492455_3_80_81_12_13::None::)/) analyses/NNS to/TO investigate/VB the/DT predictive/JJ value/NN of/IN the/DT MASC/NNP total/NN and/CC subscale/JJ scores/NNS for/IN the/DT Schedule/VB for/IN Affective/JJ Disorders/NNS and/CC Schizophrenia/NNP for/IN School/NNP -/: age/NN children/NNS -/: Present/JJ and/CC Lifetime/NN version/NN (/( K/NN -/: SADS/NN -/: PL/NN )/) ,/, DSM/NNP -/: IV/CD diagnoses/NNS of/IN generalized/VBN anxiety/NN disorder/NN (/( GAD/NN )/) ,/, separation/NN anxiety/NN disorder/NN (/( SAD/NN )/) and/CC social/JJ phobia/NN (/( SoP/NN )/) in/IN a/DT highly/RB comorbid/JJ inpatient/JJ sample/NN of/IN adolescents/NNS (/( 11/CD -/: 
1254_1254_9_11_11_12::POS_ACTION_MEMBER::localization/NN of/IN the/DT actin-binding/JJ protein/NN cofilin/NN in/IN stimulated/VBN human/JJ 
231772_0_6_7_39_41::None::of/IN three/CD neonicotinoid/JJ insecticides/NNS (/( NIs/NNS )/) ,/, thiamethoxam/NN (/( TH/NN )/) ,/, imidacloprid/NN (/( IM/NN )/) and/CC acetamiprid/NN (/( AC/NN )/) ,/, in/IN pure/JJ water/NN has/VBZ been/VBN studied/VBN using/VBG zinc/NN oxide/NN (/( ZnO/NN )/) and/CC titanium/NN dioxide/NN (/( TiO2/NN )/) 
832646_0_4_5_1_2::None::Disability/NN identity/NN predicts/VBZ lower/JJR anxiety/NN and/CC depression/NN in/IN 
669734_0_4_5_48_49::None::study/NN examined/VBD whether/IN development/NN of/IN two/CD forms/NNS of/IN cognitive/JJ control/NN (/( proactive/JJ and/CC reactive/JJ )/) between/IN early/JJ and/CC midadolescence/NN was/VBD associated/VBN with/IN the/DT onset/NN of/IN major/JJ depressive/JJ disorder/NN (/( MDD/NN )/) during/IN the/DT same/JJ period/NN and/CC if/IN it/PRP prospectively/RB predicted/VBD MDD/NN onset/NN between/IN mid/JJ -/: and/CC late/JJ adolescence/NN ./. 
87003_15_3_4_13_14::None::Helium/NNP further/RB increased/VBD TNF/NN -/: alpha/NN induced/VBD release/NN of/IN caspase/NN -/: 3/CD containing/VBG particles/NNS compared/VBN to/TO TNF/NN 
1069_1069_42_45_26_27::None::(/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC the/DT viral/JJ single-stranded/JJ DNA-binding/JJ protein/NN (/( ICP8/NN )/) 
1160_1160_2_3_2_3::None::Purification/NN of/IN cofilin/NN ,/, a/DT 21,000/CD 
710948_4_31_32_18_19::None::relapses/NNS ,/, or/CC renewed/VBN exacerbation/NN ,/, of/IN her/PRP$ MS/NN She/PRP responded/VBD well/RB after/IN beginning/VBG treatment/NN with/IN fingolimod/NN ,/, once/RB the/DT 
271641_1_6_7_26_27::None::study/NN ,/, to/TO investigate/VB the/DT effects/NNS of/IN tumor/NN growth/NN following/VBG radiotherapy/NN and/CC G/NN -/: CSF/NN administration/NN in/IN a/DT murine/JJ xenograft/NN model/NN of/IN colon/NN cancer/NN ,/, female/JJ BALB/NN 
555_555_47_48_5_6::POS_ACTION_BIND::pull-down/JJ performed/VBN with/IN Tax/NN deletion/NN mutants/NNS and/CC peptide/NN competition/NN have/VBP localized/VBN the/DT site/NN in/IN Tax/NN critical/JJ for/IN binding/VBG CBP/p300/NN to/TO a/DT highly/RB protease-sensitive/JJ region/NN around/IN amino/NN acid/NN residues/NNS 81/CD to/TO 95/CD (/( 81QRTSKTLKVLTPPIT95/NN )/) which/WDT lies/VBZ between/IN the/DT domains/NNS previously/RB proposed/VBN to/TO be/VB important/JJ for/IN CREB/NN binding/NN and/CC Tax/NN 
556_556_12_13_24_25::NEG_ACTION_INTERACT::,/, talin/NN ,/, myosin/NN ,/, or/CC actin-binding/JJ protein/NN based/VBN on/IN the/DT lack/NN of/IN reactivity/NN of/IN antigravin/NN with/IN these/DT polypeptides/NNS 
1861_1861_10_11_15_16::POS_ACTION_MUTUALCOMPLEX::containing/VBG combinations/NNS of/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN which/WDT are/VBP independent/JJ 
1916_1916_19_20_4_5::None::our/PRP$ knowledge/NN ,/, AF-6/NN is/VBZ the/DT only/JJ integral/JJ component/NN in/IN cell-cell/JJ junctions/NNS discovered/VBN thus/RB far/RB that/IN interacts/VBZ with/IN profilin/NN and/CC thus/RB could/MD 
174565_5_47_48_18_19::None::therapy/NN for/IN PD/NN This/DT study/NN identified/VBD neurexophilin/NN 3/CD (/( NXPH3/NN )/) ,/, a/DT secreted/VBN peptide/NN ,/, through/IN comparison/NN of/IN gene/NN expression/NN profiles/NNS in/IN the/DT mouse/NN striatum/NN from/IN various/JJ environments/NNS generated/VBN by/IN different/JJ doses/NNS of/IN dopaminergic/JJ (/( 
620_620_30_31_33_34::None::the/DT HHR23B/p58/NN and/CC HHR23A/NN subunits/NNS of/IN XPC/NN ./. 
103419_1_39_40_21_22::None::Cu/NN and/CC Ag/NN materials/NNS (/( CuNO3/NN ,/, Cu/NN -/: Field/NN ,/, Cu/NN -/: Nwires/NNS and/CC Cu/NN -/: NPs/NNS ;/: AgNO3/NN ,/, Ag/NN NM300K/NN ,/, Ag/NN 
788_788_38_39_34_35::POS_ACTION_ASSEMBLE::membrane/NN anchorage/NN of/IN actin/NN microfilaments/NNS ,/, i.e./FW vinculin/NN and/CC talin/NN ,/, 
432927_5_25_26_3_4::None::Animal/NN models/NNS ,/, imaging/NN and/CC pharmacological/JJ studies/NNS concur/VBP in/IN pointing/VBG out/RP dopaminergic/JJ denervation/NN in/IN the/DT aetiology/NN of/IN parkinsonian/JJ apathy/NN with/IN a/DT cardinal/JJ role/NN of/IN decreased/VBN tonic/NN D2/NN //: D3/NN 
609221_0_4_5_6_7::None::is/VBZ characterized/VBN by/IN spontaneous/JJ recurrent/JJ seizures/NNS and/CC represents/VBZ one/CD 
1201_1201_7_8_8_9::POS_ACTION_MEMBER::tails/NNS of/IN either/CC histone/NN H3/NN or/CC histone/NN H4/NN 
248192_9_10_14_37_38::None:::/: 40/CD %/NN benign/JJ paroxysmal/JJ positional/JJ vertigo/NN (/( BPPV/NN )/) ,/, 23/CD %/NN suspicious/JJ of/IN central/JJ causes/NNS ,/, 18/CD %/NN undiagnosed/JJ ,/, 15/CD %/NN Meniere/NNP disease/NN ,/, and/CC 4/CD %/NN vestibular/JJ neuronitis/NN ./. 
231976_9_9_10_29_30::None::fibrinogen/NN ,/, and/CC platelet/NN function/NN on/IN Day/NN 28/CD LP/NN compared/VBN with/IN Day/NN 5/CD thawed/VBD FFP/NNP Thrombin/NN generation/NN assays/NNS revealed/VBD that/IN the/DT total/NN ,/, lag/NN time/NN to/TO ,/, 
346198_0_13_14_16_17::None::caffeinated/VBN products/NNS and/CC agro/NN -/: industrial/JJ effluents/NNS ./. 
1450_1450_4_5_23_24::POS_ACTION_BIND::data/NNS suggest/VBP that/IN profilin/NN binding/NN to/TO actin/NN weakens/VBZ nucleotide/NN binding/NN to/TO actin/NN by/IN disrupting/VBG Mg/NN (/( 2/CD +/CC )/) coordination/NN in/IN the/DT actin/NN central/JJ cleft/NN ./. 
1156_1156_7_8_5_6::POS_ACTION_MUTUALCOMPLEX::form/VBP complexes/NNS with/IN E-cadherin/NN ,/, beta-catenin/NN ,/, and/CC alpha-catenin/NN 
696_696_21_22_21_22::None::also/RB to/TO mammalian/JJ actin/NN ,/, demonstrating/VBG that/IN 
410007_10_3_4_6_7::None::Geographical/JJ and/CC age/NN differences/NNS influence/VBP the/DT distribution/NN of/IN P/NN vivax/NN 
521445_4_18_20_4_5::medicine.disease.risk_factors::the/DT recent/JJ Musculoskeletal/JJ Infection/NN symposium/NN ,/, specific/JJ issues/NNS were/VBD discussed/VBN with/IN regard/NN to/TO the/DT treatment/NN of/IN periprosthetic/JJ joint/JJ infection/NN ,/, including/VBG medical/JJ 
187563_7_24_25_14_15::None::-/: 3/CD ,/, device/NN embolization/NN -/: 1/CD ,/, hemolysis/NN -/: 1/CD ,/, surgical/JJ VSD/NN closure/NN -/: 2/CD 
2100_2100_18_19_12_13::None::to/TO Trp104-Met115/NN of/IN cofilin/NN is/VBZ a/DT potent/JJ inhibitor/NN of/IN actin/NN polymerization/NN (/( Yonezawa/NN 
784_784_4_5_12_13::None::normal/JJ livers/NNS ,/, E-cad/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, 
1395_1395_12_13_26_27::POS_ACTION_BIND::plant/NN and/CC animal/NN actins/NNS can/MD be/VB blocked/VBN by/IN profilin-specific/JJ antibodies/NNS that/WDT react/VBP with/IN different/JJ epitopes/NNS of/IN birch/NN profilin/NN ./. 
761772_0_0_1_4_6::None::The/DT jungle/NN crow/NN (/( Corvus/NN macrorhynchos/NNS )/) belongs/VBZ to/TO 
231380_9_15_16_20_21::None::female/JJ M3R/NN -/: KO/NN are/VBP related/JJ to/TO postmenopausal/JJ osteoporotic/JJ phenotype/NN ./. 
355_355_12_13_14_15::POS_ACTION_BIND::mutant/JJ form/NN of/IN alpha-catenin/NN binds/VBZ beta-catenin/NN and/CC plakoglobin/NN ,/, 
534857_3_24_26_19_20::None::hypertensive/JJ patients/NNS with/IN ECG/NN left/VBD ventricular/JJ hypertrophy/NN in/IN atrial/JJ fibrillation/NN at/IN baseline/NN (/( 
772940_6_17_18_3_4::medicine.symptom.symptom_of::In/IN patients/NNS with/IN chronic/JJ HBV/NN infection/NN ,/, fourteen/CD sphingolipids/NNS differed/VBD significantly/RB between/IN CHB/NN and/CC HBV/NN -/: related/JJ cirrhosis/NN ./. 
297982_0_1_3_13_14::None::Nanosized/JJ titanium/NN dioxide/NN (/( TiO2/NN )/) particles/NNS belong/VBP to/TO the/DT most/RBS widely/RB manufactured/VBN nanoparticles/NNS (/( NPs/NNS )/) 
449335_7_17_18_17_19::medicine.drug.active_moieties::have/VB implication/NN for/IN nicotine/NN dependence/NN treatment/NN ./. 
435_435_13_14_4_5::POS_ACTION_BIND::domains/NNS of/IN the/DT PRP21/NN splicing/NN factor/NN are/VBP implicated/VBN in/IN the/DT binding/NN to/TO PRP9/NN and/CC PRP11/NN proteins/NNS 
774440_0_16_18_0_1::None::Obesity/NN is/VBZ a/DT major/JJ cause/NN for/IN a/DT spectrum/NN of/IN metabolic/JJ syndrome/NN -/: related/JJ diseases/NNS that/WDT include/VBP insulin/NN resistance/NN ,/, type/NN 2/CD 
712_712_15_16_24_25::None::stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN 
538_538_32_33_25_28::POS_ACTION_COLOCALIZE::increased/VBN incorporation/NN of/IN actin/NN binding/NN protein/NN ,/, talin/NN ,/, and/CC myosin/NN into/IN the/DT cytoskeletal/JJ 
1479_1479_21_22_16_17::None::LIM/NN kinase/NN and/CC cofilin/NN in/IN the/DT control/NN of/IN actin/NN dynamics/NNS ./. 
1147_1147_0_1_17_18::POS_ACTION_DISRUPT::Profilins/NNP also/RB bind/VBP polyphosphoinositides/NNS ,/, which/WDT can/MD disrupt/VB the/DT profilin-actin/NN complex/NN ,/, and/CC proline-rich/JJ ligands/NNS which/WDT localize/VBP profilin/NN to/TO sites/NNS requiring/VBG 
87_87_41_45_16_20::None::,/, only/RB a/DT alpha/NN v/LS beta/NN 3/CD can/MD be/VB detected/VBN in/IN focal/JJ contacts/NNS ,/, colocalizing/VBG with/IN vinculin/NN ,/, talin/NN ,/, and/CC the/DT ends/NNS of/IN actin/NN filaments/NNS ,/, while/IN alpha/NN v/LS beta/NN 5/CD shows/VBZ a/DT distinct/JJ 
188913_0_18_19_76_77::None::mineral/NN elements/NNS [/( calcium/NN (/( Ca/NN )/) ,/, iron/NN (/( Fe/NNP )/) ,/, copper/NN (/( Cu/NN )/) ,/, zinc/NN (/( Zn/NN )/) ,/, iodine/NN (/( I/NN )/) ,/, selenium/NN (/( Se/NN )/) ,/, molybdenum/NN (/( Mo/NN )/) ,/, and/CC chromium/NN (/( Cr/NN )/) ]/) ,/, the/DT energy/NN metabolic/JJ indicators/NNS [/( triglyceride/NN (/( TG/NN )/) ,/, glucose/NN (/( Glu/NN )/) ,/, total/JJ cholesterol/NN (/( CHO/NN )/) 
214618_2_22_23_15_16::None::the/DT diagnosis/NN of/IN acute/JJ MI/NNP However/RB ,/, high/JJ sensitivity/NN troponin/NN assays/NNS can/MD increase/VB the/DT 
1426_1426_14_15_5_6::None::denominator/NN is/VBZ impaired/JJ beta-catenin/NN association/NN with/IN either/CC E-cadherin/NN (/( PaTuII/NN )/) or/CC alpha-catenin/NN (/( BxPc3/NN and/CC 
311030_10_0_1_14_15::medicine.drug_ingredient.active_moiety_of_drug::Dopamine/NN release/NN was/VBD stimulated/VBN by/IN applying/VBG ATP/NN which/WDT activated/VBD P2X2/NN channels/NNS specifically/RB expressed/VBN in/IN dopaminergic/JJ neurons/NNS ./. 
913_913_20_21_22_23::None::release/NN of/IN G/NN actin/NN from/IN profilin/NN or/CC promoting/VBG the/DT 
369325_1_37_38_28_30::None::order/NN in/IN which/WDT cardiovascular/JJ disease/NN risk/NN factors/NNS including/VBG diabetes/NN ,/, hypertension/NN ,/, dyslipidemia/NN (/( low/JJ high/JJ 
779_779_21_24_6_7::None::mechanism/NN by/IN which/WDT pRb/NN induces/VBZ senescence/NN ,/, we/PRP have/VBP found/VBN that/IN pRb/NN causes/VBZ a/DT posttranscriptional/JJ accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( KIP1/NN 
1373_1373_13_14_16_17::None::with/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, and/CC plakoglobin/NN ./. 
784_784_12_13_4_5::NEG_ACTION_COLOCALIZE::normal/JJ livers/NNS ,/, E-cad/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, 
326118_0_54_55_56_57::None::migraine/NN in/IN a/DT double/JJ -/: dummy/NN ,/, randomized/VBN comparative/JJ 
1701_1701_43_46_11_12::None::involved/VBN in/IN the/DT Rho/NN signalling/NN pathway/NN ,/, probably/RB downstream/RB of/IN Rho/NN activation/NN ,/, and/CC mediates/VBZ the/DT stimulation/NN of/IN PLC-delta/NN ,/, which/WDT leads/VBZ to/TO actin-related/JJ cytoskeletal/JJ changes/NNS through/IN the/DT hydrolysis/NN of/IN PIP2/NN ,/, which/WDT binds/VBZ to/TO actin/NN binding/NN proteins/NNS such/JJ as/IN gelsolin/NN 
735_735_11_12_22_23::None::sensitivity/NN of/IN a/DT tropomyosin/NN mutant/NN ,/, and/CC the/DT loss/NN of/IN cytoplasmic/JJ cables/NNS seen/VBN in/IN fimbrin/NN ,/, Mdm20p/NN ,/, 
1534_1534_26_29_9_10::None::proteins/NNS FADD/MORT1/NN ,/, TRADD/NN ,/, and/CC RIP/NN and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( 
596639_0_0_1_15_17::None::Competition/NN for/IN pollinators/NNS occurs/VBZ when/WRB ,/, in/IN a/DT community/NN of/IN flowering/NN plants/NNS ,/, several/JJ simultaneously/RB flowering/VBG plant/NN species/NNS depend/VBP on/IN 
185609_1_33_34_8_9::medicine.medical_treatment.used_to_treat::increasing/VBG age/NN of/IN cancer/NN patients/NNS ,/, the/DT number/NN of/IN patients/NNS with/IN various/JJ comorbidities/NNS such/JJ as/IN membranous/JJ nephropathy/NN is/VBZ also/RB rising/VBG ,/, and/CC problems/NNS associated/VBN with/IN the/DT administration/NN of/IN chemotherapy/NN to/TO elderly/JJ patients/NNS 
205283_0_12_13_4_5::None::there/EX has/VBZ been/VBN great/JJ progress/NN achieved/VBN by/IN the/DT use/NN of/IN intensive/JJ statin/NN therapy/NN ,/, the/DT 
1380_1380_43_44_26_27::None::,/, Arp2/NN and/CC Arp3/NN ;/: and/CC five/CD apparently/RB novel/JJ proteins/NNS ,/, p40/NN ,/, p35/NN ,/, p19/NN ,/, p18/NN ,/, and/CC p14/NN (/( Machesky/NNP et/FW 
686_686_23_24_13_14::None::different/JJ E-cadherin/NN -/: catenin/NN complexes/NNS ,/, one/CD composed/VBN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, and/CC the/DT 
93_93_57_58_22_23::None::MEK/NN )/) or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC MID2/NN also/RB suppressed/VBD glc7-10/NN effectively/RB ./. 
350838_1_2_4_27_28::None::The/DT protozoan/NN Entamoeba/FW histolytica/NN ,/, which/WDT is/VBZ a/DT human/JJ intestinal/JJ parasite/NN ,/, possesses/VBZ a/DT restricted/JJ set/NN of/IN autophagy/NN -/: related/JJ (/( Atg/NN )/) proteins/NNS compared/VBN with/IN other/JJ eukaryotes/NNS and/CC thus/RB represents/VBZ 
185_185_6_7_2_3::POS_ACTION_BIND::Associations/NNS of/IN UBE2I/NN with/IN RAD52/NN ,/, UBL1/NN ,/, p53/NN ,/, 
2057_2057_3_4_12_13::POS_ACTION_ASSEMBLE::We/PRP find/VBP that/IN profilin/NN contributes/VBZ in/IN several/JJ ways/NNS to/TO Cdc42-induced/JJ nucleation/NN of/IN actin/NN filaments/NNS in/IN high/JJ 
198131_1_22_23_13_14::medicine.drug.active_moieties::users/NNS ,/, their/PRP$ smoking/NN behaviour/NN ,/, attachment/NN to/TO smoking/NN ,/, experience/NN of/IN nicotine/NN withdrawal/NN symptoms/NNS ,/, 
1711_1711_5_6_19_20::POS_ACTION_SQSIMILAR::of/IN the/DT predicted/VBN HMP-1/NN ,/, HMP-2/NN ,/, and/CC HMR-1/NN proteins/NNS are/VBP related/JJ to/TO the/DT cell/NN adhesion/NN proteins/NNS alpha-catenin/NN ,/, beta-catenin/Armadillo/NN ,/, 
372073_0_38_40_22_23::medicine.disease.treatments::neuroprotective/JJ effect/NN of/IN cabergoline/NN ,/, an/DT ergoline/NN D2/NN receptor/NN agonist/NN ,/, against/IN the/DT pesticide/NN and/CC neurotoxin/NN rotenone/NN relevant/JJ to/TO Parkinson/NNP disease/NN (/( PD/NN )/) 
1047_1047_9_10_17_18::POS_ACTION_ACTIVATE::proteins/NNS TRADD/NN and/CC FADD/NN are/VBP also/RB involved/VBN in/IN the/DT activation/NN of/IN A-SMase/NN ./. 
453075_8_22_23_16_17::None::of/IN normal/JJ muscle/NN histology/NN and/CC pathology/NN such/JJ as/IN decreased/VBN necrosis/NN and/CC resistance/NN to/TO 
713_713_9_10_14_15::None::cofilin/NN and/CC its/PRP$ actin/NN binding/NN peptide/NN compete/VBP with/IN gelsolin/NN segments/NNS 2-3/CD for/IN 
865_865_21_24_17_18::None::(/( DRP/NN or/CC utrophin/NN )/) and/CC the/DT 87K/NN postsynaptic/JJ protein/NN from/IN Torpedo/NNP electric/JJ 
856_856_16_18_22_23::POS_ACTION_UPREGULATE::CBP/NN (/( the/DT CREBbinding/NN protein/NN )/) ,/, to/TO the/DT CYBB/NN or/CC NCF2/NN promoter/NN 
590053_1_7_8_19_20::None::after/IN administration/NN include/VBP headache/NN ,/, nausea/NN ,/, and/CC influenza/NN -/: like/IN symptoms/NNS ,/, such/JJ as/IN fever/NN and/CC joint/JJ pain/NN 
332030_3_21_22_19_20::None::salt/NN -/: induced/VBN hypertension/NN were/VBD investigated/VBN ./. 
966_966_11_12_9_10::POS_ACTION_COOCCUR::of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN were/VBD seen/VBN in/IN 
881_881_15_16_25_26::POS_ACTION_BIND::the/DT domains/NNS on/IN alpha-catenin/NN that/WDT allow/VBP it/PRP to/TO associate/VB with/IN beta-catenin/plakoglobin/NN and/CC with/IN alpha-actinin/NN ./. 
1061_1061_36_37_19_20::None::;/: another/DT ,/, TRADD/NN ,/, binds/VBZ to/TO the/DT p55/NN TNF/NN receptor/NN but/CC not/RB to/TO Fas/APO1/NN ;/: and/CC the/DT third/JJ ,/, RIP/NN ,/, binds/VBZ weakly/RB 
1522_1522_10_11_15_16::None::virus/NN phosphoprotein/NN (/( P/NN )/) and/CC nucleocapsid/NN (/( N/NN )/) protein/NN has/VBZ 
423761_7_10_11_5_6::None::our/PRP$ expectations/NNS ,/, gonadectomy/NN increased/VBD the/DT synthesis/NN of/IN IgG1/NN ,/, IgG2b/NN ,/, 
99729_5_35_36_15_18::None::ischemic/JJ attack/NN ,/, peripheral/JJ arterial/JJ disease/NN ,/, myocardial/JJ infarction/NN ,/, and/CC smoking/NN were/VBD less/RBR likely/JJ to/TO have/VB LDL/NN -/: C/NN ,/, non/JJ -/: HDL/SYM -/: C/NN ,/, 
68_68_12_13_20_21::None::of/IN expression/NN of/IN E-cadherin/NN ,/, alpha-catenin/NN and/CC gamma-catenin/NN ,/, but/CC not/RB beta-catenin/NN ,/, with/IN increased/VBN 
1534_1534_16_17_34_35::POS_ACTION_Change::and/CC the/DT apoptosis-initiating/JJ caspases-8/NN and/CC -10/CD in/IN death/NN signaling/NN by/IN the/DT two/CD death-inducing/JJ TRAIL/NN receptors/NNS 1/CD and/CC 2/CD (/( TRAIL-R1/NN and/CC TRAIL-R2/NN )/) are/VBP controversial/JJ 
25905_6_3_4_18_19::None::Subsequently/RB ,/, nitrate/JJ concentration/NN in/IN the/DT feed/NN was/VBD increased/VBN in/IN a/DT step/NN -/: wise/JJ manner/NN to/TO establish/VB complete/JJ denitrification/NN of/IN 5420/CD mg/NN 
275901_0_50_51_63_65::None::available/JJ on/IN the/DT efficacy/NN of/IN Tenofovir/NNP (/( TDF/NNP )/) rescue/NN regimens/NNS in/IN patients/NNS with/IN multi/NNS -/: drug/NN resistance/NN (/( MDR/NN )/) 
1779_1779_29_30_29_30::None::interaction/NN between/IN yeast/NN profilin/NN and/CC pyrene-labeled/JJ yeast/NN 
1901_1901_33_34_29_30::None::kinase/NN inhibitors/NNS (/( CKIs/NNS )/) p27/NN and/CC p57/NN ,/, and/CC markers/NNS 
1029_1029_0_4_12_13::None::Myosin/NN heavy/JJ chain/NN A/DT staining/NN was/VBD dimmer/JJR and/CC its/PRP$ colocalization/NN with/IN filamentous/JJ actin/NN bundles/NNS in/IN growth/NN 
367649_3_23_24_3_4::None::Recent/JJ studies/NNS have/VBP demonstrated/VBN that/IN berberine/NN has/VBZ various/JJ pharmacological/JJ activities/NNS ,/, including/VBG lowering/VBG blood/NN glucose/NN ,/, regulating/VBG blood/NN lipids/NNS and/CC reducing/VBG inflammation/NN in/IN addition/NN to/TO its/PRP$ antioxidant/JJ 
149017_0_21_22_0_1::people.cause_of_death.includes_causes_of_death::Alzheimer/NN whosewhat/NN disease/NN (/( AD/NN )/) is/VBZ a/DT major/JJ neurodegenerative/JJ disease/NN of/IN old/JJ age/NN ,/, characterized/VBN by/IN progressive/JJ cognitive/JJ impairment/NN ,/, dementia/NN and/CC atrophy/NN of/IN 
394705_2_111_112_109_110::people.cause_of_death.includes_causes_of_death::lower/JJR incidence/NN of/IN chronic/JJ allograft/NN nephropathy/NN in/IN the/DT former/JJ 
2000_2000_4_5_0_3::None::Vascular/JJ endothelial/JJ cadherin/NN (/( VE-cadherin/NN )/) clusters/NNS were/VBD 
841704_4_18_19_37_39::None::ulcer/NN history/NN ,/, revascularization/NN history/NN ,/, amputation/NN history/NN ,/, gangrene/NN ,/, infection/NN ,/, Wagner/NNP grades/NNS ,/, duration/NN of/IN diabetes/NN ,/, and/CC postprandial/JJ blood/NN glucose/NN ,/, aldehyde/NN ,/, 
418321_2_48_49_9_10::None::(/( BP/NN )/) circadian/JJ pattern/NN also/RB appears/VBZ to/TO be/VB influenced/VBN by/IN OSA/NN Patients/NNS with/IN this/DT syndrome/NN exhibit/VBP a/DT high/JJ prevalence/NN of/IN non/JJ -/: dipping/VBG or/CC riser/JJR circadian/JJ patterns/NNS ,/, which/WDT are/VBP related/JJ to/TO clinical/JJ and/CC subclinical/JJ organ/NN damage/NN in/IN the/DT heart/NN and/CC brain/NN ./. 
164887_1_12_13_34_35::medicine.disease.risk_factors::the/DT frequency/NN of/IN hypertension/NN and/CC non/JJ -/: dipper/NN pattern/NN evaluated/VBN by/IN 48/CD -/: hour/NN ambulatory/JJ blood/NN pressure/NN monitoring/NN in/IN an/DT adult/JJ population/NN identified/VBD obstructive/JJ sleep/NN apnea/NN //: non/JJ -/: 
919_919_14_15_9_10::POS_ACTION_Causal::cytoplasmic/JJ domain/NN of/IN E-cadherin/NN binds/VBZ either/CC beta-catenin/NN or/CC plakoglobin/NN ,/, which/WDT both/DT 
148500_0_11_12_21_22::None::Frequency/NN Oscillations/NNS and/CC Epileptic/JJ Seizures/NNS in/IN a/DT Computational/JJ Cascade/NNP of/IN Neuronal/JJ Mass/JJ and/CC Compartmental/JJ Modeling/NN ./. 
301320_2_5_6_17_19::None::systematic/JJ review/NN we/PRP find/VBP favorable/JJ evidence/NN for/IN the/DT use/NN of/IN NAC/NN in/IN several/JJ psychiatric/JJ and/CC neurological/JJ disorders/NNS ,/, particularly/RB autism/NN 
687548_0_1_2_0_1::medicine.symptom.symptom_of::Diabetic/NNP polyneuropathy/NN (/( DPN/NN )/) 
3836_0_8_9_11_12::None::in/IN the/DT Elderly/NNP Patient/NN :/: Addressing/VBG Key/NN Questions/NNS ./. 
675416_11_61_63_44_45::None::,/, C/NN -/: reactive/JJ protein/NN as/IN a/DT marker/NN of/IN inflammation/NN ,/, and/CC procalcitonin/NN for/IN antibiotic/JJ stewardship/NN in/IN infections/NNS of/IN the/DT respiratory/JJ tract/NN and/CC sepsis/NN ./. 
275849_11_6_8_15_16::None::similarly/RB observed/VBN when/WRB E/NN coli/NN O157/NN :/: H7/NN was/VBD treated/VBN with/IN acetic/JJ acid/NN and/CC salt/NN in/IN 
113665_4_21_22_29_30::None::driven/VBN DBCs/NNS during/IN light/JJ adaptation/NN by/IN suppressing/VBG GABAA/NNP R/NN -/: mediated/VBN serial/NN inhibition/NN onto/IN rod/NN 
296153_6_27_28_10_11::None::,/, psoriasis/NN ,/, arthritis/NN ,/, allergies/NNS ,/, and/CC asthma/NN are/VBP all/DT associated/VBN with/IN changes/NNS in/IN the/DT serotonergic/JJ system/NN associated/VBN with/IN leukocytes/NNS ./. 
118_118_4_5_11_12::None::of/IN beta-catenin/NN or/CC E-cadherin/NN immunoprecipitates/NNS from/IN BMMC/NN lysate/NN revealed/VBD that/IN alpha-catenin/NN ,/, beta-catenin/NN ,/, 
117451_0_14_15_5_6::None::have/VBP demonstrated/VBN that/IN tissue/NN deposition/NN of/IN iron/NN following/VBG prolonged/JJ high/JJ dose/NN of/IN oral/JJ supplementation/NN for/IN treatment/NN 
1087_1087_7_9_23_24::POS_ACTION_Causal::that/IN in/IN brain/NN profilin/NN I/CD and/CC profilin/NN II/CD complexes/NNS link/VBP the/DT actin/NN cytoskeleton/NN and/CC endocytic/JJ membrane/NN flow/NN ,/, directing/VBG actin/NN and/CC clathrin/NN assembly/NN 
2076_2076_28_29_8_9::None::cerevisiae/FW gene/NN (/( COF1/NN )/) encoding/VBG a/DT low-M/NN (/( r/NN )/) actin-binding/JJ protein/NN of/IN 143/CD amino/NN acid/NN (/( aa/NN )/) residues/NNS (/( yeast/NN cofilin/NN ;/: Cof/NN )/) 
439403_7_24_25_9_10::None::depressed/JJ showed/VBD greater/JJR pain/NN interference/NN ,/, lower/JJR quality/NN of/IN life/NN ,/, more/JJR sleep/NN problems/NNS ,/, and/CC greater/JJR functional/JJ disability/NN than/IN nondepressed/JJ patients/NNS 
944_944_4_5_10_11::POS_ACTION_MODIFY::dynamics/NNS of/IN Dictyostelium/NNP cofilin/NN suggests/VBZ a/DT role/NN in/IN remodeling/VBG actin/NN latticework/NN into/IN bundles/NNS 
604581_3_5_6_2_3::None::We/PRP further/RB explored/VBD the/DT central/JJ mechanisms/NNS of/IN fatigue/NN at/IN 
1102_1102_6_7_2_3::None::Overexpression/NN of/IN cofilin/NN stimulates/VBZ bundling/VBG of/IN actin/NN filaments/NNS ,/, membrane/NN 
157_157_33_34_1_2::None::Archaeal/NNP histones/NNS are/VBP most/RBS similar/JJ to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN formed/VBN by/IN eukaryal/JJ histone/NN (/( H3/NN +/CC H4/NN )/) 
400251_4_14_16_27_28::None::once/RB -/: daily/JJ oral/JJ tablets/NNS containing/VBG 150/CD mg/NN elvitegravir/NN ,/, 150/CD mg/NN cobicistat/NN ,/, 200/CD mg/NN emtricitabine/NN ,/, and/CC 10/CD 
600709_1_8_9_26_27::None::to/TO its/PRP$ more/RBR aggressive/JJ form/NN ,/, non/JJ -/: alcoholic/JJ steatohepatitis/NN (/( NASH/NN )/) ,/, which/WDT may/MD develop/VB into/IN hepatic/JJ fibrosis/NN ,/, cirrhosis/NN ,/, or/CC hepatocellular/JJ 
1798_1798_24_26_33_34::POS_REG(0)_ASSEMBLE::expression/NN of/IN a/DT rac-1/NN GAP/NN alters/VBZ the/DT assembly/NN of/IN integrin/NN receptors/NNS ,/, actin/NN and/CC cytoskeletal/JJ proteins/NNS 
217_217_7_8_27_28::POS_ACTION_DOWNREGULATE::shown/VBN that/IN the/DT RAD51/NN and/CC RAD52/NN proteins/NNS interact/VBP ,/, RAD51/NN on/IN a/DT high/JJ copy/NN number/NN plasmid/NN was/VBD tested/VBN and/CC found/VBN to/TO suppress/VB the/DT rad52-20/NN allele/NN ,/, but/CC 
2000_2000_10_11_0_3::POS_ACTION_COLOCALIZE::Vascular/JJ endothelial/JJ cadherin/NN (/( VE-cadherin/NN )/) clusters/NNS were/VBD co-localized/VBN with/IN beta-catenin/NN ,/, an/DT important/JJ 
720852_5_12_13_7_8::None::of/IN MI/NN with/IN PCI/NN was/VBD noticed/VBN in/IN both/CC diabetic/JJ and/CC non/JJ -/: 
266602_0_18_19_14_16::medicine.risk_factor.diseases::high/JJ risk/NN for/IN psychotic/JJ disorder/NN and/CC healthy/JJ adolescent/JJ controls/NNS ./. 
1916_1916_19_20_24_25::None::that/IN interacts/VBZ with/IN profilin/NN and/CC thus/RB could/MD modulate/VB actin/NN modeling/NN proximal/JJ to/TO 
287311_9_1_2_29_30::None::The/DT AUROC/NN values/NNS for/IN VFA/NNP were/VBD higher/JJR than/IN those/DT for/IN BMI/NNP and/CC WHR/NNP For/IN VFA/NNP ,/, the/DT sensitivity/NN and/CC specificity/NN for/IN predicting/VBG CKD/NNP were/VBD 62.66/CD %/NN (/( 95/CD %/NN CI/NN ,/, 61.0/CD -/: 
947715_0_18_19_8_10::None::as/IN leukocytes/NNS ,/, cancer/NN cells/NNS ,/, and/CC amoeba/NN ,/, typically/RB move/VBP inside/IN the/DT narrow/JJ interstitial/JJ spacings/NNS of/IN 
93_93_24_26_28_29::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN 
322769_0_5_6_9_10::None::by/IN zero/CD -/: valent/JJ iron/NN in/IN oxic/JJ condition/NN :/: the/DT role/NN 
87003_15_5_6_6_7::None::increased/VBD TNF/NN -/: alpha/NN induced/VBD release/NN of/IN caspase/NN 
213969_5_0_1_110_112::None::This/DT review/NN discusses/VBZ recent/JJ novel/JJ targets/NNS of/IN therapies/NNS for/IN PH/NN that/WDT have/VBP been/VBN developed/VBN as/IN a/DT result/NN of/IN these/DT advances/NNS ,/, which/WDT are/VBP now/RB in/IN pre/JJ -/: clinical/JJ and/CC clinical/JJ trials/NNS (/( eg/FW ,/, imatinib/NN [/( phase/NN III/CD ]/) ;/: nilotinib/NN ,/, AT/IN -/: 877ER/NN ,/, rituximab/NN ,/, tacrolimus/NN ,/, paroxetine/NN ,/, sertraline/NN ,/, fluoxetine/NN ,/, bardoxolone/NN methyl/NN [/( phase/NN II/CD ]/) ;/: and/CC sorafenib/NN ,/, FK506/NN ,/, aviptadil/NN ,/, endothelial/JJ progenitor/NN cells/NNS (/( EPCs/NNS )/) [/( phase/NN I/NN ]/) )/) While/IN substantial/JJ progress/NN has/VBZ been/VBN made/VBN in/IN recent/JJ years/NNS in/IN targeting/VBG key/JJ molecular/JJ pathways/NNS ,/, PH/NN still/RB remains/VBZ without/IN a/DT cure/NN ,/, and/CC these/DT novel/JJ therapies/NNS provide/VBP an/DT important/JJ conceptual/JJ framework/NN of/IN categorizing/VBG patients/NNS 
810075_0_19_20_6_7::None::following/VBG pulmonary/JJ vein/NN isolation/NN for/IN paroxysmal/JJ atrial/JJ fibrillation/NN :/: a/DT retrospective/JJ comparison/NN between/IN the/DT cryoballoon/NN and/CC conventional/JJ focal/JJ tip/NN radiofrequency/NN 
157_157_33_34_8_9::None::to/TO the/DT globular/JJ histone/NN fold/NN region/NN of/IN eukaryal/JJ histone/NN H4/NN ,/, and/CC the/DT results/NNS reported/VBN are/VBP consistent/JJ with/IN archaeal/JJ nucleosomes/NNS resembling/VBG the/DT structure/NN formed/VBN by/IN eukaryal/JJ histone/NN (/( H3/NN +/CC H4/NN )/) 
1850_1850_8_9_10_11::None::directly/RB with/IN the/DT cadherin/NN ;/: alpha-catenin/NN binds/VBZ to/TO beta-catenin/plakoglobin/NN 
236038_0_14_15_4_5::None::is/VBZ the/DT major/JJ surface/NN hyaluronan/NN (/( HA/NN )/) receptor/NN implicated/VBN in/IN intercellular/JJ and/CC cell/NN -/: matrix/NN adhesion/NN 
784_784_4_5_18_19::None::normal/JJ livers/NNS ,/, E-cad/NN ,/, alpha-catenin/NN and/CC beta-catenin/NN ,/, but/CC not/RB CD44s/NNS ,/, CD44v5/NN ,/, CD44v6/NN ,/, CD44v7-8/NN ,/, and/CC CD44v10/NN 
189447_0_1_2_0_2::people.cause_of_death.includes_causes_of_death::Breast/NN cancer/NN incidence/NN is/VBZ increasing/VBG 
361641_4_5_6_16_17::medicine.drug_ingredient.active_moiety_of_drug::extracellular/JJ and/CC cytosolic/JJ Ca/NN (/( 2/CD +/CC )/) ,/, cells/NNS were/VBD exposed/VBN to/TO the/DT calcium/NN chelators/NNS ethylene/NN glycol/NN 
186443_2_5_7_24_25::None::with/IN diabetes/NN mellitus/NN type/NN 1/CD or/CC 2/CD ,/, or/CC using/VBG antidiabetic/JJ drugs/NNS (/( ADDs/NNS )/) ,/, were/VBD compared/VBN to/TO matched/VBN non/JJ -/: diabetic/JJ controls/NNS ./. 
583303_11_12_13_21_22::None::the/DT most/RBS common/JJ microorganisms/NNS in/IN children/NNS with/IN untreated/JJ uncomplicated/JJ acute/JJ tympanostomy/NN -/: tube/NN otorrhea/NN ./. 
1479_1479_21_22_13_15::None::the/DT effects/NNS of/IN LIM/NN kinase/NN and/CC cofilin/NN in/IN the/DT control/NN of/IN actin/NN dynamics/NNS ./. 
1916_1916_24_25_19_20::None::that/IN interacts/VBZ with/IN profilin/NN and/CC thus/RB could/MD modulate/VB actin/NN modeling/NN proximal/JJ to/TO 
365169_1_12_13_3_4::None::We/PRP describe/VBP a/DT cascade/NN of/IN complications/NNS -/: active/JJ pulmonary/JJ tuberculosis/NN despite/IN recent/JJ isoniazid/NN prophylactic/NN therapy/NN ,/, 
1395_1395_26_27_26_27::POS_REG(-)_Assembly::epitopes/NNS of/IN birch/NN profilin/NN ./. 
523643_0_23_24_19_20::None::LAA/NN )/) and/CC stroke/NN risk/NN score/NN in/IN patients/NNS with/IN atrial/JJ fibrillation/NN 
1069_1069_36_37_29_30::None::UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC 
761772_0_11_12_19_20::None::to/TO the/DT order/NN Passeriformes/NN of/IN bird/NN species/NNS and/CC is/VBZ important/JJ for/IN avian/JJ ecological/JJ and/CC evolutionary/JJ 
712_712_11_12_27_28::None::to/TO suggest/VB that/IN HRG/NN stimulation/NN of/IN the/DT EF-1alpha/NN promoter/NN involves/VBZ increased/VBN physical/JJ interactions/NNS with/IN acetylated/VBN histone/NN H3/NN and/CC histone/NN H4/NN ./. 
1144_1144_11_13_17_18::POS_REG(-)_POLYMERIZE::to/TO that/DT of/IN profilin/NN I/CD ,/, although/IN it/PRP inhibits/VBZ actin/NN polymerization/NN more/RBR strongly/RB 
1520_1520_16_19_19_20::POS_ACTION_MEMBER::accumulation/NN of/IN the/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27/NN (/( kip1/NN )/) 
758270_7_5_7_3_4::medicine.disease.risk_factors::In/IN chronic/JJ cigarette/NN smoke/NN related/JJ lung/NN disease/NN ,/, the/DT PGP/NN 
71991_0_23_24_9_10::None::disorders/NNS and/CC comorbid/NN health/NN problems/NNS ,/, including/VBG depression/NN //: anxiety/NN disorder/NN ,/, insomnia/NN //: sleep/VB disorder/NN ,/, fatigue/NN ,/, and/CC injury/NN 
12641_5_39_41_6_7::medicine.disease.risk_factors::on/IN antidepressants/NNS (/( AD/NN )/) ,/, rapid/JJ cycling/NN (/( RC/NN )/) subjects/NNS experienced/JJ 268/CD %/NN (/( 3.14/CD //: 1.17/CD )/) more/RBR total/JJ mood/NN episodes/NNS //: year/NN ,/, and/CC 293/CD %/NN (/( 1.29/CD //: 0.44/CD )/) more/RBR depressive/JJ episodes/NNS //: year/NN ,/, 
2013_2013_9_10_7_9::None::motif/NN for/IN the/DT Rho/NN GTPase/NN CDC42Hs/NNS as/RB well/RB as/IN 
1760_1760_5_6_13_14::POS_ACTION_BIND::phosphatases/NNS PP1/NN and/CC PP2A/NN associate/VBP with/IN and/CC activate/VB the/DT actin-binding/JJ protein/NN cofilin/NN in/IN human/JJ T/NN 
1069_1069_21_22_36_37::None::in/IN which/WDT the/DT helicase-primase/JJ components/NNS (/( UL5/NN ,/, UL8/NN ,/, and/CC UL52/NN )/) ,/, the/DT origin-binding/JJ protein/NN (/( UL9/NN )/) ,/, and/CC 
788_788_34_35_38_39::None::membrane/NN anchorage/NN of/IN actin/NN microfilaments/NNS ,/, i.e./FW vinculin/NN and/CC talin/NN ,/, 
471565_0_11_12_15_16::None::low/JJ or/CC high/JJ dialysate/NN sodium/NN concentration/NN (/( DNa/NN (/( +/CC )/) 
980_980_5_6_18_19::POS_REG(+)_LOCALIZE::stable/JJ expression/NN of/IN V12Ras/NNS into/IN keratinocytes/NNS promotes/VBZ the/DT loss/NN of/IN E-cadherin/NN and/CC alpha-catenin/NN and/CC relocalization/NN of/IN beta-catenin/NN to/TO the/DT cytoplasm/NN 
76765_3_18_19_54_56::None::)/) and/CC FPG/NNP categorized/VBD as/IN normal/JJ fasting/NN glucose/NN (/( NFG/NN :/: FPG/NNP &/CC lt/NN ;/: //: =/JJ 6.0/CD mmol/NN //: L/NN )/) ,/, impaired/JJ fasting/NN glucose/NN (/( IFG/NN :/: FPG/NNP 6.1/CD -/: 6.9/CD mmol/NN //: L/NN )/) ,/, and/CC diabetes/NN mellitus/NN (/( DM/NN :/: 
241386_9_22_23_25_26::None::mesothelioma/NN and/CC other/JJ mesothelin/NN -/: expressing/VBG cancers/NNS ./. 
2131_2131_21_22_23_24::None::the/DT localization/NN of/IN ICP8/NN (/( UL29/NN )/) to/TO prereplicative/JJ 
349493_0_10_12_0_1::medicine.disease.symptoms::Tumor/NN and/CC Patient/NN Characteristics/NNS of/IN Individuals/NNS with/IN Mismatch/NNP Repair/NNP Deficient/JJ Colorectal/JJ Cancer/NN ./. 
436497_1_11_12_26_27::None::symptoms/NNS ,/, and/CC tested/VBN impulsivity/NN as/IN a/DT moderator/NN of/IN the/DT body/NN shame/NN //: bulimic/JJ symptoms/NNS relationship/NN among/IN a/DT sample/NN of/IN female/JJ undergraduates/NNS 
1474_1474_21_24_9_10::None::(/( serum/NN and/CC laminin/NN )/) and/CC time/NN in/IN culture/NN on/IN the/DT expression/NN of/IN genes/NNS encoding/VBG myosin/NN heavy/JJ chain/NN (/( MHC/NN )/) 
138079_4_27_28_6_7::None::100/CD Mycobacterium/NN tuberculosis/NN isolates/NNS ,/, the/DT resistance/NN rates/NNS were/VBD 7/CD %/NN ,/, 7/CD %/NN ,/, 3/CD %/NN ,/, and/CC 9/CD %/NN against/IN isoniazid/NN ,/, rifampin/NN ,/, ethambutol/NN ,/, 
1782_1782_20_22_25_26::None::the/DT interactions/NNS between/IN RIP/NN kinase/NN ,/, TRADD/NN ,/, FADD/NN and/CC RAIDD/NN -/: 
185973_8_10_11_19_20::None::age/NN differences/NNS in/IN brain/NN signal/NN variability/NN reflect/VBP aging/NN -/: induced/VBN changes/NNS in/IN dopaminergic/JJ neuromodulation/NN ./. 
567_567_14_15_15_16::None::)/) through/IN the/DT p55/NN TNF/NN receptor-associated/JJ proteins/NNS TRADD/NN 
346_346_16_17_7_8::None::that/IN beta-catenin/NN and/CC plakoglobin/NN bind/VBP to/TO the/DT same/JJ region/NN of/IN alpha-catenin/NN ,/, beta-catenin/NN competed/VBD with/IN the/DT 
22703_5_7_8_50_51::None::adrenal/JJ LDL/NN receptor/NN function/NN significantly/RB reduced/VBD the/DT adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) -/: mediated/VBN stimulation/NN of/IN adrenal/JJ steroidogenesis/NN (/( P/NN &/CC lt/NN ;/: 0.001/CD )/) ,/, with/IN plasma/NN corticosterone/NN levels/NNS that/WDT were/VBD respectively/RB 44/CD -/: 59/CD %/NN lower/JJR (/( P/NN &/CC lt/NN ;/: 0.01/CD )/) as/IN compared/VBN to/TO adrenal/JJ LDL/NN 
198817_2_19_21_6_7::medicine.disease.treatments::41/CD patients/NNS with/IN surgically/RB treated/VBN CRC/NN (/( Group/NN A/NN =/JJ 22/CD patients/NNS )/) and/CC non/JJ -/: colorectal/JJ carcinomas/NNS (/( Group/NN B/NN 
405799_1_32_33_30_33::people.cause_of_death.includes_causes_of_death::with/IN type/NN 2/CD diabetes/NNS were/VBD recruited/VBN in/IN 
331666_4_6_7_37_38::None::mortality/NN was/VBD significantly/RB higher/JJR among/IN patients/NNS with/IN :/: liver/NN (/( RR/NN ,/, 29.6/CD [/( 95/CD %/NN CI/NN ,/, 29.1/CD -/: 30.1/CD ]/) )/) ,/, oral/JJ (/( 5.2/CD [/( 5.1/CD -/: 5.4/CD ]/) )/) ,/, rectum/NN (/( 2.6/CD [/( 
578166_0_7_9_10_11::None::storage/NN on/IN total/JJ phenolic/JJ content/NN and/CC antioxidant/JJ capacity/NN of/IN almond/NN 
1498_1498_21_22_4_5::None::head/NN domain/NN of/IN talin/NN thus/RB binds/VBZ to/TO integrins/NNS to/TO form/VB a/DT link/NN to/TO the/DT actin/NN cytoskeleton/NN and/CC can/MD thus/RB regulate/VB integrin/NN function/NN ./. 
853642_16_32_33_23_24::None::had/VBD added/VBN value/NN compared/VBN to/TO V/NNP //: P/NN SPECT/NN alone/RB ,/, by/IN identifying/VBG patients/NNS with/IN lung/NN 
785586_0_11_12_15_16::None::most/RBS difficult/JJ and/CC dangerous/JJ operations/NNS in/IN general/JJ surgery/NN ./. 
1234_1234_34_35_17_18::POS_ACTION_BIND::extract/VB gelsolin/NN and/CC profilin/NN ,/, respectively/RB ,/, from/IN EGTA-containing/JJ platelet/NN extracts/NNS and/CC determine/VB the/DT proportion/NN of/IN these/DT molecules/NNS bound/VBD to/TO actin/NN with/IN sufficient/JJ affinity/NN 
479047_2_7_8_19_20::None::patients/NNS ,/, average/JJ age/NN 9.7/CD years/NNS (/( range/NN 1.8/CD -/: 29.3/CD years/NNS )/) ,/, underwent/VBD surgery/NN for/IN moyamoya/NN in/IN 
428759_7_9_10_13_14::None::effectiveness/NN of/IN adjuvant/JJ ovarian/JJ suppression/NN in/IN premenopausal/JJ early/JJ breast/NN cancer/NN have/VBP 
1233_1233_19_24_26_27::POS_ACTION_MEMBER::,/, desmin/NN and/CC smooth/VB muscle/NN myosin/NN heavy/JJ chain/NN isoforms/NNS :/: SM1/NN ,/, SM2/NN and/CC 
1524_1524_12_13_18_19::POS_ACTION_BIND::)/) and/CC birch/VB profilin/NN ,/, a/DT structurally/RB well/RB conserved/VBN actin/NN -/: and/CC phosphoinositide-binding/JJ 
1140_1140_22_23_24_25::None::of/IN gelsolin/NN and/CC profilin/NN with/IN actin/NN ./. 
20599_4_51_52_45_49::None::targeted/VBN against/IN human/JJ epidermal/JJ growth/NN factor/NN receptor/NN 3/CD (/( HER3/NN )/) ./. 
93_93_24_26_50_51::None::or/CC MPK1/NN (/( MAP/NN kinase/NN )/) mimicked/VBD PKC1/NN as/IN a/DT glc7-10/NN dosage/NN suppressor/NN ,/, extra/JJ copies/NNS of/IN genes/NNS encoding/VBG upstream/JJ components/NNS of/IN the/DT Pkc1p/NN pathway/NN such/JJ as/IN ROM2/NN ,/, RHO2/NN ,/, HCS77/WSC1/SLG1/NN and/CC 
768458_5_4_5_22_23::None::result/NN demonstrated/VBD that/IN compared/VBN to/TO irbesartan/NN monotherapy/NN ,/, the/DT combination/NN of/IN irbesartan/NN and/CC spironolactone/NN both/CC in/IN low/JJ -/: and/CC conventional/JJ -/: dose/NN exhibited/VBD additional/JJ cardioprotection/NN 
